Final Programme

16 TH ECCMID NICE 2006
NICE
Final Programme
16 th European Congress of Clinical
Microbiology and Infectious Diseases
Nice / France, Nice, April 1–4, 1 – 4, 2006

For the treatment of refractory invasive fungal infections
Copyright © 2006, SP Europe, Brussels, Belgium. All rights reserved. 03/06
INTRODUCING
40 mg/ml, oral suspension
NOXAFIL is indicated in adults with the following
diseases that are refractory* or intolerant to 1 :
• Invasive aspergillosis—amphotericin B (both conventional
and lipid formulations) or itraconazole
• Fusariosis—amphotericin B (both conventional and
lipid formulations)
• Chromoblastomycosis and mycetoma—itraconazole
• Coccidioidomycosis—amphotericin B (both conventional
and lipid formulations), itraconazole, or fluconazole
*Refractory defined as progression of infection or failure to improve after a minimum of 7 days
of prior therapeutic doses of antifungal therapy. 1
Please see Summary of Product Characteristics for full
prescribing information.
Reference: 1. NOXAFIL [summary of product characteristics]. SP Europe, Brussels, Belgium; 2005.
Visit the Schering-Plough booth
at ECCMID 2006 for more information
NEW

A20337 IR.02.2006/6.5
Table of Contents
Scientific Programme Overview _______________________________________________________ 2–5
Congress Venue Overview ____________________________________________ 7
Welcome Address ______________________________________________________________________________ 9
ESCMID – News from the President ____________________________________________________ 11
Important Addresses ________________________________________________________________________ 12
Acknowledgements __________________________________________________________________________ 13
Committees ________________________________________________________________________________ 14–17
ESCMID Awards 2006 ___________________________________________________________________ 18–23
Introduction to the Scientific Programme ____________________________________________ 24
Instructions for Authors ____________________________________________________________________ 25
ESCMID Study Group and other Business Meetings _____________________________ 26
Scientific Programme __________________________________________________________________ 27–67
Saturday, April 1, 2006_______________________________________ 27– 32
Sunday, April 2, 2006 ___________________________________________________________ 33–46
Monday, April 3, 2006 _______________________________________ 47–58
Tuesday, April 4, 2006 _______________________________________ 59–67
Poster Sessions _________________________________________________________________________ 68–148
Sunday, April 2, 2006 _______________________________________ 68–95
Monday, April 3, 2006 ______________________________________ 96–124
Tuesday, April 4, 2006 ________________________________________________________ 125–148
List of Chairpersons _________________________________________________________________________ 149
List of Authors _________________________________________________________________________ 150–171
General Information __________________________________________________________________ 172–174
Social Events __________________________________________________________________________________ 175
Tours ______________________________________________________________________________________ 176–178
Industrial Exhibition __________________________________________________________________ 179–203
Exhibition Overview __________________________________________________________________ 180/181
List of Exhibitors _____________________________________________________________________________ 182
Exhibitors’ Guide _______________________________________________ 183–203
Future ECCMIDs ______________________________________________________________________________ 206
City Map of Nice ______________________________________________________________________________ 207
Shuttle Bus Schedule _______________________________________________________________________ 208
www.escmid.org/eccmid2006
page 1

Saturday,
April 1, 2006
Sunday,
April 2, 2006
Scientific Programme Overview
10
11
12
13
14
15
16
17
18
19
07
08
09
10
11
12
13
14
15
16
17
18
page 2 Final Programme
Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris
13.30 – 15.30
13.30 – 15.30
13.30 – 15.30
13.30 – 15.30
13.30 – 15.30
Practical and
theoretical aspects of
sequence-based
typing: the paradigms
of S. aureus
and S. pyogenes
ESGEM Work -
shop p.27
Quality control
and
standardisa tion
in molecular
diagnostics
ESGMD Work -
shop p.27
Management of Current control
nosocomial measures for
infections – Toxoplasma
learning from infection in preg-
clinical cases nant women and
new-born children
ESGNI Work - ESGT Work -
shop p.27 shop p.27
Antibiotic
resistance
of microbial
biofilms
ESGB Workshop
p.29
15.30 – 17.30
Evidence and ex- 15.45 – 16.45
15.45 – 16.45
perience: the role Dendograms in Antimicrobial resis -
microbial phylogene- tance in anaerobic
of echinocandins
tics and epidemio - bacteria. Experiences
in the manage- lo gical typing in Europe and USA
p.31
p.31
ment of invasive
16.45 – 17.45
16.45 – 17.45
fungal infections
ESGEM ESGARAB
MSD p.31 Meeting Meeting
p.26
p.26
15.45 – 17.15
Pathogenesis
and prevention
of nosocomial
infections –
new aspects
p.31
17.15 – 17.45
ESGNI Meeting
15.45 – 16.45
15.45 – 17.15
News in the How to prevent
field of toxo- microbial biofilm
plasmosisp.32
formation on
16.45 – 17.45 medical devices
ESGT
p.32
Meeting
17.15 – 17.45
p.26 ESGB Meeting
18.00 – 21.00
Opening
Ceremony
&
Welcome
Reception
p.26
p.26
Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris
07.15 – 08.15
07.15 – 08.15
07.15 – 08.15
Lab diagnosis of Current issues in What is the role
invasive fungal the treatment of of serology in
HBV-HIV co-infected
infections
patients
pregnancy?
p.33 p.33 p.33
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
New diagnostic Tailoring initial The challenge for Neurological Quinolone Viruses and
techniques antifungal antibiotic therapy sequelae of resistance and viral
for the
therapy in treating bacterial and efflux diagnostics
microbiology according to complicated viral infections
laboratory and epidemiological infections: how
general
trends broad is enough?
practitioner Schering-Plough
p.34 p.37 MSD p.37 p.34 p.34 p.35
11.00 – 12.00
ESCMID
Excellence
Award Lecture
11.00 – 12.00
Impact of microbial
genomics on
epidemiology and
control of ID
Poster Session I: 12.00–13.00
Poster Session II: 13.00–14.00
Poster Walks
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
The year in Is microbiological The hyper-virulent Dissemination
infectious work-up in community- strain of C. difficile: of molecular
diseases medicine acquired pneumonia sharing experiences in resistance traits
p.41 still useful? p.41 Europe and USAp.41
p.41
Diabetes and
infection
p.42
Pump it out
and resist
p.42
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
Current Readdressing the Addressing
aspects on importance of macrolide issues
MRSA Gram-negative re- in communitysistance:pathoacquired
RTI
gens, practice
patterns, and
pharmacotherapy
p.43 Wyeth p.45 Pfizer p.46
Mechanisms
of infectious
diseases:
new science
and
novel
insights
p.43
Antimicrobial
clinical trials
p.43
Epidemic
influenza
p.44
17.45 – 18.45
Late breaker
Session on
Avian influenza
p.46
p.38 p.38

Hermes
13.30 – 17.30
Pharmaco -
kinetics
and
pharmaco -
dynamics of
anti-infective
agents
ISAP
Workshop
Symposia
Keynote, Award and Special Lectures
Oral Sessions
Satellite- & Integrated Symposia
Meet-the-Expert Sessions & Educational Workshops
Business Meetings
Poster Sessions
Clio Erato Calliope Registration
Exhibition
13.30 – 15.30
The management of
neutropenic patients
with fever undergoing
chemotherapy for the
treatment of haematological
malignancies
13.30 – 14.30
ESCAR
Meeting
14.30 – 15.30
EFISG
13.30 – 15.30
EUCAST
Business
Meeting
Meeting
Wyeth p.31 p.26 p.26
15.45 – 17.15
Antimicrobial
utilisation in
Europe: future
directions
15.45 – 17.45
Nosocomial
mould
infections
10.30 – 12.30
EUCAST
National
Committees and
General
Committee
Meeting
15.45 – 17.15
Guidelines for
Helicobacter pylori
infections revisited.
The Maastricht-3 2005
consensus report
Registration:
12.30–18.30
Exhibition:
12.30–18.00
Meeting Room 3
13.30 – 17.30
European
surveillance
of nosocomial
infections,
antimicrobial
resistance
and use
in ICUs
IPSE
Workshop
Hermes Clio Erato Calliope Registration / Exhibition
07.15 – 08.15
07.15 – 08.15
07.15 – 08.15
Travel medicine and Surveillance of newly How to diagnose
evidence-based emerging pathogens and treat diabetic foot
recommendations and public health infections?
p.33 responses p.33 p.33
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
08.30 – 10.30
Evolution of In antimicrobial Clinical Addressing the
beta- therapy “use the epidemiology challenge of
lactamases best one first”: of nosocomial nosocomial
examining the
evidence
infections MRSA infections
Bayer HealthCare
Pfizer
p.34 p.37 p.35 p.38
11.00 – 12.00
11.00 – 12.00
Biofilms – Emerging viral
a highly organised infections
communityp.38
p.39
Poster Session I: 12.00–13.00
Poster Session II: 13.00–14.00
Poster Walks
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
Blood-borne viruses
in health care
facilities – the silent
enemy? p.41
Viral congenital
paediatric
diseases p.41
Brucellosis
p.41
Mycobacterial
infections
p.42
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
Foreign body Redesigning Rapid Advances in
infections ß-lactams to methods for antifungal
combat identification therapy
resistance of bacterial
clones and
Janssen-Cilag
pathogens
Gilead Sciences
p.43 p.46 p.45 p.46
p.26
p.32 p.32
p.29
17.15 – 17.45
ESGAP Meeting
p.32
17.15 – 17.45
EHSG Meeting
p.26 p.26
Registration:
07.00–18.00
Exhibition:
09.30–18.00
p.29
10
11
12
13
14
15
16
17
18
19
07
08
09
10
11
12
13
14
15
16
17
18
www.escmid.org/eccmid2006
Saturday,
April 1, 2006
Sunday,
April 2, 2006
page 3

page 4
Monday,
April 3, 2006
Tuesday,
April 4, 2006
Scientific Programme Overview
07
08
09
10
11
12
13
14
15
16
17
18
19
07
08
09
10
11
12
13
14
15
Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris
08.30 – 10.30
The pros and
cons of
combination
antimicrobial
treatment
Final Programme
08.30 – 10.30
Respiratory
tract infections:
at risk patients,
who are they?
08.30 – 10.30
Extending the
antifungal
armamentarium
07.15 – 08.15
07.15 – 08.15
07.15 – 08.15
Recent treatment
issues in tuberculosis
and nontuberculosis
mycobacteriap.47
Epidemiology and How to interpret
typing in outbreak laboratory test
investigation
p.47 results? p.47
08.30 – 10.30
Emerging viral
exotica
in Europe
08.30 – 10.30
Diagnostic
and
laboratory
methods
08.30 – 10.30
Infections in
the immunocompromised
host
sanofi aventis Pfizer
p.48 p.51 p.51 p.48 p.48 p.48
11.00 – 12.00
11.00 – 12.00
Antimicrobial intelli - WHO patient
gence: how euka ryotes
combat the quorum safety challenge
sensing strat.
11.00 – 12.00
Human papilloma -
virus: impact of
11.00 – 12.00
ESCMID Young
Investigator Award
Lectures
p.52 p.52
disease and vaccine
intervention
p.52 p.52
Poster Session III: 12.00–13.00
Poster Session IV: 13.00–14.00
Poster Walks
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
Emergence of
transferable quinolone
resistance
The year in HIV
medicine
p.53
Infectivity and Infection in the
emergence of immunocompromised
resistance in animal host (except HIV)
models p.54 p.54
Hepatitis Multidrug-resistant
Gram-negative organisms
in the hospital
p.53 and community
p.53
p.54
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 16.30
15.30 – 17.30
15.30 – 17.30
How to The heart Fungal infections: To treat or not Antibacterial Epidemiology
detect the next of the matter: host defences to treat susceptibility of MRSA
emerging
pathogen
p.55
managing
resistance in
RTIs
sanofi aventis
p.58
and clinical
interventions
Astellas
p.58
p.56
16.30 – 17.30
Problems in the
treatment of HIV
p.56
studies:
activities,
mechanisms
and drug
interactions
p.56
in Europe
p.57
Apollon Athena Méditerranée 1 Méditerranée 2 Méditerranée 3 Iris
08.30 – 10.30
Pathogenesis
and therapy
of sepsis
08.30 – 10.30
Combination
therapy for
Candida –
the case for
biologicals
07.15 – 08.15
07.15 – 08.15
07.15 – 08.15
Empirical antibiotic How to defend your Antibiotic prophylaxis
therapy for ICU- clinical microbiology in immunocomproacquired
infections
p.59
in times of budget mised hosts, including
restrictions? p.59 transplant patients
p.59
08.30 – 10.30
Non-pneumococcalcommunityacquired
RTI's –
current state of
the art
08.30 – 10.30
Antimicrobial
pharmaco -
kinetics and
pharmaco -
dynamics
08.30 – 10.30
Microbial
pathogenesis:
a diversity of
mechanisms and
host responses
p.60
Neutec Pharma
p.62 p.60 p.60 p.61
11.00 – 12.00
11.00 – 12.00
11.00 – 12.00
Epidemiological
determinants of
the genetic diversityof
viruses p.63
Toxins from
Gram-positive
bacteria p.63
Sexually transmitted
diseases and urinary
tract infections
p.63
Poster Session V: 12.00–13.00
Poster Walks
13.00 – 15.00
Origin,
epidemiology,
diagnosis and
management
of CA-MRSA
p.65
13.00 – 14.00
RTI in the
community
revisited
p.65
13.00 – 15.00
Treatment,
antifungal
resistance and
epidemiology of
fungal infections
p.66

Hermes Clio Erato Calliope Registration / Exhibition
07.15 – 08.15
07.15 – 08.15
Minimal requirements Beta-lactamases:
for an effective
infection control from bench to
surveillance bedside
08.30 – 10.30
Relationship
between
antimicrobial
resistance and
virulence
14.00 – 15.00
Infection
control
08.30 – 10.30
Fighting the
threat of
resistance
(interactive)
07.15 – 08.15
Clinical trials
and clinical
practice
08.30 – 10.30
Pneumonia and
Pneumococci
08.30 – 10.30
Lipopeptide:
the class of 2006
AstraZeneca
Chiron
p.48 p.51 p.49 p.51
11.00 – 12.00
Human genetic
susceptibility to
infection p.52
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
15.30 – 17.30
Paediatric viral Evidence-based Diagnosis of sep- Limiting
respiratory tract preventive and sis: the need for antibiotic
infections: control measures fast molecular usage in the
the major killers for selected microbiological community:
nosocomial methods benefits and
p.56
appraisal
(interactive)
Roche
Diagnostics
collateral effects
p.56
p.56 p.58
17.45 – 19.00
ESCMID
General
Assembly
Poster Session III: 12.00–13.00
Poster Session IV: 13.00–14.00
Poster Walks
Registration:
07.00–18.00
Exhibition:
09.30–18.00
Hermes Clio Erato Calliope Registration / Exhibition
07.15 – 08.15
07.15 – 08.15
07.15 – 08.15
How to manage
catheter-related
infections? p.59
Routine suscepti- Emergence of risk
bility testing: which
factors and treatment
issues for Clostridium
antibiotic to choose difficile -associated
p.59 diarrhoea p.59
08.30 – 10.30
Risk assessment
in primary care:
clairvoyance or
evidence-based
medicine?
13.00 – 15.00
Clinical
implications
of low-level
antimicrobial
resistance
p.47 p.47 p.47
08.30 – 10.30
Compliance in
antibiotics:
the last chance?
08.30 – 10.30
Antisepsis and
the prevention of
skin and soft
tissue infections
Pfizer Shuelke-Mayr
p.60 p.62 p.60 p.60
11.00 – 12.00
Issues in travel
medicine
13.00 – 15.00
Molecular
epidemiology:
a tool for public
health
11.00 – 12.00
AIDS and HIV
Poster Session V: 12.00–13.00
Poster Walks
Symposia
Keynote, Award and Special Lectures
Oral Sessions
Satellite- & Integrated Symposia
Meet-the-Expert Sessions & Educational Workshops
Business Meetings
Poster Sessions
14.00 – 15.00
14.00 – 15.00
14.00 – 15.00
p.55
Management of Galactomannan PK/PD for the clinician:
antigen detection in should we use
endocarditis invasive aspergillosis continuous infusion
(interactive) Bio-Rad p.55 techniques? p.54
p.55
13.00 – 15.00
Antibiotic
prescribing
quality
indicators
08.30 – 10.30
Update on the
influenza
pandemic threat
11.00 – 12.00
Implications of
chemotherapyrelated
mucosal
barrier injury
p.63 p.64 p.63
13.00 – 15.00
Mycobacterial
infections
p.65 p.65 p.66 p.65
Registration:
07.00–15.30
Exhibition:
09.30–13.00
07
08
09
10
11
12
13
14
15
16
17
18
19
07
08
09
10
11
12
13
14
15
Monday,
April 3, 2006
Tuesday,
April 4, 2006
www.escmid.org/eccmid2006 page 5

You are invited to a Pfizer-sponsored integrated symposium
Addressing the Challenge of
Nosocomial MRSA Infections
Sunday, 2 April, 2006 08:30-10:30
Salon Calliope, Nice Acropolis Congress Centre
Scientific Agenda
Chairs: Gary French (UK), Kamal Itani (USA)
08:30 Introduction: Addressing the Challenge of Nosocomial MRSA
Infections
Gary French (UK)
08:40 MRSA Update: Present and Future Threats
Peter Wilson (UK)
09:00 Challenges of MRSA Nosocomial Surgical Site and Complicated
Skin and Soft-Tissue Infections
Kamal Itani (USA)
09:20 MRSA in the ICU: Catheter-Related Skin and Bloodstream Infections
Emilio Bouza (Spain)
09:40 Nosocomial Pneumonia: Early Diagnosis, Better Treatments
Jean-Yves Fagon (France)
10:00 Panel Discussion and Questions
Gary French (UK)
10:25 Summary and Conclusions
Kamal Itani (USA)
Supported by an educational grant from Pfizer Inc, a platinum medal sponsor

Level 3
Level 2
LEVEL 2
Apollon
(main auditorium)
Level 1
LEVEL 1
Apollon
Congress Venue Overview
@-Corner
Shuttle Buses
Posters
Posters
Exhibition
Exhibition
Secretariat
On-site Registration
Hotels/Tours
Business Center
i
Main
Entrance
Méditerranée 2
Registration
Pre-registered
Exhibition
Poster Desk
Hospitality
Suite
Restaurant
Hermes
Press Centre
VIP
Lounge Speakers
Service Centre
Entrance
Registration
Clio Erato Calliope
Meeting Rooms
Méditerranée 1
to Rooms Méditerranée
Exhibition
Méditerranée 3
to/from Exhibition
Iris
www.escmid.org/eccmid2006
Lecture Halls
Poster Area
Exhibition
Registration, Secretariat and Smaller Rooms
Posters
Restaurant
Athena
Posters
page 7

Integrated symposium
In antimicrobial
therapy use the
best first: examining
the evidence
Sunday, April 2, 2006, 8:30 – 10:30 a.m.
Acropolis Congress Centre, Level 3, Room Clio
Integrated symposium arranged by
Chairmen: Patrick Francioli (Lausanne, CH)
Donald Low (Toronto, CA)
08:30 Introduction
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
08:40 Differentiating antibiotics on basis of
preclinical data – determining superior
antimicrobial activity
Francesco Blasi (Milan, IT)
09:10 Treatment of lower respiratory tract
infections – assessing clinical superiority
Robert Read (Sheffield, UK)
09:40 Treatment of surgical infections including
SSSIs – assessing clinical superiority
Johannes Bogner (Munich, DE)
10:10 Panel discussion
Donald Low (Toronto, CA)
10:20 Conclusions
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)

Welcome Address
Dear Friends, Dear Colleagues,
Welcome to Nice and to the 16 th ECCMID, one of the major congresses in Clinical Microbiology and Infectious
Diseases in 2006! I hope you are comfortably settled and that you will also find some time to enjoy the city
and its surroundings, which offer a great variety of cultural and tourist attractions. Such surroundings could be
a concern for the President of a meeting as it is tough competition even for a premier scientific programme
covering a wide range of interesting topics in the infection fields.
Delegates will be pleased to find a top-notch programme organisationally as well as scientifically. Sessions
have been scheduled in such a way as to avoid simultaneous presentations on similar themes. Speakers in
symposia have been invited to present their data because they are considered the most knowledgeable
specialists on the selected subjects, speakers in oral sessions have been chosen among the authors of the best
abstracts, according to the rating by three reviewers. The selection of these free communications is very
wide-ranging, thanks to a large number of submissions received for presentation at 16 th ECCMID in Nice.
Major topics of current concern will be discussed. This includes a late-breaker symposium on Sunday evening,
April 2, on avian influenza addressing the Turkish experience and the global threat by this disease.
The ever-increasing number of attendees from year to year attests to the fact that a high degree of scientific
expertise is “behind” ECCMID, making it a major event in the fields of clinical microbiology and infectious
diseases. The Scientific and Organising Committees have worked diligently to make your visit to Nice highly
satisfactory for both scientific and personal reasons and wish you a successful meeting.
Prof. Pierre Dellamonica Prof. Andreas Voss
16 th ECCMID President ECCMID Programme Director
www.escmid.org/eccmid2006
page 9

ESCMID – News from the President
Dear Colleagues and Members of European Society of Clinical Microbiology and Infectious Diseases
I would like to join Professor Pierre Dellamonica and Professor Andreas Voss in welcoming you to
this year’s ECCMID. Judging from the great number of abstracts received it is likely to become one
of the largest ECCMIDs ever.
Clearly ECCMID has now become the major European congress of clinical microbiology and infectious
diseases. We feel that the Programme Committee has managed to gradually improve the scientific
quality with a very broad range of keynote lectures, symposia and free communications. This could
not have been achieved without the large number of high quality abstracts submitted during these
last years.
ECCMID is the most important means for ESCMID to serve its members. However, the Society
also has many other activities which the members can benefit from. Each year we support young
members, especially from Eastern Europe, so that they can attend ECCMID and other activities.
We also support several postgraduate courses in various parts of Europe. Another important
part of our activities is to support and strengthen Clinical Microbiology and Infectious Diseases
as medical specialities in Europe.
Our involvement in infection-related science is mainly through the ESCMID study groups, which
cover a broad range of topics. They offer opportunities for European scientists to co-operate,
communicate and present new findings during ECCMIDs.
During the last years the co-operation between ESCMID and the European Union has increased.
ESCMID has received a grant from the EU, which partly funds EUCAST (European Committee on
Antimicrobial Susceptibility Testing). This has enabled an intensified activity within EUCAST and the
Committee has been able, in a record time, to achieve consensus on susceptibility break-points of
most antibiotics within Europe.
ESCMID has also, together with the European Respiratory Society (ERS), become a partner in GRACE,
a large EU-funded research project on community-acquired lower respiratory tract infections.
ESCMID and ERS will be responsible for the educational activities within GRACE.
Both EUCAST and GRACE are important milestones for ESCMID since they mean that ESCMID is
now recognised as a full partner in EU-sponsored projects. The Society has also been recognised by
the new European Centre for Disease Prevention and Control, ECDC where ESCMID holds a seat on
the Advisory Forum, the scientific council of the agency.
The strength of ESCMID depends on its membership. The more members we get, the stronger we
will become. I hope those of you who are not yet ESCMID members will consider the advantages
of joining us. Membership benefits include registration at a reduced price for all ESCMID events,
including ECCMID, eligibility for travel awards and access to our news service.
For more details on the advantages of being an ESCMID members come and visit us at the ESCMID
booth located on level 1 close to the main entrance.
I wish you the best of possible experiences in Nice during ECCMID.
Prof. S. Ragnar Norrby
ESCMID President
www.escmid.org/eccmid2006
page 11

Important Addresses
Address during 16 th ECCMID 2006 Phone +33 4 93 92 81 07
the Congress Nice Acropolis Fax +33 4 93 92 81 08
1, esplanade Kennedy E-mail info@akm.ch
06302 Nice Cedex 4
France
Congress President Prof. Pierre Dellamonica Phone +33 4 92 035515
CHUN – Hôpital de L’Archet Fax +33 4 93 965454
Maladies Infectieuses E-mail infectiologie@chu-nice.fr
et Tropicales
151, Route St. Antoine de Ginestière
BP 3079
F-06202 Nice Cedex 3
France
Scientific Secretariat 16 th ECCMID 2006 Phone +41 61 686 77 99
c/o ESCMID Executive Office Fax +41 61 686 77 98
P.O. Box E-mail info@escmid.org
CH-4005 Basel
Switzerland
Administrative Secretariat 16 th ECCMID 2006 Phone +41 61 686 77 11
c/o AKM Congress Service Fax +41 61 686 77 88
P.O. Box E-mail info@akm.ch
CH-4005 Basel www.escmid.org/eccmid2006
Switzerland
Accommodation AKM Travel AG Phone +41 61 690 94 11
Messeplatz 10 Fax +41 61 690 94 14
P.O. Box E-mail eccmid@akmtravel.ch
CH-4016 Basel
Switzerland
Local Agency Mediaxa Phone +33 4 97 038597
27, rue Massena Fax +33 4 97 038598
F-06000 Nice E-mail bpuissegur-mediaxa@wanadoo.fr
France
page 12 Final Programme
www.escmid.org/eccmid2006

page 13
Acknowledgements
The Organising Committee expresses its thanks and appreciation to those who are
generously contributing to the success of the 16 th European Congress of Clinical
Microbiology and Infectious Diseases.
Platinum Medal Sponsors Pfizer
Schering-Plough
Gold Medal Sponsors Bayer HealthCare AG
Merck Sharp & Dohme
Sanofi-aventis
Wyeth Pharmaceuticals
Silver Medal Sponsors Astellas
AstraZeneca
Chiron
Gilead Sciences
Janssen-Cilag
NeuTec Pharma
Sponsors BioMérieux
Bio-Rad Laboratories
Roche Diagnostics
Schülke & Mayr
ESCMID and the ECCMID Programme ISID International Society for Infectious Diseases
Committee are proud to acknowledge Emerging viral exotica in Europe (page 48)
the scientific input from the following
organisations in setting up joint symposia: ICHS International Immunocompromised Host Society
Infections in the immunocompromised host (page 48)
EUPHA European Public Health Association
Molecular epidemiology: a tool for public health
(page 65)
ISF International Sepsis Forum
Pathogenesis and therapy of sepsis (page 60)
ICAAC Programme Committee of the Interscience
Conference on Antimicrobial Agents and
Chemotherapy
Emergence of transferable quinolone resistance
(page 53)
ASM American Society for Microbiology
Origin, epidemiology, diagnosis and
management of CA-MRSA (page 65)
FEMS Federation of European Microbiological Societies
Mechanisms of infectious diseases:
new science and novel insights (page 43)
www.escmid.org/eccmid2006
page 13

Committees
Organising Committee
Pierre Dellamonica
Nice, FR
Congress President
S. Ragnar Norrby
Stockholm, SE
ESCMID President
ESCMID Executive Committee
S.R. Norrby, Stockholm, SE
President
H. Aubry-Damon, Maisons Alfort, FR
Professional Affairs Officer – Clinical Microbiology
G. Cornaglia, Verona, IT
President-elect
P. Francioli, Lausanne, CH
Secretary General
J. Garau, Barcelona, ES
Education Officer
Ex officio members
P. Dellamonica, Nice, FR
President 16 th ECCMID
C.E. Nord, Stockholm, SE
Editor CMI Supplements
B. Ruf, Leipzig, DE
President 17 th ECCMID & 25 th ICC
page 14 Final Programme
Peter Schoch
Basel, CH
ESCMID Managing Director
Andreas Voss
Nijmegen, NL
ECCMID Programme Director
E. Nagy, Szeged, HU
Treasurer
R. Read, Sheffield, UK
Professional Affairs Officer -– Infectious Diseases
M. Struelens, Brussels, BE
Past President
J. Vila, Barcelona, ES
Scientific Affairs Officer
A. Voss, Nijmegen, NL
ECCMID Programme Director
P. Schoch, Basel, CH
Managing Director
K. Towner, Nottingham, UK
CMI Editor-in-Chief

National Committee
Committees
C. Chidiac, Lyon
J. C. Desenclos, Saint Maurice
L. Gutmann, Paris
ECCMID Programme Committee
A. Voss, Nijmegen, NL
ECCMID Programme Director
G. Cornaglia, Verona, IT
P. Dellamonica, Nice, FR
B. de Pauw, Nijmegen, NL
J.C. Desenclos, Saint Maurice, FR
R. Fouchier, Rotterdam, NL
P. Francioli, Lausanne, CH
J. Garau, Barcelona, ES
ESCMID Education Committee
J. Garau, Barcelona, ES
ESCMID Education Officer
M. Falagas, Athens, GR
R. Filip, Suceava, RO
I.M. Hoepelman, Utrecht, NL
L.M.V. Peixe, Porto, PT
ESCMID Scientific Advisory Committee
J. Vila, Barcelona, ES
ESCMID Scientific Affairs Officer
T. Pal, Pecs, HU
G.-M. Rossolini, Sienna, IT
J. van Eldere, Leuven, BE
V. Jarlier, Paris
O. Lortholary, Paris
J. P. Stahl, Grenoble
C. Hatz, Basel, CH
M. Herrmann, Homburg, DE
V. Jarlier, Paris, FR
R. Leclerc, Caen, FR
S. R. Norrby, Stockholm, SE
R. Read, Sheffield, UK
B. Ruf, Leipzig, DE
M. Struelens, Brussels, BE
A. van Belkum, Leiden, NL
J. Vila, Barcelona, ES
L. Martinez-Martinez, Santander, ES
G. Schmid, Geneva, CH
A. Schwenk, London, UK
G.M. Scott, London, UK
D. Christman, Strasbourg, FR
M. Gniadkowski, Warsaw, PL
R. Canton, Madrid, ES
M. Bonten, Utrecht, NL
T. J. Evans, Glasgow, UK
C. Cordonnier, Paris, FR
A. Widmer, Basel, CH
I. Nilsson-Ehle, Lund, SE
www.escmid.org/eccmid2006
page 15

Committees
ESCMID Study Groups Chairpersons
Antibiotic Policies I. C. Gyssens, Rotterdam, NL
www.escmid.org/esgap i.gyssens@erasmusmc.nl
Antimicrobial Resistance in Anaerobic Bacteria C.E. Nord, Stockholm, SE
www.escmid.org/esgarab carl.erik.nord@labmed.ki.se
Antimicrobial Resistance Surveillance F. Baquero, Madrid, ES
www.escmid.org/esgars fbaquero.hrc@salud.madrid.org
Clostridium difficile I. R. Poxton, Edinburgh, UK
www.escmid.org/esgcd i.r.poxton@ed.ac.uk
Epidemiological Markers P. Tassios, Athens, GR
www.escmid.org/esgem ptasios@med.uoa.gr
Primary Care Topics T. Verheij, Utrecht, NL
www.escmid.org/esprit t.j.m.verheij@med.uu.nl
Helicobacter L. Percival Andersen, Copenhagen, DK
www.escmid.org/ehsg lpa@rh.dk
Molecular Diagnostics M. Ieven, Edegem, BE
www.escmid.org/esgmd greet.ieven@uza.uia.ac.be
Nosocomial Infections S. Ünal, Ankara, TR
www.escmid.org/esgni sunal@hacettepe.edu.tr
Coxiella, Anaplasma, Rickettsia and Bartonella P. Brouqui, Marseille, FR
www.escmid.org/escar philippe.brouqui@medecine.univ-mrs.fr
Fungal Infection D. Denning, Manchester, UK
www.escmid.org/efisg ddenning@man.ac.uk
Toxoplasmosis B. Evengård, Stockholm, SE
www.escmid.org/esgt birgitta.evengard@med.uu.nl
Biofilms N. Høiby, Copenhagen, DK
www.escmid.org/esgb hoiby@inet.uni2.dk
European Committee on G. Kahlmeter, Växjö, SE
Antimicrobial Susceptibility gunnar.kahlmeter@ltkronoberg.se
Testing (EUCAST)
ESCMID European Council – Representatives of Affiliated Societies
Österreichische Gesellschaft für Infektionskrankheiten H. Pichler, Wien, AS
Belgian Society of Infectious Diseases and J. van Eldere, Leuven, BE
Clinical Microbiology
Croatian Society of Infectious Diseases T. Jeren, Zagreb, HR
Croatian Society for Medical Microbiology and J. Subic-Skrlin, Zagreb, HR
Parasitology-Croatian Medical Association
Czech Society for Epidemiology and Microbiology J. Jelinkova, Prague, CZ
Danish Society for Clinical Microbiology J. Moller, Aarhus, DK
Finnish Society for Infectious Disease Physicians J. Lumio, Tampere, FI
Finnish Society for the Study of Infectious Diseases T. Vuorinen, Turku, FI
Société de Pathologie Infectieuse de Langue Francaise J.-P. Stahl, Grenoble, FR
page 16 Final Programme

Committees
Society Française de Microbiologie H. Monteuil, Strasbourg, FR
Deutsche Gesellschaft für Hygiene u. Mikrobiologie M. Frosch, Würzburg, DE
Hungarian Society of Infectiologists L. Rokuskz, Budapest, HU
Irish Society of Clinical Microbiology M. Cormican, Galway, IE
Israeli Society for Infectious Diseases I. Shalit, Petach-Tikvah, IL
Associazione Microbiologi Clinici Italiani G. Fortina, Novara, IT
Italian Society of Virology G. Palù, Padova, IT
Lithuanian Society for Infectious Diseases A. Ambrozaitis, Vilnius, LV
Dutch Society for Medical Microbiology G. J. Ruijs, Zwolle, NL
Netherlands Society for Medical Mycology J. F. Meis, Nijmegen, NL
Norwegian Society of Medical Microbioloy F. Müller, Oslo, NO
Polish Society of Epidemiology and Infectious Diseases J. Cianciara, Warsaw, PO
Polish Society of Microbiology W. Hryniewics, Warsaw, PO
Interregional Association for Clinical Microbiology R. Kozlov, Smolensk, RU
and Antimicrobial Chemotherapy
Slovak Society for Clinical Microbiology D. Kotulova, Bratislava, SR
of the Slovak Medical Association
Slovenian Association of Clinical Microbiology I. Muzlovic, Ljubljana, SI
and Hospital Infections of the SMC
Swedish Society of Infectious Diseases A. Ortqvist, Stockholm, SE
Swedish Society of Medical Microbiology A. Schwan, Uppsala, SE
Swiss Society for Infectious Diseases D. Nadal, Zürich, CH
Infectious Diseases Society of Turkey M. Ceyhan, Ankara, TR
Turkish Society of Clinical Microbiology and H. Eraksoy, Istanbul, TR
Infectious Diseases
Turkish Society for Microbiology Ö. Ang, Istanbul, TR
Association of Medical Microbiologists A. Howard, Cardiff, UK
Scottish Microbiology Association F. MacKenzie, Aberdeen, UK
British Society for Antimicrobial Chemotherapy A. Macgowan, Birmingham, UK
Paul-Ehrlich-Gesellschaft für Chemotherapie P. Kern, Ulm, DE
Scandinavian Society of Antimicrobial Chemotherapy O. Öktedalen, Oslo, NO
www.escmid.org/eccmid2006
page 17

ESCMID Awards 2006
Award for Excellence in Clinical Microbiology
and Infectious Diseases
Roland Leclercq
born 1949 in Paris, France;
MD, PhD, Professor of
Microbiology, Head of the
Department of Microbiology
and of a research group at
the University Hospital of
Caen, France, in recognition
of his outstanding contributions to our
understanding of antimicrobial resistance
mechanisms, especially in Gram-positive
organisms, their epidemiology and clinical
implications. He reported and elucidated
resistance mechanisms to lincosamides,
glycopeptides, aminoglycosides, macrolides
and streptogramins, and demonstrated that
multiresistance in Staphylococcus aureus
from cystic fibrosis patients was due to
hypermutable strains. In addition to being a
successful researcher Roland Leclercq is a
restless and dedicated teacher.
Roland Leclercq will be presented the Excellence
Award by Prof. Ragnar Norrby, ESCMID
President, on April 2, 2006, on which occasion
he will give his award lecture on Resistance to
antimicrobials: from emergence to clinical
relevance (pag 38).
Research Interests
Roland Leclercq’s research focus is on antimicrobial
resistance in Gram-positive organisms.
In particular, he reported the major types of
resistance to glycopeptides in enterococci and
a variety of new mechanisms of resistance to
macrolides and related antibiotics in streptococci
and staphylococci. More recently,
he studied the adaptation of Staphylococcus
aureus to its host via hypermutability and
its influence on antibiotic resistance.
He also participated in the development of
new antimicrobials and anticipated development
of resistance by describing mechanisms
of resistance to some of these drugs in
laboratory-generated mutants. Beyond the
basic aspects of mechanisms of resistance
to antimicrobials, his studies extend to
the clinical relevance of the findings and
epidemiological aspects.
page 18 Final Programme
Young Investigator Award for Research in
Clinical Microbiology and Infectious Diseases
Gilbert Daniel Greub
born 1967 in Neuchatel,
Switzerland; MD, PhD,
researcher at the Institute
of Microbiology, University
of Lausanne, Switzerland,
in recognition of his
outstanding research
accomplishments in the field of Chlamydia-like
organisms. He described for the first time
the developmental cycle of Parachlamydia,
studied the genetic, evolutionary history,
and interactions of this obligate intracellular
organism with amoebae and macrophages,
and demonstrated a role of Parachlamydia
in pneumonia.
Gilbert Greub will be presented his award du -
ring the ESCMID Excellence Award session on
April 2, 2006 (page 38); on April 3, he will give
a talk during the ESCMID Young Investigator
Award session on Biology and Pathogenicity
of Chlamydia-like Organisms (page 52).
Research Interests
Discovering new agents of pneumonia is the
main objective of Gilbert Greub’s research
group. To reach this goal, he uses amoebal
co-culture to selectively grow amoebaeresisting
bacteria, which allows investigation
of their pathogenicity. Gilbert Greub provided
serological and molecular evidence suggesting
a role of Parachlamydia in pneumonia.
He showed that this Chlamydia-like organism
resists to human macrophages. Furthermore,
he demonstrated that Parachlamydia remains
unrecognised by macrophages and is able to
modulate the biogenesis of phagosomes.
He also showed the existence of the crescent
body, an infectious developmental stage only
present in Parachlamydiaceae. Recently, he
discovered a F-like tra operon in a genomic
island on the chromosome of a Parachlamydiarelated
bacteria. This is the first evidence of a
putative conjugative DNA transfer among
obligate intracellular bacteria. Further ongoing
research is directed at elucidating the biology
and pathogenicity of other amoebae-resisting
chlamydiae such as Waddlia and Simkania.

ESCMID Awards 2006
Young Investigator Award for Research in
Clinical Microbiology and Infectious Diseases
(continued)
Stephan Jürgen Harbarth
born 1967 in Immenstadt,
Germany; MD, MS, Senior
Research Associate,
hospital epidemiologist
and attending physician
at the University Hospital,
Geneva, Switzerland, in
recognition of his outstanding contributions
in the field of infectious disease epidemiology,
focusing on prevention and control of nosocomial
infections and antimicrobial resistance in
hospitals. In addition, he pioneered studies on
the cultural and regulatory factors that influence
antimicrobial use in different countries.
Stephan Harbarth will be presented his award
during the ESCMID Excellence Award session
on April 2, 2006 (page 38); on April 3, he will
give a talk during the ESCMID Young
Investigator Award session on MRSA – from
Innovative Control Strategies to New
Challenges (page 52).
Research Interests
Stephan Harbarth’s research interest is
focused on the epidemiology and prevention
of antibiotic-resistant, healthcare-associated
infections. In particular, his studies on the
impact and control of nosocomial MRSA
transmission have increased our understanding
of the epidemiology of MRSA and improved
our ability to combat this microorganism.
His other important contributions to the field
of antibiotic resistance, which had an impact
on policy making, are his research on the
adverse effects of prolonged antibiotic prophylaxis
after surgery and on the ecologic
bias associated with group-level data analyses
of antibiotic-use-versus-resistance relationships
as well as several well conducted intervention
studies. For instance, in a recently
published article, Stephan Harbarth investigated
the clinical usefulness of a rapid on-admission
screening test for MRSA. A substantial
decrease in MRSA infections was seen in a
medical ICU after increasing compliance with
on-admission screening and implementing
a strategy that linked the rapid test to
pre-emptive isolation of MRSA patients.
Complementary research interests include
the molecular epidemiology of emerging
pathogens such as community-acquired
MRSA, the pharmaco-epidemiology of
antibiotic use (including international analyses
of macro-level determinants of antibiotic
overuse), and improved and rapid diagnosis
of severe infections in critically ill patients.
The Young Investigator Awards are
sponsored by Pfizer
ESCMID and bioMérieux Award for Advances
in Clinical Microbiology
Maja Rupnik
born 1967 in Maribor,
Slovenia; Assistant
Professor at Medical Faculty,
University of Maribor and
at the Institute of Public
Health, Maribor, Slovenia,
in recognition of her
outstanding contributions to our understanding
of the pathogenicity, epidemiology and
genetics of Clostridium difficile.
The toxinotyping scheme, which she developed
for differentiating strains with variant toxin
genes, is used throughout the world.
Maja Rupnik will be presented her award by
Prof Ragnar Norrby, ESCMID President, and
Dr Jean-Pierre Marcel, Medical Director of
bioMérieux, on April 2, during the ESCMID
Excellence Award session (page 38).
Research Interests
The main research focus of the awardee are
two large toxins (toxin A, TcdA and toxin B,
TcdB), both considered as the major virulence
factors of Clostridium difficile. Early research
on variability of the toxin coding region
resulted in establishment of toxinotyping –
a PCR-based method for analysis of entire
PaLoc region. Later, her research focused on
epidemiology of variant C. difficile strains,
in particular on TcdA-negative, TcdB-positive
strains (A - B + strains), and on strains that
produce an additional toxin, binary toxin CDT.
Another aspect of her research interests is the
biology of C. difficile toxins. Here she studied
the proteolytic processing of TcdB and the
crystal structure of receptor-binding regions
of TcdA. She promoted the discussion on the
unification of the nomenclature of C. difficile
toxins. The revised nomenclature is now supported
by all major groups active in the field.
www.escmid.org/eccmid2006
page 19

ESCMID Awards 2006
ESCMID Research Fellowships
The ESCMID Research Fellowships 2006
will be presented during the Assembly
of Members on April 3, at 17:45 in the
Acropolis Congress Centre in Nice,
Room Hermes
Sofia K. Kasiakou
born 1975 in Athens, Greece;
MD, Research Fellow at the
Alfa Institute of Biomedical
Sciences, Marousi, Greece
and Resident in Internal
Medicine at the Sotira
General Hospital, Athens,
Greece
Project
A multicentre, randomised, double-blind,
controlled trial of the effectiveness and safety
of intravenous colistin with or without intravenous
meropenem in ICU patients for
infections other than pneumonia due to
colistin-only-sensitive bacteria
Research Interests
The focus of Sofia Kasiakou’s research is on
projects related to the effectiveness and safety
of intravenous and aerosolised polymyxins for
the treatment of patients with multidrugresistant
Gram-negative bacterial infections.
Polymyxin B and polymyxin E (colistin),
the two polymyxins used in clinical practice,
are old antibiotics that were removed from
clinical use for many decades because of
toxicity concerns. However, the emergence
of highly-resistant pathogens brought them
back. In addition, she is interested in the
investigation of alternative modes of intravenous
administration of antibiotics,
specifically the continuous intravenous
infusion of antibiotics with time-dependent
antibacterial activity, in order to optimise
their pharmacokinetic and pharmacodynamic
properties, and thus improve clinical
outcomes.
page 20 Final Programme
Rocus R. Klont
born 1970 in Oldenzaal,
The Netherlands; MD,
Department of Medical
Microbiology, Radboud
University Nijmegen
Medical Centre, Nijmegen,
The Netherlands
Project
Development of a serological system for the
diagnosis of invasive zygomycoses
Research Interests
The main research interest of Rocus Klont
is the development of a non-invasive
diagnostic method for invasive zygomycoses.
The incidence of this disease is increasing.
These moulds cause devastating infections
in the immunocompromised host with high
mortality and morbidity. Aggressive surgery
and treatment with antifungal agents are
required to improve the patients’ outcome.
Conventional diagnostic methods such as
microscopy and culture are not sensitive
enough. Experienced technicians can
indicate if the morphology of mycelia found
in tissue specimens is consistent with
zygomycoses, but identification to genus or
species level cannot be achieved. Recovery
of zygomycetes from tissue by culture can
be very difficult even in those cases where
hyphae are visible under the microscope.
The development of a non-invasive
diagnostic technique such as the detection
of circulating zygomycete antigens may
result in earlier diagnosis of the disease
and improve clinical outcome.

ESCMID Awards 2006
ESCMID / FEMS Research Fellowship
ESCMID and FEMS offer each year two joint
fellowships to foster outstanding research in
microbiology by young Europeans. We are
delighted to announce that the 2006 ESCMID /
FEMS fellowship goes to Surbi Malhotra-
Kumar from Antwerp, The Netherlands.
Surbi Malhotra-Kumar
born 1972 in Sirsa, India; MD,
PhD, post-doctoral fellow,
Belgian Reference Centre
for Group A Streptococcus,
Department of Medical
Microbiology, University of
Antwerp, Belgium
Project
Analysis of novel genetic elements and
resistance mechanisms, fitness costs and
compensatory adaptations in macrolide-,
ketolide-, and fluoroquinolone-resistant
Group A Streptococcus
Research Interests
The research of Surbhi Malhotra-Kumar is
focused on the molecular epidemiology and
genetics of resistance to the macrolide-,
ketolide-, and fluoroquinolone group of
antimicrobials in oral streptococci, primarily
Group A Streptococcus (GAS). Using the
oro-pharyngeal flora in healthy individuals
as a model, Surbhi Malhotra-Kumar has also
analysed differences in selection pressure of
various macrolides and the resulting impact
on resistance. Continuing as a post-doctoral
fellow in the laboratory of Herman Goossens,
her current work includes: further analysis
of novel and emerging genetic elements
harboring macrolide resistance gene mutants,
elucidating the basis of ketolide resistance
in GAS, and the fitness costs of antibiotic
resistance gene carriage.
ISF Sepsis Award
Evangelos J. Giamarellos-
Bourboulis,
born 1971 in Athens, Greece;
MD, Assistent Professor of
Medicine at the Department
of Internal Medicine, Attikon
University Hospital, Athens,
Greece, in recognition of his
excellent abstract submitted for presentation at
the 16 th ECCMID.
Evangelos Giamarellos-Bourboulis will give a
short oral presentation on Blood monocytes
as a site of production of sTREM-1 in sepsis
during the joint ESCMID/ISF symposium
on Pathogenesis and Therapy of Sepsis
(page 60).
Abstract:
The pathophysiological role of blood
monocytes for the release of soluble triggering
receptor expressed on myeloid cells – 1
(sTREM-1) in patients with sepsis
E.J. Giamarellos-Bourboulis, C. Routsi,
D. Plachouras, I. Andrianakis, M. Raftogiannis,
C. Roussos, H. Giamarellou (Athens, GR)
Objective: sTREM-1 is the soluble counterpart
of the surface receptor TREM-1 that is highly
expressed on neutrophils and mature monocytes
after bacterial and fungal triggering. The
exact site of production of sTREM-1 remains
unclear. The present study aimed at investigating
the role of monocytes in the release
of sTREM-1 in patients with sepsis and its
correlation with monocyte apoptosis.
Methods: Peripheral blood monocytes
were isolated from 90 patients with septic
syndrome due to ventilator-associated pneumonia
on seven consecutive days after
presentation of sepsis, by density gradient
centrifugation of whole blood, incubation
in RPMI and removal of non-adherent cells.
Apoptotic rate on the first day was measured
by flow cytometry after incubation with
FITC-conjugated monoclonal antibodies to
Annexin-V and Propidium Iodide. Monocytes
were cultured in the absence and presence
of LPS and concentrations of sTREM-1 in
supernatants were estimated by an enzyme
immunoassay.
www.escmid.org/eccmid2006
page 21

ESCMID Awards 2006
ISF Sepsis Award (continued)
Results: Concentrations of sTREM-1 in
supernatants of isolated monocytes were
higher on the first day compared to the next
six days (a: p

Free Registration
ESCMID Awards 2006
Acosta Herrera, Belsy (Havana, CU)
Alecu, Florian Silviu (Bucharest, RO)
Allen, Vanessa (Toronto, CA)
Ambrasiené, Daiva (Kaunas, LT)
Ansari, Nasim Akhtar (New Delhi, IN)
Artemenko, Anatoly (Odessa, UA)
Balabanova, Yanina (London, UK)
Banasova, Katarina (Bratislava, SK)
Bartels, Mette Damkjaer (Hvidovre, DK)
Bednarova, Jana (Brno, CZ)
Berglund, Carolina (Örebro, SE)
Bourgeois-Nicolaos, Nadège (Paris, FR)
Bühling, Anke (Magdeburg, DE)
Castanheira, Mariana (Sao Paulo, BR)
Chanana, Vishal (Chandigarh, IN)
Christova-Tzvetanova, Iva Stefanova (Sofia, BG)
Comina, Elodie (Villeurbanne, FR)
Corrente, Marialaura (Valenzano, IT)
Dumitru, Irina (Constanta, RO)
Eisner, Alexandra (Graz, AT)
Ensor, Vicki (Birmingham, UK)
Faria, Nuno Alexandre Gomes (Oeiras, PT)
Foster, Niki Francis (Nedlands, AU)
Giotis, Efstathios (Belfast, IE)
Golkocheva, Elica (Sofia, BG)
Gonzalez-Zorn, Bruno (Madrid, ES)
Gosiewski, Tomasz (Cracow, PL)
Groussaud, Pauline (New Haw, Addlestone, UK)
Gupta, Vineet (New Delhi, IN)
Habibi, Effat (Teheran, IR)
Ikonomidis, Alexandros (Volos, GR)
Ilhan-Sungur, Esra (Istanbul, TR)
Jafari, Fereshteh (Tehran, IR)
Jashiashvili, Nino (Tbilisi, GE)
Jenkins, Claire (London, UK)
Kachanka, Elena (Minsk, BY)
Kardos, Gabor (Debrecen, HU)
Kocak Tufan, Zelina (Ankara, TR)
Kratzer, Christina (Vienna, AT)
Lochmanova, Jana (Brno, CU)
Machado, Ines (Gaia, PT)
Mahmutovic, Sabina (Sarajevo, BA)
Manolescu, Loredana (Bucharest, RO)
Markovska, Rumyana (Sofia, BG)
Maszewska, Agnieszka (Lodz, PL)
Muratov, Eugene (Odessa, UA)
Novais de Oliveira e Silva, Carla Alexandra
(Sra. Da Hora, Matosinhos, PT)
Orsolya, Dobay (Budapest, HU)
Papadopo ulos, Chelsea (Balcatta, AU)
Pinidiyapathirage, Mohitha Janani (Colombo, LK)
Popa, Mihaela (Bucharest, RO)
Popov, Dmitry A. (Moscow, RU)
Pubaibool, Jakrapun (Bangkok, TH)
Pujate, Elina (Jurmala, LT)
Raka, Lul (Kacanik, CS)
Ramazanzadeh, Rashid (Teheran, IR)
Rocha, Joana (Porto, PT)
Ruiz Blazquez, Joaquim (Badia del Valles, ES)
Schaffer, Kirsten (Dublin, IE)
Shahid, Mohammad (Aligarh, IN)
Torzewska, Agnieszka (Lodz, PL)
Türetgen, Irfan (Istanbul, TR)
Türk, Silver (Tartu, EE)
Uckay, Ilker Hasan (Geneva, CH)
Weiner, Marcin (Pulawy, PL)
Zidovec Lepej, Snjezana (Zagreb, HR)
www.escmid.org/eccmid2006
page 23

Introduction to the Scientific Programme
Educational Workshops
Once again at the beginning of ECCMID on
Saturday, April 1, 2006, 13.30–15.30/17.30,
several educational workshops have been
organised in cooperation with ESCMID Study
Groups. Please note that educational workshops
are subject to a separate registration
fee and that places are limited.
Meet-the-Expert Sessions
Sunday through to Tuesday the day will start
at 07.15 with 6 Meet-the-Expert Sessions
given by experts in their field. These sessions
permit the attendees to participate actively.
After a short presentation the expert will
open the session for discussion.
Coffee will be offered.
Keynote and ESCMID Award Lectures
At 11.00 each morning, lectures of 60 min will
be given by opinion leaders in their fields as
well as by the winners of the ESCMID Award
for Excellence 2006 and the two ESCMID
Young Investigator Awards.
Symposia
From 08.30–10.30, from 14.00–15.00 and from
15.30–17.30 each day, parallel symposia will
convene renowned speakers from Europe and
other continents who will cover a wide range
of recent developments in their field.
A number of symposia have been organised
in co-operation with ESCMID study groups
and some are joint sessions with other
societies or organisations.
Symposia arranged by the industry have been
organised in close co-operation with the
ECCMID Programme Committee. They are
an integral part of the scientific programme
(Integrated Symposia) or presented as a
Satellite Symposium on Saturday afternoon.
Oral Sessions
During the same time slots as the above
mentioned symposia, you will also find
sessions composed of abstracts selected for
oral presentation, to be recognised by the prefix
«O» before the programme numbers.
Poster Sessions
Most of the accepted abstracts are scheduled
for poster presentation from Sunday to
Tuesday. The selection was based on a blind
review by at least 3 experts in each field.
The posters will be displayed on level 3.
page 24 Final Programme
The poster exhibition is open to all participants
from 08.00 to 18.00. Please note that
posters are replaced daily. Poster authors
must be present at their posters for
discussion between 12.00 and 13.00 or
13.00 and 14.00, depending on the schedule
of their session (see page 25 for details).
Guided Poster Walks
Once again at ECCMID, guided poster walks
on selected topics will take place over lunch
time. For further details please see pages 40,
52, 53 and 64.
Publication Only
Due to the overwhelming response to the
call for abstracts, ESCMID was unable to
accommodate all worthy abstracts for
presentation during the meeting. Abstracts
in this category are not included in the
Final Programme but will be published on
the CD-ROM and the congress website.
CD-ROM
All accepted abstracts have been published as
an electronic supplement to Clinical Microbiology
and Infection (CMI), the official journal of
the European Society of Clinical Microbiology
and Infectious Diseases. For the first time in
2006, accepted abstracts are made available
to participants on CD-ROM only. No printed
abstract book will be distributed. In addition,
the CD will also include most of the full
posters (sponsored by Schering-Plough).
On-line Meeting Planner on the 16th ECCMID
Website
The final scientific programme including all
accepted abstracts is available at the congress
website: www.escmid.org/eccmid2006.
Go to link «scientific programme» to compose
your personalised programme of lectures.
You can use the search facility to find
keywords, speakers and chairpersons.
The internet corner is located on level 2 in the
industrial exhibition.
For your clarification, the following prefixes have been
used throughout the programme:
E=Meet-the-Expert Session K=Keynote Lecture
S=Symposium O=Oral Session P=Poster Session

Instructions for Authors
Audiovisual Equipment /
Speakers Service Centre (SSC)
The Speakers Service Centre (SSC) is centrally
located on Level 2 of the Nice Acropolis Congress
Centre (please refer to the overview on page 7).
All lecture rooms will be equipped with a PC
and a data projector for PowerPoint presentations
only. Presentations must be handed in
via floppy disk, CD-ROM, zip drive, memory
stick or via your own laptop before your
lecture.
It is essential for the smooth running of the
congress that all speakers hand in their Power
Point presen tations at least one hour before
the beginning of the session. Enough time
must be allowed to check the presentation
carefully and for the staff to enter the data into
the system. Speakers will have the opportunity
to check their presentations on PC’s available
in the SSC.
Poster Sessions
Publication
All accepted abstracts will be published as an
electronic supplement to Clinical Microbiology
and Infection (CMI), the official journal of
ESCMID. This year, accepted abstracts will be
made available to the participants for the first
time on CD-ROM only. No abstract book will
be distributed. In addition, the CD will also
include most of the full posters!
Please take advantage of the on-line meeting
planner facility available on the computers
in the @-corner (level 2).
Date of Poster Session Poster No Poster Poster Poster
Mounting Presentation Removal
Sunday, April 2, 2006 (I) P441–P678 08.00–09.00 12.00–13.00 17.00–18.00
Sunday, April 2, 2006 (II) P679–P940 08.00–09.00 13.00–14.00 17.00–18.00
Monday, April 3, 2006 (III) P941–P1197 08.00–09.00 12.00–13.00 17.00–18.00
Monday, April 3, 2006 (IV) P1198–P1459 08.00–09.00 13.00–14.00 17.00–18.00
Tuesday, April 4, 2006 (V) P1460–P1884 08.00–09.00 12.00–13.00 15.00–16.00
The poster measurement is: width: 147 cm; height: 97 cm. Posters will be displayed for one full day. Authors
are requested to be present at their poster during the whole time of the poster presentation and to mount and
remove their posters at the above-mentioned times.
Posters that have not been removed by the author at 18.00 are removed and disposed of by the congress staff.
Poster Walks
Once again at ECCMID, guided poster walks
on selected topics will take place over lunch
time. During each of the above poster sessions
certain abstracts will be presented in a
moderated poster walk. Chairpersons will
select quality posters on the day and discuss
these in more detail. For further details please
see pages 40, 52 and 64.
www.escmid.org/eccmid2006
page 25

Saturday, April 1, 2006
Calliope EUCAST National Committees and
10:30–12:30 General Committee Meeting
Meeting
Room 2
12:30–13:30
ESCMID Study Group and other Business Meetings
Publications Advisory Board
Press Centre Press Conference
12:30–13:30
Calliope EUCAST Business Meeting
13:30–15:30
Erato ESCMID Study Group on Coxiella, Anaplasma,
13:30–14:30 Rickettsia and Bartonella (ESCAR)
Erato ESCMID Fungal Infection Study Group (EFISG)
14:30–15:30
Hotel Sofitel ESCMID European Council
15:00–17:00
Meeting
Room 1
15:30–16:30
Meeting
Room 2
15:30–16:30
ESCMID Study Group on Primary Care Topics
(ESPRIT)
ESCMID Study Group on Molecular
Diagnostics (ESGMD)
Athena ESCMID Study Group on Epidemiological
16.45–17.45 Markers (ESGEM)
Méditerranée 1 ESCMID Study Group on Antimicrobial
16:45–17:45 Resistance in Anaerobic Bacteria (ESGARAB)
Méditerranée 3 ESCMID Study Group on Toxoplasmosis
16:45–17:45 (ESGT)
Meeting
Room 1
16:45–17:45
Meeting
Room 2
16:45–17:45
ESCMID Study Group on Clostridium difficile
(ESGCD)
ESCMID Study Group for Antimicrobial
Resistance Surveillance (ESGARS)
Méditerranée 2 ESCMID Study Group on Nosocomial
17:15–17:45 Infections (ESGNI)
Iris ESCMID Study Group on Biofilms (ESGB)
17:15–17:45
page 26 Final Programme
Clio ESCMID Study Group on Antibiotic Policies
17:15–17:45 (ESGAP)
Calliope European Helicobacter Study Group (EHSG)
17:15–17:45
Meeting
Room 3
11:00–15:00
Meeting
Room 3
15:00–17:30
Meeting
Room 1
15:15–16:15
Meeting
Room 1
Sunday, April 2, 2006
CMI Editorial Meeting
ESCMID Education Committee
IFAR Business Meeting
Monday, April 3, 2006
ESCMID Scientific Affairs Meeting
11:00–14:00 Scientific Advisory Committee
12:00–14:00 Study Group Chairs
Erato ECCMID Sponsors Meeting
12:15–13:45
Hermes ESCMID Assembly of Members
17:45–19:00

Scientific Programme Saturday, April 1, 2006
Educational Workshops *
Méditerranée 3 Current control measures for Toxoplasma
W1 13:30– infection in pregnant women and newborn
15:30 children
Convenor: Eskild Petersen (Aarhus, DK)
Faculty:
Eskild Petersen (Aarhus, DK)
Rodolphe Thiébaut (Bordeaux, FR)
Ruth Gilbert (London, UK)
Topics:
Efficacy of pre- and postnatal treatment
The SYROCOT study:
a meta-analysis of 2000 Toxoplasma infected
pregnant women and their children
The size of the problem in Europe and how do
we control Toxoplasma infections in the future?
Is there a role for Toxoplasma-free food?
ESCMID Study Group on Toxoplasmosis (ESGT)
Athena Practical and theoretical aspects of sequence-
W2 13:30– based typing: the paradigms of Staphylococcus
15:30 aureus and Streptococcus pyogenes
Convenor: Alexander Friedrich (Munster, DE)
Faculty:
Alexander Friedrich (Munster, DE)
Wofgang Witte (Wernigerode, DE)
Shona Neal (London, UK)
Alexander Mellmann (Munster, DE)
Topics:
spa typing of S. aureus
stability of DNA repeats
nucleotide differences occurring within repeats –
and how these affect interpretation of types
SCCmec typing of MRSA
emm typing of S. pyogenes
DNA sequence chromatogram editing
nucleotide differences vs. amino-acid differences
definition of identical vs. non-identical isolates
ESCMID Study Group on Epidemiological
Markers (ESGEM)
* All Educational Workshops are subject to separate registration.
Méditerranée 2 Management of nosocomial infections –
W3 13:30– learning from clinical cases
15:30 Convenor: Christian Ruef (Zurich, CH)
Faculty:
Marc Bonten (Utrecht, NL)
Christian Ruef (Zurich, CH)
Andrej Trampuz (Basel, CH)
Topics:
Infections associated with intravascular devices
Surgical site infections after implant surgery
Ventilator-associated pneumonia
ESCMID Study Group on Nosocomial
Infections (ESGNI)
Méditerranée 1 Quality control and standardisation in
W4 13:30– molecular diagnostics
15:30 Convenor: Margareta Ieven (Antwerp, BE)
Faculty:
Hubert G.M. Niesters (Rotterdam, NL)
Paul Wallace (Glasgow, UK)
Anton M. van Loon (Utrecht, NL)
Topics:
International standards: the use and utility of
standardisation
QC within the clinical molecular microbiology
laboratory: controls, compliance & traceability
Improving molecular diagnostics through
international EQAS: a review of progress
over the last decade
Alternative approaches to QC and improving
molecular diagnostics in the routine clinical
diagnostic laboratory
ESCMID Study Group on Molecular Diagnostics
(ESGMD) and QCMD
www.escmid.org/eccmid2006 page 27

Instant protection
against waterborne
microorganisms
Pall-Aquasafe
Water Filters
● New 14 day protection
for shower and tap
● Safeguarding patients
in hospital and the home
● Cost effective solution
PLEASE JOIN US
AT STAND 213
TO LEARN MORE
Quick connection • Quick protection
Filtration. Separation. Solution. SM
Walton Road
Portsmouth PO6 1TD
England
www.pall.com/healthcarewater
+44 (0)23 9230 3452 tel
+44 (0)23 9230 3324 fax
Biosvc@Pall.com e-mail
, Pall and Pall-Aquasafe are trade marks of Pall Corporation.

Scientific Programme Saturday, April 1, 2006
Iris Antibiotic resistance of microbial biofilms
W5 13:30–
15:30 Convenor: Niels Høiby (Copenhagen, DK)
Faculty:
Peter Gilbert (Manchester, UK)
Michael Givskov (Copenhagen, DK)
Christine Imbert (Poitiers, FR)
Topics:
Molecular biological methods to study bacterial
biofilms in flow cells
Interaction of conventional and biofilm-related
resistance mechanisms in bacteria
Physiology aspects on resistance to antibiotics
of bacterial biofilms
Quorum sensing inhibitors and bacterial
biofilms
Activity of new antimicrobials on fungal biofilms
ESCMID Study Group on Biofilms (ESGB)
Hermes Pharmacokinetics and pharmacodynamics of
W6 13:30– anti-infective agents
17:30 Convenor: Johan W. Mouton (Nijmegen, NL)
Faculty:
William A. Craig (Madison, US)
Hartmut Derendorf (Gainesville, US)
Ursula Theuretzbacher (Vienna, AT)
Otto Cars (Uppsala, SE)
Inga Odenholt (Malmö, SE)
Paul M. Tulkens (Brussels, BE)
Topics:
Introduction to PK/PD
PK/PD indices
Protein binding/tissue distribution
In vitro models
Animal models
PK/PD and resistance
Clinical applications of PK/PD
Arranged by the International Society of
Anti-infective Pharmacology (ISAP) and ESCMID
Meeting
Room 3
European surveillance of nosocomial
infections, antimicrobial resistance and use
W7 13:30– in Intensive Care Units
17:30 Convenor: Jean Carlet (Paris, FR)
Faculty:
Barry Cookson (London, UK)
Hakan Hanberger (Linköping, SE)
Patricia Muñoz (Madrid, ES)
Mercedes Palomar (Barcelona, ES)
Carl Suetens (Brussels, BE)
Peet Tull (Stockholm, SE)
Topics:
Surveillance of ICU-acquired infections in
Europe: overview of methodology, tools and
results of the HELICS-ICU surveillance network
How and when to use typing to support
infection control practices in the ICU
Unit-based surveillance of AMR and antibiotic
use in the ICU
HELICS case definition of ICU-acquired
pneumonia I: diagnosis in the ICU (invasive
diagnostic procedures vs. ETA)
HELICS case definition of ICU-acquired
pneumonia II: microbiology (quantitative
culture of respiratory samples – invasive BAL,
PB and non-invasive ETA)
ECDC response to and action plan for the
Clostridium difficile ribotype 027 epidemic in
Europe
Arranged by IPSE (Improving Patient Safety in
Europe) WP4 (HELICS) and WP5 in collaboration
with ESGNI and ESGARS
www.escmid.org/eccmid2006 page 29

While attending the 16 th European Congress of Clinical Microbiology and Infectious
Diseases, you are cordially invited to attend a satellite symposium entitled:
THE MANAGEMENT OF NEUTROPENIC PATIENTS WITH
FEVER UNDERGOING CHEMOTHERAPY FOR THE
TREATMENT OF HAEMATOLOGICAL MALIGNANCIES —
YESTERDAY, TODAY AND TOMORROW
NICE,FRANCE
NICE ACROPOLIS
ROOM: CLIO
SATURDAY, APRIL 1, 2006
13:30 – 15:30
To register for this particular symposium,
please visit us online at:
www.symposia-registration.com
CO-CHAIRPERSONS
Dr. Axel Glasmacher
Asst. Professor of Medicine
University of Bonn
Bonn, Germany
Dr. Jean-Pierre Marie
Head, Department of Haematology-Medical Oncology
Hotel-Dieu Hospital
Paris
Cedex France
FACULTY
Prof. Robin Williamson
Dean, The Royal Society of Medicine
London, England
Dr. Murat Akova
Professor of Medicine
Hacettepe University School of Medicine
Ankara, Turkey
Dr. David Weber
Professor of Medicine -
Pediatrics and Epidemiology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, USA
SYMPOSIUM AGENDA
Greeting
Prof. Robin Williamson (Royal Society of
Medicine)
Introductions & Program Overview
Dr. Jean-Pierre Marie (Co-Chair)
Review of Resistance Patterns Over Time
with an Emphasis on Problem Pathogens
Dr. Murat Akova
An Evidence Based Review of the Available
Antibiotic Treatment Options and a
Recommendation for Treatment Guidelines
Dr. Axel Glasmacher (Co-Chair)
Collateral Damage and What the Future
Might Hold—The Need to Balance Prudent
Antibiotic Utilization and Stewardship with
Effective Patient Management
Dr. David Weber
Q&A
Dr. Jean-Pierre Marie (Co-Chair & Moderator)
Sponsored by The Royal Society of Medicine
by an unrestricted educational grant from Wyeth Pharmaceuticals.

Satellite Symposia
Scientific Programme Saturday, April 1, 2006
Clio The management of neutropenic patients
13:30– with fever undergoing chemotherapy for the
15:30 treatment of haematological malignancies –
yesterday, today and tomorrow
Chairpersons: Jean-Pierre Marie (Paris, FR)
Axel Glasmacher (Bonn, DE)
13:30 Greeting
Introductions and programme overview
Robin Williamson (London, UK)
S1 Review of resistance patterns over time
13:40 with an emphasis on problem pathogens
Murat Akova (Ankara, TR)
S2 An evidence-based review of the available
14:10 antibiotic treatment options and a
recommendation for the treatment guidelines
Axel Glasmacher (Bonn, DE)
S3 Collateral damage and what the future might
14:40 hold – the need to balance prudent antibiotic
utilisation and stewardship with effective
patient management
David Weber (Chapel Hill, US)
15:10 Q & A
Moderator: Jean-Pierre Marie (Paris, FR)
Wyeth Pharmaceuticals satellite symposium
Apollon Evidence and experience: the role of
15:30– echinocandins in the management of invasive
17:30 fungal infections
Chairperson: Bertrand Dupont (Paris, FR)
15:30 Welcome and opening remarks
Bertrand Dupont (Paris, FR)
S4 Susceptibility, spectrum and methodology for
15:35 antifungal agents
David Perlin (Newark, US)
S5 Echinocandins for documented fungal
16:00 infections
Claudio Viscoli (Genoa, IT)
S6 Echinocandins for suspected fungal infections
16:25 Thierry Calandra (Lausanne, CH)
S7 Beyond the horizon: caspofungin
16:50 clinical update
Carole Sable (Rahway, US)
17:15 Panel discussion
17:25 Closing remarks
Bertrand Dupont (Paris, FR)
Merck, Sharpe & Dohme satellite symposium
Symposia
Athena Dendograms in microbial phylogenetics and
15:45– epidemiological typing
16:45 Chairpersons: Paul Vauterin (Rochester, US)
Panayotis Tassios (Athens, GR)
S8 Evolutionary trees in microbiology
15:45 Barry Hall (Bellingham, US)
S9 Representations of strain similarities in
16:15 molecular microbial typing
Paul Vauterin (Ghent, BE)
Symposium arranged with the ESCMID Study
Group on Epidemiological Markers (ESGEM)
Méditerranée 1 Antimicrobial resistance in anaerobic bacteria.
15:45– Experiences in Europe and North America
16:45
Chairpersons: Carl Erik Nord (Stockholm, SE)
Ellie J.C. Goldstein
(Santa Monica, US)
S10 Is antimicrobial resistance a clinical problem
15:45 in North America?
Ellie J.C. Goldstein (Santa Monica, US)
S11 Antimicrobial susceptibility patterns in
16:15 different European countries
Elisabeth Nagy (Szeged, HU)
Symposium arranged with the ESCMID Study
Group on Antimicrobial Resistance in Anaerobic
Bacteria (ESGARAB) and the Anaerobic Society
of the Americas
Méditerranée 2 Pathogenesis and prevention of nosocomial
15:45– infections – new aspects
17:15 Chairpersons: Serhat Ünal (Ankara, TR)
Marc Bonten (Utrecht, NL)
S12 Infections associated with intravascular
15:45 devices
Bart Rijnders (Rotterdam, NL)
S13 Surgical site infections after implant
16:15 surgery: a diagnostic and therapeutic
challenge
Andreas Widmer (Basel, CH)
S14 Ventilator-associated pneumonia
16:45 Wolfgang Krüger (Tubingen, DE)
Symposium arranged with the ESCMID Study
Group on Nosocomial Infections (ESGNI)
www.escmid.org/eccmid2006 page 31

Scientific Programme Saturday, April 1, 2006
Méditerranée 3 News in the field of toxoplasmosis
15:45–
16:45 Chairpersons: Birgitta Evengård (Stockholm, SE)
Francis Derouin (Paris, FR)
S15 Past, present and future drug treatment
15:45 of Toxoplasma gondii
Francis Derouin (Paris, FR)
S16 Detection and genotyping of Toxoplasma
16:15 gondii by real-time PCR and pyrosequencing
Benjamin Edvinsson (Stockholm, SE)
Symposium arranged with the ESCMID Study
Group on Toxoplasmosis (ESGT)
Iris How to prevent microbial biofilm formation
15:45– on medical devices
17:15 Chairpersons: Niels Høiby (Copenhagen, DK)
Gianfranco Donelli (Rome, IT)
S17 Analogues of natural signal molecules as
15:45 promising antibiofilm drugs
Michael Givskov (Copenhagen, DK)
S18 Drug releasing polyurethanes able to inhibit
16:15 microbial biofilm growth on medical devices
Gianfranco Donelli (Rome, IT)
S19 Candida biofilm formation on implanted
16:45 medical devices
Christine Imbert (Poitiers, FR)
Symposium arranged with the ESCMID Study
Group on Biofilms (ESGB)
Clio Antimicrobial utilisation in Europe:
15:45– future directions
17:15 Chairpersons: Inge C. Gyssens (Rotterdam, NL)
Barry Cookson (London, UK)
S20 Mapping antibiotic consumption and
15:45 resistance in the community
Maggie Heginbothom (Cardiff, UK)
S21 Can we and how do we benchmark antibiotic
16:15 consumption in hospitals?
Dominique L. Monnet (Copenhagen, DK)
S22 Point-prevalence surveys of anti-infective use
16:45 Bryony Dean Franklin (London, UK)
Symposium arranged with the ESCMID Study
Group on Antibiotic Policies (ESGAP)
page 32 Final Programme
Erato Nosocomial mould infections
15:45–
17:45 Chairpersons: David Denning (Manchester, UK)
Manuel Cuenca-Estrella (Madrid, ES)
S23 Current recommendations for the prevention
15:45 of nosocomial infection: are they applicable
to moulds?
Rosemary Barnes (Cardiff, UK)
S24 Source of moulds in the hospital setting
16:15 Jean-Pierre Gangneux (Rennes, FR)
S25 Post-operative aspergillosis
16:45 Alessandro Pasqualotto (Manchester, UK)
S26 Nosocomial infections due to emerging
17:15 moulds
Manuel Cuenca-Estrella (Madrid, ES)
Symposium arranged with the ESCMID Fungal
Infections Study Group (EFISG)
Calliope Guidelines for Helicobacter pylori
15:45– infections revisited. The Maastricht-3 2005
17:15 consensus report
Chairpersons: Klaus Mönke-Müller
(Magdeburg, DE)
Francis Mégraud (Bordeaux, FR)
S27 Indications for H. pylori eradication revisited
15:45 Ernest Kuipers (Rotterdam, NL)
S28 Diagnosis and treatment of resistant
16:15 H. pylori infection
Francis Mégraud (Bordeaux, FR)
S29 Prevention of gastric cancer by H. pylori
16:45 eradication
Klaus Mönke-Müller (Magdeburg, DE)
Symposium arranged with the European
Helicobacter Study Group (EHSG)

Scientific Programme Sunday, April 2, 2006
Meet-the-Expert Sessions
Méditerranée 2 Laboratory diagnosis of invasive
E30 fungal infections
07:15– Experts: Emmanuel Roilides (Thessaloniki, GR)
08:15– Olivier Lortholary (Paris, FR)
Objectives:
– to discuss different methods (microbiological,
serological, radiological, molecular and
histological) to diagnose invasive fungal
infections
– to provide examples of difficult cases of
invasive fungal infections and emphasise
the roles of different methods of laboratory
diagnosis
– to discuss laboratory criteria for defining a
case as definite or probable
Méditerranée 3 Current issues in the treatment of HBV-HIV
E31 co-infected patients
07:15– Experts: Dominique Salmon-Ceron (Paris, FR)
08:15 Will Irving (Nottingham, UK)
Objectives:
– to present case histories on the current
therapeutic issues for patients who need
HBV treatment but who do not need HAART
– to discuss the virological follow-up of
patients treated for both HIV and HBV
Iris What is the role of serology in pregnancy?
E32 Experts: Birgitta Evengård (Stockholm, SE)
07:15– Babill Stray-Pedersen (Oslo, NO)
08:15
Objectives:
– to discuss the importance of infections
for maternal and child health in Europe
– to define indications for screening for
toxoplasmosis and other infections during
pregnancy
– to present handling schemes for prevention
of mother-to-child transmission
– to discuss identification of infected mother
and offspring
Hermes Travel medicine and evidence-based
E33 recommendations
07:15– Experts: Alfons van Gompel (Antwerp, BE)
08:15 Christoph Hatz (Basel, CH)
Objectives:
– to provide background information for
rational advice on malaria prevention
– to define indications for travel-related
vaccinations
– to arrive at standardised “informed
decisions”
– to provide a web-based differential diagnosis
programme to assess fever after return from
tropical and subtropical countries
Clio Surveillance of newly emerging pathogens
E34 and public health responses
07:15– Experts: Maxwell Hardiman (Geneva, WHO)
08:15 Johan Giesecke (Stockholm, ECDC)
Objectives:
– to implement Annex 1 of the new International
Health Regulations –
what action is needed in Europe?
– to analyse alternative/novel surveillance
mechanisms
– to discuss what surveillance is needed in an
established flu pandemic – different tools
from those used for “normal” flu?
– to assess surveillance for newly emerging
resistant strains (e.g. C. difficile)
Erato How to diagnose and treat diabetic foot
E35 infections?
07:15– Experts: Anthony Berendt (Oxford, UK)
08:15 Eric Senneville (Tourcoing, FR)
Objectives:
– to describe optimal diagnostics approaches
– to discuss pathogens involved in diabetic
foot infection and their susceptibility to
antibiotics
– to provide the evidence for appropriate
(empirical) treatment
www.escmid.org/eccmid2006 page 33

Symposia
Scientific Programme Sunday, April 2, 2006
Apollon New diagnostic techniques for the
08:30– microbiological laboratory and general
10:30 practitioner
Chairpersons: Marc Struelens (Brussels, BE)
Roland Leclercq (Caen, FR)
S36 Breakthroughs in bacterial detection,
08:30 identification and typing
Marc Struelens (Brussels, BE)
S37 Progress in detection of bacteria responsible
08:50 for infections in challenging clinical situations
and of antimicrobial resistance
Roland Leclercq (Caen, FR)
S38 Molecular diagnostics in virology, overcoming
09:10 the hurdles
Hubert G.M. Niesters (Rotterdam, NL)
S39 Parasitology
09:30 t.b.c.
S40 Mycology
09:50 Emmanuel Roilides (Athens, GR)
Méditerranée 2 Neurological sequelae of bacterial
08:15– and viral infections
10:30 Chairpersons: Christian Chidiac (Lyon, FR)
Diederik van de Beek
(Amsterdam, NL)
S41 Campylobacter-induced Guillain-Barré
08:30 syndrome
Hubert P. Endtz (Rotterdam, NL)
S42 The involvement of Chlamydia pneumoniae
09:00 in multiple sclerosis
Enrico Fainardi (Ferrara, IT)
S43 Neurological complications of reactivated
09:30 varicella-zoster virus infection
Tomas Bergström (Göteborg, SE)
S44 Possible viral aetiology of multiple sclerosis
10:00 Peter G.E. Kennedy (Glasgow, UK)
Hermes Evolution of beta-lactamases
08:30–
10:30 Chairpersons: Giuseppe Cornaglia (Verona, IT)
Patrice Nordmann (Paris, FR)
S45 Environmental bacteria as a reservoir for
08:30 newer beta-lactamases
Patrice Nordmann (Paris, FR)
S46 CTX-M beta-lactamases: the molecular story
09:00 of a clinical success in community and hospital
Rafael Cantón (Madrid, ES)
page 34 Final Programme
S47 The role of integrons in the spread of
09:30 beta-lactamases
Gian Maria Rossolini (Siena, IT)
S48 Evolution in class A beta-lactamases: tuning
10:00 between substrate range and hydrolysis
efficiency
Marek Gniadkowski (Warsaw, PL)
Oral Sessions
Méditerranée 3 Quinolone resistance and efflux
08:30–
10:30 Chairpersons: Emmanuelle Cambau (Paris, FR)
Vincent Jarlier (Paris, FR)
O49 Mini state-of-the-art-lecture on quinolones
08:30 Emmanuelle Cambau (Paris, FR)
O50 Type II topoisomerase mutations in
08:54 Enterobacter cloacae clinical isolates
harbouring QNR and implication for
quinolone resistance
E. Cambau, C. Lascols, J. Robert, V. Cattoir,
V. Jarlier, C.J. Soussy (Creteil, Paris, FR)
O51 Emergence of plasmid-mediated quinolone
09:06 resistance QnrS determinant in
enterobacterial isolates in Europe
L. Poirel, C. Leviandier, P. Nordmann
(Le Kremlin Bicetre, FR)
O52 Detection of QnrS in clinical isolates of
09:18 Enterobacter cloacae in Spain
M.E. Cano, J.M. Rodríguez-Martínez, J. Agüero,
A. Pascual, J.M. García-Lobo, C. Velasco,
L. Martínez-Martínez (Santander, Seville, ES)
O53 Determination of the QNR – DNA gyrase
09:30 interaction site by a genetic approach
A. Cesaro, V. Cattoir, C. Lascols, C.J. Soussy,
E. Cambau (Creteil, FR)
O54 Putative implication of YceE (transporter
09:42 protein) and ompN (porin) in the resistance to
quinolones in Escherichia coli
A. Fabrega, J. Sanchez-Cespedes, M.M. Tavio,
M. Ruiz, J. Vila (Barcelona, Las Palmas, ES)
O55 Potential of fluoroquinolones to induce
09:54 the expression of the acrAB efflux pump
and the global regulator marA in
Salmonella hadar
S. Schmidt, P. Heisig (Hamburg, DE)
O56 Horizontal gene transfer contributes to
10:06 fluoroquinolone resistance in Streptococcus
pyogenes
C.B. Duesberg, S. Malhotra-Kumar, T. Welte,
H. Goossens, M.W.R. Pletz (Hannover, DE;
Antwerp, BE)

Scientific Programme Sunday, April 2, 2006
O57 New mutation at the position 81 in GyrA
10:18 in clinical strains of Mycobacterium
tuberculosis resistant to quinolone:
report of two clinical cases and functional
analysis of DNA gyrase mutant enzymes
S. Matrat, N. Veziris, V. Jarlier, E. Cambau,
C. Truffot-Pernot, J. Camuset, E. Bouvet,
A. Aubry (Paris, Créteil, Argenteuil, FR)
Iris Viruses and viral diagnostics
08:30–
10:30 Chairpersons: Ron Fouchier (Rotterdam, NL)
Françoise Brun-Vézinet (Paris, FR)
O58 HCMV infects and replicates in the adrenal
08:30 gland
M. Trevisan, G. Masi, R. Cusinato, K. Fincati,
A. Loregian, G. Palù, L. Barzon (Padua, IT)
O59 Simultaneous detection of the human
08:42 cytomegalovirus DNA and RNA by
targeting the UL73/74 gene region using
multiplex real-time polymerase chain
reaction assays
Y.-J. Chan, J.-C. Lin, C.-H. Tsai, W.-S. Weng,
D.M-T. Ho (Taipei, TW)
O60 Prospective comparison of real-time
08:54 quantitative PCR on blood with rapid culture
of urine and throat samples for monitoring
cytomegalovirus infection in hematopoietic
stem cell transplant recipients
I. Thoelen, W. Laffut, K. Van Vaerenbergh,
M. Develter, K. Theunissen, J. Maertens,
J. Van Eldere (Leuven, BE)
O61 Diagnostic relevance of screening clinical
09:06 specimens from patients attending infectious
diseases and haematology units for HHV6
DNA: a two-year experience
G. Parruti, A. Manna, A. Di Girolamo, M. Ciotti,
D. Racciatti, G. D’Amico, C. Favalli, E. Pizzigallo,
D. D’Antonio (Pescara, Chieti, Rome, IT)
O62 Echovirus 9: a prominent enterovirus
09:18 causing CNS disease in Kuwait
A. Dalwai, S. Ahmad, A. Pacsa, W. Al-Nakib
(Kuwait, KW)
O63 Detection of respiratory pathogens
09:30 by real-time PCR in clinical practice
J.W.A. Rossen, E.G. Klein Breteler,
A.J. Weersink, R. Schuurman, A.M. van Loon
(Utrecht, NL)
O64 Nucleic acid sequence based amplification
09:42 and molecular beacon detection for the realtime
identification of human metapneumo -
virus in paediatric respiratory specimens
R. Manji, F. Zhang, C. Ginocchio
(Lake Success, US)
O65 Development of a real-time NASBA for
09:54 human metapneumovirus
E. Bufflier, H. Savelli, F. Jacobs, C. Moore,
P. Van de Wiel (Grenoble, FR; Boxtel, NL;
Cardiff, UK)
O66 Viral induced asthma exacerbations not
10:06 associated with delayed viral clearance
and increased viral load
A.P.E. Sachs, L.J.R. van Elden, A.M. van Loon,
G. Kimman, T.J.M. Verheij, M. Nijhuis
(Utrecht, Bilthoven, NL)
O67 Quantitative detection of herpes simplex
10:18 virus DNA in the lower respiratory tract
J. Gooskens, K. Templeton, E. Claas,
M. van Bussel, V. Smit, A. Kroes (Leiden, NL)
Erato Clinical epidemiology of nosocomial
08:30– infections
10:30 Chairpersons: Jacques Fabry (Lyon, FR)
Geoffrey Scott (London, UK)
O68 Surgical site infections in Europe:
08:30 results from HELICS surveillance 2004
C. De Laet, C. Suetens, J. Fabry
(Brussels, BE; Lyon, FR)
O69 Deep sternal wound infections following
08:42 coronary artery bypass graft surgery:
risk factors and implications
M. Paul, C. Madar, E. Raz, R. Holinger, A. Fraser,
L. Leibovici, B. Rubinovitch (Petah Tikva, IL)
O70 Diagnosis and microbiology of prosthetic
08:54 shoulder infection
K. Piper, P. Anguita Alonso, M. Jacobson,
A. Trampuz, R. Cofield, J. Sperling,
J. Sanchez Sotelo, D. Osmon, R. Patel
(Rochester, US)
O71 The association between ventilator
09:06 associated pneumonia and ICU mortality:
approximation of attributable mortality
M. Koeman, E. Hak, A. de Smet,
G. van der Heyden, M.J.M. Bonten (Utrecht, NL)
O72 Pattern and dynamics of airways colonisation
09:18 in mechanically ventilated patients
J-E. Berdal, J. Bjørnholdt, A. Blomfeldt,
G. Bukholm, N. Smith-Erichsen (Nordbyhagen, NO)
O73 Factors influenced treatment failure
09:30 in pneumococcal pneumonia with
bacteraemia
V. Huang, I. Pencu, S. Oprea, M. Zervos
(Atlanta, Royal Oak, Detroit, US)
www.escmid.org/eccmid2006 page 35

Integrated symposium
In antimicrobial
therapy use the
best first: examining
the evidence
Sunday, April 2, 2006, 8:30 – 10:30 a.m.
Acropolis Congress Centre, Level 3, Room Clio
Integrated symposium arranged by
Chairmen: Patrick Francioli (Lausanne, CH)
Donald Low (Toronto, CA)
08:30 Introduction
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
08:40 Differentiating antibiotics on basis of
preclinical data – determining superior
antimicrobial activity
Francesco Blasi (Milan, IT)
09:10 Treatment of lower respiratory tract
infections – assessing clinical superiority
Robert Read (Sheffield, UK)
09:40 Treatment of surgical infections including
SSSIs – assessing clinical superiority
Johannes Bogner (Munich, DE)
10:10 Panel discussion
Donald Low (Toronto, CA)
10:20 Conclusions
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)

Scientific Programme Sunday, April 2, 2006
O74 Efficacy of the use of through-catheter
09:42 leukocyte cytospin blood culture for
monitoring haemodialysis catheter
colonisation. A prospective study designed
to prevent bloodstream-related infections
J.L. del Pozo, A. Aguinaga, M. Alonso, A. Serrera,
S. Hernaez, M.J. Garrido, N. García-Fernández,
J. Leiva (Pamplona, ES)
O75 Risk factors and treatment outcome of
09:54 bloodstream infections caused by
Pseudomonas aeruginosa isolates producing
the PER-1 extended-spectrum beta-lactamase
A. Endimiani, B. Pini, F. Luzzaro, G. Amicosante,
G.M. Rossolini, A. Toniolo (Varese, L’Aquila,
Siena, IT)
O76 Is transmission of MRSA frequent between
10:06 patients sharing the same hospital room?
D.S. Blanc, C. Balmelli, C. Petignat, G. Zanetti,
P. Francioli (Lausanne, CH)
O77 Outbreak of Burkolderia cenocepacia
10:18 bacteraemia associated with disinfection
napkin contamination in haemodialysis
M. Solbiati, B. Allegranzi, G. Lo Cascio,
M.G. Bonora, C. Loschiavo, N. Tessitore,
R. Fontana, E. Concia (Verona, IT)
Integrated Symposia
Athena Tailoring initial antifungal therapy
08:30– according to epidemiological trends
10:30– Chairpersons: Oliver Cornely (Cologne, DE)
Pierre Dellamonica (Nice, FR)
08:30 Opening remarks
Pierre Dellamonica (Nice, FR)
S78 Redefining the impact of antifungal
08:40 prophylaxis in high-risk patients
Oliver Cornely (Cologne, DE)
S79 Strategies for antifungal therapy in high-risk
09:10 patients: can we change what we are doing?
Christopher Kibbler (London, UK)
S80 Improving treatment decisions for antifungal
09:40 therapy: what tools are available?
Dimitrios Kontoyiannis (Houston, US)
10:10 Panel discussion
10:25 Closing remarks
Oliver Cornely (Cologne, DE)
Integrated symposium arranged by
Schering-Plough
Méditerranée 1 The challenge for antibiotic therapy in
08:30– treating complicated infections:
10:30 how broad is enough?
Chairpersons: Anthony Berendt (Oxford, UK)
Yehuda Carmeli (Tel Aviv, IL)
08:30 Opening remarks
Anthony Berendt (Oxford, UK)
S81 The change of epidemiology of
08:40 Gram-negative infections
Peter Hawkey (Birmingham, UK)
S82 The role of carbapenems in managing
09:00 Gram-negative infections
Yehuda Carmeli (Tel Aviv, IL)
S83 The role of ertapenem in the management of
09:20 diabetic foot infections
Benjamin Lipsky (Seattle, US)
09:40 Panel discussion
10:20 Closing remarks
Anthony Berendt (Oxford, UK)
Yehuda Carmeli (Tel Aviv, IL)
Integrated symposium arranged by
Merck, Sharp & Dohme
Clio In antimicrobial therapy «use the best one
08:30– first»: examining the evidence
10:30 Chairpersons: Patrick Francioli (Lausanne, CH)
Donald Low (Toronto, CA)
08:30 Introduction
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
S84 Differentiating antibiotics on basis of
08:40 preclinical data – determining superior
antimicrobial activity
Francesco Blasi (Milan, IT)
S85 Treatment of lower respiratory tract
09:10 infections – assessing clinical superiority
Robert Read (Sheffield, UK)
S86 Treatment of surgical infections including
09:40 SSSIs – assessing clinical superiority
Johannes Bogner (Munich, DE)
10:10 Panel discussion
10:20 Conclusions
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
Integrated symposium arranged by
Bayer HealthCare AG
www.escmid.org/eccmid2006 page 37

Scientific Programme Sunday, April 2, 2006
Calliope Addressing the challenge of nosocomial
08:30– MRSA infections
10:30 Chairpersons: Gary French (London, UK)
Kamal Itani (Boston, US)
08:30 Introduction: addressing the challenge of
nosocomial MRSA infections
Gary French (London, UK)
S87 MRSA update: present and future threats
08:40 Peter Wilson (London, UK)
S88 Challenges of MRSA nosocomial surgical
09:00 site and complicated skin and soft-tissue
infections
Kamal Itani (Boston, US)
S89 MRSA in the ICU: catheter related skin
09:20 and bloodstream infections
Emilio Bouza (Madrid, ES)
S90 Nosocomial pneumonia:
09:40 early diagnosis, better treatments
Jean-Yves Fagon (Paris, FR)
10:00 Panel discussion
10:25 Summary and conclusions
Kamal Irani (Bostin, US)
Integrated symposium arranged by Pfizer
Award Lecture
Apollon Presentation of ESCMID Awards –
11:00– ESCMID Excellence Award Lecture
12:00 Chairpersons: S. Ragnar Norrby (Stockholm, SE)
Marc Struelens (Brussels, BE)
11:00 Presentation of the ESCMID/bioMérieux
Award for Advances in Clinical Microbiology
11:05 Presentation of the ESCMID Young
Investigator Awards for Research in Clinical
Microbiology and Infectious Diseases
11:10 Presentation of the ESCMID Award for
Excellence in Clinical Microbiology and
Infectious Diseases
11:15 ESCMID Excellence Award Lecture:
S91 Resistance to antimicrobials:
from emergence to clinical relevance
Roland Leclercq (Caen, FR)
(see also page 18)
page 38 Final Programme
Keynote Lecture
Athena The impact of microbial genomics on
11:00– epidemiology and control of infectious
12:00 diseases
Chairperson: Jordi Vila (Barcelona, ES)
K92 James M. Musser (Houston, US)
11:00
Oral Sessions
Erato Biofilms – a highly organised community
11:00–
12:00 Chairpersons: Niels Høiby (Copenhagen, DK)
Christine Imbert (Poitiers, FR)
O93 AGR-genotyping of biofilm producing
11:00 Staphylococcus aureus
V. Cafiso, T. Bertuccio, M. Santagati, V. Demelio,
D. Spina, S. Stefani (Catania, IT)
O94 Structural comparison of biofilms
11:12 formed by Staphylococcus aureus,
Staphylococcus epidermidis, and other
coagulase-negative staphylococci
M.A. Horstkotte, S. Stepanovic, M. Lang,
D. Mack, J.K. Knobloch (Hamburg, DE;
Belgrade, CS; Swansea, UK)
O95 Differential importance of protein and
11:24 polysaccharide intercellular adhesin
mediated biofilm formation in
Staphylococcus aureus and Staphylococcus
epidermidis from prosthetic joint infections
H. Rohde, E. Burandt, L. Frommelt, N. Siemssen,
C. Burdelski, C.-J. Wang, S. Scherpe,
J.K.-M. Knobloch, J. Kaplan, D. Mack
(Hamburg, DE; Newark, US; Swansea, UK)
O96 The role of the quorum-sensing
11:36 “target of RNAIII activating protein” and
“RNAIII-inhibiting peptide” in staphylococcal
biofilm formation and control in vitro
C.A. Fux, D. Nguyen, S. Wilson, N. Balaban,
P. Stoodley (Berne, CH; Pittsburgh, Bozeman,
North Grafton, US)
O97 Using an efficient anti-biofilm procedure
11:48 to improve the safety of pacifiers
E. Comina, K. Marion, F. Renaud, E. Bergeron,
J. Freney (Lyon, FR)

Scientific Programme Sunday, April 2, 2006
Calliope Emerging viral infections
11:00–
12:00 Chairpersons: Sabine Santibanez (Berlin, DE)
Christian Drosten (Hamburg, DE)
O98 Clinical features and molecular epidemiology
11:00 of coronavirus HKU1 associated communityacquired
pneumonia
P.C.Y. Woo, S.K.P. Lau, H.W. Tsoi, Y. Huang,
R.W.S. Poon, C-M. Chu, R.A. Lee, W-K. Luk,
G.K.M. Wong, B.H.L. Wong, V.C.C. Cheng,
B.S.F. Tang, A.K.L. Wu, R.W.H. Yung, H. Chen,
Y. Guan, K-H. Chan, K-Y. Yuen (Hong Kong, HK)
O99 Stability of SARS coronavirus to high
11:12 temperature and high relative humidity
W.H. Seto, K.H. Chan, S.Y. Lam, M. Peiris
(Hong Kong, HK)
O100 First identification of Toscana
11:24 virus and other phleboviruses in sandflies
from southern France
R.N. Charrel, A. Izri, S. Temmam, P. Delaunay,
I. Toga, P. Marty, H. Dumon, X. de Lamballerie,
P. Parola (Marseille, Paris, Nice, FR)
O101 Imported cases of chikungunya virus infection
11:36 from eastern Africa
R.N. Charrel, P. Brouqui, H. Tissot Dupont,
X. de Lamballerie (Marseille, FR)
O102 Crimean-Congo haemorrhagic fever in
11:48 the East Black Sea region of Turkey:
a report of 78 cases
N. Sucu, K. Aydin, I. Köksal, R. Caylan,
G. Yilmaz (Trabzon, TR)
www.escmid.org/eccmid2006 page 39

Poster Session I
Topics Session I
Presence of authors: 12:00–13:00
Scientific Programme Sunday, April 2, 2006
– Automated methods for antibiotic
susceptibility testing
● P441–P456
– Epidemiology of MRSA P457–P478
– Sepsis P479–P485
– Tigecycline in vitro studies – I P486–P501
– ESBL and cephalosporins P502–P516
– Molecular typing P517–P539
– Bacterial pathogenesis - I P540–P554
– Emerging microbial infections P555–P569
– Vaccines and immunotherapy P570–P595
– AIDS and HIV P596–P625
– Detection of viruses P626–P656
– Nosocomial infections
★ P657–P678
12:15–13:00
Guided Poster Walks Session I
Theme: Automated methods for antibiotic
susceptibility testing
Chairperson: Derek Brown (Cambridge, UK)
Meeting point: Poster P441 at 12:15
Posters selected from within the topic marked ●
Theme: Nosocomial infections
Chairpersons: Geoffrey Scott (London, UK)
Jean Carlet (Paris, FR)
Meeting point: Poster P657 at 12:15
Posters selected from within the topic marked ★
page 40 Final Programme
13:00–14.00
Poster Session II
Topics Session II
– Infection in the immunocompromised
host (except HIV)
● P679–P702
– Antibacterial susceptibility studies - I P703–P727
– Identification and antifungal susceptibility
testing for yeasts and moulds
P728–P749
– Virology – I P750–P766
– Hepatitis P767–P790
– Paediatric infections P791–P818
– Microbial biofilms P819–P845
– Brucella and Lyme borreliosis P846–P855
– Diagnositic and laboratory methods
in parasites and fungi
P856–P870
– Toxoplasmosis P871–P882
– Staphylococci and surgical infections P883–P895
– Streptococci – skin and soft tissue infections P896–P907
– ESBL and carbapemenase producing
Gram-negative organisms
★ P908–P924
– Metallo beta-lactamases and integrons ★ P925–P940
13:00–13:45
Guided Poster Walks Session II
Theme: Infection in the immunocompromised host
(except HIV)
Chairpersons: Murat Akova (Ankara, TR)
Mathew Falagas (Athens, GR)
Meeting point: Poster P679 at 13:00
Posters selected from within the topic marked ●
Theme: ESBL and metallo-beta-lactamases
Chairperson: David Livermore (London, UK)
Meeting point: Poster P908 at 13:00
Posters selected from within the topics marked ★

Symposia
Scientific Programme Sunday, April 2, 2006
Apollon The year in infectious diseases medicine
14:00–
15:00 Chairperson: Roger Finch (Nottingham, UK)
S103 The year in infectious diseases medicine (1)
14:00 Susanna Esposito (Milan, IT)
S104 The year in infectious diseases medicine (2)
14:30 Patrick Francioli (Lausanne, CH)
Athena Is microbiological work-up in community-
14:00– acquired pneumonia still useful?
15:00 Chairpersons: Tobias Welte (Hannover, DE)
Mark Woodhead (Manchester, UK)
S105 Pro
14:00 Margareta Ieven (Antwerp, BE)
S106 Contra
14:30 Johan Van Eldere (Leuven, BE)
Méditerranée 1 The hyper-virulent strain of Clostridium
14:00– difficile: sharing experiences in Europe and
15:00 North America
Chairpersons: Ian R. Poxton (Edinburgh, UK)
Clifford McDonald (Atlanta, US)
S107 Spread of the new variant 027 of Clostridium
14:00 difficile in the Netherlands and Europe
Ed J. Kuijper (Leiden, NL)
S108 Clostridium difficile-associated disease:
14:30 a growing threat to U.S. public health
Clifford McDonald (Atlanta, US)
Symposium arranged with the ESCMID
Study Group on Clostridium difficile (ESGCD)
Hermes Blood-borne viruses in health care facilities –
14:00– the silent enemy?
15:00 Chairpersons: Catherine Cordonnier (Paris, FR)
Winfried Kern (Freiburg, DE)
S109 An overview of transmission of BBV in
14:00 healthcare facilities
Shaheen Mehtar (Cape Town, ZA)
S110 Transmissions of hepatitis B, C and HIV
14:30 associated with healthcare in Europe
Jean-Claude Desenclos (Saint-Maurice, FR)
Clio Viral congenital paediatric diseases
14:00–
15:00 Chairpersons: Babill Stray-Pedersen (Oslo, NO)
Vas Novelli (London, UK)
S111 Congenital CMV infection:
14:00 current controversies
Sergio Stagno (Birmingham, US)
S112 Congenital varicella syndrome and perinatal
14:30 varicella: epidemiology and management
Vas Novelli (London, UK)
Erato Brucellosis
14:00–
15:00 Chairpersons: Emilio Bouza (Madrid, ES)
Georgios Pappas (Ioannina, GR)
S113 Molecular methods in the diagnosis of human
14:00 brucellosis
Javier Solera (Albacete, ES)
S114 What’s new in the treatment of human
14:30 brucellosis
Georgios Pappas (Ioannina, GR)
Oral Sessions
Méditerranée 2 Dissemination of molecular resistance traits
14:00–
15:00 Chairpersons: Roxana Filip (Suceava, RO)
Kevin Towner (Nottingham, UK)
O115 Comparative genomic analysis of community-
14:00 acquired ST80-SCCmec IV Staphylococcus
aureus isolates by high-density microarray
R.V. Goering, A.R. Larsen, R. Skov, F.C. Tenover,
K. Anderson, P.M. Dunman
(Omaha, US; Copenhagen, DK; Atlanta, US)
O116 Presence of PVL among erythromycin-
14:12 and methicillin-resistant community-acquired
Staphylococcus aureus isolated from children
in Texas from 1999 to 2002
N. Aydin, T. Bogdanovich, S. Chavez-Bueno,
G. McCracken, B. Bozdogan, P.C. Appelbaum
(Aydin, TR; Hershey, Dallas, US)
O117 Identity of macrolide-resistant clones
14:24 of Streptococcus pyogenes in Portugal
supports Europe-wide dissemination of a
few lineages
C. Silva-Costa, M. Ramirez, J. Melo-Cristino
(Lisbon, PT)
www.escmid.org/eccmid2006 page 41

Scientific Programme Sunday, April 2, 2006
O118 Rapid dissemination of MDR CTX-M-15-
14:36 producing K. pneumoniae epidemic clone in
Hungary
I. Damjanova, Á. Tóth, Z. Ozsvár, E. Bauer, J. Pászti,
M. Füzi (Budapest, Székesfehérvár, HU)
O119 Evidence for low rates of ciprofloxacin
14:48 and rifampicin resistance in persistent
Helicobacter pylori infection
S.A. Chisholm, R.J. Owen (London, UK)
Méditerranée 3 Diabetes and infection
14:00–
15:00 Chairpersons: Anthony Berendt (Oxford, UK)
Eric Senneville (Tourcoing, FR)
O120 Stress hyperglycaemia as a prognostic
14:00 factor in patients with severe sepsis
L. Leonidou, M. Michalaki, A. Leonardou,
E. Polyzogopoulou, K. Fouka, M. Gerolimos,
P. Leonardos, E. Giannoulaki, V. Kyriazopoulou,
C.A. Gogos (Patras, GR)
O121 Diabetes mellitus and 30-day and 90-day
14:12 mortality after hospitalisation with
pneumonia: a population-based follow-up
study of 41,793 adult patients
R.W. Thomsen, J. Brommann, A. Riis,
H.-H. Lervang, H.C. Schønheyder, H.T. Sørensen
(Aalborg, Aarhus, DK)
O122 A clinical prediction rule for a complicated
14:24 course of urinary tract infections in patients
with type 2 diabetes in primary care
L.M.A.J. Muller, K.J. Gorter, G.E.H.M. Rutten,
A.I.M. Hoepelman, E. Hak (Utrecht, NL)
O123 Applicability of a clinical prediction rule for
14:36 lower respiratory tract infections
in elderly patients with diabetes mellitus:
a subgroup analysis
L.M.A.J. Muller, J. Bont, K.J. Gorter,
G.E.H.M. Rutten, T.J.M. Verheij, E. Hak
(Utrecht, NL)
O124 Diabetic foot infections: the evolving
14:48 characteristics, microbiology and
determinants of mortality
S. Gündes, Z. Yulugkural, M. Biyikli,
B. Buyukarslan (Kocaeli, TR)
page 42 Final Programme
Iris Pump it out and resist
14:00–
15:00 Chairpersons: Patrick Plésiat (Besançon, FR)
David Livermore (London, UK)
O125 Which Mex efflux pumps are overexpressed
14:00 in multidrug-resistant Pseudomonas
aeruginosa?
D. Hocquet, R. Fabre, M. Roussel-Delvallez,
J.D. Cavallo, B. Dehecq, P. Plésiat
(Besancon, Bégin Saint-Mandé, Lille, FR)
O126 Expression of mexY and gene PA5471
14:12 in drug-induced amikacin resistant small
colony variants of P. aeruginosa
S. Islam, A. Vang, B. Wretlind (Stockholm, SE)
O127 Contribution of efflux pumps overexpression
14:24 to carbapenem heteroresistance in
Pseudomonas aeruginosa
A. Ikonomidis, S. Pournaras, N. Spanakis,
A. Tsakris, N.J. Legakis, A.N. Maniatis
(Larissa, Athens, GR)
O128 Identification of novel mutations
14:36 in MTR locus of clinical isolates of Neisseria
gonorrhoeae
M. Ali, V. Kumar, P. Sachdeva, U. Chaudhry,
D. Saluja (Delhi, IN)
O129 Acquired beta-lactam resistance in three
14:48 Escherichia coli strains due to overexpression
of AcrAB, TolC and PBP3
M.M. Tavío, V. Aquili, N.T. Antunes,
J. Sánchez-Cespedes, Z. González-Lama, J. Vila
(Las Palmas de Gran Canaria, Barcelona, ES)
Calliope Mycobacterial infections
14:00–
15:00 Chairpersons: Enzio Tortoli (Florence, IT)
Françoise Portaels (Antwerp, BE)
O130 Epidemiology and trend of leprosy
14:00 disease in the Iranian Qazvin province during
45 years (1958–2003)
R. Qassemi Barqi (Qazvin, IR)
O131 Mycobacterium kansasii: results of a 10-year
14:12 study in Zaragoza, Spain
S. Terraza, J.A. Amiguet, P. Arazo, C. Ramos,
A. Vitoria, M.A. Lezcano, J. Cuesta (Zaragoza, ES)
O132 Comparison of conventional antimicrobial
14:24 susceptibility and oligonucleotide chip
system for detection of drug resistance in
Mycobacterium tuberculosis isolates
H. Park, E.J. Song, E.S. Song, E.Y. Lee, C.M. Kim,
S.H. Jeong, J.H. Shin, J. Jeong, S. Kim, Y.K. Park,
G.-H. Bai C.L. Chang (Busan, Ulsan, Jinju, Seoul, KR)

Scientific Programme Sunday, April 2, 2006
O133 Clinical and microbiological data of
14:36 patients infected with multidrug-resistant
Mycobacterium tuberculosis strains
carrying gyrase mutations
N. Veziris, J. Robert, C. Truffot-Pernot, V. Jarlier,
E. Cambau, A. Aubry (Paris, Créteil, FR)
O134 Implementation of automated mycobacterial
14:48 interspersed repetitive unit – variable number
of tandem repeat (MIRU-VNTR) typing in a
routine laboratory setting
C. Allix, P. Supply, M. Fauville-Dufaux
(Brussels, BE; Lille, FR)
Symposia
Apollon Current aspects on MRSA
15:30–
17:30 Chairpersons: Jerôme Etienne (Lyon, FR)
Gary L. French (London, UK)
S135 Current status of rapid detection
15:30 Jacques Schrenzel (Geneva, CH)
S136 The current situation of community-acquired
16:00 MRSA in Europe
Jerôme Etienne (Lyon, FR)
S137 MRSA transmission dynamics in hospitals:
16:30 will control policies finally succeed?
Ben Cooper (London, UK)
S138 Role of new therapeutics
17:00 Harald Labischinski (Wurzburg, DE)
Méditerranée 2 Mechanisms of infectious diseases:
15:30– new science and novel insights
17:30 Chairpersons: Philippe Sansonetti (Paris, FR)
Christoph M. Tang (London, UK)
S139 Neisseria meningitidis: new genes that
15:30 effect invasion
Christoph M. Tang (London, UK)
S140 Cell biology and shigellosis
16:00 Philippe Sansonetti (Paris, FR)
S141 Innate immunity and Streptococcus
16:30 pneumoniae
Robert Read (Sheffield, UK)
S142 Brucellosis: novel virulence determinants
17:00 and cellular organelles
Jean-Pierre Gorvel (Marseille, FR)
Joint symposium arranged with the Federation of
European Microbiolobical Societies (FEMS)
Hermes Foreign body infections
15:30–
17:30 Chairpersons: Mathias Herrmann (Homburg, DE)
Jean-Paul Stahl (Grenoble, FR)
S143 Staphylococci – versatile microorganisms
15:30 adapted to the foreign surface
Mathias Herrmann (Homburg, DE)
S144 Breast implant infection in aesthetic
16:00 and reconstructive surgery
Brigitte Pittet (Geneva, CH)
S145 Orthopaedic infections: tricky to diagnose,
16:30 hard to treat
Andrej Trampuz (Basel, CH)
S146 Piercing, tattooing and other body
17:00 modifications
Jean-Baptiste Guiard-Schmid (Paris, FR)
Oral Sessions
Méditerranée 3 Antimicrobial clinical trials
15:30–
17:30 Chairpersons: Roman Kozlov (Smolensk, RU)
David Denning (Manchester, UK)
O147 Skin disinfection with octenidine dihydro-
15:30 chloride for central venous catheter placement
and care – a randomised controlled trial
M. Dettenkofer, C. Wilson, A. Gratwohl,
D. Bolliger, C. Schmoor, D. Heim, H. Bertz,
D. Luft, S. Schulz, F.D. Daschner,
A.F. Widmer (Freiburg, DE; Basel, CH)
O148 Pooled analysis of the mortality and cardiac
15:42 safety of moxifloxacin
S. Choudhri, F. Krüsmann, C. Reiter
(West Haven, US; Wuppertal, DE)
O149 Short-course fluoroquinolones vs. single dose
15:54 fosfomycin for acute uncomplicated cystitis:
systematic review and meta-analysis
V. Rafalskiy, T. Perepanova, V. Bistryukov
(Smolensk, Moscow, RU)
O150 A clinical and laboratory evaluation of
16:06 PAR-101 in patients with Clostridium
difficile-associated diarrhoea
T.J. Louie, M. Miller, C. Donskey, K. Mullane,
E.J.C. Goldstein, D.M. Citron, M. Corrado,
S.L. Gorbach, P. Sears, S. Shangle, B. Walsh,
Y.-K. Shue (Calgary, Montreal, CA; Cleveland,
Chicago, Santa Monica, New Hope, San Diego, US)
www.escmid.org/eccmid2006 page 43

Scientific Programme Sunday, April 2, 2006
O151 Therapeutic drug monitoring in adult patients
16:18 receiving imipenem or cefepime therapy:
one-year single-centre experience
S. Vora, A A. Pascual, S. Bolay, P. Francioli,
T. Calandra, O. Marchetti (Lausanne, CH)
O152 Integrated analysis of efficacy of
16:30 faropenem medoxomil in the treatment
of uncomplicated skin and skin structure
infections
E.E.L. Wang, R. Echols, R. Tosiello (Louisville, US)
O153 One-week once-daily triple therapy with
16:42 esomeprazole, moxifloxacin and rifabutin is
effective in the treatment of Helicobacter
pylori resistant to both metronidazole and
clarithromycin
S. Miehlke, W. Schneider-Brachert, A. Morgner,
A. Madisch, C. Kirsch, E. Bästlein, C. Haferland,
C. Jebens, H. Knoth, M. Stolte, N. Lehn
(Dresden, Regensburg, Cologne, Görlitz, Jülich,
Bayreuth, DE)
O154 Prospective randomised trial comparing
16:54 rifabutin-based triple therapy and high-dose
dual therapy for eradication of Helicobacter
pylori resistant to both metronidazole and
clarithromycin
S. Miehlke, K. Hansky, W. Schneider-Brachert,
A. Madisch, A. Morgner, C. Kirsch, C. Haferland,
E. Bästlein, M. Buchner, E. Jacobs, M. Stolte,
N. Lehn (Dresden, Regensburg, Gorlitz, Cologne,
Ribnitz-Damgarten, Bayreuth, DE)
O155 A randomised study of cefuroxime vs.
17:06 ampicillin-sulbactam prophylaxis for
obstetrical and gynaecological operations:
an effect on Gram-negative anaerobic
bacteria associated postoperative surgical
site infections
E. Ziogos, K. Kanellakopoulou, A. Dervisoglou,
N. Galanakis, A. Papadimitriou, H. Giamarellou
(Nikaia, Haidari, GR)
O156 The efficacy and safety of cefepime:
17:18 systematic review and meta-analysis
M. Paul, D. Yahav, A. Fraser, N. Sarid,
L. Leibovici (Petah Tikva, IL)
page 44 Final Programme
Iris Epidemic influenza
15:30–
17:30 Chairpersons: Albert Osterhaus (Rotterdam, NL)
Derek Smith (Cambridge, UK)
O157 Mini state-of-the-art lecture:
15:30 Global monitoring of epidemic influenza
Derek Smith (Cambridge, UK)
O158 Fatal cases of influenza-associated
15:54 encephalopathy in the Netherlands
J. Gooskens, T. Kuiken, E. Claas, H. Harinck,
H. Baelde, W. Spaan, A. Kroes
(Leiden, Rotterdam, NL)
O159 Lack of discriminating signs in clinical
16:06 diagnosis of influenza
M. van der Hoeven, M. Scholing, P. Wever,
M. Hermans, R. Fijnheer, P. Schneeberger
(‘s-Hertogenbosch, NL)
O160 Unusual summer influenza outbreak in
16:18 a nursing home. Diagnosis and prophylactic
measures
J. Gaillat, G. Dennetiere, M. Valette,
E. Raffin-Bru (Annecy, Lyon, FR)
O161 Effects of statin therapy on the risk
16:30 of serious outcomes during influenza
epidemics
E. Hak, T. Verheij, G. van Essen, M.J.M. Bonten,
A. Hoes on behalf of ESPRIT
O162 Influenza vaccination in health workers
16:42 included in high-risk group population
A. Piñón, S. Oropeza, B. Acosta, C. Aragones,
B. Galindo (Havana, CU)
O163 Efficacy of influenza vaccination in patients
16:54 with liver cirrhosis
H.J. Cheong, C.W. Park, S.Y. Ki, Y.M. Cho, J.Y. Song,
J.E. Yeon, K.S. Byun, W.J. Kim (Seoul, KR)
O164 Clinical effectiveness of influenza vaccination
17:06 in adults with diabetes mellitus
I. Looijmans-van den akker, T. Verheij, E. Buskens,
G. Rutten, E. Hak (Utrecht, NL)
O165 Immunogenicity of baculovirus-expressed
17:18 trivalent influenza HA vaccine: randomised,
double-blind, dose-escalation single
institution study in adult patients with B-cell
lymphoma
A. Safdar, A. Rodriguez, F. Luis, J. Romaguera,
F. Hagemeister, P. McLaughlin, L. Kwak, R.B. Couch
(Houston, US)

Scientific Programme Sunday, April 2, 2006
Erato Rapid methods for the identification of
15:30– bacterial clones and pathogens
17:30
Chairpersons: Paula Kriz (Prague, CZ)
Fred C. Tenover (Atlanta, US)
O166 Mixed whole genome microarray technology
15:30 discerns a hospital-adapted subtype of Enterococcus
faecium, comparable to multilocus
sequence typing clonal complex (CC) 17
H.L. Leavis, W.J.B. van Wamel, R.J.L. Willems,
F.H. Schuren, A.C. Fluit, M.J.M. Bonten
(Utrecht, Zeist, NL)
O167 Genetic relationship between Streptococcus
15:42 pneumoniae isolates responsible for a case of
meningitis and for asymptomatic carriage in
children attending a day-care centre in Lisbon
T. Figueiredo, M. Ramirez, I. Santos-Sanches,
S. Nunes, A. Brito-Avô, R.M. Barros, I. Peres,
H. de Lencastre (Lisbon, Oeiras, PT; New York, US)
O168 Changes in the distribution of hypervirulent
15:54 complexes of Neisseria meningitidis in the
Czech Republic
P. Kriz, J. Kalmusova, M. Musilek, J. Felsberg,
R. Haugvicova, D. Caugant, K. Jolley, M. Maiden
(Prague, CZ; Oslo, NO; Oxford, UK)
O169 Rapid diagnosis of bacterial vaginosis by
16:06 terminal restriction fragment length
polymorphism profiling
F. Thies, W. König, B. König (Magdeburg, DE)
O170 Development and validation of real-time
16:18 PCR assays for a multi-centre study to
assess the prevalence and epidemiology of
shiga-toxin producing Escherichia coli in the
Netherlands
T. Schuurman, A. Roovers, W.K. van der Zwaluw,
A.A. van Zwet, L.J.M. Sabbe, A.M.D. Kooistra-Smid,
Y.T.H.P. van Duynhoven (Groningen, Goes,
Bilthoven, Arnhem, NL)
O171 Based upon repeat patterns: variable
16:30 number of tandem repeat pattern analysis
to infer clonal groupings of Staphylococcus
aureus strains from spa typing data
T. Weniger, C. Berssenbruegge, A. Mellmann,
J. Rothgänger, M. Sammeth, J. Stoye,
D. Harmsen (Munster, Wurzburg, Bielefeld, DE)
O172 Multiple locus variable number tandem
16:42 repeat assays do not differentiate between
community-associated and healthcareassociated
lineages of methicillin-resistant
Staphylococcus aureus
F. Tenover, R. Vaughn, L. McDougal, G. Fosheim,
J. McGowan Jr. (Atlanta, US)
O173 Molecular typing of Mycobacterium
16:54 tuberculosis by mycobacterial interspersed
repetitive unit – variable-number tandem
repeat analysis in Lisbon in 2003
E. Fernandes, R. Macedo, C. Furtado, L. Brum,
I. Portugal (Lisbon, PT)
O174 Clinical impact of a rapid PCR-based
17:06 identification of staphylococci directly from
positive blood cultures
P. Agmon, I. Oren, R. Finkelstein, H. Sprecher
(Haifa, IL)
O175 Clinical evaluation of a molecular-based
17:18 assay for the detection of methicillin-resistant
Staphylococcus aureus and Staphylococcus
aureus in positive blood cultures
D. Fuller, T. Davis, M. Parker, R. Buckner, J. Talbott
(Indianapolis, US)
Integrated Symposia
Athena Readdressing the importance of
15:30– Gram-negative resistance: pathogens,
17:30 practice patterns, and pharmacotherapy
Chairpersons: Jacques F. Acar (Paris, FR)
Mark H. Wilcox (Leeds, UK)
15:30 Welcome and introduction
Jacques F. Acar (Paris, FR)
S176 Pathogens: a review of Gram-negative
15:40 resistance epidemiological data
Timothy R. Walsh (Bristol, UK)
S177 Practice patterns: current Gram-negative
16:10 treatment strategies
Mark H. Wilcox (Leeds, UK)
S178 Pharmacotherapy: new help in the fight
16:40 against Gram-negative resistance
Jean M. Carlet (Paris, FR)
17:10 Panel discussion – Questions and answers
Moderator: Jacques F. Acar (Paris, FR)
17:25 Concluding remarks
Jacques F. Acar (Paris, FR)
Integrated symposium arranged by
Wyeth Pharmaceuticals
www.escmid.org/eccmid2006 page 45

Scientific Programme Sunday, April 2, 2006
Méditerranée 1 Addressing macrolide issues in community-
15:30– acquired respiratory tract infections
17:30 Chairpersons: Hartmut Lode (Berlin, DE)
Jeff Blumer (Cleveland, US)
15:30 Introduction
Hartmut Lode (Berlin, DE)
S179 Do macrolides have a role in the era of
15:35 resistance?
Thomas File (Ohio, US)
S180 Serum versus tissue concentrations for
16:00 macrolides: both sides of the story
Jeff Blumer (Cleveland, US)
S181 Northern versus Southern Europe debate:
16:25 the value of macrolides in the management
of RTIs
Mark Woodhead (Manchester, UK);
Francesco Blasi (Milan, IT)
17:00 Panel discussion:
Importance of macrolides in RTIs
Co-chairs and faculty
17:25 Closing remarks
Jeff Blumer (Cleveland, US)
Integrated symposium arranged by Pfizer
Clio Redesigning beta-lactams to combat
15:30– resistance
17:30 Chairpersons: Gian Maria Rossolini (Siena, IT)
Fred Goldstein (Paris, FR)
15:30 Welcome and introduction:
combating resistance in a challenging,
changing environment
Fred W. Goldstein (Paris, FR)
S182 Local surveillance: location, location, location!
15:40 David M. Livermore (London, UK)
S183 Bridge to new treatment options: antibiotic
16:05 resistance in community-acquired MRSA
Patrice Courvalin (Paris, FR)
S184 In vitro profile of a new ß-lactam with activity
16:30 against MRSA
Mark Jones (Hilversum, NL)
S185 Clinical profile of ceftobiprole, a novel
16:55 ß-lactam antibiotic
Gary J. Noel (New Jersey, US)
17:20 Questions and answers
Gian Maria Rossolini (Siena, IT)
Integrated symposium arranged by Janssen-Cilag
page 46 Final Programme
Calliope Advances in antifungal therapy
15:30–
17:30 Chairpersons: t.b.c.
S186 A revival of epidemiological data and impact
15:30 on pre-emptive strategy
t.b.c.
S187 Treatment of aspergillosis, update on
16:10 available options
Oliver Cornely (Cologne, DE)
S188 Management of high risk patients
16:50 Ben de Pauw (Nijmegen, NL)
Integrated symposium arranged by
Gilead Sciences
Late Breaker Session
Apollon Avian influenza
17:45–
18:45 Chairpersons: Andreas Voss (Nijmegen, NL)
Pierre Dellamonica (Nice, FR)
S2273 Avian flu – the Turkish experience
17:45 Serhat Ünal (Ankara, TR)
S2274 Avian flu – a threat to mankind?
18:15 Klaus Stöhr (Geneva, WHO)

Scientific Programme Monday, April 3, 2006
Meet-the-Expert Sessions
Méditerranée 2 Recent treatment issues in tuberculosis
E189 and non-tuberculosis mycobacteria
07:15– Experts: Richard Wallace (Tyler, US)
08:15– Bertrand Dautzenberg (Paris, FR)
Objectives:
– to be familiar with recently revised American
Thoracic Society recommendation for
treatment of M. avium complex (MAC) lung
disease, including a three-times-weekly
regimen
– to appreciate the limitations of susceptibility
testing for non-tuberculosis mycobacteria,
especially for MAC
– to be knowledgeable of current accepted
treatment regimens for PPD positive individuals
(converters or high risk individuals),
including those who are HIV positive
Méditerranée 3 The role of epidemiology and typing
E190 in outbreak investigation
07:15– Experts: Panayotis T. Tassios (Athens, GR)
08:15– Jean-Claude Desenclos (Saint-Maurice, FR)
Objectives:
– to describe the distinct but complementary
contributions of epidemiology and typing
– to assess different examples of outbreak
investigations, e.g.: common source vs.
person-to-person, community- vs. hospitalacquired
– to demonstrate the need for continuous
feedback between epidemiology and typing
at different stages of an investigation
Iris How to interpret laboratory test results?
E191 Experts: George Schmid (Geneva, WHO)
07:15– Achim Schwenk (London, UK)
08:15–
Objectives:
– to interpret sensitivity, specificity, and
predictive values of laboratory tests in
clinical practice
– to understand how knowing the process of
determining cut-off values for separating
positive from negative tests results can
influence clinical practice
– to understand the concepts of pre-test and
post-test probability
– to understand the concept of numbersneeded-to-test
Hermes Minimal requirements for an effective
E192 infection control surveillance
07:15– Experts: Andreas Widmer (Basel, CH)
08:15– Marc Bonten (Utrecht, NL)
Objectives:
– to provide an overview of different
surveillance systems
– to establish sensitivity and specificity of
systems in comparison to workload
– to show principles and examples of computer
support for surveillance
– to examine practical issues:
incidence vs. prevalence, pitfalls
Clio Beta-lactamases: from bench to bedside
E193 Experts: Patrice Nordmann (Paris, FR)
07:15– Yehuda Carmeli (Tel Aviv, IL)
08:15–
Objectives:
– to identify the main broad-spectrum betalactamase-mediated
resistance phenotypes
in Gram-negative rods
– to know the spread and distribution of the
expanded-spectrum beta-lactamases in
Gram-negative rods worldwide
– to discuss the therapeutic alternatives for
treating infected patients
Erato Clinical trials and clinical practice
E194 Experts: Ben de Pauw (Nijmegen, NL)
07:15– David Denning (Manchester, UK)
08:15–
Objectives:
– to identify pitfalls in clinical trial on antifungal
agents, such as inclusion and exclusion
criteria, endpoints and others
– to translate trial data for use in treatment of
invasive fungal infections
– to discuss the relevance of meta-analysis
statistics
www.escmid.org/eccmid2006 page 47

Symposia
Scientific Programme Monday, April 3, 2006
Apollon The pros and cons of combination
08:30– antimicrobial treatment
10:30 Chairpersons: Murat Akova (Ankara, TR)
Bernhard Ruf (Leipzig, DE)
S195 Single-drug therapy for community-acquired
08:30 pneumonia
Tobias Welte (Hannover, DE)
S196 Combination therapy for community-acquired
09:00 pneumonia
Antoni Torres (Barcelona, ES)
S197 Combination antifungals: in dubio agite
09:30 Murat Akova (Ankara, TR)
S198 Combination antifungals: in dubio abstine
10:00 Claudio Viscoli (Verona, IT)
Méditerranée 2 Emerging viral exotica in Europe
08:30–
10:30 Chairpersons: Jean-Claude Desenclos
(Saint-Maurice, FR)
Carl Erik Nord (Stockholm, SE)
S199 West Nile fever in Europe – is there an issue?
08:30 Jean-Claude Desenclos (Saint-Maurice, FR)
S200 Rabies and other lyssaviruses in Europe 2006
09:00 Mary J. Warrell (Oxford, UK)
S201 Toscana virus: emergence in southern Europe
09:30 Remi N. Charrel (Marseille, FR)
S202 Viral haemorrhagic fever: diagnosis and
10:00 management of highly contagious diseases
Christoph Hatz (Basel, CH)
Joint symposium arranged with the International
Society for Infectious Diseases (ISID)
Iris Infections in the immunocompromised host
08:30–
10:30 Chairpersons: Per Ljungman (Stockholm, SE)
Catherine Cordonnier (Paris, FR)
S203 Post-transplantation lymphoproliferative
08:30 disease – more surprises from EBV
David Nadal (Zurich, CH)
S204 Infections complications associated
09:00 with novel immunosuppressive therapies
Georg Maschmeyer (Potsdam, DE)
S205 Infections in non-myeloablative
09:30 stem-cell recipients
Catherine Cordonnier (Paris, FR)
page 48 Final Programme
S206 Vaccination strategies in transplant recipients
10:00 Per Ljungman (Stockholm, SE)
Joint symposium arranged with the International
Immunocompromised Host Society (ICHS)
Hermes Relationship between antimicrobial
08:30– resistance and virulence
10:30 Chairpersons: Tibor Pal (Pecs, HR)
Robert Moellering (Boston, US)
S207 Drug resistance and fitness in Mycobacterium
08:30 tuberculosis
Stewart Cole (Paris, FR)
S208 Connexion between efflux pump expression
09:00 and virulence in Pseudomonas aeruginosa
José Luis Martinez (Madrid, ES)
S209 Quinolone resistance and virulence
09:30 in uropathogenic Escherichia coli
Jordi Vila (Barcelona, ES)
S210 Efflux pump expression and bacterial
10:00 survival in Neisseria gonorrhoeae
William M. Shafer (Atlanta, US)
Oral Sessions
Méditerranée 3 Diagnostic and laboratory methods
08:30–
10:30 Chairpersons: Johan van Eldere (Leuven, BE)
Luis Martinez-Martinez
(Santander, ES)
O211 Impact on mortality and cost- effectiveness
08:30 of rapid bacterial identification and antimicrobial
susceptibility testing in comparison with
standard methods
J.J. Kerremans, P. Verboom, W.H.F. Goessens,
L. Hakkaart-van Roijen, T. Stijnen, H.A. Verbrugh,
M.A. Vos (Rotterdam, NL)
O212 Comparison of NucliSens easyMAG,
08:42 NucliSens miniMAG and Qiagen nucleic acid
extraction systems using throat swabs for
the detection of M. pneumoniae and
C. pneumoniae
K. Loens, K. Bergs, D. Ursi, H. Goossens,
M. Ieven (Edegem, BE)

Scientific Programme Monday, April 3, 2006
O213 Intelligent sample preparation to improve
08:54 nucleic acid-based pathogen detection
S. Sachse, K.H. Schmidt, M. Lehmann,
S. Russwurm, E. Straube (Jena, DE)
O214 Point-of-care detection of group B streptococci
09:06 in labouring women: a new approach to
preventing early onset neonatal GBS disease
E.H. Smith, P. Milner, J. Gray, L. Spicer
(Birmingham, UK)
O215 Sepsis diagnosis by real-time PCR
09:18 (SeptiFast Kit, Roche Diagnostics):
preliminary results and possible application
A. Raglio, M. Rizzi, M. Amer, M. Mangia,
M.G. Lucà, A. Goglio (Bergamo, IT)
O216 Evaluation of four selective media
09:30 for the detection of methicillin-resistant
Staphylococcus aureus from surveillance
specimens
B.M. Willey, N. Kreiswirth, P. Akhavan, A. Tyler,
S. Malek, V. Pong-Porter, G. Small, N. Nelson,
A. McGeer, S.M. Poutanen, T. Mazzulli, D.E. Low,
M. Skulnick (Toronto, CA)
O217 Diagnostic value of procalcitonin to
09:42 distinguish monomicrobial blood stream
infection with coagulase-negative staphylococci
from contamination: a pilot study
P. Schuetz, B. Mueller, A. Trampuz (Basel, CH)
O218 Borrelia burgdorferi serodiagnosis: evaluation
09:54 of a novel Luminex bead-based recombinantantigen
assay
D. Burki, S. Reymann, M. Toelge, J. Schipper,
L. Matter (Basel, CH; Neuried, DE)
O219 Development of a panfungal real-time PCR
10:06 H.P. Hinrikson, K. Jaton, D. Ciardo, M. Altwegg,
J. Bille, P.M. Hauser (Lausanne, Zurich, Lucerne, CH)
Erato Pneumonia and pneumococci
08:30–
10:30 Chairpersons: Javier Garau (Barcelona, ES)
Waleria Hryniewicz (Warsaw, PL)
O220 The International Circumpolar Surveillance
08:30 System for population-based surveillance
of invasive pneumococcal disease, 1999–2004
M. Bruce, T. Cottle, S. Deeks, M. Lovgren,
L. Jette, T. Hennessy, D. Parks, K. Kristinsson,
K. Brinklov Jensen, O. Lovoll, P. Nuorti,
A. Nystedt, E. Herva, A. Koch, A. Parkinson
(Anchorage, US; Ottawa, Edmonton, Montreal,
CA; Reykjavik, IS; Nuuk, GL; Oslo, NO; Helsinki, FI;
Lulea, SE; Oulu, FI; Copenhagen, DK)
O221 Invasive pneumococcal disease in the era of
08:42 human immunodeficiency virus infection
O. Perovic, A. von Gottberg, C. Feldman,
O. Perovic (Johannesburg, ZA)
O222 Are Pneumonia Severity Index and CURB-65
08:54 useful for prediction of 30-day mortality in
community-acquired pneumonia?
K. Strålin, H. Holmberg (Örebro, SE)
O223 Tigecycline is as safe and effective as
09:06 levofloxacin in treating patients with
community-acquired pneumonia
N. Dartois, H. Gandjini, E.J. Ellis-Grosse
on behalf of the Tigecycline 313 Study Group
O224 Risk factors for Pseudomonas aeruginosa
09:18 isolation in sputum at hospital admission
in patients hospitalised for acute COPD
exacerbation
C. Garcia Vidal, P. Almagro, V. Romaní, H. Monzón,
L. Cuadra, M. Rodriguez, E. Cuchí, L. Canales,
J.L. Heredia, J. Garau (Terrassa, ES)
O225 Does low antibiotic consumption influence
09:30 microbiological findings in patients with
COPD exacerbations?
Z.B. Harboe, J.H. Wandall, J.D. Knudsen
(Frederiksberg, Hvidovre, DK)
O226 Management of severe community-
09:42 acquired pneumonia
C. Brun-Buisson, A.T. Kouatchet
for the French Severe Pneumonia Study Group
O227 Treatment and mortality from bacteraemic
09:54 pneumococccal disease in Toronto, Canada
K. Green, A. Shigayeva for the Toronto Invasive
Bacterial Diseases Network (TIBDN)
O228 Antimicrobial susceptibility of pneumococcal
10:06 isolates causing bacteraemic communityacquired
pneumonia in the public and private
sectors in Gauteng, South Africa
C. Feldman, A. Brink, A. von Gottberg,
L. de Gouviea, O. Perovic, K. Klugman
(Johannesburg, ZA)
O229 Outcome of adults with penicillin high-resistant
10:18 and susceptible invasive Streptococcus
pneumoniae community-acquired pneumonia
M. Mufson, G. Chan, R. Stanek (Huntington, US)
www.escmid.org/eccmid2006 page 49

FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS
PRESCRIBING INFORMATION. CUBICIN, 350 mg powder for concentrate
for solution for infusion. (Refer to Summary of Product Characteristics (SmPC)
before prescribing.) PRESENTATION: Powder for concentrate for solution for infusion. A pale
yellow to light brown lyophilised powder. Each vial contains 350 mg daptomycin. USES: For the
treatment of complicated skin and soft-tissue infections in adults caused by susceptible Gram positive
pathogens. DOSAGE AND ADMINISTRATION: 4 mg/kg administered by iv infusion and
administered over 30 minutes every 24 hours for 7-14 days or until the infection is resolved. CUBICIN
is not recommended for use in children and adolescents (< 18 years of age). In patients
with severe renal insufficiency the dose should be adjusted. See SmPC for full details.
CONTRAINDICATIONS: Hypersensitivity to the active substance or excipient. PRECAUTIONS:
CUBICIN is not recommended for use in patients with a concurrent bacteraemia, as data are limited.
CUBICIN is not effective in pneumonia. Creatine phosphokinase and myopathy: CPK levels
should be measured at baseline and at least once weekly. Patients with CPK > 5 times upper limit
normal at baseline and other patients at higher risk of developing myopathy should be monitored
more frequently. CUBICIN should only be administered to those patients taking other medication
associated with myopathy if it is considered that the benefit to the patient outweighs the risk. Patients
should be reviewed regularly for signs or symptoms of myopathy. Patients developing unexplained
muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days.
CUBICIN should be discontinued in the presence of unexplained muscle symptoms if CPK levels reach
> 5 times upper limit normal. Peripheral neuropathy: Patients developing signs or symptoms
should be investigated and consideration given to discontinuing treatment. Renal insufficiency:
Severe renal insufficiency may increase the risk of myopathy (see above). Dose adjustment is needed
in patients with creatinine clearance (CL/cr) < 30 ml/min (4 mg/kg q 48 hours). Caution is advised
before commencing and during therapy in patients with some degree of renal insufficiency (CL/cr
< 80 ml/min). Regular monitoring of renal function is advised during concomitant administration
of potentially nephrotoxic agents. Caution is recommended in very obese patients. Appropriate
measures should be taken if super infection occurs or if antibiotic-associated or pseudo membranous
colitis are suspected. Pregnancy and lactation: CUBICIN should not be administered in pregnancy
unless the potential benefit outweighs the risk. Breastfeeding should be discontinued during treatment
with CUBICIN. Interactions: No CYP 450 interactions are expected. It is recommended that
other medications associated with myopathy should, if possible, be temporarily discontinued during
treatment with CUBICIN unless the benefit of concomitant administration outweighs the risk. Caution
is advised when daptomycin is co-administered with any other medicinal product known to reduce
renal filtration. If unexplained abnormalities or PT/INR are observed in patients taking daptomycin,
consideration should be given to a possible in vitro interaction with the laboratory test. ADVERSE
REACTIONS: For subjects in clinical trials who received CUBICIN, the most frequently reported
adverse reactions were headache, nausea, vomiting, diarrhoea, muscle pain, fungal infections, rash,
infusion site reaction, increased Creatine phosphokinase (CPK) and abnormal liver enzymes; Alanine
aminotransferase (ALT), Aspartate aminotransferase (AST) and Alkaline phosphatase. Consult SmPC
for detailed listing. PACKAGE QUANTITIES AND BASIC NHS PRICE: £62 per single vial.
MARKETING AUTHORISATION NUMBER: EU/1/05/328/001 held by Chiron Corporation
Ltd, Symphony House, 7 Cowley Business Park, High Street, Cowley, Uxbridge UB8 2AD. LEGAL
CATEGORY: POM. Date of preparation: January 2006.CUBICIN ® is a registered trademark.
Information about adverse event reporting can be found at
www.yellowcard.gov.uk and adverse events should be reported
to the MAA holder: Chiron Corporation Ltd, Symphony House,
7 Cowley Business Park, High Street, Cowley, Uxbridge UB8 2AD.
CM/06/005

Integrated Symposia
Scientific Programme Monday, April 3, 2006
Athena Respiratory tract infections: at-risk patients,
08:30– who are they?
10:30 Chairpersons: Alasdair Geddes (Birmingham, UK)
Jean-Pierre Sollet (Argenteuil, FR)
08:30 Introduction: at-risk patient definition
Alasdair Geddes (Birmingham, UK)
S230 At-risk pathogens: what are they?
08:35 Rafael Cantón (Madrid, ES)
S231 Clinical and therapeutic significance of
09:00 risk factors in RTI patients
Hartmut Lode (Berlin, DE)
S232 Guide to selection of appropriate treatment
09:30 in pneumonia
Wolfgang Graninger (Vienna, AT)
S232A Pharmacoeconomic consideration for the
10:00 use of fluoroquinolones in the treatment of
at-risk patients
Gary Milkovich (Woodbridge, US)
10:25 Conclusion
Jean-Pierre Sollet (Argenteuil, FR)
Integrated symposium arranged by
sanofi-aventis
Méditerranée 1 Extending the antifungal armamentarium
08:30–
10:30 Chairpersons: Thomas Patterson (San Antonio, US)
Patricia Ribaud (Paris, FR)
08:30 Welcome and opening remarks
Patricia Ribaud (Paris, FR)
S233 Recent developments in the mycology
08:35 laboratory
Mahmoud Ghannoum (Cleveland, US)
S234 Impact of early therapy on invasive
09:00 fungal infections
Thomas Patterson (San Antonio, US)
S235 New treatment options for candidemia –
09:25 azoles versus candins
Bart-Jan Kullberg (Nijmegen, NL)
Markus Ruhnke (Berlin, DE)
10:15 Panel discussion
10:25 Concluding remarks
Thomas Patterson (San Antonio, US)
Integrated symposium arranged by Pfizer
Clio Fighting the threat of resistance:
08:30– an interactive symposium
10:30 Chairpersons: Robert Masterton (Kilmarnock, UK)
Philippe Montravers (Paris, FR)
08:30 Welcome and introduction
Philippe Montravers (Paris, FR)
S236 Porins, pumps, enzymes and other
resistance threats
David Livermore (London, UK)
S237 Novel dosage regimens to fight resistance
George Drusano (Albany, US)
Panel discussion
S238 Interactive case history: a patient with
a severe abdominal gunshot wound
Robert Masterton (Kilmarnock, UK)
Philippe Montravers (Paris, FR)
Summary
Philippe Montravers (Paris, FR)
Integrated symposium arranged by AstraZeneca
Calliope Lipopeptide: the class of 2006
08:30–
10:30 Chairpersons: Roger Finch (Nottingham, UK)
Adolf Karchmer (Boston, US)
S239 Gram-positive infections:
08:30 lessons learnt and novel solutions
Roger Finch (Nottingham, UK)
08:50 Questions and answers
S240 Test results
09:00 Bernd Wiedemann (Bonn, DE)
09:20 Questions and answers
S241 From theory to practice
09:30 Adolf Karchmer (Boston, US)
09:50 Questions and answers
S242 Daptomycin: graduation day
10:00 Marc Bonten (Utrecht, NL)
10:20 Questions and answers
Integrated symposium arranged by Chiron
www.escmid.org/eccmid2006 page 51

Keynote Lectures
Scientific Programme Monday, April 3, 2006
Apollon Antimicrobial intelligence: how eukaryotes
11:00– combat the quorum sensing strategy
12:00 Chairperson: Robert Read (Sheffield, UK)
K243 Andrea Sbarbati (Verona, IT)
11:00
Athena Clean care is safer care: a WHO initiative
11:00– to improve patient safety worldwide
12:00 Chairperson: Andreas Voss (Nijmegen, NL)
K244 Didier Pittet (Geneva, CH)
11:00
Méditerranée 1 Human papillomavirus: impact of disease
11:00– and vaccine intervention
12:00 Chairperson: S. Ragnar Norrby (Stockholm, SE)
K245 Mario Poljak (Ljubljana, SI)
11:00
Calliope Human genetic susceptibility to infection:
11:00– from basic research to society issues
12:00 Chairperson: Pierre Dellamonica (Nice, FR)
K246 Amalio Telenti (Lausanne, CH)
11:00
Award Lectures
Méditerranée 2 ESCMID Young Investigator Award Lectures
11:00–
12:00 Chairperson: Marc Struelens (Brussels, BE)
S2271 Biology and pathogenecity of Chlamydia-like
11:00 organisms
Gilbert Greub (Lausanne, CH)
S2272 MRSA – from innovative control strategies to
11:30 new challenges
Stephan Harbarth (Geneva, CH)
The ESCMID Young Investigator Awards are
sponsored by Pfizer (see also page 18/19)
page 52 Final Programme
Poster Session III
Topics Session III
Presence of authors: 12:00–13:00
– Molecular detection of microbes
● P941–P963
– Molecular detection of respiratory microbes ● P964–P975
– Diagnostic and laboratory methods
for bacteria – I
P976–P998
– Bloodstream infections P999–P1013
– ICU infections P1014–P1028
– Gastro-intestinal and hepatic infections P1029–P1038
– Respiratory tract infections P1039–P1062
– Sexually transmitted diseases P1063–P1068
– Travel medicine, tropical and
parasitic diseases
P1069–P1092
– Seroepidemiology P1093–P1101
– Mycobacterial infections P1102–P1142
– Experimental infections: treatment
and pathogenesis
P1143–P1158
– Bacterial pathogenesis – II
★ P1159–P1197
12:15–13:00
Guided Poster Walks Session III
Theme: Molecular detection
Chairperson: Margareta Ievens (Edegem, BE)
Meeting point: Poster P941 at 12:15
Posters selected from within the topics marked ●
Theme: Bacterial pathogenesis
Chairpersons: Christoph Tang (London, UK)
William Shafer (Atlanta, US)
Meeting point: Poster P1159 at 12:15
Posters selected from within the topic marked ★

Poster Session IV
Topics Session IV
Presence of authors: 13:00–14:00
Scientific Programme Monday, April 3, 2006
– Mechanism of antifungal action and ● P1198–P1232
resistance to antifungals in fungal disease
– Antimicrobial resistance, P1233–P1257
permeability and fitness
– Antimicrobial susceptibility testing P1258–P1286
– Antibacterial susceptibility studies – II P1287–P1310
– Tigecycline in vitro studies – II P1311–P1329
– Nosocomial infection control: P1330–P1340
MRSA and VRE
– Regional spread and outbreaks caused P1341–P1354
by nosocomial pathogens
– Multidrug-resistant Gram-negative P1355–P1372
organisms: survey and risk factors
– Epidemiology of resistance to antibiotics – I P1373–P1402
– Beta-lactamases P1403–P1420
– Non-molecular diagnostics of MRSA ★ P1421–P1431
– Antibiotic susceptibility testing:
★ P1432–P1459
management, specific organisms and
resistant traits
13:00–13:45
Guided Poster Walks Session IV
Theme: Mechanisms of antifungal action
Chairpersons: Jacques Bille (Lausanne, CH)
David Denning (Manchester, UK)
Meeting point: Poster P1198 at 13:00
Posters selected from within the topic marked ●
Theme: MRSA diagnostics and susceptibility testing
Chairpersons: Wolfgang Witte (Wernigerode, DE)
Jerome Etienne (Lyon, FR)
Meeting point: Poster P1421 at 13:00
Posters selected from within the topics marked ★
Symposia
Apollon Emergence of transferable quinolone
14:00– resistance
15:00 Chairpersons: David Hooper (Boston, US)
Laurent Gutmann (Paris, FR)
S247 World emergence of qnr, a novel family
14:00 of quinolone resistance genes
David Hooper (Boston, US)
S248 The toxin-antitoxin systems: function
14:30 and distribution in the bacterial world
Laurence Van Melderen (Gosselies, BE)
Joint symposium arranged with the
ICAAC Program Committee
Athena The year in HIV medicine
14:00–
15:00 Chairperson: Giovanni Di Perri (Turin, IT)
S249 The year in HIV medicine (1)
14:00 Françoise Brun-Vezinet (Paris, FR)
S250 The year in HIV medicine (2)
14:30 Frank-Detlef Goebel (Munich, DE)
Méditerranée 3 Hepatitis
14:00–
15:00 Chairpersons: Andy Hoepelman (Utrecht, NL)
Will Irving (Nottingham, UK)
S251 Co-infection with HIV, HBV and HCV
14:00 Dominique Salmon-Ceron (Paris, FR)
S252 Hepatitis C is still a nosocomial infection
14:30 Will Irving (Nottingham, UK)
Clio Management of endocarditis
14:00–
15:00 Chairpersons: Patrick Francioli (Lausanne, CH)
José Miró (Barcelona, ES)
S253 Antibiotic treatment of infective endocarditis
14:00 due to antibiotic resistant bacteria
José Miró (Barcelona, ES)
S254 Management of complicated endocarditis
14:30 Bruno Hoen (Besançon, FR)
www.escmid.org/eccmid2006 page 53

Scientific Programme Monday, April 3, 2006
Calliope PK/PD for the clinician: should we use
14:00– continuous infusion techniques?
15:00 Chairpersons: William Craig (Madison, US)
George Drusano (Albany, US)
S255 Beta-lactams
14:00 Johan Mouton (Nijmegen, NL)
S256 Glycopeptides
14:30 Niels Frimodt-Moller (Copenhagen, DK)
Oral Sessions
Méditerranée 1 Infectivity and emergence of resistance
14:00– in animal models
15:00 Chairpersons: Gian Maria Rossolini (Siena, IT)
Philippe Moreillon (Lausanne, CH)
O257 Infectivity of probiotic Lactobacillus
14:00 rhamnosus and Lactobacillus paracasei in a
rat model of experimental endocarditis
V. Vankerckhoven, S. Piu, P. Moreillon,
M. Vancanneyt, H. Goossens, J.M. Entenza
(Wilrijk, BE; Lausanne, CH; Ghent, BE)
O258 Dissemination of Borrelia burgdorferi
14:12 sensu lato in mice: influence of the species
and of the primary human isolation site
S.J. De Martino, C. Sordet, Y. Piemont,
C. Barthel, E. Collin, J. Sibilia, B. Jaulhac
(Strasbourg, FR)
O259 Subinhibitory concentrations of phenyl lactic
14:24 acid produced by Lactobacillus probiotic
strains attenuate the virulence of
Peudomonas aeruginosa and Staphylococcus
aureus in mouse infection model
M.C. Balotescu, V. Lazar, A. Israil, L. Ditu,
C. Larion, I. Alexandru, C. Bleotu, R. Cernat
(Bucharest, RO)
O260 Rifampin induction of resistance in
14:36 Acinetobacter baumannii, in vitro and in
an experimental pneumonia murine model
M.E. Pachón-Ibáñez, F. Fernández-Cuenca,
F. Docobo-Pérez, J. Pachón, A. Pascual
(Seville, ES)
O261 Experimental dose regimen modelling
14:48 of intestinal emergence of Enterococcus
faecalis resistant to linezolid in gnotobiotic
mice
N. Bourgeois-Nicolaos, B. Couson, L. Massias,
A. Andremont, F. Doucet-Populaire
(Paris, Le Chesnay, FR)
page 54 Final Programme
Méditerranée 2 Infection in the immunocompromised
14:00– host (except HIV)
15:00 Chairpersons: Nicole Blijlevens (Nijmegen, NL)
Leonard Leibovici (Petah-Tiqva, IL)
O262 Epidemiology of fungal infections in
14:00 haematological stem cells transplanted
patients: SEIFEM 2004 study
L Pagano, M. Caira, M.T. Van Lint, G. Irrera,
A Bonini, A. Candoni, C. Caramatti, M. Picardi,
R. Invernizzi, D. Mattei, L. Fianchi, P. Falcucci,
G. Reddiconto, C.G. Valentini, L. Melillo,
M.R. Fadda, A. Nosari, C. Girmenia, F. Aversa
on behalf of SEIFEM (Sorveglianza Epidemiologica
Infezioni Fungine Nelle Emopatie Maligne)
O263 Clustering of Pneumocystis jiroveci
14:12 pneumonia cases in renal transplant
recipients: coincidence or a clue for patientto-patient
transmission?
M.G.J. de Boer, L.E.S. Bruijnesteijn van
Coppenraet, A. Gaasbeek, S.P. Berger,
L.B.S. Gelinck, E.J. Kuijper, F.P. Kroon,
J.P. Vandenbroucke (Leiden, NL)
O264 Nosocomial legionellosis outbreak occurring
14:24 in immunosuppressed patients in a cancer
centre
C. Gudiol, J. Carratala, M.A. Dominguez,
R. Verdaguer, A. Fernandez-Sevilla, F. Gudiol
(Barcelona, ES)
O265 Implications of the evidence for antibiotic
14:00 prophylaxis for cancer patients with
neutropenia: updated meta-analysis
L. Leibovici, A. Gafter-Gvili, M. Paul, A. Fraser,
M. Cullen (Petah Tikva, IL; Birmingham, UK)
O266 Bacteraemia in Danish patients with
14:36 haematological malignancies: coverage and
impact of inappropriate empirical antibiotic
treatment on 7-day and 30-day mortality
M. Nørgaard, H. Larsson, G. Pedersen,
H.C. Schønheyder, H.T. Sørensen
(Aalborg, Aarhus, DK)
Iris Multidrug-resistant Gram-negative
14:00– organisms in the hospital and community
15:00 Chairpersons: Rafael Cantón (Madrid, ES)
Marek Gniadkowski (Warsaw, PL)
O267 Risk factors for faecal carriage of extended
14:00 spectrum beta-lactamase producing
Escherichia coli and Klebsiella spp. in the
community
Ö.K. Azap, H. Arslan, S.Ö. Karaman,
T. Togan (Ankara, TR)

Scientific Programme Monday, April 3, 2006
O268 Differences in the epidemiology of
14:12 extended-spectrum beta-lactamase producing
Escherichia coli according to the types of
enzymes
J. Rodríguez-Bano, M.D. Navarro, L. Romero,
M.A. Muniain, J.R. Hernández-Bello, A. Pascual
(Seville, ES)
O269 Frequency and predictors of colonisation
14:24 of the respiratory tract by Gram-negative
bacteria with the blaVIM gene in patients of a
newly established intensive care unit
M. Horianopoulou, N. Legakis, M. Kanellopoulou,
S. Lambropoulos, A. Tsakris, M. Falagas (Athens, GR)
O270 Epidemiological investigation of quinolone
14:36 resistance in infections due to extendedspectrum
beta-lactamase-producing
Enterobacteriaceae in a tertiary hospital
A. Katsandri, A. Vasilakopoulou, V. Mela,
G.L. Petrikkos, C. Kosmidis, J. Papaparaskevas,
A. Avlamis (Athens, GR)
O271 The changing epidemiology of sequential
14:48 outbreaks of multiresistant Acinetobacter
baumannii bacteraemia: a ten-year study in
an intensive care unit
J.J. Camarena, R. Gonzalez, R. Zaragoza,
J.C. Navarro, S. Sancho, A. Artero, J.M. Nogueira
(Valencia, ES)
Hermes Infection control
14:00–
15:00 Chairpersons: Benedetta Allegranzi (Vicenza, IT)
Serhat Ünal (Ankara, TR)
O272 New World Health Organization alcohol-
14:00 based formulations to implement handrubbing
as the gold standard for hand hygiene worldwide
B. Allegranzi, A. Voss, M. Rotter, S. Sattar,
W. Griffiths, S. Dharan, L. Donaldson, D. Pittet
(Verona, IT; Nijmegen, NL; Vienna, AT; Ottawa CA;
Geneva, CH)
O273 Decrease of external ventricular- or lumbar
14:12 drain-related infections by a multidisciplinary
approach
M.A. Leverstein-van Hall, T.E.M. Hopmans,
H.E.M. Blok, J.W. Berkelbach van der Sprenkel,
M.J.M. Bonten on behalf of the UMCU Working
Party Neurosurgical Drain infections
O274 Evidence for the effectiveness of ‘Search
14:24 and destroy’ of methicillin-resistant
Staphylococcus aureus in the Netherlands
M.J.C.A. van Trijp, D.C. Melles, A. Ott,
W.D.H. Hendriks (Rotterdam, NL)
O275 Reducing the impact of methicillin-
14:36 resistant Staphylococcus aureus infection in
an intensive care unit: a nine-year analysis
A. Pan, E. Raineri, P. Mondello, L. Ferrari,
G. Carnevale, A. Acquarolo, S. Lorenzotti, S. Magri,
L. Soavi, L. Crema (Brescia, Cremona, IT)
O276 Comparison of the bacterial efficacy
14:48 and acceptability of an alcohol-based hand
rinse with two alcohol-based hand gels
during routine patient care
F. Barbut, E. Maury, L. Goldwirt, D. Neyme,
R. Aman, B. Rossi, P. Boelle, G. Offenstadt
(Paris, FR)
Integrated Symposium
Erato Galactomannan antigen detection in
14:00– invasive aspergillosis: test optimisation and
15:00 impact on patient management
Chairpersons: Jacques Bille (Lausanne, CH)
Paul E. Verweij (Nijmegen, NL)
S277 Optimisation of the cut-off value of the
14:00 Platelia Aspergillus ELISA
Paul E. Verweij (Nijmegen, NL)
S278 Galactomannan and computed tomography-
14:30 based preemptive antifungal therapy in
neutropenic patients at high risk for invasive
fungal infections
Johan Maertens (Leuven, BE)
Integrated symposium arranged by
Bio-Rad Laboratories
Symposia
Apollon How to detect the next emerging pathogen
15:30–
17:30 Chairpersons: Xavier De Lamballerie (Marseille, FR)
Marion Zambon (London, UK)
S279 From clinicians and microbiologists to
15:30 the WHO: expectations from the new
international health regulations
Maxwell Hardiman (Geneva, WHO)
S280 What is the role of the European CDC for
16:00 the detection of emerging pathogens?
Johan Giesecke (Stockholm, ECDC)
S281 Lessons learnt from SARS, H7N7 and
16:30 H5N1 avian flu
Christian Drosten (Hamburg, DE)
S282 How to detect new viral agents and
17:00 what Europe should do
Xavier de Lamballerie (Marseille, FR)
www.escmid.org/eccmid2006 page 55

Scientific Programme Monday, April 3, 2006
Méditerranée 2 To treat or not to treat
15:30–
16:30 Chairpersons: Frank Detlef Goebel (Munich, DE)
Wolfgang Graninger (Vienna, AT)
S283 Positive blood culture with Staphyloccus
15:30 epidermidis
Winfried V. Kern (Freiburg, DE)
S284 Candida infections
16:00 Wolfgang Graninger (Vienna, AT)
16:30– Problems in the treatment of HIV
17:30
Chairpersons: Frank Detlef Goebel (Munich, DE)
Wolfgang Graninger (Vienna, AT)
S285 HIV-treatment: when, how and against what –
16:30 recent surprises
Jens Lundgren (Copenhagen, DK)
S286 The management of therapeutic failure
17:00 Giovanni Di Perri (Turin, IT)
Hermes Paediatric respiratory tract infections:
15:30– the major killers
17:30 Chairpersons: S. Ragnar Norrby (Stockholm, SE)
Annika Linde (Solna, SE)
S287 The link between asthma and viral respiratory
15:30 infections
Nikos Papadopoulos (Athens, GR)
S288 Paediatric influenza: severity and need
16:00 for protection
Annika Linde (Solna, SE)
S289 Human metapneumovirus infections
16:30 in children: approaches for prevention
Bernadette van den Hoogen (Rotterdam, NL)
S290 Paediatric tuberculosis: not to be forgotten
17:00 Sam Walters (London, UK)
Clio Evidence-based preventive and control
15:30– measures for selected nosocomial pathogens:
17:30 a critical appraisal
Chairpersons: Christian Ruef (Zurich, CH)
Andreas Voss (Nijmegen, NL)
S291 MRSA
15:30 Marc Bonten (Utrecht, NL)
S292 Multi-drug resistant Gram-negative bacteria
16:00 Yehuda Carmeli (Tel Aviv, IL)
S293 Norovirus
16:30 Andreas Widmer (Basel, CH)
page 56 Final Programme
S294 Risk factors for the acquisition of
17:00 vancomycin-resistant enterococci (VRE) and
clinical practice
Evelina Tacconelli (Rome, IT)
Calliope Limiting antibiotic usage in the community:
15:30– benefits and collateral effects
17:30
Chairpersons: Dominique L. Monnet
(Copenhagen, DK)
Hermann Goossens (Edegem, BE)
S295 What impact does the European ban of
15:30 antibiotics in animal feed have on antibiotic
resistance of animal bacteria?
Frank M. Aarestrup (Copenhagen, DK)
S296 What is the impact of reductions in antibiotic
16:00 use on antibiotic resistance in the community?
Pentti Huovinen (Turku, FI)
S297 Have reductions in antibiotic use in
16:30 general practice led to re-emergence of
infections?
Richard Wise (Birmingham, UK)
S298 Clinical and public health impact of
17:00 antibiotic resistance
Brigitte Dunais (Nice, FR)
Oral Sessions
Méditerranée 3 Antibacterial susceptibility studies:
15:30– activities, mechanisms and drug interactions
17:30 Chairpersons: Timothy Walsh (Bristol, UK)
Gunnar Kahlmeter (Växjö, SE)
O299 Evaluation of drug interactions and CYP450
15:30 inhibition with faropenem medoxomil
A. Beaudry, F. Dean, S.C. Gill, C. Black, K. Khan
(Louisville, Austin, US)
O300 Bactericidal activities of daptomycin
15:42 and vancomycin in vancomycin-susceptible
Staphylococcus aureus and heterogeneously
vancomycin intermediate S. aureus strains
M. Wootton, T.R. Walsh, A.P. MacGowan
(Bristol, UK)
O301 The high activity of meropenem against
15:54 Gram-negative bacteria from a paediatric
intensive care unit in Poland (1997–2005)
J.A. Patzer, D. Dzierzanowska, A. Pawinska,
P.J. Turner (Warsaw, PL; Macclesfield, UK)
O302 Morphological and bactericidal effects
16:06 of amoxicillin and clarithromycin on
Helicobacter pylori
F. Can, M. Demirbilek, G. Karabay, H. Arslan
(Ankara, TR)

Scientific Programme Monday, April 3, 2006
O303 A comparison of susceptibility to antibiotics
16:18 in nosocomial and non-nosocomial infections
in a hospital in Israel
A. Zalounina, S. Andreassen, M. Paul, L. Leibovici
(Aalborg, DK; Tel-Aviv, IL)
O304 Comparative minimum inhibitory and mutant
16:30 prevention concentrations of contemporary
(2004–2005) urinary tract pathogens tested
against ciprofloxacin and levofloxacin
J. Blondeau, S. Borsos, C. Hesje (Saskatoon, CA)
O305 Activity of moxifloxacin against community-
16:42 acquired MRSA and other quinolone-susceptible
MRSA isolates
J. von Freyberg, S. Scherpe, M.A. Horstkotte,
J.K. Knobloch (Hamburg, DE)
O306 Antimicrobial susceptibility patterns
16:54 correlate with staphylococcal cassette
chromosome mec types for hospital- and
community-acquired methicillin-resistant
Staphylococcus aureus
A. Kilic, H.J. Li, S.E. Sefers, C.W. Stratton,
Y.W. Tang (Nashville, US)
O307 Comparative MIC and MPC results for
17:06 5 quinolone compounds repeatedly tested
against American type culture collection
control strains: suggested MPC quality
control value ranges
J. Blondeau, C. Hesje, S. Borsos, L. Blondeau,
B. Blondeau (Saskatoon, CA)
O308 Investigation of tolerance to triclosan of
17:18 five international MRSA clones
Z. Al-Doori, D. Morrison, G.F.S. Edwards,
C.G. Gemmell (Glasgow, UK)
Iris Epidemiology of MRSA in Europe
15:30–
17:30 Chairpersons: Hajo Grundmann (Bilthoven, NL)
Didier Pittet (Geneva, CH)
O309 MRSA incidences and proportions: how well
15:30 do these correlate on a European level?
M.E.A. de Kraker, N. van de Sande, J. Monen,
M.A. Borg, G. Kahlmeter, J. Kolman,
H. Grundmann and EARSS participants
O310 Statistical analysis of trends in mandatory
15:42 MRSA bacteraemia in NHS acute hospital
trusts
A. Pearson, A. Charlett (London, UK)
O311 Massive spread of the New York/Japan
15:54 MRSA clone (ST5-SCCmec II) in a European
country
T. Conceição, M. Aires de Sousa, M. Füzi, Á. Tóth,
J. Pászti, E. Ungvári, W. van Leeuwen,
A. van Belkum, H. Grundmann, H. de Lencastre
(Oeiras, PT; Budapest, HU; Rotterdam, Bilthoven NL;
New York, US)
O312 Molecular characterisation of MRSA in
16:06 the south-eastern part of Norway from 1991
to 2005
A.E. Fossum, K. Alm-Kristiansen, G. Bukholm
(Lørenskog, NO)
O313 National Danish case-control study of
16:18 community onset infections caused by
methicillin-resistant Staphylococcus aureus
S. Böcher, A. Gervelmeyer, D.L. Monnet,
K. Mølbak, R. Skov (Copenhagen, DK)
O314 EUREGIO MRSA-net Twente/Münsterland:
16:30 A Dutch-German cross-border network for
surveillance and control of methicillinresistant
S. aureus
A.W. Friedrich, F. Verhoeven, A. Mellmann,
A.K. Sonntag, L.J.E.W.C. Gemert-Pijnen,
I. Daniels-Haardt, M.G.R. Hendrix
(Munster, DE; Enschede, NL)
O315 Prospective surveillance and decolonisation
16:42 of Panton-Valentine leucocidin-positive MRSA
among residents and staff of three German
nursing homes
F.M.E. Wagenlehner, H.J. Linde, E. Bambl,
U. Raab, D. Kahlau, C. Höller, N. Lehn,
W. Witte, K.G. Naber (Straubing, Regensburg,
Oberschleissheim, Wernigerode, DE)
O316 The first national methicillin-resistant
16:54 Staphylococcus aureus prevalence study in
Belgian nursing homes indicates high carriage
rates among residents
B. Jans, C. Suetens, O. Denis, M. Struelens
(Brussels, BE)
O317 The EPISA study: characterisation of fusidic
17:06 acid and methicillin-resistant Staphylococcus
aureus causing skin and soft tissue infections
in outpatients in France
A.R. Larsen, A. Santerre Henriksen, V. Jarlier,
P. Menday, R.L. Skov (Copenhagen, Ballerup, DK;
Paris, FR)
O318 Methicillin-resistant Staphylococcus
17:18 aureus in children with allergy
I. Kuznecovs (Riga, LV)
www.escmid.org/eccmid2006 page 57

Integrated Symposia
Scientific Programme Monday, April 3, 2006
Athena The heart of the matter:
15:30– managing resistance in RTIs
17:30 Chairpersons: Robert C. Moellering Jr (Boston, US)
David Farrell (London, UK)
15:30 Introduction
Robert C. Moellering Jr (Boston, US)
S319 What are the antibiotic attributes involved in
15:40 resistance developmentt
Steve Jenkins (New York, US)
S320 Recent key findings from multinational
16:00 resistance surveys
David Farrell (London, UK)
S321 The impact of antimicrobial resistance on
16:20 therapeutic outcome in RTIs
Robert C. Moellering Jr (Boston, US)
S322 Redefining sinusitis management:
16:40 the French experience
Christian Dubreuil (Lyon, FR)
17:00 Question and answers
17:20 Concluding remarks
David Farrell (London, UK)
Integrated symposium arranged by sanofi-aventis
Méditerranée 1 Fungal infections: host defences and
15:30– clinical interventions
17:30 Chairpersons: Olivier Lortholary (Paris, FR)
William Steinbach (Durham, US)
15:30 Welcome and introduction
Olivier Lortholary (Paris, FR)
S323 Host defence to invasive fungal infections
15:35 and opportunities for immunotherapy
Bart Jan Kullberg (Nijmegen, NL)
S324 Current and future treatment options
16:00 in yeast infections
Helen Sambatakou (Athens, GR)
S325 Micafungin in the treatment of invasive
16:20 candidiasis: results of a randomised
phase III study
Olivier Lortholary (Paris, FR)
S326 New insights on antifungal use in children
16:50 and neonates
William Steinbach (Durham, US)
17:15 Panel discussion and concluding remarks
Integrated symposium arranged by
Astellas Pharma
page 58 Final Programme
Erato Diagnosis of sepsis: the need for fast
15:30– molecular microbiological methods
17:30 Chairpersons: Georg Peters (Munster, DE)
Marc Struelens (Brussels, BE)
15:30 Introduction
Georg Peters (Munster, DE)
S327 Inadequate treatment in bloodstream
15:40 infections
Emilio Bouza (Madrid, ES)
S328 Evaluation of a new PCR-based assay for
16:05 rapid pathogen detection in patients with
clinical sepsis
Klaus-Peter Hunfeld (Frankfurt, DE)
S329 A clinician’s perspective: potential value
16:30 of nucleic acid based diagnosis
Lutz Lehmann (Bonn, DE)
16:55 Panel discussion – Question and answers
17:20 Closing remarks
Marc Struelens (Brussels, BE)
Integrated symposium arranged by
Roche Diagnostics

Scientific Programme Tuesday, April 4, 2006
Meet-the-Expert Sessions
Méditerranée 2 Empirical antibiotic therapy for ICU-acquired
E330 infections
07:15– Experts: John Marshall (Toronto, CA)
08:15– Jean Carlet (Paris, FR)
Objectives:
– to provide attendees with microbiological
results, such as susceptibility data, needed
to guide empirical therapy
– to outline the PK/PD issues
– to evaluate the impact of appropriate empirical
therapy on outcome, in particular in the light
of recent international guidelines
– to explain the ecological impact of broad
antibiotic therapies
– to describe the concept of de-escalation
Méditerranée 3 How to defend your clinical microbiology in
E331 times of budget restrictions?
07:15– Experts: Vincent Jarlier (Paris, FR)
08:15– Matthias Herrmann (Homburg, DE)
Objectives:
– to develop select aspects on pre-analytical,
analytical and post-analytical measures for
enhancing the impact and cost effectiveness
of clinical microbiological diagnostics
– to formulate outlines for convincing budget
directors of the cost effectiveness of
decentralised diagnostic microbiology and
of the assurance of prompt microbiological
diagnosis
– to define the risks of inappropriate management
as a result of insufficient diagnostics
Iris Antibiotic prophylaxis in immunocompromised
E332 hosts, including transplant patients:
07:15– when and how?
08:15– Experts: Georg Maschmeyer (Potsdam, DE)
Thierry Calandra (Lausanne, CH)
Objectives:
– to identify the subgroups of patients expected
to benefit from antimicrobial prophylaxis
– to define the goals of prophylaxis for these
groups
– to give an overview on strategies for infection
prevention
– to discuss results of clinical studies on anti -
biotic prophylaxis in immunocompromised
hosts
– to assess potential benefits, risks and costs
of antibiotic prophylaxis
Hermes How to manage catheter-related infections?
E333 Experts: Emilio Bouza (Madrid, ES)
07:15– Niels Høiby (Copenhagen, DK)
08:15–
Objectives:
– to review the epidemiology of catheterrelated
bloodstream (CR-BSI) infections
– to review the diagnostic methods of CR-BSI
including methods with or without catheter
withdrawal
– to review the indications to withdraw or
maintain the infected catheter
– to review drugs, duration and procedures of
administration of antimicrobial agents to
control CR-BSI
– to review information regarding prevention
of CR-BSI with evidence-based criteria
Clio Routine susceptibility testing:
E334 which antibiotic to choose?
07:15– Experts: Laurent Gutmann (Paris, FR)
08:15– Philippe Moreillon (Lausanne, CH)
Objectives:
– to better define which antibiotic should be
tested
– to better define why this antibiotic should be
tested
– to better define which interpretations can be
deduced from the expected phenotypes
Erato Emergence of risk factors and treatment
E335 issues for Clostridium difficile-associated
07:15– diarrhoea (CDAD)
08:15– Experts: Ed Kuijper (Leiden, NL)
Clifford McDonald (Atlanta, US)
Objectives:
– to understand the changing epidemiology of
CDAD and possible reasons for this change
– to identify important infection control issues
and controversies that are unique to the
control of CDAD
– to define the optimal diagnostic approach
for CDAD
– to analyse therapeutic implications of CDAD
due to toxinotype III, ribotype 027
– to show examples of CDAD as an emerging
community-acquired disease
www.escmid.org/eccmid2006 page 59

Symposia
Scientific Programme Tuesday, April 4, 2006
Athena Pathogenesis and therapy of sepsis
08:30–
10:30 Chairpersons: John Marshall (Toronto, CA)
Thierry Calandra (Lausanne, CH)
08:30 Presentation of the International
Sepsis Forum Award 2006
(see also page 21)
S336 Blood monocytes as a site of
08:35 production of sTREM-1 in sepsis
E.J. Giamarellos-Bourboulis (Athens, GR)
S337 TLRs and NLRs in the pathogenesis of sepsis
08:50 Thierry Calandra (Lausanne, CH)
S338 Host defense in pneumococcal pneumonia
09:15 Tom van der Poll (Amsterdam, NL)
S339 Sepsis markers in 2006
09:40 John Marshall (Toronto, CA)
S340 Methicillin and vancomycin resistance in
10:05 severe staphylococcal infections
Philippe Moreillon (Lausanne, CH)
Joint symposium arranged with the
International Sepsis Forum (ISF)
Méditerranée 2 Non-pneumococcal community-
08:30– acquired respiratory tract infections
10:30 – current state of the art
Chairpersons: Nicole Guiso (Paris, FR)
Peter Appelbaum (Hershey, US)
S341 The role of H. influenzae and B. pertussis
08:30 in community-acquired respiratory
tract infection
Javier Garau (Barcelona, ES)
S342 Changing drug susceptibility in
09:00 H. influenzae with special reference to
macrolides, azalides, ketolides and
quinolones
Peter C. Appelbaum (Hershey, US)
S343 Legionnaires disease 2006: update
09:30 on diagnosis and clinical management
Jordi Carratala (Barcelona, ES)
S344 Pertussis vaccine in perspective
10:00 Nicole Guiso (Paris, FR)
page 60 Final Programme
Hermes Risk assessment in primary care:
08:30– clairvoyance or evidence-based medicine?
10:30 Chairpersons: Theo Verheij (Utrecht, NL)
Thierry Christiaens (Ghent, BE)
S345 Lower respiratory tract infections:
08:30 quantitative and qualitative perspectives
Chris Butler (Cardiff, UK)
S346 Cystitis, mostly simple but not always
09:00 Thierry Christiaens (Ghent, BE)
S347 Prognosis of otitis media
09:30 Paul Little (Southampton, UK)
S348 Bacterial meningitis in adults
10:00 Diederik van de Beek (Amsterdam, NL)
Symposium arranged with the ESCMID Study
Group on Primary Care Topics (ESPRIT)
Calliope Update on the influenza pandemic threat
08:30–
10:30 Chairpersons: Ron Fouchier (Rotterdam, NL)
Christian Drosten (Hamburg, DE)
S349 H5N1 and other pandemic threats
08:30 Ron Fouchier (Rotterdam, NL)
S350 Vaccine development
09:00 Sylvie van der Werff (Paris, FR)
S351 Diagnosis and treatment
09:30 Maria Zambon (London, UK)
S352 Pandemic preparedness
10:00 Johan Giesecke (Stockholm, ECDC)
Oral Sessions
Méditerranée 3 Antimicrobial PK/PD
08:30–
10:30 Chairpersons: Niels Frimodt-Møller
(Copenhagen, DK)
Ursula Theuretzbacher (Vienna, AT)
O353 Impact of sample size on the performance
08:30 of multiple model pharmacokinetic
simulations
V.H. Tam, S. Kabbara, R.F. Yeh, R.H. Leary
(Houston, Los Angeles, US)
O354 Continuous versus intermittent intravenous
08:42 administration of antibiotics with timedependent
antibacterial action: a systematic
review of pharmacokinetic and pharmaco -
dynamic parameters
S. Kasiakou, K. Lawrence, N. Choulis, M. Falagas
(Athens, GR)

Scientific Programme Tuesday, April 4, 2006
O355 Testing the mutant selection window
08:54 hypothesis with in vitro dynamic models:
pros and cons
A. Firsov, I. Lubenko, S. Zinner
(Moscow, RU; Cambridge, US)
O356 Pharmacodynamic evaluation of the
09:06 bactericidal activity of telavancin against extracellular
and intracellular MSSA and MRSA
M. Barcia-Macay, M. Mingeot-Leclercq,
P.M. Tulkens, F. Van Bambeke (Brussels, BE)
O357 Comparative pharmacodynamics (PD)
09:18 of moxifloxacin and levofloxacin against
S. pneumoniae following exposure to
bioequivalent PD-surrogate parameters
A. Dalhoff, S. Schubert, H. Stass
(Kiel, Wuppertal, DE)
O358 Pharmacokinetics of moxifloxacin in tissues
09:30 of the female urogenital tract
H. Stass, H. Delesen, D. Kubitza, A. Halabi,
C.H. Gleiter (Wuppertal, Kiel, Tubingen, DE)
O359 Pharmacokinetics of moxifloxacin in
09:42 tissues of the GI-tract
H. Stass, A.D. Rink, H. Delesen, D. Kubitza,
M.W. Buechler, C.M. Seiler, K.-H. Vestweber
(Wuppertal, Heidelberg, Leverkusen, DE)
O360 Evaluation of tigecycline penetration
09:54 into colon wall tissue and epithelial lining
fluid using a population pharmacokinetic
model and Monte Carlo simulation
C.M. Rubino, L. Ma, S.M. Bhavnani,
J. Korth-Bradley, J. Speth, E.J. Ellis-Grosse,
P.G. Ambrose, G.L. Drusano
(Albany, Philadelphia, US)
O361 Pharmacokinetic-pharmacodynamic analyses
10:06 of efficacy using estimates of serum and
effect site tigecycline exposures in patients
with complicated intra-abdominal infections
S.M. Bhavnani, C.M. Rubino, P.G. Ambrose,
J. Korth-Bradley, J. Speth, E.J. Ellis-Grosse,
G.L. Drusano (Albany, Philadelphia, US)
O362 Ceftazidime dose and dosing interval deter-
10:18 mine the selection of resistant Enterobacter
cloacae isolates in the intestinal flora of rats
treated for a Klebsiella pneumoniae pulmonary
infection
W.H.F. Goessens, J.W. Mouton, M. ten Kate,
A. Ott, I.A.J.M. Bakker-Woudenberg
(Rotterdam, Nijmegen, NL)
Iris Microbial pathogenesis: a diversity of
08:30– mechanisms and host responses
10:30 Chairpersons: Jean-Pierre Gorvel (Marseille, FR)
Alex van Belkum (Leiden, NL)
O363 The role of triggering receptor expressed
08:30 on myeloid cells-1 (trem-1) and of its soluble
form for the evolution of septic syndrome
M. Raftogiannis, V. Markaki, D. Plachouras,
I. Validakis, M. Kontogiorgi, E.J. Giamarellos-
Bourboulis, C. Roussos, H. Giamarellou
(Athens, GR)
O364 Caenorhabditis elegans killing model:
08:42 a new tool to study uropathogenic
Escherichia coli virulence
J.P. Lavigne, A.B. Blanc-Potard, G. Blossier,
D. O’Callaghan, A. Sotto (Nîmes, FR)
O365 Clumping factor B is essential for human
08:54 Staphylococcus aureus nasal colonisation
H. Wertheim, H.A.M. Boelens, D.C. Melles,
H. Verbrugh, T. Foster, A. van Belkum
(Rotterdam, NL; Dublin, IE)
O366 Alanine esters of enterococcal lipoteichoic
09:06 acid have a role in biofilm formation and
resistance to antimicrobial peptides
F. Fabretti, C. Theilacker, A. Kropec, S. Koch,
J. Huebner (Freiburg, DE; Boston, US)
O367 Quinolones induce the partial and total loss of
09:18 uropathogenic Escherichia coli pathogenicity
islands by two different pathways
S. Soto, M.T. Jimenez de Anta, J. Vila
(Barcelona, ES)
O368 Recombinant expression and characterisation
09:30 of putative streptococcal pyrogenic exotoxins
SPEGdys, SPELdys, and SPEMdys from Strepto -
coccus dysgalactiae, subsp. equisimilis
K.H. Schmidt, S. Sachse, S. Rödiger, D. Gerlach,
E. Straube, J. Rödel (Jena, DE)
O369 Release of activin A by microglial cells upon
09:42 stimulation with bacterial TLR-agonists
S. Ebert, R. Nau, U. Michel (Gottingen, DE)
O370 Regulation of putative extra cellular virulence
09:54 factors in Staphylococcus epidermidis by the
alternative sigma factor sigmaB
J.C. Kneschke, S. Jaeger, D. Mack, J.K. Knobloch
(Hamburg, DE; Swansea, UK)
O371 Oral lactobacilli and periodontitis
10:06 A.K. Szkaradkiewicz, B. Tukiendorf,
J. Stopa (Poznan, PL)
www.escmid.org/eccmid2006 page 61

Integrated Symposia
Scientific Programme Tuesday, April 4, 2006
Méditerranée 1 Combination therapy for candida –
08:30– the case for biologicals
10:30 Chairpersons: Bertrand Dupont (Paris, FR)
Markus Ruhnke (Berlin, DE)
S372 21st century yeasts
08:30 Rosemary Barnes (Cardiff, UK)
S373 HSP90 the eukaryotic problem
09:00 James Burnie (Manchester, UK)
S374 Immunomodulatory therapy in yeast
09:30 infections
Jorge Garbino (Geneva, CH)
S375 A rational approach to combination therapies
10:00 Tomas Walsh (Bethesda, US)
Integrated symposium arranged by
Neutec Pharma
Clio Compliance in antibiotics: the last chance?
08:30–
10:30 Chairpersons: Giuseppe Cornaglia (Verona, IT)
Jean-Claude Pechère (Geneva, CH)
08:30 Introduction
S376 Reassessing antibiotic resistance:
08:40 the compliance conundrum
Giuseppe Cornaglia (Verona, IT)
S377 Surveys of patient compliance
09:00 Jean-Claude Pechère (Geneva, CH)
S378 Health and economic outcomes:
09:20 why compliance matters
Dyfrig Hughes (Bangor, UK)
S379 Taking action: transforming results
09:40 into practice
Thomas File (Ohio, US)
10:00 Panel discussion and closing remarks
Integrated symposium arranged by Pfizer
page 62 Final Programme
Erato Antisepsis and the prevention of skin and
08:30– soft tissue infections
10:30 Chairpersons: Curtis G. Gemmell (Glasgow, UK)
Christian Ruef (Zurich, CH)
S380 Overview of old and new antiseptic agents
08:30 Curtis G. Gemmell (Glasgow, UK)
S381 Susceptibility of multi-resistant Gram-
08:55 positive cocci to various antiseptic agent
Donald Morrison (Glasgow, UK)
S382 The use of local antisepsis to prevent catheter
09:20 infections
Marcus Dettenkofer (Freiburg, DE)
S383 Catheter care in the immunocompromised
09:45 host
Andreas Tietz (Basel, CH)
S384 Mode of action of antiseptic agents
10:10 Peter Geroncy-Bermes, (Nordenstedt, DE)
Integrated symposium arranged by
Schülke & Mayr

Keynote Lectures
Scientific Programme Tuesday, April 4, 2006
Athena Epidemiological determinants of the
11:00– genetic diversity of viruses
12:00 Chairperson: Alex van Belkum (Leiden, NL)
K385 Neil Ferguson (London, UK)
11:00
Méditerranée 1 Mitochondria: a newly discovered target for
11:00– Gram-positive and -negative bacterial toxins
12:00 Chairperson: Elisabeth Nagy (Szeged, HU)
K386 Patrice Boquet (Nice, FR)
11:00
Calliope Implications of chemotherapy-related
11:00– mucosal barrier injury
12:00 Chairperson: Claudio Viscoli (Genoa, IT)
K387 Nicole Blijlevens (Nijmegen, NL)
11:00
Symposium
Clio Issues in travel medicine
11:00–
12:00 Chairpersons: Christoph Hatz (Basel, CH)
David Hill (London, UK)
S388 Immunisation for travel – new developments
11:00 David Hill (London, UK)
S389 Treatment of imported malaria
11:30 Tomas Jelinek (Berlin, DE)
Oral Sessions
Méditerranée 3 Sexually transmitted diseases and urinary
11:00– tract infections
12:00–
Chairpersons: Susanne Esposito (Milan, IT)
Kurt Naber (Straubing, DE)
O390 Rectal lymphogranuloma venereum in
11:00 San Francisco in the 1980s
J. Schachter, J. Moncada, J. Spaargaren
(San Francisco, US; Amsterdam, NL)
O391 The role of Chlamydia trachomatis in chronic
11:12 prostatitis/chronic pelvic pain syndrome
M. Sukhorukova, R. Kozlov, I. Malev, O. Shipulina,
L. Stratchounski (Smolensk, Moscow, RU)
O392 Acceptability of self-taken vaginal swabs and
11:24 first-catch urine samples for the diagnosis
of urogenital Chlamydia trachomatis and
Neisseria gonorrhoeae with an amplified DNA
assay in young women attending a public
health STD clinic
C.J.P.A. Hoebe, C.W. Rademaker, E.E.H.G. Brouwers,
H.L.G. Ter Waarbeek (Heerlen, NL)
O393 Asymptomatic bacteriuria, a lasting
11:36 or fluctuating condition among elderly living
in the community?
N. Rodhe, M. André, L. Englund, S. Mölstad
(Falun, Jönköping, SE)
O394 Recurrent urinary tract infections caused
11:48 by Escherichia coli
S. Gualandris, A. Endimiani, G. Brigante,
F. Luzzaro, A. Toniolo (Varese, IT)
www.escmid.org/eccmid2006 page 63

Scientific Programme Tuesday, April 4, 2006
Erato AIDS and HIV
11:00–
12:00 Chairpersons: Pierre Marie Roger (Nice, FR)
Giovanni Di Perri (Turin, IT)
O395 AIDS indicative diseases across Europe
11:00 G. Likatavicius, I. Devaux, J. Alix, A. Nardone
on behalf of EuroHIV
O396 Polymorphisms in toll-like receptors
11:12 influence susceptibility to HIV infection
and its clinical course
P.-Y. Bochud, M. Hersberger, P. Taffé, M. Bochud,
C. Stein, T. Calandra, P. Francioli, A. Telenti,
R.F. Speck, A. Aderem & The Swiss HIV
Cohort Study
O397 Chronic immune activation as a major
11:24 determinant of AIDS pathogenesis:
role of the type I interferon response
S. Staprans, S. Klucking, A. Barry, R. Chavan,
K. Dalbey, G. Silvestri, M. Feinberg (Atlanta, US)
O398 Elevated circulating HLA-G levels in
11:36 HIV-infected patients with and without
visceral leishmaniasis
L. Donaghy, F. Gros, L. Amiot, C. Mary,
A. Maillard, C. Guiguen, J-P. Gangneux
(Rennes, Marseille, FR)
O399 Study on the genotypic resistance of
11:48 archived and circulating viral strains in blood
of treated HIV-infected individuals
O. Turriziani, C. Scagnolari, C. Stano, G. Forte,
M. Bucci, F. Bellomi, C. Fimiani, I. Mezzaroma,
G. D’Ettorre, C. D’Agostino, E. Riva, S. Vita,
C. Ajassa, G Antonelli (Rome, IT)
page 64 Final Programme
Poster Session V
Topics Session V
Presence of authors: 12:00–13:00
– Antibiotic prescribing - quality indicators ● P1460–P1487
– Professional and public health issues ● P1488–P1492
– Pharmacoeconomics and electronic
resources
P1493–P1511
– Antimicrobial PK / PD P1512–P1556
– New and not so new antimicrobials P1557–P1585
– Resistance, linezolid, glycopeptides
and inhibitors of protein synthesis
P1586–P1609
– Epidemiology of resistance to
antibiotics – II
P1610–P1634
– Clostridium difficile revisited P1635–P1649
– Virology - II P1650–P1675
– Bacterial pathogenesis – III P1676–P1701
– Antimicrobial clinical trials P1702–P1718
– Diagnostic and laboratory
methods for bacteria – II
P1719–P1741
– Molecular detection of microbial
ribosomal genes
P1742–P1764
– Antibacterial susceptibility studies – III P1765–P1778
– Tigecycline in vivo studies P1779–P1787
– Nosocomial infection: control
of environment, viral infections
P1788–P1801
– Regional spread of antibiotic resistance P1802–P1823
– Interesting case reports P1824–P1829
– Meningitis and endocarditis
★ P1830–P1841
– Epidemiology and outbreaks
★ P1842–P1851
– Urinary tract infection P1852–P1861
– FUO, soft tissue and miscellaneous
infections
★ P1862–P1874
– Paediatric viral infections
★ P1875–P1884
12:15–13:00
Guided Poster Walks Session V
Theme: Antibiotic prescribing – quality indicators
Chairpersons: Herman Goossens (Edegem, BE)
Dominique Monnet (Copenhagen, DK)
Meeting point: Poster P1460 at 12:15
Posters selected from within the topics marked ●
Theme: A closer look at outbreaks & infections
Chairpersons: Wolfgang Graninger (Vienna, AT)
Ethan Rubinstein (Winnipeg, CA)
Meeting point: Poster P1830 at 12:15
Posters selected from within the topics marked ★

Symposia
Scientific Programme Tuesday, April 4, 2006
Méditerranée 2 Origin, epidemiology, diagnosis, and
13:00– management of community-acquired
15:00 MRSA
Chairpersons: Robert Skov (Copenhagen, DK)
Stephen Lerner (Detroit, US)
S400 Origin
13:00 Mark C. Enright (London, UK)
S401 Epidemiology
13:30 Fred Tenover (Atlanta, US)
S402 Diagnosis
14:00 Robert Skov (Copenhagen, DK)
S403 Management
14:30 Henry F. Chambers (San Francisco, US)
Joint symposium arranged with the American
Society for Microbiology (ASM)
Hermes Clinical implications of low-level
13:00– antimicrobial resistance
15:00 Chairpersons: Gunnar Kahlmeter (Vaxjö, SE)
Johan Mouton (Nijmegen, NL)
S404 Staphylococcus aureus
13:00 Fred Goldstein (Paris, FR)
S405 Streptococcus pneumoniae
13:30 Javier Garau (Barcelona, ES)
S406 Escherichia coli
14:00 Niels Frimodt-Møller (Copenhagen, DK)
S407 Pseudomonas aeruginosa
14:30 Alasdair MacGowan (Bristol, UK)
Symposium arranged with the European
Committee on Antimicrobial Susceptibility
Testing (EUCAST)
Clio Molecular epidemiology:
13:00– a tool for public health
15:00 Chairpersons: Alexander Krämer (Bielefeld, DE)
Sara Haeggman (Solna, SE)
S408 Reconstructing HCV transmission history
13:00 using phylogenetic and population genetic
methods
Oliver G. Pybus (Oxford, UK)
S409 Molecular typing for surveillance of MRSA at
13:30 national level
Sara Haeggman (Solna, SE)
S410 Genotyping of measles viruses to monitor
14:00 the elimination process of the disease
Sabine Santibanez (Berlin, DE)
S411 Using RFLP fingerprinting for outbreak
management in tuberculosis control
Gerard de Vries (Rotterdam, NL)
Joint symposium arranged with the
European Public Health Association (EUPHA)
Calliope Mycobacterial infections
13:00–
15:00 Chairpersons: Richard Wallace (Tyler, US)
Stewart Cole (Paris, FR)
S412 Molecular biology for diagnosis
13:00 and identification of mycobacteria
Enrico Tortoli (Florence, IT)
S413 Infections due to mycobacteria other
13:30 than M. tuberculosis (MOTT) in non-HIV
patients
Richard Wallace (Tyler, US)
S414 Buruli ulcer (M. ulcerans)
14:00 Françoise Portaels (Antwerp, BE)
S415 New anti-mycobacterial agents
14:30 Vincent Jarlier (Paris, FR)
www.escmid.org/eccmid2006 page 65

Oral Sessions
Scientific Programme Tuesday, April 4, 2006
Méditerranée 3 Respiratory tract infection in the community
13:00– revisited
14:00
Chairpersons: Daniel Christmann (Strasbourg, FR)
Thomas File (Akron, US)
O416 The management of sore throat by
13:00 Finnish general practitioners
P.O. Honkanen, U.-M. Rautakorpi, S. Huikko,
T. Klaukka, P. Huovinen, E. Palva, R. Roine,
H. Sarkkinen, H. Varonen, M. Mäkelä
for MIKSTRA collaborative study group
O417 Prevalence of Streptococcus viridans isolates
13:12 in nasopharyngeal samples from children
attending day-care centres in the Alpes
Maritimes, France
H. Carsenti-Dellamonica, G. Melica, C. Pradier,
B. Dunais, G. Mancini, M. Sabah, P. Bruno,
P. Toubol, P. Dellamonica for the GEPIE Group
O418 Erythromycin-resistance in commensal
13:24 throat streptococci in asylum seekers
C.J.P.A. Hoebe, E.J.W.N. Niekamp, P.J.P. Tolsema,
E. Stobberingh (Heerlen, Maastricht, NL)
O419 The role of antibiotics in acute uncomplicated
13:36 maxillary sinusitis in ambulatory care:
a randomised controlled trial
L. Prezas, A. Antoniadou, P. Panagopoulos,
T. Tsaganos, A. Agathagelides, G. Danielides,
T. Stathas, M. Rigatou, N. Karvelis, E. Moshavakis,
T. Papaeliadis, E. Ferekidis, S. Symeonidis,
H. Giamarellou (Athens, Salonica, Patra, GR)
O420 Prevalence of respiratory diseases in
13:48 sheltered homeless in Marseille, France
S. Badiaga, H. Richet, P. Azass, F. Rey, H. Tissot
Dupont, C. Foucault, C. Rovery, M. Drancourt,
D. Raoult, P. Brouqui (Marseille, FR)
page 66 Final Programme
Iris Treatment, antifungal resistance
13:00– and epidemiology of fungal infections
15:00
Chairpersons: Manuel Cuenca-Estrella (Madrid, ES)
Emmanuel Roilides
(Thessaloniki, GR)
O421 Posaconazole as prophylaxis for invasive
13:00 fungal infections in high-risk patients: efficacy
and safety results from two clinical trials
J. Maertens, A.J. Ullmann, S. Durrant,
J. Holowiecki, J.H. Lipton, D. Stockelberg,
D.J. Winston, J. Perfect, N. Boparai, C. Hardalo,
D. Angulo-Gonzalez, O.A. Cornely
(Leuven, BE; Mainz, DE; Brisbane, AU;
Katowice, PL; Toronto, CA; Gothenburg, SE;
Los Angeles, Durham, Kenilworth, US; Cologne, DE)
O422 Mortality in patients at high risk for invasive
13:12 fungal infection: effect of posaconazole
prophylaxis
O.A. Cornely, J. Maertens, S. Durrant,
J. Holowiecki, J.H. Lipton, D. Stockelberg,
D.J. Winston, J. Perfect, R. Suresh, L. Pedicone,
H. Patino, A.J. Ullmann (Cologne, DE; Leuven, BE;
Brisbane, AU; Katowice, PL; Toronto, CA;
Gothenburg, SE; Los Angeles, Durham,
Kenilworth, US; Mainz, DE)
O423 Epidemiology of fungal infections in
13:24 haematological malignancies in Italy:
SEIFEM-2004 study (Sorveglianza Epidemiologica
Infezioni Fungine nelle Emopatie
Maligne)
L. Pagano, M. Caira, A. Candoni, L. Corvatta,
M. Offidani, B. Martino, D. Pastore, M. Picardi,
A. Bonini, A. Chierichini, R. Fanci, C. Caramatti,
C. Benatti, A. Gallamini, M.R. Fadda, L. Melillo,
B. Allione, L Fianchi, P. Falcucci, C.G. Valentini,
M.T. Van Lint, A. Nosari, C. Girmenia
on behalf of SEIFEM (Studio Epidemiologico
Infezioni Fungine nelle Emopatie Maligne)
O424 Micafungin versus liposomal amphotericin B
13:36 in the treatment of invasive candidiasis in
neutropenic and non-neutropenic patients
O. Lortholary, E. Kuse, P. Chetchotisakd,
C. Arns da Cunha, M. Ruhnke, C. Barrios,
D. Raghunadharao, J.S. Sekhon, S. Koblinger
(Paris, FR; Hannover, DE; Khon Kaen, TH;
Curitiba, BR; Berlin, DE; Porto Alegre, BR;
Hyderabad, Ludhiana, IN; Munich, DE)
O425 Clinical effects of micafungin, an
13:48 echinocandin antifungal agent, on systemic
fungal infection in the areas of surgery,
emergency, and intensive care medicine
N. Aikawa, S. Kusachi, S. Oda, Y. Takesue,
H. Tanaka (Tokyo, Chiba, Hiroshima, JP)

Scientific Programme Tuesday, April 4, 2006
O426 Universal role of glucan synthase subunit
14:00 Fks1p in echinocandin resistance
D. Perlin, S. Park (Newark, US)
O427 Human serum alters antifungal efficacy
14:12 of echinocandin drugs
D. Perlin, S. Park (Newark, US)
O428 In vitro resistance to amphotericin B and
14:24 caspofungin in clinical isolates of C. glabrata
were confirmed in a mouse model
M. Krogh-Madsen, M.C. Arendrup, L. Heslet,
J.D. Knudsen (Hvidovre, Copenhagen, DK)
O429 Effects of amphotericin B formulations
14:36 on antifungal activity of human monocytes
and neutrophils against medically important
filamentous fungi
J. Dotis, M. Simitsopoulou, M. Dalakiouridou,
T. Konstantinou, T. Walsh, E. Roilides
(Thessaloniki, GR; Bethesda, US)
O430 Determination of the effect of aminocandin
14:48 on Aspergillus fumigatus and Candida
albicans morphology and ultrastructure
using confocal scanning laser microscopy
and scanning electron microscopy
M.A. Ghannoum, S. Dutta, J. Chandra
(Cleveland, US)
Erato Antibiotic prescribing quality indicators
13:00–
15:00 Chairpersons: Ethan Rubinstein (Winnipeg, CA)
Inge Gyssens (Rotterdam, NL)
O431 Developing valid antibiotic prescribing
13:00 quality indicators for ambulatory care based
on European Surveillance of Antimicrobial
Consumption (ESAC)
S. Coenen, M. Ferech, H. Goossens
and the ESAC Project Group
O432 Surveillance of antimicrobial use and
13:12 antimicrobial resistance in German intensive
care units (SARI) – data summary from 2001
to 2004
E. Meyer, F. Schwab, P. Gastmeier, H. Ruden,
K. de With, F. Daschner, D. Jonas
(Freiburg, Berlin, Hannover, DE)
O433 Marked change in the distribution
13:24 of antibiotics used in Danish hospitals:
is Denmark becoming less conservative?
A. Muller, C.T. Brandt, L. Bagger-Skjøt,
N. Frimodt-Møller, D.L. Monnet
(Copenhagen, DK)
O434 Dose regimen as an explanatory factor
13:36 for the variation of outpatient antibiotic
use between European countries
M. Ferech, S. Coenen, P. Stephens,
H. Goossens and the ESAC Project Group
O435 Antimicrobial prescribing practices by
13:48 physician specialty in the United States
K.J. Suda, K.W. Garey, C.T. Bertram,
L.H. Danziger (Memphis, Houston,
Deerfield, Chicago, US)
O436 Impact of a French local community-
14:00 oriented antibiotic-reducing programme
on the incidence of invasive diseases
A. Malicki, V. Blanc, P. Bruno, P. Touboul,
F. Berthier, P. Hofliger, T. Fosse, B. Dunais,
P. Dellamonica, C. Pradier on behalf of GEPIE
O437 Evolution of antibiotic consumption in a
14:12 geriatric ward of a university hospital:
results of a five-year policy involving
a multidisciplinary collaboration team
B. Delaere, D. Schoevaerdts, C. Swine,
Y. Glupczynski (Yvoir, BE)
O438 Determinants of antibiotic overprescribing
14:24 in lower respiratory tract infections in primary
care
M. Kuyvenhoven, A. Akkerman, J. van der Wouden,
T. Verheij (Utrecht, Rotterdam, NL)
O439 Antibiotic use in two cohorts of German
14:36 intensive care units, 2001–2002
K. de With, E. Meyer, M. Steib-Bauert,
F. Schwab, F.D. Daschner, W.V. Kern
(Freiburg, Berlin, DE)
O440 Benefit of appropriate empirical antibiotic
14:48 treatment: 30-day mortality and duration of
hospital stay
A. Fraser, M. Paul, N. Almanasreh, E. Tacconelli,
U. Frank, R. Cauda, S. Borok, S. Andreassen,
A.D. Nielsen, L. Leibovici
on behalf of the TREAT Study Group
www.escmid.org/eccmid2006 page 67

Poster Sessions Sunday, April 2, 2006
12:00–13:00
Automated methods for antibiotic susceptibility
testing
P441 Vancomycin reformulation in a MicroScan
Dried Overnight Panel: a multicentre
evaluation with Gram-positive cocci
including VRSA
B. Zimmer, S. Mirrett, L.B. Reller, M. Weinstein,
J. Hindler, R. Carey, S. McAllister, D. Bruckner,
J. Johnston, K. Sei (West Sacramento, Durham,
New Brunswick, Los Angeles, Atlanta, US)
P442 Direct identification and susceptibility testing
of Gram-positive cocci from positive Bactec
blood cultures with BD Phoenix Automated
Microbiology System
T.-D. Huang, C. Laurent, J. Gigi, A. Simon
(Brussels, BE)
P443 Evaluation of MicroScan WalkAway 96 for
susceptibility testing of Gram-negative bacilli
to quinolones
M. Armengol, J. Calvo, L. Martinez-Martinez
(Santander, ES)
P444 False resistance to amikacin in Pseudomonas
aeruginosa with the MicroScan WalkAway
96 system
F. Unda, J. Calvo, M. Armengol, L. Martínez-
Martínez (Santander, ES)
P445 Evaluation of identification and antimicrobial
susceptibility testing of bacterial pathogens
by VITEK 2 Compact System
E. Stefaniuk, A. Mrowka, W. Hryniewicz
(Warsaw, PL)
P446 Evaluation of the Vitek-2 system using AST-
N020 y AST-N041 cards for susceptibility
testing of beta-lactam-resistant Escherichia
coli and Klebsiella pneumoniae strains of
clinical origin
J. Calvo, C. Salas, J.R. Hernández, B. Ruiz,
M.C. Conejo, M. Armengol, A. Pascual,
L. Martinez-martinez (Santander, Seville, ES)
P447 Susceptibility testing of unusual species of
Enterobacteriaceae: comparison of disk
diffusion, Vitek 2, and broth microdilution
N. Stone, C. O’Hara, P. Williams, J. McGowan Jr.,
F. Tenover (Atlanta, US)
P448 Evaluation of new VITEK 2 AST cards for
detection of ESBL mediated resistance in
E. coli and Klebsiella spp.
H. Rodriguez-Villalobos, J. Smet, C. Nonhoff,
S. Crevecoeur, R. De Mendonça, M. Struelens
(Brussels, BE)
page 68 Final Programme
P449 Detection of ESBL mediated resistance in
Enterobacter spp. by using new VITEK2 AST
cards and advanced expert system
J. Smet, H. Rodriguez-Villalobos, C. Nonhoff,
S. Crevecoeur, R. De Mendonça, M. Struelens
(Brussels, BE)
P450 Comparison of the E-test method with the
VITEK 2 antimicrobial susceptibility detection
system for screening of extended-spectrum
beta-lactamase Klebsiella and E. coli strains
in a Greek university hospital
O. Vasilaki, C. Manolopoulos, G. Raptis,
S. Alexiou-Daniel (Thessaloniki, GR)
P451 Evaluation of the VITEK 2® ESBL test in
detecting ESBL-positive clinical Escherichia
coli and Klebsiella pneumoniae isolates
J.A. Severin, N.M. Mertaniasih, K. Kuntaman,
N. Lemmens, H.A. Verbrugh, W.H.F. Goessens
(Rotterdam, NL; Surabaya, ID)
P452 Overestimation of extended-spectrum
beta-lactamases by VITEK-2 and possible
consequences for antibiotics policy
C. Ceyssens, L. Ide, J. Verhaegen, K. Lagrou,
J. Van Eldere (Leuven, BE)
P453 Detection of decreased susceptibility of
Staphylococcus aureus to vancomycin with
the VITEK 2 System
K. Engelhard, R. Griffith, J. Mayer, J. Slaughter,
M. Ullery, L. Beiner, S. Messina-Powell, D. Pyse,
G. Zambardi, D. Shortridge (Hazelwood, US;
LaBalme, FR)
P454 Bench validation of methicillin-resistance
detection by Vitek 2 AST P-536 card combined
with cefoxitin disc diffusion in clinical
staphylococci isolates
G. Prod’hom, K. Jaton, J. Bille, A. Wenger
(Lausanne, CH)
P455 Capability of the VITEK ® 2 System to screen
the beta-lactamase producing Enterococcus
faecalis
N. Bal, V. Monnin, B.E. Murray, G. Zambardi,
I. Canard, C. Davenas, P. Dufour
(La Balme les Grottes, FR; Houston, US)
P456 Performance evaluation of the Streptococcus
pneumoniae antimicrobial susceptibility
investigative use only SPCA3 card on the
VITEK ® 2 system
C. Brosnikoff, J. Fuller, S. Shokoples, R. Rennie,
M. Traczewski, S. Brown, D. Fuller, R. Buckner,
J. Talbott, T. Davis (Edmonton, CA; Wilsonville,
Indianapolis, US)

12:00–13:00
Epidemiology of MRSA
Poster Sessions Sunday, April 2, 2006
P457 Molecular epidemiology of community-associated
methicillin-resistant Staphylococcus
aureus
S. Donabedian, V. Huang, A. Singh, S. Davis,
M. Perri, D. Vager, K. Speirs, B. Robinson-Dunn,
M. Hayden, R. Muder, M. Zervos (Detroit,
Atlanta, Royal Oak, Chicago, Pittsburgh, US)
P458 Clinical epidemiology of community-associated
methicillin-resistant Staphylococcus aureus
S. Davis, A. Singh, M. Perri, C. Manierski,
S. Donabedian, D. Vager, V. Huang, K. Spiers,
B. Robinson-Dunn, M. Hayden, R. Muder,
M. Zervos (Detroit, Royal Oak, Atlanta, Chicago,
Pittsburgh, US)
P459 Comparison of epidemic MRSA isolated in the
three Nordic countries Denmark, Finland and
Sweden during 2003–2004 –
How similar are they?
S. Haeggman, A. Rhod Larsen, A. Vainio,
B. Olsson-Liljequist, R. Skov, J. Vuopio-Varkila
(Solna, SE; Copenhagen, DK; Helsinki, FI)
P460 Genotyping as a tool for naming epidemic
methicillin-resistant Staphylococcus aureus
strains in Finland
A. Vainio, M. Karden-Lilja, S. Ibrahem,
A-M. Kerttula, S. Salmenlinna, A. Virolainen,
J. Vuopio-Varkila (Helsinki, FI)
P461 Hospital- and community-acquired methicillinresistant
Staphylococcus aureus in Germany
C. von Eiff, F. Hasenberg, A. Anders, F. Kipp,
A.W. Friedrich, G. Peters, S.G. Gatermann,
K. Becker (Munster, Bochum, DE)
P462 Molecular spa and SCCmec typing of MRSA
isolates from northern Germany
N. Wiese, H. Mueller, I. Fenner, K. Lunkenheimer,
T. Fenner (Hamburg, Lubeck, DE)
P463 Methicillin-resistant S. aureus in German
university hospitals: changes in resistance
2002 – 2005
I. Noll, B. Wiedemann, J. Beer, T. Pietzcker,
W. Pfister, S. Schubert, S. Ziesing, O. Hamouda
(Berlin, Bonn, Leipzig, Ulm, Jena, Kiel,
Hannover, DE)
P464 Methicillin-resistant Staphylococcus aureus
epidemiological setting in the emergency
ward of a large French teaching hospital
B. Téqui, N. Asseray, D. Lepelletier, D. Tewick,
M.E. Juvin, G. Potel, H.B. Drugeon (Nantes, FR)
P465 Molecular characterisation of Staphylococcus
aureus isolated in a nationwide prevalence
study in Spain
O. Cuevas, E. Cercenado, A. Vindel, C. Castellares,
J. Guinea, E. Bouza (Madrid, ES)
P466 First report of infection with communityacquired
methicillin-resistant Staphylococcus
aureus in Spain
E. Cercenado, M. Marín, A. Vindel, B. Padilla,
O. Cuevas, A. Navarro, E. Bouza
(Madrid, Majadahonda, ES)
P467 Epidemiology of methicillin-resistant
Staphylococcus aureus in Bilbao
J.L. Barrios, M.J. Unzaga, C. Ezpeleta, D. Suárez,
J. Sánchez, J.A. Alava, A.B. López, R. Cisterna
(Bilbao, ES)
P468 Identification epidemic methicillin-resistant
S. aureus in Russian hospitals: multicentre
study 1998 – 2002
O. Dmitrenko, V. Prohorov, I. Shilov, N. Lavrova,
A. Gintsburg (Moscow, RU)
P469 Methicillin-resistant Staphylococcus aureus
nasal colonisation in a rehabilitating / nursing
home in Italy
A. Pan, T. Ceruti, M. Bresciani, C. Geroldi,
S. Lorenzotti, S. Magri, L. Soavi, L. Signorini,
A. Pani (Brescia, Cremona, IT)
P470 Methicillin-resistant Staphylococcus aureus
from airway secretions from patients with
cystic fibrosis
H. Alexandrou-Athanasoulis, S. Doudounakis,
A. Sergounioti, I. Loucou, A. Pangalis (Athens, GR)
P471 A new computer software for methicillinresistant
Staphylococcus aureus typing based
on spa-sequencing: comparison to MLST
K. Boye, M.D. Bartels, A. Mellmann, D. Harmsen,
H. Westh (Hvidovre, DK; Munster, DE)
P472 A multiplex PCR for easy screening of
methicillin-resistant Staphylococcus aureus
SCCmec types I to V
K. Boye, M.D. Bartels, A.R. Larsen, H. Westh
(Hvidovre, Copenhagen, DK)
P473 Evaluation of real-time PCR as a rapid method
to detect carriage of methicillin-resistant
S. aureus in the investigation of a ST30
outbreak
M.D. Bartels, K. Kristoffersen, K. Boye, H. Westh
(Hvidovre, DK)
www.escmid.org/eccmid2006
page 69

Poster Sessions Sunday, April 2, 2006
P474 Methicillin-resistant Staphylococcus aureus
and pig-farming
B. van Dijke, H. Koppen, W. Wannet,
X. Huijsdens, H. de Neeling, A. Voss
(Weert, Bilthoven, Nijmegen, NL)
P475 Methicillin-resistant coagulase-negative
staphylococci isolated from horses
M. Corrente, G. Greco, V. Martella, G. Normanno,
E. Tarsitano, C. Buonavoglia (Valenzano, IT)
P476 First report of non-prototypic Tn1546 among
vanA vancomycin-resistant-enterococci
isolated from domestic chickens in Korea:
evidence of communication between VRE
niche of human and those of chicken?
M.N. Kim, S.H. Lee, E.J. Lee, H.S. Jun, H. Sung
(Seoul, KR)
P477 Identification and genotyping of vancomycinresistant
enterococci isolated from slaughtered
poultry in Hungary from 2001 to 2004
Á. Ghidán, O. Dobay, É.J. Kaszanyitzky, K. Nagy,
F. Rozgonyi, S.G.B. Amyes
(Budapest, HU; Edinburgh, UK)
P478 Antimicrobial susceptibility of enterococcal
strains isolated from slaughter animals in
Hungary from 2001 to 2004
É.J. Kaszanyitzky, M. Tenk, Á. Ghidán,
G. Fehérvári, M. Papp (Budapest, HU)
12:00–13:00
Sepsis
P479 Analysis of mortality in septic shock patients
J. Martinez Alario, J. Villegas, S. Huidobro,
C. Christophe Henry, R. Santacreu, M.L. Mora
(Tenerife, ES)
P480 The significance, clinical presentation and
evolution of recurrent E. coli bloodstream
infections
M. Sanz, A. Fernandez, P. Muñoz, E. Cercenado,
M. Rodríguez-Creixems, J. Feyjoo, E. Bouza
(Madrid, ES)
P481 The influence of SIRS criteria on outcome in
Gram-negative versus Gram-positive sepsis
M. Lupse, A. Bica, A. Slavcovici, A. Radulescu,
C. Bondor, D. Tatulescu (Cluj-Napoca, RO)
P482 Haemophilus influenzae bloodstream
infections: a reappraisal
G. Muñoz, L. Cuadra, E. Calbo, M. Xercavins,
J. Garau (Terrassa, ES)
page 70 Final Programme
P483 Protein C levels in plasma and APACHE II
scoring system for risk evaluation in patients
with sepsis
E. Doyuk Kartal, E. Karkac, N. Erben, S. Nayman
Alpat, I. Özgünes, Z. Gulbas, G. Usluer
(Eskisehir, TR)
P484 The role of plasma BNP levels in the early
prognostic stratification of septic patients at
the emergency department
G. Ruggiano, R. Camajori Tedeschini, A. Rosselli
(Florence, IT)
P485 Monocyte CD14 and soluble CD14 in
predicting the mortality of patients with
severe community-acquired infection
H. Aalto, A. Takala, H. Kautiainen, H. Repo
(Helsinki, Heinola, FI)
12:00–13:00
Tigecycline in vitro studies – I
P486 Tigecycline in vitro activity in an outpatient
vs. inpatient global population
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P487 Tigecycline antibacterial activity in current
(2004 – 06) U.S. pathogen population
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P488 In vitro evaluation of tigecycline against
261 recent isolates of vancomycin-resistant
enterococci C T.E.S.T. Program 2006
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P489 Evaluating tigecycline against cross-resistant
Enterobacteriaceae in the Global T.E.S.T.
Program
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P490 Tigecycline in vitro activity in current
European pathogens – T.E.S.T. Program 2006
D. Hoban, S. Bouchillon, B. Johnson,
T. Stevens, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P491 Tigecycline in vitro activity against multidrugresistant
Acinetobacter spp. in the T.E.S.T.
Program Global Data
D. Hoban, B. Johnson, S. Bouchillon,
T. Stevens, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)

Poster Sessions Sunday, April 2, 2006
P492 Evaluating cross-resistance for Enterobac -
teriaceae as compared to tigecycline for the
T.E.S.T. Program in Europe
D. Hoban, B. Johnson, S. Bouchillon,
T. Stevens, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P493 Tigecycline in vitro activity against inpatient
and outpatient pathogens collected from
centres in Europe – T.E.S.T. Program 2006
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P494 Tigecycline in vitro activity against often
difficult to treat pathogens from centres in
Asia/Pacific Rim – T.E.S.T. Program 2006
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P495 Acinetobacter resistance in clinical isolates
from the United States evaluated against
tigecycline and 10 comparators
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P496 The in vitro activity of tigecycline and
10 comparators in a global population –
T.E.S.T. Program 2006
S. Bouchillon, T. Stevens, J. Johnson,
D. Hoban, B. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P497 Tigecycline in vitro evaluation of 1,145 methicillin-resistant
Staphylococcus aureus
S. Bouchillon, T. Stevens, J. Johnson,
D. Hoban, B. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P498 Antibiotic cross-resistance for Staphylococcus
aureus and Enterococcus spp. among tigecycline
and 10 comparator antimicrobial agents –
T.E.S.T. Program in Europe 2006
S. Bouchillon, T. Stevens, J. Johnson,
D. Hoban, B. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P499 Asia and Pacific Rim community vs. hospitalacquired
infections: in vitro activity against
tigecycline and comparators
T. Stevens, J. Johnson, D. Hoban,
B. Johnson, S. Bouchillon, M. Dowzicky
(Schaumburg, Colllegeville, US)
P500 Extended-spectrum beta-lactamase producing
Enterobacteriaceae evaluated in vitro against
tigecycline and comparator agents –
T.E.S.T. Program 2006
T. Stevens, J. Johnson, D. Hoban,
B. Johnson, S. Bouchillon, M. Dowzicky
(Schaumburg, Collegeville, US)
P501 Activity of tigecycline against wellcharacterised
multi-resistant Gram-positive
strains
C. Cascone, A. Lupo, S. Borbone, M. Mezzatesta,
M. Santagati, S. Stefani (Catania, IT)
12:00–13:00
ESBLs and cephalosporins
P502 Prevalence of extended-spectrum betalactamases
among Enterobacteriaceae:
a Bulgarian survey
R. Markovska, E. Keuleyan, I. Schneider,
M. Sredkova, D. Ivanova, K. Rachkova,
B. Markova, T. Kostyanev, E. Draghijeva, I. Mitov,
A. Bauernfeind (Sofia, BG; Munich, DE; Pleven,
Stara Zagora, BG)
P503 Surveillance of PER-1 producers among
Gram-negative bacilli isolated at a tertiary
care hospital over a five-year period and
analysis of the genetic location of blaper-1
B. Eraç, Z. Gülay (Izmir, TR)
P504 Plasmid-mediated carbapenem-hydrolysing
oxacillinase OXA-58 in Acinetobacter
baumannii in Italy
A. Giordano, A. Bertini, P. Varesi, L. Villa,
A.M. Dionisi, I. Luzzi, C. Mancini, A. Carattoli
(Rome, IT)
P505 Outbreak of OXA-58-producing carbapenemresistant
Acinetobacter baumannii isolates in
a paediatric university hospital in Athens,
Greece
L. Poirel, E. Lebessi, C. Héritier, A. Patsoura,
M. Foustoukou, P. Nordmann (Le Kremlin Bicetre, FR;
Athens, GR)
P506 Characterisation of conjugative plasmids
encoding CTX-M-type extended-spectrum
beta-lactamases in Italian clinical isolates of
Escherichia coli
C. Mugnaioli, F. De Luca, A. Carattoli,
G.M. Rossolini (Siena, Rome, IT)
P507 Unusual CTX-M enzyme variants in the
United Kingdom
E. Karisik, M.J. Ellington, R. Pike, E.J. Fagan,
D.M. Livermore, N. Woodford (London, UK)
www.escmid.org/eccmid2006
page 71

Poster Sessions Sunday, April 2, 2006
P508 Differential expression of CTX-M-15 betalactamase
between two major Escherichia
coli strains in the UK
E. Karisik, M.J. Ellington, R. Pike,
D.M. Livermore, N. Woodford (London, UK)
P509 Dominance of CTX-M beta-lactamases among
Escherichia coli isolates in an Algerian
hospital
N. Ramdani-Bouguessa, N. Mendonça,
J. Leitão, E. Ferreira, M. Tazir, M.M. Caniça
(Algiers, DZ; Lisbon, PT)
P510 Extended-spectrum beta-lactamases and
plasmid-mediated AmpC enzymes among
clinical isolates of Escherichia coli and
Klebsiella pneumoniae, Taiwan
J-J. Yan, P-R. Hsueh, J-J. Lu, F-Y. Chang,
J-M. Shyr, J-H. Wan, Y-C. Liu, Y-C. Chuang,
Y-C. Yang, S-M. Tsao, H-H. Wu, L-S. Wang,
T-P. Lin, H-M. Wu, H-M. Chen, J-J. Wu
(Tainan, Taipei, Taichung, Hualien, TW)
P511 Salmonella enterica serovar enteritidis
producing a TEM-52 B-lactamase.
First report in Spain
M. Fernández Vázquez, J.L. Muñoz-Bellido,
J.A. García-Rodríguez (Salamanca, ES)
P512 Biochemical characterisation of the plasmidencoded
class C B-lactamase FOX-7
J.D. Docquier, S. Prandi, S. Cresti, G.M. Rossolini
(Siena, IT)
P513 Analysis of the promoter/attenuator region
of the ampC gene in clinical isolates of
Escherichia coli with “AmpC phenotype”
M.C. Conejo, G. Amblar, F. Fernández-Cuenca,
A. Pascual, E.J. Perea, L. Martínez-Martínez
(Seville, ES)
P514 Evaluation of an AmpC disk test and genetic
detection of imported ampC-genes in
Norwegian clinical strains of E. coli
B. Haldorsen, E. Lundblad, B. Aasnæs, K. Dahl,
A. Hanssen, G. Simonsen, T. Walsh,
A. Sundsfjord (Tromsø, NO; Bristol, UK)
P515 Detection of extended-spectrum betalactamase
in Enterobacteriaceae with AmpC
beta-lactamase type of inducible resistance
Sp. Fokas, St. Fokas, E. Lauranou, I. Sarris,
M. Kalkani, M. Dionysopoulou (Sparta, GR)
P516 Modelling the effect of copy number of
plasmids carrying ESBL genes on resistance
levels to beta-lactam antibiotics
M. Stepanova, M. Edelstein (Smolensk, RU)
page 72 Final Programme
12:00–13:00
Molecular typing
P517 Genetic relatedness between sporadic and
epidemic methicillin-resistant Staphylococcus
aureus in Belgian hospitals
M. Hallin, R. De Mendonca, O. Denis, A. Deplano,
R. De Ryck, S. Rottiers, M.J. Struelens (Brussels, BE)
P518 Analysis of polymorphisms within mid-region
inserts of vacuolating cytotoxin alleles of
Helicobacter pylori to identify genotypic
markers of geographic adaptation
R.J. Owen (London, UK)
P519 Differences in group A Streptococcus clinical
and molecular epidemiology between Belgian
and Brazilian children
P.R. Smeesters, A. Vergison, D. Campos Junior,
E. de Aguiar, L. Van Melderen
(Brussels, BE; Brasília, BR; Gosselies, BE)
P520 AFLP analysis of international Clostridium
difficile strains of different toxin type reveals
major toxin-dependent clonal clusters
H. Pituch, W. van Leeuwen,
P. Obuch-Woszczatynski, D. Wultanska, H. Kato,
F. Meisel-Mikolajczyk, M. Luczak, A. van Belkum
(Warsaw, PL; Rotterdam, NL; Tokyo, JP)
P521 Molecular epidemiology and genetic diversity
of Mycobacterium tuberculosis clinical
isolates in Okinawa, Ryu-Kyu islands, Japan
J. Millet, T. Zozio, C. Miyagi-Shiohira, N. Yamane,
N. Rastogi, C. Sola (Abymes, FR; Okinawa, JP)
P522 A view of the Neisseria gonorrhoeae
population transmitted in Arkhangelsk,
Russia: phenotypic and genetic characteristics
M. Unemo, V. Vorobieva, N. Firsova, T. Ababkova,
I. Lenev, B. Haldorsen, H. Fredlund, V. Skogen
(Örebro, SE; Tromsö, NO; Arkhangelsk, RU)
P523 Discrimination between E. coli O157 isolates
using PCR-mediated fingerprinting based on
SER element
G. Kardos, M. Antal, I. Tóth, I. Kiss, B. Nagy
(Debrecen, Budapest, HU)
P524 Application of amplified fragment length
polymorphism as an epidemiological tool for
infections due to Mycobacterium haemophilum
L.E.S. Bruijnesteijn van Coppenraet, N. Buffing,
M.W. van der Bijl, J.A. Lindeboom, P.H. Savelkoul,
E.J. Kuijper (Leiden, Amsterdam, NL)

Poster Sessions Sunday, April 2, 2006
P525 Distribution of toxinotypes and detection of
binary toxin in 199 Clostridium difficile strains
at a university hospital, Montpellier, France
A. Boulier, H. Marchandin, D. Decre, J. Campos,
R. Devine, H. Jean-Pierre (Montpellier, Paris, FR)
P526 Molecular analysis of pneumococci isolated
from invasive infections of children in
Hungary
M. Füzi, B. Libisch, B. Krucso, J. Pászti,
T. Tirczka, Z. Meszner (Budapest, HU)
P527 Prevalence and typing of adenoviruses in
stool of Iranian children with acute diarrhoea:
a comparative study by molecular and
serological assays
F. Roohvand, F. Motevali, M. Ghazanfari,
S. Salmanzadeh-Ahrabi, F. Jafari, M. Zali
(Tehran, IR)
P528 Molecular and physiological characterisation
of fungal opportunists belonging to the genus
Trichoderma
L. Kredics, Z. Antal, A. Szekeres, L. Hatvani,
M. Láday, M. Komon, J. Varga, L. Manczinger,
C. Vágvölgyi, E. Nagy, C. Kubicek, I.S. Druzhinina
(Szeged, Budapest, HU; Vienna, AT)
P529 SeqNet.org: a European-wide certification
trial for sequence-based typing of microbial
pathogens
A.W. Friedrich, A. Mellmann, W. Witte,
D. Harmsen, H. de Lencastre, W. Hryniewicz,
J. Scheres, H. Westh and the SeqNet.org
participants
P530 Genetic typing of enteroviruses for the
investigation of two local outbreaks in
France in 2005
A. Mirand, F. Girault, C. Archimbaud, Y. Michel,
F. Charbonné, H. Peigue-Lafeuille, J.L. Bailly
(Clermont-Ferrand, Paris, FR)
P531 Development of a novel SNP based assay to
speciate Brucella isolates
M.R. Stubberfield, J.C. Scott, A.M. Whatmore
(Addlestone, UK)
P532 Multiplex SCCmec typing of hospital,
community and multi-resistant methicillinresistant
Staphylococcus aureus
J. Rollason, A.C. Hilton, J.M. Caddick,
P.A. Lambert, T. Worthington, T.S.J. Elliott
(Birmingham, UK)
P533 Fast, accurate, and automated workflow for
multi locus sequence typing of Staphylococcus
aureus
J. Tan, M. Langvik, A. Yang, B. Turner, A. Rico,
S. Jankowski, J. Theelen, A. Pradhan, R. Nutter
(Foster City, US; Loerenskog, NO)
P534 Use of the isoschizomers SmaI and XmaI to
generate a common PFGE pattern database
for both mef-negative and mef-positive
S. pyogenes isolates
P.T. Tassios, G. Diamantopoulou, A. Stathi,
L. Zachariadou, A. Pangalis, J. Papaparaskevas,
N.J. Legakis & the Hellenic Strep-EURO Group
P535 Genotypes of Chlamydophila psittaci causing
zoonotic infection
E.R. Heddema, E.J. van Hannen, B. Duim,
Y. Pannekoek (Amsterdam, Nieuwegein, NL)
P536 A comparative study of Escherichia coli
strains isolated from the intestinal mucosa of
Crohn’s disease patients and healthy subjects
M. Martinez-Medina, X. Aldeguer,
F. Gonzalez-Huix, D. Acero, L.J. Garcia-Gil
(Girona, ES)
P537 Molecular typing of Shigella sonnei isolates
by RAPD-PCR and ribotyping
F. Jafari, S. Salmanzadeh-Ahrabi, M.M. Feizabadi,
H. Mohaghegh-Shalmani, M. Zali (Tehran, IR)
P538 Evaluation of gyrB RFLP analysis for the
typing of clinical and environmental strains of
Stenotrophomonas maltophilia
N.F. Foster, B.J. Chang, A.J. Plant, T.V. Riley
(Perth, AU)
P539 Molecular analysis of Mycobacterium kansasii
isolates from Taiwan
T.-S. Wu, M.-H. Lee, H.-S. Leu
(Taoyuan Hsien, TW)
12:00–13:00
Bacterial pathogenesis – I
P540 Resistance to colistin and carbapenems
with detection of class 1 integrons on
Pseudomonas aeruginosa clinical isolates
E. Platsouka, H. Kraniotaki, G. Tourouki, V. Doga,
E. Perivolioti, K. Kanellos, G. Kalogeras,
O. Paniara (Athens, GR)
P541 Molecular epidemiology of Pseudomonas
aeruginosa strains isolated from intensive
care unit
P. Nowak, A. Targosz, A. Budak, M. Skalkowska,
E. Filip (Cracow, PL)
www.escmid.org/eccmid2006
page 73

Poster Sessions Sunday, April 2, 2006
P542 Increase in incidence of serogroup C invasive
meningococcal disease in Italy and rise of
decreased susceptibility to penicillin
P. Mastrantonio, C. Fazio, A. Neri, T. Sofia,
P. Stefanelli (Rome, IT)
P543 Detection and identification of bacterial DNA
in cardiac valves from infective endocarditis
cases
M. Kemp, J. Bangsborg, A. Kjærulf, T. Schmidt,
J. Christensen, A. Irmukhamedov, N.E. Bruun,
R. Dargis, K. Andresen, J.J. Christensen
(Copenhagen, DK)
P544 Spectrum of bacterial pathogens causing IE
in our hospital
M. Slany, J. Cerny, T. Freiberger (Brno, CZ)
P545 Molecular characterisation and prevalence of
tick-borne diseases pathogens in Lithuania
D. Ambrasiene, J. Turcinaviciene, A. Paulauskas,
R. Mikalauskas (Kaunas, Vilnius, LT)
P546 Tick-borne Rickettsiae in Russia
S. Shpynov, P.E. Fournier, N. Rudakov,
I. Tarsevich, D. Raoult (Omsk, RU; Marseille, FR;
Moscow, RU)
P547 Microbiological characterisation of invasive
group A streptococci in the UK during 2003–04
S. Neal, C. Dhami, M. Emery, S. Flynn, T. Lamagni,
N. Alhaddad, C. Keshishian, A. Efstratiou
(London, UK)
P548 Detection of pcaA gene in M. tuberculosis
strains isolated from clinical specimens
R. Ramazanzadeh (Tehran, IR)
P549 Isolation and identification of Legionella
(legionnaires’ disease agents) from fish ponds
and environmental water sources by culture
and PCR methods
S.M. Moosavian, A. Dashti (Ahwaz, IR)
P550 Three females with asymptomatic infection of
Mycoplasma pneumoniae, carrying genes for
MDS and lymphoma detected with FISH
technique
S. Kokkinou, A. Lindou, K. Pavlou,
A. Charalambopoulou, I. Fotopoulou, H. Alafaki,
R. Hatzikyriakou, E. Fakiri (Athens, GR)
P551 Aseptic meningitis: aetiologic diagnosis
L. Santos, J. Simões, S. Conde, R. Costa
(Porto, PT)
P552 Characterisation of the recombinant
S-adenosylhomocysteine hydrolase from
Cryptosporidium parvum
F. Stejskal, V. Ctrnacta, I. Hrdy, J.S. Keithly
(Prague, CZ; Albany, US)
page 74 Final Programme
P553 VIM-1- producing Klebsiella pneumoniae
strains with class 1 integrons isolated from
bloodstream infections
H. Kraniotaki, E. Platsouka, H. Belesiotou,
G. Antonakis, E. Kontou, O. Paniara (Athens, GR)
P554 Molecular detection of the cefoxitin-resistance
gene, cfxA, and the 3’ regulatory sequence
of its resistance element, MTn4555
J. Soki, M. Toth, Z. Bessenyei, E. Urban, E. Nagy
(Szeged, HU)
12:00–13:00
Emerging microbial infections
P555 Severe cutaneous anthrax and toxaemic
shock
M. Doganay, O. Yildiz, E. Alp, D. Esel, B. Aygen
(Kayseri, TR)
P556 Visceral leishmaniasis in immuno -
compromised patients: two cases and
review of the literature
M. Weisser, B. Khanlari, U. Flückiger (Basel, CH)
P557 Nontyphoidal Salmonella invasive bloodstream
infections resistant to quinolone
and/or an extended-spectrum cephalosporin
in a country with extensive use of these
antimicrobials in food animals
W. Kulwichit, T. Chatsuwan, C. Unhasuta,
C. Pulsrikarn, A. Bangtrakulnonth,
A. Chongthaleong (Bangkok, TH)
P558 Detection of Coxiella burnetii and anti-
Coxiella antibodies by molecular and
serological methods among risk groups
M. Eyigor, S. Kirkan, B. Gultekin, S. Yaman,
S. Tekbiyik, N. Aydin (Aydin, TR)
P559 Dermatophytosis by Trichophyton violaceum:
an emerging pathogen in European urban
areas
M. Aguilar, A. Badell, J. Graells, R. Olivella,
M. Gomis (Cornellà de Llobregat, ES)
P560 Characterisation of Listeria monocytogenes
strains isolated from human and ruminant
clinical cases and from food products by
serotyping and automated ribotyping
E. Bozzetta, M. Pezzolato, R. Nappi, C. Grattarola,
R. Serra, A. Catalano, L. Decastelli, M. Caramelli
(Turin, IT)
P561 Lethal Ehrlichia ruminantium infections in
humans in South Africa
M.E.P. Allsopp, M. Louw, E.C. Meyer,
K. Matsumoto, P. Brouqui
(Onderstepoort, ZA; Marseille, FR)

Poster Sessions Sunday, April 2, 2006
P562 Value of serology in diagnosing Lympho -
granuloma venereum
T. Meyer, C. Noah, R. Arndt, H.J. Stellbrink,
S. Unger, A. Plettenberg (Hamburg, DE)
P563 Investigation of Francisella tularensis using
real time TaqMan PCR in water sources in
Turkey where tularaemia cases seen mostly
as pharyngeal form
A. Karadenizli, H. Leblebicioglu, G. Celebi,
D. Ozdemir, S. Gurcan, H. Vahaboglu
(Kocaeli, Samsun, Zonguldak, Bolu, Edirne, TR)
P564 Outbreak of tularaemia: the first case-control
study in Turkey
H. Leblebicioglu, S. Esen, D. Turan, Y. Tanyeri,
A. Karadenizli, F. Ziyagil, G. Goral (Samsun,
Kocaeli, Amasya, Bursa, TR)
P565 Tularaemia: a misdiagnosed disease in France
B. Doudier, L. De labrusse, J.M. Rolain, D. Raoult,
P. Brouqui (Marseille, FR)
P566 Anaerobic bacteraemia in patients with
leukaemia and lymphoma. Oropharyngeal
mucositis and status of haematologic disease
are the most important predisposing
conditions
A. Candoni, S. Buttignol, E. Simeone, R. Fanin
(Udine, IT)
P567 Non-toxigenic Corynebacterium diphtheriae
as a cause of bacterial endocarditis in children
with congenital heart defects
M.G. Dove, R.P. Loxton, E.J. Olivier, B. Prinsloo
(Pretoria, ZA)
P568 Shiga toxin producing Escherichia coli isolated
from one-humped camels (Camelus dromedarius)
T. Pál, Á. Sonnevend, K. Al-Dhaheri, M. Herpay,
T. Mag, A. Usmani, J. Kolodziejek, N. Nowotny
(Al Ain, AE; Budapest, HU; Vienna, AT)
P569 Achievements of the first European project on
severe group A streptococcal disease
A. Jasir, C. Schalen (Lund, SE)
12:00–13:00
Vaccines and immunotherapy
P570 Evaluation of gamma-interferon kinetic in
vaccinated BALB/c mice by gD expression
vector of HSV-1 and its recombinant protein
E. Arefian, T. Bamdad, H. Soleimanjahi, F. Sabahi,
A. Ghaemi, J. Keiani (Tehran, IR)
P571 Is MMRV vaccination cost-effective in HCWs
in Turkey?
A. Celikbas, O. Ergonul, S. Aksaray, N. Tuygun,
G. Tanir, H. Esener, S. Eren, N. Baykam,
E. Guvener, B. Dokuzoguz (Ankara, TR)
P572 Parasitic diseases in children as one of the
reasons for postvaccinal complications
M.V. Kuropatenko, L.A. Jelenina
(Saint-Petersburg, RU)
P573 Vaccination with adeno-associated virus
vector encoding severe acute respiratory
syndrome coronavirus S protein induces
potent and prolonged antibodies
L. Du, Y. Zhou, Y. He, S. Ma, K.Y. Yuen, S. Jiang,
B.J. Zheng (Hong Kong, HK; Beijing, CN;
New York, US)
P574 Appropriateness of rabies post-exposure
treatment received by patients presenting
to an anti-rabies treatment unit
M.J. Pinidiyapathirage, O. Wimalaratne
(Ragama, Colombo, LK)
P575 Adverse effects of rabies postexposure
prophylaxis
F. Mattner, S. Kuhn, F. Bitz, M. Goedecke,
S. Becker, K. Radsack, B. Jansen, A. Viertel,
P. Gastmeier, F. Biertz, A. Heim, C. Henke-Gendo,
A. Martens, T. Schulz, M. Strueber (Hannover,
Hannoversch Münden, Marburg, Mainz, DE)
P576 Design and construction of an expression
vector containing immunogenic epitopes of
HIV-1 P24 and gp 41 proteins as a vaccine
candidate against HIV-1
F. Roodbari, F. Mahboudi, F. Sabahi,
F. Barkhordary, R. Sarami Foroshani, A. Adeli
(Tehran, IR)
P577 Clinical course study in post BCG vaccination
adenitis
A. Hamedi, A. Velayati (Mashad, Tehran, IR)
P578 A flow cytometric opsonophagocytic assay
for measurement of functional antibodies
elicited after immunisation with the Neisseria
meningitidis serogroup A capsular polysaccharide-serogroup
B outer membrane vesicle
conjugate vaccine in animal model
M. Kheirandish, S.D. Siadat, Q. Behzadiyannejad,
B. Tabaraiee, H. Ahmadi, S. Najar Pirayeeh,
M. Nejati, K. Mahmoodi (Tehran, IR)
www.escmid.org/eccmid2006
page 75

Poster Sessions Sunday, April 2, 2006
P579 Immunological evaluation of Neisseria
meningitidis serogroup B outer membrane
vesicle containing PorA conjugated with
Neisseria meningitidis serogroup
A capsular polysaccharide in rabbit
S.D. Siadat, Q. Behzadiyannejad, B. Tabaraiee,
H. Ahmadi, S. Najarpirayeeh, D. Nouroziyan
Shamasbi, M. Nejati, M. Kheirandish, H. Rezvan,
K. Moosavi Hossaini, B. Adibi Motlagh, A. Moshiri
(Tehran, IR)
P580 Efficacious vaccination against serogroup C
meningococcal disease by one shot at the age
of 14 month in the Netherlands
A. van der Ende, S. de Greeff, H. de Melker,
L. Spanjaard (Amsterdam, Bilthoven, NL)
P581 Streptococcus pneumoniae: proteomics of
surface proteins for vaccine development
C. Morsczeck, J. Sigh, M. Bille-Nielsen,
M. Pfeiffer, T. Prokhorova, A. Boysen,
J. Petersen, N. Frimodt-Møller, N. Pia, J. Crawford,
T. Kofoed (Odense, Copenhagen, DK)
P582 Seropathotypes, adherence ability and
inflammatory effect induced to cellular
substratum by enteropathogenic E. coli
strains isolated from aquatic environments
R. Cernat, V. Lazar, M.C. Balotescu (Bucharest, RO)
P583 Characterisation of intestinal lactobacilli as
potential second-generation probiotics
P. Kõll, R. Mändar, I. Smidt, M. Mikelsaar (Tartu, EE)
P584 Immunological determinants of disease
pathogenesis in Indian leishmaniasis
N. Ansari, V. Ramesh, S. Saluja, P. Salotra
(New Delhi, IN)
P585 Association of polymorphism in genes
encoding human innate immunity factors
and persistent nasal Staphylococcus aureus
colonisation
A. van Belkum, H. Wertheim, C. de Jongh,
M. Emonts, J.L. Nouwen, A. Cole, A.L. Cole,
H.A.M. Boelens, S. Snijders, H. Verbrugh,
W.B. van Leeuwen (Rotterdam, NL; Orlando, US)
P586 Interference with pathogenic bacteria in
cystic fibrosis
Å. Sullivan, F. Karpati, L. Hjelte, B. Wretlind,
C.E. Nord (Stockholm, SE)
P587 New insights into the role platelets in
antifungal host defence
C. Lass-Flörl, S. Unterdorfer, W. Nussbaumer,
M.P. Dierich (Innsbruck, AT)
page 76 Final Programme
P588 The role of mannose-binding lectin in
susceptibility to infection in premature
neonates
A. Dzwonek, O. Neth, J. Hawdon, E. Gulczynska,
H. Tchorzewski, M. Turner, N. Klein
(London, UK; Lodz, PL)
P589 Immunoprophylaxis of wound and urinary
tract infections in urological patients by
application of immunostimulator Urostim
R. Vacheva-Dobrevsky, I. Saltirov, P. Nenkov,
T. Petkov, E. Savov, J. Doncheva (Sofia, BG)
P590 Faropenem enhances the bactericidal activity
of human neutrophils in vitro
K. Clawson Stone, I.A. Critchley, U.A. Ochsner,
N. Janjic (Louisville, US)
P591 Light microscopic appearances of resident
macrophages in the adrenal glands of
pregnant and non-pregnant guinea pigs,
and their immuno-endocrinological
significance
E. Ozbek, A. Ozbek (Erzurum, TR)
P592 Blood lymphocyte subsets in patients with
tick-borne encephalitis
I. Zeltina, V. Sondore, O. Shitova, B. Rozentale
(Riga, LV)
P593 Evaluation of a new immunoassay to detect
antibodies against Treponema pallidum in
sera samples
M.S. Garcia-Valdivia, J.R. León,
M.A. Rodriguez-Iglesias (Cadiz, ES)
P594 Monocyte chemoattractant protein-1:
role in the pathogenesis and progression
of acute pyelonephritis in infants
E. Demetriou, F. Haliotis, A. Margeli, M. Sourani,
L. Zachariadou, I. Papassotiriou (Athens, GR)
P595 Vaccination delays maedi-visna lentivirus
infection in naturally infected sheep flock
M. Gudnadóttir, A. Demosthenous
(Reykjavik, IS; Limmasol, CY)
12:00–13:00
AIDS and HIV
P596 Free anonymous HIV testing sites are an
opportunity to offer hepatitis B virus
vaccination to high-risk non-immune patients
E. Bouvet, P. Preziosi, M. Branger, M. Rotily
(Paris, Bagneux, FR)
P597 Morphologic and molecular evidence of viral
infection in human brainstem
V. Militello, A. Porzionato, G. Masi, M. Trevisan,
G. Sarasin, V. Macchi, L. Barzon, R. De Caro,
G. Palù (Padua, IT)

Poster Sessions Sunday, April 2, 2006
P598 Prevalence and risk factors of QTc interval
prolongation in HIV-positive patients
P. Chinello, F. Papetti, E. Boumis, A. Conte,
B. Gigli, F. Lisena, C. Angeletti, N. Petrosillo
(Rome, IT)
P599 Prevalence of paediatric septicaemia in a
tertiary hospital in Tanzania and the impact
of aetiology, antimicrobial susceptibility
and HIV co-infection on clinical outcome
B. Blomberg, K.P. Manji, W.K. Urassa,
M. Holberg-Petersen, M.G. Tellevik, N. Langeland
(Bergen, NO; Dar es Salaam, TZ; Oslo, NO)
P600 Microarray analysis during adipogenesis
identifies new genes altered by antiretroviral
drugs
L. Barzon, M. Pacenti, K. Fincati, F. Favaretto,
G. Milan, R. Vettor, G. Palù (Padua, IT)
P601 Indeterminate HIV Western blot profiles:
how may we proceed?
G. Saliba, S. Matheron, F. Damond (Paris, FR)
P602 Best practices in model-based HIV drug
development
W. Poland, R. Bruno, M. Hovde,
J. Kuwabara-Wagg (Mountain View, US;
Marseilles, FR; Kennett Square, US)
P603 Primary pneumocystis infection in children
hospitalised with acute respiratory tract
infection
H.H. Larsen, M.-L. von Linstow, B. Lundgren,
B. Høgh, H. Westh, J.D. Lundgren (Hvidovre, DK)
P604 Increasing reports of gynecomastia among
HIV-infected patients treated with highly
active antiretroviral therapy. Epidemiological
and clinical correlates, and suggestions for
pathogenetic investigation
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P605 Insulin resistance and glucose intolerance in
HIV-infected subjects during their protease
inhibitor treatment: three oral hypoglycemic
drugs in comparison
L. Calza, R. Manfredi, F. Chiodo (Bologna, IT)
P606 Advanced, lethal acute myelogenous
leukaemia during HIV disease favourably
managed with HAART
R. Manfredi, S. Sabbatani, F. Chiodo (Bologna, IT)
P607 Isolated, dual nucleoside analogue antiretroviral
therapy in the year 2005. Frequency,
reasons, significance and outcome of this
persisting phenomenon, nine years after
the introduction of HAART
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P608 The two non-nucleoside HIV reverse
transcriptase inhibitors: significantly
different dysmetabolic profile between
efavirenz and nevirapine
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P609 Opportunism related to a late, first AIDS
diagnosis. Paradoxical increasing frequency
at the time of HAART
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P610 Immigration and HIV infection in North-Eastern
Italy. Inpatient admissions, 2000–2004
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P611 Management of hyperlipidaemia related to
antiretroviral therapy with the novel statin
rosuvastatin: a pilot study
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P612 Increased frequency of syphilis among
patients who remained unaware of their
underlying HIV infection
R. Manfredi, L. Calza, S. Sabbatani, F. Chiodo
(Bologna, IT)
P613 Loss of bone mass in chronically HIV-infected
patients. Significant association with male
gender amd protease inhibitor administration
L. Calza, L. Tampellini, B. Farneti, M. Borderi,
M. Pajno, C. Biagetti, R. Manfredi, F. Chiodo
(Bologna, IT)
P614 Different HIV 1-subtypes and diseases
observed in a group of immigrants
hospitalised between 2001–2005
M.E. Valencia, A. Holguin, A. Alvarez, V. Moreno,
M. Lago, J. González Lahoz (Madrid, ES)
P615 Immigrants with HIV infection:
hospitalisations during 5 years
V. Moreno, M.E. Valencia, A. Holguin, A. Alvarez,
M. Lago, J. González Lahoz (Madrid, ES)
P616 Poor response to trimethoprim-sulfametho -
xazole in HIV-infected patients with
Pneumocystis jiroveci pneumonia and
concurrent opportunistic infections
P. Werarak, S. Ratanasiri, S. Sungkanuparph,
S. Kiertiburanakul (Bangkok, TH)
P617 Impact of occult HBV infection in HIV patients
naive for anti-retroviral therapy
P. Filippini, N. Coppola, R. Pisapia, C. Marrocco,
A. Zaccariello, C. Nacca, G. De Stefano, T. Ferraro,
C. De Stefano, E. Sagnelli (Naples, Caserta,
Matera, Catanzaro, Potenza, IT)
www.escmid.org/eccmid2006
page 77

Poster Sessions Sunday, April 2, 2006
P618 Studies of the mechanism of the inhibitory
effect on HIV-1 infection by stimulation of the
VPAC2 neuroendocrine receptor
P.B. Bokaei, D. Sakac, X-Z. Ma, D.R. Branch
(Toronto, CA)
P619 Dramatic changes in survival and death rates
after AIDS through the evolution of antiretroviral
therapy, Paris
C. Couzigou, C. Semaille, R. Pinget, Y. Le Strat,
J. Pillonel, F. Lot, F. Cazein, D. Vittecoq,
J.C. Desenclos and the AIDS Survival Study Group
P620 Determinants of persistent nasal carriage and
population structure of Staphylococcus
aureus in HIV patients
D.C. Melles, E. Hardeman, L. van den Boogaard,
H.A.M. Boelens, J. Peters, J.K. Peeters,
M. van Min, W. van Leeuwen, H.A. Verbrugh,
A. van Belkum, J.L. Nouwen
(Rotterdam, Wageningen, NL)
P621 Pulmonary hypertension among HIV positive
subjects: findings from the Latium Regional
Registry
N. Petrosillo, E. Boumis, S. Cicalini, P. Chinello
on behalf of Latium Registry of Pulmonary
Hypertension in HIV
P622 Proteinuria in tenofovir-exposed and nonexposed
patients: audit of screening processes
within a United Kingdom HIV cohort
M.J. Parsonage, J. Vilar, G. Barlow, F. Qasim
(Cottingham, Manchester, UK)
P623 A meta-analysis of the frequency of side
effects for HAART drugs
S. Andreassen, L. Vidal, U. Pielmeier
(Aalborg, DK; Tel Aviv, IL)
P624 Immune-virological status and psycho-social
factors concerning vertically contamined
HIV-infected children at the time of transfer
to adult care
V. Mondain, J. Durant, E. Cua, I. Perbost,
F. Monpoux, A. Deville, P. Boutte, P. Dellamonica
(Nice, FR)
P625 Variation in interpretation and counselling of
blood exposure incidents
P.T.L . van Wijk, A. Timen, M. Pelk-Jongen,
C. Wijkmans, A. Voss, P. Schneeberger
(‘s-Hertogenbosch, Utrecht, Nijmegen, NL)
page 78 Final Programme
12:00–13:00
Detection of viruses
P626 The measurement of 9-carboxymethoxy -
methylguanine in human body fluids by
high-performance liquid chromatography
M. Darville, A. Lovering, A. MacGowan
(Bristol, UK)
P627 Transient HBsAg reactivity after hepatitis B
vaccination
C. Koidl, B. Waitzl, A. Holensteiner, C. Kreuzer,
E. Daghofer, E. Marth (Graz, Vienna, AT)
P628 Development of human anti-rubella IgG
and IgM assays for the Abbott ARCHITECT
Instrument
G.T. Maine, R. Vickstrom, K. Krishnan, J. Prostko,
Z. Kogan, J. Morey, J. Lagedrost, J. Jacob,
Rn. Stricker, Rt. Stricker, B. Pustowoit
(Abbott Park, US; Geneva, CH; Leipzig, DE)
P629 Preliminary evaluation of the Abbott
ARCHITECT anti-cytomegalovirus IgG,
IgM and IgG avidity assays
G.T. Maine, I. Curdt, J. Herzogenrath, H. Braun,
R. Eichler, H. Christ, M. Hausmann, R. Stricker,
R. Stricker, T. Lazzarotto (Abbott Park, US;
Wiesbaden, DE; Geneva, CH; Bologna, IT)
P630 A novel method for distinguishing between
bacterial and viral infections that incorporates
standard clinical laboratory data and
quantitative analysis of neutrophil
complement receptors, CR1 and CR3
J. Nuutila, U. Hohenthal, I. Laitinen, P. Kotilainen,
A. Rajamäki, J. Nikoskelainen, E-M. Lilius (Turku, FI)
P631 Epitope specific IgG response to Epstein-Barr
virus capsid protein p18 among different age
groups
I. Astrakhantseva, O. Morozova, S. Rjabinina,
V. Puzyrev, T. Ulanova, A. Burkov, A. Obriadina
(Nizhny Novgorod, RU)
P632 Antigenic properties of new recombinant
polypeptide from TBEV gE protein
V. Pimenov, R. Plokhov, N. Savelieva,
J. Zagriadskaya, V. Puzyrev, T. Ulanova,
A. Obriadina (Niznyi Novgorod, RU)
P633 Development a new enzyme immunoassay
for detection anti-EBNA1 antibody to Epstein-
Barr virus based on new p72 mosaic protein
O. Morozova, M. Gladysheva, T. Ulanova,
V. Puzyrev, A. Burkov, A. Obriadina
(Nizhny Novgorod, RU)

Poster Sessions Sunday, April 2, 2006
P634 Rapid detection of rotavirus in children:
comparison of Vikia rota-adeno and Diarlex
MB, two immunochromatographic tests
H. Crehalet, F. Vandenesch, A.M. Freydiere
(Lyon, FR)
P635 Evaluation of rubella IgG and IgM assays on
the new vidia instrument
L. Grangeot-Keros, C. Vauloup-Fellous
(Clamart, FR)
P636 RNA extraction from respiratory samples
using the NucliSens easyMAG system
P. van Deursen, A. Verhoeven, P. de Bie,
M. Jacobs (Boxtel, NL)
P637 Evaluation of automated sample processing
using the MagNA Pure LC instrument for use
with the COBAS AMPLICOR HCV (ver 2) test
S. Palladino, I. Kay (Perth, AU)
P638 Development of sensitive and specific realtime
PCR assay for simultaneous diagnostics
and genotyping of cytomegalovirus
O. Vankova, O. Morozova, T. Ulanova, V. Loparev
(Nizhny Novgorod, RU; Atlanta, US)
P639 Detection of human papillomavirus
(Type 16, 18) in pathological sample from
patients with cervical cancer by PCR and
RFLP methods
P. Maleknejad, S. Shahsavan (Tehran, IR)
P640 Detection of human papillomavirus by
PCR genotyping and immunostaining in
population of Bosnian women
S. Mahmutovic, P. Gravitt, A. Hardick, E. Beslagic,
M. Slakovic, M. Herawi, C.A. Gaydos
(Sarajevo, BA; Baltimore, US)
P641 A novel system for the simultaneous
detection of seven respiratory viruses
D. Canter, B. Brigham, R. Haigis, M. Smith,
J. Shaw (San Diego, US)
P642 Evaluation of the multiplex reverse
transcription real time PCR ProFlu-1 LC
real-time assay for the detection of RSV,
influenza A and influenza B in a single test
J. Le Goff, C. Chemin, C. Charpentier, M. Matta,
A. Si-Mohamed, L. Belec, P. Lebon (Paris, FR)
P643 Detection of respiratory pathogens including
coronaviruses using PCR
I. Duerud, T.O. Jonassen, M. Steinbakk,
C.M. Jonassen (Lørenskog, Oslo, NO)
P644 An evaluation of the predictive value of HPV
testing and genotyping in the mass-screening
against cervical cancer in Norway
T. Nguyen, T.Ø. Jonassen, V. Lauvrak,
U. Westerhagen, A. Trope, S. Thoresen,
M. Steinbakk, A.K. Lie (Lørenskog, Oslo, NO)
P645 Comparison between two commercial assays
for HBV monitoring
S. Galli, M. Meliconi, G. Furlini (Bologna, IT)
P646 Detection of herpes simplex viruses type I and
II in dermal, genital, oral, cerebrospinal fluid,
and lower respiratory specimens by a Roche
HSV I/II analytic specific reagent kit on realtime
polymerase chain reaction
S. Liu, J. Tichota-Lee, D.S. DeBoer, S.A. Marum,
R.J. Van Santen, M.R. Koch (Sioux Falls, US)
P647 Survey of Crimean-Congo haemorrhagic fever
in Iranian suspected patients by Elisa and
RT-PCR method
S. Chinikar, F. Ahmadnejad , A. Fayaz, R. Mirahmadi,
N. Hoseini, N. Afzali, B. Hooshmand, M. Bouloy,
A. Lundkvist, M. Nilsson, A. Mirazimi
(Tehran, IR; Paris, FR; Stockholm, SE)
P648 Comparative evaluation of the vidas and
liaison toxoplasmosis, cytomegalovirus and
rubella panels in a French university hospital
M.J. Carles, C. Enault, L. Lachaud, S. Charachon
(Nîmes, FR)
P649 Different sensitivity of chemiluminescent
immunoassay for the detection of HBsAg
A. Rodella, L. Terlenghi, E. Cariani, N. Manca
(Brescia, IT)
P650 Evaluation of a new assay for simultaneous
detection of HCV core antigen and anti-HCV
antibodies
S. Carlos, C. Fornieles, N. Chueca, M. Alvarez,
C. Bernal (Granada, ES)
P651 Comparison of molecular and serological
assays in the diagnosis of HCV infection
C. Fornieles, S. Carlos , N. Chueca, A. Peña,
F. García, C. Bernal (Granada, ES)
P652 Evaluation of an automated multiplexed
assay of heterophile antibody in comparison
with a latex agglutination test for assessment
of Epstein-Barr virus induced infectious
mononucleosis
C. Lingenfelter, A. Villarreal, D. Kaur, H. Scholz
(Hercules, US)
www.escmid.org/eccmid2006
page 79

Poster Sessions Sunday, April 2, 2006
P653 Real-time polymerase chain reaction and HCV
RNA quantification: comparison of Cobas
Ampliprep-Cobas TaqMan and branched DNA
technology
T. Allice, S. Gabella, S. Varetto, F. Pittaluga,
A. Smedile, F. Cerutti, V. Ghisetti (Turin, IT)
P654 Automated fractal microscope for virus-cell
monitoring
O.P. Fedchuk, A.O. Fedchuk, A.S. Fedchuk
(Odessa, UA)
P655 Comparison of HCV genotype and subtype
determination using Inno-LiPA HCV II and a
laboratory-developed HCV 5’UTR sequencing
procedure
S. Gabella, T. Allice, S. Varetto, F. Pittaluga,
V. Ghisetti (Turin, IT)
P656 Comparison of IMMULITE ® 2000 anti-HAV IgM
and anti-HAV total to Abbott AxSYM ® assays
C. Lee (Los Angeles, US)
12:00–13:00
Nosocomial infections
P657 National Resource for Infection Control (NRIC)
S.S. DSouza, S. Wiseman, P. Kostkova,
J. Mani-Saada (London, UK)
P658 An independent review of computerised
systems for alert organism and alert
condition surveillance
M. Jones, A. Pearson, S. Hanratty for the
Infection Control IT Implementation and
Evaluation Project Board, UK
P659 Knowledge, attitudes and practices of health
care workers in Kosovo hospitals regarding
nosocomial infections
L. Raka, S. Kalenic, D. Zoutman, L. Berisha,
M. Berisha, D. Salihu, L. Begolli, S. Krasniqi,
A. Jaka, I. Begolli (Pristina, CS; Zagreb, HR;
Kingston, CA)
P660 Worldwide implementation strategy of the
World Health Organization “Guidelines on
Hand Hygiene in Health Care”
B. Allegranzi, P. Philip, J. Storr, M. Fletcher,
S. Lazzari, L. Donaldson, D. Pittet
(Verona, IT; Geneva, CH; Lyon, FR)
P661 Considerations on optimal glove use within
the World Health Organization “Guidelines on
Hand Hygiene in Health Care”
B. Allegranzi, G. Dziekan, E. Larson, C.L. Pessoa
da Silva, P. Philip, L. Donaldson, D. Pittet
(Verona, IT; Manila, PH; New York, US; Geneva, CH)
page 80 Final Programme
P662 Alcoholic hand disinfectant use in a general
hospital: impact of an intervention
E. Divari-Katsiki, C Loupa, H. Antonopoulou,
K.J Karnezi, V. Tsolaki, M. Lelekis (Athens, GR)
P663 Does sufficient hand hygiene influence
hospital-acquired infections?
S. Laustsen, E. Lund, R. Andersen Leth,
J. Kjølseth Møller on behalf of the Hospital
Hygiene Group, Aarhus University Hospital,
Denmark
P664 Adherence to hand hygiene in an Italian
hospital
A. Pan, K. Posfay-Barbre, P. Catenazzi, N. Poli,
A. Grandi, S. Lorenzotti, S. Magri, L. Soavi,
P. Mondello, G. Carnevale (Brescia, Cremona IT;
Geneve, CH)
P666 Evaluation of parameters influencing
compliance of HCWs with hand hygiene in
two university departments of internal
medicine in a Greek tertiary hospital
S. Athanasia, E. Giannitsioti, H. Fitrou,
A. Papadopoulos, P. Bourvani, K. Athanassiou,
P. Evangelopoulou, A. Ghika, H. Giamarellou
(Athens, GR)
P667 Nosocomial meningitis after spinal anesthesia
R. Kryeziu, L. Raka, G. Mulliqi-Osmani, H. Hyseni,
I. Dedushaj, D. Kryeziu, N. Ramadani, S. Omeragiq,
S. Muçaj (Pristina, CS)
P668 Infections after open heart surgery
C. Ezpeleta, E. Gomez, C. Busto, I. Atutxa,
J.A. Alava, J. Unzaga, R. Cisterna (Bilbao, ES)
P669 Surgical site infections after colon surgery
C. Ezpeleta, I. Atutxa, E. Gomez, C. Busto,
J.A. Alava, J. Unzaga, R. Cisterna (Bilbao, ES)
P670 Hospital-acquired infection: a hospital-wide
prevalence study at a London hospital
N. Desai, B. Houston, E. Stewart, J. Ikonnen,
S. Watts, S. Chuttarsing, I. Eltringham
(London, UK)
P671 Surveillance of nosocomial bloodstream
infections
R.A. Leth, J.K. Møller (Aarhus, DK)
P672 A morbidity and mortality conference to
evaluate nosocomial infections and hospital
mortality
M. Demory, A. Decoster (Lomme, FR)

Poster Sessions Sunday, April 2, 2006
P673 Point prevalence of nosocomial infections in
Western Greece
E. Jelastopulu, F. Mesolara, C. Petropoulos,
M. Kardara, I. Detorakis (Patras, Erymanthia, GR)
P674 Levofloxacin plus rifampicin treatment of
staphylococcal prosthetic-joint infections
with prosthesis retention
J. Barberán, M.J. Giménez, L. Aguilar,
G. Carroquino, B. Sánchez, D. Martínez, J. Prieto
(Madrid, ES)
P675 Prosthetic joint infections: results of a
collaborative protocol between orthopaedist
surgeons and infectious diseases physicians
J. Vicente, V. Abril, R. Benítez, A. Bru, P. Segarra,
M. Gomis, S. Escrivá, E. Ballester,
M. García-Deltoro, M. García-Rodríguez,
L. Castellano, E. Ortega (Valencia, ES)
P676 Predictive value of oral colonisation by Candida
yeasts on the onset of a nosocomial infection
in elderly hospitalised patients
S. Fanello, J.P. Bouchara, V. Delbos, E. Parot,
M. Sauteron (Angers, FR)
P677 Impact of antifungal treatment on Candida-
Pseudomonas interaction
S. Nseir, E. Josefowicz, B. Cavestri, B. Sendid,
C. Di Pompeo, S. Soubrier, A. Durocher (Lille, FR)
P678 Nosocomial urinary tract infections caused by
extended-spectrum beta-lactamases producing
Enterobacteriaceae in Latvia
R. Paberza, T. Chumak, A. Zilevica, S. Selderina,
L. Luzbinska, J. Storozenko, B. Rozentale
(Riga, LV)
13:00–14:00
Infection in the immunocompromised host
(except HIV)
P679 Comparison of cytomegalovirus viral load
measured by real-time PCR with pp65 antigenemia
for the diagnosis of cytomegalovirus
disease in solid organ transplant recipients
S. Hernando, M.D. Folgueira, C. Lumbreras,
J.R. Otero (Madrid, ES)
P680 Incidence of acquired toxoplasmosis in
seronegative recipients of solid organ
transplant
V. Meroni, E. Zerrilli, F. Genco, B. Nocita,
F. Poletti, L. Minoli (Pavia, IT)
P681 Changing trends of bacteraemia in patients
with cancer: analysis of 2,080 quantitative
blood cultures during 1998 and 2004
A. Safdar, G. Rodriguez, M. Balakrishnan,
J. Tarrand, K. Rolston (Houston, US)
P682 Infections complicating unrelated donor cord
blood stem cell transplantation: 281 episodes
in recipients of 100 CBST at a comprehensive
cancer centre (1996 – 2005)
A. Safdar, G. Rodriguez, K. Chan, M. DeLima,
K. Rolston, R. Champlin (Houston, US)
P683 A risk profile for invasive aspergillosis in liver
transplant recipients
M. Rosenhagen, R. Feldhues, H.K. Geiss,
T. Hoppe-Tichy (Heidelberg, DE)
P684 Antifungal prophylaxis with caspofungin
in high-risk liver transplant recipients:
a non-comparative, open-label prospective
clinical trial
J. Fortun, P. Muñoz, J.M. Cisneros, M. Montejo,
A. Ramos, C. Sanz-Rodriguez on behalf of
GESITRA
P685 Effect of quinolone prophylaxis on resistance
in afebrile neutropenic patients –
systematic review
A. Gafter-Gvili, M. Paul, A. Fraser, L. Leibovici
(Petah Tikva, IL)
P686 The complications associated with use of
peripherally inserted central catheters in
cancer patients in Northern Ireland
R. McMullan, V. Coyle, R. Wilson, S. Hedderwick
(Belfast, UK)
P687 Prospective study of viral infection and
nephropathy in paediatric renal transplant
recipients
L. Murer, M. De Pieri, L. Barzon, M. Pacenti,
M.A. Biasolo, C. Mengoli, M. Della Vella,
C. Carasi, G. Montini, G. Zacchello, G. Palù
(Padua, IT)
P688 Trend towards reduced burden of proven/
probable invasive fungal infections in adult
non-allo-HSCT neutropenic patients with
acute leukaemia
L. Senn, T. Calandra, J. Robinson, O. Marchetti
(Lausanne, CH)
P689 Prevalence of HHV6 and parvovirus B19 in
transplant recipients liver tissue:
clinical outcomes and viral correlates
S.G. Parisi, S. Barbieri, C. Boldrin, P. Boccagni,
M.A. Biasolo, P. Feltracco, U. Cillo, A. Bortolato,
I. Cerbaro, D. D’Amico, G. Palù (Padua, IT)
P690 Nocardiosis: a retrospective study of
41 French cases
F. Laurent, B. Pangon, R. Sanchez, P. Boiron
(Lyon, Le Chesnay, Périgueux, FR)
www.escmid.org/eccmid2006
page 81

Poster Sessions Sunday, April 2, 2006
P691 Kluyvera species as opportunistic pathogens
in paediatric cancer patients
H. El-Mahalawy, H. Morcos, L Shalaby (Cairo, EG)
P692 Risk factors for pulmonary aspergillosis in
patients with cancer and pneumonia
M. Aguilar-Guisado, E. Cordero, J.M. Cisneros,
I. Espigado, M. Noguer, R. Parody, J. Pachón
(Seville, ES)
P693 Pneumonia risk factors in patients with febrile
neutropenia
M. Aguilar-Guisado, E. Cordero, J.M. Cisneros,
I. Espigado, M. Noguer, R. Parody, J. Pachón
(Seville, ES)
P694 Once daily outpatient quinolone monotherapy
for low-risk febrile neutropenic cancer
patients
K. Rolston, S. Patel, S. Frisbee-Hume,
E. Manzullo, R. Benjamin (Houston, US)
P695 Empiric monotherapy with cefepime in
standard-risk, paediatric, febrile neutropenic
patients
K. Rolston, C. Mullen (Houston, Rochester, US)
P696 Urinary tract infections after renal transplantation:
bacterial isolates and resistance
patterns
S. Karampa, G. Miserlis, P. Sikalidou,
D. Takoudas, D. Sofianou (Thessaloniki, GR)
P697 Seroepidemiology of Bartonella henselae/
quintana in immunocompromised patients
(human immunodeficiency virus infected/
end-stage renal disease patients)
M. Pape, P. Kollaras, K. Mandraveli, A. Sioulis,
P. Nikolaidis, S. Alexiou-Daniel (Thessaloniki, GR)
P698 Tobramycin once vs. three times a day given
with penicillin G to cancer patients with
febrile neutropenia: a prospective randomised
multicentre trial
D. Torfoss, E.A. Høiby for the Norwegian Febrile
Neutropenia Study Group
P699 Enterococcal bacteraemia in patients with
haematological malignancies
N.S. Bagirova, N.V. Dmitrieva (Moscow, RU)
P700 Aetiology of infections and antimicrobial
resistance in patients treated for cancer
at a cancer institute in Slovakia.
Results from June 1999 to May 2003
O. Babelova, R. Babela, V. Krcmery (Trnava, SK)
P701 Interest of Candida antigen and antibody
ELISA for hepatosplenic candidiasis diagnosis
F. Persat, A. Thiebaut, F. Loiseau, M.A. Piens,
S. Picot, M. Michallet (Lyon, FR)
page 82 Final Programme
P702 Cefepime therapy is effective for children with
febrile neutropenia
G.T. Kovacs, M. Csoka, H. Erlaky, M. Garami,
J. Muller (Budapest, HU)
13:00–14:00
Antibacterial susceptibility studies – I
P703 A comparison study of amoxicillin-clavulanate
and azithromycin efficacy in treatment of
acute sinusitis
M. Zangeneh, N. Shariati, A. Yazdanyar,
M. Jamshidi Makiani, S. Haghighi (Tehran, IR)
P704 In vitro activities of various piperacillin and
sulbactam combinations against bacterial
pathogens isolated from intensive care units
in Taiwan: SMART program 2004 data
P.R. Hsueh, M.N. Hung, C.Y. Liu for the
Surveillance of Multicenter Antimicrobial
Resistance in Taiwan (SMART)
P705 Hetero-glycopeptide-intermediate Staphylococcus
aureus: prevalence and antibiotic
susceptibilities in long-term care facilities
from the Flemish part of Belgium
P. Declercq, A. Bolmstrom (Izegem, BE; Solna, SE)
P706 Uncomplicated urinary tract infections, what
about fosfomycin and nitrofurantoin in 2006?
P. Honderlick, J. Gravisse, P. Cahen, D. Vignon
(Suresnes, FR)
P707 Antimicrobial activity of linezolid and other
agents against nosocomial pneumonia
Streptococcus pneumoniae isolates
M.M. Ijzerman, M.A. Cohen, M.D. Huband,
P.J. Pagano, K.J. Tack (Ann Arbor, US)
P708 Low-level resistance to ciprofloxacin in
Salmonella strains isolated from humans
in Belarus
D. Tapalski (Gomel, BY)
P709 The influence of UV radiation on the
antibacterial activity of ciprofloxacin in
aqueous solutions
A.V. Polishchuk, E.T. Karaseva, V.E. Karasev
(Vladivostok, RU)
P710 In vitro activity of linezolid against
Bacteroides and Prevotella recovered from
soft tissue infections
H. Canawati, S. Bughi, A. Sharma, H. Canawati
(Downey, US)

Poster Sessions Sunday, April 2, 2006
P711 In vitro activities of cefepime, cefpirome and
ceftazidime in combination with amikacin or
ciprofloxacin against Pseudomonas aeruginosa
B. Ozbek, G. Otuk (Istanbul, TR)
P712 Antimicrobial resistance of Streptococcus
pneumoniae and Haemophilus influenzae in
Lithuania
I. Narkeviciute, G. Bernatoniene (Vilnius, LT)
P713 Cefepime alone or in combination with
clavulanic acid, gentamicin, and tobramycin
against clinical isolates of methicillin-resistant
Staphylococcus aureus
J. Chin, M. Rybak, C. Cheung, K. Lau, H. Sader,
R. Jones (Detroit, US)
P714 In vitro activities of daptomycin, linezolid,
and quinupristin-dalfopristin against clinical
isolates of Staphylococcus aureus and
Staphylococcus epidermidis from Germany
M. Kresken, J. Brauers (Rheinbach, DE)
P715 In vitro antichlamydial activity of moxifloxacin
versus a range of antimicrobial
agents
R. Cevenini, M. Donati, S. Pignanelli, S. Accardo,
F. Cavrini, C. Mazzeo (Bologna, IT)
P716 Time-killing of viable Staphylococcus spp.
against Helicobacter pylori clinical isolates
J. Díaz-Regañón, T. Alarcón, E. Aznar,
D. Domingo, M. López-Brea (Madrid, ES)
P717 IBC-1 survey in Acinetobacter baumannii
isolates in a tertiary care hospital in
Thessaloniki, Greece
K. Koraki, P. Karapavlidou, D. Sofianou
(Thessaloniki, GR)
P718 Antibacterial activity of fractions of Quercus
infectoria (nut galls) against enterohaemorrhagic
Escherichia coli
S.P. Voravuthikunchai, S. Suwalak, T. Supawita
(Hatyai, Songkla, TH)
P719 In vitro synergy between glycopeptides and
carbapenems against methicillin-resistant
Staphylococcus aureus
Ö.K. Azap, H. Arslan, F. Timurkaynak, G. Yapar,
Ü. Çazir (Ankara, TR)
P720 Susceptibility rates of co-trimoxazole,
cefepime, imipenem, meropenem against
ESBL-producing and non-producing E. coli
and Klebsiella strains
Ö.K. Azap, F. Timurkaynak, G. Yapar, Ü. Çazir,
H. Arslan (Ankara, TR)
P721 Comparison of the minimal inhibitory
concentration values of vancomycin and
teicoplanin against staphylococci with the
results obtained 7 years ago
Ö.K. Azap, F. Timurkaynak, E. Oruç, T. Togan,
H. Arslan (Ankara, TR)
P722 Serotypes and quinolone resistance in
Salmonella enterica isolated from Greek
diarrhoeal patients
S. Maraki, G. Samonis, E. Nioti, A. Georgiladakis,
Y. Tselentis (Heraklion, Crete, GR)
P723 Co-trimoxazole resistance in urinary tract
infection agent E. coli in 1995 and 2005:
a multi-centre study in Ankara, Turkey
N. Coplu, H. Simsek, A. Gozalan, G. Hascelik,
S. Ercis, Z. Senses, M. Baysallar, I. Mumcu,
N. Balaban, S. Terzioglu, S. Ozkan, B. Esen
(Ankara, TR)
P724 Profile and phenotypes of resistance of
microorganisms from pregnant women
with asymptomatic bacteriuria in Russia
A. Shevelev, V. Kulakov, A. Ankirskaya,
A. Nikonov, S. Belokrysenko, V. Krasnopolski,
E. Dvoinikova, E. Ailamazyan, A. Savicheva,
G. Ershov, N. Nikiforovski, L. Stratchounski
(Smolensk, Moscow, Saint-Petersburg,
Volgograd, RU)
P725 Activity of moxifloxacin against the
urogenital mycoplasmas Ureaplasma spp.
and Mycoplasma hominis
C.M. Bebear, H. Renaudin, C. Planty, S. Pereyre,
Ch. Bebear (Bordeaux, FR)
P726 Activity of moxifloxacin against Mycoplasma
genitalium
C.M. Bebear, H. Renaudin, J.S. Jensen,
Ch. Bebear (Bordeaux, FR)
P727 Emergence of extended-spectrum betalactamases
in a university hospital,
Hamburg, Germany in 2004
BS Timmerbeil, E Stürenburg, P Heisig
(Hamburg, DE)
13:00–14:00
Identification and antifungal susceptibility
testing for yeasts and moulds
P728 Candida krusei: the most frequent Candida
non-albicans species isolated from superficial
candidosis in Romania
F.S. Alecu, C. Tenea (Bucharest, RO)
www.escmid.org/eccmid2006
page 83

Poster Sessions Sunday, April 2, 2006
P729 Variation of galactomannan level during
24-hour period in haematooncological
patients with/without invasive aspergillosis
Z. Racil, I. Kocmanova, E. Kubicova,
J. Lochmanova, A. Sevcikova, J. Mayer
on behalf of the Working party of opportunistic
infections, IHOK, Brno, CZ
P730 Laboratory diagnosis of pulmonary
aspergillosis in tuberculosis patients
A. Kulko, I. Doroshkova (Moscow, RU)
P731 Identification of Malassezia isolates of
patients with pityriasis versicolor by using
PCR-restriction enzyme method
H. Mirhendi, K. Makimura, B. Tarazooei,
N. Jalalizand (Tehran, IR; Tokyo, JP)
P732 Haemolytic activity of Candida albicans and
C. dubliniensis isolated from the oral cavity
of immunocompromised patients
I. Kosalec, B. Matica, N. Jarza-Davila, T. Maretic,
J. Granic, S. Pepeljnjak (Zagreb, HR)
P733 Candida albicans panuveitis and an uneven
therapeutic ground, passing through all
available and potentially effective antifungal
drugs: fluconazole, liposomal amphotericin B,
caspofungin, and voriconazole
R. Manfredi, S. Sabbatani, G. Marinacci, F. Chiodo
(Bologna, IT)
P734 AIDS-associated Cryptococcus laurentii
meningoencephalitis resistant to amphotericin
B, apparently prompted by a cured
Cryptococcus neoformans disease
R. Manfredi, C. Fulgaro, G. Legnani, S. Sabbatani
(Bologna, IT)
P735 Outbreak of neonatal candidiasis: drug
susceptibility and molecular epidemiology
of the isolates
S. Asticcioli, E. Nucleo, G. Perotti, L. Sacco,
R. Daturi, C. Matti, A. Cardillo, L. Pagani (Pavia, IT)
P736 A new in vitro model system to study
antimycotic drugs
S. Cagnacci, A. Palenzona, E.A. Debbia,
A. Marchese, R. Corvò, L. Rossi
(Genoa, San Remo, IT)
P737 EFISG survey of current practices in clinical
mycology laboratory services in Europe
J. Bille, G. Atherton, D.W. Denning, O. Lortholary,
C. Lass-Flörl, M.C. Arendrup, M. Cuenca,
E. Roilides, M. Tod, S. Bretagne, A. Voss,
P. Gaustad, H. Sambatakou, P. Eggimann,
J. Garbino, M. Akova, A. Ullmann, H. Hebart,
P. Muñoz, F.M. Mueller for EFISG (ESCMID
Fungal Infection Study Group)
page 84 Final Programme
P738 Comparison of the Sensititre YeastOne colorimetric
antifungal panel with reference M38:
a method for testing susceptibility Aspergillus
spp. to caspofungin
E. López-Oviedo, C. Martín, A. Martos, C. Castro,
M. Ramirez, A. Romero, J. Palomares, E. Martín-
Mazuelos (Seville, ES)
P739 Efficacy of anidulafungin against Candida
albicans in candidaemia and other forms of
invasive candidiasis
B. Goldstein, B. Johnson, W. Wible, D.S. Krause,
H. Schlamm (King of Prussia, Shaumberg,
New York, US)
P740 Ability of Spanish clinical laboratories in
diagnosing Candida krusei infections and in
monitoring susceptibility testing. Results of
the SEIMC Quality Control Program
R. Guna, J.L. Pérez, N. Orta, C. Gimeno for the
Programa de Control de Calidad SEIMC, Spain
P741 FungaLit-multi-parameter bioassay for
antifungal compounds mode-of-action studies
O. Kozlova, N. Christofi (Edinburgh, UK)
P742 Fungaemia at a tertiary-care hospital:
species distribution, antifungal susceptibility
and antifungal therapy
K. Lagrou, J. Verhaegen, W.E. Peetermans,
T. De Rijdt, J. Maertens, E. Van Wijngaerden
(Leuven, BE)
P743 A new in vitro kinetic model to study the
pharmacodynamics of antifungal agents:
Comparison of the activity of voriconazole
and amphotericin B administered alone
and in combination against Candida albicans
A. Lignell, A. Johansson, J. Larsson, O. Cars,
E. Löwdin, J. Sjölin (Uppsala, Linköping, SE)
P744 Is terbinafine a good antifungal drug to
combine with voriconazole or caspofungin?
Study of the activity of double combinations
against invasive clinical isolates of A. fumigatus
J. Guinea, T. Peláez, P. Muñoz, Ó. Cuevas-Lobato,
E. Bouza (Madrid, ES)
P745 In vitro activity of fluconazole and voric
onazole against invasive Candida albicans
isolates in patients with candidaemia from
2001–2005 in Hong Kong
M. Hui, R.W.F Li, P.L. Chan, M.L. Chin, K.C. Chu,
C.Y. Chan (Shatin, HK)
P746 The effect of aminocandin compared to
caspofungin and micafungin
M.A. Ghannoum, S. Dutta, N. Isham (Cleveland, US)

Poster Sessions Sunday, April 2, 2006
P747 Antifungal susceptibility testing of
dermatophytes isolated from a worldwide
tinea capitis clinical trial
M.A. Ghannoum, J. Matevish, A. Cirino, N. Isham
(Cleveland, US)
P748 In vitro activities of caspofungin and four
other antifungal agents against Trichophyton
spp. isolates
M. Demirbilek, F. Can, T. Gulec, Y. Saray,
H. Arslan (Ankara, TR)
P749 Update on Candida albicans antifungal
resistance trends among hospitalised patients
in a tertiary hospital in Greece
E.I. Kazakos, C. Manolopoulos, V. Papageorgiou,
E. Tsiakiri, S. Alexiou-Daniel (Thessaloniki, GR)
13:00–14:00
Virology – I
P750 Subclinical reactivation of VZV in patients
with tick-borne encephalitis
K. Soltysova, K. Roubalova, D. Picha,
V. Maresova, H. Rohacova (Prague, CZ)
P751 Epstein-Barr virus and p53 protein expression
in gastric carcinoma without Helicobacter
pylori infection
A. Szkaradkiewicz, W. Majewski, M. Wal,
P. Majewski, J. Bierla (Poznañ, PL)
P752 Cytomegalovirus and Epstein-Barr virus in
ulcerative colitis and Crohn’s disease
A. Szkaradkiewicz, R. Marciniak, P. Majewski,
I. Chudzicka-Strugala, A. Wasilewska, M. Drews
(Poznañ, PL)
P753 Cytomegalovirus infection in recipients of
liver transplant in Ireland
C.F. De Gascun, D. Houlihan, S. Coughlan,
P.G. O’Reilly, F.M. Fitzpatrick, J. Hegarty,
W.W. Hall (Dublin, IE)
P754 Incidence of primary CMV infection during
pregnancy and its transmission rate to the
foetus and newborn
A. Naessens, A. Casteels, L. De Catte,
S. Lauwers, W. Foulon (Brussel, BE)
P755 In situ PCR and in situ RT-PCR to distinguish
productive and non-productive human cyto -
megalovirus infection in blood leukocytes
B. Zawilinska, M. Kosz-Vnenchak, K. Bulek,
J. Kopec, E. Daszkiewicz (Cracow, PL)
P756 A real-time PCR assay to detect human
cytomegalovirus DNA in whole blood of solid
organ transplant patients: optimal threshold
for guiding pre-emptive therapy
T. Lazzarotto, C. Vaccari, L. Gabrielli, P. Monari,
S. Pop, M.P. Landini (Bologna, IT)
P757 Evaluation of a real-time NASBA assay for the
detection of herpes simplex virus type 1 and 2
C. Zintilini, P. Van de Wiel, F. Jacobs, B. Deiman,
S. Vermeer (Grenoble, FR; Boxtel, NL)
P758 Detection of herpes simplex virus in cerebro -
spinal fluid using real-time PCR
E. Aznar, J. Díaz-Regañón, T. Alarcón, C. Sánchez-
Zamora, M. López-Brea, L. Cardeñoso (Madrid, ES)
P759 BK polyoma virus replication in de novo renal
transplant recipients. Results of a prospective
study
M. Koukoulaki, E. Grispou, G. Saroglou,
D. Pistolas, K. Balaska, T. Apostolou,
M. Anagnostopoulou, V. Hadjiconstantinou,
O. Paniara, S. Drakopoulos, N. Legakis (Athens, GR)
P760 JC virus genotype distribution differs
between healthy and immunocompromised
Irish individuals
K. Schaffer, N. Sheehy, S. Coughlan, C. Bergin,
W.W. Hall (Dublin, IE)
P761 Prevalence of human papillomavirus
genotypes in genital samples
A. Suárez, C. Sánchez, E. Vázquez, J.J. Picazo
(Madrid, ES)
P762 Prevalence of human papillomavirus types in
cervical samples from HIV-infected women
F. Zara, A. Spinillo, R. Brerra, B. Gardella,
R. Mainini (Pavia, IT)
P763 Physical status of HPV-16 in patients with
LSIL or cervical carcinoma
S. Szostek, M. Klimek, J. Kopec, B. Zawilinska
(Cracow, PL)
P764 Prevalence of HPV in Lithuania according to
data based on PCR technique
I. Gulbinovic, K. Asmonaite, D. Ambrasiene
(Vilnius, Kaunas, LT)
P765 Focal epithelial hyperplasia disease in Panares
Indians from Bolivar state, Venezuela
M. Correnti, S. Hurtado, V. Tovar, M.E. Cavazza,
M. Avila, M. Guevara, T. Sanabria, L. Pocaterra
(Caracas, VE)
P766 Gen tax evidence of HTLV-1 co-infections
in HIV-positive patients in a hospital in Bilbao,
Spain
N. Ortiz, M. Basaras, M. Sota, R. Cisterna
(Bilbao, ES)
www.escmid.org/eccmid2006
page 85

13:00–14:00
Hepatitis
Poster Sessions Sunday, April 2, 2006
P767 Virologial and clinical aspect of HBV silent
infection in patient with chronic hepatitis C
E. Sagnelli, N. Coppola, C. Marrocco,
M. Imparato, R. Pisapia, G. Piai, L. Cimmino,
C. Del Vecchio Blanco, A. Giorgio, V. Messina,
F. Piccinino, P. Filippini (Naples, Caserta, IT)
P768 Fulminant hepatitis due to hepatitis B virus
A. Vata, M. Hurmuzache, D. Mihalache, D. Florea,
D. Scripcariu, C. Luca, D. Dimitriu, V. Luca (Iasi, RO)
P769 Acute /recent HCV infection in seronegative
blood donors and IDUs, viral replication
kinetics, immune response and disease
outcome
T. Tsertsvadze, L. Sharvadze, L. Dzigua,
N. Chkhartishvili (Tbilisi, GE)
P770 Phylogenetic analysis in a HCV type 5 infected
population in the French central district of
Clermont-Ferrand
C. Henquell, C. Bonny, S. Ughetto, H. Odent-
Malaure, V. Tixier, J.L. Bailly, P. Deny, H. Peigue-
Lafeuille, A. Abergel
(Clermont-Ferrand, Bobigny, FR)
P771 Quantification of hepatitis C virus in human
plasma samples by using real-time reverse
transcriptase PCR
K. Shahzamani, F. Sabahi, S. Merat (Tehran, IR)
P772 PEG-interferon-alpha 2a (40kda) in patients
on chronic haemodialysis with chronic
C hepatitis: early results
M.K. Celen, C. Ayaz, N.U. Yuce, S. Hosoglu,
M.F. Geyik (Diyarbakir, TR)
P773 Hepatitis C virus infection in haemodialysis
patients
N. Petrosillo, A. Di Napoli, P. Pezzotti, D. Di Lallo,
S. Di Giulio, C. Trivelloni, G. Guasticchi
on behalf of Lazio Dialysis Registry
P774 Anti-HCV IgG Avidity Index in acute hepatitis
C and chronic hepatitis C
N. Coppola, R. Pisapia, S. Martini, C. Marrocco,
L.M. Vatiero, M. Pisaturo, G. Tonziello, P. Filippini,
F. Piccinino, E. Sagnelli (Naples, IT)
P775 Hepatitis B virus genotypes:
a Lebanese hospital-based study
I. Jureidini, P. Rassam, S. Keleshian, J.P. Aoun,
S. Khoury, Z. Daoud, N. Irani- Hakimé (Beirut, LB)
page 86 Final Programme
P776 Evaluation of Bayer Advia Centaur chemiluminescent
assays for the analysis of hepatitis B
HBs antigen and HBc total antibodies and
hepatitis C total antibodies
D. Burki, F. Rich, J. Carlsen, L. Matter (Basel, CH)
P777 Relationships between luetic infection and
acute viral hepatitis
R.F. Botgros, C.P. Popescu, S-A. Florescu,
A.M. Nicolescu, M. Cotiga, L. Raduta,
P.I. Calistru, E. Ceausu (Bucharest, RO)
P778 The distribution of HBV genotypes,
serotypes and YMDD variants among chronic
HBV patients in Kuwait
M. Ali, S. Farhan, H. Askar, F. Hassan, S. Ahmad,
W. Al-Nakib (Kuwait, KW)
P779 Immunogenicity of recombinant hepatitis B
vaccine in treatment-naïve and treatmentexperienced
chronic hepatitis C patients.
The effect of pegylated interferon plus
ribavirin treatment
I.S. Elefsiniotis, M. Pirounaki, E. Vezali,
K. Kamposioras, K. Pantazis, H. Brokalaki,
A. Moulakakis, G. Saroglou (Athens, GR)
P780 Serum neopterin levels in patients with
replicative and non-replicative HBV carriers
I. Kaleli, M. Demir, N. Cevahir, M. Yilmaz,
S. Demir (Denizli, TR)
P781 Investigation of the serum neopterin levels in
patients with infected hepatitis B
I. Gonen, F.Z. Akcam, O. Kaya, G. Yayli (Isparta, TR)
P782 The HBV seroprevalance among high school
students in Izmir, Turkey
B. Karaca, H. Tarakci, E. Tumer, H. Guven
(Izmir, TR)
P783 The epidemiology of hepatitis A in Poland.
Prevalence of hepatitis A antibodies in
population
W. Janaszek-Seydlitz, B. Bucholc, J. Slusarczyk,
A.A. Wiatrzyk (Warsaw, PL)
P784 Changing epidemiology of acute hepatitis A
and hepatitis B in Italy. Further counselling
and prophylactic measures are needed for
male homo-bisexual subjects?
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P785 Intrafamilial transmission of hepatitis E in
France
A. Ducancelle, E. Nicand, C. Payan, H. Le Guillou,
P. Calès, F. Lunel-Fabiani (Angers, Paris, Brest, FR)

Poster Sessions Sunday, April 2, 2006
P786 Molecular detection and sequence analysis of
hepatitis E viruses in humans and animals in
Hungary
G. Reuter, D. Fodor, P. Forgách, B. Molnár,
J. Zentai, A. Kátai, G. Szucs
(Pécs, Szeged, Budapest, Vecsés, HU)
P787 TT virus prevalence and distribution of
genotypes and genogroups in Korea
H.S. Kim, K.M. Lee (Anyang, KR)
P788 Presence and significance of TT virus infection
in voluntary blood donors and patients on
maintenance hemodialysis in Tabriz, Iran
L. Gachkar, M. Taremi, M. Khoshbaten,
M. Kheradpajouh (Tehran, IR)
P789 The prevalence and phylogeny of GBV-C/
HGV in eastern Taiwanese indigenes
H.-F. Liu, D.-H. Chen, C.-W. Teng, C.-L. Lin,
Y.-J. Lee, L.-Y. Wang (Taipei-Tamshui, Keelung,
Hualien, TW)
P790 Three years lamivudine therapy in adults with
HBeAg-positive chronic hepatitis B
M.K. Celen, C. Ayaz, S. Hosoglu, M.F. Geyik,
M. Ulug (Diyarbakir, TR)
13:00–14:00
Paediatric infectious diseases
P791 Antimicrobial susceptibility of Haemophilus
influenzae ocular isolates collected from
outpatients in paediatric hospital
A. Makri, T. Guajardo, H. Papavasileiou, H. Iliadis,
I. Varzakakos, N. Manios, A. Voyatzi (Penteli, GR)
P792 Bacterial pathogens isolated from children
with bloodstream infection
A. Makri (Athens, GR)
P793 Characterisation of Haemophilus
influenzae isolates from conjunctivitis
(Portugal, 2001–2005)
M.P. Bajanca-Lavado, D. Louro, M.M. Caniça
(Lisbon, PT)
P794 Antimicrobial susceptibility and serotyping of
pneumococci in a Tunisian paediatric hospital
H. Smaoui, J. El Amri, A. Kechrid (Tunis, TN)
P795 Pneumococcal infection in a children’s
hospital in 2004, Taoyuan, Taiwan
Y.C. Huang (Taoyuan, TW)
P796 Repeated isolation of a pneumococcus from a
child suffering from IRAK-4 deficiency
O. Dobay, J. Szabó, Á. Borbély, M. Erdõs,
F. Rozgonyi, K. Nagy, L. Maródi
(Budapest, Debrecen, HU)
P797 Nasopharyngeal colonisation by
Streptococcus pneumoniae in children.
Impact of amoxicillin treatment
A. Díaz, R. Garcia, C. García-Rey, E. Cuchí, E. Calbo,
L. Tobeña, M. Díaz-Infantes, J.E. Martín-Herrero,
J. Garau and the Spanish Pneumococcal Infection
Study Network
P798 Prevention of perinatal group B streptococcal
infections: evaluation of a new chromogenic
medium STREPTO B ID
C. Roure, V. Fiaty, Y. Gilles, H. Salord, S. Tigaud
(Lyon, FR)
P799 Invasive group a streptococcal infections and
incidence of resistance in children’s hospital
D. Garantziotou, M. Vlachou, O. Koureli,
T. Apostolaki, P. Michail, V. Rouli, A. Gatopoulou,
A. Spiliopoulou (Patras, GR)
P800 Community-acquired methicillin-resistant
Staphylococcus aureus in Greek children
J. Dotis, M. Tsiakou, M. Tsivitanidou, D. Sofianou,
E. Roilides (Thessaloniki, GR)
P801 Seroprevalence of serogroup specific antibodies
against different serogroups of Neisseria
meningitidis (Serogroup A, C, W 135 and Y) in
healthy individuals in different age groups
I. Yildirim, R. Borrow, G. Lal, N. Andrews
(Ankara, TR; Manchester, London, UK)
P802 Increasing nasopharyngeal carriage rate of
Neisseria meningitidis serogroup W135 in
healthy Turkish primary school students after
2000 Hajj epidemic
I. Yildirim, S. Ercis, S. Uygun, G. Secmeer
(Ankara, TR)
P803 Evaluation of IgA secretory antibodies in
children with Helicobcater pylori infection
M.E. Cavazza, D. Ortiz, M.I. Urrestarazu,
M. Correnti, G. Daoud, N. Daoud , M. Perrone
(Caracas, VE)
P804 Resistance pattern of Staphylococcus aureus
clinical isolates from children
A. Kyratsa, E. Kontekaki, N. Charalambaki,
A. Zambou, E. Trikka-Graphakos (Athens, GR)
P805 Incidence and antimicrobial resistance of
pathogens causing gastroenteritis in
childhood
A. Kyratsa, E. Kontekaki, F. Ioannidou, Z. Kyriazi,
E. Trikka-Graphakos (Athens, GR)
P806 Evaluation of bacterial microflora in the colon
of children with inflammatory bowel disease
T. Gosiewski, M. Strus, P. Heczko, M. Brzychczy-
Wolch, K. Fyderek (Cracow, PL)
www.escmid.org/eccmid2006
page 87

Poster Sessions Sunday, April 2, 2006
P807 Molecular epidemiology of Escherichia coli
diarrhoea in children in Tehran
S. Salmanzadeh-Ahrabi, E. Habibi, F. Jafari,
M. Zali (Tehran, IR)
P808 Antimicrobial susceptibility of urinary
pathogens in children from two tertiary care
Greek hospitals
O. Vasilaki, P. Sikalidou, S. Karampa, A. Tzanakari,
S. Alexiou-Daniel, D. Sofianou (Thessaloniki, GR)
P809 Urinary tract infection in neonates, a five-year
study (2000–2005)
Z. Mosayebi, A. Movahedian, R. Moniri
(Kashan, IR)
P810 Longitudinal development of tobramycin
resistance in Pseudomonas aeruginosa
isolates from children with cystic fibrosis and
the effect on clinical outcome
M.M. Doyle, P. McNally, G. Leen, J. Dier,
P. Greally, P.G. Murphy (Dublin, IE)
P811 Predictors of mortality in children with
candidaemia
A.C. Pasqualotto, A.B. de Moraes, R.R. Zanini,
L.C. Severo (Manchester, UK; Porto Alegre, BR)
P812 Bacterial isolates during bacteraemia in
neonatal units of a medical university hospital
in Gdansk
B. Rybak, D. Piasecka-Pazik, A. Samet, M. Bronk,
J. Szczapa (Gdansk, PL)
P813 Incubation time for clinically significant
positive neonatal blood cultures
H.L. Lim, A.J. Bint, A. Fenton, S.J. Moss
(Newcastle-upon-Tyne, UK)
P814 Predictive value of procalcitonin and serum
amyloid A protein levels in early detection of
pyelonephritis in childhood
M.P. Sourani, F. Haliotis, A. Kariyiannis, E. Hantzi,
L. Zachariadou, S. Avlonitis, I. Papassotiriou,
K. Karavanaki (Athens, GR)
P815 Is there a place for moxifloxacin in paediatric
practice? A report from a tertiary care
paediatric hospital
S. Jourdain, O. Stevart, P.R. Smeesters, P. Lepage,
A. Vergison (Brussels, BE)
P816 Leptin as an acute-phase reactant in urinary
tract infections in children
E. Demetriou, A. Margeli, F. Haliotis, M. Sourani,
L. Zachariadou, I. Papassotiriou, A. Konstantopoulos
(Athens, GR)
page 88 Final Programme
P817 Treatment of acute otitis media in primary
paediatric care and the risk factors for
antibiotic prescribing
K. Banasova, H. Hupkova, V. Foltan, J. Trupl
(Bratislava, SK)
P818 The hygiene hypotheses revisited? Recurrent
childhood upper respiratory tract infections
do not reduce the risk of adult atopic disease
M.M. Rovers, W.A. Balemans, A.G. Schilder,
E.A. Sanders, G.A. Zielhuis, C.K. van der Ent
(Utrecht, NL)
13:00–14:00
Microbial biofilms
P819 Genetic analysis of the biofilm phenotype in
methicillin-resistant Staphylococcus aureus
E. O’Neill, H. Humphreys, J.P. O’Gara (Dublin, IE)
P820 Combined exposure to sub-inhibitory levels
of vancomycin and therapeutic levels of
aspirin enhances biofilm formation by
Staphylococcus epidermidis
M. Aljeldah, M. Upton (Manchester, UK)
P821 Lactobacillus as a competitive bacteria in
Staphylococcus strains biofilm formation
E. Walencka, B. Sadowska, M. Wieckowska-
Szakiel, W. Hryniewicz, B. Rozalska
(Lodz, Warsaw, PL)
P822 Dual species biofilms: do staphylococci like
other bacteria?
E. Walencka, B. Sadowska, B. Rozalska (Lodz, PL)
P823 Evaluation of the biofilm-forming ability of
Staphylococcus aureus and Staphylococcus
epidermidis mastitis isolates
M. Oliveira, R. Bexiga, S.F. Nunes, L.M. Cavaco,
F. Bernardo, C.L. Vilela (Lisbon, PT; Glasgow, UK;
Copenhagen, DK)
P824 Comparative activity of linezolid,
quinupristin/dalfopristin and vancomycin
against biofilm produced by cystic fibrosis
isolates of Staphylococcus aureus normal
and small colony variant phenotypes
P. Morelli, M. Mentasti, G. Manno (Genoa, IT)
P825 Low prevalence of BAP gene (coding for
biofilm-associated protein) in French isolates
of Staphylococcus aureus recovered from
human and animals species
E. Vautor, H. Carsenti-Dellamonica, R. Thiery
(Sophia-Antipolis, Nice, FR)

Poster Sessions Sunday, April 2, 2006
P826 Contribution of biofilm phenotype to the
pathogenesis of Staphylococcus epidermidis
neurosurgical device-related meningitis
N. Stevens, H. Humphreys, E. O’Neill,
J.P. O’Gara, C. Greene, T. Dillane, T. Sattar
(Dublin, IE)
P827 Biofilm formation of invasive GAS isolates
collected in immunocompromised and
immunocompetent patients
R. Gattringer, S. Reichmann, W. Graninger,
E. Presterl (Vienna, AT)
P828 Biofilm formation by E. faecalis in the
microtitre-plate assay does not correspond
to biofilm formation on clinically relevant
materials
A. Hallgren, G. Dunny (Linköping, SE;
Minneapolis, US)
P829 Cell surface hydrophobicity, motility, and
biofilm formation of Stenotrophomonas
maltophilia clinical isolates
G. Di Bonaventura, C. Picciani, A. Pompilio,
R. Piccolomini (Chieti, IT)
P830 Molecular epidemiology and phenotypic
characteristics of chronic Pseudomonas
aeruginosa populations in cystic fibrosis
lungs
H.K. Johansen, L. Yang, A. Frost, L. Jelsbak,
J. Haagensen, N. Høiby, S. Molin
(Copenhagen, Lyngby, DK)
P831 Morphological changes induced by sub -
inhibitory concentrations of imipenem and
piperacillin/tazobactam on surface properties
and adhesion abilities of Pseudomonas
aeruginosa
A.P. Fonseca, C.I. Extremina, A. Freitas da
Fonseca, J.C. Sousa (Porto, PT)
P832 Influence of the salt concentration on biofilm
formation by Salmonella spp.
I. Cirkovic, M. Svabic Vlahovic, N. Opavski,
V. Mijac, S. Djukic, S. Stepanovic, I. Cirkovic
(Belgrade, CS)
P833 Effect of the acquisition of quinolone
resistance in biofilm formation by
Acinetobacter baumannii clinical isolates
S. Marti, J. Sanchez-Cespedes, S. Soto,
E. Oliveira, D. Bellido, L. Actis, J. Vila
(Barcelona, ES; Miami, US)
P834 Virulence factors of Proteus mirabilis involved
in encrustation of urinary catheters
A. Torzewska, S. Klinder, A. Czyrznikowska,
A. Rozalski (Lodz, PL)
P835 In vitro biofilm formation by Candida spp.
on the surface of polyurethane and PVC
catheters
D. Estivill, Á. Torres-Lana, Á. Arias, M.P. Arévalo
(Manresa, La Laguna, ES)
P836 Biofilm production in well characterised
Candida spp. isolated in Italy during the
period 2002–2005 from paediatric and adult
patients
A. Marchese, L. Gualco, R. Bandettini, C. Peri,
L. Pescetto, L. Ricagni, A. Cavallero, M.C. Ossi,
E.A. Debbia, G.C. Schito (Genoa, Milan, IT)
P837 Biofilm communities on different construction
materials
A. Kimiran Erdem, E. Arslan, N. Dogruöz, Z. Zeybek,
N. Sanli Yürüdü, I. Türetgen, A. Cotuk (Istanbul,
TR)
P838 Biofilm-positive microbes isolated from the
environment of life-boxes for allogenic transplantations
and from immunocompromised
patients
V. Hola, L. Horakova, F. Ruzicka, M. Votava,
R. Tejkalova (Brno, CZ)
P839 The effectiviness of impregnation of graft
with cefazolin in foreign body infection
D. Kilic, C. Agalar, E. Denkbas, F. Agalar,
E. Ozturk, M. Emirdogan, O. Deveci (Ankara, TR)
P840 Biofilm production by different strains of
Salmonella typhimurium: genetics,
morphology and role of surface and
nutrient content of medium
J.M. Romanova, N. Alekseeva, A.L. Andreev,
T.A. Smirnova, T.V. Stepanova, A.L. Gintsburg
(Moscow, RU)
P841 Biofilm-associated anaerobic sulphate
reducing bacteria on galvanized steel surfaces
E. Ilhan-Sungur, I. Türetgen, A. Cotuk (Istanbul, TR)
P842 Mechanism and effects of biofilm formation
on fat-based materials
G. Cayli, I. Türetgen (Istanbul, TR)
P844 The development of an Aspergillus fumigatus
biofilm model to determine the effectiveness
of antifungal treatments in vivo
J. Butcher, G. Ramage, C. Williams (Glasgow, UK)
P845 Influence of subinhibitory vancomycin
concentrations on biofilm formation in
coagulase negative staphylococci
A. Longauerova, D. Kotulova, L. Slobodnikova
(Bratislava, SK)
www.escmid.org/eccmid2006
page 89

Poster Sessions Sunday, April 2, 2006
13:00–14:00
Brucella and Lyme borreliosis
P846 Brucellosis: retrospective evaluation of
133 hospitalised cases
Y.Z. Demiroglu, T. Turunc, H. Uncu, H. Arabaci,
S. Colakoglu, H. Arslan (Ankara, TR)
P847 Brucellar epididymo-orchitis in south-eastern
Anatolia, Turkey
M.K. Celen, M.F. Geyik, C. Ayaz, S. Hosoglu,
M. Ulug (Diyarbakir, TR)
P848 Neurobrucellosis: experience with 8 cases
C. Ayaz, M.K. Celen, M. Ulug, S. Hosoglu,
M.F. Geyik (Diyarbakir, TR)
P849 The effects of oxidative stress in patients with
infection of Brucella melitensis
M. Gul, E. Kurutas, P. Ciragil, M. Kilinc, M. Aral,
O.F. Kokoglu (Kahramanmaras, TR)
P850 Doxycycline plus streptomycin versus
ciprofloxacin plus rifampicin in spinal
brucellosis
E. Alp, R. Koc, A. Durak, O. Yildiz, B. Aygen,
B. Sumerkan, M. Doganay (Kayseri, TR)
P851 Epidemiological features and clinical
manifestations of adult brucellosis in Turkey
M.A. Yetkin, C. Bulut, G.R. Yilmaz, F.S. Erdinc,
S. Kinikli, B. Oral, N. Tulek, A.P. Demiröz
(Ankara, Samsun, TR)
P852 Analysis of the risk factors for brucellosis in
an endemic region
O. Ergonul, S. Deniz, N. Baykam, A. Celikbas,
B. Dokuzoguz (Ankara, TR)
P853 Neurologic involvement among brucellosis
cases
K. Ugurlu, O. Ergonul, S. Eren, A. Celikbas,
N. Baykam, B. Dokuzoguz (Ankara, TR)
P854 Clinical manifestations of Lyme borreliosis in
Bulgaria and identification of Borrelia species
in ticks
I. Christova, E. Tasseva, T. Gladnishka (Sofia, BG)
P855 Seasonal patterns of the activity of hostseeking
Ixodes ricinus ticks in a tick-borne
encephalitis and Lyme borreliosis natural
focus (Czech Republic)
M. Daniel, K. Zitek, J. Valter, I. Kott, V. Danielova,
J. Holubova, B. Kriz (Prague, CZ)
page 90 Final Programme
13:00–14:00
Diagnositic and laboratory methods in
parasites and fungi
P856 Diagnosis of Giardia lamblia with microscopy,
striptest, ELISA and real-time PCR
M. Brinkman, D. Vastert, H. Wilke, B. Mulder
(Enschede, NL)
P857 Diagnosis of Cryptosporidium parvum
with microscopy, striptest, ELISA and
real-time PCR
D. Vastert, M. Brinkman, H. Wilke, B. Mulder
(Enschede, NL)
P858 New diagnostic method for pneumocystis
using flow cytometry
C. Pina Vaz, S. Costa de Oliveira, G. Monteiro,
T. Carvalho, A. Rodrigues (Porto, PT)
P859 Rapid identification and separation of the
yeast according to their isoelectric point
F. Ruzicka, V. Hola, M. Horka, M. Votava
(Brno, CZ)
P860 Evaluation of a rapid colorimetric test based
on trehalose use for identification of Candida
glabrata
S. Kirdar, B. Gultekin, G. Evcil, A. Ozkutuk,
G. Sener, N. Aydin (Aydin, TR)
P861 Immunodiagnosis of invasive candidiasis:
prospective serological evaluation of at-risk
patients in the French university hospital
of Grenoble
M. François, O. Faure, B. Lebeau, R. Grillot,
H. Pelloux, C. Pinel (Grenoble, FR)
P862 Influence of culture medium on performance
of a yeast identification system (MICRONAUT
Candida®)
G. Haase, H. Schulze (Aachen, Bornheim, DE)
P863 Function of Candida albicans ALS5 and
ALS7 genes on adhesion to FEP (polymer of
tetrafluoroethylene and hexafloropropylene)
catheter and polyurethane catheter
P.L. Chan, R.W.F. Li, M.L. Chin, K.C. Chu, M. Hui,
C.Y. Chan (Sha Tin, Hong Kong, HK)
P864 Comparative evaluation of Candida DNA,
mannan, anti-mannan antibodies and
(1-3)-beta-D-glucan in the diagnosis of
candidaemia
Z.U. Khan, F. Alam, A.S. Mustafa (Kuwait, KW)
P865 Evaluation of tobacco agar for differentiation
of Cryptococcus neoformans
Z.U. Khan, R. Chandy (Kuwait, KW)

Poster Sessions Sunday, April 2, 2006
P866 Comparison of Aspergillus fumigatus DNA
and galactomannan in serum and broncho -
alveolar lavage specimens of experimentally
infected rats
S. Ahmad, Z.U. Khan, A. Theyyathel (Kuwait, KW)
P867 Candida spp. colonisation and serum
anticandidal antibody levels in patients with
chronic urticaria
M.C. Ergon, T. Ilknur, M. Yucesoy, S. Ozkan
(Izmir, TR)
P868 Performance of three differential media for
the presumptive identification of yeasts
M. Yucesoy, M.C. Ergon, S. Ozer (Izmir, TR)
P869 Detection of Aspergillus galactomannan
antigen levels for antimicrobial agents by
ELISA
M. Yucesoy, M.C. Ergon (Izmir, TR)
P870 Mycological evaluation and suitability for
detecting dermatophytes on sabouraudgentamicin-chloramphenicol-2-agar
M. Mempel (Munich, DE)
13:00–14:00
Toxoplasmosis
P871 Pregnant women and toxoplasmosis
I. Machado, I. Sousa, H. Angelo (Porto, Lisbon, PT)
P872 Congenital toxoplasmosis prevention in
Portugal
I. Machado, I. Sousa, H. Angelo
(Porto, Lisbon, PT)
P873 Screening for Toxoplasma gondii, rubella
virus and cytomegalovirus in pregnant
women
S. Baka, E. Makrakis, D. Hassiakos, I. Logginidis,
S. Meretaki, E. Kouskouni (Athens, GR)
P874 Screening for acute toxoplasma infection
during pregnancy: compliance to the French
programme of 41086 pregnancies in the
Rhône-Alpes region
C. Cornu, A. Bissery, R. Ecochard, F. Gueyffier,
F. Peyron, M. Wallon (Bron, Lyon, FR)
P875 High prevalence of IgM antibodies against
Toxoplasma gondii in Mexican pregnant
women
R. Figueroa, D. Correa, M. Vela, A. Fernandez,
I. Cañedo, M. Perez, H. Luna, C. Gonzalez,
E. Calderon, H. Gonzalez, J. Ortiz, J.L. Hernandez,
V. Ortega (Mexico City, MX)
P876 Impact of health education for the primary
prevention of Toxoplasma infection in
pregnancy: lessons from the ERIS study
M. Wallon, D.T. Nguyen Hoang Hanh, F. Peyron,
G. Chêne (Lyon, Bordeaux, FR)
P877 Multicentre proficiency testing programme
for molecular detection of Toxoplasma gondii
in amniotic fluid
K. Kaiser, A. Van Loon, H. Pelloux, J. Ferrandiz,
S. Picot, P. Wallace, F. Peyron (Lyon, FR; Utrecht, NL;
Grenoble, FR; Glasgow, UK)
P878 Using the new IMMULITE 2000 toxoplasmosis
IgM (µ-capture) kit for the diagnosis of human
toxoplasmosis
E. Woitrin, I. Jost, R. Fassotte (Dudelange, LU)
P879 Development of novel cytomegalovirus and
toxoplasma IgG avidity assays using an
antigen competitive format “AVIcomp” on
the Abbott ARCHITECT Instrument
G.T. Maine, S. Hsu, D. Smith, I. Curdt,
J. Herzogenrath (Abbott Park, US; Wiesbaden, DE)
P880 Preliminary evaluation of the Abbott
ARCHITECT anti-toxoplasma IgG, IgM and IgG
avidity assays
G.T. Maine, S. Hsu, C. Patel, D. Smith, J. Munoz,
M. Gardiner, M. Palafox, E. Frias, L. Gu, M. Wilson,
R. Holzman, Rn. Stricker, Rt. Stricker
(Abbott Park, US; Geneva, CH)
P881 Performance evaluation of the VIDIA
toxoplasmosis IgG and IgM assays
P. Thulliez, C. Leprince, M. Marcoux, J. Piche
(Paris, Marcy l’Etoile, FR)
P882 Toxoplasma gondii antibodies in 72 patients
who attended emergency wards in three
hospitals in Stockholm due to infective cat
bites
K. Westling, C. Jorup-Rönström, B. Evengård
(Stockholm, SE)
13:00–14:00
Staphylococci and surgical infections
P883 Survey of the epidemiology of methicillinresistant
Staphylococcus aureus infections
in Greece
V. Chini, A. Foka, O. Koureli, A. Athanassiadou,
G. Dimitracopoulos, I. Spiliopoulou (Patras, GR)
P884 Nasal carriage rates of Staphylococcus aureus
which are resistant and sensitive to oxacillin
in hospital staff and hospitalised patients
H. Irmak, S. Cesur, F. Yildiz, C. Bulut, S. Kinikli,
A.P. Demiröz, Z. Aygün (Ankara, TR)
www.escmid.org/eccmid2006
page 91

Poster Sessions Sunday, April 2, 2006
P885 Nasal carriage of Staphylococcus aureus
among patients and personnel of a
haemodialysis unit
A. Sergounioti, F. Sergouniotis, A. Basdeki,
P. Sergouniotis, E. Papoulia, E. Petinaki
(Amfissa, Larissa, GR)
P886 MRSA carriage in children undergoing cardiac
surgery in Georgia
A. Nanuashvili, N. Jashiashvili (Tbilisi, GE)
P887 Coagulase-negative staphylococci in a
surgical hospital
A. Zilevica, R. Treimane, R. Paberza, T. Tracevska
(Riga, LV)
P888 Prevalence of methicillin-resistant Staphylococcus
aureus infection among inpatients
colonised with MRSA
C. McVeigh, S.F. FitzGerald, L.E. Fenelon
(Dublin, IE)
P889 The role of screening and antibiotic
prophylaxis in the prevention of percutaneous
gastrostomy site infection caused by
methicillin-resistant Staphylococcus aureus
S. Thomas, S. Cantrill, D.J. Waghorn,
A. McIntyre (High Wycombe, UK)
P890 Surgical site infection and delayed sternal
closure after open-heart surgery
A. Arnaiz, J.P. Horcajada, J.M. Bernal,
J.D. García-Palomo, A. Sarralde, M.C. Fariñas
(Santander, ES)
P891 The importance of risk indexes for stratifying
surgical site infection rates
S. Cairns, R. Hill, J. Reilly (Glasgow, UK)
P892 MRSA hand colonisation among health
care workers
Z. Kocak Tufan, H. Irmak, S. Cesur, C. Bulut,
S. Kinikli, A.P. Demiroz (Ankara, TR)
P893 Susceptibility of MRSA to octenidine
dihydrochloride
Z. Al-Doori, D. Morrison, P. Goroncy-Bermes,
G.F.S. Edwards, C.G. Gemmell
(Glasgow, UK; Norderstedt, DE)
P894 Study on bacterial contamination of surgical
rooms and delivery centres of Hamadan
hospitals and health care centres
R. Yousefi mashouf, S. Sahamas Vala
(Hamadan, IR)
P895 Reduction in the incidence of staphylococcal
infections in hospital environment after the
starting of the guideline of perioperative
antibiotic prophylaxis
G. Gattuso, D. Tomasoni, L. Palvarini, D. Berra,
C. Chiarelli, R. Stradoni, A. Scalzini (Mantua, IT)
page 92 Final Programme
13:00–14:00
Streptococci – skin and soft tissue infections
P896 Characterisation of a clone of methicillinresistant
Staphylococcus aureus responsible
for community-acquired staphylococcal toxic
shock syndromes
P.-Y. Donnio, C. Michelet, C. Collet, N. Lafforgue,
O. Petsaris, P. Tattevin, M. Cormier (Rennes, FR)
P897 Antibiotic resistance of Gram-positive
bacteria that cause severe skin and soft tissue
infections in a Turkish university hospital
S. Gündes, F. Özkan, S. Akhan (Kocaeli, TR)
P898 Contrasting features of Group A streptococci
from asymptomatic carriage and diverse
infection sites
D. Rolo, R. Pires, L. Sobreira, A. Morais, L. Lito,
M.J. Salgado, R.M. Barros, I. Peres, G. Trigueiro,
C. Cardoso, J.G. Marques, I. Santos-Sanches
Caparica, Oeiras, Lisbon, Miraflores, PT)
P899 Description of the epidemiology of multiple
clusters of Streptococcus pyogenes infection
in a rehabilitation hospital
J. Dave, J. Bell, C. Fraser, H. Venkatesh, E. Olson,
M. Emery, A. Efstratiou (Edinburgh, London, UK)
P900 The EPISA study: a recent epidemiological
study in outpatients with skin and soft tissue
infection in France
V. Jarlier, P. Bernard, P. Menday, A. Santerre
Henriksen (Paris, Reims, FR; Ballerup, DK)
P901 Serotypes and antimicrobial susceptibilities
of pneumococci isolated from children with
acute otitis media during 2003–2004
I. Paraskakis, H. Kirikou, A. Makri, M. Papadatou,
E. Bozavoutoglou, E. Petridou, A. Charisiadou,
A. Chrissaki, A. Vogiatzi, N.J. Legakis,
D.A. Kafetzis (Athens, GR)
P902 Serotype distribution and antimicrobial
resistance of Streptococcus pneumoniae
causing invasive disease in childhood
(2001-2004); microbiological observations
from Central Greece prior to the systemic
pneumococcal vaccination era
I. Paraskakis, A. Charisiadou, H. Kirikou, A. Makri,
M. Papadatou, E. Bozavoutoglou, A. Chrissaki,
H. Papavasileiou, D.A. Kafetzis, N.J. Legakis,
A. Pangalis (Athens, GR)
P903 Clinical characteristics and outcome of
22 patients with invasive infection due to
vancomycin-resistant E. faecium
C. Theilacker, H. Bertz, M. Bussmann,
J. Huebner, W.V. Kern for the VRE Task Force

Poster Sessions Sunday, April 2, 2006
P904 Molecular characterisation of group B
Streptococcus serotype III subtypes 1–4 in
Hong Kong
M. Ip, E. Cheuk, M. Tsui, F. Kong, D.T.N. Leung,
G.L. Gilbert (Hong Kong, HK; Westmead –
Sydney, AU)
P905 Role of isolation of Corynebacterium spp.
organisms in different clinical settings,
including intensive care
R. Manfredi, A. Nanetti, S. Morelli, R. Valentini,
L. Calza, F. Chiodo (Bologna, IT)
P906 Skin colonisation of Corynebacterium
jeikeium
M. Demirbilek, F. Can, A. Kundakci, A. Guven,
E. Sirma, P. Cay, H. Arslan (Ankara, TR)
P907 Serotype distribution of Streptococcus
pneumoniae-resistant strains isolated in
Western Pomeranian Region of Poland in
2001–2003
M. Nowosiad, S. Giedrys-Kalemba (Szczecin, PL)
13:00–14:00
ESBL and carbapemenase producing
Gram-negative organisms
P908 First report of a metallo beta-lactamase
produced by a Klebsiella pneumoniae clinical
isolate in the United Kingdom
F. M’Zali, T.A. Collyns, M. Taylor, M. Elliot,
H. Inns, S. Picton, N. Young (Leeds, UK)
P909 Pandrug-resistant Providencia rettgeri
producing PER-1 extended-spectrum betalactamase
and VIM-2 metallo-beta-lactamase
K.S. Shin, B.R. Son, J. Kim (Cheongju, Daegu, KR)
P910 An outbreak of VIM-4 producing multidrugresistant
Pseudomonas aeruginosa isolates
from three different towns in Hungary
B. Libisch, M. Muzslay, M. Knausz, M. Gacs,
L. Rókusz, J. Minárovits, I. Kustos, M. Füzi
(Budapest, Gyõr, Pécs, HU)
P911 Molecular epidemiology of VIM-producing
P. aeruginosa isolated in four European
countries
C. Giske, B. Libisch, C. Colinon, E. Scoulica,
M. Füzi, G. Kronvall, G.M. Rossolini (Stockholm, SE;
Budapest, HU; Siena, IT; Heraklion, GR)
P912 Metallo-beta-lactamase-producing
Pseudomonas spp. and Acinetobacter spp.
in Korean hospitals: emergence of SIM-1producing
Acinetobacter baumannii
K. Lee, M.N. Kim, T.Y. Choi, K.S. Hong, S. Lee,
D.H. Whang, D. Yong, Y. Chong (Seoul, KR)
P913 Outbreak of multidrug-resistant Acinetobacter
baumannii producing the carbapenem
hydrolysing beta-lactamase OXA-58 in a
general intensive care unit in southern Italy
L. Pagani, R. Migliavacca, E. Nucleo,
M.M. D’Andrea, M. Spalla, C. Terulla, E. Aquilini,
M. Labonia, M. Li Bergoli, G.M. Rossolini
(Pavia, Siena, San Giovanni Rotondo, IT)
P914 Carbapenem-hydrolysing oxacillinase
OXA-40 in an Acinetobacter haemolyticus
clinical isolate
S. Quinteira, L. Peixe (Porto, PT)
P915 Influence of carbapemen resistance on
outcome in Acinetobacter baumannii
bacteraemia in an intensive care unit
R. Zaragoza, J.J. Camarena, A. Artero, S. Sancho,
R. Gonzalez, J.C. Navarro, J.M. Nogueira
(Valencia, ES)
P916 Risk factors for nosocomial imipenemresistant
Acinetobacter baumannii infections
G. Baran, A. Erbay, H. Bodur, P. Onguru, E. Akinci,
N. Balaban, M.A. Cevik (Ankara, TR)
P917 Dissemination of extended-spectrum betalactamase
producers in natural environments
in northern Portugal
J. Rocha, H. Neto Ferreira (Porto, PT)
P918 The presence of extended-spectrum betalactamase-producing
Escherichia coli is a
prognostic factor for patients with E. coli
bacteraemia
G. Peralta, J. Pelayo, E. Lopez, L. Garcia-Mauriño,
M.P. Roiz, I. De Benito, J.C. Garrido, S. Sanchez-
Ortiz, P. Fombellida, M.J. Rodriguez-Lera,
L. Ansorena (Torrelavega, ES)
P919 Extended-spectrum beta-lactamase producing
Enterobacteriaceae in Lebanese ICU patients:
epidemiology and patterns of resistance
Z. Daoud, N. Hanna, R. Hajj, C. Moubareck,
F. Doucet-Populaire, N. Hakimé
(Beirut, LB; Paris, FR)
P920 Susceptibility pattern and prevalence trend
over four years of extended-spectrum
beta-lactamase producing Klebsiella spp.
from intensive care units:
MYSTIC Program Brazil
C. Kiffer, S. Andrade, P.J. Turner, C. Mendes
(Sao Paulo, BR; Cheshire, UK)
P921 Nosocomial outbreak due to an extendedspectrum
betalactamase producer Enterobacter
cloacae
A. Manzur, A. Soriano, L. Calatayud, F. Tubau,
M. Saballs, M. Pujol, F. Gudiol, J. Ariza
(Hospitalet Llobregat, ES)
www.escmid.org/eccmid2006
page 93

Poster Sessions Sunday, April 2, 2006
P922 Clinical and epidemiologic features of extendedspectrum
beta-lactamases strains for a twoyear
period in a third level hospital
M.V. García, R. Rodriguez, M.M. Gallardo,
F. Ropero, E. Granados, A. Hernandez, A. Pinedo
(Málaga, ES)
P923 Risk factors for cephalosporin-resistant
(ESBL and AMPc producing) Gram-negative
enteric bacilli infection in renal and kidneypancreas
transplant patients
L. Linares, C. Cervera, F. Marco, J.A. Martinez,
R. Perello, F. Cofán, M.J. Ricart, N. Esforzado,
F. Oppenheimer, A. Moreno (Barcelona, ES)
P924 Distribution of class 1 and class 2 integron
types among ESBL-producing Entero -
bacteriaceae recovered from Portuguese
hospitals
E. Machado, R. Cantón, F. Baquero, J. Sousa,
T. Coque, L. Peixe (Porto, PT; Madrid, ES)
13:00–14:00
Metallo beta-lactamases and integrons
P925 Interactions of ceftobiprole with serine
carbapenemases
A.M. Queenan, W. Shang, K. Bush (Raritan, US)
P926 Post-genomic detection of CAR-1, a new
subclass B3 metallo-beta-lactamase from the
important plant pathogen Erwinia carotovora
M. Stoczko, J.M. Frère, G.M. Rossolini,
J.D. Docquier (Siena, IT; Liège, BE)
P927 Co-existence of VIM-type metallo-betalactamase
and PER-1 type extended-spectrum
beta-lactamase in clinical isolates of
Pseudomonas aeruginosa
G. Metan, N. Gurkan Aydin, P. Zarakolu
(Kayseri, Ankara, TR)
P928 VIM-2 metallo-beta-lactamase in
Pseudomonas aeruginosa strains from
Zagreb, Croatia
B. Bedenic, A. Mazzariol, N. Jarza-Davila,
V. Plecko, G. Cornaglia, R. Fontana
(Zagreb, HR; Verona, IT)
P929 First detection of blaVIM-2 and blaVIM-4
metallo-beta-lactamase genes in
Pseudomonas putida isolates in Belgium
P. Bogaerts, H. Rodriguez, C. Bauraing,
A. Deplano, Y. Glupczynski, M.J. Struelens
(Yvoir, Brussels, BE)
page 94 Final Programme
P930 Genetic structure of a VIM-2-encoding
integron from a Pseudomonas aeruginosa
clinical isolate from Belgium
J.D. Docquier, M.M. D’Andrea, G. Christiaens,
R. Boreux, T. Giani, J.M. Frère, P. De Mol,
G.M. Rossolini (Siena, IT; Liège, BE)
P931 Spread of In58 containing blaVIM-2 among
Pseudomonas aeruginosa
A. Brizio, A. Silva, E. Canas, T. Ferreira, L. Lito,
J. Melo-Cristino, M.J. Salgado, A. Duarte
(Lisbon, PT)
P932 Metallo-beta-lactamase gene blaSPM-1:
evaluation of its vicinities in unrelated
Pseudomonas aeruginosa strains isolated
from distinct Brazilian hospitals
M. Castanheira, M.A. Toleman, T.R. Walsh,
H.S. Sader, A.C.C. Pignatari, A.C. Gales
(Sao Paulo, BR; Bristol, UK; North Liberty, US)
P933 Discrepancy in the metallo-beta-lactamase
phenotypic tests results associated with
diversity in the promoter region of class 1
integrons
M. Castanheira, R.C. Picao, R.E. Mendes,
A.C.C. Pignatari, H.S. Sader, A.C. Gales
(Sao Paulo, BR; North Liberty, US)
P934 Biochemical characterisation of IND-NF16
metallo-beta-lactamase
M. Perilli, B. Segatore, B. Caporale, C. Pellegrini,
G. Celenza, F. De Santis, M. Fiore, C. Luzi,
J.D. Docquier, G.M. Rossolini, G. Amicosante
(L’Aquila, Siena, IT)
P935 Phenotypic detection of metallo-betalactamases
in Acinetobacter baumannii
strains intermediately resistant to imipenem
and susceptible to meropenem
A. Koutsoukou, A. Stylianakis, S. Tsiplakou,
M. Tachtatzis, E. Tsakona, I. Feskou, A. Sideri
(Athens, GR)
P936 Metallo-beta-lactamase production in
Gram-negative bacteria detected by double
disk synergy and combined disk tests in
Turkey
I. Yildirim, D. Gur, S. Uygun, G. Secmeer
(Ankara, TR)
P937 Real-time PCR detection of free circular
intermediates of gene cassettes inserted in
resistance integrons
S. Pollini, E. Del Tordello, M.R. Oggioni,
G.M. Rossolini (Siena, IT)

Poster Sessions Sunday, April 2, 2006
P938 ISAba1 transposition induced by ciprofloxacin
produces hyperexpression of the AmpC
cephalosporinase of Acinetobacter baumannii
M. Ruiz, S. Martí, F. Fernández Cuenca,
Á. Pascual, J. Vila (Barcelona, Seville, ES)
P939 Prevalence of class 1 integrons and MIC
values in indigenous and pathogenic
E. coli strains in different age groups
K. Truusalu, E. Sepp, J. Shchepetova, K. Loivuke,
P. Naaber, K. Stroo, K. Sepp, M. Mikelsaar
(Tartu, EE)
P940 New integron-independent trimethoprim
resistance gene dfr24, detected in urinary
isolate of Escherichia coli
M. Grape, L. Sundström, G. Kronvall
(Stockholm, Uppsala, SE)
www.escmid.org/eccmid2006
page 95

Poster Sessions Monday, April 3, 2006
12:00–13:00
Molecular detection of microbes
P941 Direct detection of Salmonella spp. in faecal
specimens by real-time PCR assay
I. Pachiadakis, V. Karavassilis, A. Vasdeki,
A. Melidou, A. Goudouva, P. Lisgara, E. Petinaki,
A. Maniatis (Larissa, GR)
P942 Multicentric evaluation of Onychodiag® for
diagnosis of dermatophyte onychomycosis by
PCR-ELISA
C. Savin, S. Huck, C. Rolland, M. Benderdouche,
O. Faure, G. Noacco, J. Menotti, E. Candolfi,
H. Pelloux, R. Grillot, F. Derouin, S. Coupé
(Emerainville, Strasbourg, Grenoble, Paris, FR)
P943 Validation of PCR-RFLP analysis of the gap
gene as a useful tool for the species-level
identification of staphylococcal isolates
S. Grzeszczuk, A. Sabat, M. Bartoszewicz,
A. Przondo-Mordarska, W. Hryniewicz
(Warsaw, Wroclaw, PL)
P944 Clonal complexity in coagulase negative
Staphylococcus catheter-related bloodstream
infection
C. Aldea-Mansilla, D. García de Viedma,
E. Cercenado, E. Bouza, M. Marín (Madrid, ES)
P945 Effect of treatment on Toxoplasma-specific
IgG antibodies and IgG avidity maturation
V. Meroni, F. Genco, G. Ferraris, L. Bollani,
L. Piccoli, C. Bodini, P. Lanzarini (Pavia, Milan, IT)
P946 Evaluation of rapid molecular methods in
diagnosis of B-streptococci under delivery
B. König, B. Ghebremedhin, W. König
(Magdeburg, DE)
P947 Diagnosis of human brucellosis using
AMOS PCR
W. Yu, K. Nielsen, T. Grushina,
T. Meka-Mechenko (Nepean, CA; Almaty, KZ)
P948 Evaluation and comparison of molecular tests
for identification of methicillin-resistant
Staphylococcus aureus
A-M. Kerttula, A. Vainio, S. Mero, T. Pasanen,
J. Vuopio-Varkila, A. Virolainen (Helsinki, FI)
P949 Comparison of fluorescent in situ hybridization
and histological method for diagnosis of
Helicobacter pylori in gastric biopsy samples
S. Tajbakhsh, A.R. Samarbaf-Zadeh,
S.M. Moosavian (Bushehr, Ahwaz, IR)
page 96 Final Programme
P950 Comparison of a real-time PCR assay and a
chromogenic MRSA selective medium for the
detection of methicillin-resistant Staphylococcus
aureus directly from nasal and rectal swabs
R. Reyes, B. Catanzariti, E. Isaac, M. John,
L. Stoakes, J. Vandierendonck, Z. Hussain
(London/Ontario, CA)
P951 Evaluation of SeptiFast – a new commercially
available broad-range real-time PCR assay for
detection of bacteria and fungi in blood
G. Lisby, H. Westh (Hvidovre, DK)
P952 Multiple aetiology of urethritis and cervicitis
in sexually transmitted disease clinics
caused by Chlamydia trachomatis, Neisseria
gonorrhoeae, Mycoplasma genitalium,
and Trichomonas vaginalis
C.A. Gaydos, N.E. Maldeis, A. Hardick, J. Hardick,
M. Barnes, B.J. Wood (Baltimore, US)
P953 Advances in diagnostic testing of Chlamydia
trachomatis
M. Eickhoff, S. Cramer, T. Grewing
(Hamburg, DE)
P954 LCR method for detection of Chlamydia
trachomatis in patients with chronic
nonbacterial prostatitis
N. Draskovic (Belgrade, CS)
P955 Improvement of an existing magnetic particle
based NAAT sample preparation system for
C. trachomatis in urine by significantly
reducing processing time while maintaining
sensitivity
M. Anglés d’Auriac, T. Engen, U.H. Refseth
(Oslo, NO)
P956 A comparative study of three different
PCR assays for detection of Mycoplasma
genitalium in genital specimens from men
and women
A. Edberg, E. Johansson, E. Wikander, A. Höög,
T. Ahlqvist, M. Jurstrand, L. Falk, J.S. Jensen,
H. Fredlund (Karlstad, Örebro, SE; Copenhagen, DK)
P957 A new real-time quantitative TaqMan PCR to
detect Chlamydia trachomatis DNA in urine
and in urogenital swabs
K. Jaton, J. Bille, C. André, G. Greub (Lausanne, CH)
P958 First void urine can be used as transport
medium for cervical swab specimen for
detection of Mycoplasma genitalium by
polymerase chain reaction
T. Ahlqvist, A. Edberg, E. Johansson, H. Fredlund,
F. Aronsson (Karlstad, Örebro, SE)

Poster Sessions Monday, April 3, 2006
P959 Automation for generic nucleic acid sample
prep in a routine diagnostic laboratory
T.E. Schutzbank, N. Kahmann, C. Jarvis,
M. Weimer, A. Yount, K. Lopez (Dayton, US)
P960 Multiplex real-time PCR for detection of
Candida infections in blood
Å. Innings, M. Ullberg, A. Johansson, C.J. Rubin,
N. Noréus, M. Isaksson, B. Herrmann (Uppsala, SE)
P961 The application of MALDI-TOF mass
spectrometry for the quality control of NCTC
strains
L. Molenaar, D. Dare, H. Sutton, J. Russell,
H. Shah, M. Roberts, M. Lunt
(London, Manchester, UK)
P962 LightCycler® SeptiFast Test: rapid detection
of nosocomial pathogens by real-time PCR
T. Emrich, M. Moczko, S. Lohmann, J. Mayr,
H. Stockinger, G. Haberhausen (Penzberg, DE)
P963 Comparison of real-time and conventional
PCR assays for diagnosis of cat scratch
disease in patients with lymph node
enlargement
C. Le Brun, S.J. De Martino, Y. Hansmann, J. Debs,
C. Walter, Y. Piemont, B. Jaulhac (Strasbourg, FR)
12:00–13:00
Fast detection of respiratory microbes
P964 Advances in PCR detection of Pneumocystis
jiroveci in immunocompromised patients:
count seems to be important
J. Lochmanova, Z. Racil, M. Lengerova,
D. Minarikova, P. Volfova, D. Dvorakova, J. Mayer
(Brno, CZ)
P965 Evaluation of a new assay for the detection
and differentiation of B. pertussis,
B. parapertussis and B. bronchiseptica
based on real-time PCR technology
A. Burmeister, T. Grewing, H. Petersen,
N. Kahmann, T.E. Schutzbank, M. Hess
(Hamburg, DE; Moraine, US)
P966 Molecular diagnosis of Mycoplasma
pneumoniae and Chlamydia pneumoniae
infections by real-time NASBA
P. van Aarle, P. van Deursen, K. Loens,
P. Sillekens, M. Overdijk, M. Ieven, H. Goossens
(Boxtel, NL; Edegem, BE)
P967 Development of a real-time PCR using SYBR
Green and melting curve analysis to identify
Bordetella pertussis and Bordetella
parapertussis in clinical specimens,
and evaluation of its effectiveness in current
practice
P. Lehours, A. Menard, J. Sarlangue, C. Laguente,
C.H. Bebear, F. Megraud, B. De Barbeyrac
(Bordeaux, FR)
P968 Diagnosis of pertussis by real-time
LightCycler PCR
M. Alves, G. Rocha, A. Magalhães-Sant’Ana,
C. Nogueira (Coimbra, PT)
P969 Bordetella pertussis real-time PCR: sample
preparation by different kits from one
manufacturer
M. Riffelmann, C. Wirsing von Koenig, J. Schmetz,
S. Bock (Krefeld, DE)
P970 Comparison of specificity and sensitivity of
various diagnostic methods of ureaplasma
respiratory tract infections in newborns
M. Biernat-Sudolska, D. Rojek-Zakrzewska,
B. Zawilinska (Cracow, PL)
P971 Evaluation of real-time nucleic acid
sequence-based amplification and dipstickbased
detection with conventional NASBA
and PCR for rapid detection of Mycoplasma
pneumoniae in respiratory specimens
K. Ohkusu, M. Komatsu, N. Ishiwada, T. Hoshino,
N. Takeda, H. Sakata, T. Takeshima, T. Ezaki
(Gifu, Nara, Chiba, Hokkaido, Shizuoka, JP)
P972 Identification of Legionella species using DNA
sequence analysis and online tools
N.K. Fry, B. Afshar, W. Bellamy, A. Underwood,
R.M. Ratcliff, T.G. Harrison
(London, UK; Adelaide, AU)
P973 A real-time PCR for Mycoplasma pneumoniae
V.J. Chalker, D. Pitcher, T.G. Harrison (London, UK)
P974 Detection of Legionella DNA in clinical
samples using real-time PCR
L. Franzin, D. Cabodi, N. Bonfrate, F. Tortorelli
(Turin, IT)
P975 Rapid diagnosis of Mycobacterium
tuberculosis by a triplex real-time PCR assay
W. Sougakoff, C. Truffot-Pernot, G. Millot,
V. Jarlier (Paris, FR)
www.escmid.org/eccmid2006
page 97

Poster Sessions Monday, April 3, 2006
12:00–13:00
Diagnostic and laboratory methods
for bacteria – I
P976 The antimicrobial susceptibility and API
CORYNE profile code for 34 strains of the
newly reported Corynebacterium resistens
Y. Otsuka, Y. Kawamura, Y. Yamaguti,
H. Takahashi, K. Ohkusu, H. Hanaki, T. Ezaki
(Tokyo, Gifu, JP)
P977 Rapid phenotypic detection of pneumococci
and beta-haemolytic streptococci directly
from blood cultures
J. Montgomery, B. Mayall (Melbourne, AU)
P978 Perioperative monitoring of the endotoxin
chemical markers and procalcitonin blood
plasma concentrations in cardiosurgical
patients
N.V. Beloborodova, D.A. Popov, A.Y. Olenin,
A.S. Archipova, E.A. Chernevskaya (Moscow, RU)
P979 Are blood cultures necessary in the
management of women with complicated
pyelonephritis?
Y. Chen, O. Nitzan, W. Saliba, B. Chazan,
R. Colodner, R. Raz (Afula, Haifa, IL)
P980 Procalcitonin marker for sepsis diagnosis
A. Emami Naeini, S. Montazerolghaem
(Isfahan, IR)
P981 Brain natriuretic peptide as diagnostic and
prognostic marker in patients with bacterial
infection and sepsis
A. Charalampopoulos, A. Stavrianou,
C. Kotsovassilis, P. Tsiodra, C. Keramidas
(Athens, GR)
P982 The value of the automatized blood culture
systems in the diagnosis of CAPD peritonitis
Ö.K. Azap, F. Timurkaynak, S. Sezer, Ü. Cagir,
G. Yapar, H. Arslan, N. Özdemir (Ankara, TR)
P983 No beneficial impact of shortened micro -
biological procedures for either hospitalised
patients overall or for patients with
bacteraemia
M.J. Bruins, H.C.A. Oord, P. Bloembergen,
M.J.H.M. Wolfhagen, A.F. Casparie, J.E. Degener,
G.J.H.M. Ruijs (Zwolle, Rotterdam, Groningen, NL)
P984 Routine use of the BacT/ALERT FAN
anaerobic bottle: indicated or not?
B. Van Meensel, J. Verhaegen, J. Frans,
H. Castryck, N. Blanckaert (Leuven, BE)
page 98 Final Programme
P985 Developing clinical rules and a urinary
dipstick rule to predict urinary tract infection
in primary care settings
P. Little, S. Turner, K. Rumsby, G. Warner,
M. Moore, H. Smith, C. Hawkes, M. Mullee
(Southampton, Hastings, UK)
P986 Quantitative sputum culture versus direct
sputum culture
O. Akan, E. Ozyilmaz, K. Ahmed, S. Uysal,
M. Gulhan (Ankara, TR)
P987 Quantitative urine microscopy as a quick,
reliable examination for bacteriuria
S. Mhalla, A. Ferjani, N. Hannechi, J. Boukadida
(Sousse, TN)
P988 Detection of extended-spectrum betalactamases
among Enterobacteriaceae
using automated microbiology systems
and manual detection procedures
H. Seifert, H.K. Geiss, D. Mack, E. Stürenburg,
I. Wiegand (Cologne, Heidelberg, DE; Swansea, UK;
Hamburg, Bonn, DE)
P989 Assessment of the delay in reporting blood
culture results – development of a method to
identify defects in quality
U. Saarela, P. Kärpänoja, H. Sarkkinen (Lahti, FI)
P990 Validation of commercial kits for detection of
antibodies to Legionella
P. Elverdal, S.A. Uldum (Copenhagen, DK)
P991 Intrathecal synthesis of anti-Borrelia
antibodies in multiple sclerosis
J. Bednarova, P. Stourac (Brno, CZ)
P992 Antimicrobial susceptibility as a complementary
diagnostic tool for the identification of
rarely encountered non-fermenting Gramnegative
bacteria
Y. Glupczynski, G. Detry, C. Berhin, M. Janssens,
G. Wauters (Yvoir, Brussels, BE)
P993 An improved protocol for the serological
diagnosis of atypical pneumonia
C. Jenkins, I. Balakrishnan (London, UK)
P994 Potential antigenic determinants of
Chlamydia trachomatis major outer
membrane protein modeled by overlapped
recombinant proteins
N. Savel’eva, J. Zagriadskaya, S. Klimashevskaya,
V. Puzyrev, A. Obriadina, A. Burkov, T. Ulanova
(Nizhnyi Novgorod, RU)

Poster Sessions Monday, April 3, 2006
P995 Evaluation of the Giardia-strip: an in vitro
immunochromatographic test for the
detection of Giardia lamblia cysts in faecal
specimens
D. Van Kerkhoven, M. Lontie, J. Verhaegen,
K. Lagrou (Leuven, BE)
P996 Use of the T tube test in the setting of a
paediatric tuberculosis clinic
J. Paton, C. Lucas, C. Williams (Glasgow, UK)
P997 Do hyaluran levels determine the outcome of
bacterial infections?
H. Lydatakis, I. Hager, I. Binikos, P. Afentra,
H. Chrisanthidou, T. Peppas, S. Pappas,
I. Diamantis (Piraeus, Athens, GR)
P998 Evaluation of the new chromogenic medium :
CHROMagar Salmonella Plus for the detection
of all Salmonella species including Salmonella
typhi and Salmonella lactose plus
A. Rambach, Q. Tran, A.C. Le Dantec (Paris, FR)
12:00–13:00
Bloodstream infections
P999 Characteristics of healthcare-associated
bloodstream infections in adults in Korea
Y.K. Kim, S.Y. Shin, M.S. Kim, Y.S. Park, Y-A. Kim,
H.J. Yoon, J.Y. Choi, Y.G. Song, K.H. Roh,
D. Yong, K. Lee, J.M. Kim (Seoul, KR)
P1000 Secular trends of antimicrobial resistance of
blood isolates in a newly founded Greek
hospital
P. Rafailidis, S. Kasiakou, P. Morfou,
G. Georgoulias, D. Nikita, M. Falagas (Athens, GR)
P1001 Hospital-acquired bacteraemia: occurrence of
pathogens throughout a decade
H. Moraitou, M. Makarona, A. Koundourakis,
I. Kousseris, N. Makrygiannis, V. Tzolos,
M. Panagi, S. Kanavaki (Athens, GR)
P1002 Positive central venous catheter cultures and
bloodstream infections
C. Papadopoulou, Z. Afkou, G. Kythreotou,
D. Tokatlidou, M. Tsivitanidou, D. Sofianou
(Thessaloniki, GR)
P1003 Laboratory-based epidemiology of nosocomial
candidaemia in a tertiary teaching hospital
L.G.O. Cardoso, P. Trabasso (Campinas, BR)
P1004 Nosocomial bloodstream infection following
cardiac surgery in children
N. Jashiashvili, A. Nanuashvili, M. Chkhaidze
(Tbilisi, GE)
P1005 Nosocomial bloodstream infections in the
cardiovascular surgery centre, Iasi, Romania
A. Mereuta, M. Dan, L. Colar, G. Tinica,
G.I.M. Georgescu, D. Buiuc (Iasi, RO)
P1006 Rifampin and minocycline impregnated
central venous catheters: a meta-analysis
of randomised controlled trials assessing
catheter colonisation and catheter-related
bloodstream infection
M. Falagas, K. Fragoulis, I. Bliziotis,
I. Chatzinikolaou (Athens, GR)
P1007 Infections related with tunelled haemodialysis
catheter
T. Aldabó, R. Luque, M.J. Marcos, Y. Blanco,
J. Ibeas, E. Bouza for the Red Española de
Investigación en Patología Infecciosa (REIPI)
P1008 Bacillus spp. bacteraemia in children on
parenteral nutrition
E. Lebessi, G. Antonaki, A. Zafiropoulou,
K. Malliou, N. Paleologou, M. Foustoukou
(Athens, GR)
P1009 Survey of virulence factors of clinical isolates
from neutropenic patients with enterococcal
bacteraemia
S.H. Park, S-M. Choi, D-G. Lee, J-H. Choi, J-H. Yoo,
W-S. Shin (Seoul, KR)
P1010 Accuracy of surveillance blood culture to
identify patients with low response to
treatment and high 30-days mortality risk
in MRSA bacteraemia: comparison to a
standard clinical and biological follow-up
E. Forestier, Y. Hansmann, V. Remy, M. Mosheni,
N. Lefebvre, O. Lesens, D. Christmann
(Strasbourg, Clermont-Ferrand, FR)
P1011 Methicillin resistance as a risk factor for
mortality in Staphylococcus aureus
bacteraemia: an analysis from EARSS
Enhanced Bacteraemia Surveillance in
Ireland, 2005
A. Oza, S. Murchan, R. Cunney on behalf of the
Irish EARSS Steering Group
P1012 Mortality from sepsis in Russia:
identifying a gap in epidemiological data
D. Galkin, I. Gudkov, S. Zouzov, R. Kozlov
(Smolensk, RU)
P1013 Cloxacillin sensitivity evolution in
Staphylococcus aureus bacteraemias from
2001 to 2005 and their resistant phenotypes
M.M. Gallardo, M.V. García, R. Rodriguez,
E. Granados, F. Ropero, A. Hernandez, A. Pinedo
(Málaga, ES)
www.escmid.org/eccmid2006
page 99

12:00–13:00
ICU infections
Poster Sessions Monday, April 3, 2006
P1014 Surveillance of hospital-acquired infections in
intensive care units
J.L. Barrios, C. Ezpeleta, R. Blanco, M.J. Unzaga,
J.A. Alava, R. Cisterna (Bilbao, ES)
P1015 Infections in intensive care unit admitted
multiple trauma patients: incidence, risk
factors and mortality rate
Y-H. Choi, S-H. Baik, Y-J. Lee, K-S. Lee, Y-J. Oh,
J-H. Park, S-S. Shin, K-J. Park, S-C. Hwang
(Suwon, KR)
P1016 Nosocomial infections in a neonatal intensive
care unit: evaluation of frequency, risk factors
and cost
I. Özgünes, H. Naz, N. Tekin, F. Aksit, E.D. Kartal,
N. Erben, S.N. Alpat, G. Usluer (Eskisehir, TR)
P1017 Colonisation surveillance can predict
microbial aetiology of infection in the
critically ill
F. Kontopidou, E. Papadomichelakis,
A. Antoniadou, E. Koratzanis, E. Galani,
A. Armaganidis, H. Giamarellou (Athens, GR)
P1018 Administration of antibiotics via the
respiratory tract for the prevention of
ICU-acquired pneumonia: a meta-analysis
of comparative trials
M. Falagas, I. Siempos, I. Bliziotis, K. Rellos,
A. Michalopoulos (Athens, GR)
P1019 Serial evaluation of CPIS and C-reactive
protein for diagnosing ventilator-associated
pneumonia
M. Koeman, M.J.M. Bonten (Utrecht, NL)
P1020 Aetiology and timing of bloodstream
infections in a liver intensive care unit
F. Pink, E. Sizer, W. Bernal, G. Auzinger,
J. Wendon, I. Eltringham (London, UK)
P1021 Epidemiology of bloodstream infections
in an Israeli general intensive care unit:
a six-year analysis
T. Mashiach, H. Sprecher, R. Finkelstein (Haifa, IL)
P1022 Pseudomonas aeruginosa infection in ICU
patients: highlighting the silent epidemic
A. Agodi, M. Barchitta, L. Giaquinta, M.A. Romeo,
C. Denaro (Catania, IT)
P1023 Meta-analyses of the impact of inappropriate
antibiotic therapy on mortality in patients
with ventilator-associated pneumonia and
bloodstream infections
E. Gillespie, A. Patel, C. Coleman (Hartford, US)
page 100 Final Programme
P1024 Antibiotic resistance and mortality in patients
with severe pneumonia
R. Erbes, M. Raffenberg, H. Mauch, S. Wagner,
M. Schmidt-Ioanas, H. Lode (Berlin, DE)
P1025 Antimicrobial resistance patterns of Gramnegative
bacteria isolated from intensive care
unit in a Greek hospital
P. Sikalidou, S. Karampa, C. Papadopoulou,
G. Kythreotou, D. Sofianou (Thessaloniki, GR)
P1026 Incidence of methicillin-resistant S. aureus in
a prospective study in critical patients
(2002–2004)
P. Palacián, A. Rezusta, Y. Martin, J. Castillo,
M. Revillo (Zaragoza, ES)
P1027 Screening for MRSA on nasal swabs at
admittance at intensive care units
C. Pina-Vaz, R. Carneiro, M. Espinar,
M. Machado-Vaz, A. Rodrigues (Porto, PT)
P1028 Genotypic characterisation and epidemiologic
analysis of vancomycin-resistant enterococci
isolated from patients in intensive care unit
A. Lambiase, M. Del Pezzo, F. Rossano
(Naples, IT)
12:00–13:00
Gastro-intestinal and hepatic infections
P1029 Norovirus as a cause of acute gastroenteritis
in northern Greece: detection with IDEIA and
RT-PCR
S. Mitka, A. Ifantidou, S. Sotiriadis,
D. Karabaxoglou, A. Kansouzidou
(Thessaloniki, GR)
P1030 Epidemiology and molecular analysis of
norovirus outbreaks in Ireland
S. Kelly, B. Foley, S. Coughlan, L. Dunford,
H. O’Neill, B. Smyth, P. McKeown, M. Lynch
(Dublin, Belfast, IE)
P1031 Emergence of Vibrio cholerae O1 biotype
EL Tor, serotype Inaba during last summer
outbreak in Iran
M. Rahbar, R. Sabourian, M. Saremi, M. Abbasi,
H. Masoumi Asl, M. Soroush (Tehran, IR)
P1032 National surveillance of Campylobacter
infections and resistance in the Netherlands;
an overview 2000–2004
B.C. van Hees, M.J. Veldman-Ariesen,
B.M. de Jongh, M. Tersmette, W. van Pelt
(Nieuwegein, Bilthoven, NL)

Poster Sessions Monday, April 3, 2006
P1033 The epidemiology and clinical presentation of
hydatid cyst disease in patients in Imam,
Sina, Shariati and paediatric medical centre
hospitals between 1372–1382
Z. Abdi Liae, A. Soudbakhsh, M. Solemani,
K. Kiyani (Tehran, IR)
P1034 Echinococcus granulosus: lethal effect of low
voltage direct electric current on hydatid cyst
protoscoleces
R. Ghasemikhah, H. Ghasemikhah,
M. Sharbatkhory (Tehran, IR)
P1035 Single and multiple pyogenic liver abscesses:
aetiology, clinical course and treatment
F. Mateos, I. Terrancle, G. Peralta, L. Fuentes,
J. Pérez-Arellano, F. Amoros, R. Serrano, M.P. Geijo,
I. Tárraga, M. Rguez-Martín, B. Rguez-Martín,
J. Blanch, E. Martínez-Alfaro for the Infectious
Diseases Group of the Spanish Society for
Internal Medicine (SEMI)
P1036 Comparison of pyogenic liver abscess caused
by non-Escherichia coli and E. coli
F. Mateos, I. Terrancle, G. Peralta, L. Fuentes,
R. Serrano, V. Navarro, M. Hernández, B. Roca,
F. Marcos, I. Tárraga, A. Hernández-Belmonte,
E. Martínez-Alfaro for the Infectious Diseases
Group of the Spanish Society for Internal
Medicine (SEMI)
P1037 Diabetes mellitus as a risk and prognostic
factor for pyogenic liver abscess in Denmark
R.W. Thomsen, P. Jepsen, H.T. Sørensen
(Aalborg, Aarhus, DK)
P1038 Bacteraemia is a poor prognostic factor in
spontaneous bacterial peritonitis
J.H. Cho, W.B. Park, H.B. Kim, N.J. Kim,
M-D. Oh, K.W. Choe (Seoul, KR)
12:00–13:00
Respiratory tract infections
P1039 Aetiology of lower respiratory tract infections
among primary care patients of family
physicians in Silesian province in the
2000–2005 period
I. Szymczyk, W. Lukas, J. Skorupka, J. Józwiak
(Zabrze, PL)
P1040 Chronic exposure to smoking is not a risk
factor for community-acquired pneumonia in
the elderly population
Y.K. Cho, B.J. Park, H. Kim, N-K. Choi, S-M. Lee
(Incheon, Seoul, KR)
P1041 Antibiotic resistance patterns among
respiratory pathogens isolated during
2003–2005 at a Turkish tertiary hospital
Z. Gülay, H. Özkul (Izmir, TR)
P1042 Differences between Bedouin and Jewish
population in clinical characteristics of
patients admitted with community-acquired
pneumonia
V. Novack, L. Avnon, K. Riesenberg, F. Schlaeffer
(Beer Sheva, IL)
P1043 Prognostic impact of haematological and nonhaematological
malignancies on mortality of
hospitalised pneumonia: a Danish populationbased
cohort study
M. Nørgaard, A. Riis, R.W. Thomsen,
H.C. Schønheyder, H.T. Sørensen
(Aalborg, Aarhus, DK)
P1044 Outbreak of three related cases of psittacosis
detected by real-time PCR
B.M. de Jongh, J.A. Kaan, A.J. Meinders,
J.J. Mager, E.J. van Hannen (Nieuwegein, NL)
P1045 Audit of sputum samples before and after a
national smoking ban
J. Fennell, B. Cryan, G. Corcoran (Cork, IE)
P1046 Prognostic factors in patients with pneumococcal
bacteraemia in a county teaching
hospital, Spain
G. Peralta, E. Lopez, J. Pelayo, M.P. Roiz,
I. De Benito, C. Fariñas, M.B. Sanchez,
J.C. Garrido (Torrelavega, ES)
P1047 Ambulatory treatment with telithromycin
versus clarithromycin of community-acquired
pneumonia in Spain
B. Puchades (Valencia, ES)
P1048 Comparative assessment of levofloxacin and
macrolides in acute exacerbation of chronic
bronchitis: clinical efficacy and symptom-free
intervals
L. Dvoretsky, N. Dubrovskaya, S. Yakovlev,
S.A. Grudinina, O.Y. Filimonova, S. Sidorenko
(Moscow, RU)
P1049 Lower respiratory tract infections caused by
Haemophilus influenzae
D. Kofteridis, D. Alegakis, G. Chrysofakis,
T. Anastasopoulos, A. Repa, S. Maraki , G. Samonis
(Heraklion Crete, GR)
www.escmid.org/eccmid2006
page 101

Poster Sessions Monday, April 3, 2006
P1050 Outcomes and diagnostic workups for patients
with community-acquired pneumonia
according to Pneumonia Severity Index
categories: results of a large single-year series
E. Pérez-Trallero, A.M. Martín-Sánchez, R. Dal-Ré,
J.E. Martín-Herrero, J. Garau, F. Baquero
on behalf of the NACER Group
P1051 Factors influencing length of hospital stay
in a large, single-year series of communityacquired
pneumonia
E. Pérez-Trallero, F. Baquero, C. García-Rey,
J.E. Martín-Herrero, A.M. Martín-Sánchez,
J. Garau on behalf of the NACER Group
P1052 Physicians’ attitude towards guidelines and
on choice of regimen for respiratory
infections
T.A. Peppas, O. Kosmopoulou, I. Binikos,
I. Skoura, I.F. Hager, S.I. Pappas, N. Galanakis
(Piraeus, GR)
P1053 Influence of aetiologic diagnosis on mortality
in hospitalised patients with communityacquired
pneumonia: results of a large singleyear
series
J. Garau, F. Baquero, E. Pérez-Trallero, J.L. Pérez,
A.M. Martín-Sánchez, C. García-Rey
on behalf of the NACER Group
P1054 Echo-guided management of complicated
parapneumonic effusion in children
C.Y. Chiu, K.S. Wong, Y.C. Huang, T-Y. Lin
(Taoyuan, TW)
P1055 Real-life treatment of acute exacerbation of
chronic bronchitis – moxifloxacin compared
to macrolides
T. Schaberg, M. Möller, T. File, K. Stauch,
H. Landen (Rotenburg, Hanau, DE; Akron, US;
Leverkusen, DE)
P1056 Bulgarian Surveillance Tracking Antimicrobial
Resistance – BulSTAR: community-acquired
pneumonia: 2004
T. Velinov, M. Petrov, A. Bachvarova,
T. Kantardjiev (Sofia, BG)
P1057 Clinical manifestations of complicated
pneumococcal pneumonia
M.H. Tsai, T-Y. Lin, Y.C. Huang, C.H. Chiu
(Keelung, Taoyuan, TW)
P1058 Elderly patients hospitalised with communityacquired
pneumonia. Validation and
comparative evaluation of a prognostic rule
F. Alcazar, A. Plata, A. Villalobos, I. Perez de
Pedro, S. Santamaria, B. Sobrino, L. Valiente,
M.A. Garcia-Ordoñez (Malaga, ES)
page 102 Final Programme
P1059 Heart failure and mortality within 90 days
after hospitalised pneumonia:
a population-based cohort study
R.W. Thomsen, N. Kasatpibal, A. Riis,
M. Nørgaard, H.T. Sørensen
(Aalborg, Aarhus, DK; Chiang Mai, TH)
P1060 Rising incidence and persistently high
mortality of hospitalised pneumonia:
a 10-year population-based study in Denmark
R.W. Thomsen, A. Riis, M. Nørgaard, J. Jacobsen,
S. Christensen, C.J. McDonald, H.T. Sørensen
(Aalborg, Aarhus, DK; Indianapolis, US)
P1061 Once daily sequential intravenous/oral
(IV/PO) moxifloxacin is equivalent to IV
ceftriaxone plus twice daily IV/PO
levofloxacin in the treatment of severe
community-acquired pneumonia requiring
hospitalisation: the MOTIV study
A. Torres, R. Read, H. Lode, J. Carlet, J.H. Winter,
J. Garau, T. Welte, P. Arvis, M.-A. Le Berre,
S.H. Choudhri (Barcelona, ES; Sheffield, UK;
Berlin, DE; Paris, FR; Dundee, UK; Hannover, DE;
Puteaux, FR; West Haven, US)
P1062 Antibiotic therapy of acute lower respiratory
tract infections within Slovakia
K. Banasova, H. Hupkova, V. Foltan
(Bratislava, SK)
12:00–13:00
Sexually transmitted diseases
P1063 Sexually transmitted infections in Kosovo
L. Gashi, N. Ramadani, I. Dedushaj, A. Kalaveshi,
I. Humolli (Pristina, CS)
P1064 Determinants of human papilloma virus
infections in HIV-infected women
S. Ribeiro-Ayeh, D. Labeith, U. Frank
(Mannheim, Freiburg i.Br., DE)
P1065 Infection with HSV in HIV/AIDS patients
L. Manolescu, P. Marinescu, C. Sultana,
S. Ruta (Bucharest, Giurgiu, RO)
P1066 Prevalence of HIV, hepatitis B and C and
syphilis and risk behaviour among drug users
inside and outside prison
C.J.P.A. Hoebe, H.L.G. Ter Waarbeek,
C.W. Rademaker, A. Smismans
(Heerlen, Maastricht, NL)
P1067 Antimicrobial resistance in Neisseria
gonorrhoeae in northeast Romania
A. Badescu, A. Enache, Z. Petrescu, D. Buiuc
(Iasi, RO)

Poster Sessions Monday, April 3, 2006
P1068 Use of polymorphic Treponema pallidum
repeat genes to elucidate syphilis
transmisssion networks in Amsterdam,
Netherlands
S.M. Bruisten, M. Dierdorp, M-E. Kolader,
J.S.A. Fennema, R.A. Coutinho (Amsterdam, NL)
12:00–13:00
Travel medicine, tropical and parasitic
diseases
P1069 Animal-associated injuries and related
diseases among travellers
P. Gautret, P. Gazin, G. Soula, J. Delmont,
P. Brouqui, P. Parola, P. Pandey, D. Kraklau,
M. Shaw, G. Brown, J. Torresi, E. Schwartz
for the GeoSentinel Surveillance Network
P1070 The use of saliva to soothe blood-sucking
arthropod bites and the transmission of
human herpesvirus 8 (HHV-8)
R. Romano, F. Candura, G. Russo, A. Al Hamdani,
L. Ceccherini Nelli, F. Benvegnu’, V. Ascoli,
M. Coluzzi (Rome, Pisa, Padua, IT)
P1071 Prolonged viraemia and viral shedding of
hepatitis E virus in a traveller with fulminant
hepatitis
M. Riffelmann, I. Greiffendorf, M. Roggendorf,
W. Jilg (Krefeld, Essen, Regensburg, DE)
P1072 Dengue fever associated with severe reactive
thrombocytosis and gangrene of the toes:
a case report
S.K. Surrun, D.A. Kandiah (Singapore, SG)
P1073 Localisation of Rift Valley fever virus in
different organs and blood of infected mice
using developed PCR test
A. Belov, N. Potapova (Moscow, RU)
P1074 Presentation of a case with pityriasis rosea
and Brucella infection
F. Kaptan, S. Ural, S. El, N. Turker, N.A. Coskun,
B. Ormen, G. Yilmaz, M. Ermete (Izmir, TR)
P1075 Imported chronic Chagas disease in Valencia,
Spain: epidemiological and clinical features
P. Segarra, M. García-Rodríguez, V. Abril,
C. Parada, E. Ortega, T. Fraile, J. Ballester,
M. García-Deltoro (Valencia, ES)
P1076 Anti-Acanthamoeba activity of caspofungin
S. Bouyer, C. Imbert, C. Kauffmann-Lacroix,
G. Daniault, M-H. Rodier (Poitiers, FR)
P1077 Cyclospora cayetenensis infection in five
immunocompetent patients in a Turkish
university hospital
B. Sancak, Y. Akyon, S. Erguven (Ankara, TR)
P1078 Malaria: current status in Latvia
J. Keiss, I. Zeltina, A. Jeruma, V. Sondore,
N. Ivanova, L. Viksna, B. Rozentale (Riga, LV)
P1079 Correlation of serum bilirubin level with
mortality in P. falciparum malaria
A.K. Aribandi, M.S. Albur (Sheffield, UK)
P1080 Leishmaniasis in travellers in endemic areas
S. Halichidis, S. Rugina, E. Dumea
(Constanta, RO)
P1081 Unusual clinical presentation of visceral
leishmaniasis in an immunocompetent
patient
T. Kontopoulou, E. Vaidakis, E. Bournakis,
N. Alexiou, I. Porfyridis, E. Sioula (Athens, GR)
P1082 Efficacy of medical treatment in hydatid
disease
I. Dumitru, S. Rugina, E. Dumitru, E. Dumea
(Constanta, RO)
P1083 The in vitro effect of levamisole and
praziquantel combination on Echinococcus
granulosus protoscolices
A. Guvenli, M. Hokelek (Samsun, TR)
P1084 Multiple hydatid cysts in the left main
pulmonary artery: an extremely rare location
O.K. Aribas, E. Turk-Aribas, F. Kanat, I. Erayman,
T. Yuksek (Konya, TR)
P1085 An extremely rare location of cardiac hydatid
cyst: interventricular septum
I. Erayman, E. Turk Aribas, S. Avcu, M. Bitirgen
(Konya, TR)
P1086 A 5-year study of intestinal parasitosis in a
general hospital, Piraeus, Greece
S. Konstantopoulou, A. Mourikis, P. Karle,
M. Dimitriou, E. Vlachou, F. Vagia, A. Karle
(Athens, GR)
P1087 Filariasis infection in immigrants in a
Spanish hospital
N. Portocarrero, A. Amor, M. Baquero,
M. Subirats (Madrid, ES)
P1088 Hepatobiliary ascariasis: a case report
A.T. Bastug, A. Erbay, H. Bodur, E. Akinci,
M.A. Cevik (Ankara, TR)
P1089 The pinworm (Enterobius sp.) infection in
lung mimicking tuberculoma – case report
H. Järv, V. Adamson, P. Naaber (Tartu, EE)
P1090 Malnutrition in children in Nairobi’s slums
A. Kolenova, A. Ondrusova (Trnava, SK)
www.escmid.org/eccmid2006
page 103

Poster Sessions Monday, April 3, 2006
P1091 Incidence of tropical diseases at university
clinic in Mapuordit, Sudan
S. Seckova, A. Augustinova, J. Bencza,
M. Bartkoviak, A. Doczeova, M. Taziarova,
V. Sladeckova, M. Vilimova, Z. Kniezova,
K. Kutna, M. Ocenas (Trnava, SK)
P1092 Saturday night fever
R. Gowda, A. Tunbridge, M. McKendrick
(Sheffield, UK)
12:00–13:00
Seroepidemiology
P1093 Epidemiological features of diphtheria in
Belarus
I.A. Karpov, A. Kachanka, M. Kozatchenko
(Minsk, BY)
P1094 An analysis of the factors effecting the
prognose of tetanus in a university hospital
between 1991 and 2005
K. Aydin, G. Yilmaz, F. Aksoy, I. Koksal,
R. Caylan (Trabzon, TR)
P1095 Determination of tetanus antibody levels
among emergency department patients
presenting with injuries
K. Caglar, K. Hizel, A. Altuncekic, A. Demircan,
R. Karakus (Ankara, TR)
P1096 Tetanus immunisation status among women
of child-bearing age in three provinces in
Turkey
B. Esen, D. Kurtoglu, N. Coplu, A. Gozalan,
K. Miyamura, S. Ishida, L. Akin
(Ankara, TR; Tokyo, JP)
P1097 Serological evidence of acute/recent pertussis
infection in Turkey: how big is the threat for
infants?
B. Esen, N. Coplu, D. Kurtoglu, A. Gozalan,
L. Akin (Ankara, TR)
P1098 Immunity against tetanus and effect of its
vaccination in Turkey
N. Coplu, B. Esen, A. Gozalan, D. Kurtoglu,
K. Miyamura, S. Ishida (Ankara, TR; Tokyo, JP)
P1099 Prevalence of pertussis antibody and
vaccination status in three provinces in Turkey
D. Kurtoglu, A. Gozalan, N. Coplu, K. Miyamura,
S. Ishida, M. Morita, L. Akin, B. Esen
(Ankara, TR; Tokyo, JP)
P1100 Analysis of the changes in the tetanus course
during the last 40 years – own observations
A. Kalinowska-Nowak, A. Garlicki, M. Bocizga-
Jasik, T. Mach (Cracow, PL)
page 104 Final Programme
P1101 Seroepidemiology of rubella in reproductive
age women in Attica area of Greece during
fifteen years (1990 – 2004)
P. Karabogia-Karafillidis, M. Orfanidou,
H. Vagiakou, E. Sideris, E. Kontekaki, A. Kefalakis,
H. Malamou-Lada (Athens, GR)
12:00–13:00
Mycobacterial infections
P1102 Diagnosis of tuberculosis in suspects in
endemic area by using enzyme-linked
immunospot assay for gamma-interferon
P.R. Hsueh, J.Y. Wang, C.H. Chou, L.N. Lee,
H.L. Hsu, I.S. Jan, P.C. Yang, K.T. Luh (Taipei, TW)
P1103 Autoantibodies to cytokines in patients with
mycobacterial infections
G.A. Fernandez-Ramirez, M.E. Rosales,
I. Avila-Miyazawa, L. Ceron-Gutierrez, C. Espitia
Pinzon, J. Cabiedes, E. Sada, J.A. Montaraz-
Crespo, R. Doffinger, G. Barcenas-Morales
(Mexico City, MX; Cambridge, UK)
P1104 Tuberculin skin testing among health care
workers in a country with a high tuberculosis
prevalence: booster and conversion rates
K. Hizel, F. Ozer, I. Maral, F. Aktas (Ankara, TR)
P1105 Clinical evaluation of a real-time PCR kit for
the detection and partial differentiation of
the M. tuberculosis complex
S. Cramer, M. Hess, F.C. Bange
(Hamburg, Hannover, DE)
P1106 Serodiagnostic potential of mammalian cell
entry proteins encoded by mce3 operon of
Mycobacterium tuberculosis
S. El-Shazly, A.S. Mustafa, S. Ahmad, R. Al-Attiyah
(Kuwait, KW)
P1107 Rapid identification of mycobacterial species
with test INNO-LiPA mycobacteria v2 isolated
from sputum samples obtained from HIVnegative
patients
J. Paluch-Oles, M. Koziol-Montewka,
M. Dzbrowska, M. Montewka, A. Bogut
(Lublin, PL)
P1108 A new automated method for sample
preparation of Mycobacterium tuberculosis
respiratory specimens based on magnetic
particles
J. Lysèn, T. Engen, H.K. Høidal Berthelsen,
M. Espelund, S. Jeansson, U.H. Refseth
(Oslo, NO)

Poster Sessions Monday, April 3, 2006
P1109 Gold nanoparticle probe-based diagnostic
system for rapid and sensitive detection of
Mycobacterium tuberculosis
M. Koziol-Montewka, J. Paluch-Oles,
P. Baptista (Lublin, PL; Lisbon, PT)
P1110 Development of tools for detection of DNA
and mRNA from mycobacteria in clinical
samples
N. Potapova (Moscow, RU)
P1111 Diagnosis of tuberculous pleuritis by nested
polymerase chain reaction: a comparison of
four different volumes of pleural fluid
N. Jaimchariyatam, K. Kawkitinarong,
K. Naweewitphadung, N. Udomsantisuk,
S. Tumwasorn, W. Kulwichit (Bangkok, TH)
P1112 The value of the QuantiFERON-Gold TB test in
the management of patients with suspected
active tuberculosis
J. Democratis, S. Bailey, M. Barer, N. Pereira,
I. Stephenson, K.G. Nicholson, M.J. Wiselka,
J. Democratis (Leicester, UK)
P1113 Prospective MIRU-VNTR typing of
Mycobacterium tuberculosis isolates: initial
epidemiological analysis of isolates typed in
the Midlands from 2003–2005
J.T. Evans, E.G. Smith, S. Gardiner, J. Mowbray,
H. Mossop, B. Olowokure, P. Monk, P.M. Hawkey
(Birmingham, Leicester, UK)
P1114 Evaluation of clinical utility on direct
detection of MTBC on clinical samples by
BD Protec ET System
J.S. Lin, Y.Y. Yu, C.Y. Lin (Changhua, TW)
P1115 Clonal diversity of Mycobacterium
tuberculosis in sputum specimen from
individual patients of pulmonary tuberculosis
C. Shiohira, Y. Bhusal, N. Yamane (Okinawa, JP)
P1116 Agreement of QuantiFERON-TB Gold In-Tube
and T Spot-TB in HIV-infected patients from
Sub-Saharan Africa in Switzerland
M. Reichmuth, C. Thurnherr, F. Suter-Riniker,
P. Vernazza, H. Furrer, T. Bodmer
for the Swiss HIV Cohort Study
P1117 Role of serologic tests (IgG, IgA, IgM
antibodies against A60 mycobacterial
antigen) in diagnosis of tuberculosis
H. Emadi, M. Rasoolinejad, O. Zarghom,
S. Siroos Jafari, Z. Ahmadinejad, Z. Abdi Liae,
S. Davoudi, M. Hassibi, A. Soodbakhsh
(Tehran, IR)
P1118 Implementing DOTS in settings with high
prevalence of drug-resistant tuberculosis
Y. Balabanova, I. Fedorin, S. Zakharova,
V. Nikolayevskyy, R. Atun, R. Coker,
F. Drobniewski (London, UK; Samara, RU)
P1119 Multidrug-resistant tuberculosis:
guideline tailoring for immigrants
T. Bregenzer, F. Schmid, C. Ebnöther (Aarau, CH)
P1120 Rapid drug sensitivity testing of
M. tuberculosis based on culture on
a porous ceramic support
C. Ingham, A. Ben Ayad, R. Hummelink,
B. Mulder (Den Bosch, Enschede, NL)
P1121 Identification of the Mycobacterium
tuberculosis subtype strongly associated with
multidrug resistance within the Beijing family
V. Nikolayevskyy, T. Brown, Y. Balabanova,
Y. Bazhora, A. Asmolov, F. Drobniewski
(London, UK; Odessa, UA)
P1122 Extrapulmonary tuberculosis in sector III of
Zaragoza, Spain during 2000–2005
M.P. Macipe, A. Vitoria, J.A. Amiguet, A.I. López-
Calleja, M.A. Arias, P. Crusells, J. Cuesta,
C. Rubio (Zaragoza, ES)
P1123 Evaluation of tuberculin skin test and
Quantiferon-TB gold for the identification of
LTBI or active TB among irregular immigrants
in Milan, Italy
G. Orlando, S. Merli, A. Valerio, L. Cordier,
M. Bergonzi, A. Villa, A. Cargnel (Milan, IT)
P1124 Tuberculosis epidemiology in a health care
area of Santiago de Compostela
(Galicia, NW Spain) from 1996 to 2004
V. Túñez, M.L. Pérez del Molino, P.A. Romero,
M. Conde, F. Pardo (Santiago de Compostela, ES)
P1125 Tuberculosis in paediatric and adult
population in Athens, Greece (1994–2004)
S. Kanavaki, S. Karabela, A. Skroubellou,
E. Varonou, S. Anagnostou, A. Raftopoulou,
H. Moraitou, N. Spyridis, S. Nikolaou (Athens, GR)
P1126 Screening of immigrants for tuberculosis in
Greece: implications for health care needs
M. Matsagoura, M. Kompoti, A. Koutsovasili,
A. Salta, A. Papaefstathiou, M. Matsagoura
(Thiva, GR)
P1127 Epidemiology of Mycobacterium bovis
disease in Ferrol, Spain, 1991–2004
J.F. García Rodríguez, H. Álvarez Díaz,
V. Trasancos Buitrago, M.V. Lorenzo García,
A. Mariño Callejo, P. Sesma Sánchez (Ferrol, ES)
www.escmid.org/eccmid2006
page 105

Poster Sessions Monday, April 3, 2006
P1128 Tuberculosis as re-emerging disease in Italy.
Which correlations with HIV infection and
other risk factors, comparing native residents
and foreign immigrants?
R. Manfredi, S. Sabbatani, G. Legnani, F. Chiodo
(Bologna, IT)
P1129 A randomised trial of a short course with
isoniazid plus rifampin in front of isoniazid
during six months in latent tuberculosis
infection
D. Vañó, M.P. Geijo, C. Rosa, A. Molina, M. Pérez,
J.F. Dimas (Cuenca, ES)
P1130 Mycobacterium sherrisii: a new opportunistic
agent in HIV-infected patients?
P. Loulergue, F. Lamontagne, V. Vincent,
A. Rossier, G. Pialoux (Paris, FR)
P1131 Presence of mycobacteria in colon biopsies
from patients with inflammatory bowel
disease
I. Szpinda, A.T. Jorde, I. Olsen, B. Djønne,
M. Vatn, T. Tønjum (Oslo, NO)
P1132 Prevalence of nontuberculous mycobacteria
in a Belgian adult cystic fibrosis population
M. Develter, W. Laffut, L. Dupont, J. Verhaegen
(Leuven, BE)
P1133 Tuberculous Empyema necessitatis involving
chest wall and retroperitoneum
O.K. Aribas, E. Turk-Aribas, I. Erayman, F. Kanat,
A. Ozturk (Konya, TR)
P1134 Increasing incidence of Mycobacterium
xenopi in Zaragoza, Spain: an emerging
pathogen or a product of improved laboratory
methods?
S. Terraza, J.A. Amiguet, A. Vitoria, M.A. Lezcano,
C. Ramos, P. Arazo, J. Cuesta (Zaragoza, ES)
P1135 Mycobacterium chelonae and continuous
ambulatory peritoneal dialysis associated
peritonitis. An unrecognised entity?
I. Gupta, P. Cockwell, I. Das (Birmingham, UK)
P1136 Nontuberculous mycobacterial keratitis after
photorefractive keratectomy for myopia
D. Mylona-Petropoulou, G. Vrioni, G. Ganteris,
D. Miltsakakis, A. Kyratsa, C. Mougnai,
A. Kouris, S. Levidiotou, H. Malamou-Lada
(Athens, Ioannina, GR)
P1137 Leprosy elimination campaign in the Qazvin
province, Iran, 2004
R. Qassemi Barqi (Qazvin, IR)
page 106 Final Programme
P1138 The first reported European case of intravascular
catheter infection with Mycobacterium
neoaurum
S. Musaad, N. Young, G. Robinson, D. Gascoyne-
Binzi, A. Rajgopal, A. Barrett, D. Norfolk,
T.A. Collyns (Leeds, Newcastle, UK)
P1139 Impact of differents antimycobacterial
drugs on the survival of patients with
Mycobacterium xenopi pulmonary infection:
89 cases
C. Andrejak, F.X. Lescure, Y. Yazdanpanah,
Y. Douadi, T. May, B. Hoen, P. Chavanet,
G. Laurans, V. Jounieaux, J.L. Schmit
(Amiens, Tourcoing, Nancy, Besancon, Dijon, FR)
P1140 BCG infection following BCG therapy for
bladder carcinoma: results of a multicentre
study, about 23 cases
A. Godel, E. Bonnet, L. Porte, F. Busato,
M. Alvarez, B. Doudie, P. Brouqui,
H. Laurichesse, P. Massip, B. Marchou
and the InfectioSud Group
P1141 Extrapulmonary tuberculosis in immuno -
competent adults
T. Turunc, Y.Z. Demiroglu, H. Uncu, S. Colakoglu,
H. Arslan (Ankara, TR)
P1142 Cigarette smoking and its association with
pulmonary tuberculosis in adults
M. Rasoolinejad, A. Farazi, M. Haj Ab-dul Baghi,
P. Hashemi, P. Kheirandish (Tehran, IR)
12:00–13:00
Experimental infections: treatment and
pathogenesis
P1143 Does reduced susceptibility to disinfectants
compromise colonisation and persistence of
Salmonella enterica serovar typhimurium in
chickens?
S.W. Cooles, M.A. Webber, L.P. Randall,
N.G. Coldham, L.J.V. Piddock, M.J. Woodward
(Addlestone, Birmingham, UK)
P1144 A study on rat’s pulmonary inflammatory
reaction induced by N-protein of SARS-CoV
and effects of glucocorticoids on it
L. He, D. Hao, J. Qu (Shanghai, CN)
P1145 Brain damage in pneumococcal meningitis:
establishment of an infant mouse model
D. Grandgirard, O. Steiner, S.L. Leib (Bern, CH)
P1146 PCR and culture correlate well for measuring
cure rates for short course treatment of
infections with the Lyme disease spirochete
C. Pavia, D. Liveris, S. Bittker
(Old Westbury, Valhalla, US)

Poster Sessions Monday, April 3, 2006
P1147 Efficacy of aminocandin (IP960/HMR3270) in
temporarily and persistently neutropenic
murine models of disseminated aspergillosis
P. Warn, A. Sharp, D.W. Denning (Manchester, UK)
P1148 Therapeutic drug monitoring of 5-flucytosine
in children aged under 12 years. An elevenyear
review of serum concentrations from a
United Kingdom clinical assay reference
laboratory
M. Soltani, C.M. Tobin, K.E. Bowker,
A.M. Lovering, A.P. MacGowan (Bristol, UK)
P1149 Experimental dermatophytosis in guinea pigs:
is voriconazole an option for treatment?
D.M. Saunte, N. Frimodt-Moller, E.L. Svejgaard,
M. Haedersdal, M.C. Arendrup (Copenhagen, DK)
P1150 Moxifloxacin is markedly more effective than
levofloxacin, gatifloxacin or azithromycin in
the treatment of pneumococcal pneumonia in
mice caused by a macrolide-resistant isolate
D.J. Bast, L. Dresser, C.L. Duncan, L.A. Mandell,
D.E. Low, J.C.S. de Azavedo (Toronto, CA)
P1151 Moxifloxacin is highly active in a murine
Gelfoam® implant model of complicated skin
and skin structure infections
K. Merfort, S. Obertegger, R. Endermann
(Wuppertal, DE)
P1152 Efficacy of continuous or bolus IV ceftazidime
and combination therapy in septic neutro -
penic mice
J. Buijs, A.S.M. Dofferhoff, J.W. Mouton,
J.W.M. van der Meer (Heerlen, Nijmegen, NL)
P1153 Amoxicillin early and delayed treatment of
serotype 6 pneumococcal acute otitis media
in previously immunised vs. non-immunised
gerbils
C. Martínez-Marín, G. del Prado, L. Huelves,
M. Gracia, C. Ponte, C. Cenjor, M.J. Giménez,
L. Aguilar, F. Soriano (Madrid, ES)
P1154 Efficacy of amoxicillin-clavulanate in an
experimental murine pneumonia model
caused by AmpC non-hyperproducing clinical
isolates of E. coli resistant to cefoxitin
F. Docobo-Pérez, F. Fernández-Cuenca,
M.E. Pachón-Ibáñez, A. Pascual, C. Pichardo,
L. Martínez-Martínez, J. Pachón (Seville, ES)
P1155 Telithromycin is effective against susceptible,
fluoroquinolone-resistant and macrolideresistant
strains of Streptococcus pneumoniae
in a murine model of pneumonia
J.C.S. de Azavedo, C. Duncan, L. Dresser,
L.A. Mandell, D.E. Low, D.J. Bast
(Toronto, Hamilton, CA)
P1156 Efficacy of daptomycin in the treatment of
experimental endocarditis due to susceptible
and multidrug-resistant enterococci
J.M. Entenza, M. Giddey, J. Vouillamoz,
P. Moreillon (Lausanne, CH)
P1157 Intracellular killing of Staphylococcus aureus
in vivo: comparison of six antibiotics
A. Sandberg, R.L. Skov, N. Frimodt-Møller
(Copenhagen, DK)
P1158 Efficacy of telavancin in the treatment of
experimental endocarditis due to
glycopeptide-intermediately susceptible
Staphylococcus aureus
J.M. Miró, F. Marco, C. Garcia de la Maria,
Y. Armero, E. Amat, D. Soy, A. Moreno,
A. del Rio, M. Almela, C.A. Mestres, J. Gatell,
M.T. Jimenez de Anta for the Barcelona Hospital
Clinic Endocarditis Study Group
12:00–13:00
Bacterial pathogenesis – II
P1159 Alteration in virulence characteristics of
planktonic and biofilm cells of Pseudomonas
aeruginosa following exposure to
macrophage secretory products
R. Mittal, S. Sharma, S. Chhibber, K. Harjai
(Chandigarh, IN)
P1160 Genetic analysis of alginate production in
140 cystic fibrosis P. aeruginosa isolates from
Scandinavian patients
O. Ciofu, T. Wassermann, U. Johansen, N. Høiby
for the Scandinavian Cystic Fibrosis Study
Consortium
P1161 Effect of different growth phases on surface
properties and adhesion of Pseudomonas
aeruginosa
A.P. Fonseca, C.I. Extremina, A. Freitas da Fonseca,
J.C. Sousa (Porto, PT)
P1162 Effect of subinhibitory concentrations of
ceftazidime and meropenem on the morphology
and adherence ability of Pseudomonas
aeruginosa wild-type strains
J. Vranes, S. Bekic, S. Ljubin-Sternak, B. Bedenic,
N. Bauk, G. Mlinaric-Galinovic, L. Glavas-Obrovac
(Zagreb, Osijek, HR)
P1163 In vitro study of the influence of phenyl lactic
acid produced by lactobacillus probiotic
strains on the pathogenic features of
Pseudomonas aeruginosa strains
V. Lazar, L. Ditu, M.C. Balotescu, C. Bleotu,
M. Bucur, O. Dracea, O. Banu, R. Cernat
(Bucharest, RO)
www.escmid.org/eccmid2006
page 107

Poster Sessions Monday, April 3, 2006
P1164 Bloodstream infections due to Pseudomonas
aeruginosa: clinical outcome associated with
pathogenesis-related genes
A. Endimiani, B. Pini, A. Baj, F. Luzzaro, A. Toniolo
(Varese, IT)
P1165 MR imaging in experimental meningitis –
in vivo correlates for disease severity
C.T. Brandt, H. Simonsen, J.D. Lundgren,
C. Østergaard, N. Frimodt-Møller, L.V. Søgaard,
O.B. Paulsson, I. Rowland (Copenhagen, DK)
P1166 Transmission of community-acquired
methicillin-resistant Staphylococcus aureus
infection in household contacts in Taiwan
Y-C. Huang, C-F. Ho, C-J. Chen, L-H. Su
(Kweishan, Taoyuan, TW)
P1167 Characterisation of Panton–Valentine
leukocidin-positive Staphylococcus aureus
strains isolated in the Czech Republic
P. Petras, I. Machova, M. Marejkova, R. Pantucek,
V. Ruzickova, J. Doskar (Prague, Brno, CZ)
P1168 Increased incidence of higher vancomycin
minimal inhibitory concentration and
changing pattern of antibiotic susceptibility in
methicillin-resistant Staphylococcus aureus
isolates: a single institution study
D. Lu, P. Holtom (Los Angeles, US)
P1169 Prevalence of different virulence factors in
enteroaggregative Escherichia coli isolates
causing diarrhoea in children in Ifakara,
Tanzania
E. Mendez Arancibia, J. Ruiz, M. Vargas,
J. Gascon, J. Vila (Barcelona, ES)
P1170 Profound difference in virulence genes
carriage between Pakistani and Swedish
Escherichia coli strains belonging to
phylogenetic group B2
F.L. Nowrouzian (Göteborg, SE)
P1171 Pathogenicity island I of Escherichia coli
CFT073 and Yersinia high-pathogenicity island
are significantly associated with persistence
of E. coli in the intestine of Swedish infants
A.E. Östblom, I. Adlerberth, A.E. Wold,
F.L. Nowrouzian (Göteborg, SE)
P1172 Relationships between phylogenetic groups
of Escherichia coli isolates and clinical
characteristics in 161 patients with
bacteraemia
F. Jaureguy, E. Carbonnelle, S. Bonacorsi,
E. Bingen, B. Picard, X. Nassif, O. Lortholary
(Bobigny, Paris, FR)
page 108 Final Programme
P1173 Burden of Clostridium difficile associated
disease in NHS hospital trusts in England
A.D. Pearson, K. Wagner, A. Talebi, E. Robinson,
L. Saker (London, UK)
P1174 In vitro investigation of pro-inflammatory
properties of Helicobacter pylori strains
involved in low-grade gastric mucosa
associated lymphoid tissue lymphoma
P. Lehours, G. Lasne, A. Gallois, A. Menard,
A. Ruskone Fourmestraux, J.C. Delchier,
F. Megraud (Bordeaux, Paris, Creteil, FR)
P1175 Reduced activation of microglial cells by
Streptococcus pneumoniae after treatment
with nonbacteriolytic antibiotics in
comparison to ceftriaxone
A. Spreer, I.M. Hernekamp, M. Lotz, S. Ebert,
H. Eiffert, R. Nau (Gottingen, DE)
P1176 Contribution of chemokines CXCL10 and
CXCL11 and their receptor CXCR3 to the
accumulation of memory CD4+ T-cells in the
cerebrospinal fluid of patients with tick-borne
encephalitis and neuroborreliosis
S. Zidovec Lepej, O. Dakovic Rode, L. Misic
Majerus, B. Barsic, A. Vince, T. Jeren
(Zagreb, Koprivnica, HR)
P1177 Assessment of monocytic function in patients
with septic syndrome induced by ventilatorassociated
pneumonia
T. Tsaganos, M. Raftogiannis, D. Zervakis,
D. Plachouras, C. Skalioti, S. Kollias,
E.J. Giamarellos-Bourboulis, C. Roussos,
H. Giamarellou (Athens, GR)
P1178 Monocytes in systematic inflammatory
response syndrome: differences between
sepsis and acute pancreatitis
F. Baziaka, T. Tsaganos, V. Kousoulas,
V. Karagianni, A. Pelekanou, A. Antonopoulou,
E.J. Giamarellos-Bourboulis (Athens, GR)
P1179 Recombinant Escherichia coli as a model
to study a potential pathogenic agent of
Burkholderia pseudomallei – phospholipase C
B. Sadowska, M. Wieckowska-Szakiel,
W. Rudnicka, S. Korbsrisate, B. Rozalska
(Lodz, PL; Bangkok, TH)
P1180 Fusobacterium necrophorum in young
patients with tonsillitis and healthy controls
examined by real-time PCR. Concomitant
Group C streptococci may aggravate
tonsillitis
A. Jensen, L.H. Kristensen, J. Prag (Viborg, DK)

Poster Sessions Monday, April 3, 2006
P1181 Expression, immunogenicity and apoptotic
potential of Salmonella enterica serovar Typhi
69 kDa phenotype under oxidative stress, iron
limitation and anaerobic conditions
V. Chanana, S. Majumdar, P. Rishi
(Chandigarh, IN)
P1182 Gram-positive and Gram-negative bacteria
induce different cytokines from human
peripheral blood mononuclear cells
irrespective of taxonomic relatedness
S. Johansson, A. Bigsten, C. Hessle, A. Wold
(Goteborg, SE)
P1183 Invasiveness of Providencia alcalifaciens to
HEp-2 cells
A. Maszewska, A. Torzewska, A. Rozalski
(Lodz, PL)
P1184 The exchange of virulence-related and
drug-resistance genes among clinical isolates
of enterococci
N. Amirmozafari, M. Alebouyeh, H. Forohesh
(Tehran, IR)
P1185 Modulation of GRO-alpha and TNF-alpha
production by peripheral blood mononuclear
cells treated with killed Helicobacter pylori
G. Stassi, A. Arena, A. Cascio, C. Iaria,
M. Calapai, D. Gazzara, D. Iannello (Messina, IT)
P1186 Elevated sialidase and prolidase combined
with vaginal pH>5 are biomarker for low birth
weight and early preterm birth
S. Cauci, J. McGregor, P. Thorsen, J. Grove,
D. De Santo, F. De Seta, P. Lanzafame,
S. Guaschino (Udine, IT; Los Angeles, US;
Aarhus, DK; Trieste, IT)
P1187 Levels of IgA against Gardnerella vaginalis
hemolysin (anti-Gvh IgA) before and after
therapy of bacterial vaginosis
S. Cauci, S. Driussi, G. Casabellata,
M. Di Santolo, P. Lanzafame, D. De Santo,
F. De Seta, S. Guaschino (Udine, IT)
P1188 Q fever in Northern Greece: epidemiologic
and clinical data from 58 acute and chronic
cases
M. Pape (Thessaloniki, GR)
P1189 Gram-negative commensal gut bacteria
aggravate small intestinal inflammation via
toll-like receptor 4
M.M. Heimesaat, A. Fischer, H.-K. Jahn,
J. Niebergall, O. Liesenfeld, R.R. Schumann,
S. Bereswill, U.B. Göbel (Berlin, DE)
P1190 The condition of a mucous stomach
membrane of region blood-groove after
shigellosis
M. Chemich, A. Snitsar (Sumy, UA)
P1191 In vitro model to analyse the effect of
mycobacteria infection on HIV replication
A. Boluda, R. Delgado, M.D. Folgueira
(Madrid, ES)
P1192 Prevalence of non-tuberculosis mycobacteria
in the Southeast of Iran
T. Naserpour Farivar, B. Sharifi Moud, M. Naderi,
M. Salehi, N. Salari, N. Naserfar (Zahedan, IR)
P1193 Systemic inflammation in the field of
experimental multiple trauma:
when does bacterial translocation
and subsequent sepsis occur?
P. Koutoukas, T. Tsaganos, N. Efstathopoulos,
K. Panousis, P. Kaldis, M. Klonaris, E.J. Giamarellos-
Bourboulis, A. Papalois (Athens, GR)
P1194 Identification of Borrelia burgdorferi sensu
lato species in erythema migrans and cardial
involvement by real-time PCR and electron
microscopy
D. Hulinska, M. Bojar, V. Hulinsky, P. Bartunek
(Prague, Nymburk, CZ)
P1195 Seroepidemiological study on toxoplasmic
infection among high-school girls by IFAT test
in Iran, 2002–2003
M. Mahmoudi (Esfahan, IR)
P1196 The faith of Shigella species during contact
with the water-borne free-living amoeba
Acanthamoebae castellanii
A. Saeed, H. Abd, G. Sandström (Stockholm, SE)
P1197 Mannose-rich capsular polysaccharides
enhance uptake and killing of Klebsiella
pneumoniae by human plymorphonuclear
leukocytes
H. Sahly, Y. Keisari, U. Stallforth-Siegel, I. Ofek
(Kiel, DE; Tel Aviv, IL)
13:00–14:00
Mechanism of antifungal action and
resistance to antifungals in fungal disease
P1198 Management of semi-invasive aspergillosis
and Aspergillus empyema with combination
of systemic antifungals and intrapleural
amphotericin B in an immunocompetent
patient
Y. Tezer, O. Memikoglu, H. Kurt (Ankara, TR)
www.escmid.org/eccmid2006
page 109

Poster Sessions Monday, April 3, 2006
P1199 Clinical presentation and epidemiology of
Mucorales infections in Geneva university
hospitals
I. Uçkay, M. Djordjevic, J. Garbino, C. Garzoni,
Y. Chalandon, V. Jacomo, P. Rohner,
C. Van Delden (Geneva, CH; Nis, CS)
P1200 Caspofungin therapy in documented fungal
infections: Spanish experience before
licencing of the drug
C. Sanz-Rodriguez, J.M. Cisneros, J.M. Aguado,
R. Martino on behalf of the Spanish Caspofungin
Clinical Study Group
P1201 Zygomycosis in a general hospital during
a 17-year period. Is there an increase in
incidence after introducing voriconazole?
M. Torres-Narbona, J. Guinea, J. Martínez-
Alarcón, T. Peláez, P. Muñoz, E. Bouza
(Madrid, ES)
P1202 Candida colonisation, colonisation index and
invasive candidiasis in patients at a multi -
disciplinary intensive care unit, Sweden
C. Agvald-Ohman, L. Klingspor, H. Hjelmqvist,
C. Edlund (Huddinge, SE)
P1203 Treatment of invasive Pseudallescheria boydii
infections with voriconazole or voriconazole
plus caspofungin
A. Pan, A. Soresina, C. Cattaneo, S. Lorenzotti,
S. Magri, N. Manca, A. Plebani, G. Pinsi, G. Rossi,
L. Soavi, L. Signorini, R. Stellini, G. Carosi
(Brescia, IT)
P1204 The emergence of caspofungin resistance
during treatment of recurrent Candida
glabrata candidaemia
N. Daneman, A.K. Chan, S.M. Poutanen,
R. Rennie, C. Sand, S. Porter
(Toronto, Edmonton, Vancouver, CA)
P1205 An open-label study of anidulafungin in
invasive candidiasis and candidaemia
R. Betts, D. Kett, K. Clark, H.T. Schlamm,
D.S. Krause (Rochester, Miami, New York, US)
P1206 Systemic fungal infection due to Trichosporon
beigelii in immunocompromised patients
I. Radonjic, S. Mitrovic, V. Arsic Arsenijevic,
I. Kranjcic Zec, A. Dzamic (Belgrade, CS)
P1207 Epidemiology of dermatophytosis in
Khouzestan province, southwest Iran,
from 2002 to 2005
A. Rafiei, M. Omidian, M. Radmanesh, M. Mapar,
R. Yaghobi, R. Rasaei, R. Taddaion (Ahwaz, IR)
page 110 Final Programme
P1208 Cutaneous infection by Absidia corymbifera
and Syncephalastrum racemosum treated
with amphotericin B and surgical debridement
R. Bandettini, E. Mantero, A.M. Tamisani, P. Tuo,
R. Ceccarelli, L. Pescetto, L. Ricagni, G. Melioli
(Genoa, IT)
P1209 The Janus head of Histoplasma
E. Vlieghe, M. Ieven, H. Jansens, B. Hendriks,
K. Van de Vyvere, P. Fonteyne, E. Van den Enden,
R. Colebunders (Antwerp, Brussels, BE)
P1210 Successful therapy of zygomycosis with
posaconazole in a patient intolerant of
liposomal amphotericin B
S. Savvanis, A. Papadopoulos, D. Kavvatha,
H. Giamarellou (Athens, GR)
P1211 Carbon assimilation profiles as a tool for
Zygomycetes species identification
P. Schwarz, O. Lortholary, F. Dromer, E. Dannaoui
(Paris, FR)
P1212 Is posaconazole a new treatment option for
brain abscess?
L. Matkham, C. Garzoni, B. Hirschel, S. Harbarth,
K. Bouchuigui-Waf, J. Garbino (Geneva, CH)
P1213 Clinical and epidemiological analysis of
candida bloodstream infection in a university
hospital
M. Cuervo, M.A. Miguel, M. Lecuona, S. Campos,
M.I. Montesinos, A. Torres, T. Delgado, A. Sierra
(La Laguna Sta Cruz Tenerife, ES)
P1214 A prospective French national survey to
evaluate renal function in patients treated
with amphotericin B lipid formulations
S. Faouzi (Villejuif, FR)
P1215 Fungal peritonitis in continuous ambulatory
peritoneal dialysis patients
B. Arda, O. Sipahi, G. Asci, M. Ozkahya,
S. Ulusoy (Izmir, TR)
P1216 Intra-abdominal fungal infection in surgical
patients
I. Gutiérrez, N. Batista, A. Varona, O. Díez
(Santa Cruz de Tenerife, ES)
P1217 Mucormycoses: a report of eleven cases
T. Turunc, Y.Z. Demiroglu, H. Uncu,
S. Colakoglu, H. Arslan (Baskent, TR)
P1218 Bipolaris spicifera isolation from the nasal
polyps of an allergic boy: a case report
A. Sergounioti, H. Kirikou, A. Velegraki,
K. Chryssaki, M. Choulakis, K. Stefanaki,
A. Pangalis (Athens, GR)

Poster Sessions Monday, April 3, 2006
P1219 Mucormycosis: still a problem
(a report of four cases)
L. Ammari, B. Kilani, H. Tiouiri ben Aissa,
F. Kanoun, E. Chaker, A. Goubontini,
T. Ben Chaabane (Tunis, TN)
P1220 Candida deep sternal wound infections:
an emerging problem?
T. Ejlertsen, I. Modrau, L. Lemming,
B.S. Rasmussen (Aalborg, DK)
P1221 Survey on dermatophytosis in patients
referred to a dermatology hospital in Ghazvin,
Iran
M.R. Aghamirian, D. Keshavarz, J.H. Hashemi
(Ghazvin, IR)
P1222 Caspofungin and G-CSF as first-line therapy
of pulmonary invasive fungal infections in
32 neutropenic patients with haematologic
malignancies
A. Candoni (Udine, IT)
P1223 Clinical analysis of cryptococcal meningitis
(with 72 case reports)
G. Shi (Shanghai, CN)
P1224 The prevalance of aetiologic agents of
dermatophytosis in wrestlers in Isfahan, Iran
S. Shadzi, A. Karbassian, N. Kassaian, M. Khademi,
Z. Nokhodian (Isfahan, IR)
P1225 Slowly progressing, and indolent pulmonary
mucormycosis (zigomycosis) in a patient with
an underlying multiple sclerosis, managed
without immunosuppressive therapy
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P1226 AIDS-defining fungal opportunism in the
HAART era. Trend of frequency and reduced
incidence when HIV protease inhibitors are
administered
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P1227 Concurrent invasive cryptococcosis and
candidiasis in AIDS presenters. Clinical
epidemiology and features never observed
also during the pre-HAART era
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P1228 A 3-year study of resistance of Candida
pathogens obtained from patients with
fungaemia with emphasis on new antifungal
agents
A. Koutsoukou, A. Stylianakis, S. Tsiplakou,
M. Tachtatzis, E. Tsakona, A. Vourtsi, A. Sideri
(Athens, GR)
P1229 Candida embolic stroke and secondary fungal
mycotic aneurysm
C. Garzoni, I. Uckay, L. Markham, R. Sztajzel,
K. Bouchuigui-Waf, P. Temperli, J. Garbino
(Geneva, CH)
P1230 Monitoring of voriconazole blood levels
for prevention of serious neurological adverse
events
A A. Pascual, S. Bolay, O. Marchetti
(Lausanne, CH)
P1231 Influence of azoles on mixed long-term
continuous flow cultures of Candida albicans
and Candida glabrata under aerobic and
anaerobic conditions
H. Bernhardt, M. Knoke, K. Zimmermann,
G. Schwesinger, J. Bufler, K. Ludwig,
J. Bernhardt (Greifswald, Karlsruhe, Rostock, DE)
P1232 Investigation of synergistic effect of sertraline
on fluconazole-resistant Candida spp. by
microbiological methods and electron
microscopy
N. Nuhoglu, T. San, G. Soyletir (Istanbul, TR)
13:00–14:00
Antimicrobial resistance, permeability
and fitness
P1233 Fitness costs of antimicrobial resistance
associated with chromosomal mutations and
plasmid-borne resistance genes in Escherichia
coli: in vitro and in vivo studies
A. Petersen, F.M. Aarestrup, M. Bisgaard, J. Olsen
(Frederiksberg, Copenhagen, DK)
P1234 The fitness cost imposed by plasmid RP1 on
Escherichia coli differs from strain to strain
V.I. Enne, P.M. Bennett (Bristol, UK)
P1235 Long-term persistence of resistant strains
in the human intestinal microflora due to
restored fitness
S. Löfmark, H. Billström, C. Jernberg, C. Edlund
(Stockholm, SE)
P1236 Mutators among UK CTX-M B-lactamaseproducing
E. coli pose a risk for the
emergence of fosfomycin resistance
M.J. Ellington, D.M. Livermore, T.L. Pitt,
L.M.C. Hall, N. Woodford (London, UK)
P1237 Ertapenem promoted the selection of totally
resistant pathogens
F. Walsh, S. Bracher, P. Turner, S.G.B. Amyes
(Edinburgh, Cheshire, UK)
www.escmid.org/eccmid2006
page 111

Poster Sessions Monday, April 3, 2006
P1238 Convergent selection of ceftazidime
resistance mutations at position 167 of
CTX-M-3 beta-lactamase in hypermutable
Escherichia coli strains
M. Stepanova, M. Edelstein (Smolensk, RU)
P1239 Mechanisms of high-level ciprofloxacin
resistance in clinical isolates of Escherichia
coli collected in the British Isles
S. Mushtaq, M.J. Ellington, D.M. Livermore,
N. Woodford (London, UK)
P1240 Evaluation of the accumulation of 99m
Tc-ciprofloxacin in S. aureus and P. aeruginosa
J.M. Sierra, D. Rodriguez-Puig, A. Soriano,
J. Mensa, C. Piera, J. Vila (Barcelona, ES)
P1242 Occurence of MexCD-OprJ overexpressing
efflux mutants of Pseudomonas aeruginosa
isolated from hospitalised patients
K. Jeannot, D. Hocquet, P. Plésiat (Besançon, FR)
P1243 Eight non-antimicrobial medicaments induce
multidrug-resistance in Escherichia coli Ag100
strain
M.M. Tavío, V. Aquili, M. Perilli, L. Macià,
C. Balagué, Z. González-Lama, G. Amicosante
(Las Palmas de Gran Canaria, ES; L´Aquila, IT;
Rosario, AR)
P1244 The role of the multi-drug efflux systems of
Pseudomonas aeruginosa in tea tree oil
tolerance
C.J. Papadopoulos, C.F. Carson, B.J. Chang,
T.V. Riley (Perth, AU)
P1245 Comparative analysis of Salmonella
typhimurium proteomes from MAR mutants
and following treatment with salicylate
N.G. Coldham, L.P. Randall, L.J.V. Piddock,
M.J. Woodward (Surrey, Birmingham, UK)
P1246 Emergence of Enterobacter aerogenes strains
resistant to imipenem mediated by the
coexistence of metallo-beta-lactamase
production and outer membrane permeability
M. Biendo, G. Laurans, B. Canarelli, D. Thomas,
F. Hamdad Daoudi, F. Rousseau, C. Adjide, F. Eb
(Amiens, FR)
P1247 Resistance to cefoxitin and susceptibility to
amoxicillin-clavulanate in clinical isolates of
Escherichia coli not hyperproducing AmpC
and lacking the OmpF porin
F. Fernández Cuenca, G. Amblar, L. Martínez-
Martínez, A. Pascual (Seville, ES)
page 112 Final Programme
P1248 Are target gene mutations the major
mechanisms of fluoroquinolone-resistance in
salmonellae?
Y. Jin, J.M. Ling (Hong Kong, HK)
P1249 Emergence of plasmid-mediated Ambler class
A beta-lactamase in association with the
plasmid-mediated quinolone resistance QnrS
determinant in Enterobacter cloacae
L. Poirel, C. Leviandier, A. Soares, P. Nordmann
(Le Kremlin Bicetre, FR)
P1250 Detection of plasmid-mediated low-level
resistance to fluoroquinolones in
Enterobacter cloacae
P. Higgins, H. Seifert, H. Wisplinghoff
(Cologne, DE)
P1251 First characterisation of fluoroquinolone
resistance in Streptococcus suis
J.A. Escudero, A. San Millan, A.M. Catalan,
A.G. De la Campa, M.A. Moreno, L. Dominguez,
B. Gonzalez-Zorn (Madrid, ES)
P1252 Step-wise parC and gyrA mutations in
Streptococcus pneumoniae: the role of the
Lys137 to Asn mutation in fluoroquinolone
resistance
V. Allen, K. Green, D.J. Bast, J. Azavedo,
C. Duncan, D.E. Low (Toronto, CA)
P1253 Molecular characterisation of antibiotic
resistance mechanisms in Salmonella enterica
isolates in Ireland
D. Lee, S. Fanning, A. Coffey (Cork, Dublin, IE)
P1254 Multidrug-resistant tuberculosis in Lisbon
in 2003
I. Portugal, R. Macedo, E. Fernandes, J. Perdigão,
I. João, E. Pereira, L. Brum (Lisbon, PT)
P1255 Genotypic assessment of rifampin resistance
in Mycobacterium tuberculosis isolated in
Belarus
V. Slizen, S. Zaker, L. Surkova, A. Bahrmand,
M. Taghikhani, L. Titov (Minsk, BY; Tehran, IR)
P1256 Metronidazole heteroresistant C. difficile
strains: morphotypes with cell-wall
thickening
J. Martínez-Alarcón, T. Peláez, J. García-Bordas,
P. Sandoval, L. Alcalá, E. Cercenado, E. Bouza
(Madrid, ES)
P1257 Incidence and antimicrobial resistance pattern
of anaerobic bacteria isolated from clinical
cases
P. Giannopoulou, E. Kontekaki, A. Kyratsa,
Z. Kyriazi, E. Trikka-Graphakos (Athens, GR)

Poster Sessions Monday, April 3, 2006
13:00–14:00
Antimicrobial susceptibility testing
P1258 Analysis of the mechanism of Acinetobacter
baumannii resistance to carbapenems in
Jinan
D. Wu, Z. Geng, X. Yu, J. Hong
(Jinan, Shandong, CN)
P1259 Grouping of CTX-M extended-spectrum
beta-lactamases by pyrosequencing
S.D. Nyberg, K. Rantakokko-Jalava, P. Huovinen,
J. Jalava (Turku, FI)
P1260 Phenotypic antimicrobial resistance patterns
of Enterobacteriaceae, Pseudomonas
aeruginosa, and Acinetobacter spp.
Multicenter Intensive Care Unit Surveillance
Survey (ISS), 1996–2003
M. Abramson, G. Gallagher, S. Rawlins, H. Wilson
(West Point, US)
P1261 Antimicrobial activity of daptomycin tested
against Gram-positive strains collected from
European medical centres in 2005: results of
the Daptomycin Surveillance Programme
H. Sader, J. Streit, T. Fritsche, R. Jones
(North Liberty, US)
P1262 Antimicrobial activity of cefepime tested
against ceftazidime-resistant Gram-negative
clinical strains from North American hospitals:
report from the SENTRY Antimicrobial
Surveillance Program, 1998–2004
H. Sader, T. Fritsche, R. Jones (North Liberty, US)
P1263 Frequency of occurrence and antimicrobial
susceptibility of bacterial isolates causing
bloodstream infections in European medical
dentres: report from 9 years of the SENTRY
Antimicrobial Surveillance Program in Europe
(1997–2005)
H. Sader, D. Biedenbach, T. Fritsche, R. Jones
(North Liberty, US)
P1264 Influence of serum-resistance properties and
multidrug-resistance of Pseudomonas
aeruginosa on mortality and duration of
mechanical ventilation in patients with
Pseudomonas aeruginosa pneumonia
A. Vitkauskiene, V. Dudzevicius, D. Adukauskiene,
J. Braziulyte, R. Sabaniauskaite, R. Sakalauskas,
H. Sahly (Kaunas, LT; Kiel, DE)
P1265 Antimicrobial potency and spectrum of
activity for meropenem: report from the USA
MYSTIC Programme (2005)
P. Rhomberg, T. Fritsche, H. Sader, R. Jones
(North Liberty, US)
P1266 Difference in quinolone resistance in
Pseudomonas aeruginosa from cystic fibrosis
and non-cystic fibrosis patients
B. Henrichfreise, I. Wiegand, I. Noll, W. Pfister,
B. Wiedemann (Bonn, Berlin, Jena, DE)
P1267 Molecular typing and alterations analysis of
penicillin-binding proteins 1A, 2X and 2B
and MurM protein and in 33 isolates of
Streptococcus pneumoniae with vary
penicillin and amoxicillin MICs
K. Kosowska-Shick, P.C. Appelbaum (Hershey, US)
P1268 Molecular epidemiology of extendedspectrum
beta-lactamase-producing Klebsiella
pneumoniae and Serratia marcescens in a
neonatal intensive care unit
V. Crivaro, M. Bagattini, A. Di Popolo, F. Gentile,
M.F. Salza, F. Rossano, P. Villari, M. Triassi,
R. Zarrilli (Naples, Campobasso, Rome, IT)
P1269 Epidemiology of Haemophilus influenzae
strains collected in 2004 in France and in vitro
assessment of their susceptibility to betalactams
H. Dabernat, G. Faucon, M. Seguy, C. Delmas
(Toulouse, FR)
P1270 Overdetection of imipenem resistance
by VITEK 2 in blaVIM 12 producing Klebsiella
pneumoniae with E-test low level
carbapenem MICs
D. Tokatlidou, Z. Afkou, C. Papadopoulou,
S. Pournaras, D. Sofianou
(Thessaloniki, Larissa, GR)
P1271 Viridans group streptococci in blood culture
isolates, antibiotic susceptibility and
identification of resistance genes
K. Westling, I. Julander, P. Ljungman, S. Jalal,
C. Nord, B. Wretlind (Stockholm, SE)
P1272 Evidence of an efflux pump mediating a
mar phenotype in two ciprofloxacin-resistant
marR-mutant Escherichia coli isolates
F. Fendukly, G. Kronvall, K. Dornbusch
(Stockholm, SE)
P1273 First report of a linkage between tet(M) and
erm(B) genes in Clostridium difficile clinical
isolates
P. Spigaglia, F. Barbanti, P. Mastrantonio
(Rome, IT)
P1274 Dissemination of 16S rRNA methylase in
AmpC producing Enterobacter cloacae,
Citrobacter freundii and Serratia marcescens
in Korea
S. Lee, Y-J. Park, J-K. Yu, K. Lee, Y. Arakawa
(Seoul, KR; Tokyo, JP)
www.escmid.org/eccmid2006
page 113

Poster Sessions Monday, April 3, 2006
P1275 Resistance mechanisms in S. pneumoniae in
the Netherlands
J.W. Mouton, D. Klomberg, S. Meijers,
C. Klaassen (Nijmegen, NL)
P1276 Fluoroquinolone resistance in Streptococcus
pneumoniae: screening for first-step
mutations
C. Ardanuy, L. Balsalobre, A.G. de la Campa,
L. Calatayud, E. Bouza, R. Martín, R. Pallares,
J. Liñares for the Spanish Pneumococcal
Infection Study Network
P1277 Telithromycin resistance in pneumococci
M. Rantala, P. Huovinen, J. Jalava and Finnish
Study Group for Antimicrobial Resistance
P1278 Theoretical framework on the uses of
standardised antibiotic phenotype and
pattern indexes
I.C. Acuner (Samsun, TR)
P1279 Trends in antibacterial resistance of
Streptococcus pneumoniae: PROTEKT Global
Years 1–5
D.J. Farrell, R. Cantón, W. Hryniewicz
(London, UK; Madrid, ES; Warsaw, PL)
P1280 Activity of telithromycin against Streptococcus
pneumoniae isolates resistant to other
antibacterials: PROTEKT Year 5
G.C. Schito, D.J. Farrell, J.A. Ramirez
(Genoa, IT; London, UK; Louisville, US)
P1281 Evaluation of the VITEK 2 AST-N 041 card for
detection of extended-spectrum betalactamase
producing E. coli and Klebsiella
pneumoniae
S.H. Koo, J.S. Goh, J.U. Kang, K.C. Kwon,
J.W. Park (Daejeon, KR)
P1282 Antibiotic susceptibility among invasive and
non-invasive Streptococcus pyogenes isolates
in Sweden; 2002–2004
B. Luca, J. Darenberg, B. Henriques Normark,
A. Norrby-Teglund, C. Schalen, A. Jasir
(Lund, Stockholm, Solna, SE)
P1283 Evaluation of cefoxitin disk test in the
detection of methicillin-resistant blood CoNS
clinical isolates in a tertiary university
department
R. Vorou, E. Giannitsioti, I. Galani, E. Koratzanis,
H. Giamarellou (Athens, GR)
page 114 Final Programme
P1284 Quantitative antibiotic susceptibility of
Staphylococcus aureus strains isolated from
blood of septic patients with special attention
to MRSA
F. Rozgonyi, N. Pesti, K. Kristóf, H. Lagler,
G. Kotolácsi, E. Presterl, W. Graninger
(Budapest, HU; Vienna, AT)
P1285 Antimicrobial resistance trends in invasive
strains of S. aureus, E. coli, Streptococcus
pneumoniae, and Enterococcus spp. in
Romania – a four-year participation in the
EARSS
I. Codita, M.C. Balotescu, A. Israil, M. Popa,
D. Tatu-Chitoiu, V. Ungureanu, M. Pana, M. Ghita
(Bucharest, RO)
P1286 In vitro susceptibility of methicillin-resistant
Staphylococcus aureus and vancomycinresistant
Enterococcus faecium to vancomycin,
daptomycin, linezolid, pristinomycin and
other antibiotics
Z. Samra, O. Ofir, H. Shmuely (Petach-Tiqua, IL)
13:00–14:00
Antibacterial susceptibility studies – II
P1287 MBL mediated carbapenem resistance in
P. aeruginosa and A. baumannii in cancer
patients
E. Chinou, M. Georgouli, P. Giannakakos,
M. Alexiou, H. Skouteli, P. Golemati (Athens, GR)
P1288 Efficiency of cefoperazone, sulbactam alone
and in two combinations against multidrugresistant
Acinetobacter baumannii strains
isolated from nosocomial infections in seven
different intensive care units in Turkey
A. Karadenizli, S. Akhan, S. Gundes, F. Kolayli,
H. Vahaboglu (Kocaeli, TR)
P1289 High incidence of moxifloxacin resistance
among Bacteroides spp. isolates in Greece.
Results from the Hellenic Study Group on
Gram-negative anaerobic bacteria
A. Katsandri, D.P. Houhoula, G.L. Petrikkos,
N.J. Legakis, J. Papaparaskevas, A. Pantazatou,
A. Avlamis (Athens, GR)
P1290 Laboratory investigation of the combination
effect of imipenem/colistin and sulbactam/
colistin on clinical isolates of multidrugresistant
Acinetobacter baumannii
H-S. Leu, L-H. Su, J-W. Wang (Taoyuan, TW)
P1291 Current state of antimicrobial resistance of
S. pneumoniae isolated from children in
Russia: results of multicentre study PEHASus
O. Sivaja, R. Kozlov (Smolensk, RU)

Poster Sessions Monday, April 3, 2006
P1292 In vitro bacteriostatic and bactericidal activity
of pristinamycin against Streptococcus
pyogenes: influence of macrolide resistance
mechanism
H.B. Drugeon, M.E. Juvin, C. Dib-Smahi
(Nantes, Paris, FR)
P1293 In vitro activity of antimicrobial agent
combinations against Brucella melitensis
isolates by E test
S. Kaya Firat, B. Oral, F.S. Erdinc, M.A. Yetkin,
N. Tulek, A.P. Demiröz (Ankara, Samsun, TR)
P1294 Incidence and resistance patterns of
pathogens from lower respiratory tract
infections
O. Dorobat, A. Moisoiu, D. Talapan
(Bucharest, RO)
P1295 Comparative study of some antibacterial
agents in patients with shigellosis
M. Stoycheva-Vartigova, P. Koroljova (Plovdiv, BG)
P1296 Preliminary report on a specific anti-
Helicobacter pylori microbicidal peptides
produced by clinical strain of Candida
albicans
E. Karczewska, P. Mak, A. Targosz, D. Trojanowska,
M. Wcislo, A. Budak (Cracow, PL)
P1297 In vitro demonstration of synergy with two
bacteriophage lytic enzymes (Cpl-1 and Pal),
autolysin (LytA), and cefotaxime against
Streptococcus pneumoniae
M. Gracia, V. Rodriguez-Cerrato, E. Garcia,
P. Garcia, R. Lopez, G. del Prado, C. Martinez-
Marin, L. Huelves, C. Ponte, F. Soriano
on behalf of the Spanish Pneumococcal Infection
Study Network (G03/103)
P1298 Activity of moxifloxacin and comparators
against isolates of Chlamydia trachomatis
from the UK
L. Williams, J. Northwood, I. Morrissey
(London, UK)
P1299 The antimicrobial susceptibility of bacteraemia
isolates of Gram-negative pathogens in seven
haematological centres in Russia
G. Kliasova, A. Mironova, L. Speranskaya, S. Ptitcin,
A. Maschan, N. Yuritcina, S. Vereschagina,
T. Kaporskaya, L. Krainova, T. Pospelova, O. Markina
(Moscow, Samara, Irkutsk, Novosibirsk, Ekaterinburg,
RU)
P1300 Extending observed susceptibilities with
predicted susceptibilities based on a
retrospective statistical analysis
A.D. Nielsen, S. Andreassen, M. Paul,
L. Leibovici on behalf of the TREAT Study group
P1301 Moxifloxacin in vitro activity against
non-pneumococcal streptococci isolated from
six recent clinical studies
J.E. Ambler, S. Choudhri, D. Haverstock, J. Song,
P. Reimnitz (West Haven, US; Leverkusen, DE)
P1302 In vitro combination of rifampin with other
antimicrobial agents against clinical isolates
of Stenotrophomonas maltophilia
S. Gandotra, M. El-Azizi, A. Adamski, J. Koirala,
N. Khardori (Springfield, US)
P1303 Activity of Thymus vulgaris L. essential
oil against potential causative agents of
premature delivery
L. Suvajdzic, M. Bogavac, B. Bozin, N. Mimica-
Dukic, M. Mikov, N. Simin
(Novi Sad, CS; Otago, NZ)
P1304 Sensitivity testing and empirical treatment of
pneumonia and acute exacerbations of COPD
S. Marinkovic, I. Marekovic, B. Balabanic-Kamauf,
F. Pavicic, M. Jakopovic, M. Korsic (Zagreb, HR)
P1305 Comparative in vitro activity of levofloxacin
against enterobacteria isolated from intraabdominal
infections
M. Mohseni Zadeh, S. Kopp, F. Jehl
(Strasbourg, FR)
P1306 Activity of beta-lactam/beta-lactamase
inhibitor combinations against ESBL
producing Enterobacteriaceae
B. Rybak, L. Naumiuk, M. Bronk, A. Samet
(Gdansk, PL)
P1307 Dynamic bactericidal activity of ceftazidime
in combination with glycopeptides
and azithromycin against Pseudomonas
aeruginosa
B. Repetto, A. Palenzona, A. Marchese,
E.A. Debbia (Genoa, IT)
P1308 Comparative antimicrobial susceptibilities of
Streptococcus pneumoniae and Haemophilus
influenzae in a university hospital in Turkey
A. Ilki, P. Sagiroglu, N. Elgormus, U. Over-Hasdemir,
G. Soyletir (Istanbul, TR)
P1309 Reliability of daptomycin E-test strips for
susceptibility testing
R. Cantón, J. Bille, A. MacGowan, C.E. Nord,
G. Schito, H. Seifert, C. Soussy, M. Struelens,
J. Verhoef, I. Morrissey (Madrid, ES; Lausanne,
CH; Bristol, UK; Stockholm, SE; Genoa, IT;
Cologne, DE; Creteil, FR; Brussels, BE;
Utrecht, NL; London, UK)
P1310 In vitro antimicrobial activity of gatifloxacin
against staphylococci
C. Tuchilus, A. Poiata, A. Vornicu, O. Gacea,
D. Buiuc (Iasi, RO)
www.escmid.org/eccmid2006
page 115

Poster Sessions Monday, April 3, 2006
13:00–14:00
Tigecycline in vitro studies – II
P1311 Sampling of Staphylococcus aureus and
Enterococcus species isolates resistant to
other drugs evaluated against tigecycline –
T.E.S.T. Program Global Data
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P1312 Tigecycline in vitro activity against
Staphylococcus aureus and Enterococcus
strains resistant to other drugs in United
States, 2004–2006
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P1313 In vitro activity of multidrug-resistant
Acinetobacter against tigecycline from the
T.E.S.T. Program in Europe
J. Johnson, D. Hoban, B. Johnson,
S. Bouchillon, T. Stevens, M. Dowzicky
(Schaumburg, Collegeville, US)
P1314 Tigecycline in vitro activity against
multidrug-resistant Acinetobacter from global
population in the T.E.S.T. Program 2006
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P1315 Multidrug-resistant Acinetobacter in the
United States evaluated against tigecycline –
T.E.S.T. Program 2006
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P1316 Determining tigecycline’s in vitro activity
multidrug-resistant Enterobacteriaceae from
the T.E.S.T. Program – Global Data
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
P1317 Cross-resistance in clinical isolates of
Enterobacteriaceae from the United States
evaluated against tigecycline and 10
comparator antimicrobial agents
B. Johnson, S. Bouchillon, T. Stevens,
J. Johnson, D. Hoban, M. Dowzicky
(Schaumburg, Collegeville, US)
page 116 Final Programme
P1318 In vitro activity of tigecycline and comparators
against community and hospital-acquired
infections in the United States –
T.E.S.T. Program 2006
D. Hoban, B. Johnson, S. Bouchillon,
T. Stevens, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P1319 In vitro activity tigecycline and ten broad
spectrum comparators against multidrugresistant
Staphylococcus aureus:
a multi-nation evaluation
D. Hoban, B. Johnson, S. Bouchillon,
T. Stevens, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P1320 Continuity of mutant prevention concentration
values for gatifloxacin, gemifloxacin and
moxifloxacin against clinical isolates of
Streptococcus pneumoniae (1994–2004)
J. Blondeau, S. Borsos (Saskatoon, CA)
P1321 In vitro activity of tigecycline against
tetracycline-resistant Gram-positive cocci
isolated from patients with bacteraemia
S. Forsthuber, H. Lagler, K. Stich, S. Reichmann,
A. Georgopoulos, W. Graninger, E. Presterl
(Vienna, AT)
P1322 Benchmarking tigecycline activity against
Gram-positive and Gram-negative pathogens
with multidrug-resistance phenotypes
derived from patient specimens from USA
and Europe
D. Draghi, M. Jones, D. Sahm, C. Thornsberry
(Herndon, US; Plaisir, FR)
P1323 A Nordic study exploring the activity of
tigecycline against tetracycline-resistant
Gram-positive and Gram-negative bacteria
L.E. Nilsson, T. Koernig, N. Frimodt Møller,
G. Skov Simonsen , M. Vaara (Linköping, Solna,
SE; Copenhagen, DK; Tromsø, NO; Helsinki, FI)
P1324 Antimicrobial activity of tigecycline against
CTX-M extended-spectrum betalactamaseproducing
Enterobacteriaceae isolated from
Austrian patients
A. Eisner, G. Feierl, L. Masoud, A. Grisold,
E. Marth (Graz, AT)
P1325 In vitro efficacy of tigecycline tested
against community-associated methicillinresistant
S. aureus including analyses of
72 co-resistance patterns
R. Jones, M. Stillwell, H. Sader, T. Fritsche
(North Liberty, US)

Poster Sessions Monday, April 3, 2006
P1326 In vitro activity of tigecycline tested against
an international collection of minocyclineresistant
bacterial pathogens (2000–2004)
T. Fritsche, H. Sader, R. Jones (North Liberty, US)
P1327 Antimicrobial activity of tigecycline, a
glycylcycline, tested against carbapenemaseproducing
Enterobactereaceae
H. Sader, T. Fritsche, L. Deshpande, R. Jones
(North Liberty, US)
P1328 Activity of tigecycline tested against an
international collection (2000–2004) of
AmpC-producing Enterobacteriaceae
T. Fritsche, H. Sader, R. Jones (North Liberty, US)
P1329 Evaluation of the in vitro activity of tigecycline
against multidrug-resistant Gram-negative
and Gram-positive isolates
F. Kontopidou, E. Koratzanis, A. Antoniadou,
E. Giannitsioti, P. Evangelopoulou, S. Kanavaki,
S. Karambela, L. Zerva, H. Giamarellou (Athens, GR)
13:00–14:00
Nosocomial infection control: MRSA and VRE
P1330 Importance of premorbid and ICU-acquired
nasal colonisation
A. Molnar, E. Hajdu, Z. Peto, R. Benko,
A. Hortobagyi (Szeged, HU)
P1331 Management of an outbreak of vancomycinresistant
enterococci in a German university
hospital hemato-oncology department
D. Mlangeni, H. Bertz, M. Bussmann, A. Conrad,
J. Huebner, D. Jonas, M. Kist, A. Serr,
M. Dettenkofer for the VRE Task Force,
University Hospital Freiburg, DE
P1332 The Uro-Quick system for detecting
vancomycin resistance in enterococci
S. Roveta, C. Cassanelli, A. Marchese,
E.A. Debbia (Genoa, IT)
P1333 Impact of infection control interventions on
hospital MRSA: a time-series analysis
A. Mahamat, F.M. MacKenzie, K. Brooker,
D.L. Monnet, I.M. Gould (Nîmes, FR; Aberdeen,
Elgin, UK; Copenhagen, DK)
P1334 Reservoirs and transmission routes of
methicillin-resistant Staphylococcus aureus
and methicillin-susceptible Staphylococcus
aureus in a tertiary hospital:
one-year surveillance
N.A. Faria, D.C. Oliveira, M.L. Amorim, E. Calado,
C. Vasconcelos, A.P. Castro, J.M. Amorim,
H. de Lencastre (Oeiras, Porto, PT; New York, US)
P1335 A patient-centred approach to a clinical audit
of the clinical practice in MRSA control
A. Guleri, J. Roberts (Liverpool, UK)
P1336 Patient decontamination to control MRSA in
an intensive care unit
I.M. Gould, F.M. MacKenzie, G. MacLennan
(Aberdeen, UK)
P1337 Usefulness of axillar swab in the detection of
methicillin-resistant Staphylococcus aureus
colonisation
J. de Otero, C. Capo, M.A. Rada, E. Padilla,
A. Serra (Manacor, ES)
P1338 A prospective study comparing IDI-MRSA
real-time PCR assay (SmartCycler) versus
chromogenic culture method for detection of
methicillin-resistant Staphylococcus aureus
B. Ghebremedhin, W. König, B. König
(Magdeburg, DE)
P1339 Molecular MRSA screening:
finding negatives a.s.a.p.
E.J. van Hannen, P. Foppen, B.M. de Jongh
(Nieuwegein, NL)
P1340 Effect of nose carrier screening in liver
transplant candidates for preventing
Staphylococcus aureus infections after
transplantation: a retrospective study
V. Lamonaca, R. Di Stefano, G. Caruana,
R. Volpes, M. Campanella, G. Vizzini, P. Grossi,
B. Gridelli (Palermo, IT)
13:00–14:00
Regional spread and outbreaks caused by
nosocomial pathogens
P1341 European intercountry dissemination of a
glycopeptide resistant E. faecalis clone
C. Novais, T.M. Coque, J.C. Sousa, M. Del Grosso,
L. Peixe (Porto, PT; Madrid, ES; Rome, IT)
P1342 Genomic diversity of vancomycin-resistant
Enterococcus faecium isolated in France
L. Mihaila-Amrouche, J. Loubinoux, A. Doloy,
G. Collobert, N. Gaitch, A. Bouvet (Paris, FR)
P1343 Molecular epidemiology of vanA-containing
Enterococcus faecium in a university general
hospital in Greece
M. Souli, I. Galani, L. Galani, A. Antoniadou,
M. Pantelaki, N. Siafakas, V. Sakka, F. Kontopidou,
S. Athanasia, V. Veloni, S. Tsiodras, L. Zerva,
H. Giamarellou (Chaidari, GR)
www.escmid.org/eccmid2006
page 117

Poster Sessions Monday, April 3, 2006
P1344 Establishment of polyclonal endemicity
with hospital-adapted ampicillin-resistant
Enterococcus faecium in a Dutch hospital
J. Top, R.J.L. Willems, H. Blok, A. Troelstra,
M.J.M. Bonten (Utrecht, NL)
P1345 Colonisation of vancomycin-resistant
enterococci in paediatric unit of a teaching
hospital in Turkey
H. Guducuoglu, E. Aktas, F. Begendik Comert,
K. Aygul, N. Ozlu, S. Baykal (Van, Zonguldak, TR)
P1346 A nosocomial VRE outbreak in the context of
regional changes in VRE prevalence
D. Jonas, K. Biehler, A. Serr, M. Kist, A.-M. Fahr,
M. Dettenkofer, J. Hübner, H. Bertz, F. Daschner
(Freiburg, Heidelberg, DE)
P1347 Epidemiology and control of a cluster of
USA300 methicillin-resistant Staphylococcus
aureus (USA300-MRSA) skin/soft tissue
infections in an inner-city haemodialysis unit
C. Manierski, K. Obeid, K. Reyes, S. Davis, M. Ajluni,
A. Singh, M. Perri, S. Donabedian, D. Vager,
M. Zervos (Detroit, US)
P1348 Outbreak of surgical site infections in a
cardiac surgical unit caused by an epidemic
methicillin-susceptible Staphylococcus
aureus clone
M. Pujol, A. Hornero, O. Arch, A. Manzur,
M.A. Dominguez, A. Garcia, C. Peña, F. Gudiol,
J. Ariza (Hospitalet Llobregat, ES)
P1349 Food-borne nosocomial outbreak of
Salmonella enterica serotype enteritidis in a
teaching hospital in Greece
A. Gikas, S. Maraki, E.I. Kritsotakis, D. Babalis,
M. Roumbelaki, E. Scoulica, C. Panoulis,
E. Saloustros, E. Kontopodis, G. Samonis,
Y. Tselentis (Heraklion, GR)
P1350 A Chryseobacterium meningosepticum
colonisation outbreak in a neonatal intensive
care unit
E. Galanakis, S. Maraki, E. Scoulica, A. Manoura,
C. Giannacopoulou, Y. Tselentis (Heraklion, Crete, GR)
P1351 Spreading of beta-lactamase genes among
nosocomial isolates collected from Moscow
clinics
N.K. Fursova, A.N. Kruglov, I.V. Abaev,
Y.N. Kovalev, E.I. Pecherskikh, E.I. Astashkin,
D.M. Pachkunov, S. Pryamchuk, V.A. Anisimova,
M.E. Mitzevich (Obolensk, Moscow, RU)
page 118 Final Programme
P1352 An epidemic of hospital-acquired bacteraemia
due to Alcaligenes denitrificans:
true threat or fighting windmills?
H. Moraitou, M. Makarona, A. Gioga, I. Kousseris,
E. Galani, N. Makrygiannis, S. Triantafyllou,
A. Pefanis, S. Kanavaki (Athens, GR)
P1353 Infections with hepatitis B and C viruses in
haemodialysed patients
A. Pisula, E. Janczewska-Kazek, A. Piskorowska-
Plis, J. Wieczorek, A. Boron-Kaczmarska
(Opole, Chorzow, Szczecin, PL)
P1354 Phenotypes and genotypes of slime
positive – methicillin-resistant Staphylococcus
epidermidis clinical isolates
A. Foka, V. Chini, E. Petinaki, F. Kolonitsiou,
E.D. Anastassiou, G. Dimitracopoulos,
I. Spiliopoulou (Patras, Larissa, GR)
13:00–14:00
Multidrug-resistant Gram-negative
organisms: survey and risk factors
P1355 Antimicrobial resistance of Entero -
bacteriaceae isolated from patients in
Austrian intensive care units
C. Jebelean, H. Mittermayer (Linz, AT)
P1356 Risk factors for polymyxin-only susceptible
Pseudomonas aeruginosa bacteraemia
P. Koletsi, P. Kopterides, A. Michalopoulos,
Z. Mastora, K. Rellos, M. Falagas (Athens, GR)
P1357 Exposure to fluoroquinolones is a risk factor
for polymyxin-only susceptible Acinetobacter
baumannii bacteraemia
P. Kopterides, P. Koletsi, P. Morfou, K. Rellos,
Z. Mastora, M. Rizos, M. Falagas (Athens, GR)
P1358 Multiresistant strains of Escherichia coli
isolated from dogs
M. Totaro, M. Corrente, A.L. Bellacicco, V. Martella,
G. Greco, C. Buonavoglia (Valenzano, IT)
P1359 Clonal diversity and distribution of tetracycline
resistance genes among E. coli strains
isolated from aquatic environments
R. Cernat, V. Lazar, M.C. Balotescu (Bucharest, RO)
P1360 Laboratory identification and transmission of
Burkholderia cepacia and Stenotrophomonas
maltophilia in an intensive care unit
W. Pfister, W. Barclay, F. Gerlach, E. Straube
(Jena, DE)

Poster Sessions Monday, April 3, 2006
P1361 Is Stenotrophomonas maltophilia an
emerging pathogen in German ICUs?
E. Meyer, F. Schwab, P. Gastmeier, H. Ruden,
F. Daschner, D. Jonas
(Freiburg, Berlin, Hannover, DE)
P1362 Achromobacter xylosoxidans from the airway
secretions of patients with cystic fibrosis
H. Alexandrou-Athanasoulis, S. Doudounakis,
A. Sergounioti, K. Halmouki, A. Pangalis
(Athens, GR)
P1363 Genotypic and phenotypic analysis of
Pseudomonas aeruginosa isolates from
sputum of patients with cystic fibrosis
following antimicrobial treatment
O. Perovic, E. Marais, A. Duse, M. Mer,
G. Richards, O. Perovic (Johannesburg, ZA)
P1364 Genodiversity of resistant P. aeruginosa in
ICUs varies in relation to antimicrobial usage
and resistance rates
D. Jonas, E. Meyer, F. Schwab, B. Spitzmüller,
F. Daschner, H. Grundmann
(Freiburg, Berlin, DE; Bilthoven, NL)
P1365 Relationship between prior antibiotic
exposure and multidrug-resistant
Pseudomonas aeruginosa
T.P. Lodise, N. Patel, J. Graves, B.M. Lomaestro
(Albany, US)
P1366 Multiresistant Pseudomonas aeruginosa
outbreak caused by multiple sources and
strains
C. Petignat, I. Federli, G. Zanetti, A. Wenger,
J. Bille, P. Francioli, D.S. Blanc (Lausanne, CH)
P1367 Nosocomial Acinetobacter baumannii
vs. Klebsiella pneumoniae bloodstream
infections: risk factors and outcomes
M. Paul, E. Robenstock, A. Fraser, L. Leibovici,
S. Perez, S. Pitlik, I. Ostfeld, Z. Samra,
M. Weinberger (Petah Tikva, IL)
P1368 Neurosurgical meningitis due to
Acinetobacter baumannii: comparasion
between different treatments
A. Rodríguez-Guardado, A. Blanco, J. Torres,
V. Asensi, V. Pintado, F. Pérez, M. Lantero,
E. Bustillo, J. Maradona, J. Cartón
(Oviedo, Madrid, ES)
P1369 Clinical epidemiology of biofilm production in
Acinetobacter baumannii clinical isolates
J. Rodríguez-Bano, S. Martí, S. Soto,
J.M. Cisneros, J. Pachón, A. Pascual,
L. Martínez-Martínez, J. Vila on behalf of the GEIH
P1370 Dissemination of tetracycline and
chloramphenicol resistance genes in
Portuguese Salmonella isolates carrying
class 1 integrons
P. Antunes, J. Machado, L. Peixe
(Porto, Lisbon, PT)
P1371 Epidemiological types and integrons in
multidrug-resistant Acinetobacter baumannii
strains from intensive care units in Rome,
Italy
S. D’Arezzo, A. Capone, N. Petrosillo, P. Visca
on behalf of Gruppo Romano Acinetobacter
baumannii (GRAB)
P1372 Ward investigation after hospitalising a
case with pandrug-resistant Acinetobacter
baumannii infection
Y-H. Huang, Y-C. Huang, C-H. Lin, L-H. Su,
C-T. Wu (Kweishan, Taoyuan, TW)
13:00–14:00
Epidemiology of resistance to antibiotics – I
P1373 Increase of resistant Enterobacter isolates
and correlation with antibiotic consumption
at the ward level
P. Haller, S. Tschudin, M. Dangel, M. Simcock,
R. Frei, H. Plagge, A.F. Widmer, M. Battegay,
U. Fluckiger, S. Bassetti for the Multidisciplinary
Antimicrobial Group, University Hospital Basel, CH
P1374 Risk factors for carbapenem-resistant
Pseudomonas aeruginosa among patients
with respiratory tract infections
N. Patel, T.P. Lodise (Albany, US)
P1375 Risk factors associated with S. pneumoniae
multiple resistance in Belgium over a 10-year
period
J. Van Eldere, R.M. Mera, L.A. Miller, J. Verhaegen,
J.A. Poupard (Leuven, BE; New Orleans,
Upper Providence, Philidelphia, US)
P1376 Association between antimicrobial resistance
and virulence in Escherichia coli blood and
faeces isolates from humans in Denmark
L. Bagger-Skjøt, D. Sandvang, C.H. Lester,
L.J. Porsbo, D.L. Monnet, N. Frimodt-Møller,
A.M. Hammerum
(Copenhagen, Bagsværd, Søborg, DK)
www.escmid.org/eccmid2006
page 119

Poster Sessions Monday, April 3, 2006
P1377 Antimicrobial resistance surveillance in
2004 in Korea: further increase of
vancomycin-resistant Enterococcus faecium,
expanded-spectrum beta-lactam-resistant
Klebsiella pneumoniae and imipenemresistant
Pseudomonas aeruginosa and
Acinetobacter spp.
K. Lee, C.H. Rhim, J.H. Cho, W.G. Lee,
Y. Uh, H.J. Kim, D. Yong, Y. Chong
for the KONSAR Group (Seoul, Korea)
P1378 Prevalence of antibiotic resistance and
antibiotic resistance genes among
Enterococcus faecium from pigs and poultry
in the United Kingdom
V.I. Enne, E. Pleydell, P.M. Bennett
(Bristol, Weybridge, UK)
P1379 Antibiotic susceptibility of bacteria isolated
from hospitalised patients in Mauritius
M.I. Issack (Quatre-Bornes, MU)
P1380 Antimicrobial resistance patterns in
14 neonatal intensive care units in Bogota,
Colombia 2001–2004
G. Buitrago, G.A. Contreras, A.L. Leal,
C.A. Alvarez, Grupo para el Control de la
Resistencia Bacteriana de Bogotá (GREBO)
P1381 Integrating susceptibility data from two
surveillance programmes with unique
methodological techniques: the Antibiogram
Resistance Method Or isolate-based
Resistance monitoring (ARMOR) study
B. Epstein, J. Gums, P. Turner, for the
Antibiogram Resistance Method Or isolate-based
Resistance Monitoring (ARMOR) Study Group
P1382 Antimicrobial resistance of major Gramnegative
bacterial pathogens during a
7-year period
A. Slavcovici, M. Lupse, M. Flonta, V. Zanc,
D. Tatulescu, A. Almas, D. Carstina
(Cluj-Napoca, RO)
P1383 Serious developments of antimicrobial
resistance in Europe: results from EARSS
(European Antimicrobial Resistance
Surveillance System)
N. Bruinsma, M.E.A. de Kraker, G. Kahlmeter,
G. Cornaglia, F. Baquero, J. Monen, H. Grundmann
and EARSS participants
P1384 Stenotrophomonas maltophilia surveillance
in a Greek tertiary care hospital
K. Koraki, P. Karapavlidou, D. Sofianou
(Thessaloniki, GR)
page 120 Final Programme
P1385 Activity of ertapenem and tigecycline against
recent isolates from community-acquired
lower respiratory infections in the UK and
Ireland
R. Reynolds, D. Felmingham, BSAC Working
Party on Respiratory Resistance Surveillance
P1386 Trends in resistance of bacteraemia isolates in
the UK and Ireland and current activity of
ceftobiprole
R. Reynolds, R. Hope, BSAC Working Party on
Bacteraemia Resistance Surveillance
P1387 Eight years of Belgian MYSTIC surveillance:
1998–2005
M. Ieven, M. Delmee, P. De Mol, H. Goossens,
Y. Glupczynski, D. Pierard, M. Struelens,
J. Verhaegen, G. Verschraegen (Edegem, Brussels,
Liège, Yvoir, Leuven, Ghent, BE)
P1388 Resistance of Streptococcus pneumoniae
nasopharyngeal isolates from children in
selected Russian orphanages: 2003 vs. 2004
R.S. Kozlov, O.U. Stetsiouk, J.A. Poupard,
L.S. Stratchounski (Smolensk, RU; Philadelphia, US)
P1389 Geographical and temporal analysis of the
changes in S. pneumoniae multiple resistance
to antibiotics in Belgium over a 10-year period
R.M. Mera, J. Van Eldere, L.A. Miller, J.A. Poupard,
J. Verhaegen (New Orleans, US; Leuven, BE;
Upper Providence, Philadelphia, US)
P1390 Selection and characterisation of biocide
resistant Salmonella enterica serovar
Typhimurium
M. Webber, M. Woodward, L.J.V. Piddock
(Birmingham, Weybridge, UK)
P1391 Polymyxin B resistance in multidrug-resistant
Pseudomonas aeruginosa
J.L. Sampaio, C. Mendes, S.I. Sinto, P.C. Koga,
A.C. Arruda, C. Kiffer (Sao Paulo, BR)
P1392 Antibiotic resistance does not impede
persistence of Escherichia coli in the infantile
intestinal microbiota
N. Karami, E. Lindberg, A. Wold, I. Adlerberth,
F.L. Nowrouzian (Göteborg, SE)
P1393 Evaluation of daptomycin and other
anti-staphylococcal antibiotics against clinical
strains of community- and hospital-derived
MRSA
M. Rybak, M. Amjad, C. Cheung, K. Lau, G. Kaatz
(Detroit, US)

Poster Sessions Monday, April 3, 2006
P1394 Susceptibility of recent European
Gram-positive bacteria to daptomycin
C. Soussy, J. Bille, R. Cantón, A. MacGowan,
C.E. Nord, G. Schito, H. Seifert, M. Struelens,
J. Verhoef, I. Morrissey (Creteil, FR; Lausanne,
CH; Madrid, ES; Bristol, UK; Stockholm, SE;
Genoa, IT; Cologne, DE; Brussels, BE; Utrecht, NL;
London, UK)
P1395 Exposure of Staphylococcus aureus isolates
to daptomycin (DA) alone or DA plus
vancomycin (VA) leads to a diminished
macrophage inflammatory response
(compared with VA alone)
B. English, E. Maryniw, A. Talati, E. Meals
(Memphis, US)
P1396 Further increase of fluoroquinolone resistance
among Escherichia coli isolates in a Central
European area
M. Kresken, D. Hafner on behalf of the Working
Group for Antimicrobial Resistance of the
Paul-Ehrlich-Society for Chemotherapy
P1397 Risk factors for invasive infection with
fluoroquinolone-resistant S. pneumoniae and
failure of oral outpatient fluoroquinolone
therapy
K. Green, A. McGeer, D.E. Low, for the Toronto
Invasive Bacterial Diseases Network (TIBDN)
P1398 Mechanisms of resistance to quinolones in
Shigella spp. causing traveller’s diarrhoea
L. Mensa, E. Mendez Arancibia, M. Navia,
F. Marco, J. Vila, J. Gascón, J. Ruiz (Barcelona, ES)
P1399 Emergence of high-level fluoroquinoloneresistance
in clinical isolates of group G
streptococci
G. Brigante, F. Luzzaro, A. Bettaccini, G. Lombardi,
B. Pini, G. Sokeng, A. Toniolo (Varese, IT)
P1400 Comparative analysis of levofloxacin and
ciprofloxacin activity against Gram-negative
pathogens collected in five European
countries grouped by site of infection, from
GLOBAL Surveillance Study – 2005
M. Jones, D. Draghi, D. Sahm, C. Thornsberry
(Plaisir, FR; Herndon, US)
P1401 European surveillance study on the in vitro
susceptibility of clinical bacterial isolates to
telavancin
W. Jansen, A. Verel, A. Fleer, J. Verhoef,
D. Milatovic (Utrecht, NL)
P1402 Molecular epidemiology of invasive high-level
gentamicin resistance Enterococcus faecium
isolates in Denmark
C.H. Lester, D. Sandvang, H.C. Schønheyder,
J.O. Jarløv, D.S. Hansen, T.G. Jensen,
N. Frimodt-Møller, A.M. Hammerum
(Copenhagen, Bagsværd, Aalborg, Hillerød,
Odense, DK)
13:00–14:00
Beta-lactamases
P1403 CTX-M extended spectrum beta-lactamases in
community-acquired infections caused by
Escherichia coli in the North West of Spain,
Pontevedra, Galicia
P. Álvarez, M. Álvarez, C. García-Riestra, V. Pulian,
M. Hernández, M. García (Pontevedra, Vigo,
Santiago de Compostela, ES)
P1404 Five-year evaluation of clonal dissemination
and expansion of VIM-1 producing
Enterobacteriaceae in Greece: a report from
the SENTRY Antimicrobial Surveillance
Program (2001–2005)
L. Deshpande, N. Legakis, R. Jones, H. Sader
(North Liberty, US)
P1405 VIM-1 producing Enterobacter cloacae strains
from Madrid, Spain: report from the SENTRY
Antimicrobial Surveillance Program 2005
L. Deshpande, H. Sader, M. Tato, F. Baquero,
R. Jones, R. Cantón (North Liberty, US)
P1406 Occurrence and prevalence of CTX-M type
beta-lactamases in Gram-negative bacteria
from tertiary care hospital, North India
M. Shahid, V.M. Ensor, P.M. Hawkey
(Aligarh, IN; Birmingham, UK)
P1407 Characterisation of class 1 integrons carrying
the genes for VIM- and IMP-type metallobeta-lactamases
in Pseudomonas aeruginosa
strains from Russia
O. Shevchenko, M. Edelstein, V. Kretchikov,
L. Stratchounski (Smolensk, RU)
P1408 Prevalence of AmpC over-expression in bloodstream
isolates of Pseudomonas aeruginosa
V.H. Tam, A.N. Schilling, M.T. LaRocco, L.O. Gentry,
K. Lolans, J.P. Quinn, D.A. Melnick, K.W. Garey
(Houston, Chicago, Wilmington, US)
P1409 Characterisation of ESBL producing
salmonellae isolated in Hungary in
2000–2004
N. Nógrády, Á. Tóth, J. Pászti, M. Füzi
(Budapest, HU)
www.escmid.org/eccmid2006
page 121

Poster Sessions Monday, April 3, 2006
P1410 Phenotypic and genotypic identification of
metallo-beta-lactamases in Pseudomonas
aeruginosa in a university hospital, Ankara,
Turkey
A. Cakar, B. Sener, G. Hascelik (Ankara, TR)
P1411 Prevalence of CTX-M producing bacteria in
Ireland
D. Morris, M. McManus, C. Slater, V. Buckley,
L.E. Fenelon, G. Corbett-Feeney, M. Cormican
(Galway, Dublin, IE)
P1412 Widespread dissemination of blaOXA-51-like
among carbapenem-resistant Acinetobacter
spp. isolates in Brazil
D.E. Xavier, A.C. Gales, A.S. Pereira,
A.C.C. Pignatari, M. Castanheira (Sao Paulo, BR)
P1413 Genetic analysis of metallo-beta-lactamase
producing Klebsiella pneumoniae and
Pseudomonas aeruginosa isolates in the
intensive care unit of a university general
hospital in Greece
E. Koratzanis, I. Galani, M. Souli, Z. Chryssouli,
H. Giamarellou (Chaidari, GR)
P1414 Detection of extended-spectrum betalactamases
in E. coli and Klebsiella spp.
by isoelectric focusing and PCR
L. Oksuz, N. Gurler (Istanbul, TR)
P1415 Molecular characterisation of Enterobacte -
riaceae producing CTX-M-1-like ESBL
(CTX-M-1, -3, -15, and -32) in Madrid, Spain
(2000–2004)
A. Novais, R. Cantón, R. Moreira, F. Baquero,
T.M. Coque (Madrid, ES)
P1416 Repeated occurrence of extended-spectrum
beta-lactamase CTX-M-9 in Salmonella
enterica, serotype Virchow, isolated in Spain
from 2002 to 2005
S. Herrera, R. Ramiro, R. Gonzalez-Sanz,
S. Valdezate, R. Diez, A. Aladueña, M.A. Echeita
(Majadahonda. Madrid, ES)
P1417 High clonal and plasmid diversity of CTX-
M-14 and SHV-12 producing isolates in the
community (Madrid, Spain)
A. Valverde, T.M. Coque, A. Novais, J.C. Galán,
F. Baquero, R. Cantón (Madrid, ES)
P1418 Dissemination of acquired metallo-betalactamases
in Gram-negative pathogens:
first Italian countrywide survey
L. Pagani, F. Luzzaro, C. Mugnaioli, M. Spalla,
F. De Luca, M. Perilli, G. Babini, G. Gesu,
G. Amicosante, A. Toniolo, G.M. Rossolini
(Pavia, Varese, Siena, L’Aquila, Milan, IT;
Erembodegem, BE)
page 122 Final Programme
P1419 Phenotypic and molecular detection of
metallo-beta-lactamases in imipenemresistant
Pseudomonas aeruginosa in a
hospital centre, Coimbra, Portugal
A. Pena, A.F. Alves, R.M. Leitão, O.M. Cardoso
(Coimbra, PT)
P1420 Prevalence and molecular characterisation of
beta-lactamases in Gram-negative rods
isolated from oral flora
V. Toussaint, C. Voha, I. Madinier, T. Fosse
(Nice, FR)
13:00–14:00
Non-molecular diagnostics of MRSA
P1421 Implementation of BBL CHROMagar
orientation for routine urine cultures in a
high-volume clinical laboratory
S. Whittier, P. Della-Latta (New York, US)
P1422 Evaluation of chromogenic Biomérieux
MRSA ID medium for direct detection of
methicillin-resistant Staphylococcus aureus
from surveillance cultures and from clinical
samples
C. Sánchez-Carrillo, E. Cercenado, M. Marín,
J. Jensen, M. Guembe, M. Rivera, E. Bouza
(Madrid, ES)
P1423 Comparative evaluation of the chromogenic
MRSA ID media with standard procedure for
screening of methicillin-resistant Staphylococcus
aureus carriers and detection of highlevel
resistance to mupirocin by disk diffusion
I. Mansoor, J. Brouillard, S. Cannoot, C. Ducastel
(Baudour, Ath, BE)
P1424 Direct identification and methicillin
susceptibility of Staphylococcus aureus from
blood-culture bottles using the Vitek 2 system
C. Flórez, E. López-Oviedo, C. Martín, J. Cabezas,
D. Morilla, E. Martín-Mazuelos (Seville, ES)
P1425 Evaluation of BBL CHROMagar MRSA
medium to detect methicillin-resistant
Staphylococcus aureus
B.M.W. Diederen, M. van Leest, I. van Duijn,
P. Willemse, P.H.J. van Keulen, J.A.J.W. Kluytmans
(Tilburg, Breda, NL)
P1426 Evaluation of MRSASelect medium to detect
methicillin-resistant Staphylococcus aureus
B.M.W. Diederen, M. van Leest, I. van Duijn,
P. Willemse, P.H.J. van Keulen, J.A.J.W. Kluytmans
(Tilburg, Breda, NL)

Poster Sessions Monday, April 3, 2006
P1427 Detection of nasal carriage of Staphylococcus
aureus and methicillin-resistant Staphylo -
coccus aureus in general population with a
new chromogenic medium: MRSA ID agar
P. Ciragil, M. Gul, M. Aral, S. Alkis
(Kahramanmaras, TR)
P1428 Evaluation of Bio-Rad MRSA-Select for the
detection of methicillin-resistant Staphylo -
coccus aureus
L. Louie, D. Soares, H. Gardner, H. Meaney,
M. Vearncombe, A. Simor (Toronto, Ontario, CA)
P1429 Rapid detection of methicillin-sensitive and
resistant Staphylococcus aureus direct from
blood cultures
J. Montgomery, J. Bywater, B. Mayall
(Melbourne, AU)
P1430 Optimisation of screening for methicillinresistant
Staphylococcus aureus by using the
chromogenic medium MRSA ID
M.J. Bruins, M.J. Egbers, G.J.H.M. Ruijs,
M.J.H.M. Wolfhagen (Zwolle, NL)
P1431 Comparison of four commercial media for the
detection of MRSA carriage from nasal and
perineal specimens
L. Stoakes, R. Reyes, J. Daniel, G. Lennox, M. John,
R. Lannigan, Z. Hussain (London/Ontario, CA)
13:00–14:00
Antibiotic susceptibility testing: management,
specific organisms and resistant traits
P1432 External quality assessment for antimicrobial
susceptibility testing with ESBL-producing
Enterobacteriaceae
C. Walton, D. Brown (London, Cambridge, UK)
P1433 Analysis of the comparative workflow and
accuracy of two automated identification and
susceptibility testing systems
Y. Gil, M.G. García, B. Barreda, J.L. Gómez-Garcés
(Madrid, ES)
P1434 A rapid DNA-based assay to detect
M. tuberculosis resistance
S. Nikolaou, S. Anagnostou, A. Raftopoulou,
F. Kontos, S. Karabela, S. Kanavaki (Athens, GR)
P1435 Use of 2, 3, 5- triphenyl tetrazolium
chloride for detection of drug resistance in
Mycobacterium tuberculosis
J. Ghanaat, K. Ghazvini, T. Rashed, P. Farnia,
A. Mohammadzadeh, M. Behdani (Mashhad, IR)
P1436 Direct E-test on lower respiratory tract
samples: improving antimicrobial use in
ventilator-associated pneumonia
E. Bouza, M.V. Torres, C. Radice, E. Cercenado,
P. Muñoz, R. de Diego, C. Sanchez (Madrid, ES)
P1437 Piperacillin/sulbactam: determination of zone
diameter interpretive criteria using the new
DIN recommendations
H. Grimm, W. Heizmann, H. Kruepe, A. Rodloff
(Weingarten, Berlin, Fulda, Leipzig, DE)
P1438 The culture and antibiotic sensitivity testing
of pathogenic micro-organisms on a highly
porous ceramic
C. Ingham, P. Wever, P. Schneeberger
(Den Bosch, NL)
P1439 Susceptibility pattern and toxigenicity of
Clostidium difficile strains isolated from
patients with diarrhoea in a tertiary hospital
in Athens
M. Orfanidou, H. Kafkoula-Alevizou, P. Karabogia-
Karafillidis, E. Kontekaki, M. Theodoropoulos,
A. Strouza, H. Malamou-Lada (Athens, GR)
P1440 Comparison of dalbavancin MIC values tested
against Gram-positive organisms using Etest
(AB BIODISK) and reference dilution methods
T. Fritsche, H. Sader, R. Jones, B. Goldstein
(North Liberty, US)
P1441 Evaluation of daptomycin 5, 10 and 15 mcg
disks on IsoSensitest and Mueller Hinton agar
against Staphylococcus aureus
L. Koeth, R. Smyth, G. Kahlmeter
(Westlake, US; Vaxjo, SE)
P1442 Evaluation of effect of low concentrations of
calcium in daptomycin 30 mcg disks on
IsoSensitest agar against Staphylococcus
L. Koeth, R. Smyth, G. Kahlmeter
(Westlake, US; Vaxjo, SE)
P1443 Evaluation of Cefoxitin Disk for detection of
methicillin-resistant Staphylococcus aureus
M. Rahbar, S. Moulanaee, P. Islami, R. Atifeh,
K. Pirayesh (Tehran, IR)
P1444 Estimating methicillin resistance in
staphylococcus hospital strains: a comparison
between Kirby-Bauer disc diffusion
antibiogram and PBP2a detection with latex
A. Ksanthos, V. Kafarakis, E. Christoforaki,
A. Vittoraki, D. Drygiannakis
(Rethymnon, Crete, GR)
www.escmid.org/eccmid2006
page 123

Poster Sessions Monday, April 3, 2006
P1445 Detection of methicillin resistance in
Staphylococcus aureus clinical isolates by
phenotypic methods and PCR amplification
of mecA gene
M.A. El-Sweify, M.F. Ahmed Fahmy Ali,
A.A. Heiba, G.I. Gebreel (Ismailiya, EG)
P1446 Evaluation of diagnostic methods for
detecting methicillin-resistant Staphylo -
coccus aureus strains in clinical microbiology
laboratories in Finland
A. Virolainen, A. Nissinen, A-M. Kerttula,
J. Vuopio-Varkila and the Finnish Study Group
for Antimicrobial Resistance
P1447 Efficacy of practised screening methods
for selection of cephalosporin-resistant
Enterobacteriaceae
R. Hope, N.A.C. Potz, M. Warner,
D.M. Livermore (London, UK)
P1448 Accurate and rapid antbiotic susceptibility
testing of Haemophilus influenzae by flow
cytometry
M. O’Donoghue, W.L. Pong, M.V. Boost
(Hong Kong, HK)
P1449 Detection of Helicobacter pylori and
clarithromycin resistance by real-time PCR in
children
Y. Akyön, S. Tuncer, H. Demir, M. Misirlioglu,
Y. Usta (Ankara, TR)
P1450 Comparison of E-test, disc-diffusion
and Phoenix for antibiotic susceptibility
assessment of Stenotrophomonas
maltophilia strains
M. Mentasti, P. Morelli, G. Manno (Genoa, IT)
P1451 Prospective evaluation of imipenem/EDTA
combined disk and E-test for detection of
MBL producing Pseudomonas aeruginosa
L. Bergès, A. Deplano, H. Rodriguez-Villalobos,
A. Mazzariol, M.J. Struelens
(Anderlecht, BE; Verona, IT)
P1452 Phenotypic detection of metallo-betalactamases
and extended-spectrum betalactamases
among Gram-negative bacterial
clinical isolates
N. Fam, M. Diab, H. Gomaa, I. El-Defrawy
(Giza, EG)
P1453 Reliability of carbapenem resistance in
Pseudomonas spp. detected by automated
systems
O. Karatuna, G. Soyletir (Istanbul, TR)
page 124 Final Programme
P1454 Detection of extended spectrum beta-lactamases
in Enterobacteriaceae strains using
four different methods in a Tunisian paediatric
hospital
N.E. Jlili, H. Smaoui, S. Rejiba, A. Kechrid
(Tunis, TN)
P1455 The reliability of in vitro susceptibility tests
for multiresistant Pseudomonas aeruginosa
isolates
B. Sener, S. Ak, G. Hascelik (Ankara, TR)
P1456 Performance of cefoxitin in phenotypic
susceptibility testing of cMRSA, ST80, and
hMRSA,ST45
C. Cuny, W. Witte (Wernigerode, DE)
P1457 Phenotypic characterisation of heterogeneous
methicillin-susceptible Staphylococcus aureus
correlates to patient outcome
V. Huang, M. Perri, D. Vager, M. Zervos
(Atlanta, Detroit, US)
P1458 Decreased susceptibility to glycopeptides in
methicillin-resistant Staphylococcus aureus:
a 20-year study in a large French teaching
hospital, 1983–2002
J. Robert, R. Bismuth, V. Jarlier (Paris, FR)
P1459 Trends in resistance to some antibiotics in
selected bacterial species – S. aureus,
S. pneumoniae, E. faecalis, E. faecium –
causing invasive infections in the Czech
Republic in 2000–2004
B. Mackova (Prague, CZ)

Poster Sessions Tuesday, April 4, 2006
12:00–13:00
Antibiotic prescribing – quality indicators
P1460 Is self-medication with antibiotics in Europe
driven by prescribed use?
L. Grigoryan, F.M. Haaijer-Ruskamp,
J.G.M. Burgerhof, J.E. Degener, R. Deschepper,
D. Monnet, A. Di Matteo, E.A. Scicluna, A. Bara,
C. Stålsby Lundborg, J. Birkin and the SAR group
P1461 Adjustment of antibiotic treatment according
to the results of blood cultures leads to
decreased antibiotic use and costs
D. Berild, A. Mohseni, L.M. Diep, M. Jensenius,
S.H. Ringertz (Oslo, NO)
P1462 Impact of an active surveillance system on
antimicrobial use and resistance in a neurosurgical
intensive care unit
E. Meyer, J. Buttler, F. Schwab, E. Strehl,
P. Gastmeier, H. Ruden, K. de With, J. Zentner,
F. Daschner (Freiburg, Berlin, Hannover, DE)
P1463 Similar illness burden but different antibiotic
prescription to children: a population-based
study
K. Hedin, M. Andre, A. Håkansson, N. Rodhe,
S. Mölstad, C. Petersson (Växjö, Falun, Malmö,
Linköping, SE)
P1464 Decreasing outpatient antibiotic prescribing
in Germany, 1995-2004, does not include
newer macrolides, fluoroquinolones and
extended-spectrum beta-lactams
W.V. Kern, K. de With, K. Nink, H. Schröder
(Freiburg, Bonn, DE)
P1465 Severe community-acquired pneumonia
admitted to the intensive care unit: impact of
antibiotic therapy delay on hospital mortality
P.F. Laterre, T. Dugernier, X. Wittebole,
C. Collienne, M.N. France, R. Wunderink
(Brussels, BE; Chicago, US)
P1466 Antibiotics cycling in the intensive care unit:
next stage – cefoperazone/sulbactam
D. Protsenko, S. Yakovlev, B. Gelfand,
O. Romashov, A. Yaroshetskiy, O. Ignatenko
(Moscow, RU)
P1467 Antibiotic consumption in German acute care
hospitals
M. Steib-Bauert, K. de With, E. Meyer, P. Straach,
W.V. Kern (Freiburg, Frankfurt, DE)
P1468 Impact of formulary change in medical
intensive care unit on outcome of infection
and antimicrobial resistance
V. Huang, J. Jinson, M. Zervos (Atlanta, Detroit, US)
P1469 Intravenous antibiotic use in Scottish
hospitals; evaluation of the Glasgow
antimicrobial audit tool
R.A. Seaton, D. Nathwani, P. Burton, E. Douglas
(Glasgow, Dundee, UK)
P1470 Use of glycopeptides in 47 French hospitals
A.M. Rogues, C. Dumartin, H. Boulestreau,
P. Parneix, N. Marty, J.P. Gachie
(Bordeaux, Toulouse, FR)
P1471 Antibiotic management of acute lower
respiratory tract infections among Dutch
elderly patients in primary care
J. Bont, C. Birkhoff, T. Verheij, E. Hak
on behalf of ESPRIT
P1472 Prospective evaluation of consultations
performed by infectious diseases trainees
O. Sipahi, M. Tasbakan, H. Pullukcu, B. Arda,
T. Yamazhan, S. Mizrakci, S. Senol, S. Atalay,
D. Koseli, G. Arsu, S. Calik, H. Sipahi, C. Buke,
S. Ulusoy (Izmir, TR)
P1473 Study of the influence of online practice
guidelines on the appropriateness of antibiotic
prescribing in a university-affiliated
psychiatric hospital
J.F. Westphal, C. Nonnenmacher, D. Gregoire,
M. Hittinger, C. Oulerich, F. Jehl
(Brumath, Strasbourg, FR)
P1474 Pilot implementation of multidisciplinary
antibiotic management teams in Belgian
hospitals: two-year progress report, 2003–04
L. Sourdeau, M.J. Struelens, W.E. Peetermans,
C. Suetens, M. Costers for the Hospital Care
Working Group of Belgium Antibiotic Policy
Coordination Committee
P1475 Antibiotic prescribing practices at two linked
London teaching hospitals
P. Panesar, G. Scott, P. Wilson, C. Kibbler,
I. Balakrishnan (London, UK)
P1476 Comparison of different antibiotic
consumption measurement methods
in large multi disciplinary hospital
E. Pujate, I. Apine, U. Dumpis (Riga, LV)
P1477 A study of prescribing patterns and errors of
antibiotics in a Saudi hospital
M. Al-Jamal, M. Al-Barrak (Riyadh, SA)
P1478 Effect of a policy for restriction of selected
classes of antibiotics on antimicrobial drug
cost and resistance
M. Falagas, I. Bliziotis, A. Michalopoulos,
G. Sermaides, V. Papaioannou, D. Nikita,
N. Choulis (Athens, GR)
www.escmid.org/eccmid2006
page 125

Poster Sessions Tuesday, April 4, 2006
P1479 Estimating hospital versus ambulatory care
consumption of antibiotics in southwestern
Germany
K. de With, M. Steib-Bauert, H. Schröder, K. Nink,
W.V. Kern (Freiburg, Bonn, DE)
P1480 Antibiotic use profile and temporal trends
during a 5-year period at a Greek university
hospital: implications for antibiotic policy
changes
E.I. Kritsotakis, P. Assithianakis, P. Kanellos,
N. Tzagarakis, M.C. Ioannides, A. Gikas
(Heraklion, GR)
P1481 Appropriate use of aminoglycosides:
the impact of an antibiotic control team
C. Rioux, P. Lesprit, J.R. Zahar, A. Hulin,
A. Bernier-Combes, C. Brun-Buisson, E. Girou
(Créteil, Paris, FR)
P1482 Hospital antibiotic consumption in southern
and eastern Mediterranean countries:
preliminary results from the ARMed project
P. Zarb, M.A. Borg, H. Goossens, M. Ferech
for the ARMed Participants
P1483 Russian pharmacoepidemiology study of the
antibiotic prescription during pregnancy
V. Rafalskiy, R. Tchilova, A. Ischenko, I. Toropova,
I. Nedorezenyuk, E. Maneeva, O. Suplotova,
N. Antonovitch, N. Shevchenko
(Smolensk, Moscow, Yakutsk, Vladivostok,
Barnaul, Krasnodar, RU)
P1484 Curbing pneumococcal resistance in
orphanages: interventions on the basis of
prospective surveillance of nasopharyngeal
isolates
O.U. Stetsiouk, R.S. Kozlov, J.A. Poupard,
L.S. Stratchounski (Smolensk, RU; Philadelphia, US)
P1485 Antibiotic consumption in ambulatory care in
Latvia, 2004
S. Berzina, M. Ferech, G. Ozolins, H. Goossens
(Riga, LV; Antwerp, BE)
P1486 Trends in glycopeptide antibiotics consumption
over a six-year period in a general
hospital, Athens, Greece
C. Loupa, G. Kouppari, H. Papadaki,
E. Divari-Katsiki, I. Koti, K. Papaefstathiou,
M. Tsimoraga, A. Karaitianou, M. Zoumberi,
M. Lelekis (Athens, GR)
P1487 An audit of linezolid use in a university
teaching hospital, Galway, Ireland
S. Mcnicholas, A. Barber, G. Corbett-Feeney,
M. Cormican (Galway, IE)
page 126 Final Programme
12:00–13:00
Professional and public health issues
P1488 The future of clinical microbiology in Belgium
W. Laffut, J. Van Eldere (Lier, Leuven, BE)
P1489 Analysis of 6871 infectious disease
consultations
Y. Wiener-Well, Y. Schlesinger, D. Raveh,
A.M. Yinnon (Jerusalem, IL)
P1490 Bridging the gap between health care and
public health; capacity building in infectious
disease control
J. Doosje, M. Jambroes, A. Timen,
J. van Steenbergen, V. van Casteren
(Utrecht, Bilthoven, NL; Brussels, BE)
P1491 EUREGIO MRSA-net Twente/Münsterland:
fighting (CA-)MRSA international under
different cultural perspectives
F. Verhoeven, J.E.W.C. van Gemert-Pijnen,
M.G.R. Hendrix, A.W. Friedrich, M.F. Steehouder
(Enschede, NL; Munster, DE)
P1492 Prevention of rabies in Georgia
R. Tsiklauri (Tbilisi, GE)
12:00–13:00
Pharmacoeconomics and electronic resources
P1493 The expected economic burden of methicillinresistant
Staphylococcus aureus in complicated
skin and skin structure infections:
a modelling approach
A. Kuznik, R. Mallick, D. Weber
(Collegeville, Chapel Hill, US)
P1494 Treatment of complicated skin and skin
structure infections in the US: expected cost
differences between tigecycline and
vancomycin/aztreonam
R. Mallick, A. Kuznik, D. Weber
(Collegeville, Chapel Hill, US)
P1495 The economic impact of linezolid in the
treatment of skin and soft tissue MRSA
infections in Italy
M. Eandi, P. Dale, S. Sorensen, T. Baker,
M. Procaccini, S. Duttagupta (Turin, IT; London, UK;
Bethesda, US; Rome, IT; New York, US)
P1496 Outpatient and home parenteral antimicrobial
therapy for the treatment of cellulitis:
evaluation of efficacy and cost
H. Ziglam, R. Tilley, C. Wootton, J. Morrison,
D. Nathwani (Dundee, UK)

Poster Sessions Tuesday, April 4, 2006
P1497 Cost-effectiveness analysis of intravenous
moxifloxacin compared to levofloxacin in
hospitalised elderly patients with communityacquired
pneumonia
A. Lloyd, D. Battleman, S. Choudhri, A. John,
M. Kubin (London, UK; Arlington, West Haven,
Kenilworth, US; Wuppertal, DE)
P1498 Economic impact of invasive fungal infections
in ICU patients in a tertiary care hospital in
Switzerland
A. Imhof, W. Zingg, R. Laffer, C. Ruef (Zurich, CH)
P1499 Cost-effectiveness of voriconazole to
amphotericin B deoxycholate in early and
late treatment of invasive aspergillosis
R. Greene, J. Mauskopf, C. Roberts, T. Zyczynski,
H. Schlamm (Boston, Research Triangle Park,
New York, US)
P1500 A multi-centre comparison of nursing staff
time required for the preparation and
administration of liposomal amphotericin B
and amphotericin B deoxycholate to
voriconazole
E. Flynn, B.A. Oppenheim, P. Ribaud,
G. Barbabietola, V. Démarez, A. Marciniak,
C. Roberts, K. Barker (Auburn, New York, US;
Manchester, Sandwich, UK; Paris, Creteil, FR;
Foligno, IT)
P1501 Need of cost-effectiveness investigation
focused on diagnosis, management and
prevention of osteopenia and osteoporosis
in the setting of HIV disease treated with
HAART: when to act, how to act, which
patients are the first target of intervention
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
P1502 A comparative study on the cost of new
drugs in different therapeutic categories
M. Falagas, K. Fragoulis, G. Zouglakis, I. Karydis
(Athens, GR)
P1503 Usage and expenditure of 4f-quinolones in a
tertiary hospital in 2003 and 2004
T.A. Peppas, K. Malengou, N. Zachos,
D. Voutsinas, O. Kosmopoulou, N. Galanakis
(Piraeus, Athens, GR)
P1504 Usage and expenditure of antimicrobials in a
tertiary hospital in 2003 and 2004
T.A. Peppas, N. Zachos, K. Malengou,
O. Kosmopoulou, I.F. Hager, M. Savvala,
E. Dimitrakopoulou, N. Galanakis (Athens, GR)
P1505 Antibiotic utilisation in Croatia, 2004
D. Sˇtimac, I. Vukusˇic, J. Culig, Z. Sˇostar, S. Tomic
(Zagreb, HR)
P1506 A comparative analysis of prescriptions for
antibiotics issued by outpatient doctors in
urban areas in 1999 and 2005
W. Drzastwa, E. Drzastwa, W. Lukas, E. Mizgala,
G. Golczyk, H. Trzeciak (Zabrze, PL)
P1507 Internet guide on antimicrobial resistance
A. Sosa, F. Traub, S. Valovic, P. Chea (Boston, US)
P1508 An educational web portal on febrile
neutropenia: www.febrilnotropeni.net
H. Akan, M. Akova, T. Çalikoglu, K.H. Gülkesen
on behalf of the Turkish Febrile Neutropenia
Study Group
P1509 NeLI and NRIC survey: information needs of
infectious disease professionals
P. Kostkova, S. D’Souza, G. Madle, J. Mani-Saada,
S. Wiseman, A. Roy, J. Weinberg (London, UK)
P1510 Training in infection
S. D’Souza, P. Kostkova, F. Cooke, A. Holmes
(London, UK)
P1511 Research designs and statistical methods in
medical abstracts
M. Kompoti, M. Matsagoura, A. Koutsovasilis,
A. Koutsovasili, S. Drimis (Athens, GR)
12:00–13:00
Antimicrobial PK / PD
P1512 NXL103-oral streptogramin: a phase I,
double-blind, single escalating oral dose
study to evaluate safety, tolerability and
pharmacokinetics in healthy adult male
volunteers
M. Rangaraju, J. Rey, J. Hodgson
(Romainville, Vitry sur Seine, FR)
P1513 Correlation of vancomycin and daptomycin
susceptibility in Staphylococcus aureus
in reference to accessory gene regulator
polymorphism and function
W. Rose, M. Rybak, B. Tsuji, G. Kaatz,
G. Sakoulas (Detroit, New York, US)
P1514 Teicoplanin efficiently penetrates into the
rabbit infected vitreous but may enhance
expression of virulence factors at subinhibitory
concentrations
E. Forestier, F. Jehl, C. Gallion, R. Andres,
S. Bronner, L. Leininger, G. Prévost
(Strasbourg, FR)
www.escmid.org/eccmid2006
page 127

Poster Sessions Tuesday, April 4, 2006
P1515 Pharmacokinetics of temocillin in intensive
care patients and Monte Carlo simulations
to evaluate susceptible breakpoints
J.W. Mouton, R. DeJongh, V. Basma, P. Tulkens,
S. Carryn (Nijmegen, NL; Genk, Brussels, BE)
P1516 Tissue penetration and pharmacokinetics
of moxifloxacin in diabetic foot infections:
an interim analysis
J. Majcher-Peszynska, K. Karrasch, M. Saß,
R. Mundkowski, A. Gussmann, P. Kujath,
B. Ruf, W. Schareck, H. Koch, B. Drewelow
(Rostock, Bad Saarow, Lubeck, Leipzig,
Beeskow, DE)
P1517 Fluoquinolones effects on patient lymphocytes
during prolonged treatments
E. Bertazzoni Minelli, A. Benini, D. Doria,
P. Franceschetti, M.E. Fracasso (Verona, IT)
P1518 Penetration of ertapenem in human pancreas.
Results of a prospective clinical trial
S. Motamedi, M.H. Schoenberg (Munich, DE)
P1519 Bacterial strain-independent pharmacodynamics
of linezolid/doxycycline combinations
with Staphylococcus aureus: five-day simulations
using an in vitro dynamic model
M. Smirnova, I. Alferova, I. Lubenko, Y. Portnoy,
S. Zinner, A. Firsov (Moscow, RU; Cambridge, US)
P1520 Anti-staphylococcal effects of telavancin in an
in vitro dynamic model: impact of different
half-lives and initial concentrations
I. Lubenko, M. Smirnova, E. Strukova, S. Vostrov,
S. Zinner, A. Firsov (Moscow, RU; Cambridge, US)
P1521 Pharmacokinetics of amoxicillin in pregnant
women with pre-term premature rupture of
the membranes
A.E. Muller, J. DeJongh, P.M. Oostvogel,
R.A. Voskuyl, P.J. Dörr, M. Danhof, J.W. Mouton
(The Hague, Leiden, Nijmegen, NL)
P1522 Penetration of piperacillin and tazobactam in
severe acute pancreatitis
S. Foerster, E. Eckleben, U. Werner, E. Klar,
B. Drewelow, R. Wacke (Rostock, Wismar, DE)
P1523 PK/PD challenges of in vitro time-kill curves –
a new modelling approach
S. Schmidt, O. Burkhardt, W. Treyaprasert,
H. Derendorf (Gainesville, US; Bangkok, TH)
page 128 Final Programme
P1524 Pharmacodynamic profiling of ceftobiprole
for the treatment of complicated skin and
skin structure infections and nosocomial
pneumonia
T.P. Lodise, L. Ma, R. Pypstra, J. Kahn,
G.L. Drusano, G.L. Noel (Albany, Raritan, US;
Basel, CH)
P1525 Investigation of different levofloxacin
regimens in patients with acute complicated
urinary tract infections
P. Tenke, R. Benko (Budapest, Szeged, HU)
P1526 Penetration of linezolid into sternal bone
of patients undergoing routine cardiopulmonary
bypass surgery
S. Metallidis, N. Charokopos, E. Alexiadou,
A. Tsona, M. Chatzidimitriou, G. Lazaraki,
O. Vasilaki, J. Nikolaidis, G. Theodoridis,
P. Nikolaidis (Thessaloniki, GR)
P1527 The antibacterial effect of daptomycin,
teicoplanin and vancomycin against S. aureus
studied in an in vitro pharmacokinetic model
of infection
A. Noel, K. Bowker, A. MacGowan (Bristol, UK)
P1528 No effect of vitamin B6 co-administration
for the prevention of linezolid-induced
myelosuppression
D. Plachouras, E. Giannitsioti, F. Kontopidou,
S. Athanasia, S. Savanis, K. Pontikis,
A. Antonopoulou, A. Papadopoulos,
H. Giamarellou (Haidari, GR)
P1529 Therapeutic drug monitoring of colistin –
a seven-year review from a UK clinical
antibiotic assay service
K. Bowker, A. Noel, S. Tomaselli, A. MacGowan
(Bristol, UK)
P1530 Antibacterial effect of moxifloxacin and
ceftriaxone, first doses, on Streptococcus
pneumoniae studied in an in vitro model
K. Bowker, A. Noel, A. MacGowan (Bristol, UK)
P1531 Emergence of resistance in E. coli and Ent.
cloacae after exposure to ceftriaxone or
ertapenem in an in vitro model of infection
K. Bowker, A. Noel, A. MacGowan (Bristol, UK)
P1532 Comparative serum activity of telithromycin,
azithromycin, and amoxicillin/clavulanate
against aerobic and anaerobic respiratory
pathogens
G. Stein, S. Schooley, E.J.C. Goldstein, K. Tyrrell,
D.M. Citron (East Lansing, Santa Monica, US)

Poster Sessions Tuesday, April 4, 2006
P1533 Urinary bactericidal activity of levofloxacin
(750 mg) against fluoroquinolone-resistant
uropathogens
G. Stein, S. Schooley, D. Nicolau
(East Lansing, Hartford, US)
P1534 Meropenem and cloxacillin are active against
MRSA clinical isolates (including VISA) in
acidic broth and in THP-1 macrophages
S. Lemaire, F. Van Bambeke, P. Tulkens,
M.P. Leclercq, J. Coyette, Y. Glupczynski
(Brussels, Liège, Yvoir, BE)
P1535 Comparative activity of dalbavancin against
European Gram-positive isolates
I. Morrissey, C. Dencer, J.W.T. Dallow, J. Childers,
A. Brook, J. Cowan (London, UK)
P1536 Population pharmacokinetics of dalbavancin
and pharmacodynamic simulations of a weekly
regimen
J.A. Dowell, B.P. Goldstein, M. Buckwalter,
M. Stogniew, B. Damle (New York, US)
P1537 Distribution of radioactivity in bone and related
structures following administration of
[14C]-dalbavancin to New Zealand White
rabbits
E. Solon, J.W. Dowell, J. Lee, S.P. King, B. Damle
(Newark, New York, US)
P1538 Telavancin transmembrane clearance during
in vitro continuous venovenous hemofiltration
J.H. Patel, M.C. Grio, M.D. Churchwell,
J. Seroogy, S. Barriere, B.A. Mueller (Ann Arbor,
South San Francisco, US)
P1539 Telavancin pharmacokinetics during in vitro
continuous venovenous haemodialysis
J.H. Patel, M.C. Grio, M.D. Churchwell,
J. Seroogy, S. Barriere, B.A. Mueller
(Ann Arbor, South San Francisco, US)
P1540 Carbapenems – differences in their antibacterial
activity due to their protein binding
S. Schmidt, O. Burkhardt, S. Schubert, A. Dalhoff,
H. Derendorf (Gainesville, US; Kiel, DE)
P1541 Experimental pitfalls in protein binding
measurements
S. Schmidt, O. Burkhardt, M. Sahre, H. Derendorf
(Gainesville, US)
P1542 In vitro postantibiotic effect of faropenem on
penicillin-resistant Streptococcus pneumoniae
and beta-lactamase-producing Haemophilus
influenzae
C.L. Young, I.A. Critchley, U.A. Ochsner, N. Janjic
(Louisville, US)
P1543 Telavancin is more efficacious than
vancomycin in a murine model of
bacteraemic peritonitis induced by
methicillin-resistant Staphylococcus aureus
S. Hegde, N. Reyes, B. Benton, R. Skinner
(South San Francisco, US)
P1544 Proper use of carbapenems for blood-derived
clinical isolates of Pseudomonas aeruginosa
Y. Kobayashi (Tokyo, JP)
P1545 Penetration of moxifloxacin into normal and
infected subcutaneous tissue in patients with
spinal cord injury measured by microdialysis
J. Barth, D. Jäger, M. Müller, O. Burkhardt,
H. Derendorf (Halle, DE; Vienna, AT;
Gainesville, US)
P1546 Postantibiotic effect and postantibiotic subminumum
inhibitory concentration effects of
ciprofloxacin, levofloxacin and moxifloxacin
on Staphylococcus aureus and Pseudomonas
aeruginosa
I. Kaleli, M. Demir, N. Cevahir, E. Mete, U. Yildirim,
S. Tikvesli (Denizli, TR)
P1547 Lack of horizontal transmission of fluoroquinolone
resistance between S. mitis and
S. pneumoniae
S. Campbell, C. Howley, R.J. Davidson
(Halifax, CA)
P1548 Activity of ertapenem and metronidazole
against Bacteroides fragilis and Escherichia
coli in an in vitro pharmacokinetic/pharmacodynamic
model employing pure
and mixed cultures
R. Schaumann, C. Vorwerk, R. Habt, J. Forberg,
A. Rodloff (Leipzig, DE)
P1549 Penetration of ciprofloxacin into human
cerebrospinal fluid and brain tissue
A. Tsona, S. Metallidis, E. Koumentaki,
J. Nikolaidis, P. Kollaras, G. Lazaraki, P. Nikolaidis
(Thessaloniki, GR)
P1550 Pharmacodynamic comparison of three
carbapenems against extended-spectrum
beta-lactamase producing Escherichia
coli and Klebsiella spp. from the MYSTIC
Program in Brazil
C. Kiffer, C. Mendes, K.J. Eagye, J.L. Kuti,
D. Nicolau (Sao Paulo, BR; Hartford, US)
www.escmid.org/eccmid2006
page 129

Poster Sessions Tuesday, April 4, 2006
P1551 Activity of moxifloxacin, levofloxacin and
azithromycin physiological concentrations in
serum and epithelial lining fluid against in
vivo selected Streptococcus pneumoniae
mutants and its parental strain
D. Sevillano, L. Aguilar, L. Alou, M.J. Giménez,
F. Cafini, O. Echeverría, E. Pérez-Trallero, J. Prieto
(Madrid, San Sebastián, ES)
P1552 Effects of levofloxacin, ciprofloxacin and
azithromycin on the competitive growth of
Streptococcus pneumoniae, as a model
approach to selection of resistant populations
L. Alou, M.J. Giménez, D. Sevillano, L. Aguilar,
O. Echeverría, F. Cafini, E. Valero, A. Fenoll,
J. Prieto (Madrid, Majadahonda, ES)
P1553 Re-evaluation of the role of broad-spectrum
cephalosporins against staphylococci applying
contemporary in vitro results and pharmacokinetic-pharmacodynamic
principals
H. Sader, S.M. Bhavnani, P.G. Ambrose, R. Jones
(North Liberty, US)
P1554 Pharmacokinetic-pharmacodynamic modelling
of in vitro activity of azithromycin against
four different bacterial strains
W. Treyaprasert, U. Suvanakoot, H. Derendorf
(Bangkok, TH; Gainesville, US)
P1555 Dose optimisation of enrofloxacin for use in
chickens against Salmonella enterica serovar
Typhimurium DT104 to improve efficacy and
minimise selection of resistance
L.P. Randall, S.W. Cooles, K. Stapleton,
N.G. Coldham, L.J.V. Piddock, M.J. Woodward
(New Haw, Birmingham, UK)
P1556 Nephrotoxicity of intravenous colistin:
a prospective evaluation
M. Falagas, K. Fragoulis, S. Kasiakou,
G. Sermaides, A. Michalopoulos (Athens, GR)
12:00–13:00
New and not so new antimicrobials
P1557 Molecular design of novel antimicrobial
agents on the base of 4-thiazolidone
derivatives
A. Artemenko, E. Muratov, V. Kuz’min, A. Fedtchuk,
N. Mykhaylovska, R. Lesyk, B. Zimenkovsky
(Odessa, L’viv, UA)
P1558 Computational design of the new antimicrobials
based on the substituted crown ethers
E. Muratov, A. Artemenko, V. Kuz’min, I. Konup,
L. Konup, S. Kotlyar, G. Kamalov, A. Fedtchuk,
N. Mykhaylovska (Odessa, UA)
page 130 Final Programme
P1559 Enzymatic characterisation of methionyl
tRNA synthetase inhibition by REP8839
T. Jarvis, J. Bullard, L. Green, W. Ribble, J. Bertino,
U.A. Ochsner, I.A. Critchley, N. Janjic
(Louisville, US)
P1560 Antimicrobial activity of some new thioureides
of 2-(4-chlorophenoxy)-benzoic acid
C. Limban, M.C. Balotescu, V. Missir, I. Chirita,
G. Mihaescu, A. Israil (Bucharest, RO)
P1561 In vitro antimicrobial activities of novel
dianthraquinones produced by a marine
Streptomyces sp. against clinical Staphylococcus
aureus and Enterococcus faecium
isolates
K.L. LaPlante, K. Lor, A. Socha, D.C. Rowley
(Providence, North Kingston, US)
P1562 Efficacy of the novel antimicrobial peptide
plectasin to staphylococci
D. Sandvang, P.H. Mygind, S. Jenabian,
D.R. Segura, H. Kristensen (Bagsværd, DK)
P1563 In vitro antimicrobial activity of the novel
polymeric guanidine Akacid plus ®
C. Kratzer, S. Tobudic, W. Graninger, A. Buxbaum,
A. Georgopoulos (Vienna, AT)
P1564 Investigation of emergence of bacterial
resistance to the novel antibacterial photo -
dynamic agent XF-42
L. Borsetto, E. Reddi, W. Rhys-Williams,
W.G. Love (Padua, IT; Brighton, UK)
P1565 Efficacy testing of the topical antimicrobial
XF-73 using a novel ex vivo porcine skin model
T. Maisch, R.M. Szeimies, N. Lehn,
W. Rhys-Williams, W.G. Love (Regensburg, DE;
Brighton, UK)
P1566 Novel antimicrobial photodynamic agents
active against epidemic methicillin-resistant
Staphylococcus aureus
G. French, A. King, K. Shannon, W.G. Love,
W. Rhys-Williams (London, Brighton, UK)
P1567 The in vitro bactericidal activity of NXL101,
a novel bacterial topisomerase inhibitor,
against Gram-positive cocci
M. Borgonovi, C. Delachaume, A.M. Girard,
J. Lowther (Romainville, FR)
P1568 Protein targets of N-chlorotaurine in bacteria
R. Arnitz, B. Moser, B. Sarg, H.W. Ott, H. Lindner,
M. Nagl (Innsbruck, AT)

Poster Sessions Tuesday, April 4, 2006
P1569 Anti-staphylococcal activity of ceftobiprole in
recent clinical trial isolates
K. Bush, R. Strauss, K. Amsler, M. Heep,
S. Bajaksouzian, A. Windau, M. Jacobs
(Raritan, US; Basel, CH; Cleveland, US)
P1570 Potency of garenoxacin tested against an
international collection of Staphylococcus
aureus isolates, including oxacillin- and
ciprofloxacin-resistant subsets (2004–2005)
T. Fritsche, H. Sader, M. Stillwell, R. Jones
(North Liberty, US)
P1571 Garenoxacin activity tested against S. pneumoniae,
H. influenzae and M. catarrhalis with
elevated or resistant fluoroquinolone MIC
values
R. Jones, H. Sader, T. Fritsche, P. Strabala,
D. Biedenbach (North Liberty, US)
P1572 Evaluation of garenoxacin activity tested
against all patterns of multiresistant
S. pneumoniae: multi-centre studies of nearly
15,000 isolates
R. Jones, M. Stillwell, H. Sader, T. Fritsche,
D. Johnson (North Liberty, US)
P1573 Garenoxacin activity and potency against
S. pneumoniae and H. influenzae respiratory
tract isolates (2004–2005): report from a
Worldwide Surveillance Network
R. Jones, P. Strabala, T. Fritsche, H. Sader
(North Liberty, US)
P1574 In vitro activity of garenoxacin tested against
ciprofloxacin-susceptible and -resistant
Enterobacteriaceae and Acinetobacter spp.
strains collected worldwide by the SENTRY
Antimicrobial Surveillance Program
(2004–2005)
H. Sader, T. Fritsche, P. Strabala, R. Jones
(North Liberty, US)
P1575 Microbiologic efficacy of garenoxacin vs.
comparators in complicated skin and skin
structure infections
D. Krievins, C. Le Devehat, G. Herrera
(Riga, LV; Nevers, FR; San Jose, CR)
P1576 Dual action of gemifloxacin in acute bacterial
sinusitis in patients with allergic rhinitis:
antibacterial and immunomodulatory effects?
H. Lode, J. Garau, T. File, P. Ball, G. Tillotson,
I. Morrissey (Berlin, DE; Barcelona, ES; Akron,
US; St Andrews, UK; Waltham, US; London, UK)
P1577 Garenoxacin efficacy against multidrugresistant
Streptococcus pneumoniae:
retrospective analysis of community-acquired
pneumoniae isolates obtained from nine
phase II and III clinical studies (1999–2003)
T. Black, H. Waskin, R. Hare (Kenilworth, US)
P1578 Clinical outcome of community-acquired
pneumonia infections treated with
gemifloxacin: the effect of patient risk factors
J. Garau, T. File, P. Ball, H. Lode, G. Tillotson,
I. Morrissey (Madrid, ES; Akron, US; St Andrews, UK;
Berlin, DE; Waltham, US; London, UK)
P1579 Microbiological efficacy of garenoxacin vs.
comparators against common pathogens
associated with community-acquired
pneumonia
M. De Salvo, H. Vasconcelos Lopes, P. Kasemets,
H. Waskin (Buenos Aires, AR; Sao Paulo, BR;
Tampere, FI; Kenilworth, US)
P1580 Efficacy of garenoxacin in the treatment of
community-acquired pneumonia caused by
multidrug-resistant Streptococcus pneumoniae
G. Dien, J. Gaillat, L. Dunbar, L. Vives, H. Waskin
(Hyeres, Annecy, FR; New Orleans, US;
St Gaudens, FR; Kenilworth, US)
P1581 In vitro bactericidal activity of daptomycin
against Staphylococcus aureus and Enterococcus
spp.: comparison with vancomycin,
teicoplanin and linezolid
H. Drugeon, M. Juvin (Nantes, FR)
P1582 Comparative in vitro activities of telavancin
and other antibacterial agents against
selected Gram-positive bacteria
J. Brauers, M. Kresken, S. Bagel (Rheinbach, DE)
P1583 Evaluation of daptomycin, vancomycin,
teicoplanin and linezolid against Staphylococcus
aureus, Enterococcus faecalis and
Enterococcus faecium utilising in vitro
time-kill methodology
J. Brauers, M. Kresken, A. Menke, A. Orland,
I. Morrissey (Rheinbach, DE; London, UK)
P1584 The effect of human serum on the bactericidal
activity of daptomycin and comparators
against Staphylococcus aureus and
Enterococcus spp.
I. Morrissey, A. Leakey, R. Maxfield, T. Veltman,
R. Woods, M. Robbins (London, UK)
P1585 Daptomycin activity against multi-resistant
Staphylococcus haemolyticus bloodstream
isolates from severe infections
F. Campanile, M. Venditti, S. Borbone,
D. Bongiorno, A. Penni, S. Stefani
(Catania, Rome, IT)
www.escmid.org/eccmid2006
page 131

Poster Sessions Tuesday, April 4, 2006
12:00–13:00
Resistance, linezolid, glycopeptides and
inhibitors of protein synthesis
P1586 Mechanism of action of ceftobiprole:
structural basis for anti-MRSA activity
A. Lovering, F. Danel, M.G.P. Page,
N.J. Strynadka (Vancouver, CA; Basel, CH)
P1587 Incidence of Staphylococcus aureus with
reduced susceptibility to glycopeptides in a
French hospital (November 2004 – April 2005)
C. Morate, A. Charron, C. Bebear, J. Maugein
(Bordeaux, FR)
P1588 Distribution of different aminoglycosides
resistance genes among the Iranian
population of enterococci
M.M. Feizabadi, S. Khatibi, A. Asgharzadeh,
S. Gharavi (Tehran, IR)
P1589 Prevalence and genetic analysis of methicillinresistant
Staphylococcus aureus expressing
high-level and low-level mupirocin resistance
M. Kural, T. Us, Y. Akgun (Eskisehir, TR)
P1590 Emergence and spread of acquired fusidic
acid resistance in Staphylococcus aureus
A. J O’Neill, F.B. McLaws, I. Chopra (Leeds, UK)
P1591 Telithromycin activity is reduced by efflux in
Streptococcus pneumoniae
C. Benvenuti, R. Koncan, G. Bahar, A. Mazzariol,
G. Cornaglia (Verona, IT; Ankara, TR)
P1592 An unusual phenotype of Enterococcus
faecalis in Greece expressing low-level
resistance to clindamycin and dalfopristin
but susceptibility to quinupristin-dalfopristin
M. Maniati, F. Kontos, P. Liakos, E. Petinaki,
I. Spiliopoulou, A. Maniatis (Larissa, Patras, GR)
P1593 The presence of erm TR gene is responsible
for the macrolide-resistance of Streptococcus
agalactiae
A. Pratti, E. Akrivoussi, V. Karavassilis, E. Petinaki,
A. Maniatis (Larissa, GR)
P1594 Emergence of novel clindamycin resistance
phenotype among invasive Streptococcus
pyogenes isolates in Sweden
A. Jasir, B. Luca, C. Schalen (Lund, SE)
P1595 Resistance mechanisms of telithromycinresistant
clinical isolates of Streptococcus
pneumoniae in Europe
A. Al-Lahham, M. van der Linden, R.R. Reinert
(Aachen, DE)
page 132 Final Programme
P1596 Genotypes and serotypes correlation among
macrolide-resistant Streptococcus agalactiae
isolates in Zaragoza, Spain (2002 – 2004)
M.E. Llaneza, C. Seral, F.J. Castillo, E. Duran,
C. García, I. Millán, J.A. Sáez-Nieto, M.C. Rubio,
R. Gómez-Lus (Zaragoza, ES)
P1597 Distribution of serotypes in tetracyclineresistant
Streptococcus group B isolated in
Zaragoza, Spain
M.E. Llaneza, C. Seral, F.J. Castillo, S. Salvo,
A. Martinez, M. Pardos, M.C. Rubio,
J.A. Sáez-Nieto, R. Gómez-Lus
(Zaragoza, Madrid, ES)
P1598 Prevalence, type and genetic elements
involved in macrolide resistance in
viridans streptococci
M.S. Hernández Iglesias, J.L. Muñoz-Bellido,
J.A. García-Rodríguez (Salamanca, ES)
P1599 Characterisation of a Streptococcus pneumoniae
strain carrying erm(A) isolated in Italy
R. Camilli, M. Del Grosso, F. Iannelli, M. Monaco,
A. Pantosti (Rome, Siena, IT)
P1600 Linezolid resistance in 3 clinical isolates of
coagulase negative staphylococci isolated
from bloodstream infections
A. Koutsoukou, S. Tsiplakou, A. Stylianakis,
M. Tachtatzis, A. Ntouroupi, A. Sideri, E. Tsakona
(Athens, GR)
P1601 Correlation between MIC and number of
mutated 23S rRNA genes in oxazolidinoneresistant
Staphylococcus aureus
S.E. North, M.J. Ellington, A.P. Johnson,
D.M. Livermore, N. Woodford (London, UK)
P1602 Rapid emergence of resistance to linezolid
during linezolid therapy of an Enterococcus
faecium infection
J. Seedat, G. Zick, I. Klare, C. Konstabel,
N. Weiler, H. Sahly (Kiel, Wernigerode, DE)
P1603 Different prevalence of the main tet
determinants among S. sonnei and S. flexneri
L. Mensa, E. Pisos, S. Capilla, F. Marco, J. Vila,
J. Gascón, J. Ruiz (Barcelona, Las Palmas de
Gran Canaria, Zaragoza, ES)
P1604 Distribution and genetic determinants of
tetracycline resistance in Laribacter
hongkongensis isolates from humans and fish
S.K.P. Lau, P.C.Y. Woo, M.W.S. Li, G.K.M. Wong,
K.Y. Yuen (Hong Kong, HK)
P1605 Succesful treatment of infective endocarditis
with linezolid
T. Hryniewiecki, U. Lopaciuk, J. Stepinska
(Warsaw, PL)

Poster Sessions Tuesday, April 4, 2006
P1606 Linezolid for the treatment of infections
caused by Gram-positive organisms in China
Y. Zhang, D. Lin, J. Wu, F. Wang, J. Zheng,
J. Miao, L. Zheng, R. Sheng, X. Zhou, H. Shen,
M.M. Ijzerman, R. Croos-Dabrera, W. Sheng
(Shanghai, Hangzhou, Beijing, CN; Ann Arbor, US)
P1607 Eradication in one patient, by rifamycinlinezolid,
of a methicillin-resistant Staphylococcus
aureus producing Panton-Valentine
leukocidin, responsible for 7 relapses over
18 months, and decolonisation of her family
by mupirocin
L. Hocqueloux, M. Niang, L. Martin, J-F. Aumaitre,
J-L. Vaur, J. Etienne, D-M. Poisson
(Orléans, Lyon, FR)
P1608 Multiple brain abscesses and purulent
meningitis by Listeria monocytogenes in an
otherwise healthy man. Favourable linezolid
response, hampered by a suspected early
drug myelotoxicity
R. Manfredi, S. Sabbatani, G. Marinacci,
E. Salizzoni, F. Chiodo (Bologna, IT)
P1609 Discrepancy between favourable in vitro
microbiological data and a severe clinical
course of a staphylococcal knee and soft tissue
infection responsive to oxazolidinone linezolid
only after failure of all other therapeutic
attempts
R. Manfredi, S. Sabbatani, F. Chiodo (Bologna, IT)
12:00–13:00
Epidemiology of resistance to antibiotics – II
P1610 Contemporary prevalence of BRO betalactamases
in M. catarrhalis: report from
the SENTRY Antimicrobial Surveillance
Program (USA; 1997–2004)
L. Deshpande, H. Sader, R. Jones
(North Liberty, US)
P1611 Penicillin susceptibility of beta haemolytic
streptococci: a six-year surveillance
O. Karatuna, S. Karavelioglu, G. Soyletir
(Istanbul, TR)
P1612 Trends in macrolide resistance among
pneumococcal carriage strains in French
day-care centres: 1999 to 2004
H. Carsenti-Dellamonica, M. Roussel-Delvallez,
B. Dunais, C. Pradier, P. Bruno, P. Touboul,
C. Laurans, E. Bonnet, P. Dellamonica
(Nice, Lille, Paris, FR)
P1613 Macrolide-resistant Streptococcus pneumoniae
in Slovenia 1999–2004: correlation with
macrolide use
M. Cizman, S. Zad-Pecar, M. Paragi
for the Slovenian Meningitis Study Group
P1614 Multiple drug resistance explains best the
changes in S. pneumoniae resistance in a
ten-year surveillance study in Belgium
J. Van Eldere, R.M. Mera, L.A. Miller, J. Verhaegen,
J.A. Poupard (Leuven, BE; New Orleans,
Upper Providence, Philadelphia, US)
P1615 Molecular mechanisms of antimicrobial
resistance in Salmonella typhimurium
isolates, causing bacteraemia in children
under five years of age in southern
Mozambique
J. Ruiz, I. Mandomando, P. Esquivel, J. Vila,
J. Gascon, P.L. Alonso (Barcelona, ES; Manhiça, MZ;
Resistencia, AR)
P1616 Small outbreaks of VEB-1 ESBL producing
Acinetobacter baumannii in Belgian nursing
homes and hospitals through cross-border
transfer of patients from northern France
B. Jans, C. Suetens, Y. De Gheldre, E. Leens,
P. Bogaerts, B. Coignard, Y. Glupczynski
(Brussels, Yvoir, BE; Saint-Maurice, FR)
P1617 Types of extended-spectrum beta-lactamases
in Salmonella spp. and decreased susceptibility
to fluoroquinolones
S. Ercis, Z. Gulay, D. Gur, B. Erdem, G. Hascelik,
A. Tunger, S. Gedikoglu, I. Tuncer, B. Sumerkan
(Ankara, Izmir, Bursa, Konya, Kayseri, TR)
P1618 Incidence of faecal carriage of ESBL-producing
Enterobacteriaceae in hospital and community
patients during two non-outbreak periods of
time
F.J. Castillo, M. Pardos, C. Seral, I. Millan, C. Pitart,
M.E. Llaneza, M.C. Rubio-Calvo (Zaragoza, ES)
P1619 ESBLs in Enterobacteriaceae from university
hospitals. APUA-Bulgaria Chapter study
E. Keuleyan, R. Markovska, I. Schneider,
M. Sredkova, P. Sotirova, D. Ivanova, A. Bauernfeind
(Sofia, BG; Munich, DE; Pleven, Stara Zagora, BG)
P1620 Emergence of multidrug-resistant Gramnegative
bacteria during selective
decontamination of the digestive tract on
an intensive care unit
N. al Naiemi, E.R. Heddema, A. Bart, E. de Jonge,
C.M. Vandenbroucke-Grauls, P.H.M. Savelkoul,
B. Duim (Amsterdam, NL)
www.escmid.org/eccmid2006
page 133

Poster Sessions Tuesday, April 4, 2006
P1621 Therapy-driven selection of carbapenem
resistance in CTX-M-producing Klebsiella
pneumoniae
D.G. Pillay, P. De, R. Merard, J.W.T. Dallow,
M.E. Kaufmann, R.L.R. Hill, D.M. Livermore,
N. Woodford (Sutton Coldfield, London, UK)
P1622 Wide geographic spread of diverse acquired
AmpC beta-lactamases in Escherichia coli and
Klebsiella spp. in the UK and Ireland
N. Woodford, E.J. Fagan, R. Hope, K.L. Hopkins,
M.E. Kaufmann, J.O. Kistler, M.F.I. Palepou,
R. Pike, M.E. Ward, D.M. Livermore (London, UK)
P1623 Doripenem European surveillance:
antimicrobial activity against 6,480 contemporary
pathogens (2004)
T. Fritsche, H. Sader, R. Jones (North Liberty, US)
P1624 Phenotypic and genetic characterisations of
enterococcal isolates in Tehran sewage, with
emphasis on detection of vanA and vanB
genes
F. Rahimi, K. Borhani, M. Talebi, J. Vandyousefi,
M.R. Pourshafie (Tehran, IR)
P1625 Antibiotic susceptibility of vancomycin-resistant
enterococci isolated in Greek hospitals
A. Christidou, A. Gikas, E. Scoulica,
M. Roumpelaki, A. Georgiladakis, E.I. Kritsotakis,
G. Haliotis, S. Levidiotou, J. Kioumis,
A. Skoutelis, P. Nikolaidis, Y. Tselentis (Heraklion,
Halkis, Ioanina, Thessaloniki, Patra, GR)
P1626 Molecular characterisation of Tn1546 from
enterococci isolated from Portuguese human,
animal and environmental sources
C. Novais, T.M. Coque, J.C. Sousa, L. Peixe
(Porto, PT; Madrid, ES)
P1627 Trends in prevalence rates and beta-lactamase
production of Haemophilus influenzae
nasopharyngeal carriage strains in children’s
day-care centres in south-eastern France
B. Dunais, H. Carsenti-Dellamonica, C. Pradier,
P. Bruno, P. Touboul, M. Sabah, G. Mancini,
P. Dellamonica (Nice, FR)
P1628 Susceptibility of Haemophilus influenzae in
the Netherlands
J.W. Mouton, D. Klomberg, S. Meijers,
C. Klaassen (Nijmegen, NL)
P1629 A current perspective on Streptococcus
pneumoniae and Haemophilus influenzae
resistance trends in Europe:
GLOBAL Surveillance Study, 2005
M. Jones, D. Draghi, C. Thornsberry, D. Sahm
(Plaisir, FR; Herndon, US)
page 134 Final Programme
P1630 Eight years of antimicrobial surveillance in
Haemophilus influenzae isolated in Portugal
(1997–2004)
M.P. Bajanca-Lavado, D. Louro, M.M. Caniça
and GEMVSA (Multicentric Study Group on
Antimicrobial Susceptibility)
P1631 Antimicrobial susceptibility of respiratory
Haemophilus influenzae strains in northern
Greece
K. Koraki, P. Karapavlidou, D. Sofianou
(Thessaloniki, GR)
P1632 Current state of Gram-negative hospitalacquired
urinary tract infections in Russian
intensive care units: pathogens and their
resistance phenotypes
E. Khaykina, G. Reshedko, E. Ryabkova
on behalf of the Rosnet Group
P1633 Antimicrobial susceptibility of Gram-negative
anaerobic bacteria from two hospitals in
Smolensk, Russia
D. Galkin, O. Kretchikova, M. Sukhorukova,
R. Kozlov (Smolensk, RU)
P1634 Bloodstream infections in an Estonian
university hospital
P. Mitt, K. Lõivukene, V. Adamson, K. Kermes,
T. Laeneste, M. Maimets, P. Naaber (Tartu, EE)
12:00–13:00
Clostridium difficile revisited
P1635 Clinical features of Clostridium difficile
associated diarrhoea and molecular
characterisation of the strains over a five-year
period in a French university hospital
F. Barbut, B. Gariazzo, V. Lalande, R. Luiuz,
B. Burghoffer, J.C. Petit (Paris, FR)
P1636 The development and application of a new
exact typing method for Clostridium difficile:
multi-locus variable number of tandem repeat
analysis
R.J. van den Berg, I. Schaap, K.E. Templeton,
C.H.W. Klaassen, E.J. Kuijper
(Leiden, Nijmegen, NL)
P1637 Comparative study of Clostridium difficile
diarrhoea in elderly patients treated with
moxifloxacin versus amoxycillin for lower
respiratory tract infections
L. Mooney, M. Wilcox (Leeds, UK)

Poster Sessions Tuesday, April 4, 2006
P1638 Prevalence and association of macrolidelincosamide-streptogramin
B resistance with
resistance to moxifloxacin in Clostridium
difficile strains isolated from symptomatic
adults and children hospitalised in two
university hospitals in Warsaw
H. Pituch, D. Wultanska, G. Nurzynska,
P. Obuch-Woszczatynski, F. Meisel-Mikolajczyk,
M. Luczak (Warsaw, PL)
P1639 National surveillance to the incidence of
Clostridium difficile-associated diarrhoea in
the Netherlands
S. Paltansing, R. Guseinova, R. van den Berg,
C. Visser, E. van der Vorm, E.J. Kuijper
(Leiden, Amsterdam, NL)
P1640 Outbreak of Clostridium difficile PCR-ribotype
027 toxinotype III in Harderwijk,
the Netherlands
S.B. Debast, N. Vaessen, A. Choudry,
R. van den Berg, E. Kuijper (Harderwijk, Leiden, NL)
P1641 Clostridium difficile PCR ribotype 027,
toxinotype III in the Netherlands
D.W. Notermans, T. van der Kooi, E.J. Kuijper,
R.J. van den Berg, D. Veenendaal, E. van Kregten,
S.B. Debast, C.E. Visser, A. Popma,
S. van den Hof (Bilthoven, Leiden, Haarlem,
Amersfoort, Harderwijk, Amsterdam, NL)
P1642 Incidence of Clostridium difficile infections in
a tertiary Greek hospital
M. Kanellopoulou, M. Martsoukou,
N. Skarmoutsou, A. Charalambopoulou, E. Liapi,
G. Kaderakis, E. Papafrangas (Athens, GR)
P1643 Comparison of methods for detection of
Clostridium difficile toxins
J. Leeming, R. Ferguson, D. Kulpoo, V. Kemp,
J. Watts, D. Carrington (Bristol, UK)
P1644 Location of the enterotoxin gene in strains
of Clostridium perfringens associated with
gastroenteritis
K.A. Grant, S. Kenyon, R. Halford-Maw, E. Pettitt,
J. McLauchlin (London, Chesterfield, UK)
P1645 Novel multiplex-PCR method for simultaneous
detection of Clostridium difficile toxin A and
toxin B and the binary toxin (cdtA/cdtB)
genes applied on a Danish cohort
K.E.P. Olsen, S. Persson (Copenhagen, DK)
P1646 Prevalence of Clostridium difficile-associated
diarrhoea in hospitalised patients with
nosocomial diarrhoea in university of
medical sciences hospitals, Tehran, Iran
N. Sadeghifard, M.H. Salari, M.R. Ghasemi,
F. Aminharati (Ilam, Tehran, IR)
P1647 Emergence of toxin A(-)/toxin B(+) variant
Clostridium difficile
B-M. Shin, E-C. Kim, K. Lee, E-Y. Kwak
(Seoul, KR)
P1648 Impact of antimicrobial treatment on
dominant faecal microbiota: the emergence of
Clostridium difficile
M.F. De La Cochetiere, T. Durand, V. Lalande,
P. Lepage, J.C. Petit, J.P. Galmiche, L. Beaugerie
on behalf of the Molecular Bacteriology Group
P1649 Quantitative C. difficile and anaerobic flora
cultures during treatment of C. difficileassociated
diarrhoea with PAR-101
T.J. Louie, J. Emery, W. Krulicki, D. MacCannell,
B. Byrne, M. Mah (Calgary, CA)
12:00–13:00
Virology – II
P1650 Improved detection of enterovirus in
cerebrospinal fluid with a minor groove
binder – conjugated fluorogenic TaqMan probe
B. Vincart, F. Brancart, P. Gilot, N. De Schrijver,
S. Betermiez, M. Delforge, C. Liesnard
(Brussels, BE)
P1651 Molecular typing of an uncommon enter o -
virus, coxsackievirus A7, frequently
associated with certain diseases in Kuwait
A. Dalwai, S. Ahmad, E. Hussein, A. Pacsa,
W. Al-Nakib (Kuwait, KW)
P1652 The new proposed enterovirus type 75 is
causing meningitis in Spain
A. Avellon, G. Trallero, G. Rubio, N. Rabella,
I. Casas, G. Palacios (Majadahonda, Bilbao,
Barcelona, ES; New York, US)
P1653 Evolution of G1 rotavirus strains in Italian
children in an 18-year period
S. Arista, G.M. Giammanco, S. De Grazia,
S. Ramirez, C. Colomba, A. Cascio
(Palermo, Messina, IT)
P1654 Epidemic spread of recombinant noroviruses
with four capsid types in Hungary
G. Reuter, H. Vennema, M. Koopmans, G. Szucs
(Pécs, HU; Bilthoven, NL)
www.escmid.org/eccmid2006
page 135

Poster Sessions Tuesday, April 4, 2006
P1655 Human metapneumovirus infection in Cuba:
first report
B. Acosta, I. Casas, P. Pérez Breña, C. Savón,
A. Goyenechea, S. Oropeza, A. Piñón
(Havana City, CU; Madrid, ES)
P1656 Detection of human metapneumovirus in
paediatric nasopharyngeal aspirates by a
TaqMan minor groove binder probe assay:
a one-year prospective study in Belgium
W. Verstrepen, P. Bruynseels, A. De Smet,
A. Mertens (Antwerp, BE)
P1657 Nucleic acid sequence based amplification
and molecular beacon detection for the realtime
identification of respiratory syncytial
virus in paediatric respiratory specimens
R. Manji, F. Zhang, C. Ginocchio (Lake Success, US)
P1658 Genetic diversity and molecular epidemiology
of respiratory syncytial virus over six
consecutive seasons in Cuba
O. Valdes, C. Savon, A. Goyenechea, L. Palerm,
Gr. Gonzalez, Gu. Gonzalez, J. Melero, I. Martinez
(Havana City, CU; Madrid, ES)
P1659 Point mutations in respiratory syncytial virus
detected by LightCycler PCR and melting
curve analysis
U. Germer, L. Nielsen, K. Boye, H. Westh
(Copenhagen, DK)
P1660 Evaluation of a real-time NASBA assay for the
detection of influenza A and B virus
K. Brengel-Pesce, F. Jacobs, J. Telles, A. Lefeuvre,
P. Van de Wiel (Grenoble, FR; Boxtel, NL)
P1661 Clinical manifestations and progression of
mumps meningitis in children in Romania
L. Raduta, S-A. Florescu, A.G. Tudor, M. Cotiga,
C.P. Popescu, R.F. Botgros, P.I. Calistru,
E. Ceausu, L. Paun (Bucharest, RO)
P1662 Rare manifestation of mumps: anterior uveitis
E. Turk Aribas, I. Erayman, A.C. Inkaya, B. Kandemir,
M. Bitirgen (Konya, TR)
P1663 Clinical and epidemiological aspects of a
measles epidemic, Bucharest, Romania
S-A. Florescu, M. Cotiga, C.P. Popescu,
L. Raduta, G. Scurtu, R.F. Botgros, G. Enache,
P.I. Calistru, E. Ceausu (Bucharest, RO)
P1664 Recombinant measles proteins, as the
improved analogue of whole virus based
antigen in ELISA to diagnostics reproach
genotypes A and D6
M. Kulak, N. Netesova, P. Belavin, G.M. Ignatyev
(Novosibirsk, RU)
page 136 Final Programme
P1665 Intrauterine infection of Crimean-Congo
haemorrhagic fever: the courses of two
episodes
A. Celikbas, O. Ergonul, U. Yildirim, A. Zenciroglu,
D. Erdogan, I. Ziraman, N. Yilmaz, F. Saracoglu,
N. Demirel, O. Cakmak, B. Dokuzoguz (Ankara, TR)
P1666 The attack and the infection rate of Crimean-
Congo haemorrhagic fever virus infection in
an endemic region
O. Ergonul, H. Zeller, S. Menekse, A. Celikbas,
S. Eren, N. Baykam, B. Dokuzoguz
(Ankara, TR; Lyon, FR)
P1667 Dengue virus infections in children and
adolescents
B. Larrú Martínez, E. Quiroz, M. Castrejón de
Wong, E. Castaño Guerra, J. Nieto, O. Saldana de
Suman, D. Estripeaut Calderon, X. Sáez-Llorens
(Madrid, ES; Panama, PA)
P1668 Diagnosis of dengue infection by enzymelinked
immunosorbent assay and reverse
transcription-polymerase chain reaction from
oral specimens
J. Pupaibool, S. Krajiw, K. Arunyingmongkol,
A. Nisalak, C. Pancharoen, U. Thisyakorn,
W. Kulwichit (Bangkok, TH)
P1669 Serologic evidence for hantaviruses in the
northern and eastern Tyrol (Austria) and the
southern Tyrol (Italy)
G. Walder, A. Lanthaler, J. Simeoni, G. Morosetti,
D. Schönitzer, O. Prinoth, M.P. Dierich, P. Kreidl
(Innsbruck, AT; Meran, Bozen, IT)
P1670 Molecular characterisation of a pantropic
variant of canine coronavirus
N. Decaro, V. Martella, G. Elia, M. Campolo,
C. Desario, M. Tempesta, C. Buonavoglia
(Valenzano, IT)
P1671 SARS coronavirus-like virus in Chinese
horseshoe bats in Hong Kong
S.K.P. Lau, P.C.Y. Woo, K.S.M. Li, Y. Huang,
H.W. Tsoi, B.H.L. Wong, S.S.Y. Wong,
S.Y. Leung, K.H. Chan, K.Y. Yuen
(Hong Kong, HK)
P1672 Porcine caliciviruses in piglets in Italy
V. Martella, E. Lorusso, M. Camero, A. Lavazza,
G. Pezzotti, G. Elia, N. Decaro, C. Buonavoglia
(Valenzano-Bari, Brescia, Perugia, IT)
P1673 Detection of calicivirus genome in calves
using Ni/E3 primers
M. Mahzounieh, T. Zahraeisalehi,
E. Moghtadaei Khorasgani
(Shahrekord, Tehran, IR)

Poster Sessions Tuesday, April 4, 2006
P1674 Assessment of reovirus epidemiology in dogs
G. Elia, M.S. Lucente, A.L. Bellacicco, M. Camero,
N. Cavaliere, N. Decaro, V. Martella
(Valenzano, Foggia, IT)
P1675 Molecular epidemiology of parvovirus B19 in
Slovenia
T. Ursic, M. Petrovec (Ljubljana, SI)
12:00–13:00
Bacterial pathogenesis – III
P1676 Characterisation of human brucellosis in
Great Britain by classical typing and VNTR
molecular typing
P. Groussaud, S.D. Brew, A.M. Whatmore,
J.A. Stack (New Haw, UK)
P1677 IS711-fingerprinting of Brucella isolates from
humans
E. Stubberfield (Surrey, UK)
P1678 Rapid diagnosis of brucellar epididymo-orchitis
by real-time PCR assay in urine samples
J.D. Colmenero, M.I. Queipo-Ortuño, J.M. Reguera,
N.L. Muñoz, A. Villalobos, A. Plata, P. Morata
(Malaga, ES)
P1679 Molecular diagnosis and characterisation of
human isolates
C.E. Dawson (Weybridge, UK)
P1680 Real-time detection of Campylobacter jejuni
and Campylobacter coli from environmental
samples and single nucleotide polymorphism
profiling of map A positive strains to
determine their clonal complexes
S. Lai, E. Best, S.B. Surman-Lee, R.J. Owen,
J.V. Lee (London, UK)
P1681 Species identification of human Campylobacter
strains
U-M. Nakari, A. Koivumäki, A. Siitonen
(Helsinki, FI)
P1682 Phenotypic typing of Cryptosporidium species
isolated from children in Kuwait:
a role in unique transmission
J. Iqbal, P. Hira (Safat, KW)
P1683 Chlamydophila pneumoniae in patients
undergoing aortic valve replacement
M. Edvinsson, Y. Molin, E. Hjelm, S. Thelin,
G. Friman, C. Nyström-Rosander (Uppsala, SE)
P1684 Molecular epidemiology of diarrheagenic
E. coli in children with acute diarrhoea in
Tehran, Iran and the antibiotic susceptibility
of isolated strains
F. Jafari, S. Salmanzadeh-Ahrabi, M.M. Aslani,
F. Baghbani-Arani, M. Azimi-Rad, M.R. Zali
(Tehran, IR)
P1685 Identification of shiga toxin-producing
Escherichia coli in raw beef using DNA
hybridization with digoxigenin-labelled
probes and multiplex PCRs
M. Weiner, J. Osek (Pulawy, PL)
P1686 Correlation between virulence pattern,
phylogenetic group and extended spectrum
betalactamases genes in Escherichia coli
strains isolated from blood cultures
M. Damian, C. Usein, D. Tatu-Chitoiu, S. Ciontea,
D. Jardan, A. Palade (Bucharest, RO)
P1687 Isolation of shiga toxin producing Escherichia
coli from meat samples, phenotypic and
genotypic characterisation of isolated strains
F. Baghbani-Arani, F. Jafari, M.R. Zali,
S. Salmanzadeh-Ahrabi (Tehran, IR)
P1688 Factors affecting the conjugative transfer of
plasmid pIP501 in Enterococcus faecalis
A.M. Al-qurashi (Dammam, SA)
P1689 Presence of seven virulence genes in Swedish
Enterococcus faecium blood-culture isolates
collected during a five-year period
H. Billström, Å. Sullivan, B. Lund (Stockholm, SE)
P1690 Transcriptomic analysis of the alkalinetolerance
response in Listeria monocytogenes
10403S
E. Giotis, A. Muthaiyan, D. McDowell, I. Blair,
B. Wilkinson (Newtonabbey, UK; Normal, US)
P1691 Engineering improved listerial stress
tolerance “with a twist”!
R. Sleator, C. Hill (Cork, IE)
P1693 Application of fluorescent in situ hybridization
for detection of Helicobacter pylori
A.R. Samarbaf-Zadeh, S. Tajbakhsh,
S.M. Moosavian (Ahwaz, IR)
P1694 Prevalence of Helicobacter pylori oral carriage
in a children’s community
D. De Vito, M. Santantonio, M.F. Coscia, C. Rizzo,
R.A. Monno, G. Rizzo (Bari, IT)
www.escmid.org/eccmid2006
page 137

Poster Sessions Tuesday, April 4, 2006
P1695 The role of Helicobacter pylori in otitis media
with effusion
T. Yilmaz, M. Ceylan, Y. Akyon, O. Ozcakir,
B. Gursel (Ankara, TR)
P1696 Distribution of the serine-aspartate repeat
protein-encoding sdr genes among nasal
carriage and invasive Staphylococcus aureus
strains
A. Sabat, D. Melles, G. Martirosian,
H. Grundmann, A. van Belkum, W. Hryniewicz
(Warsaw, PL; Rotterdam, NL; Katowice, PL;
Bilthoven, NL)
P1697 Sequencing of lukS-PV and lukF-PV in
methicillin-sensitive and methicillin-resistant
Staphylococcus aureus of diverse genetic
backgrounds in a Swedish county
C. Berglund, B. Söderquist (Örebro, SE)
P1698 The first case of Staphylococcus pseudintermedius
in humans isolated from an ICD lead
L. Van Hoovels, A. Vankeerberghen,
K. Van Vaerenbergh, A. Boel, H. De Beenhouwer
(Aalst, BE)
P1699 Characterisation of Staphylococcus aureus
isolates recovered from dairy sheep farms
(agr group, adherence, slime, resistance to
antibiotics)
E. Vautor, M. Sabah, G. Mancini, M. Pepin,
H. Carsenti-Dellamonica
(Sophia-Antipolis, Nice, FR)
P1700 Detection of virulence genes in Staphylococus
aureus isolates from dairy sheep, goats and
cows mastitis, using single-dye DNA
microarray
E. Vautor, V. Magnone, G. Rios, M. Pepin,
P. Barbry (Sophia-Antipolis, FR)
P1701 Detection of DNA sequences distinguishing
two closely related genomes of Staphylo -
coccus aureus from subclinical versus
gangrenous ewe mastitis strains
N. Chevalier, C. Huard, R. Thiery, E. Vautor
(Sophia-Antipolis, FR)
12:00–13:00
Antimicrobial clinical trials
P1702 Outpatient treatment of acute pyelonephritis
in pregnancy after 24 weeks.
A randomised controlled trial
Z. Ahmadinejad, S. Hantooshzadeh (Tehran, IR)
P1703 Experience with daptomycin in patients with
renal insufficiency
B.A. Mueller, S. Levy, K. Lamp, L. Friedrich,
R. Russo (Ann Arbor, Lexington, US)
page 138 Final Programme
P1704 In vitro activity of second line antibiotics
against Helicobacter pylori infection
A. Pérez de Ayala, T. Alarcón, D. Monclús,
E. Aznar, J.L. Navarro, N. Arenal, M. López-Brea
(Madrid, ES)
P1705 Vibrio antibodies in serum and breast milk
samples of parturient women in Calabar,
Nigeria
S. Utsalo (Calabar, NG)
P1706 Moxifloxacin vs. clarithromycin for treatment
of community-acquired pneumonia associated
with common respiratory pathogens:
a pooled analysis
R. Grossman, M. Niederman, R. Perroncel,
S. Choudhri, D. Haverstock (Mississauga, CA;
Mineola, West Haven, US)
P1707 Variability of creatinine clearance measurements
in inpatients with community-acquired
pneumonia
R. Grossman, S. Choudhri, D. Haverstock
(Mississauga, CA; West Haven, US)
P1708 A prospective, controlled, randomised, nonblind,
comparative study of the efficacy and
safety of high-dose single daily ceftriaxone
plus ciprofloxacin versus thrice-daily
ceftazidime plus amikacin in the empirical
therapy of febrile neutropenic patients
S. Metallidis, P. Kollaras, A. Tsona, T. Giannakakis,
V. Seitanidis, T. Kordosis, A. Hatzitolios,
J. Nikolaidis, P. Nikolaidis (Thessaloniki,
Athens, GR)
P1709 The ‘Day 28 phenomenon’: single-dose
azithromycin microspheres (Zmax) reduce
respiratory symptoms in the post-treatment
period
D. Jorgensen, C. Roberts, D. Cardinale, J. Breen,
M. Dunne, F. Whaley (New London, New York,
Ann Arbor, US)
P1710 Integrated analysis of efficacy of faropenem
medoxomil in the treatment of communityacquired
pneumonia
E.E.L. Wang, R. Echols, R. Tosiello (Louisville, US)
P1711 Propionibacterium acnes strains isolated from
acne vulgaris and severe infections
C. Oprica, C.E. Nord (Stockholm, SE)
P1712 Antimicrobial activity of Unisepta quick
and Deconex solarsept on the surface
contamination and dental instrument in
dental clinics in Iran
F. Shahcheraghi (Tehran, IR)

Poster Sessions Tuesday, April 4, 2006
P1713 Macrolide as long-term treatment in patients
with bronchiectasis colonised by
Pseudomonas aeruginosa
M. Schmidt-Ioanas, M. Allewelt, A. Polzin,
T. Blum, H. Lode (Berlin, DE)
P1714 Fungal pathogens from haematoncology
patients and their susceptibility to new and
old antifungal drugs
M.A. Petrou (London, UK)
P1715 Faropenem medoxomil in the treatment of
acute bacterial sinusitis: an integrated
analysis
S. Kowalsky, R. Tosiello, R. Echols (Milford, US)
P1716 Faropenem medoxomil in the treatment of
acute exacerbation of chronic bronchitis:
an integrated analysis
S. Kowalsky, R. Tosiello, R. Echols (Milford, US)
P1717 An integrated safety analysis of faropenem
medoxomil: results of 5,023 subjects from
phase II/III clinical trials
R. Echols, R. Tosiello (Milford, US)
P1718 The efficacy of non-surgical and systemic
antibiotic treatment regimens in smoking and
non-smoking patients
E. Pähkla, K. Lõivukene, P. Naaber, M. Saag
(Tartu, EE)
12:00–13:00
Diagnostic and laboratory methods for
bacteria – II
P1719 The usefulness of the measurement of
laminin in patients with bacterial infections
H. Lydatakis, I. Hager, T. Miha, V. Babali,
N. Tsimberakis, H. Tamvakos, S. Pappas,
I. Diamantis (Piraeus, Athens, GR)
P1720 Performance and clinical significance of a
direct tube coagulase test using serum
separator tubes for rapid identification of
Staphylococcus aureus from blood culture
broth
D. Kwa, T. Schülin-Casonato, P. Sturm
(Nijmegen, NL)
P1721 Evaluation of the results of the Spanish
SEIMC External Quality Control Program for
the diagnosis of Enterococcus faecalis and
Klebsiella pneumoniae infections
R. Guna, J.L. Pérez, N. Orta, C. Gimeno
on behalf of SEIMC
P1722 Evaluation of the RIDASCREEN ® Borrelia IgG
and IgM for the serological diagnosis of Lyme
borreliosis
A. Bonnet-Pierroz, A. Resenterra, O. Péter
(Sion, CH)
P1723 Is it necessary to incubate the BacT/Alert
blood culture bottles more than 3 days?
A. Vilas, D. Fontanals, I. Sanfeliu, I. Pons,
D. Mariscal (Sabadell, ES)
P1724 An enzyme immunoassay for anti-diphtheria
antibodies: a practical alternative to the Vero
cell assay
R. Budd, E. Harley, R. George, A. Efstratiou,
K. Broughton, A. Bradwell
(Birmingham, London, UK)
P1725 Evaluation of accuracy limits of countable
colony-forming units on agar plates
J. Arbique, A. Rendell, K. Forward (Halifax, CA)
P1726 Direct microscopy: a valuable instrument for
diagnosis and prognosis of periodontal
disease
F.S. Alecu, C. Defta, M. Giurgiu, S. Dumitriu
(Bucharest, RO)
P1727 Identification of species and glycopeptide
resistance among enterococcal isolates by
BD Phoenix
N. Siafakas, M. Pantelaki, E. Kalogeropoulou,
S. Chaniotaki, L. Galani, A. Antoniadou, L. Zerva
(Athens, GR)
P1728 An audit of sputum requisition practices
P. Lal, I. Balakrishnan (London, UK)
P1729 A new approach to laboratory diagnostic of
infectious gastroenteritis – a follow-up
B. Olesen, D.S. Hansen, H. Tybring, A. Hansen,
K.E.P. Olsen, B.G. Bruun (Hillerød, Copenhagen, DK)
P1730 Recognition of Staphylococcus aureus
isolates as small colony variants applying
Fourier-transform infrared spectroscopy
K. Becker, N. Al Laham, W. Fegeler, R.A. Proctor,
G. Peters, C. von Eiff (Munster, DE; Madison, US)
P1731 Levels of sTREM-1 in cerebrospinal fluid as a
marker for bacterial meningitis
M. Weisfelt, R. Determann, J. de Gans,
A. van der Ende, M.J. Schultz, D. van de Beek
(Amsterdam, NL)
P1732 Systematic review of rapid diagnostic tests
for enterohaemorrhagic E. coli
I. Abubakar, L. Irvine, L. Shepstone, S. Schelenz,
C. Aldus, P. Hunter (Norwich, UK)
www.escmid.org/eccmid2006
page 139

Poster Sessions Tuesday, April 4, 2006
P1733 Antibodies against Bordetella pertussis
detected by slow agglutination test and
ELISA in two age-related groups of vaccinated
people suspected of acute pertussis:
a comparative study
Z. Medkova, O. Stepanikova (Brno, CZ)
P1734 Accuracy of the MicroScan WalkAway system
to identify coagulase-negative staphylococci
A. Sáez, B. Ruiz, L. Martínez-Martínez
(Santander, ES)
P1735 The Polish National External Quality Assesment
Scheme (POLMICRO 2005) –
detection of BLNAR Haemophilus influenzae
E. Stefaniuk, B. Chmylak, J. Fiett, E. Zurek,
W. Hryniewicz (Warsaw, PL)
P1736 Serological diagnosis of syphilis by a
completely automated chemiluminescent
immunoassay: Architect syphilis TP
R. Vezzo, L. Vigorè, V. Giuffrè (Monza, IT)
P1737 Usefulness of Sysmex UF-100 and Coral UTI
Screen in the diagnosis of urinary tract
infection
M. Schinella, P. Rizzonelli, A. Frizzi, L. Collini,
P. Gualdi (Rovereto, IT)
P1738 Comparison of the blood and bone marrow
culture positivity rates for the diagnosis of
brucellosis
S. Iseri, C. Bulut, H. Irmak, M.A. Yetkin, S. Kinikli,
N. Tulek, A.P. Demiröz (Ankara, Samsun, TR)
P1739 Serological findings in blood sera of patients
with Yersinia-triggered arthritis
E. Golkocheva, R. Stoilov, H. Najdenski (Sofia, BG)
P1740 Identification and susceptibility results by
direct inoculation of Vitek 2 cards from
positive Bact/Alert 3D system
M.A. Miguel, M. Cuervo, M. Lecuona,
S. Campos, M.I. Montesinos, A. Sierra
(La Laguna Sta Cruz Tenerife, ES)
P1741 Investigation of Listeria monocytogenes “O”
antibodies in maternal and cord sera with the
agglutination test
E. Us, A.T. Cengiz, O. Gelisen (Ankara, TR)
page 140 Final Programme
12:00–13:00
Molecular detection of microbial ribosomal
genes
P1742 Prospective evaluation of a real-time PCR assay
for direct detection of methicillin-resistant
Staphylococcus aureus in clinical specimens
from hospitalised patients
N. de San, O. Denis, M-F. Gasasira,
R. De Mendonça, C. Nonhoff, M.J. Struelens
(Brussels, BE)
P1743 Rapid and sensitive detection of methicillinresistant
Staphylococcus aureus from blood
culture bottle by real-time PCR
C. Eroglu, H. Yilmaz, U. Cakmak, D. Turan,
H. Leblebicioglu (Samsun, TR)
P1744 PCR detection of Class B, C and D betalactamases
in environmental and clinical
Aeromonas strains
T. Fosse, C. Giraud-Morin, F. La Louze (Nice, FR)
P1745 Detection of enterotoxine B producing
Staphylococcus aureus directly from milk
M. Popa, I. Codita, M. Surdeanu, M. Straut,
S. Cretoiu, M. Negut (Bucharest, RO)
P1746 Genotypic detection of resistance to fluoroquinolones
by PCR-RFLP in Acinetobacter
baumannii clinical isolates
E. García-peñuela, T. Alarcón, A. Pérez de Ayala,
N. Arenal, J.L. Navarro, M. López-Brea (Madrid, ES)
P1747 Evaluation of a rapid amplification-detection
assay for the identification of vancomycinresistant
enterococci
J. Fuller, L. Turnbull, S. Shokoples, B. Lui,
L. Rosmus, R. Rennie (Edmonton, CA)
P1748 Application of minimal sequence quality
values prevents misidentification of blashv
type in single bacterial isolates carrying
different SHV extended-spectrum betalactamase
genes
N. al Naiemi, B. Duim, K. Schipper,
C.M. Vandenbroucke-Grauls, A. Bart
(Amsterdam, NL)
P1749 Antimicrobial susceptibilities and
epidemiological analysis of Salmonella
typhimurium human isolates in Slovakia by
phage typing and pulsed-field gel
electrophoresis
V. Majtán, L. Majtánova, M. Szabóová
(Bratislava, SK)

Poster Sessions Tuesday, April 4, 2006
P1750 Novel reverse hybridisation assay to identify
CTX-M genotype in cephalosporin-resistant
isolates from UK and India
V.M. Ensor, M. Shahid, R. Hope, M. Warner,
N. Woodford, D.M. Livermore, P.M. Hawkey
(Birmingham, London, UK; Aligarh, IN)
P1751 Detection of mexA and mexX efflux genes in
P. aeruginosa: correlation between QC-RT-PCR
and real-time PCR
N. Mesaros, Y. Glupczynski, D. Pierard, A. Dediste,
Y. Van Laethem, P. Tulkens, M. Mingeot-Leclercq,
F. Van Bambeke (Brussels, Yvoir, BE)
P1752 Molecular detection of penicillin resistance in
Streptococcus pneumomiae
N.G. Rizk, N.A. Abo Khadr, S.M. Abdel Salam,
N.M. Gamil, M. Hassan (Alexandria, EG)
P1753 Lipopolysaccharide-binding protein is a marker
of severity in patients with bacteraemia
S. Gaïni, S.S. Pedersen, C. Pedersen,
O.G. Koldkjær (Odense, Sønderborg, DK)
P1754 Pyrosequencing of the GRA6 gene to
discriminate type I, II and III Toxoplasma
gondii in clinical samples
B. Edvinsson, B. Evengård on behalf of the ESGT
P1755 Virulence genes in Escherichia coli isolates
from calves in Shahrekord area, Iran
T. Zahraeisalehi, M. Mahzounieh, F. Asadian,
M. Khosravi, M. Boniadian (Tehran, Shahrekord, IR)
P1756 Periplasmic expression of active recombinant
shiga toxin (Stx) 1
M. Oloomi, S. Bouzari (Tehran, IR)
P1757 Characterisation of Gram-positive anaerobic
cocci by biochemical tests and partial 16S
rRNA sequencing
A. Bryk, A. Kanervo-Nordstrom, M. Hyvonen,
E. Kononen (Helsinki, FI)
P1758 23S PCR as a supplementary method for
diagnosis of infectious arthritis.
A prospective study
C. Moser, K. Andresen, A. Kjerulf, S. Salamon,
M. Kemp, J.J. Christensen (Copenhagen, DK)
P1759 Direct detection of Cardiobacterium hominis
by broad-range 16S rRNA PCR and
sequencing in the serum of a patient
with infective endocarditis
E. Malli, D. Klapsa, A. Vasdeki, M. Morava,
M. Pitsitaki, E. Petinaki, A. Maniatis (Larissa, GR)
P1760 Identification of dangerous bacterial
pathogens by 16S ribosomal RNA gene
sequence analysis
W. Ruppitsch, A. Stoeger, A. Indra, D. Schmid,
K. Grif, C. Schabereiter-Gurtner, A. Hirschl,
F. Allerberger (Vienna, AT)
P1761 Identification of nontuberculous mycobacteria
by sequence analysis of the 16S ribosomal
RNA, the heat-shock protein 65 and the RNA
polymerase beta-subunit genes
S. Shin, J.H. Yoon, E-C. Kim (Seoul, KR)
P1762 Evaluation of the genotype MTBDR assay for
the simultaneous detection of resistance to
rifampicin and isoniazid of Mycobacterium
tuberculosis clinical strains
F. Brossier, C. Truffot-Pernot, N. Veziris, V. Jarlier,
W. Sougakoff (Paris, FR)
P1763 Variation in the streptococcal 16S rDNA
detected by pyrosequencing
M. Haanperä, P. Huovinen, J. Jalava (Turku, FI)
P1764 Evaluation of partial 16S rRNA gene
sequencing for identification of clinical
isolates of Nocardia species
M. Marín, M. Sánchez, M. del Rosal,
E. Cercenado, P. Martín-Rabadán, E. Bouza
(Madrid, ES)
12:00–13:00
Antibacterial susceptibility studies – III
P1765 Anaerobic bacteraemia due to Fusobacterium
necrophorum and Clostiridium cadaveris:
a case report
M. Panopoulou, E. Alepopoulou, E. Chrisafidou,
A. Tsaroucha, C. Simopoulos, S. Kartali
(Alexandroupolis, GR)
P1766 Fluoroquinolone resistance among Entero -
bacteriaceae strains isolated from urinary
tract infections
V. Skandami-Epitropaki, P. Fostira, A. Tsiringa,
A. Xanthaki, K. Zampitha, M. Toutouza (Athens, GR)
P1767 Susceptibility of Pseudomonas aeruginosa
isolated from the MYSTIC Programme to the
carbapenems: meropenem and imipenem
P.J. Turner (Macclesfield, UK)
P1768 Third Belgian multicentre survey of antibiotic
susceptibility of anaerobic bacteria
I. Wybo, D. Piérard, I. Verschraegen, M. Reynders,
K. Vandoorslaer, S Lauwers
for the BVIKM-SBIMC/ GOSPIZ-GDEPIH
working group
www.escmid.org/eccmid2006
page 141

Poster Sessions Tuesday, April 4, 2006
P1769 Comparative in vitro activity of levofloxacin
against Escherichia coli isolated from acute
pyelonephritis in France in 2005
C.J. Soussy, C. Lascols, C. Dib-Smahi
and The Multicenter Group Study
P1770 In vitro activity of double and triple
combinations of colistin, imipenem,
rifampicin and linezolid against epidemic
strains of multidrug-resistant Acinetobacter
baumannii producing OXA carbapenamases
D.W. Wareham, D.C. Bean (London, UK)
P1771 A comparative in vitro evaluation of
resistance development after exposure to
teicoplanin, vancomycin, linezolid and
quinupristin/dalfopristin in Staphylococcus
spp. and Enterococcus spp.
E. De Vecchi, L. Nicola, M.R. Gismondo, L. Drago
(Milan, IT)
P1772 In vitro activity of antimicrobial agents
against Legionella obtained from hotel water
systems in Turkey
H. Erdogan, F. Can, M. Demirbilek, F. Ergin, H. Arslan
(Antalya, Ankara, TR)
P1773 In vitro activity of colistin against panresistant
Acinetobacter baumannii
S. Quinteira, H. Ramos, J.M. Amorim, L. Peixe
(Porto, PT)
P1774 Emergence of high-level gentamicin resistance
in clinical enterococcal isolates of
companion animals in Portugal
C. Pomba, M. Delgado, T. Ribeiro, T. Crespo,
M.F. Silva Lopes, J.H. Duarte Correia
(Lisbon, Oeiras, PT)
P1775 Study of antibiotic-resistant Streptococcus
pneumoniae strains, isolated in Romania,
between 2004 – 2005
M. Pana, M. Ghita, R. Papagheorghe,
N. Popescu, I. Nistor, M. Nica, G. Bancescu,
M. Andrei, S. Botea, D. Blana, V. Ungureanu
(Bucharest, RO)
P1776 Penicillin resistance in Streptococcus agalactiae
F. Cavallini, S. Cagnacci, E. Maioli, R. Bandettini,
E. Debbia, A. Marchese (Genoa, IT)
P1777 Ciprofloxacin susceptibility of the most
common isolates at bacterial conuctivitis
M. Dimitrova (Stip, MK)
P1778 Antimicrobial resistance patterns of
Acinetobacter baumannii in clinical isolates
G.T. Tsilika, V.P. Pliatsika, M.T. Tsivitanidou,
D.S. Sofianou (Thessaloniki, GR)
page 142 Final Programme
12:00–13:00
Tigecycline in vivo studies
P1779 Ecological impact of tigecycline on the normal
oropharyngeal and intestinal microflora
C.E. Nord, E. Sillerström, E. Wahlund, V. Parks,
M.L. Odell, J. Vouis (Stockholm, SE; Paris, FR;
Solna, Uppsala, SE)
P1780 Single-centre experience of the use of
tigecycline in the treatment of deep-seated
multidrug-resistant Acinetobacter in patients
with multiorgan failure
E. Sizer, W. Bernal, G. Auzinger, I. Eltringham,
S. Stoll, L. Sawkeng, J. Wendon (London, UK)
P1781 Pharmacokinetic-pharmacodynamic model
for the safety of tigecycline in patients with
complicated intra-abdominal infections
A. Meagher, K. Liolios, J. Passarell, B. Cirincione,
S. Van Wart, J. Fiedler-Kelly, T. Babinchak,
E. Ellis-Grosse (Buffalo, Collegeville, US)
P1782 Predictors of excess health resource
utilisation in treatment of hospitalised
patients with community-acquired pneumonia:
retrospective analysis of a clinical study
comparing intravenous tigecycline and
levofloxacin
R. Mallick, S. Sun (Collegeville, US)
P1783 Tigecycline effective in treating patients with
intra-abdominal or skin/skin structure
infections who have bacteraemia
E.J. Ellis-Grosse, R. Maroko (Collegeville, US)
P1784 Tigecycline vs. imipenem/cilastatin for
treatment of complicated intra-abdominal
infections: European experience
R. Maroko, N. Dartois, Y. Brault, J. Goodrich,
E.J. Ellis-Grosse on behalf of the 301 and
306 cIAI Study Groups
P1785 Tigecycline is safe and effective in the
treatment of complicated skin and skin
structure infections: European experience
of two double-blind phase 3 comparison
studies with vancomycin/aztreonam
R. Maroko, N. Dartois, D. Sarkozy, J. Goodrich,
E.J. Ellis-Grosse on behalf of the Tigecycline 300
and 305 Study Groups
P1786 Safety and tolerability of tigecycline
R. Maroko, N. Dartois, G. Rose, E.J. Ellis-Grosse
(Collegeville, US; Paris, FR)

Poster Sessions Tuesday, April 4, 2006
P1787 Tigecycline as effective as imipenem/
cilastatin in the treatment of complicated
intra-abdominal infections: experience in
India
M.K. Ramesh, R.A. Sastry, A. Rekha, A.C. Ashok,
P. Dhar, E.J. Ellis-Grosse
on behalf of Tigecycline 301 Study Group
12:00–13:00
Nosocomial infection: control of environment,
viral infections
P1788 Bacterial flora contamination of blood
pressure cuffs in use on hospital wards
N. Walker, R. Gupta, J. Cheesbrough
(Preston, UK)
P1789 Needlestick and sharp injuries of health care
personnel in a newly founded tertiary
hospital: a prospective study
M. Falagas, I. Karydis, G. Georgoulias,
P. Hatzopoulou, D. Nikita, I. Kostogiannou
(Athens, GR)
P1790 Epidemiology of occupational needlestick and
sharps injury among healthcare-workers in
Turkey
S. Hosoglu on behalf of the Occupational
Infections study group, Turkey
P1791 Microbiological approach to reprocessing of
single-use devices for interventional cardiology
I. Caola, F. Tessarolo, M. Disertori, G.M. Guarrera,
G. Nollo, P. Caciagli (Trento, IT)
P1792 Room disinfection in the hospital setting
using Akacid plus ®
C. Kratzer, S. Tobudic, W. Graninger, A. Buxbaum,
A. Georgopoulos (Vienna, AT)
P1793 Study on the antiviral efficacy of Citrofresh ® ,
a flavonoid based organic acid complex
sanitizer
Z. Nack (North-Geelong, AU)
P1794 Rapid environmental recontamination of an
intensive care unit after decontamination
with hydrogen peroxide vapour
K.J. Hardy, S. Gossain, P.M. Hawkey,
B.A. Oppenheim, N. Henderson, F. Gao
(Birmingham, UK)
P1795 Survival of some nosocomial infections
agents on the surface of different covering
materials
H. Yazgi, M.H. Uyanik, M. Ertek, A.E. Aktas,
H. Igan, A. Ayyildiz (Erzurum, TR)
P1796 Evaluation of infection control practices in 31
haematopoietic stem-cell transplant facilities
in German-speaking countries: variation of
measures reflects lacking evidence
S. Wenzler-Röttele, A. Conrad, W.V. Kern,
H. Bertz, F.D. Daschner, M. Dettenkofer
(Freiburg, DE)
P1797 Microbiological analysis of saline solutions
used in wound cleansing
C. Nogueira, M. Alves, A. Magalhães-Sant’Ana,
C. Miguéns, J. Gouveia (Coimbra, Pampilhosa da
Serra, PT)
P1798 Frequencies of CMV-IE specific memory T
cells are inversely correlated with alloimmune
memory and serum creatinine in kidney
transplant patients
P. Nickel, G. Bold, F. Presber, C. Schönemann,
J. Pratschke, D. Bitti, F. Kern, H.-D. Volk, P. Reinke
(Berlin, DE)
P1799 Universal precautions: knowledge, attitude
and practice of healthcare workers regarding
HIV, hepatitis B and C
V. Gupta, S. Bhoi, A. Goel, P. Aggarwal
(New Delhi, IN)
P1800 Molecular characterisation of acute hepatitis
A outbreaks in health care workers
H. Choi, S.Y. Jeong, S. Lee, M.A. Lee (Seoul, KR)
P1801 Management of a norovirus-associated
gastroenteritis outbreak on two psychiatric
wards
A. Buehling, U. Arnold (Magdeburg, DE)
12:00–13:00
Regional spread of antibiotic resistance
P1802 Nosocomial colonisation and infection of ICU
patients caused by persistent and multi -
resistant clones of Acinetobacter baumannii
E. Vagiakou, A. Karabinis, D. Mylona-Petropoulou,
E. Paramythiotou, P. Tassios, L. Tzouvelekis,
C. Mergioti, G. Diamantopoulou, N. Legakis,
H. Malamou-Lada (Athens, GR)
P1803 Decrease of antibiotic resistance of group A
streptococci in Korea
S. Kim, E.-H. Koh, I.-G. Bae, N.Y. Lee (Jinju, KR)
P1804 Analysis of skin and soft tissue infections in
European medical centres: report from the
SENTRY Antimicrobial Surveillance Program
(1998–2005)
G. Moet, P. Strabala, H. Sader, T. Fritsche, R. Jones
(North Liberty, US)
www.escmid.org/eccmid2006
page 143

Poster Sessions Tuesday, April 4, 2006
P1805 Mechanisms of carbapenem resistance in
multiresistant Pseudomonas aeruginosa
strains from Germany
B. Henrichfreise, I. Wiegand, W. Pfister,
B. Wiedemann (Bonn, Jena, DE)
P1806 Worldwide antimicrobial susceptibility
patterns of inducible Enterobacteriaceae
isolated from intraabdominal infections:
results from SMART 2004
F. Baquero, P-R. Hsueh, D.L. Paterson, F. Rossi,
V. Satishchandran, T.A. Snyder, S. Rawlins,
G. Gallagher, M.A. Abramson, M.J. DiNubile,
J.W. Chow (Madrid, ES; Taipei, TW; Pittsburgh, PA,
US; São Paulo, BR; West Point, PA, US)
P1807 Worldwide antimicrobial susceptibility
patterns of Gram-negative bacilli isolated
from intraabdominal infections:
results from SMART 2004
F. Rossi, F. Baquero, P-R. Hsueh, D.L. Paterson,
V. Satishchandran, T.A. Snyder, S. Rawlins,
G. Gallagher, M.A. Abramson, M.J. DiNubile,
J.W. Chow (São Paulo, BR; Madrid, ES; Taipei, TW;
Pittsburgh, West Point, US)
P1808 Characterisation of streptogramin resistance
genes among Enterococcus faecium isolates
from Austrian animal husbandry
A. Eisner, G. Gorkiewicz, G. Feierl, F. Dieber,
E. Marth, J. Köfer (Graz, AT)
P1809 Characterisation of macrolide-resistant Strepto -
coccus pneumoniae isolates from Russia
S.A. Grudinina, O.Y. Filimonova, E.N. Ilina,
A. Al-Lahham, M.V. Malakhova, L.G. Stolyarova,
S.V. Sidorenko, R.R. Reinert
(Moscow, RU; Aachen, DE)
P1810 Occurrence of tet(W) gene in a Clostridium
difficile clinical isolate
P. Mastrantonio, F. Barbanti, P. Spigaglia (Rome, IT)
P1811 Macrolide resistance determinants are
prevalent and readily selected for in viridans
group streptococci among healthy Norwegian
adults
P. Littauer, B. Haldorsen, M. Krämer, B. Aasnæs,
G.S. Simonsen, A. Sundsfjord (Tromsø, NO)
P1812 Relationships in genotype, phenotype, T type
and PFGE type among macrolide-resistant
Streptococcus pyogenes strains isolated in
the Czech Republic
V. Jakubù, P. Urbá?ková, L. Straková (Prague, CZ)
page 144 Final Programme
P1813 Analysis of trends for susceptibility of the
B. fragilis group from 1997–2004, a US survey
D.R. Snydman, N.V. Jacobus, L.A. McDermott,
R. Ruthazer, Y. Golan, D.W. Hecht, S.M. Finegold,
E.J.C. Goldstein, L. Harrell, S. Jenkins,
C.L. Pierson, J. Rihs, R. Venezia, V.L. Yu,
S.L. Gorbach (Boston, Chicago, Los Angeles,
Santa Monica, Durham, Charlottte, Ann Arbor,
Pittsburgh, Baltimore, US)
P1814 Observed duration of nasopharyngeal
carriage of penicillin-resistant pneumococci:
relations to age and serogroup
P. Geli, L. Högberg, H. Ringberg, E. Melander,
M. Lipsitch, K. Ekdahl (Solna, Malmö, Lund, SE;
Boston, US; Stockholm, SE)
P1815 Erythromycin-resistant Streptococcus
pneumoniae isolated in Spain: serotypes,
clones and mechanisms of resistance
L. Calatayud, J. Linares, C. Ardanuy,
E. Cercenado, A. Fenoll, E. Bouza, R. Pallares,
R. Martin for the Spanish Pneumococcal
Infection Study Network
P1816 Changing patterns of antimicrobial resistances
among bacterial isolates recovered from
European patients hospitalised with
pneumonia: report from the SENTRY Antimicrobial
Surveillance Programme (1998–2004)
T. Fritsche, H. Sader, D. Biedenbach, J. Streit,
R. Jones (North Liberty, US)
P1817 Distribution of capsular and surface poly -
saccharide serotypes of methicillin-resistant
Staphylococcus aureus in Germany
C. von Eiff, K.L. Taylor, A.I. Fattom, G. Peters,
K. Becker (Munster, DE; Rockville, US)
P1818 Molecular epidemiology of methicillinresistant
Staphylococcus aureus isolates
collected in a national screening study in
hospitals in Luxembourg in 2003
J. Mossong, P. Marques, M. Sertznig,
D. Hansen-Koenig, D. Meunier, R. Hemmer,
A. Hakim, F. Schneider on behalf of the National
Group on Preventing Nosocomial Infections
(GNPIN)
P1819 First detection of vancomycin-resistant
enterococci in Russia: genetic background
A. Mironova, E. Cherkashin, G. Kliasova,
V. Tishkov, A. Brilliantova, S. Rezvan, S. Sidorenko
(Moscow, RU)
P1820 Study of resistance and clonal relatedness of
clinical isolates of Stenotrophomonas
maltophilia from a hospital in northern Spain
C. Valderrey, E. Sevillano, F. Calvo, L. Gallego
(Bilbao, ES)

Poster Sessions Tuesday, April 4, 2006
P1821 Invasive pneumococcal disease in adults in
North-Rhine Westphalia, Germany, 2001–2004
M. van der Linden, A. Al-Lahham, R. Reinert
(Aachen, DE)
P1822 Surveillance of carbapenem resistance among
Enterobacteriaceae: species and geographic
distribution
C.A. Wood, J.W. Chow, T.A. Snyder,
M.A. Abramson, G. Gallagher, M.J. DiNubile,
R.M. Gesser (West Point, US)
P1823 Exploring the molecular basis for differences
in phenotype of Salmonella enteritidis typing
phage
N. DeLappe, D. Morris, M. Cormican (Galway, IE)
12:00–13:00
Interesting case reports
P1824 Sporadic orofaringeal tularaemia in 2 cases
Y. Tezer, C. Kader, O. Memikoglu, H. Kurt
(Ankara, TR)
P1825 Tularaemia presenting with tonsillopharyngitis
and cervical lymphadenitis:
two case reports
B. Kandemir, I. Erayman, M. Bitirgen,
E. Turk Aribas, A.C. Inkaya, S. Guler (Konya, TR)
P1826 A case of nonclostridial crepitant cellulitis
which is due to Escherichia coli
C. Ayaz, M. Ulug, M.K. Celen, M.F. Geyik,
S. Hosoglu (Diyarbakir, TR)
P1827 A case of iliopsoas abscess which is due to
Pseudomonase aeruginosa
C. Ayaz, M. Ulug, M.K. Celen, M.F. Geyik,
S. Hosoglu (Diyarbakir, TR)
P1828 Cervical lymphadenitis in a diabetic woman
F. Çokça, A. Azap, S. Göçmen, H. Erdi Sanli,
S. Gül (Ankara, Kirikkale, TR)
P1829 Bacterial spondylodiscitis: an evaluation of
67 patients
I. Villa Blanco, O. García Regata, J.D. García
Palomo, J.L. Peña, J.P. Horcajada, M.C. Fariñas
(Santander, ES)
12:00–13:00
Meningitis and endocarditis
P1830 Fastidious Gram-negative micro-organisms
as causative agents of cerebral abscess.
Consequences on medical and surgical
treatment
R. Manfredi, S. Sabbatani, F. Chiodo (Bologna, IT)
P1831 Aetiologies and antimicrobial resistance
profiles of purulent meningitis study carried
out in a hospital of infectious diseases, Algiers
D. Mohammedi, M. Ouar-korichi, N. Kerrad,
D. Ouerdane, F. Mechouet, S. Khaled
(Algiers, DZ)
P1832 Management of meningitis and knowledge of
meningitis guidelines amongst medical staff
in a large teaching hospital in England
V. Price, M. Pareek, M.J. Wiselka (Leicester, UK)
P1833 Prevalence of penicillin-resistant pneumo cocci
in Streptococcus pneumoniae meningitis
D. Dimitriu, L. Cochior, A. Vata, O. Filip, V. Luca,
C. Luca, D. Mihalache, C. Dorobat, M. Negoita
(Iasi, RO)
P1834 Community-acquired bacterial meningitis in
the elderly
M. Weisfelt, D. van de Beek, L. Spanjaard,
J.B. Reitsma, J. de Gans (Amsterdam, NL)
P1835 Incidence of serogroups and penicillin
susceptibility in Neisseria meningitidis
isolates (1996–2004)
F. Pardo, P.A. Romero, M.L. Pérez del Molino,
A. Gómez, L. Moldes, M. Treviño, V. Túñez
(Santiago de Compostela, ES)
P1836 A four-year retrospective analysis of infective
endocarditis in a Belgian university hospital
N. de Visscher, B. Delaere, B. Krug, Y. Glupczynski
(Yvoir, BE)
P1837 Prosthetic valve endocarditis in southern
Spain. Study of 111 cases
A. Plata, A. Villalobos, J.M. Reguera, A. Alarcon,
J. Galvez, J. Ruiz, J.M. Lomas, J. De la Torre,
F. Miralles on behalf of the Andalusian Group for
the Study of Cardiovascular Infections
P1838 Outcome of infective endocarditis
E.E. Hill, S. Vanderschueren, P. Herijgers,
M-C. Herregods, P. Claus, W.E. Peetermans
(Leuven, BE)
P1839 Epidemiology and aetiology of infective
endocarditis
E.E. Hill, P. Claus, M-C. Herregods, P. Herijgers,
S. Vanderschueren, W.E. Peetermans
(Leuven, BE)
P1840 The role of aminoglycosides in combination
with a beta-lactam for the treatment of
bacterial endocarditis: a meta-analysis of
comparative trials
M. Falagas, D. Matthaiou, P. Papastamataki,
I. Bliziotis (Athens, GR)
www.escmid.org/eccmid2006
page 145

Poster Sessions Tuesday, April 4, 2006
P1841 Outpatient antimicrobial therapy for infective
endocarditis. Single-centre experience
C. Cervera, A. Del Río, L. García, M. Sala,
A. Olivera, M. Almela, A. Moreno, C. Mestres,
F. Marco, J.M. Miró (Barcelona, ES)
12:00–13:00
Epidemiology and outbreaks
P1842 Outbreak of botulism type E associated with
eating traditional soup in a family group in
Iran
P. Vahdani, D. Yadegarynia, M. Keshtkar Jahromi,
O. Eilami, M. Zare Dehabadi (Tehran, IR)
P1843 An outbreak of group G streptococcal
pharyngitis among hospital personnel
considered to be food-borne
N. Karabiber, A. Gurbuz Ertas, M. Karahan,
E. Aykut Arca, Z.C. Karahan, A. Tekeli
(Ankara, TR)
P1844 Outbreak of acute gastroenteritis in an air
force base in Western Greece
E. Jelastopulu, T. Constantinidis, T. Kolokotronis,
D. Venieri, G. Komninou, C. Bantias
(Patras, Andravida, GR)
P1845 Occurrence, characterisation and antimicrobial
resistance pattern of Staphylococcus
aureus strains isolated from dairy products in
southern Italy
G. La Salandra, E. Goffredo, C. Pedarra,
M.C. Nardella, A. Parisi, A. Dambrosio,
N.C. Quaglia, G.V. Celano, G. Normanno
(Foggia, Valenzano, IT)
P1846 Eco-epidemiology of cryptosporidiosis
1999–2003, in HSE West, Ireland
D. McKeown, R. Cloughley (Galway City, IE)
P1847 Bacterial flora in pharyngeal swabs of family
practitioners’ patients from Silesian province,
Poland
J. Józwiak, I. Szymczyk, W. Lukas, B. Boruta,
J. Skorupka (Zabrze, PL)
P1848 Micro organisms isolated from corneal and
conjunctival samples in a Spanish teaching
hospital
N. Arenal, D. Domingo, J.L. Navarro, J.M. Azcona,
E. Garcia-Peñuela, M. Lopez-Brea (Madrid, ES)
page 146 Final Programme
P1849 Spectrum and susceptibilities of bacteria
isolated from the vitreous fluid of patients
undergoing vitrectomy
D. Mylona-Petropoulou, N. Markomichelakis,
K. Ziva, N. Ikonomopoulos, M. Theodoropoulos,
C. Koutsandrea, H. Malamou-Lada (Athens, GR)
P1850 The prevalence of intestinal parasitic infection
in the students of primary schools in Nazloo
region in Urmia during 2004 – 2005
K. Hazrati Tappeh (Urmia, IR)
P1851 Legionella pneumophila as an occupational
risk factor for inter-city bus drivers
Y. Polat, Ç. Ergin, I. Kaleli, A. Pinar
(Denizli, Ankara, TR)
12:00–13:00
Urinary tract infection
P1852 The frequency of and risk factors for
asymptomatic bacteriuria in type 2 diabetes
mellitus
H. Turan, K. Serefhanoglu, A.N. Torun,
S. Kulaksizoglu, M. Kulaksizoglu, B. Pamuk,
H. Arslan (Konya, Ankara, TR)
P1853 Descriptive study of complicated pyelonephritis
A. Villalobos, A. Plata, I. Portales, N. Macías,
A. Federico, S. Santamaría, D. López, G. Uribarri,
J.D. Colmenero (Malaga, ES)
P1854 Urinary tract infections in women suffering
from urinary incontinence in individual family
practice
E. Mizgala, W. Lukas, H. Trzeciak, W. Drzastwa
(Zabrze, PL)
P1855 Incidence and in vitro antibiotic resistance of
streptococci in community-acquired urinary
tract infections
E. Ikonomopoulou, C. Verra, H. Pavlidou,
K. Papadopoulos, N. Baikoussis, E. Stavrianou,
I. Katsarou, A. Christopoulos, A. Gioka, A. Regli
(Patras, GR)
P1856 Virulence and resistance of Escherichia coli
isolates from pregnant and non-pregnant
women with community-acquired urinary
tract infections in a Kuwait hospital
E. Draghijeva, P. Egbase, S. Mathai (Kuwait, KW)
P1857 The penetration of telithromycin in
gynaecological tissues and activity in
cervicitis patients
H. Mikamo (Gifu, JP)

Poster Sessions Tuesday, April 4, 2006
P1858 Acute uncomplicated pyelonephritis may be
safely treated with 7 days of an oral fluoroquinolone.
Analysis of two prospective multicentre
studies in the emergency department
D. Elkharrat, P. Veyssier, H. Botto, E. Vicaut,
G. Pottel, H. Drugeon, F. Tremolieres
for the French AUP Study Group
P1859 Coryneform bacteria in prostatitis patients:
species composition and antibiotic
susceptibility
S. Türk, P. Korrovits, K. Ausmees, M. Punab,
R. Mändar (Tartu, EE)
P1860 Serologic evaluation of cytomegalovirus and
Listeria monocytogenes in women with
abortion
M. Jamshidi, M. Amirian, A. Sotode, M. Zangane
(Bandar Abbas, IR)
P1861 Serum and prostatic tissue concentrations
of moxifloxacin (400 mg) after a single
intravenous infusion in patients with
benign prostatic hyperplasia undergoing
transurethral resection of the prostate
F.M.E. Wagenlehner, C. Lunz, F. Kees, W.F. Wieland,
K.G. Naber (Straubing, Regensburg, DE)
12:00–13:00
FUO, soft tissue and miscellaneous infections
P1862 A prospective multi-centre study of the value
of F-18-fluorodeoxyglucose positron emission
tomography as part of a structured diagnostic
protocol in patients with fever of unknown
origin
C.P. Bleeker-Rovers, F.J. Vos, A.H. Mudde,
A.S. Dofferhoff, L.F. de Geus-Oei, A.J. Rijnders,
P.F.M. Krabbe, F.H.M. Corstens, W.J.G. Oyen,
J.W.M. van der Meer (Nijmegen, Doetinchem,
Arnhem, NL)
P1863 Emergence of clindamycin-resistant
Streptococcus pyogenes causing cellulitis
C. Gudiol, J. Carratala, N. Fernandez-Sabe,
R. Alfonso, L. Calatayud, F. Tubau, C. Ardanuy,
F. Gudiol (Barcelona, ES)
P1864 Risk factors for community-acquired
bacteraemic Gram-negative cellulitis
G. Peralta, E. Padrón, M.P. Roiz, M.J. Rodriguez-
Lera, I. De Benito, L. García-Mauriño,
J.C. Garrido, L. Ansorena, M.J. Grande,
M.B. Sánchez (Torrelavega, Santander, ES)
P1865 Is erysipelas-associated tinea pedis a site of
streptococcal colonisation?
L. Hocqueloux, L. Bret, M. Niang, D.M. Poisson
(Orleans, FR)
P1866 Bacteriology of acute erysipelas
T. Siljander, S. Vähäkuopus, M. Karppelin,
J. Syrjänen, M. Toropainen, J. Kere, J. Vuopio-
Varkila (Helsinki, Tampere, FI; Huddinge, SE)
P1867 The evaluation of Fournier’s gangrene severity
index score in 11 patients
M. Ulug, M.K. Celen, M.F. Geyik, C. Ayaz, S. Girgin
(Diyarbakir, TR)
P1868 Clinical outcomes of Staphylococcus aureus
infections in the community
S. Davis, M. Perri, A. Singh, K. Spiers, M. Hayden,
R. Muder, M. Zervos (Detroit, Royal Oak,
Chicago, Pittsburgh, US)
P1869 Microbiological analysis of root canals
associated with periapical abscesses and
the antimicrobial susceptibility of isolated
bacteria
S. Ozbek, A. Ozbek, M. Koseoglu, S. Evcil,
A. Erdogan, A. Ayyildiz (Erzurum, TR)
P1870 Human infections due to Pasteurella multocida
in a tertiary care hospital: a twelve-year review
A. Christidou, S. Maraki, Z. Gitti,
K. Magurean-Zervaki, Y. Tselentis (Heraklion, GR)
P1871 Infections caused by Nocardia cyriacigeorgici
in Zaragoza, Spain: identification and
antibiotic susceptibility
C. Villuendas, B. Moles, V. Rodriguez-Nava,
A. Couble, F. Laurent, M. Revillo, P. Boiron
(Zaragoza, ES; Lyon, FR)
P1872 High frequency of single-step resistance
mutations in Nocardia farcinica exposed
to quinolones
U.S. Jensen, J.D. Knudsen, K. Schønning
(Hvidovre, DK)
P1873 Correlation between clinico-laboratory
findings and a positive IgM ELISA test for
leptospira: a retrospective study
E. Mendrinou, P. Goudas, A. Regli (Patra, GR)
P1874 Evaluation of continuous ambulatory
peritoneal dialysis-related peritonitis
attacks in Ankara
S. Tekin Koruk, M.A. Yetkin, I. Koruk, F.S. Erdinc,
S. Sahan, N. Tulek, M. Duranay, A.P. Demiröz
(Ankara, Konya, Samsun, TR)
www.escmid.org/eccmid2006
page 147

Poster Sessions Tuesday, April 4, 2006
12:00–13:00
Paediatric viral infections
P1875 Particularities of measles outbreak in
Constanta, Romania
C.S. Cambrea, S. Rugina, M. Ilie, C. Marcas,
D. Tanase, I. Cretu, C.N. Rugina (Constanta, RO)
P1877 Human metapneumovirus infection in
children presenting to hospital in Belfast
E. McHenry, P.V. Coyle, P. Jackson, M. Shields
(Belfast, UK)
P1878 Prevalence of parainfluenza and influenza
viruses amongst children with upper
respiratory tract infection
U. Arslan, D. Findik, I. Tuncer (Konya, TR)
P1879 Clinical features of children with adenovirus
serotype 3 infection
C-H. Lin, Y-C. Huang, C-G. Huang, T-Y. Lin, T-Y. Lin
(Kweishan, Taoyuan, TW)
P1880 Infectious mononucleosis-like syndrome in a
children’s hospital in Greece
I. Varzakakos, K. Papavsileiou, H. Papavasileiou,
A. Makri, D. Sbokou, Z. Karakatsani, A. Voyatzi
(Athens, GR)
P1881 Detection of enterovirus, parvovirus B19 and
human herpes virus type 6 by real-time PCR
in blood samples of infants with febrile
syndrome
M. García-Álvarez, M.D. Folgueira, C. Prieto,
M.J. Babiano, P. Rojo, J.R. Otero (Madrid, ES)
P1882 Molecular epidemiology and clinical features
of rotavirus infection in Iranian children
M. Taremi, F. Farahtaj, L. Gachkar, E. Mazaheri
Tehrani, H. Edalatkhah, A. Fayaz, M. Zali
(Tehran, IR)
P1883 Serological study of prevalent rotaviruses in
Tehran
E. Habibi, S. Ghorbani, A. Jarollahei, Z. Habibi
(Tehran, Zanjan, IR)
P1884 Neurological manifestations in Varicella
C.P. Popescu, S-A. Florescu, M. Cotiga,
G. Enache, R.F. Botgros, L. Raduta, P.I. Calistru,
E. Ceausu (Bucharest, RO)
page 148 Final Programme

Name Page Name Page Name Page Name Page
Acar J. F. 45
Akova M. 48
Allegranzi B. 55
Appelbaum P. 60
Berendt A. 37, 42
Bille J. 55
Blijlevens N. 54
Blumer J. 46
Bonten M. 31
Bouza E. 41
Brun-Vézinet F. 34
Calandra T. 60
Cambau E. 34
Cantón R. 54
Carlet J. 29
Carmeli Y. 37
Chidiac C. 34
Christiaens T. 60
Christmann D. 65
Cole S. 65
Cookson B. 32
Cordonnier C. 41, 48
Cornaglia G. 34, 62
Cornely O. 37
Craig W. 54
Cuenca-Estrella M. 32, 66
De Lamballerie X. 55
Dellamonica P. 37, 46, 52
Denning D. 32, 43
Derouin F. 32
Desenclos J-C. 48
Di Perri G. 53, 64
Donelli G. 32
Drosten C. 39, 60
Drusano G. 54
Dupont B. 31, 62
Esposito S. 63
Etienne J. 43
Evengård B. 32
Fabry J. 35
Farrell D. 58
File T. 65
Filip R. 41
Finch R. 41, 51
Fouchier R. 35, 60
Francioli P. 37, 53
French G.L. 38, 43
Friedrich A. 27
Frimodt-Møller N. 60
List of Chairpersons
Garau J. 49
Geddes A. 51
Gemmell C.G. 62
Glasmacher A. 31
Gniadkowski M. 54
Goebel F.D. 56
Goldstein E. 31
Goldstein F. 46
Goossens H. 56, 64
Gorvel J-P. 61
Graninger W. 56, 64
Grundmann H. 57
Guiso N. 60
Gutmann L. 53
Gyssens I.C. 32, 66
Haeggman S. 65
Hatz C. 63
Herrmann M. 43
Hill D. 63
Hoepelman A. 53
Høiby N. 29, 32, 38
Hooper D. 53
Hryniewicz W. 49
Ieven M. 27
Imbert C. 38
Irving W. 53
Itani K. 38
Jarlier V. 34
Kahlmeter G. 56, 65
Karchmer A. 51
Kern W. 41
Kozlov R. 43
Krämer A. 65
Kriz P. 45
Leclercq R. 34
Leibovici L. 54
Lerner S. 65
Linde A. 56
Livermore D. 42
Ljungman P. 48
Lode H. 46
Lortholary O. 58
Low D. 37
McDonald C. 41
Marie J.P. 31
Marshall J. 60
Martinez-Martinez L. 48
Masterton R. 51
Mègraud F. 32
Miró J. 53
Moellering Jr R. 48, 58
Mönke-Müller K. 32
Monnet D.L. 56, 64
Montravers P. 51
Moreillon P. 54
Mouton J.W. 29, 65
Naber K. 63
Nagy E. 63
Nord C.E. 31, 48
Nordmann P 34
Norrby S.R. 38, 52, 56
Novelli V. 41
Osterhaus A. 44
Pal T. 48
Pappas G. 41
Patterson T. 51
Pechère J-C. 62
Peters G. 58
Petersen E. 27
Pittet D. 57
Plésiat P. 42
Portaels F. 42
Poxton I.R. 41
Read R. 52
Ribaud P. 51
Roger P.M. 64
Roilides E. 66
Rossolini G.M. 46, 54
Rubinstein E. 64, 66
Ruef C. 27, 56, 62
Ruf B. 48
Ruhnke M. 62
Sansonetti P. 43
Santibanez S. 39
Scott G. 35
Senneville E. 42
Skov R. 65
Smith D. 44
Sollet J-P. 51
Stahl J-P. 43
Steinbach W. 58
Stray-Pedersen B. 41
Struelens M. 34, 38,
52, 58
Tang C. 43
Tassios P. 31
www.escmid.org/eccmid2006
Tenover F.C. 45
Theuretzbacher U. 60
Tortoli E. 42
Towner K. 41
Ünal S. 31, 55
van Belkum A. 61, 63
van de Beek D. 34
Van Eldere J. 48
Vauterin P. 31
Verheij T. 60
Verweij P.E. 55
Vila J. 38
Viscoli C. 63
Voss A. 46, 52, 56
Wallace R. 65
Walsh T. 56
Welte T. 41
Wilcox M. 45
Woodhead M. 41
Zambon M. 55
page 149

List of Authors
Name Number Name Number Name Number Name Number
Aalto, H. P485
Aarestrup, F.M. S295, P1233
Aasnæs, B. P514, P1811
Ababkova, T. P522
Abaev, I.V. P1351
Abbasi, M. P1031
Abd, H. P1196
Abdel Salam, S.M. P1752
Abdi Liae, Z. P1033, P1117
Abergel, A. P770
Abo Khadr, N.A. P1752
Abramson, M.A.P1260, P1806,
P1807, P1822
Abril, V. P675, P1075
Abubakar, I. P1732
Accardo, S. P715
Acero, D. P536
Acosta, B. O162, P1655
Acquarolo, A. O275
Actis, L. P833
Acuner, I.C. P1278
Adamski, A. P1302
Adamson, V. P1089, P1634
Adeli, A. P576
Aderem, A. O396
Adibi Motlagh, B. P579
Adjide, C. P1246
Adlerberth, I. P1171, P1392
Adukauskiene, D. P1264
Afentra, P. P997
Afkou, Z. P1002, P1270
Afshar, B. P972
Afzali, N. P647
Agalar, C. P839
Agalar, F. P839
Agathagelides, A. O419
Aggarwal, P. P1799
Aghamirian, M.R. P1221
Agmon, P. O174
Agodi, A. P1022
Aguado, J.M. P1200
Agüero, J. O52
Aguilar, L.P674, P1153, P1551,
P1552
Aguilar, M. P559
Aguilar-Guisado, M. P692, P693
Aguinaga, A. O74
Agvald-Ohman, C. P1202
Ahlqvist, T. P956, P958
Ahmad, S. O62, P778, P866,
P1106, P1651
Ahmadi, H. P578, P579
Ahmadinejad, Z. P1117, P1702
Ahmadnejad, F. P647
Ahmed, K. P986
Ahmed Fahmy Ali, M.F. P1445
Aikawa, N. O425
Ailamazyan, E. P724
Aires de Sousa, M. O311
Ajassa, C. O399
Ajluni, M. P1347
Ak, S. P1455
Akan, H. P1508
Akan, O. P986
Akcam, F.Z. P781
Akgun, Y. P1589
Akhan, S. P897, P1288
Akhavan, P. O216
Akin, L. P1096, P1097, P1099
Akinci, E. P916, P1088
Akkerman, A. O438
Akova, M. S1, S197,
P737, P1508
Akrivoussi, E. P1593
Aksaray, S. P571
Aksit, F. P1016
Aksoy, F. P1094
Aktas, A.E. P1795
Aktas, E. P1345
Aktas, F. P1104
Akyon, Y. P1077, P1449,
P1695
Al Hamdani, A. P1070
Al Laham, N. P1730
al Naiemi, N. P1620, P1748
Al-Attiyah, R. P1106
Al-Barrak, M. P1477
Al-Dhaheri, K. P568
Al-Doori, Z. O308, P893
Al-Jamal, M. P1477
Al-Lahham, A. P1595, P1809,
P1821
Al-Nakib, W. O62, P778,
P1651
Al-qurashi, A.M. P1688
Aladueña, A. P1416
Alafaki, H. P550
Alam, F. P864
Alarcon, A. P1837
Alarcón, T. P716, P758,
P1704, P1746
Alava, J.A. P467, P668,
P669, P1014
Albur, M.S. P1079
Alcalá, L. P1256
Alcazar, F. P1058
Aldabó, T. P1007
Aldea-Mansilla, C. P944
Aldeguer, X. P536
Aldus, C. P1732
Alebouyeh, M. P1184
Alecu, F.S. P728, P1726
Alegakis, D. P1049
Alekseeva, N. P840
Alepopoulou, E. P1765
Alexandrou-Athanasoulis, H.P470,
P1362
Alexandru, I. O259
Alexiadou, E. P1526
Alexiou, M. P1287
Alexiou, N. P1081
Alexiou-Daniel, S. P450, P697,
P749, P808
Alferova, I. P1519
Alfonso, R. P1863
Alhaddad, N. P547
Ali, Maisa P778
Ali, Mashook O128
Alix, J. O395
Aljeldah, M. P820
Alkis, S. P1427
Allegranzi, B. O77, O272,
P660, P661
Allen, V. P1252
Allerberger, F. P1760
Allewelt, M. P1713
Allice, T. P653, P655
Allione, B. O423
Allix, C. O134
Allsopp, M.E.P. P561
Alm-Kristiansen, K. O312
Almagro, P. O224
Almanasreh, N. O440
Almas, A. P1382
Almela, M. P1158, P1841
Alonso, M. O74
Alonso, P.L. P1615
Alou, L. P1551, P1552
Alp, E. P555, P850
Alpat, S.N. P1016
Altuncekic, A. P1095
Altwegg, M. O219
Alvarez, A. P614, P615
Alvarez, C.A. P1380
Álvarez, Maximiliano P1403
Alvarez, Marta P650
Alvarez, Muriel P1140
Álvarez, P. P1403
Álvarez Díaz, H. P1127
Alves, A.F. P1419
page 150 Final Programme
Alves, M. P968, P1797
Aman, R. O276
Amat, E. P1158
Amblar, G. P513, P1247
Ambler, J.E. P1301
Ambrasiene, D. P545, P764
Ambrose, P.G. O360, O361, P1553
Amer, M. O215
Amicosante, G. O75, P934,
P1243, P1418
Amiguet, J.A. O131, P1122, P1134
Aminharati, F. P1646
Amiot, L. O398
Amirian, M. P1860
Amirmozafari, N. P1184
Amjad, M. P1393
Ammari, L. P1219
Amor, A. P1087
Amorim, J.M. P1334, P1773
Amorim, M.L. P1334
Amoros, F. P1035
Amsler, K. P1569
Amyes, S.G.B. P477, P1237
Anagnostopoulou, M. P759
Anagnostou, S. P1125, P1434
Anastasopoulos, T. P1049
Anastassiou, E.D. P1354
Anders, A. P461
Andersen Leth, R. P663
Anderson, K. O115
Andrade, S. P920
André, C. P957
André, M. O393, P1463
Andreassen, S.O303, O440, P623,
P1300
Andreev, A.L. P840
Andrei, M. P1775
Andrejak, C. P1139
Andremont, A. O261
Andres, R. P1514
Andresen, K. P543, P1758
Andrews, N. P801
Angeletti, C. P598
Angelo, H. P871, P872
Anglés d’Auriac, M. P955
Anguita Alonso, P. O70
Angulo-Gonzalez, D. O421
Anisimova, V.A. P1351
Ankirskaya, A. P724
Ansari, N. P584
Ansorena, L. P918, P1864
Antal, M. P523
Antal, Z. P528
Antonaki, G. P1008
Antonakis, G. P553
Antonelli, G O399
Antoniadou, A.O419, P1017, P1329,
P1343, P1727
Antonopoulou, A. P1178, P1528
Antonopoulou, H. P662
Antonovitch, N. P1483
Antunes, N.T. O129
Antunes, P. P1370
Aoun, J.P. P775
Apine, I. P1476
Apostolaki, T. P799
Apostolou, T. P759
Appelbaum, P.C. O116, S342,
P1267
Aquili, V. O129, P1243
Aquilini, E. P913
Arabaci, H. P846
Aragones, C. O162
Arakawa, Y. P1274
Aral, M. P849, P1427
Arazo, P. O131, P1134
Arbique, J. P1725
Arch, O. P1348
Archimbaud, C. P530
Archipova, A.S. P978
Arda, B. P1215, P1472
Ardanuy, C. P1276, P1815,
P1863
Arefian, E. P570
Arena, A. P1185
Arenal, N. P1704, P1746,
P1848
Arendrup, M.C. O428, P737, P1149
Arévalo, M.P. P835
Arias, Á. P835
Arias, M.A. P1122
Aribandi, A.K. P1079
Aribas, O.K. P1084, P1133
Arista, S. P1653
Ariza, J. P921, P1348
Armaganidis, A. P1017
Armengol, M. P443, P444, P446
Armero, Y. P1158
Arnaiz, A. P890
Arndt, R. P562
Arnitz, R. P1568
Arnold, U. P1801
Arns da Cunha, C. O424
Aronsson, F. P958
Arruda, A.C. P1391
Arsic Arsenijevic, V. P1206
Arslan, E. P837
Arslan, H. O267, O302, P719,
P720, P721, P748, P846,
P906, P982, P1141,
P1217, P1772, P1852
Arslan, U. P1878
Arsu, G. P1472
Artemenko, A. P1557, P1558
Artero, A. O271, P915
Arunyingmongkol, K. P1668
Arvis, P. P1061
Asadian, F. P1755
Asci, G. P1215
Ascoli, V. P1070
Asensi, V. P1368
Asgharzadeh, A. P1588
Ashok, A.C. P1787
Askar, H. P778
Aslani, M.M. P1684
Asmolov, A. P1121
Asmonaite, K. P764
Asseray, N. P464
Assithianakis, P. P1480
Astashkin, E.I. P1351
Asticcioli, S. P735
Astrakhantseva, I. P631
Atalay, S. P1472
Athanasia, S. P666, P1343,
P1528
Athanassiadou, A. P883
Athanassiou, K. P666
Atherton, G. P737
Atifeh, R. P1443
Atun, R. P1118
Atutxa, I. P668, P669
Aubry, A. O57, O133
Augustinova, A. P1091
Aumaitre, J-F. P1607
Ausmees, K. P1859
Auzinger, G. P1020, P1780
Avcu, S. P1085
Avellon, A. P1652
Aversa, F. O262
Avila, M. P765
Avila-Miyazawa, I. P1103
Avlamis, A. O270, P1289
Avlonitis, S. P814
Avnon, L. P1042
Ayaz, C. P772, P790, P847,
P848, P1826,
P1827, P1867
Aydin, K. O102, P1094
Aydin, N. O116, P558, P860
Aygen, B. P555, P850

List of Authors
Name Number Name Number Name Number Name Number
Aygul, K. P1345
Aygün, Z. P884
Aykut Arca, E. P1843
Ayyildiz, A. P1795, P1869
Azap, A. P1828
Azap, Ö.K. O267, P719,
P720, P721, P982
Azass, P. O420
Azavedo, J. P1252
Azcona, J.M. P1848
Azimi-Rad, M. P1684
Aznar, E. P716, P758, P1704
Babali, V. P1719
Babalis, D. P1349
Babela, R. P700
Babelova, O. P700
Babiano, M.J. P1881
Babinchak, T. P1781
Babini, G. P1418
Bachvarova, A. P1056
Badell, A. P559
Badescu, A. P1067
Badiaga, S. O420
Bae, I.-G. P1803
Baelde, H. O158
Bagattini, M. P1268
Bagel, S. P1582
Bagger-Skjøt, L. O433, P1376
Baghbani-Arani, F. P1684, P1687
Bagirova, N.S. P699
Bahar, G. P1591
Bahrmand, A. P1255
Bai, G.-H. O132
Baik, S-H. P1015
Baikoussis, N. P1855
Bailey, S. P1112
Bailly, J.L. P530, P770
Baj, A. P1164
Bajaksouzian, S. P1569
Bajanca-Lavado, M.P. P793, P1630
Baka, S. P873
Baker, T. P1495
Bakker-Woudenberg, I.A.J.M. O362
Bal, N. P455
Balaban, Neriman P723, P916
Balaban, Naomi O96
Balabanic-Kamauf, B. P1304
Balabanova, Y. P1118, P1121
Balagué, C. P1243
Balakrishnan, I. P993, P1475,
P1728
Balakrishnan, M. P681
Balaska, K. P759
Balemans, W.A. P818
Ball, P. P1576, P1578
Ballester, E. P675
Ballester, J. P1075
Balmelli, C. O76
Balotescu, M.C. O259, P582,
P1163, P1285,
P1359, P1560
Balsalobre, L. P1276
Bambl, E. O315
Bamdad, T. P570
Banasova, K. P817, P1062
Bancescu, G. P1775
Bandettini, R. P836, P1208, P1776
Bange, F.C. P1105
Bangsborg, J. P543
Bangtrakulnonth, A. P557
Bantias, C. P1844
Banu, O. P1163
Baptista, P. P1109
Baquero, F.P924, P1050, P1051,
P1053, P1383, P1405,
P1415, P1417,
P1806, P1807
Baquero, M. P1087
Bara, A. P1460
Baran, G. P916
Barbabietola, G. P1500
Barbanti, F. P1273, P1810
Barber, A. P1487
Barberán, J. P674
Barbieri, S. P689
Barbry, P. P1700
Barbut, F. O276, P1635
Barcenas-Morales, G. P1103
Barchitta, M. P1022
Barcia-Macay, M. O356
Barclay, W. P1360
Barer, M. P1112
Barker, K. P1500
Barkhordary, F. P576
Barlow, G. P622
Barnes, M. P952
Barnes, R. S23, S372
Barreda, B. P1433
Barrett, A. P1138
Barriere, S. P1538, P1539
Barrios, C. O424
Barrios, J.L. P467, P1014
Barros, R.M. O167, P898
Barry, A. O397
Barsic, B. P1176
Bart, A. P1620, P1748
Bartels, M.D. P471, P472, P473
Barth, J. P1545
Barthel, C. O258
Bartkoviak, M. P1091
Bartoszewicz, M. P943
Bartunek, P. P1194
Barzon, L. O58, P597, P600,
P687
Basaras, M. P766
Basdeki, A. P885
Basma, V. P1515
Bassetti, S. P1373
Bast, D.J. P1150, P1155, P1252
Bästlein, E. O153, O154
Bastug, A.T. P1088
Batista, N. P1216
Battegay, M. P1373
Battleman, D. P1497
Bauer, E. O118
Bauernfeind, A. P502, P1619
Bauk, N. P1162
Bauraing, C. P929
Baykal, S. P1345
Baykam, N. P571, P852,
P853, P1666
Baysallar, M. P723
Bazhora, Y. P1121
Baziaka, F. P1178
Bean, D.C. P1770
Beaudry, A. O299
Beaugerie, L. P1648
Bebear, C.M. P725, P726
Bebear, Ch. P725, P726,
P967, P1587
Becker, K. P461, P1730, P1817
Becker, S. P575
Bedenic, B. P928, P1162
Bednarova, J. P991
Beer, J. P463
Begendik Comert, F. P1345
Begolli, I. P659
Begolli, L. P659
Behdani, M. P1435
Behzadiyannejad, Q. P578, P579
Beiner, L. P453
Bekic, S. P1162
Belavin, P. P1664
Belec, L. P642
Belesiotou, H. P553
Bell, J. P899
Bellacicco, A.L. P1358, P1674
Bellamy, W. P972
Bellido, D. P833
Bellomi, F. O399
Beloborodova, N.V. P978
Belokrysenko, S. P724
Belov, A. P1073
Ben Ayad, A. P1120
Ben Chaabane, T. P1219
Benatti, C. O423
Bencza, J. P1091
Benderdouche, M. P942
Benini, A. P1517
Benítez, R. P675
Benjamin, R. P694
Benko, R. P1330, P1525
Bennett, P.M. P1234, P1378
Benton, B. P1543
Benvegnu’, F. P1070
Benvenuti, C. P1591
Berdal, J-E. O72
Berendt, A. E35
Bereswill, S. P1189
Berger, S.P. O263
Bergeron, E. O97
Bergès, L. P1451
Bergin, C. P760
Berglund, C. P1697
Bergonzi, M. P1123
Bergs, K. O212
Bergström, T. S43
Berhin, C. P992
Berild, D. P1461
Berisha, L. P659
Berisha, M. P659
Berkelbach O273
van der Sprenkel, J.W.
Bernal, C. P650, P651
Bernal, J.M. P890
Bernal, W. P1020, P1780
Bernard, P. P900
Bernardo, F. P823
Bernatoniene, G. P712
Bernhardt, H. P1231
Bernhardt, J. P1231
Bernier-Combes, A. P1481
Berra, D. P895
Berssenbruegge, C. O171
Bertazzoni Minelli, E. P1517
Berthier, F. O436
Bertini, A. P504
Bertino, J. P1559
Bertram, C.T. O435
Bertuccio, T. O93
Bertz, H. O147, P903, P1331,
P1346, P1796
Berzina, S. P1485
Beslagic, E. P640
Bessenyei, Z. P554
Best, E. P1680
Betermiez, S. P1650
Bettaccini, A. P1399
Betts, R. P1205
Bexiga, R. P823
Bhavnani, S.M. O360, O361, P1553
Bhoi, S. P1799
Bhusal, Y. P1115
Biagetti, C. P613
Biasolo, M.A. P687, P689
Bica, A. P481
Biedenbach, D. P1263, P1571,
P1816
Biehler, K. P1346
Biendo, M. P1246
Bierla, J. P751
Biernat-Sudolska, M. P970
Biertz, F. P575
Bigsten, A. P1182
Bille, J. O219, P454, P737,
P957, P1309,
P1366, P1394
Bille-Nielsen, M. P581
Billström, H. P1235, P1689
www.escmid.org/eccmid2006
Bingen, E. P1172
Binikos, I. P997, P1052
Bint, A.J. P813
Birkhoff, C. P1471
Birkin, J. P1460
Bisgaard, M. P1233
Bismuth, R. P1458
Bissery, A. P874
Bistryukov, V. O149
Bitirgen, M. P1085, P1662,
P1825
Bitti, D. P1798
Bittker, S. P1146
Bitz, F. P575
Biyikli, M. O124
Bjørnholdt, J. O72
Black, C. O299
Black, T. P1577
Blair, I. P1690
Blana, D. P1775
Blanc, D.S. O76, P1366
Blanc, V. O436
Blanc-Potard, A.B. O364
Blanch, J. P1035
Blanckaert, N. P984
Blanco, A. P1368
Blanco, R. P1014
Blanco, Y. P1007
Blasi, F. S84, S181
Bleeker-Rovers, C.P. P1862
Bleotu, C. O259, P1163
Blijlevens, N. K387
Bliziotis, I. P1006, P1018,
P1478, P1840
Bloembergen, P. P983
Blok, H.E.M. O273, P1344
Blomberg, B. P599
Blomfeldt, A. O72
Blondeau, B. O307
Blondeau, J. O304, O307, P1320
Blondeau, L. O307
Blossier, G. O364
Blum, T. P1713
Blumer, J. S180
Boccagni, P. P689
Böcher, S. O313
Bochud, M. O396
Bochud, P.-Y. O396
Bocizga-Jasik, M. P1100
Bock, S. P969
Bodini, C. P945
Bodmer, T. P1116
Bodur, H. P916, P1088
Boel, A. P1698
Boelens, H.A.M. O365, P585, P620
Boelle, P. O276
Bogaerts, P. P929, P1616
Bogavac, M. P1303
Bogdanovich, T. O116
Bogner, J. S86
Bogut, A. P1107
Boiron, P. P690, P1871
Bojar, M. P1194
Bokaei, P.B. P618
Bolay, S. O151, P1230
Bold, G. P1798
Boldrin, C. P689
Bollani, L. P945
Bolliger, D. O147
Bolmstrom, A. P705
Boluda, A. P1191
Bonacorsi, S. P1172
Bondor, C. P481
Bonfrate, N. P974
Bongiorno, D. P1585
Boniadian, M. P1755
Bonini, A O262, O423
Bonnet, E. P1140, P1612
Bonnet-Pierroz, A. P1722
Bonny, C. P770
page 151

List of Authors
Name Number Name Number Name Number Name Number
Bonora, M.G. O77
Bont, J. O123, P1471
Bonten, M.J.M.Workshop 3, O71,
O161, O166, E192,
S242, O273, S291,
P1019, P1344
Boost, M.V. P1448
Boparai, N. O421
Boquet, P. K386
Borbély, Á. P796
Borbone, S. P501, P1585
Borderi, M. P613
Boreux, R. P930
Borg, M.A. O309, P1482
Borgonovi, M. P1567
Borhani, K. P1624
Borok, S. O440
Boron-Kaczmarska, A. P1353
Borrow, R. P801
Borsetto, L. P1564
Borsos, S. O304, O307, P1320
Bortolato, A. P689
Boruta, B. P1847
Botea, S. P1775
Botgros, R.F. P777, P1661,
P1663, P1884
Botto, H. P1858
Bouchara, J.P. P676
Bouchillon, S.P486, P487, P488,
P489, P490, P491, P492,
P493, P494, P495, P496,
P497, P498, P499, P500,
P1311, P1312, P1313,
P1314, P1315, P1316,
P1317, P1318, P1319
Bouchuigui-Waf, K. P1212, P1229
Boukadida, J. P987
Boulestreau, H. P1470
Boulier, A. P525
Bouloy, M. P647
Boumis, E. P598, P621
Bourgeois-Nicolaos, N. O261
Bournakis, E. P1081
Bourvani, P. P666
Boutte, P. P624
Bouvet, A. P1342
Bouvet, E. O57, P596
Bouyer, S. P1076
Bouza, E. S89, S327, E333, P465,
P466, P480, P744,
P944, P1007, P1201,
P1256, P1276, P1422,
P1436, P1764, P1815
Bouzari, S. P1756
Bowker, K.E. P1148, P1527,
P1529, P1530,
P1531
Boye, K. P471, P472,
P473, P1659
Boysen, A. P581
Bozavoutoglou, E. P901, P902
Bozdogan, B. O116
Bozin, B. P1303
Bozzetta, E. P560
Bracher, S. P1237
Bradwell, A. P1724
Brancart, F. P1650
Branch, D.R. P618
Brandt, C.T. O433, P1165
Branger, M. P596
Brauers, J. P714, P1582, P1583
Brault, Y. P1784
Braun, H. P629
Braziulyte, J. P1264
Breen, J. P1709
Bregenzer, T. P1119
Brengel-Pesce, K. P1660
Brerra, R. P762
Bresciani, M. P469
Bret, L. P1865
Bretagne, S. P737
Brew, S.D. P1676
Brigante, G. O394, P1399
Brigham, B. P641
Brilliantova, A. P1819
Brink, A. O228
Brinklov Jensen, K. O220
Brinkman, M. P856, P857
Brito-Avô, A. O167
Brizio, A. P931
Brokalaki, H. P779
Brommann, J. O121
Bronk, M. P812, P1306
Bronner, S. P1514
Brook, A. P1535
Brooker, K. P1333
Brosnikoff, C. P456
Brossier, F. P1762
Broughton, K. P1724
Brouillard, J. P1423
Brouqui, P. O101, O420, P561,
P565, P1069, P1140
Brouwers, E.E.H.G. O392
Brown, D. P1432
Brown, G. P1069
Brown, S. P456
Brown, T. P1121
Bru, A. P675
Bruce, M. O220
Bruckner, D. P441
Bruijnesteijn van
Coppenraet, L.E.S. O263, P524
Bruins, M.J. P983, P1430
Bruinsma, N. P1383
Bruisten, S.M. P1068
Brum, L. O173, P1254
Brun-Buisson, C. O226, P1481
Brun-Vezinet, F. S249
Bruno, P. O417, O436,
P1612, P1627
Bruno, R. P602
Bruun, B.G. P1729
Bruun, N.E. P543
Bruynseels, P. P1656
Bryk, A. P1757
Brzychczy-Wolch, M. P806
Bucci, M. O399
Buchner, M. O154
Bucholc, B. P783
Buckley, V. P1411
Buckner, R. O175, P456
Buckwalter, M. P1536
Bucur, M. P1163
Budak, A. P541, P1296
Budd, R. P1724
Buechler, M.W. O359
Buehling, A. P1801
Buffing, N. P524
Bufflier, E. O65
Bufler, J. P1231
Bughi, S. P710
Buijs, J. P1152
Buitrago, G. P1380
Buiuc, D. P1005, P1067, P1310
Buke, C. P665, P1472
Bukholm, G. O72, O312
Bulek, K. P755
Bullard, J. P1559
Bulut, C. P851, P884, P892,
P1738
Buonavoglia, C. P475, P1358,
P1670, P1672
Burandt, E. O95
Burdelski, C. O95
Burgerhof, J.G.M. P1460
Burghoffer, B. P1635
Burkhardt, O. P1523, P1540,
P1541, P1545
Burki, D. O218, P776
Burkov, A. P631, P633, P994
page 152 Final Programme
Burmeister, A. P965
Burnie, J. S373
Burton, P. P1469
Busato, F. P1140
Bush, K. P925, P1569
Buskens, E. O164
Bussmann, M. P903, P1331
Bustillo, E. P1368
Busto, C. P668, P669
Butcher, J. P844
Butler, C. S345
Buttignol, S. P566
Buttler, J. P1462
Buxbaum, A. P1563, P1792
Buyukarslan, B. O124
Byrne, B. P1649
Byun, K.S. O163
Bywater, J. P1429
Cabezas, J. P1424
Cabiedes, J. P1103
Cabodi, D. P974
Caciagli, P. P1791
Caddick, J.M. P532
Cafini, F. P1551, P1552
Cafiso, V. O93
Cagir, Ü. P982
Caglar, K. P1095
Cagnacci, S. P736, P1776
Cahen, P. P706
Caira, M. O262, O423
Cairns, S. P891
Cakar, A. P1410
Cakmak, O. P1665
Cakmak, U. P1743
Calado, E. P1334
Calandra, T. S6, O151, E332,
S337, O396, P688
Calapai, M. P1185
Calatayud, L. P921, P1276,
P1815, P1863
Calbo, E. P482, P797
Calderon, E. P875
Calès, P. P785
Calik, S. P1472
Çalikoglu, T. P1508
Calistru, P.I. P777, P1661,
P1663, P1884
Calvo, F. P1820
Calvo, J. P443, P444, P446
Calza, L. P604, P605, P607,
P608, P609, P610,
P611, P612, P613,
P784, P905, P1225,
P1226, P1227, P1501
Camajori Tedeschini, R. P484
Camarena, J.J. O271, P915
Cambau, E. O49, O50, O53,
O57, O133
Cambrea, C.S. P1875
Camero, M. P1672, P1674
Camilli, R. P1599
Campanella, M. P1340
Campanile, F. P1585
Campbell, S. P1547
Campolo, M. P1670
Campos, J. P525
Campos, S. P1213, P1740
Campos Junior, D. P519
Camuset, J. O57
Can, F. O302, P748,
P906, P1772
Canales, L. O224
Canard, I. P455
Canarelli, B. P1246
Canas, E. P931
Canawati, H. P710, P710
Candolfi, E. P942
Candoni, A. O262, O423,
P566, P1222
Candura, F. P1070
Cañedo, I. P875
Caniça, M.M. P509, P793, P1630
Cannoot, S. P1423
Cano, M.E. O52
Canter, D. P641
Cantón, R. S46, S230, P924,
P1279, P1309, P1394,
P1405, P1415, P1417
Cantrill, S. P889
Caola, I. P1791
Capilla, S. P1603
Capo, C. P1337
Capone, A. P1371
Caporale, B. P934
Caramatti, C. O262, O423
Caramelli, M. P560
Carasi, C. P687
Carattoli, A. P504, P506
Carbonnelle, E. P1172
Cardeñoso, L. P758
Cardillo, A. P735
Cardinale, D. P1709
Cardoso, C. P898
Cardoso, L.G.O. P1003
Cardoso, O.M. P1419
Carey, R. P441
Cargnel, A. P1123
Cariani, E. P649
Carles, M.J. P648
Carlet, J.M. S178, E330, P1061
Carlos, S. P650, P651
Carlsen, J. P776
Carmeli, Y. S82, E193, S292
Carneiro, R. P1027
Carnevale, G. O275, P664
Carosi, G. P1203
Carratala, J. O264, S343,
P1863
Carrington, D. P1643
Carroquino, G. P674
Carryn, S. P1515
Cars, O. Workshop 6, P743
Carsenti-Dellamonica, H. O417,
P825, P1612,
P1627, P1699
Carson, C.F. P1244
Carstina, D. P1382
Cartón, J. P1368
Caruana, G. P1340
Carvalho, T. P858
Casabellata, G. P1187
Casas, I. P1652, P1655
Cascio, A. P1185, P1653
Cascone, C. P501
Casparie, A.F. P983
Cassanelli, C. P1332
Castanheira, M. P932, P933,
P1412
Castaño Guerra, E. P1667
Casteels, A. P754
Castellano, L. P675
Castellares, C. P465
Castillo, F.J. P1596, P1597,
P1618
Castillo, J. P1026
Castrejón de Wong, M. P1667
Castro, A.P. P1334
Castro, C. P738
Castryck, H. P984
Catalan, A.M. P1251
Catalano, A. P560
Catanzariti, B. P950
Catenazzi, P. P664
Cattaneo, C. P1203
Cattoir, V. O50, O53
Cauci, S. P1186, P1187
Cauda, R. O440
Caugant, D. O168
Cavaco, L.M. P823

List of Authors
Name Number Name Number Name Number Name Number
Cavaliere, N. P1674
Cavallero, A. P836
Cavallini, F. P1776
Cavallo, J.D. O125
Cavazza, M.E. P765, P803
Cavestri, B. P677
Cavrini, F. P715
Cay, P. P906
Caylan, R. O102, P1094
Cayli, G. P842
Cazein, F. P619
Çazir, Ü. P719, P720
Ceausu, E. P777, P1661,
P1663, P1884
Ceccarelli, R. P1208
Ceccherini Nelli, L. P1070
Celano, G.V. P1845
Celebi, G. P563
Celen, M.K. P772, P790, P847,
P848, P1826,
P1827, P1867
Celenza, G. P934
Celikbas, A.P571, P852, P853,
P1665, P1666
Cengiz, A.T. P1741
Cenjor, C. P1153
Cerbaro, I. P689
Cercenado, E.P465, P466, P480,
P944, P1256, P1422,
P1436, P1764, P1815
Cernat, R. O259, P582,
P1163, P1359
Cerny, J. P544
Ceron-Gutierrez, L. P1103
Ceruti, T. P469
Cerutti, F. P653
Cervera, C. P923, P1841
Cesaro, A. O53
Cesur, S. P884, P892
Cevahir, N. P780, P1546
Cevenini, R. P715
Cevik, M.A. P916, P1088
Ceylan, M. P1695
Ceyssens, C. P452
Chaker, E. P1219
Chalandon, Y. P1199
Chalker, V.J. P973
Chambers, H.F. S403
Champlin, R. P682
Chan, A.K. P1204
Chan, C.Y. P745, P863
Chan, G. O229
Chan, K-H. O98, O99, P1671
Chan, K. P682
Chan, P.L. P745, P863
Chan, Y.-J. O59
Chanana, V. P1181
Chandra, J. O430
Chandy, R. P865
Chang, B.J. P538, P1244
Chang, C.L. O132
Chang, F-Y. P510
Chaniotaki, S. P1727
Charachon, S. P648
Charalambaki, N. P804
Charalambopoulou, A. P550, P1642
Charalampopoulos, A. P981
Charbonné, F. P530
Charisiadou, A. P901, P902
Charlett, A. O310
Charokopos, N. P1526
Charpentier, C. P642
Charrel, R.N. O100, O101, S201
Charron, A. P1587
Chatsuwan, T. P557
Chatzidimitriou, M. P1526
Chatzinikolaou, I. P1006
Chaudhry, U. O128
Chavan, R. O397
Chavanet, P. P1139
Chavez-Bueno, S. O116
Chazan, B. P979
Chea, P. P1507
Cheesbrough, J. P1788
Chemich, M. P1190
Chemin, C. P642
Chen, C-J. P1166
Chen, D.-H. P789
Chen, H-M. P510
Chen, H.L. O98
Chen, Y. P979
Chêne, G. P876
Cheng, V.C.C. O98
Cheong, H.J. O163
Cherkashin, E. P1819
Chernevskaya, E.A. P978
Chetchotisakd, P. O424
Cheuk, E. P904
Cheung, C. P713, P1393
Chevalier, N. P1701
Chhibber, S. P1159
Chiarelli, C. P895
Chierichini, A. O423
Childers, J. P1535
Chin, J. P713
Chin, M.L. P745, P863
Chinello, P. P598, P621
Chini, V. P883, P1354
Chinikar, S. P647
Chinou, E. P1287
Chiodo, F. P604, P605, P606,
P607, P608, P609, P610,
P611, P612, P613, P733,
P784, P905, P1128, P1225,
P1226, P1227, P1501,
P1608, P1609, P1830
Chirita, I. P1560
Chisholm, S.A. O119
Chiu, C.H. P1057
Chiu, C.Y. P1054
Chkhaidze, M. P1004
Chkhartishvili, N. P769
Chmylak, B. P1735
Cho, J.H. P1038, P1377
Cho, Y.K. P1040
Cho, Y.M. O163
Choe, K.W. P1038
Choi, H. P1800
Choi, J-H. P1009
Choi, J.Y. P999
Choi, N-K. P1040
Choi, S-M. P1009
Choi, T.Y. P912
Choi, Y-H. P1015
Chong, Y. P912, P1377
Chongthaleong, A. P557
Chopra, I. P1590
Chou, C.H. P1102
Choudhri, S.H. O148, P1061,
P1301, P1497,
P1706, P1707
Choudry, A. P1640
Choulakis, M. P1218
Choulis, N. O354, P1478
Chow, J.W. P1806, P1807,
P1822
Chrisafidou, E. P1765
Chrisanthidou, H. P997
Chrissaki, A. P901, P902
Christ, H. P629
Christensen, John P543
Christensen, J.J. P543, P1758
Christensen, S. P1060
Christiaens, G. P930
Christiaens, T. S346
Christidou, A. P1625, P1870
Christmann, D. P1010
Christofi, N. P741
Christoforaki, E. P1444
Christophe Henry, C. P479
Christopoulos, A. P1855
Christova, I. P854
Chrysofakis, G. P1049
Chryssaki, K. P1218
Chryssouli, Z. P1413
Chu, C-M. O98
Chu, K.C. P745, P863
Chuang, Y-C. P510
Chudzicka-Strugala, I. P752
Chueca, N. P650, P651
Chumak, T. P678
Churchwell, M.D. P1538, P1539
Chuttarsing, S. P670
Ciardo, D. O219
Cicalini, S. P621
Cillo, U. P689
Cimmino, L. P767
Ciofu, O. P1160
Ciontea, S. P1686
Ciotti, M. O61
Ciragil, P. P849, P1427
Cirincione, B. P1781
Cirino, A. P747
Cirkovic, I. P832, P832
Cisneros, J.M.P684, P692, P693,
P1200, P1369
Cisterna, R. P467, P668, P669,
P766, P1014
Citron, D.M. O150, P1532
Cizman, M. P1613
Claas, E. O67, O158
Clark, K. P1205
Claus, P. P1838, P1839
Clawson Stone, K. P590
Cloughley, R. P1846
Cochior, L. P1833
Cockwell, P. P1135
Codita, I. P1285, P1745
Coenen, S. O431, O434
Cofán, F. P923
Coffey, A. P1253
Cofield, R. O70
Cohen, M.A. P707
Coignard, B. P1616
Çokça, F. P1828
Coker, R. P1118
Colakoglu, S. P846, P1141,
P1217
Colar, L. P1005
Coldham, N.G. P1143, P1245,
P1555
Cole, Alexander. P585
Cole, Amy L. P585
Cole, S. S207
Colebunders, R. P1209
Coleman, C. P1023
Colinon, C. P911
Collet, C. P896
Collienne, C. P1465
Collin, E. O258
Collini, L. P1737
Collobert, G. P1342
Collyns, T.A. P908, P1138
Colmenero, J.D. P1678, P1853
Colodner, R. P979
Colomba, C. P1653
Coluzzi, M. P1070
Comina, E. O97
Conceição, T. O311
Concia, E. O77
Conde, M. P1124
Conde, S. P551
Conejo, M.C. P446, P513
Conrad, A. P1331, P1796
Constantinidis, T. P1844
Conte, A. P598
Contreras, G.A. P1380
Cooke, F. P1510
Cookson, B. Workshop 7
Cooles, S.W. P1143, P1555
www.escmid.org/eccmid2006
Cooper, B. S137
Coplu, N.P723, P1096, P1097,
P1098, P1099
Coppola, N. P617, P767, P774
Coque, T.M.P924, P1341, P1415,
P1417, P1626
Corbett-Feeney, G. P1411, P1487
Corcoran, G. P1045
Cordero, E. P692, P693
Cordier, L. P1123
Cordonnier, C. S205
Cormican, M. P1411, P1487, P1823
Cormier, M. P896
Cornaglia, G.S376, P928, P1383,
P1591
Cornely, O.A. S78, S187,
O421, O422
Cornu, C. P874
Corrado, M. O150
Correa, D. P875
Corrente, M. P475, P1358
Correnti, M.E. P765, P803
Corstens, F.H.M. P1862
Corvatta, L. O423
Corvò, R. P736
Coscia, M.F. P1694
Coskun, N.A. P1074
Costa, R. P551
Costa de Oliveira, S. P858
Costers, M. P1474
Cotiga, M.P777, P1661, P1663,
P1884
Cottle, T. O220
Cotuk, A. P837, P841
Couble, A. P1871
Couch, R.B. O165
Coughlan, S. P753, P760, P1030
Coupé, S. P942
Courvalin, P. S183
Couson, B. O261
Coutinho, R.A. P1068
Couzigou, C. P619
Cowan, J. P1535
Coyette, J. P1534
Coyle, P.V. P1877
Coyle, V. P686
Craig, W.A. Workshop 6
Cramer, S. P953, P1105
Crawford, J. P581
Crehalet, H. P634
Crema, L. O275
Crespo, T. P1774
Cresti, S. P512
Cretoiu, S. P1745
Cretu, I. P1875
Crevecoeur, S. P448, P449
Critchley, I.A. P590, P1542, P1559
Crivaro, V. P1268
Croos-Dabrera, R. P1606
Crusells, P. P1122
Cryan, B. P1045
Csoka, M. P702
Ctrnacta, V. P552
Cua, E. P624
Cuadra, L. O224, P482
Cuchí, E. O224, P797
Cuenca, M. P737
Cuenca-Estrella, M. S26
Cuervo, M. P1213, P1740
Cuesta, J. O131, P1122,
P1134
Cuevas, O. P465, P466
Cuevas-Lobato, Ó. P744
Culig, J. P1505
Cullen, M. O265
Cunney, R. P1011
Cuny, C. P1456
Curdt, I. P629, P879
Cusinato, R. O58
Czyrznikowska, A. P834
page 153

List of Authors
Name Number Name Number Name Number Name Number
D’Agostino, C. O399
D’Amico, D. P689
D’Amico, G. O61
D’Andrea, M.M. P913, P930
D’Antonio, D. O61
D’Arezzo, S. P1371
D’Ettorre, G. O399
D’Souza, S. P1509, P1510
Dabernat, H. P1269
Daghofer, E. P627
Dahl, K. P514
Dakovic Rode, O. P1176
Dal-Ré, R. P1050
Dalakiouridou, M. O429
Dalbey, K. O397
Dale, P. P1495
Dalhoff, A. O357, P1540
Dallow, J.W.T. P1535, P1621
Dalwai, A. O62, P1651
Dambrosio, A. P1845
Damian, M. P1686
Damjanova, I. O118
Damle, B. P1536, P1537
Damond, F. P601
Dan, M. P1005
Danel, F. P1586
Daneman, N. P1204
Dangel, M. P1373
Danhof, M. P1521
Daniault, G. P1076
Daniel, J. P1431
Daniel, M. P855
Danielides, G. O419
Danielova, V. P855
Daniels-Haardt, I. O314
Dannaoui, E. P1211
Danziger, L.H. O435
Daoud, G. P803
Daoud, Z. P775, P919
Daoud, N. P803
Dare, D. P961
Darenberg, J. P1282
Dargis, R. P543
Dartois, N.O223, P1784, P1785,
P1786
Darville, M. P626
Das, I. P1135
Daschner, F.D.O147, O432, O439,
P1346, P1361, P1364,
P1462, P1796
Dashti, A. P549
Daszkiewicz, E. P755
Daturi, R. P735
Dautzenberg, B. E189
Dave, J. P899
Davenas, C. P455
Davidson, R.J. P1547
Davis, S. P457, P458,
P1347, P1868
Davis, T. O175, P456
Davoudi, S. P1117
Dawson, C.E. P1679
De, P. P1621
de Aguiar, E. P519
de Azavedo, J.C.S. P1150, P1155
De Barbeyrac, B. P967
De Beenhouwer, H. P1698
De Benito, I. P918, P1046,
P1864
de Bie, P. P636
de Boer, M.G.J. O263
De Caro, R. P597
De Catte, L. P754
de Diego, R. P1436
de Gans, J. P1731, P1834
De Gascun, C.F. P753
de Geus-Oei, L.F. P1862
De Gheldre, Y. P1616
de Gouviea, L. O228
De Grazia, S. P1653
de Greeff, S. P580
de Jonge, E. P1620
de Jongh, B.M. P1032, P1044,
P1339
de Jongh, C. P585
de Kraker, M.E.A. O309, P1383
De la Campa, A.G. P1251, P1276
De La Cochetiere, M.F. P1648
De la Torre, J. P1837
De labrusse, L. P565
De Laet, C. O68
de Lamballerie, X. O100, O101,
S282
de Lencastre, H. O167, O311,
P529, P1334
De Luca, F. P506, P1418
De Martino, S.J. O258, P963
de Melker, H. P580
De Mendonça, R. P448, P449,
P517, P1742
De Mol, P. P930, P1387
de Moraes, A.B. P811
de Neeling, H. P474
de Otero, J. P1337
de Pauw, B. S188, E194
De Pieri, M. P687
De Rijdt, T. P742
De Ryck, R. P517
De Salvo, M. P1579
de San, N. P1742
De Santis, F. P934
De Santo, D. P1186, P1187
De Schrijver, N. P1650
De Seta, F. P1186, P1187
de Smet, A. O71
De Smet, A.M. P1656
De Stefano, C. P617
De Stefano, G. P617
De Vecchi, E. P1771
de Visscher, N. P1836
De Vito, D. P1694
de With, K. O432, O439, P1462,
P1464, P1467, P1479
de Vries, G. S411
Dean, F. O299
Dean Franklin, B. S22
Debast, S.B. P1640, P1641
Debbia, E.A.P736, P836, P1307,
P1332, P1776
DeBoer, D.S. P646
Debs, J. P963
Decaro, N. P1670, P1672, P1674
Decastelli, L. P560
Declercq, P. P705
Decoster, A. P672
Decre, D. P525
Dediste, A. P1751
Dedushaj, I. P667, P1063
Deeks, S. O220
Defta, C. P1726
Degener, J.E. P983, P1460
Dehecq, B. O125
Deiman, B. P757
DeJongh, J. P1521
DeJongh, R. P1515
Del Grosso, M. P1341, P1599
Del Pezzo, M. P1028
del Pozo, J.L. O74
del Prado, G. P1153, P1297
del Rio, A. P1158, P1841
del Rosal, M. P1764
Del Tordello, E. P937
Del Vecchio Blanco, C. P767
Delachaume, C. P1567
Delaere, B. O437, P1836
DeLappe, N. P1823
Delaunay, P. O100
Delbos, V. P676
Delchier, J.C. P1174
Delesen, H. O358, O359
page 154 Final Programme
Delforge, M. P1650
Delgado, M. P1774
Delgado, R. P1191
Delgado, T. P1213
DeLima, M. P682
Della Vella, M. P687
Della-Latta, P. P1421
Dellamonica, P.O417, O436, P624,
P1612, P1627
Delmas, C. P1269
Delmée, M. P1387
Delmont, J. P1069
Démarez, V. P1500
Demelio, V. O93
Demetriou, E. P594, P816
Demir, H. P1449
Demir, M. P780, P1546
Demir, S. P780
Demirbilek, M. O302, P748,
P906, P1772
Demircan, A. P1095
Demirel, N. P1665
Demiroglu, Y.Z. P846, P1141,
P1217
Demiröz, A.P. P851, P884,
P892, P1293,
P1738, P1874
Democratis, J. P1112, P1112
Demory, M. P672
Demosthenous, A. P595
Denaro, C. P1022
Dencer, C. P1535
Denis, O. O316, P517, P1742
Deniz, S. P852
Denkbas, E. P839
Dennetiere, G. O160
Denning, D.W. E194, P737,
P1147
Deny, P. P770
Deplano, A. P517, P929, P1451
Derendorf, H. Workshop 6,
P1523, P1540, P1541,
P1545, P1554
Derouin, F. S15, P942
Dervisoglou, A. O155
Desai, N. P670
Desario, C. P1670
Deschepper, R. P1460
Desenclos, J.-C. S110, E190,
S199, P619
Deshpande, L. P1327, P1404,
P1405, P1610
Determann, R. P1731
Detorakis, I. P673
Detry, G. P992
Dettenkofer, M. O147, S382,
P1331, P1346, P1796
Devaux, I. O395
Deveci, O. P839
Develter, M. O60, P1132
Deville, A. P624
Devine, R. P525
Dhami, C. P547
Dhar, P. P1787
Dharan, S. O272
Di Bonaventura, G. P829
Di Girolamo, A. O61
Di Giulio, S. P773
Di Lallo, D. P773
Di Matteo, A. P1460
Di Napoli, A. P773
Di Perri, G. S286
Di Pompeo, C. P677
Di Popolo, A. P1268
Di Santolo, M. P1187
Di Stefano, R. P1340
Diab, M. P1452
Diamantis, I. P997, P1719
Diamantopoulou, G. P534, P1802
Díaz, A. P797
Díaz-Infantes, M. P797
Díaz-Regañón, J. P716, P758
Dib-Smahi, C. P1292, P1769
Dieber, F. P1808
Diederen, B.M.W. P1425, P1426
Dien, G. P1580
Diep, L.M. P1461
Dier, J. P810
Dierdorp, M. P1068
Dierich, M.P. P587, P1669
Diez, R. P1416
Díez, O. P1216
Dillane, T. P826
Dimas, J.F. P1129
Dimitracopoulos, G. P883, P1354
Dimitrakopoulou, E. P1504
Dimitriou, M. P1086
Dimitriu, D. P768, P1833
Dimitrova, M. P1777
DiNubile, M.J. P1806, P1807,
P1822
Dionisi, A.M. P504
Dionysopoulou, M. P515
Disertori, M. P1791
Ditu, L. O259, P1163
Divari-Katsiki, E. P662, P1486
Djønne, B. P1131
Djordjevic, M. P1199
Djukic, S. P832
Dmitrenko, O. P468
Dmitrieva, N.V. P699
Dobay, O. P477, P796
Docobo-Pérez, F. O260, P1154
Docquier, J.D. P512, P926,
P930, P934
Doczeova, A. P1091
Dofferhoff, A.S.M. P1152, P1862
Doffinger, R. P1103
Doga, V. P540
Doganay, M. P555, P850
Dogruöz, N. P837
Dokuzoguz, B.P571, P852, P853,
P1665, P1666
Doloy, A. P1342
Domingo, D. P716, P1848
Dominguez, L. P1251
Dominguez, M.A. O264, P1348
Donabedian, S. P457, P458, P1347
Donaghy, L. O398
Donaldson, L. O272, P660, P661
Donati, M. P715
Doncheva, J. P589
Donelli, G. S18
Donnio, P.-Y. P896
Donskey, C. O150
Doosje, J. P1490
Doria, D. P1517
Dornbusch, K. P1272
Dorobat, C. P1833
Dorobat, O. P1294
Doroshkova, I. P730
Dörr, P.J. P1521
Doskar, J. P1167
Dotis, J. O429, P800
Douadi, Y. P1139
Doucet-Populaire, F. O261, P919
Doudie, B. P1140
Doudier, B. P565
Doudounakis, S. P470, P1362
Douglas, E. P1469
Dove, M.G. P567
Dowell, J.A. P1536
Dowell, J.W. P1537
Dowzicky, M.P486, P487, P488,
P489, P490, P491, P492,
P493, P494, P495, P496,
P497, P498, P499, P500,
P1311, P1312, P1313,
P1314, P1315, P1316,
P1317, P1318, P1319

List of Authors
Name Number Name Number Name Number Name Number
Doyle, M.M. P810
Doyuk Kartal, E. P483
Dracea, O. P1163
Draghi, D. P1322, P1400,
P1629
Draghijeva, E. P502, P1856
Drago, L. P1771
Drakopoulos, S. P759
Drancourt, M. O420
Draskovic, N. P954
Dresser, L. P1150, P1155
Drewelow, B. P1516, P1522
Drews, M. P752
Drimis, S. P1511
Driussi, S. P1187
Drobniewski, F. P1118, P1121
Dromer, F. P1211
Drosten, C. S281
Drugeon, H. P1581, P1858
Drugeon, H.B. P464, P1292
Drusano, G.L. S237, O360,
O361, P1524
Druzhinina, I.S. P528
Drygiannakis, D. P1444
Drzastwa, E. P1506
Drzastwa, W. P1506, P1854
DSouza, S.S. P657
Du, L. P573
Duarte, A. P931
Duarte Correia, J.H. P1774
Dubreuil C. S322
Dubrovskaya, N. P1048
Ducancelle, A. P785
Ducastel, C. P1423
Dudzevicius, V. P1264
Duerud, I. P643
Duesberg, C.B. O56
Dufour, P. P455
Dugernier, T. P1465
Duim, B. P535, P1620, P1748
Dumartin, C. P1470
Dumea, E. P1080, P1082
Dumitriu, S. P1726
Dumitru, E. P1082
Dumitru, I. P1082
Dumon, H. O100
Dumpis, U. P1476
Dunais, B. S298, O417, O436,
P1612, P1627
Dunbar, L. P1580
Duncan, C.L. P1150, P1155,
P1252
Dunford, L. P1030
Dunman, P.M. O115
Dunne, M. P1709
Dunny, G. P828
Dupont, L. P1132
Durak, A. P850
Duran, E. P1596
Duranay, M. P1874
Durand, T. P1648
Durant, J. P624
Durocher, A. P677
Durrant, S. O421, O422
Duse, A. P1363
Dutta, S. O430, P746
Duttagupta, S. P1495
Dvoinikova, E. P724
Dvorakova, D. P964
Dvoretsky, L. P1048
Dzamic, A. P1206
Dzbrowska, M. P1107
Dziekan, G. P661
Dzierzanowska, D. O301
Dzigua, L. P769
Dzwonek, A. P588
Eagye, K.J. P1550
Eandi, M. P1495
Eb, F. P1246
Ebert, S. O369, P1175
Ebnöther, C. P1119
Echeita, M.A. P1416
Echeverría, O. P1551, P1552
Echols, R.O152, P1710, P1715,
P1716, P1717
Eckleben, E. P1522
Ecochard, R. P874
Edalatkhah, H. P1882
Edberg, A. P956, P958
Edelstein, M. P516, P1238,
P1407
Edlund, C. P1202, P1235
Edvinsson, B. S16, P1754
Edvinsson, M. P1683
Edwards, G.F.S. O308, P893
Efstathopoulos, N. P1193
Efstratiou, A. P547, P899,
P1724
Egbase, P. P1856
Egbers, M.J. P1430
Eggimann, P. P737
Eichler, R. P629
Eickhoff, M. P953
Eiffert, H. P1175
Eilami, O. P1842
Eisner, A. P1324, P1808
Ejlertsen, T. P1220
Ekdahl, K. P1814
El, S. P1074
El Amri, J. P794
El-Azizi, M. P1302
El-Defrawy, I. P1452
El-Mahalawy, H. P691
El-Shazly, S. P1106
El-Sweify, M.A. P1445
Elefsiniotis, I.S. P779
Elgormus, N. P1308
Elia, G. P1670, P1672,
P1674
Elkharrat, D. P1858
Ellington, M.J.P507, P508, P1236,
P1239, P1601
Elliot, M. P908
Elliott, T.S.J. P532
Ellis-Grosse, E.J. O223, O360,
O361, P1781, P1783,
P1784, P1785,
P1786, P1787
Eltringham, I. P670, P1020, P1780
Elverdal, P. P990
Emadi, H. P1117
Emami Naeini, A. P980
Emery, J. P1649
Emery, M. P547, P899
Emirdogan, M. P839
Emonts, M. P585
Emrich, T. P962
Enache, A. P1067
Enache, G. P1663, P1884
Enault, C. P648
Endermann, R. P1151
Endimiani, A. O75, O394, P1164
Endtz, H.P. S41
Engelhard, K. P453
Engen, T. P955, P1108
English, B. P1395
Englund, L. O393
Enne, V.I. P1234, P1378
Enright, M. S400
Ensor, V.M. P1406, P1750
Entenza, J.M. O257, P1156
Epstein, B. P1381
Eraç, B. P503
Erayman, I. P1084, P1085,
P1133, P1662, P1825
Erbay, A. P916, P1088
Erben, N. P483, P1016
Erbes, R. P1024
Ercis, S. P723, P802, P1617
Erdem, B. P1617
Erdi Sanli, H. P1828
Erdinc, F.S. P851, P1293,
P1874
Erdogan, A. P1869
Erdogan, D. P1665
Erdogan, H. P1772
Erdõs, M. P796
Eren, S. P571, P853, P1666
Ergin, Ç. P1851
Ergin, F. P1772
Ergon, M.C. P868, P867, P869
Ergonul, O.P571, P852, P853,
P1665, P1666
Erguven, S. P1077
Erlaky, H. P702
Ermete, M. P1074
Eroglu, C. P1743
Ershov, G. P724
Ertek, M. P1795
Escrivá, S. P675
Escudero, J.A. P1251
Esel, D. P555
Esen, B. P723, P1096, P1097,
P1098, P1099
Esen, S. P564
Esener, H. P571
Esforzado, N. P923
Espelund, M. P1108
Espigado, I. P692, P693
Espinar, M. P1027
Espitia Pinzon, C. P1103
Esposito, S. S103
Esquivel, P. P1615
Estivill, D. P835
Estripeaut Calderon, D. P1667
Etienne, J. S136, P1607
Evangelopoulou, P. P666, P1329
Evans, J.T. P1113
Evcil, G. P860
Evcil, S. P1869
Evengård, B. E32,
P882, P1754
Extremina, C.I. P831, P1161
Eyigor, M. P558
Ezaki, T. P971, P976
Ezpeleta, C.P467, P668, P669,
P1014
Fabre, R. O125
Fabrega, A. O54
Fabretti, F. O366
Fabry, J. O68
Fadda, M.R. O262, O423
Fagan, E.J. P507, P1622
Fagon, J.-Y. S90
Fahr, A.-M. P1346
Fainardi, E. S42
Fakiri, E. P550
Falagas, M. O269, O354,
P1000, P1006, P1018,
P1356, P1357, P1478,
P1502, P1556,
P1789, P1840
Falcucci, P. O262, O423
Falk, L. P956
Fam, N. P1452
Fanci, R. O423
Fanello, S. P676
Fanin, R. P566
Fanning, S. P1253
Faouzi, S. P1214
Farahtaj, F. P1882
Farazi, A. P1142
Farhan, S. P778
Faria, N.A. P1334
Fariñas, C. P1046
Fariñas, M.C. P890, P1829
Farneti, B. P613
Farnia, P. P1435
www.escmid.org/eccmid2006
Farrell, D.J. S320, P1279, P1280
Fassotte, R. P878
Fattom, A.I. P1817
Faucon, G. P1269
Faure, O. P861, P942
Fauville-Dufaux, M. O134
Favalli, C. O61
Favaretto, F. P600
Fayaz, A. P647, P1882
Fazio, C. P542
Fedchuk, A.O. P654
Fedchuk, A.S. P654
Fedchuk, O.P. P654
Federico, A. P1853
Federli, I. P1366
Fedorin, I. P1118
Fedtchuk, A. P1557, P1558
Fegeler, W. P1730
Fehérvári, G. P478
Feierl, G. P1324, P1808
Feinberg, M. O397
Feizabadi, M.M. P537, P1588
Feldhues, R. P683
Feldman, C. O221, O228
Felmingham, D. P1385
Felsberg, J. O168
Feltracco, P. P689
Fendukly, F. P1272
Fenelon, L.E. P888, P1411
Fennell, J. P1045
Fennema, J.S.A. P1068
Fenner, I. P462
Fenner, T. P462
Fenoll, A. P1552, P1815
Fenton, A. P813
Ferech, M. O431, O434,
P1482, P1485
Ferekidis, E. O419
Ferguson, N. K385
Ferguson, R. P1643
Ferjani, A. P987
Fernandes, E. O173, P1254
Fernandez, A. P875
Fernandez, A. P480
Fernández Cuenca, F. P938, P1247
Fernández Vázquez, M. P511
Fernández-Cuenca, F.O260, P513,
P1154
Fernandez-Ramirez, G.A. P1103
Fernandez-Sabe, N. P1863
Fernandez-Sevilla, A. O264
Ferrandiz, J. P877
Ferrari, L. O275
Ferraris, G. P945
Ferraro, T. P617
Ferreira, E. P509
Ferreira, T. P931
Feskou, I. P935
Feyjoo, J. P480
Fianchi, L O262, O423
Fiaty, V. P798
Fiedler-Kelly, J. P1781
Fiett, J. P1735
Figueiredo, T. O167
Figueroa, R. P875
Fijnheer, R. O159
File, T. S179, S379, P1055,
P1576, P1578
Filimonova, O.Y. P1048, P1809
Filip, E. P541
Filip, O. P1833
Filippini, P. P617, P767, P774
Fimiani, C. O399
Fincati, K. O58, P600
Finch, R. S239
Findik, D. P1878
Finegold, S.M. P1813
Finkelstein, R. O174, P1021
Fiore, M. P934
Firsov, A. O355, P1519, P1520
page 155

List of Authors
Name Number Name Number Name Number Name Number
Firsova, N. P522
Fischer, A. P1189
Fitrou, H. P666
FitzGerald, S.F. P888
Fitzpatrick, F.M. P753
Fleer, A. P1401
Fletcher, M. P660
Flonta, M. P1382
Florea, D. P768
Florescu, S-A. P777, P1661,
P1663, P1884
Flórez, C. P1424
Flückiger, U. P556, P1373
Fluit, A.C. O166
Flynn, E. P1500
Flynn, S. P547
Fodor, D. P786
Foerster, S. P1522
Foka, A. P883, P1354
Fokas, Sp. P515
Fokas, St. P515
Foley, B. P1030
Folgueira, M.D. P679, P1191,
P1881
Foltan, V. P817, P1062
Fombellida, P. P918
Fonseca, A.P. P831, P1161
Fontana, R. O77, P928
Fontanals, D. P1723
Fonteyne, P. P1209
Foppen, P. P1339
Forberg, J. P1548
Forestier, E. P1010, P1514
Forgách, P. P786
Fornieles, C. P650, P651
Forohesh, H. P1184
Forsthuber, S. P1321
Forte, G. O399
Fortun, J. P684
Forward, K. P1725
Fosheim, G. O172
Fosse, T. O436, P1420,
P1744
Fossum, A.E. O312
Foster, N.F. P538
Foster, T. O365
Fostira, P. P1766
Fotopoulou, I. P550
Foucault, C. O420
Fouchier, R. S349
Fouka, K. O120
Foulon, W. P754
Fournier, P.E. P546
Foustoukou, M. P505, P1008
Fracasso, M.E. P1517
Fragoulis, K. P1006, P1502,
P1556
Fraile, T. P1075
France, M.N. P1465
Franceschetti, P. P1517
Francioli, P. O76, S104,
O151, O396,
P1366
François, M. P861
Frank, U. O440, P1064
Frans, J. P984
Franzin, L. P974
Fraser, A. O69, O156, O265,
O440, P685, P1367
Fraser, C. P899
Fredlund, H. P522, P956,
P958
Frei, R. P1373
Freiberger, T. P544
Freitas da Fonseca, A. P831, P1161
French, G. P1566
Freney, J. O97
Frère, J.M. P926, P930
Freydiere, A.M. P634
Frias, E. P880
Friedrich, A.W.Workshop 2, O314,
P461, P529, P1491
Friedrich, L. P1703
Friman, G. P1683
Frimodt-Møller, N. S256, S406,
O433, P581, P1149,
P1157, P1165, P1323,
P1376, P1402
Frisbee-Hume, S. P694
Fritsche, T.P1261, P1262, P1263,
P1265, P1325, P1326,
P1327, P1328, P1440,
P1570, P1571, P1572, P1573,
P1574, P1623, P1804, P1816
Frizzi, A. P1737
Frommelt, L. O95
Frost, A. P830
Fry, N.K. P972
Fuentes, L. P1035, P1036
Fulgaro, C. P734
Fuller, D. O175, P456
Fuller, J. P456, P1747
Furlini, G. P645
Furrer, H. P1116
Fursova, N.K. P1351
Furtado, C. O173
Fux, C.A. O96
Füzi, M. O118, O311, P526,
P910, P911, P1409
Fyderek, K. P806
Gaasbeek, A. O263
Gabella, S. P653, P655
Gabrielli, L. P756
Gacea, O. P1310
Gachie, J.P. P1470
Gachkar, L. P788, P1882
Gacs, M. P910
Gafter-Gvili, A. O265, P685
Gaillat, J. O160, P1580
Gaïni, S. P1753
Gaitch, N. P1342
Galán, J.C. P1417
Galanakis, E. P1350
Galanakis, N. O155, P1052,
P1503, P1504
Galani, E. P1017, P1352
Galani, I. P1283, P1343, P1413
Galani, L. P1343, P1727
Gales, A.C. P932, P933, P1412
Galindo, B. O162
Galkin, D. P1012, P1633
Gallagher, G. P1260, P1806,
P1807, P1822
Gallamini, A. O423
Gallardo, M.M. P922, P1013
Gallego, L. P1820
Galli, S. P645
Gallion, C. P1514
Gallois, A. P1174
Galmiche, J.P. P1648
Galvez, J. P1837
Gamil, N.M. P1752
Gandjini, H. O223
Gandotra, S. P1302
Gangneux, J-P. S24, O398
Ganteris, G. P1136
Gao, F. P1794
Garami, M. P702
Garantziotou, D. P799
Garau, J. O224, S341, S405,
P482, P797, P1050,
P1051, P1053, P1061,
P1576, P1578
Garbino, J. S374, P737, P1199,
P1212, P1229
Garcia, A. P1348
García, C. P1596
Garcia, E. P1297
García, F. P651
page 156 Final Programme
García, L. P1841
García, M.G. P1433
García, M.V. P922, P1013
Garcia, P. P1297
Garcia, R. P797
García, M. P1403
Garcia de la Maria, C. P1158
García de Viedma, D. P944
García Regata, O. P1829
García Rodríguez, J.F. P1127
Garcia Vidal, C. O224
García-Álvarez, M. P1881
García-Bordas, J. P1256
García-Deltoro, M. P675, P1075
García-Fernández, N. O74
Garcia-Gil, L.J. P536
García-Lobo, J.M. O52
Garcia-Mauriño, L. P918, P1864
Garcia-Ordoñez, M.A. P1058
García-Palomo, J.D. P890, P1829
García-Peñuela, E. P1746, P1848
García-Rey, C. P797, P1051,
P1053
García-Riestra, C. P1403
García-Rodríguez, J.A. P511, P1598
García-Rodríguez, M. P675, P1075
Garcia-Valdivia, M.S. P593
Gardella, B. P762
Gardiner, M. P880
Gardiner, S. P1113
Gardner, H. P1428
Garey, K.W. O435, P1408
Gariazzo, B. P1635
Garlicki, A. P1100
Garrido, J.C. P918, P1046,
P1864
Garrido, M.J. O74
Garzoni, C. P1199, P1212,
P1229
Gasasira, M-F. P1742
Gascon, J. P1169, P1398,
P1603, P1615
Gascoyne-Binzi, D. P1138
Gashi, L. P1063
Gastmeier, P. O432, P575,
P1361, P1462
Gatell, J. P1158
Gatermann, S.G. P461
Gatopoulou, A. P799
Gattringer, R. P827
Gattuso, G. P895
Gaustad, P. P737
Gautret, P. P1069
Gaydos, C.A. P640, P952
Gazin, P. P1069
Gazzara, D. P1185
Gebreel, G.I. P1445
Gedikoglu, S. P1617
Geijo, M.P. P1035, P1129
Geiss, H.K. P683, P988
Gelfand, B. P1466
Geli, P. P1814
Gelinck, L.B.S. O263
Gelisen, O. P1741
Gemert-Pijnen, L.J.E.W.C. O314
Gemmell, C.G. S380, O308, P893
Genco, F. P680, P945
Geng, Z. P1258
Gentile, F. P1268
Gentry, L.O. P1408
George, R. P1724
Georgescu, G.I.M. P1005
Georgiladakis, A. P1625, P722
Georgopoulos, A.P1321, P1563,
P1792
Georgouli, M. P1287
Georgoulias, G. P1000, P1789
Gerlach, D. O368
Gerlach, F. P1360
Germer, U. P1659
Geroldi, C. P469
Gerolimos, M. O120
Gervelmeyer, A. O313
Gesser, R.M. P1822
Gesu, G. P1418
Geyik, M.F. P772, P790, P847,
P848, P1826,
P1827, P1867
Ghaemi, A. P570
Ghanaat, J. P1435
Ghannoum, M.A. S233, O430,
P747, P746
Gharavi, S. P1588
Ghasemi, M.R. P1646
Ghasemikhah, H. P1034
Ghasemikhah, R. P1034
Ghazanfari, M. P527
Ghazvini, K. P1435
Ghebremedhin, B. P946, P1338
Ghidán, Á. P477, P478
Ghika, A. P666
Ghisetti, V. P653, P655
Ghita, M. P1285, P1775
Ghorbani, S. P1883
Giamarellos-Bourboulis, E.J.S336,
O363, P1177,
P1178, P1193
Giamarellou, H. O155, O363,
O419, P666, P1017,
P1177, P1210, P1283,
P1329, P1343,
P1413, P1528
Giammanco, G.M. P1653
Giani, T. P930
Giannacopoulou, C. P1350
Giannakakis, T. P1708
Giannakakos, P. P1287
Giannitsioti, E. P666, P1283,
P1329, P1528
Giannopoulou, P. P1257
Giannoulaki, E. O120
Giaquinta, L. P1022
Giddey, M. P1156
Giedrys-Kalemba, S. P907
Giesecke, J. E34, S280, S352
Gigi, J. P442
Gigli, B. P598
Gikas, A. P1349, P1480,
P1625
Gil, Y. P1433
Gilbert, G.L. P904
Gilbert, P. Workshop 5
Gilbert, R. Workshop 1
Gill, S.C. O299
Gilles, Y. P798
Gillespie, E. P1023
Gilot, P. P1650
Giménez, M.J. P674, P1153,
P1551, P1552
Gimeno, C. P740, P1721
Ginocchio, C. O64, P1657
Gintsburg, A.L. P468, P840
Gioga, A. P1352
Gioka, A. P1855
Giordano, A. P504
Giorgio, A. P767
Giotis, E. P1690
Girard, A.M. P1567
Giraud-Morin, C. P1744
Girault, F. P530
Girgin, S. P1867
Girmenia, C. O262, O423
Girou, E. P1481
Giske, C. P911
Gismondo, M.R. P1771
Gitti, Z. P1870
Giuffrè, V. P1736
Giurgiu, M. P1726
Givskov, M. Workshop 5, S17
Gladnishka, T. P854

List of Authors
Name Number Name Number Name Number Name Number
Gladysheva, M. P633
Glasmacher, A. S2
Glavas-Obrovac, L. P1162
Gleiter, C.H. O358
Glupczynski, Y. O437, P929,
P992, P1387, P1534,
P1616, P1751, P1836
Gniadkowski, M. S48
Göbel, U.B. P1189
Göçmen, S. P1828
Godel, A. P1140
Goebel, F.-D. S250
Goedecke, M. P575
Goel, A. P1799
Goering, R.V. O115
Goessens, W.H.F. O211, O362,
P451
Goffredo, E. P1845
Goglio, A. O215
Gogos, C.A. O120
Goh, J.S. P1281
Golan, Y. P1813
Golczyk, G. P1506
Goldstein, B.P. P739, P1440, P1536
Goldstein, E.J.C. S10, O150,
P1532, P1813
Goldstein, F. S404
Goldwirt, L. O276
Golemati, P. P1287
Golkocheva, E. P1739
Gomaa, H. P1452
Gómez, A. P1835
Gomez, E. P668, P669
Gómez-Garcés, J.L. P1433
Gómez-Lus, R. P1596, P1597
Gomis, M.T. P675
Gomis, M. P559
Gonen, I. P781
Gonzalez, C. P875
Gonzalez, GR. P1658
Gonzalez, GU. P1658
Gonzalez, H. P875
Gonzalez, R. O271, P915
González Lahoz, J. P614, P615
Gonzalez-Huix, F. P536
González-Lama, Z. O129, P1243
Gonzalez-Sanz, R. P1416
Gonzalez-Zorn, B. P1251
Goodrich, J. P1784, P1785
Gooskens, J. O67, O158
Goossens, H.O56, O212, O257,
O431, O434, P966,
P1387, P1482, P1485
Goral, G. P564
Gorbach, S.L. O150, P1813
Gorkiewicz, G. P1808
Goroncy-Bermes, P. S384, P893
Gorter, K.J. O122, O123
Gorvel, J.-P. S142
Gosiewski, T. P806
Gossain, S. P1794
Goubontini, A. P1219
Goudas, P. P1873
Goudouva, A. P941
Gould, I.M. P1333, P1336
Gouveia, J. P1797
Gowda, R. P1092
Goyenechea, A. P1655, P1658
Gozalan, A. P723, P1096,
P1097, P1098, P1099
Gracia, M. P1153, P1297
Graells, J. P559
Granados, E. P922, P1013
Grande, M.J. P1864
Grandgirard, D. P1145
Grandi, A. P664
Grangeot-Keros, L. P635
Granic, J. P732
Graninger, W. S232, S284,
P827, P1284, P1321, P1563, P1792
Grant, K.A. P1644
Grape, M. P940
Grattarola, C. P560
Gratwohl, A. O147
Graves, J. P1365
Gravisse, J. P706
Gravitt, P. P640
Gray, J. O214
Greally, P. P810
Greco, G. P475, P1358
Green, K. O227, P1252, P1397
Green, L. P1559
Greene, C. P826
Greene, R. P1499
Gregoire, D. P1473
Greiffendorf, I. P1071
Greub, G. P957
Grewing, T. P953, P965
Gridelli, B. P1340
Grif, K. P1760
Griffith, R. P453
Griffiths, W. O272
Grigoryan, L. P1460
Grillot, R. P861, P942
Grimm, H. P1437
Grio, M.C. P1538, P1539
Grisold, A. P1324
Grispou, E. P759
Gros, F. O398
Grossi, P. P1340
Grossman, R. P1706, P1707
Groussaud, P. P1676
Grove, J. P1186
Grudinina, S.A. P1048, P1809
Grundmann, H. O309, O311,
P1364, P1383, P1696
Grushina, T. P947
Grzeszczuk, S. P943
Gu, L. P880
Guajardo, T. P791
Gualandris, S. O394
Gualco, L. P836
Gualdi, P. P1737
Guan, Y. O98
Guarrera, G.M. P1791
Guaschino, S. P1186, P1187
Guasticchi, G. P773
Gudiol, C. O264, P1863
Gudiol, F. O264, P921,
P1348, P1863
Gudkov, I. P1012
Gudnadóttir, M. P595
Guducuoglu, H. P1345
Guembe, M. P1422
Guevara, M. P765
Gueyffier, F. P874
Guiard-Schmid, J.-B. S146
Guiguen, C. O398
Guinea, J. P465, P744, P1201
Guiso, N. S344
Gul, M. P849, P1427
Gül, S. P1828
Gülay, Z. P503, P1041, P1617
Gulbas, Z. P483
Gulbinovic, I. P764
Gulczynska, E. P588
Gulec, T. P748
Guler, S. P1825
Guleri, A. P1335
Gulhan, M. P986
Gülkesen, K.H. P1508
Gultekin, B. P558, P860
Gums, J. P1381
Guna, R. P740, P1721
Gündes, S. O124, P897, P1288
Gupta, I. P1135
Gupta, R. P1788
Gupta, V. P1799
Gur, D. P936, P1617
Gurbuz Ertas, A. P1843
Gurcan, S. P563
Gurkan Aydin, N. P927
Gurler, N. P1414
Gursel, B. P1695
Guseinova, R. P1639
Gussmann, A. P1516
Gutiérrez, I. P1216
Gutmann, L. E334
Guven, A. P906
Guven, H. P782
Guvener, E. P571
Guvenli, A. P1083
Haagensen, J. P830
Haaijer-Ruskamp, F.M. P1460
Haanperä, M. P1763
Haase, G. P862
Haberhausen, G. P962
Habibi, E. P807, P1883
Habibi, Z. P1883
Habt, R. P1548
Hadjiconstantinou, V. P759
Haedersdal, M. P1149
Haeggman, S. S409, P459
Haferland, C. O153, O154
Hafner, D. P1396
Hagemeister, F. O165
Hager, I. P997, P1719
Hager, I.F. P1052, P1504
Haghighi, S. P703
Haigis, R. P641
Haj Ab-dul Baghi, M. P1142
Hajdu, E. P1330
Hajj, R. P919
Hak, E. O71, O122, O123,
O161, O164, P1471
Håkansson, A. P1463
Hakim, A. P1818
Hakimé, N. P919
Hakkaart-van Roijen, L. O211
Halabi, A. O358
Haldorsen, B. P514, P522,
P1811
Halford-Maw, R. P1644
Halichidis, S. P1080
Haliotis, F. P594, P814, P816
Haliotis, G. P1625
Hall, B. S8
Hall, L.M.C. P1236
Hall, W.W. P753, P760
Haller, P. P1373
Hallgren, A. P828
Hallin, M. P517
Halmouki, K. P1362
Hamdad Daoudi, F. P1246
Hamedi, A. P577
Hammerum, A.M. P1376, P1402
Hamouda, O. P463
Hanaki, H. P976
Hanberger, H. Workshop 7
Hanna, N. P919
Hannechi, N. P987
Hanratty, S. P658
Hansen, A. P1729
Hansen, D.S. P1402, P1729
Hansen-Koenig, D. P1818
Hansky, K. O154
Hansmann, Y. P963, P1010
Hanssen, A. P514
Hantooshzadeh, S. P1702
Hantzi, E. P814
Hao, D. P1144
Harbarth, S. P1212
Harboe, Z.B. O225
Hardalo, C. O421
Hardeman, E. P620
Hardick, A. P640, P952
Hardick, J. P952
Hardiman, M. E34, S279
Hardy, K.J. P1794
www.escmid.org/eccmid2006
Hare, R. P1577
Harinck, H. O158
Harjai, K. P1159
Harley, E. P1724
Harmsen, D. O171, P471, P529
Harrell, L. P1813
Harrison, T.G. P972, P973
Hascelik, G. P723, P1410,
P1455, P1617
Hasenberg, F. P461
Hashemi, J.H. P1221
Hashemi, P. P1142
Hassan, F. P778
Hassan, M. P1752
Hassiakos, D. P873
Hassibi, M. P1117
Hatvani, L. P528
Hatz, C. E33, S202
Hatzikyriakou, R. P550
Hatzitolios, A. P1708
Hatzopoulou, P. P1789
Haugvicova, R. O168
Hauser, P.M. O219
Hausmann, M. P629
Haverstock, D. P1301, P1706,
P1707
Hawdon, J. P588
Hawkes, C. P985
Hawkey, P.M.S81, P1113, P1406,
P1750, P1794
Hayden, M. P457, P458,
P1868
Hazrati Tappeh, K. P1850
He, L. P1144
He, Y. P573
Hebart, H. P737
Hecht, D.W. P1813
Heczko, P. P806
Heddema, E.R. P535, P1620
Hedderwick, S. P686
Hedin, K. P1463
Heep, M. P1569
Hegarty, J. P753
Hegde, S. P1543
Heginbothom, M. S20
Heiba, A.A. P1445
Heim, A. P575
Heim, D. O147
Heimesaat, M.M. P1189
Heisig, P O55, P727
Heizmann, W. P1437
Hemmer, R. P1818
Henderson, N. P1794
Hendriks, B. P1209
Hendriks, W.D.H. O274
Hendrix, M.G.R. O314, P1491
Henke-Gendo, C. P575
Hennessy, T. O220
Henquell, C. P770
Henrichfreise, B. P1266, P1805
Henriques Normark, B. P1282
Herawi, M. P640
Heredia, J.L. O224
Herijgers, P. P1838, P1839
Héritier, C. P505
Hermans, M. O159
Hernaez, S. O74
Hernandez, A. P922, P1013
Hernandez, J.L. P875
Hernández, J.R. P446
Hernández, Ma. P1403
Hernández, Mi. P1036
Hernández Iglesias, M.S. P1598
Hernández-Bello, J.R. O268
Hernández-Belmonte, A. P1036
Hernando, S. P679
Hernekamp, I.M. P1175
Herpay, M. P568
Herregods, M-C. P1838, P1839
Herrera, G. P1575
page 157

List of Authors
Name Number Name Number Name Number Name Number
Herrera, S. P1416
Herrmann, B. P960
Herrmann, M. S143, E331
Hersberger, M. O396
Herva, E. O220
Herzogenrath, J. P629, P879
Hesje, C. O304, O307
Heslet, L. O428
Hess, M. P965, P1105
Hessle, C. P1182
Higgins, P. P1250
Hill, C. P1691
Hill, D. S388
Hill, E.E. P1838, P1839
Hill, R. P891
Hill, R.L.R. P1621
Hilton, A.C. P532
Hindler, J. P441
Hinrikson, H.P. O219
Hira, P. P1682
Hirschel, B. P1212
Hirschl, A. P1760
Hittinger, M. P1473
Hizel, K. P1095, P1104
Hjelm, E. P1683
Hjelmqvist, H. P1202
Hjelte, L. P586
Ho, C-F. P1166
Ho, D.M-T. O59
Hoban, D. P486, P487, P488,
P489, P490, P491,
P492, P493, P494,
P495, P496, P497,
P498, P499, P500,
P1311, P1312, P1313,
P1314, P1315, P1316,
P1317, P1318, P1319
Hocqueloux, L. P1607, P1865
Hocquet, D. O125, P1242
Hodgson, J. P1512
Hoebe, C.J.P.A. O418, O392, P1066
Hoen, B. S254, P1139
Hoepelman, A.I.M. O122
Hoes, A. O161
Hofliger, P. O436
Högberg, L. P1814
Høgh, B. P603
Hohenthal, U. P630
Høiby, E.A. P698
Høiby, N. E333, P830,
P1160
Høidal Berthelsen, H.K. P1108
Hokelek, M. P1083
Hola, V. P838, P859
Holberg-Petersen, M. P599
Holensteiner, A. P627
Holguin, A. P614, P615
Holinger, R. O69
Höller, C. O315
Holmberg, H. O222
Holmes, A. P1510
Holowiecki, J. O421, O422
Holtom, P. P1168
Holubova, J. P855
Holzman, R. P880
Honderlick, P. P706
Hong, J. P1258
Hong, K.S. P912
Honkanen, P.O. O416
Höög, A. P956
Hooper, D. S247
Hooshmand, B. P647
Hope, R. P1386, P1447,
P1622, P1750
Hopkins, K.L. P1622
Hopmans, T.E.M. O273
Hoppe-Tichy, T. P683
Horakova, L. P838
Horcajada, J.P. P890, P1829
Horianopoulou, M. O269
Horka, M. P859
Hornero, A. P1348
Horstkotte, M.A. O94, O305
Hortobagyi, A. P1330
Hoseini, N. P647
Hoshino, T. P971
Hosoglu, S. P772, P790, P847,
P848, P1790,
P1826, P1827
Houhoula, D.P. P1289
Houlihan, D. P753
Houston, B. P670
Hovde, M. P602
Howley, C. P1547
Hrdy, I. P552
Hryniewicz, W.P445, P529, P821,
P943, P1279,
P1696, P1735
Hryniewiecki, T. P1605
Hsu, H.L. P1102
Hsu, S. P879, P880
Hsueh, P-R.P510, P704, P1102,
P1806, P1807
Huang, C-G. P1879
Huang, T.-D. P442
Huang, V. O73, P457, P458,
P1457, P1468
Huang, Y-C.P795, P1166, P1372,
P1054, P1057, P1879
Huang, Y-H. P1372
Huang, Yi. O98, P1671
Huard, C. P1701
Huband, M.D. P707
Hübner, J. P1346
Huck, S. P942
Huebner, J. O366, P903, P1331
Huelves, L. P1153, P1297
Hughes, D. S378
Hui, M. P745, P863
Huidobro, S. P479
Huijsdens, X. P474
Huikko, S. O416
Hulin, A. P1481
Hulinska, D. P1194
Hulinsky, V. P1194
Hummelink, R. P1120
Humolli, I. P1063
Humphreys, H. P819, P826
Hunfeld, K.-P. S328
Hung, M.N. P704
Hunter, P. P1732
Huovinen, P.S296, O416, P1259,
P1277, P1763
Hupkova, H. P817, P1062
Hurmuzache, M. P768
Hurtado, S. P765
Hussain, Z. P950, P1431
Hussein, E. P1651
Hwang, S-C. P1015
Hyseni, H. P667
Hyvonen, M. P1757
Iannelli, F. P1599
Iannello, D. P1185
Iaria, C. P1185
Ibeas, J. P1007
Ibrahem, S. P460
Ide, L. P452
Ieven, M. S105, O212, P966,
P1209, P1387
Ifantidou, A. P1029
Igan, H. P1795
Ignatenko, O. P1466
Ignatyev, G.M. P1664
Ijzerman, M.M. P707, P1606
Ikonnen, J. P670
Ikonomidis, A. O127
Ikonomopoulos, N. P1849
Ikonomopoulou, E. P1855
Ilhan-Sungur, E. P841
page 158 Final Programme
Iliadis, H. P791
Ilie, M. P1875
Ilina, E.N. P1809
Ilki, A. P1308
Ilknur, T. P867
Imbert, C. Workshop 5, S19,
P1076
Imhof, A. P1498
Imparato, M. P767
Indra, A. P1760
Ingham, C. P1120, P1438
Inkaya, A.C. P1662, P1825
Innings, Å. P960
Inns, H. P908
Invernizzi, R. O262
Ioannides, M.C. P1480
Ioannidou, F. P805
Ip, M. P904
Iqbal, J. P1682
Irani- Hakimé, N. P775
Irmak, H. P884, P892,
P1738
Irmukhamedov, A. P543
Irrera, G. O262
Irvine, L. P1732
Irving, W. E31, S252
Isaac, E. P950
Isaksson, M. P960
Ischenko, A. P1483
Iseri, S. P1738
Isham, N. P746, P747
Ishida, S. P1096, P1098,
P1099
Ishiwada, N. P971
Islam, S. O126
Islami, P. P1443
Israil, A. O259, P1285, P1560
Issack, M.I. P1379
Itani, K. S88
Ivanova, D. P502, P1619
Ivanova, N. P1078
Izri, A. O100
Jackson, P. P1877
Jacob, J. P628
Jacobs, E. O154
Jacobs, Femke O65, P757, P1660
Jacobs, Michael P1569
Jacobs, Marcel P636
Jacobsen, J. P1060
Jacobson, M. O70
Jacobus, N.V. P1813
Jacomo, V. P1199
Jaeger, S. O370
Jafari, F. P527, P537, P807,
P1684, P1687
Jäger, D. P1545
Jahn, H.-K. P1189
Jaimchariyatam, N. P1111
Jaka, A. P659
Jakopovic, M. P1304
Jakubù, V. P1812
Jalal, S. P1271
Jalalizand, N. P731
Jalava, J. P1259, P1277,
P1763
Jambroes, M. P1490
Jamshidi Makiani, M. P703, P1860
Jan, I.S. P1102
Janaszek-Seydlitz, W. P783
Janczewska-Kazek, E. P1353
Janjic, N. P590, P1542,
P1559
Jankowski, S. P533
Jans, B. O316, P1616
Jansen, B. P575
Jansen, W. P1401
Jansens, H. P1209
Janssens, M. P992
Jardan, D. P1686
Jarlier, V. O50, O57, O133,
O317, E331, S415, P900,
P975, P1458, P1762
Jarløv, J.O. P1402
Jarollahei, A. P1883
Järv, H. P1089
Jarvis, C. P959
Jarvis, T. P1559
Jarza-Davila, N. P732, P928
Jashiashvili, N. P886, P1004
Jasir, A. P569, P1282,
P1594
Jaton, K. O219, P454,
P957
Jaulhac, B. O258, P963
Jaureguy, F. P1172
Jean-Pierre, H. P525
Jeannot, K. P1242
Jeansson, S. P1108
Jebelean, C. P1355
Jebens, C. O153
Jehl, F. P1305, P1473,
P1514
Jelastopulu, E. P673, P1844
Jelenina, L.A. P572
Jelinek, T. S389
Jelsbak, L. P830
Jenabian, S. P1562
Jenkins, C. P993
Jenkins, S. S319, P1813
Jensen, A. P1180
Jensen, Julia P1422
Jensen, J.S. P726, P956
Jensen, T.G. P1402
Jensen, U.S. P1872
Jensenius, M. P1461
Jeong, J. O132
Jeong, S.H. O132
Jeong, S.Y. P1800
Jepsen, P. P1037
Jeren, T. P1176
Jernberg, C. P1235
Jeruma, A. P1078
Jette, L. O220
Jiang, S. P573
Jilg, W. P1071
Jimenez de Anta, M.T. O367,
P1158
Jin, Y. P1248
Jinson, J. P1468
Jlili, N.E. P1454
João, I. P1254
Johansen, H.K. P830
Johansen, U. P1160
Johansson, A. P743, P960
Johansson, E. P956, P958
Johansson, S. P1182
John, A. P1497
John, M. P950, P1431
Johnson, A.P. P1601
Johnson, B. P486, P487, P488,
P489, P490, P491, P492,
P493, P494, P495, P496,
P497, P498, P499, P500,
P739, P1311, P1312,
P1313, P1314, P1315,
P1316, P1317, P1318,
P1319
Johnson, D. P1572
Johnson, J. P486, P487, P488,
P489, P490, P491, P492,
P493, P494, P495, P496,
P497, P498, P499, P500,
P1311, P1312, P1313,
P1314, P1315, P1316,
P1317, P1318, P1319
Johnston, J. P441
Jolley, K. O168
Jonas, D.O432, P1331, P1346,
P1361, P1364

List of Authors
Name Number Name Number Name Number Name Number
Jonassen, C.M. P643
Jonassen, T.O. P643, P644
Jones, MarkS184, P1322, P1400,
P1629
Jones, Melanie P658
Jones, R.P713, P1261, P1262,
P1263, P1265, P1325,
P1326, P1327, P1328,
P1404, P1405, P1440,
P1553, P1570, P1571,
P1572, P1573, P1574,
P1610, P1623, P1804,
P1816
Jorde, A.T. P1131
Jorgensen, D. P1709
Jorup-Rönström, C. P882
Josefowicz, E. P677
Jost, I. P878
Jounieaux, V. P1139
Jourdain, S. P815
Józwiak, J. P1039, P1847
Julander, I. P1271
Jun, H.S. P476
Jureidini, I. P775
Jurstrand, M. P956
Juvin, M. P464, P1292,
P1581
Kaan, J.A. P1044
Kaatz, G. P1393, P1513
Kabbara, S. O353
Kachanka, A. P1093
Kader, C. P1824
Kaderakis, G. P1642
Kafarakis, V. P1444
Kafetzis, D.A. P901, P902
Kafkoula-Alevizou, H. P1439
Kahlau, D. O315
Kahlmeter, G. O309, P1383,
P1441, P1442
Kahmann, N. P959, P965
Kahn, J. P1524
Kaiser, K. P877
Kalaveshi, A. P1063
Kaldis, P. P1193
Kaleli, I. P780, P1546,
P1851
Kalenic, S. P659
Kalinowska-Nowak, A. P1100
Kalkani, M. P515
Kalmusova, J. O168
Kalogeras, G. P540
Kalogeropoulou, E. P1727
Kamalov, G. P1558
Kamposioras, K. P779
Kanat, F. P1084, P1133
Kanavaki, S. P1001,
P1125, P1329,
P1352, P1434
Kandemir, B. P1662, P1825
Kandiah, D.A. P1072
Kanellakopoulou, K. O155
Kanellopoulou, M. O269, P1642
Kanellos, K. P540
Kanellos, P. P1480
Kanervo-Nordstrom, A. P1757
Kang, J.U. P1281
Kanoun, F. P1219
Kansouzidou, A. P1029
Kantardjiev, T. P1056
Kaplan, J. O95
Kaporskaya, T. P1299
Kaptan, F. P1074
Karabaxoglou, D. P1029
Karabay, G. O302
Karabela, S. P1125, P1434
Karabiber, N. P1843
Karabinis, A. P1802
Karabogia-Karafillidis, P. P1101,
P1439
Karaca, B. P782
Karadenizli, A. P563, P564, P1288
Karagianni, V. P1178
Karahan, M. P1843
Karahan, Z.C. P1843
Karaitianou, A. P1486
Karakatsani, Z. P1880
Karakus, R. P1095
Karaman, S.Ö. O267
Karambela, S. P1329
Karami, N. P1392
Karampa, S. P696, P808,
P1025
Karapavlidou, P. P717, P1384,
P1631
Karasev, V.E. P709
Karaseva, E.T. P709
Karatuna, O. P1453, P1611
Karavanaki, K. P814
Karavassilis, V. P941, P1593
Karavelioglu, S. P1611
Karbassian, A. P1224
Karchmer, A. S241
Karczewska, E. P1296
Kardara, M. P673
Karden-Lilja, M. P460
Kardos, G. P523
Karisik, E. P507, P508
Kariyiannis, A. P814
Karkac, E. P483
Karle, A. P1086
Karle, P. P1086
Karnezi, K.J P662
Kärpänoja, P. P989
Karpati, F. P586
Karpov, I.A. P1093
Karppelin, M. P1866
Karrasch, K. P1516
Kartal, E.D. P1016
Kartali, S. P1765
Karvelis, N. O419
Karydis, I. P1502, P1789
Kasatpibal, N. P1059
Kasemets, P. P1579
Kasiakou, S. O354, P1000,
P1556
Kassaian, N. P1224
Kaszanyitzky, É.J. P477, P478
Kátai, A. P786
Kato, H. P520
Katsandri, A. O270, P1289
Katsarou, I. P1855
Kauffmann-Lacroix, C. P1076
Kaufmann, M.E. P1621, P1622
Kaur, D. P652
Kautiainen, H. P485
Kavvatha, D. P1210
Kawamura, Y. P976
Kawkitinarong, K. P1111
Kay, I. P637
Kaya, O. P781
Kaya Firat, S. P1293
Kazakos, E.I. P749
Kechrid, A. P794, P1454
Kees, F. P1861
Kefalakis, A. P1101
Keiani, J. P570
Keisari, Y. P1197
Keiss, J. P1078
Keithly, J.S. P552
Keleshian, S. P775
Kelly, S. P1030
Kemp, M. P543, P1758
Kemp, V. P1643
Kennedy, P.G.E. S44
Kenyon, S. P1644
Keramidas, C. P981
Kere, J. P1866
Kermes, K. P1634
Kern, F. P1798
Kern, W.V. S283, O439,
P903, P1464, P1467,
P1479, P1796
Kerrad, N. P1831
Kerremans, J.J. O211
Kerttula, A-M. P460, P948,
P1446
Keshavarz, D. P1221
Keshishian, C. P547
Keshtkar Jahromi, M. P1842
Kett, D. P1205
Keuleyan, E. P502, P1619
Khademi, M. P1224
Khaled, S. P1831
Khan, K. O299
Khan, Z.U. P864, P865, P866
Khanlari, B. P556
Khardori, N. P1302
Khatibi, S. P1588
Khaykina, E. P1632
Kheirandish, M. P578, P579
Kheirandish, P. P1142
Kheradpajouh, M. P788
Khoshbaten, M. P788
Khosravi, M. P1755
Khoury, S. P775
Ki, S.Y. O163
Kibbler, C. S79, P1475
Kiertiburanakul, S. P616
Kiffer, C. P920, P1391,
P1550
Kilani, B. P1219
Kilic, A. O306
Kilic, D. P839
Kilinc, M. P849
Kim, C.M. O132
Kim, E-C. P1647, P1761
Kim, H. P1040
Kim, H.B. P1038
Kim, H.J. P1377
Kim, H.S. P787
Kim, J. P909
Kim, J.M. P999
Kim, M.N. P476, P912
Kim, M.S. P999
Kim, N.J. P1038
Kim, S. O132, P1803
Kim, W.J. O163
Kim, Y-A. P999
Kim, Y.K. P999
Kimiran Erdem, A. P837
Kimman, G. O66
King, A. P1566
King, S.P. P1537
Kinikli, S. P851, P884,
P892, P1738
Kioumis, J. P1625
Kipp, F. P461
Kirdar, S. P860
Kirikou, H. P901, P902,
P1218
Kirkan, S. P558
Kirsch, C. O153, O154
Kiss, I. P523
Kist, M. P1331, P1346
Kistler, J.O. P1622
Kiyani, K. P1033
Kjerulf, A. P543, P1758
Kjølseth Møller, J. P663
Klaassen, C.H.W.P1275, P1628,
P1636
Klapsa, D. P1759
Klar, E. P1522
Klare, I. P1602
Klaukka, T. O416
Klein, N. P588
Klein Breteler, E.G. O63
Kliasova, G. P1299, P1819
Klimashevskaya, S. P994
Klimek, M. P763
www.escmid.org/eccmid2006
Klinder, S. P834
Klingspor, L. P1202
Klomberg, D. P1275, P1628
Klonaris, M. P1193
Klucking, S. O397
Klugman, K. O228
Kluytmans, J.A.J.W. P1425,
P1426
Knausz, M. P910
Kneschke, J.C. O370
Kniezova, Z. P1091
Knobloch, J.K. O94, O95,
O305, O370
Knoke, M. P1231
Knoth, H. O153
Knudsen, J.D. O225, O428,
P1872
Kobayashi, Y. P1544
Koblinger, S. O424
Koc, R. P850
Kocak Tufan, Z. P892
Koch, A. O220
Koch, H. P1516
Koch, M.R. P646
Koch, S. O366
Kocmanova, I. P729
Koeman, M. O71, P1019
Koernig, T. P1323
Koeth, L. P1441, P1442
Köfer, J. P1808
Kofoed, T. P581
Kofteridis, D. P1049
Koga, P.C. P1391
Kogan, Z. P628
Koh, E.-H. P1803
Koidl, C. P627
Koirala, J. P1302
Koivumäki, A. P1681
Kokkinou, S. P550
Kokoglu, O.F. P849
Köksal, I. O102, P1094
Kolader, M-E. P1068
Kolayli, F. P1288
Koldkjær, O.G. P1753
Kolenova, A. P1090
Koletsi, P. P1356, P1357
Kõll, P. P583
Kollaras, P. P697, P1549,
P1708
Kollias, S. P1177
Kolman, J. O309
Kolodziejek, J. P568
Kolokotronis, T. P1844
Kolonitsiou, F. P1354
Komatsu, M. P971
Komninou, G. P1844
Komon, M. P528
Kompoti, M. P1126, P1511
Koncan, R. P1591
Kong, F. P904
König, B. O169, P946, P1338
König, W. O169, P946, P1338
Kononen, E. P1757
Konstabel, C. P1602
Konstantinou, T. O429
Konstantopoulos, A. P816
Konstantopoulou, S. P1086
Kontekaki, E.P804, P805, P1101,
P1257, P1439
Kontogiorgi, M. O363
Kontopidou, F. P1017, P1329,
P1343, P1528
Kontopodis, E. P1349
Kontopoulou, T. P1081
Kontos, F. P1434, P1592
Kontou, E. P553
Kontoyiannis, D. S80
Konup, I. P1558
Konup, L. P1558
Koo, S.H. P1281
page 159

List of Authors
Name Number Name Number Name Number Name Number
Kooistra-Smid, A.M.D. O170
Koopmans, M. P1654
Kopec, J. P755, P763
Kopp, S. P1305
Koppen, H. P474
Kopterides, P. P1356, P1357
Koraki, K. P717, P1384,
P1631
Koratzanis, E. P1017, P1283,
P1329, P1413
Korbsrisate, S. P1179
Kordosis, T. P1708
Koroljova, P. P1295
Korrovits, P. P1859
Korsic, M. P1304
Korth-Bradley, J. O360, O361
Koruk, I. P1874
Kosalec, I. P732
Koseli, D. P1472
Koseoglu, M. P1869
Kosmidis, C. O270
Kosmopoulou, O.P1052, P1503,
P1504
Kosowska-Shick, K. P1267
Kostkova, P. P657, P1509,
P1510
Kostogiannou, I. P1789
Kostyanev, T. P502
Kosz-Vnenchak, M. P755
Koti, I. P1486
Kotilainen, P. P630
Kotlyar, S. P1558
Kotolácsi, G. P1284
Kotsovassilis, C. P981
Kott, I. P855
Kotulova, D. P845
Kouatchet, A.T. O226
Koukoulaki, M. P759
Koumentaki, E. P1549
Koundourakis, A. P1001
Kouppari, G. P1486
Koureli, O. P799, P883
Kouris, A. P1136
Kouskouni, E. P873
Kousoulas, V. P1178
Kousseris, I. P1001, P1352
Koutoukas, P. P1193
Koutsandrea, C. P1849
Koutsoukou, A. P935, P1228,
P1600
Koutsovasili, A. P1126, P1511
Koutsovasilis, A. P1511
Kovacs, G.T. P702
Kovalev, Y.N. P1351
Kowalsky, S. P1715, P1716
Kozatchenko, M. P1093
Koziol-Montewka, M. P1107,
P1109
Kozlov, R.S. O391, P1012,
P1291, P1388,
P1484, P1633
Kozlova, O. P741
Krabbe, P.F.M. P1862
Krainova, L. P1299
Krajiw, S. P1668
Kraklau, D. P1069
Krämer, M. P1811
Kraniotaki, H. P540, P553
Kranjcic Zec, I. P1206
Krasniqi, S. P659
Krasnopolski, V. P724
Kratzer, C. P1563, P1792
Krause, D.S. P739, P1205
Krcmery, V. P700
Kredics, L. P528
Kreidl, P. P1669
Kreiswirth, N. O216
Kresken, M. P714, P1396,
P1582, P1583
Kretchikov, V. P1407
Kretchikova, O. P1633
Kreuzer, C. P627
Krievins, D. P1575
Krishnan, K. P628
Kristensen, H. P1562
Kristensen, L.H. P1180
Kristinsson, K. O220
Kristóf, K. P1284
Kristoffersen, K. P473
Kritsotakis, E.I. P1349, P1480,
P1625
Kriz, B. P855
Kriz, P. O168
Kroes, A. O67, O158
Krogh-Madsen, M. O428
Kronvall, G. P911, P940, P1272
Kroon, F.P. O263
Kropec, A. O366
Krucso, B. P526
Kruepe, H. P1437
Krug, B. P1836
Krüger, W. S14
Kruglov, A.N. P1351
Krulicki, W. P1649
Krüsmann, F. O148
Kryeziu, D. P667
Kryeziu, R. P667
Ksanthos, A. P1444
Kubicek, C. P528
Kubicova, E. P729
Kubin, M. P1497
Kubitza, D. O358, O359
Kuhn, S. P575
Kuijper, E.J. S107, O263,
E335, P524, P1636,
P1639, P1640, P1641
Kuiken, T. O158
Kuipers, E. S27
Kujath, P. P1516
Kulak, M. P1664
Kulakov, V. P724
Kulaksizoglu, M. P1852
Kulaksizoglu, S. P1852
Kulko, A. P730
Kullberg, B.J. S235, S323
Kulpoo, D. P1643
Kulwichit, W. P557, P1111,
P1668
Kumar, V. O128
Kundakci, A. P906
Kuntaman, K. P451
Kural, M. P1589
Kuropatenko, M.V. P572
Kurt, H. P1198, P1824
Kurtoglu, D. P1096, P1097,
P1098, P1099
Kurutas, E. P849
Kusachi, S. O425
Kuse, E. O424
Kustos, I. P910
Kuti, J.L. P1550
Kutna, K. P1091
Kuwabara-Wagg, J. P602
Kuyvenhoven, M. O438
Kuz’min, V. P1557, P1558
Kuznecovs, I. O318
Kuznik, A. P1493, P1494
Kwa, D. P1720
Kwak, E-Y. P1647
Kwak, L. O165
Kwon, K.C. P1281
Kyratsa, A. P804, P805,
P1136, P1257
Kyriazi, Z. P805, P1257
Kyriazopoulou, V. O120
Kythreotou, G. P1002, P1025
La Louze, F. P1744
La Salandra, G. P1845
Labeith, D. P1064
page 160 Final Programme
Labischinski, H. S138
Labonia, M. P913
Lachaud, L. P648
Láday, M. P528
Laeneste, T. P1634
Laffer, R. P1498
Lafforgue, N. P896
Laffut, W. O60, P1132, P1488
Lagedrost, J. P628
Lagler, H. P1284, P1321
Lago, M. P614, P615
Lagrou, K. P452, P742, P995
Laguente, C. P967
Lai, S. P1680
Laitinen, I. P630
Lal, G. P801
Lal, P. P1728
Lalande, V. P1635, P1648
Lam, S.Y. O99
Lamagni, T. P547
Lambert, P.A. P532
Lambiase, A. P1028
Lambropoulos, S. O269
Lamonaca, V. P1340
Lamontagne, F. P1130
Lamp, K. P1703
Landen, H. P1055
Landini, M.P. P756
Lang, M. O94
Langeland, N. P599
Langvik, M. P533
Lannigan, R. P1431
Lantero, M. P1368
Lanthaler, A. P1669
Lanzafame, P. P1186, P1187
Lanzarini, P. P945
LaPlante, K.L. P1561
Larion, C. O259
LaRocco, M.T. P1408
Larrú Martínez, B. P1667
Larsen, A.R. O115, O317,
P472
Larsen, H.H. P603
Larson, E. P661
Larsson, H. O266
Larsson, J. P743
Lascols, C. O50, O53, P1769
Lasne, G. P1174
Lass-Flörl, C. P587, P737
Laterre, P.F. P1465
Lau, K. P713, P1393
Lau, S.K.P. O98, P1604,
P1671
Lauranou, E. P515
Laurans, C. P1612
Laurans, G. P1139, P1246
Laurent, C. P442
Laurent, F. P690, P1871
Laurichesse, H. P1140
Laustsen, S. P663
Lauvrak, V. P644
Lauwers, S P754, P1768
Lavazza, A. P1672
Lavigne, J.P. O364
Lavrova, N. P468
Lawrence, K. O354
Lazar, V. O259, P582, P1163,
P1359
Lazaraki, G. P1526, P1549
Lazzari, S. P660
Lazzarotto, T. P629, P756
Le Berre, M.-A. P1061
Le Brun, C. P963
Le Dantec, A.C. P998
Le Devehat, C. P1575
Le Goff, J. P642
Le Guillou, H. P785
Le Strat, Y. P619
Leakey, A. P1584
Leal, A.L. P1380
Leary, R.H. O353
Leavis, H.L. O166
Lebeau, B. P861
Lebessi, E. P505, P1008
Leblebicioglu, H. P563, P564,
P1743
Lebon, P. P642
Leclercq, M.P. P1534
Leclercq, R. S37, S91
Lecuona, M. P1213, P1740
Lee, C. P656
Lee, D-G. P1009
Lee, D. P1253
Lee, E.J. P476
Lee, E.Y. O132
Lee, J. P1537
Lee, J.V. P1680
Lee, K-S. P1015
Lee, K. P912, P999, P1274,
P1377, P1647
Lee, K.M. P787
Lee, L.N. P1102
Lee, M.-H. P539
Lee, M.A. P1800
Lee, N.Y. P1803
Lee, R.A. O98
Lee, S-M. P1040
Lee, S. P912, P1274
Lee, S.H. P476, P1800
Lee, W.G. P1377
Lee, Y-J. P1015
Lee, Y.J. P789
Leeming, J. P1643
Leen, G. P810
Leens, E. P1616
Lefebvre, N. P1010
Lefeuvre, A. P1660
Legakis, N.J.O127, O269, P534,
P759, P901, P902,
P1289, P1404, P1802
Legnani, G. P734, P1128
Lehmann, L. S329
Lehmann, M. O213
Lehn, N. O153, O154,
O315, P1565
Lehours, P. P967, P1174
Leib, S.L. P1145
Leibovici, L. O69, O156, O265,
O303, O440, P685,
P1300, P1367
Leininger, L. P1514
Leitão, J. P509
Leitão, R.M. P1419
Leiva, J. O74
Lelekis, M. P662, P1486
Lemaire, S. P1534
Lemmens, N. P451
Lemming, L. P1220
Lenev, I. P522
Lengerova, M. P964
Lennox, G. P1431
León, J.R. P593
Leonardos, P. O120
Leonardou, A. O120
Leonidou, L. O120
Lepage, P. P815, P1648
Lepape, A. W1
Lepelletier, D. P464
Leprince, C. P881
Lervang, H.-H. O121
Lescure, F.X. P1139
Lesens, O. P1010
Lesprit, P. P1481
Lester, C.H. P1376, P1402
Lesyk, R. P1557
Leth, R.A. P671
Leu, H-S. P539, P1290
Leung, D.T.N. P904
Leung, S.Y. P1671
Leverstein-van Hall, M.A. O273

List of Authors
Name Number Name Number Name Number Name Number
Leviandier, C. O51, P1249
Levidiotou, S. P1136, P1625
Levy, S. P1703
Lezcano, M.A. O131, P1134
Li, H.J. O306
Li, K.S.M. P1671
Li, M.W.S. P1604
Li, R.W.F P745, P863
Li Bergoli, M. P913
Liakos, P. P1592
Liapi, E. P1642
Libisch, B. P526, P910, P911
Lie, A.K. P644
Liesenfeld, O. P1189
Liesnard, C. P1650
Lignell, A. P743
Likatavicius, G. O395
Lilius, E-M. P630
Lim, H.L. P813
Limban, C. P1560
Lin, C-H. P1372, P1879
Lin, C.-L. P789
Lin, C.Y. P1114
Lin, D. P1606
Lin, J.-C. O59
Lin, J.S. P1114
Lin, T-P. P510
Lin, T-Y. P1054, P1057,
P1879, P1879
Liñares, J. P1276, P1815
Linares, L. P923
Lindberg, E. P1392
Linde, A. S288
Linde, H.J. O315
Lindeboom, J.A. P524
Lindner, H. P1568
Lindou, A. P550
Ling, J.M. P1248
Lingenfelter, C. P652
Liolios, K. P1781
Lipsitch, M. P1814
Lipsky, B. S83
Lipton, J.H. O421, O422
Lisby, G. P951
Lisena, F. P598
Lisgara, P. P941
Lito, L. P898, P931
Littauer, P. P1811
Little, P. S347, P985
Liu, C.Y. P704
Liu, H.-F. P789
Liu, S. P646
Liu, Y-C. P510
Liveris, D. P1146
Livermore, D.M. S182, S236
P507, P508, P1236,
P1239, P1447, P1601,
P1621, P1622, P1750
Ljubin-Sternak, S. P1162
Ljungman, P. S206, P1271
Llaneza, M.E. P1596, P1597,
P1618
Lloyd, A. P1497
Lo Cascio, G. O77
Lochmanova, J. P729, P964
Lode, H. S231, P1024, P1061,
P1576, P1578, P1713
Lodise, T.P. P1365, P1374,
P1524
Loens, K. O212, P966
Löfmark, S. P1235
Logginidis, I. P873
Lohmann, S. P962
Loiseau, F. P701
Loivuke, K. P939
Lõivukene, K. P1634, P1718
Lolans, K. P1408
Lomaestro, B.M. P1365
Lomas, J.M. P1837
Lombardi, G. P1399
Longauerova, A. P845
Lontie, M. P995
Looijmans-van den akker, I. O164
Lopaciuk, U. P1605
Loparev, V. P638
López, A.B. P467
López, D. P1853
Lopez, E. P918, P1046
Lopez, K. P959
Lopez, R. P1297
López-Brea, M. P716, P758,
P1704, P1746, P1848
López-Calleja, A.I. P1122
López-Oviedo, E. P738, P1424
Lor, K. P1561
Loregian, A. O58
Lorenzo García, M.V. P1127
Lorenzotti, S. O275, P469,
P664, P1203
Lortholary, O.E30, S186, S325,
O424, P737,
P1172, P1211
Lorusso, E. P1672
Loschiavo, C. O77
Lot, F. P619
Lotz, M. P1175
Loubinoux, J. P1342
Loucou, I. P470
Louie, L. P1428
Louie, T.J. O150, P1649
Loulergue, P. P1130
Loupa, C P662, P1486
Louro, D. P793, P1630
Louw, M. P561
Love, W.G. P1564, P1565,
P1566
Lovering, A.M. P626, P1148,
P1586
Lovgren, M. O220
Lovoll, O. O220
Low, D.E.O216, P1150, P1155,
P1252, P1397
Löwdin, E. P743
Lowther, J. P1567
Loxton, R.P. P567
Lu, D. P1168
Lu, J-J. P510
Lubenko, I. O355, P1519,
P1520
Luca, B. P1282, P1594
Luca, C. P768, P1833
Lucà, M.G. O215
Luca, V. P768, P1833
Lucas, C. P996
Lucente, M.S. P1674
Luczak, M. P520, P1638
Ludwig, K. P1231
Luft, D. O147
Luh, K.T. P1102
Lui, B. P1747
Luis, F. O165
Luiuz, R. P1635
Luk, W-K. O98
Lukas, W. P1039, P1506,
P1847, P1854
Lumbreras, C. P679
Luna, H. P875
Lund, B. P1689
Lund, E. P663
Lundblad, E. P514
Lundgren, B. P603
Lundgren, J.D. S285, P603, P1165
Lundkvist, A. P647
Lunel-Fabiani, F. P785
Lunkenheimer, K. P462
Lunt, M. P961
Lunz, C. P1861
Lupo, A. P501
Lupse, M. P481, P1382
Luque, R. P1007
Luzbinska, L. P678
Luzi, C. P934
Luzzaro, F. O75, O394,
P1164, P1399, P1418
Luzzi, I. P504
Lydatakis, H. P997, P1719
Lynch, M. P1030
Lysèn, J. P1108
M’Zali, F. P908
Ma, L. O360, P1524
Ma, S. P573
Ma, X-Z. P618
MacCannell, D. P1649
Macchi, V. P597
Macedo, R. O173, P1254
MacGowan, A.P. O300, S407,
P626, P1148, P1309,
P1394, P1527, P1529,
P1530, P1531
Mach, T. P1100
Machado, E. P924
Machado, I. P871, P872
Machado, J. P1370
Machado-Vaz, M. P1027
Machova, I. P1167
Macià, L. P1243
Macías, N. P1853
Macipe, M.P. P1122
Mack, D. O94, O95, O370,
P988
MacKenzie, F.M. P1333, P1336
Mackova, B. P1459
MacLennan, G. P1336
Madar, C. O69
Madinier, I. P1420
Madisch, A. O153, O154
Madle, G. P1509
Maertens, J.O60, S278, O421,
O422, P742
Mag, T. P568
Magalhães-Sant’Ana, A. P968,
P1797
Mager, J.J. P1044
Magnone, V. P1700
Magri, S. O275, P469,
P664, P1203
Magurean-Zervaki, K. P1870
Mah, M. P1649
Mahamat, A. P1333
Mahboudi, F. P576
Mahmoodi, K. P578
Mahmoudi, M. P1195
Mahmutovic, S. P640
Mahzounieh, M. P1673, P1755
Maiden, M. O168
Maillard, A. O398
Maimets, M. P1634
Maine, G.T. P628, P629,
P879, P880
Mainini, R. P762
Maioli, E. P1776
Maisch, T. P1565
Majcher-Peszynska, J. P1516
Majewski, P. P751, P752
Majewski, W. P751
Majtán, V. P1749
Majtánova, L. P1749
Majumdar, S. P1181
Mak, P. P1296
Makarona, M. P1001, P1352
Mäkelä, M. O416
Makimura, K. P731
Makrakis, E. P873
Makri, A. P791, P792, P901,
P902, P1880
Makrygiannis, N. P1001, P1352
Malakhova, M.V. P1809
Malamou-Lada, H. P1101,
P1136, P1439, P1802, P1849
www.escmid.org/eccmid2006
Maldeis, N.E. P952
Malek, S. O216
Maleknejad, P. P639
Malengou, K. P1503, P1504
Malev, I. O391
Malhotra-Kumar, S. O56
Malicki, A. O436
Malli, E. P1759
Mallick, R. P1493, P1494,
P1782
Malliou, K. P1008
Manca, N. P649, P1203
Mancini, C. P504
Mancini, G. O417, P1627,
P1699
Manczinger, L. P528
Mändar, R. P583, P1859
Mandell, L.A. P1150, P1155
Mandomando, I. P1615
Mandraveli, K. P697
Maneeva, E. P1483
Manfredi, R. P604, P605, P606,
P607, P608, P609,
P610, P611, P612,
P613, P733, P734,
P784, P905, P1128,
P1225, P1226,
P1227, P1501, P1608,
P1609, P1830
Mangia, M. O215
Mani-Saada, J. P657, P1509
Maniati, M. P1592
Maniatis, A.N. O127, P941,
P1592, P1593,
P1759
Manierski, C. P458, P1347
Manios, N. P791
Manji, K.P. P599
Manji, R. O64, P1657
Manna, A. O61
Manno, G. P824, P1450
Manolescu, L. P1065
Manolopoulos, C. P450, P749
Manoura, A. P1350
Mansoor, I. P1423
Mantero, E. P1208
Manzullo, E. P694
Manzur, A. P921, P1348
Mapar, M. P1207
Maradona, J. P1368
Marais, E. P1363
Maraki, S. P722, P1049,
P1349, P1350,
P1870
Maral, I. P1104
Marcas, C. P1875
Marchandin, H. P525
Marchese, A. P736, P836,
P1307, P1332,
P1776
Marchetti, O. O151, P688,
P1230
Marchou, B. P1140
Marciniak, A. P1500
Marciniak, R. P752
Marco, F. P923, P1158,
P1398, P1603,
P1841
Marcos, F. P1036
Marcos, M.J. P1007
Marcoux, M. P881
Marejkova, M. P1167
Marekovic, I. P1304
Maresova, V. P750
Maretic, T. P732
Margeli, A. P594, P816
Marín, M. P466, P944,
P1422, P1764
Marinacci, G. P733, P1608
Marinescu, P. P1065
page 161

List of Authors
Name Number Name Number Name Number Name Number
Marinkovic, S. P1304
Mariño Callejo, A. P1127
Marion, K. O97
Mariscal, D. P1723
Markaki, V. O363
Markham, L. P1229
Markina, O. P1299
Markomichelakis, N. P1849
Markova, B. P502
Markovska, R. P502, P1619
Maródi, L. P796
Maroko, R. P1783, P1784,
P1785, P1786
Marques, J.G. P898
Marques, P. P1818
Marrocco, C. P617, P767,
P774
Marshall, J. E330, S339
Martella, V. P475, P1358,
P1670, P1672,
P1674
Martens, A. P575
Marth, E. P627, P1324,
P1808
Marti, S. P833, P938, P1369
Martín, C. P738, P1424
Martin, L. P1607
Martín, R. P1276, P1815
Martin, Y. P1026
Martín-Herrero, J.E.P797, P1050,
P1051
Martín-Mazuelos, E. P738, P1424
Martín-Rabadán, P. P1764
Martín-Sánchez, A.M.P1050, P1051,
P1053
Martinez, A. P1597
Martínez, D. P674
Martinez, I. P1658
Martinez, J.A. P923
Martinez, J.L. S208
Martinez Alario, J. P479
Martínez-Alarcón, J. P1201, P1256
Martínez-Alfaro, E. P1035, P1036
Martínez-Marín, C. P1153, P1297
Martínez-Martínez, L.O52, P443,
P444, P446, P513,
P1154, P1247,
P1369, P1734
Martinez-Medina, M. P536
Martini, S. P774
Martino, B. O423
Martino, R. P1200
Martirosian, G. P1696
Martos, A. P738
Martsoukou, M. P1642
Marty, N. P1470
Marty, P. O100
Marum, S.A. P646
Mary, C. O398
Maryniw, E. P1395
Maschan, A. P1299
Maschmeyer, G. S204, E332
Mashiach, T. P1021
Masi, G. O58, P597
Masoud, L. P1324
Masoumi Asl, H. P1031
Massias, L. O261
Massip, P. P1140
Masterton, R. S238
Mastora, Z. P1356, P1357
Mastrantonio, P. P542, P1273,
P1810
Maszewska, A. P1183
Mateos, F. P1035, P1036
Matevish, J. P747
Mathai, S. P1856
Matheron, S. P601
Matica, B. P732
Matkham, L. P1212
Matrat, S. O57
Matsagoura, M.P1126, P1126,
P1511
Matsumoto, K. P561
Matta, M. P642
Mattei, D. O262
Matter, L. O218, P776
Matthaiou, D. P1840
Matti, C. P735
Mattner, F. P575
Mauch, H. P1024
Maugein, J. P1587
Maury, E. O276
Mauskopf, J. P1499
Maxfield, R. P1584
May, T. P1139
Mayall, B. P977, P1429
Mayer, Jiri P729, P964
Mayer, Joe P453
Mayr, J. P962
Mazaheri Tehrani, E. P1882
Mazzariol, A. P928, P1451,
P1591
Mazzeo, C. P715
Mazzulli, T. O216
McAllister, S. P441
McCracken, G. O116
McDermott, L.A. P1813
McDonald, C. S108, E335
McDonald, C.J. P1060
McDougal, L. O172
McDowell, D. P1690
McGeer, A. O216, P1397
McGowan Jr., J. O172, P447
McGregor, J. P1186
McHenry, E. P1877
McIntyre, A. P889
McKendrick, M. P1092
McKeown, D. P1846
McKeown, P. P1030
McLauchlin, J. P1644
McLaughlin, P. O165
McLaws, F.B. P1590
McManus, M. P1411
McMullan, R. P686
McNally, P. P810
Mcnicholas, S. P1487
McVeigh, C. P888
Meagher, A. P1781
Meals, E. P1395
Meaney, H. P1428
Mechouet, F. P1831
Medkova, Z. P1733
Mégraud, F. S28, P967, P1174
Mehtar, S. S109
Meijers, S. P1275, P1628
Meinders, A.J. P1044
Meisel-Mikolajczyk, F. P520, P1638
Meka-Mechenko, T. P947
Mela, V. O270
Melander, E. P1814
Melero, J. P1658
Melica, G. O417
Meliconi, M. P645
Melidou, A. P941
Melillo, L. O262, O423
Melioli, G. P1208
Melles, D.C. O274, O365,
P620, P1696
Mellmann, A.Workshop 2, O171,
O314, P471, P529
Melnick, D.A. P1408
Melo-Cristino, J. O117, P931
Memikoglu, O. P1198, P1824
Mempel, M. P870
Menard, A. P967, P1174
Menday, P. O317, P900
Mendes, C. P920, P1391,
P1550
Mendes, R.E. P933
Mendez Arancibia, E. P1169, P1398
page 162 Final Programme
Mendonça, N. P509
Mendrinou, E. P1873
Menekse, S. P1666
Mengoli, C. P687
Menke, A. P1583
Menotti, J. P942
Mensa, J. P1240
Mensa, L. P1398, P1603
Mentasti, M. P824, P1450
Mer, M. P1363
Mera, R.M. P1375, P1389,
P1614
Merard, R. P1621
Merat, S. P771
Meretaki, S. P873
Mereuta, A. P1005
Merfort, K. P1151
Mergioti, C. P1802
Merli, S. P1123
Mero, S. P948
Meroni, V. P680, P945
Mertaniasih, N.M. P451
Mertens, A. P1656
Mesaros, N. P1751
Mesolara, F. P673
Messina, V. P767
Messina-Powell, S. P453
Mestres, C.A. P1158, P1841
Meszner, Z. P526
Metallidis, S. P1526, P1549,
P1708
Metan, G. P927
Mete, E. P1546
Meunier, D. P1818
Meyer, E.C. O432, O439,
P561, P1361, P1364,
P1462, P1467
Meyer, T. P562
Mezzaroma, I. O399
Mezzatesta, M. P501
Mhalla, S. P987
Miao, J. P1606
Michail, P. P799
Michalaki, M. O120
Michallet, M. P701
Michalopoulos, A.P1018, P1356,
P1478, P1556
Michel, U. O369
Michel, Y. P530
Michelet, C. P896
Miehlke, S. O153, O154
Migliavacca, R. P913
Miguel, M.A. P1213, P1740
Miguéns, C. P1797
Miha, T. P1719
Mihaescu, G. P1560
Mihaila-Amrouche, L. P1342
Mihalache, D. P768, P1833
Mijac, V. P832
Mikalauskas, R. P545
Mikamo, H. P1857
Mikelsaar, M. P583, P939
Mikov, M. P1303
Milan, G. P600
Milatovic, D. P1401
Militello, V. P597
Milkovich, G. S232A
Millán, I. P1596, P1618
Miller, L.A. P1375, P1389,
P1614
Miller, M. O150
Millet, J. P521
Millot, G. P975
Milner, P. O214
Miltsakakis, D. P1136
Mimica-Dukic, N. P1303
Minarikova, D. P964
Minárovits, J. P910
Mingeot-Leclercq, M. O356, P1751
Minoli, L. P680
Mirahmadi, R. P647
Miralles, F. P1837
Mirand, A. P530
Mirazimi, A. P647
Mirhendi, H. P731
Miró, J.M. S253, P1158, P1841
Mironova, A. P1299, P1819
Mirrett, S. P441
Miserlis, G. P696
Misic Majerus, L. P1176
Misirlioglu, M. P1449
Missir, V. P1560
Mitka, S. P1029
Mitov, I. P502
Mitrovic, S. P1206
Mitt, P. P1634
Mittal, R. P1159
Mittermayer, H. P1355
Mitzevich, M.E. P1351
Miyagi-Shiohira, C. P521
Miyamura, K. P1096, P1098,
P1099
Mizgala, E. P1506, P1854
Mizrakci, S. P1472
Mlangeni, D. P1331
Mlinaric-Galinovic, G. P1162
Moczko, M. P962
Modrau, I. P1220
Moellering, R. S321
Mönke-Müller K. S29
Moet, G. P1804
Moghtadaei Khorasgani, E. P1673
Mohaghegh-Shalmani, H. P537
Mohammadzadeh, A. P1435
Mohammedi, D. P1831
Mohseni, A. P1461
Mohseni Zadeh, M. P1305
Moisoiu, A. P1294
Mølbak, K. O313
Moldes, L. P1835
Molenaar, L. P961
Moles, B. P1871
Molin, S. P830
Molin, Y. P1683
Molina, A. P1129
Møller, J.K. P671
Möller, M. P1055
Molnar, A. P1330
Molnár, B. P786
Mölstad, S. O393, P1463
Monaco, M. P1599
Monari, P. P756
Moncada, J. O390
Monclús, D. P1704
Mondain, V. P624
Mondello, P. O275, P664
Monen, J. O309, P1383
Moniri, R. P809
Monk, P. P1113
Monnet, D.L.S21, O313, O433,
P1333, P1376, P1460
Monnin, V. P455
Monno, R.A. P1694
Monpoux, F. P624
Montaraz-Crespo, J.A. P1103
Montazerolghaem, S. P980
Monteiro, G. P858
Montejo, M. P684
Montesinos, M.I. P1213, P1740
Montewka, M. P1107
Montgomery, J. P977, P1429
Montini, G. P687
Montravers, P. S238
Monzón, H. O224
Mooney, L. P1637
Moore, C. O65
Moore, M. P985
Moosavi Hossaini, K. P579
Moosavian, S.M. P549, P949,
P1693

List of Authors
Name Number Name Number Name Number Name Number
Mora, M.L. P479
Morais, A. P898
Moraitou, H. P1001, P1125,
P1352
Morata, P. P1678
Morate, C. P1587
Morava, M. P1759
Morcos, H. P691
Moreillon, P. O257, E334,
S340, P1156
Moreira, R. P1415
Morelli, P. P824, P1450
Morelli, S. P905
Moreno, A. P923, P1158,
P1841
Moreno, M.A. P1251
Moreno, V. P614, P615
Morey, J. P628
Morfou, P. P1000, P1357
Morgner, A. O153, O154
Morilla, D. P1424
Morita, M. P1099
Morosetti, G. P1669
Morozova, O. P631, P633,
P638
Morris, D. P1411, P1823
Morrison, D. O308, S381,
P893
Morrison, J. P1496
Morrissey, I. P1298, P1309,
P1394, P1535,
P1576, P1578, P1583,
P1584
Morsczeck, C. P581
Mosayebi, Z. P809
Moser, B. P1568
Moser, C. P1758
Moshavakis, E. O419
Mosheni, M. P1010
Moshiri, A. P579
Moss, S.J. P813
Mossong, J. P1818
Mossop, H. P1113
Motamedi, S. P1518
Motevali, F. P527
Moubareck, C. P919
Mougnai, C. P1136
Moulakakis, A. P779
Moulanaee, S. P1443
Mourikis, A. P1086
Mouton, J.W.S255, O362, P1152,
P1275, P1515, P1521,
P1628
Movahedian, A. P809
Mowbray, J. P1113
Mrowka, A. P445
Muçaj, S. P667
Mudde, A.H. P1862
Muder, R. P457, P458,
P1868
Mueller, B. O217
Mueller, B.A. P1538, P1539,
P1703
Mueller, F.M. P737
Mueller, H. P462
Mufson, M. O229
Mugnaioli, C. P506, P1418
Mulder, B. P856, P857,
P1120
Mullane, K. O150
Mullee, M. P985
Mullen, C. P695
Muller, A. O433
Muller, A.E. P1521
Muller, J. P702
Muller, L.M.A.J. O122, O123
Müller, M. P1545
Mulliqi-Osmani, G. P667
Mumcu, I. P723
Mundkowski, R. P1516
Muniain, M.A. O268
Muñoz, G. P482
Munoz, J. P880
Muñoz, N.L. P1678
Muñoz, P. Workshop 7, P480,
P684, P737, P744,
P1201, P1436
Muñoz-Bellido, J.L. P511, P1598
Muratov, E. P1557, P1558
Murchan, S. P1011
Murer, L. P687
Murphy, P.G. P810
Murray, B.E. P455
Musaad, S. P1138
Mushtaq, S. P1239
Musilek, M. O168
Musser, J. K92
Mustafa, A.S. P864, P1106
Muthaiyan, A. P1690
Muzslay, M. P910
Mygind, P.H. P1562
Mykhaylovska, N. P1557, P1558
Mylona-Petropoulou, D.P1136,
P1802, P1849
Naaber, P. P939, P1089,
P1634, P1718
Naber, K.G. O315, P1861
Nacca, C. P617
Nack, Z. P1793
Nadal, D. S203
Naderi, M. P1192
Naessens, A. P754
Nagl, M. P1568
Nagy, B. P523
Nagy, E. S11, P528, P554
Nagy, K. P477, P796
Najar Pirayeeh, S. P578, P579
Najdenski, H. P1739
Nakari, U-M. P1681
Nanetti, A. P905
Nanuashvili, A. P886, P1004
Napolitano, L.M. S88
Nappi, R. P560
Nardella, M.C. P1845
Nardone, A. O395
Narkeviciute, I. P712
Naserfar, N. P1192
Naserpour Farivar, T. P1192
Nassif, X. P1172
Nathwani, D. P1469, P1496
Nau, R. O369, P1175
Naumiuk, L. P1306
Navarro, A. P466
Navarro, J.C. O271, P915
Navarro, J.L. P1704, P1746,
P1848
Navarro, M.D. O268
Navarro, V. P1036
Navia, M. P1398
Naweewitphadung, K. P1111
Nayman Alpat, S. P483
Naz, H. P1016
Neal, S. Workshop 2,
P547
Nedorezenyuk, I. P1483
Negoita, M. P1833
Negut, M. P1745
Nejati, M. P578, P579
Nelson, N. O216
Nenkov, P. P589
Neri, A. P542
Netesova, N. P1664
Neth, O. P588
Neto Ferreira, H. P917
Neyme, D. O276
Nguyen, D. O96
Nguyen, T. P644
Nguyen Hoang Hanh, D.T. P876
Niang, M. P1607, P1865
Nica, M. P1775
Nicand, E. P785
Nicholson, K.G. P1112
Nickel, P. P1798
Nicola, L. P1771
Nicolau, D. P1533, P1550
Nicolescu, A.M. P777
Niebergall, J. P1189
Niederman, M. P1706
Niekamp, E.J.W.N. O418
Nielsen, A.D. O440, P1300
Nielsen, K. P947
Nielsen, L. P1659
Niesters, H.G.M. Workshop 4, S38
Nieto, J. P1667
Nijhuis, M. O66
Nikiforovski, N. P724
Nikita, D. P1000, P1478,
P1789
Nikolaidis, J. P1526, P1549,
P1708
Nikolaidis, P. P697, P1526,
P1549, P1625,
P1708
Nikolaou, S. P1125, P1434
Nikolayevskyy, V. P1118, P1121
Nikonov, A. P724
Nikoskelainen, J. P630
Nilsson, L.E. P1323
Nilsson, M. P647
Nink, K. P1464, P1479
Nioti, E. P722
Nisalak, A. P1668
Nissinen, A. P1446
Nistor, I. P1775
Nitzan, O. P979
Noacco, G. P942
Noah, C. P562
Nocita, B. P680
Noel, A. P1527, P1529,
P1530, P1531
Noel, G.L. S185, P1524
Nógrády, N. P1409
Nogueira, C. P968, P1797
Nogueira, J.M. O271, P915
Noguer, M. P692, P693
Nokhodian, Z. P1224
Noll, I. P463, P1266
Nollo, G. P1791
Nonhoff, C. P448, P449, P1742
Nonnenmacher, C. P1473
Nord, C.E. P586, P1271,
P1394, P1394,
P1711, P1779
Nordmann, P. S45, O51,E193,
P505, P1249
Noréus, N. P960
Norfolk, D. P1138
Nørgaard, M. O266, P1043,
P1059, P1060
Normanno, G. P475, P1845
Norrby-Teglund, A. P1282
North, S.E. P1601
Northwood, J. P1298
Nosari, A. O262, O423
Notermans, D.W. P1641
Nouroziyan Shamasbi, D. P579
Nouwen, J.L. P585, P620
Novack, V. P1042
Novais, A. P1415, P1417
Novais, C. P1341, P1626
Novelli, V. S112
Nowak, P. P541
Nowosiad, M. P907
Nowotny, N. P568
Nowrouzian, F.L.P1170, P1171,
P1392
Nseir, S. P677
Ntouroupi, A. P1600
Nucleo, E. P735, P913
www.escmid.org/eccmid2006
Nuhoglu, N. P1232
Nunes, Sonja O167
Nunes, Sadro F. P823
Nuorti, P. O220
Nurzynska, G. P1638
Nussbaumer, W. P587
Nutter, R. P533
Nuutila, J. P630
Nyberg, S.D. P1259
Nystedt, A. O220
Nyström-Rosander, C. P1683
O’Callaghan, D. O364
O’Donoghue, M. P1448
O’Gara, J.P. P819, P826
O’Hara, C. P447
O’Neill, A. J P1590
O’Neill, E. P819, P826
O’Neill, H. P1030
O’Reilly, P.G. P753
Obeid, K. P1347
Obertegger, S. P1151
Obriadina, A. P631, P632,
P633, P994
Obuch-Woszczatynski, P.P520,
P1638
Ocenas, M. P1091
Ochsner, U.A. P590, P1542,
P1559
Oda, S. O425
Odell, M.L. P1779
Odenholt, I. Workshop 6
Odent-Malaure, H. P770
Ofek, I. P1197
Offenstadt, G. O276
Offidani, M. O423
Ofir, O. P1286
Oggioni, M.R. P937
Oh, M-D. P1038
Oh, Y-J. P1015
Ohkusu, K. P971, P976
Oksuz, L. P1414
Olenin, A.Y. P978
Olesen, B. P1729
Oliveira, D.C. P1334
Oliveira, E. P833
Oliveira, M. P823
Olivella, R. P559
Olivera, A. P1841
Olivier, E.J. P567
Oloomi, M. P1756
Olowokure, B. P1113
Olsen, I. P1131
Olsen, J. P1233
Olsen, K.E.P. P1645, P1729
Olson, E. P899
Olsson-Liljequist, B. P459
Oltmanns, P. S380
Omeragiq, S. P667
Omidian, M. P1207
Ondrusova, A. P1090
Onguru, P. P916
Oord, H.C.A. P983
Oostvogel, P.M. P1521
Opavski, N. P832
Oppenheim, B.A. P1500, P1794
Oppenheimer, F. P923
Oprea, S. O73
Oprica, C. P1711
Oral, B. P851, P1293
Oren, I. O174
Orfanidou, M. P1101, P1439
Orland, A. P1583
Orlando, G. P1123
Ormen, B. P1074
Oropeza, S. O162, P1655
Orta, N. P740, P1721
Ortega, E. P675, P1075
Ortega, V. P875
Ortiz, D. P803
page 163

List of Authors
Name Number Name Number Name Number Name Number
Ortiz, J. P875
Ortiz, N. P766
Oruç, E. P721
Osek, J. P1685
Osmon, D. O70
Ossi, M.C. P836
Östblom, A.E. P1171
Østergaard, C. P1165
Ostfeld, I. P1367
Otero, J.R. P679, P1881
Otsuka, Y. P976
Ott, A. O274, O362
Ott, H.W. P1568
Otuk, G. P711
Ouar-Korichi, M. P1831
Ouerdane, D. P1831
Oulerich, C. P1473
Over-Hasdemir, U. P1308
Overdijk, M. P966
Owen, R.J. O119, P518, P1680
Oyen, W.J.G. P1862
Oza, A. P1011
Ozbek, A. P591, P1869
Ozbek, B. P711
Ozbek, E. P591
Ozbek, S. P1869
Ozcakir, O. P1695
Ozdemir, D. P563
Özdemir, N. P982
Ozer, F. P1104
Ozer, S. P868
Özgünes, I. P483, P1016
Ozkahya, M. P1215
Özkan, F. P897
Ozkan, Sebnem P867
Ozkan, Sengul P723
Özkul, H. P1041
Ozkutuk, A. P860
Ozlu, N. P1345
Ozolins, G. P1485
Ozsvár, Z. O118
Ozturk, A. P1133
Ozturk, E. P839
Ozyilmaz, E. P986
Paberza, R. P678, P887
Pacenti, M. P600, P687
Pachiadakis, I. P941
Pachkunov, D.M. P1351
Pachón, J. O260, P692,
P693, P1154,
P1369
Pachón-Ibáñez, M.E. O260, P1154
Pacsa, A. O62, P1651
Padilla, B. P466
Padilla, E. P1337
Padrón, E. P1864
Pagani, L. P735, P913,
P1418
Pagano, L O262, O423
Pagano, P.J. P707
Page, M.G.P. P1586
Pähkla, E. P1718
Pajno, M. P613
Pál, T. P568
Palacián, P. P1026
Palacios, G. P1652
Palade, A. P1686
Palafox, M. P880
Palenzona, A. P736, P1307
Paleologou, N. P1008
Palepou, M.F.I. P1622
Palerm, L. P1658
Palladino, S. P637
Pallares, R. P1276, P1815
Palomar, M. Workshop 7
Palomares, J. P738
Paltansing, S. P1639
Palù, G. O58, P597, P600,
P687, P689
Paluch-Oles, J. P1107, P1109
Palva, E. O416
Palvarini, L. P895
Pamuk, B. P1852
Pan, A. O275, P469,
P664, P1203
Pana, M. P1285, P1775
Panagi, M. P1001
Panagopoulos, P. O419
Pancharoen, C. P1668
Pandey, P. P1069
Panesar, P. P1475
Pangalis, A.P470, P534, P902,
P1218, P1362
Pangon, B. P690
Pani, A. P469
Paniara, O. P540, P553, P759
Pannekoek, Y. P535
Panopoulou, M. P1765
Panoulis, C. P1349
Panousis, K. P1193
Pantazatou, A. P1289
Pantazis, K. P779
Pantelaki, M. P1343, P1727
Pantosti, A. P1599
Pantucek, R. P1167
Papadaki, H. P1486
Papadatou, M. P901, P902
Papadimitriou, A. O155
Papadomichelakis, E. P1017
Papadopoulos, A.P666, P1210,
P1528
Papadopoulos, C.J. P1244
Papadopoulos, K. P1855
Papadopoulos, N. S287
Papadopoulou, C.P1002, P1025,
P1270
Papaefstathiou, A. P1126
Papaefstathiou, K. P1486
Papaeliadis, T. O419
Papafrangas, E. P1642
Papageorgiou, V. P749
Papagheorghe, R. P1775
Papaioannou, V. P1478
Papalois, A. P1193
Papaparaskevas, J.O270, P534,
P1289
Papassotiriou, I. P594, P814,
P816
Papastamataki, P. P1840
Papavasileiou, H. P791, P902,
P1880
Papavsileiou, K. P1880
Pape, M. P697, P1188
Papetti, F. P598
Papoulia, E. P885
Papp, M. P478
Pappas, G. S114
Pappas, S. P997, P1052,
P1719
Parada, C. P1075
Paragi, M. P1613
Paramythiotou, E. P1802
Paraskakis, I. P901, P902
Pardo, F. P1124, P1835
Pardos, M. P1597, P1618
Pareek, M. P1832
Parisi, A. P1845
Parisi, S.G. P689
Park, B.J. P1040
Park, C.W. O163
Park, H. O132
Park, J-H. P1015
Park, J.W. P1281
Park, K-J. P1015
Park, S. O426, O427
Park, S.H. P1009
Park, W.B. P1038
Park, Y-J. P1274
Park, Y.K. O132
page 164 Final Programme
Park, Y.S. P999
Parker, M. O175
Parkinson, A. O220
Parks, D. O220
Parks, V. P1779
Parneix, P. P1470
Parody, R. P692, P693
Parola, P. O100, P1069
Parot, E. P676
Parruti, G. O61
Parsonage, M.J. P622
Pasanen, T. P948
Pascual, Andres O151, P1230
Pascual, Alvaro O52, O260,
O268, P446, P513,
P938, P1154,
P1247, P1369
Pasqualotto, A.C. S25, P811
Passarell, J. P1781
Pastore, D. O423
Pászti, J. O118, O311,
P526, P1409
Patel, A. P1023
Patel, C. P880
Patel, J.H. P1538, P1539
Patel, N. P1365, P1374
Patel, R. O70
Patel, S. P694
Paterson, D.L. P1806, P1807
Patino, H. O422
Paton, J. P996
Patsoura, A. P505
Patterson, T. S234
Patzer, J.A. O301
Paul, M. O69, O156, O265,
O303, O440, P685,
P1300, P1367
Paulauskas, A. P545
Paulsson, O.B. P1165
Paun, L. P1661
Pavia, C. P1146
Pavicic, F. P1304
Pavlidou, H. P1855
Pavlou, K. P550
Pawinska, A. O301
Payan, C. P785
Pearson, A.D. O310, P658,
P1173
Pechère, J.-C. S377
Pecherskikh, E.I. P1351
Pedarra, C. P1845
Pedersen, C. P1753
Pedersen, G. O266
Pedersen, S.S. P1753
Pedicone, L. O422
Peetermans, W.E.P742, P1474,
P1838, P1839
Peeters, J.K. P620
Pefanis, A. P1352
Peigue-Lafeuille, H. P530, P770
Peiris, M. O99
Peixe, L. P914, P924,
P1341, P1370,
P1626, P1773
Peláez, T. P744, P1201,
P1256
Pelayo, J. P918, P1046
Pelekanou, A. P1178
Pelk-Jongen, M. P625
Pellegrini, C. P934
Pelloux, H. P861, P877,
P942
Pena, A. P1419
Peña, A. P651
Peña, C. P1348
Peña, J.L. P1829
Pencu, I. O73
Penni, A. P1585
Pepeljnjak, S. P732
Pepin, M. P1699, P1700
Peppas, T. P997, P1052,
P1503, P1504
Peralta, G. P918, P1035,
P1036, P1046,
P1864
Perbost, I. P624
Perdigão, J. P1254
Perea, E.J. P513
Pereira, A.S. P1412
Pereira, E. P1254
Pereira, N. P1112
Perello, R. P923
Perepanova, T. O149
Peres, I. O167, P898
Pereyre, S. P725
Pérez, F. P1368
Pérez, J.L. P740, P1053,
P1721
Perez, Martha P875
Pérez, Montserrat P1129
Perez, S. P1367
Pérez Breña, P. P1655
Pérez de Ayala, A. P1704,
P1746
Perez de Pedro, I. P1058
Pérez del Molino, M.L. P1124,
P1835
Pérez-Arellano, J. P1035
Pérez-Trallero, E.P1050, P1051,
P1053, P1551
Perfect, J. O421, O422
Peri, C. P836
Perilli, M.G. P934, P1243,
P1418
Perivolioti, E. P540
Perlin, D. S4, O426,
O427
Perotti, G. P735
Perovic, O. O221, O221,
O228, P1363,
P1363
Perri, M. P457, P458,
P1347, P1457,
P1868
Perroncel, R. P1706
Perrone, M. P803
Persat, F. P701
Persson, S. P1645
Pescetto, L. P836,
P1208
Pessoa da Silva, C.L. P661
Pesti, N. P1284
Péter, O. P1722
Peters, G. P461, P1730,
P1817
Peters, J. P620
Petersen, A. P1233
Petersen, E. Workshop 1
Petersen, H. P965
Petersen, J. P581
Petersson, C. P1463
Petignat, C. O76, P1366
Petinaki, E. P885, P941,
P1354, P1592,
P1593, P1759
Petit, J.C. P1635
Petit, J.C. P1648
Petkov, T. P589
Peto, Z. P1330
Petras, P. P1167
Petrescu, Z. P1067
Petridou, E. P901
Petrikkos, G.L. O270, P1289
Petropoulos, C. P673
Petrosillo, N. P598, P621,
P773, P1371
Petrou, M.A. P1714
Petrov, M. P1056
Petrovec, M. P1675
Petsaris, O. P896

List of Authors
Name Number Name Number Name Number Name Number
Pettitt, E. P1644
Peyron, F. P874, P876,
P877
Pezzolato, M. P560
Pezzotti, G. P1672
Pezzotti, P. P773
Pfeiffer, M. P581
Pfister, W. P463, P1266,
P1360, P1805
Philip, P. P660, P661
Pia, N. P581
Piai, G. P767
Pialoux, G. P1130
Piasecka-Pazik, D. P812
Picao, R.C. P933
Picard, B. P1172
Picardi, M. O262, O423
Picazo, J.J. P761
Picciani, C. P829
Piccinino, F. P767, P774
Piccoli, L. P945
Piccolomini, R. P829
Picha, D. P750
Pichardo, C. P1154
Piche, J. P881
Picot, S. P701, P877
Picton, S. P908
Piddock, L.J.V. P1143, P1245,
P1390, P1555
Pielmeier, U. P623
Piemont, Y. O258, P963
Piens, M.A. P701
Piera, C. P1240
Pierard, D. P1387, P1751,
P1768
Pierson, C.L. P1813
Pietzcker, T. P463
Pignanelli, S. P715
Pignatari, A.C.C. P932, P933,
P1412
Pike, R. P507, P508,
P1622
Pillay, D.G. P1621
Pillonel, J. P619
Pimenov, V. P632
Pina-Vaz, C. P858, P1027
Pinar, A. P1851
Pinedo, A. P922, P1013
Pinel, C. P861
Pinget, R. P619
Pini, B. O75, P1164,
P1399
Pinidiyapathirage, M.J. P574
Pink, F. P1020
Piñón, A. O162, P1655
Pinsi, G. P1203
Pintado, V. P1368
Piper, K. O70
Pirayesh, K. P1443
Pires, R. P898
Pirounaki, M. P779
Pisapia, R. P617, P767,
P774
Pisaturo, M. P774
Piskorowska-Plis, A. P1353
Pisos, E. P1603
Pistolas, D. P759
Pisula, A. P1353
Pitart, C. P1618
Pitcher, D. P973
Pitlik, S. P1367
Pitsitaki, M. P1759
Pitt, T.L. P1236
Pittaluga, F. P653, P655
Pittet, B. S144
Pittet, D. K244, O272,
P660, P661
Pituch, H. P520, P1638
Piu, S. O257
Pizzigallo, E. O61
Plachouras, D. O363, P1177,
P1528
Plagge, H. P1373
Plant, A.J. P538
Planty, C. P725
Plata, A. P1058, P1678,
P1837, P1853
Platsouka, E. P540, P553
Plebani, A. P1203
Plecko, V. P928
Plésiat, P. O125, P1242
Plettenberg, A. P562
Pletz, M.W.R. O56
Pleydell, E. P1378
Pliatsika, V.P. P1778
Plokhov, R. P632
Pocaterra, L. P765
Poiata, A. P1310
Poirel, L. O51, P505, P1249
Poisson, D.M. P1607, P1865
Poland, W. P602
Polat, Y. P1851
Poletti, F. P680
Poli, N. P664
Polishchuk, A.V. P709
Poljak, M. K245
Pollini, S. P937
Polyzogopoulou, E. O120
Polzin, A. P1713
Pomba, C. P1774
Pompilio, A. P829
Pong, W.L. P1448
Pong-Porter, V. O216
Pons, I. P1723
Ponte, C. P1153, P1297
Pontikis, K. P1528
Poon, R.W.S. O98
Pop, S. P756
Popa, M. P1285, P1745
Popescu, C.P. P777, P1661,
P1663, P1884
Popescu, N. P1775
Popma, A. P1641
Popov, D.A. P978
Porfyridis, I. P1081
Porsbo, L.J. P1376
Portaels, F. S414
Portales, I. P1853
Porte, L. P1140
Porter, S. P1204
Portnoy, Y. P1519
Portocarrero, N. P1087
Portugal, I. O173, P1254
Porzionato, A. P597
Posfay-Barbre, K. P664
Pospelova, T. P1299
Potapova, N. P1073, P1110
Potel, G. P464
Pottel, G. P1858
Potz, N.A.C. P1447
Poupard, J.A. P1375, P1388,
P1389, P1484,
P1614
Pournaras, S. O127, P1270
Pourshafie, M.R. P1624
Poutanen, S.M. O216, P1204
Pradhan, A. P533
Pradier, C. O417, O436,
P1612, P1627
Prag, J. P1180
Prandi, S. P512
Pratschke, J. P1798
Pratti, A. P1593
Presber, F. P1798
Presterl, E. P827, P1284,
P1321
Prévost, G. P1514
Prezas, L. O419
Preziosi, P. P596
Price, V. P1832
Prieto, C. P1881
Prieto, J. P674, P1551,
P1552
Prinoth, O. P1669
Prinsloo, B. P567
Procaccini, M. P1495
Proctor, R.A. P1730
Prod’hom, G. P454
Prohorov, V. P468
Prokhorova, T. P581
Prostko, J. P628
Protsenko, D. P1466
Pryamchuk, S. P1351
Przondo-Mordarska, A. P943
Ptitcin, S. P1299
Puchades, B. P1047
Pujate, E. P1476
Pujol, M. P921, P1348
Pulian, V. P1403
Pullukcu, H. P1472
Pulsrikarn, C. P557
Punab, M. P1859
Pupaibool, J. P1668
Pustowoit, B. P628
Puzyrev, V. P631, P632,
P633, P994
Pybus, O.G. S408
Pypstra, R. P1524
Pyse, D. P453
Qasim, F. P622
Qassemi Barqi, R. O130, P1137
Qu, J. P1144
Quaglia, N.C. P1845
Queenan, A.M. P925
Queipo-Ortuño, M.I. P1678
Quinn, J.P. P1408
Quinteira, S. P914, P1773
Quiroz, E. P1667
Raab, U. O315
Rabella, N. P1652
Racciatti, D. O61
Rachkova, K. P502
Racil, Z. P729, P964
Rada, M.A. P1337
Rademaker, C.W. O392, P1066
Radice, C. P1436
Radmanesh, M. P1207
Radonjic, I. P1206
Radsack, K. P575
Radulescu, A. P481
Raduta, L. P777, P1661,
P1663, P1884
Rafailidis, P. P1000
Rafalskiy, V. O149, P1483
Raffenberg, M. P1024
Raffin-Bru, E. O160
Rafiei, A. P1207
Raftogiannis, M. O363, 177
Raftopoulou, A. P1125,
P1434
Raghunadharao, D. O424
Raglio, A. O215
Rahbar, M. P1031, P1443
Rahimi, F. P1624
Raineri, E. O275
Rajamäki, A. P630
Rajgopal, A. P1138
Raka, L. P659, P667
Ramadani, N. P667, P1063
Ramage, G. P844
Ramazanzadeh, R. P548
Rambach, A. P998
Ramdani-Bouguessa, N. P509
Ramesh, M.K. P1787
Ramesh, V. P584
Ramirez, J.A. P1280
Ramirez, Mário O117, O167
Ramirez, Mercedes P738
www.escmid.org/eccmid2006
Ramirez, S. P1653
Ramiro, R. P1416
Ramos, A. P684
Ramos, C. O131, P1134
Ramos, H. P1773
Randall, L.P. P1143, P1245,
P1555
Rangaraju, M. P1512
Rantakokko-Jalava, K. P1259
Rantala, M. P1277
Raoult, D. P546, O420,
P565
Raptis, G. P450
Rasaei, R. P1207
Rashed, T. P1435
Rasmussen, B.S. P1220
Rasoolinejad, M. P1117, P1142
Rassam, P. P775
Rastogi, N. P521
Ratanasiri, S. P616
Ratcliff, R.M. P972
Rautakorpi, U.-M. O416
Raveh, D. P1489
Rawlins, S. P1260, P1806,
P1807
Raz, E. O69
Raz, R. P979
Read, R. S85, S141, P1061
Reddi, E. P1564
Reddiconto, G. O262
Refseth, U.H. P955, P1108
Regli, A. P1855, P1873
Reguera, J.M. P1678, P1837
Reichmann, S. P827, P1321
Reichmuth, M. P1116
Reilly, J. P891
Reimnitz, P. P1301
Reinert, R.R. P1595, P1809,
P1821
Reinke, P. P1798
Reiter, C. O148
Reitsma, J.B. P1834
Rejiba, S. P1454
Rekha, A. P1787
Reller, L.B. P441
Rellos, K. P1018, P1356,
P1357
Remy, V. P1010
Renaud, F. O97
Renaudin, H. P725, P726
Rendell, A. P1725
Rennie, R. P456, P1204,
P1747
Repa, A. P1049
Repetto, B. P1307
Repo, H. P485
Resenterra, A. P1722
Reshedko, G. P1632
Reuter, G. P786, P1654
Revillo, M. P1026, P1871
Rey, F. O420
Rey, J. P1512
Reyes, K. P1347
Reyes, N. P1543
Reyes, R. P950, P1431
Reymann, S. O218
Reynders, M. P1768
Reynolds, R. P1385, P1386
Rezusta, A. P1026
Rezvan, H. P579
Rezvan, S. P1819
Rguez-Martín, B. P1035
Rguez-Martín, M. P1035
Rhim, C.H. P1377
Rhod Larsen, A. P459
Rhomberg, P. P1265
Rhys-Williams, W. P1564,
P1565, P1566
Ribaud, P. P1500
Ribble, W. P1559
page 165

List of Authors
Name Number Name Number Name Number Name Number
Ribeiro, T. P1774
Ribeiro-Ayeh, S. P1064
Ricagni, L. P836, P1208
Ricart, M.J. P923
Rich, F. P776
Richards, G. P1363
Richet, H. O420
Rico, A. P533
Riesenberg, K. P1042
Riffelmann, M. P969, P1071
Rigatou, M. O419
Rihs, J. P1813
Riis, A. O121, P1043,
P1059, P1060
Rijnders, A.J. P1862
Rijnders, B. S12
Riley, T.V. P538, P1244
Ringberg, H. P1814
Ringertz, S.H. P1461
Rink, A.D. O359
Rios, G. P1700
Rioux, C. P1481
Rishi, P. P1181
Riva, E. O399
Rivera, M. P1422
Rizk, N.G. P1752
Rizos, M. P1357
Rizzi, M. O215
Rizzo, C. P1694
Rizzo, G. P1694
Rizzonelli, P. P1737
Rjabinina, S. P631
Robbins, M. P1584
Robenstock, E. P1367
Robert, J. O50, O133,
P1458
Roberts, C. P1499, P1500,
P1709
Roberts, J. P1335
Roberts, M. P961
Robinson, E. P1173
Robinson, G. P1138
Robinson, J. P688
Robinson-Dunn, B. P457, P458
Roca, B. P1036
Rocha, G. P968
Rocha, J. P917
Rödel, J. O368
Rodella, A. P649
Rodhe, N. O393, P1463
Rodier, M-H. P1076
Rödiger, S. O368
Rodloff, A. P1437, P1548
Rodrigues, A. P858, P1027
Rodriguez, A. O165
Rodriguez, G. P681, P682
Rodriguez, H. P929
Rodriguez, M. O224
Rodriguez, R. P922, P1013
Rodríguez-Bano, J. O268,
P1369
Rodriguez-Cerrato, V. P1297
Rodríguez-Creixems, M. P480
Rodríguez-Guardado, A. P1368
Rodriguez-Iglesias, M.A. P593
Rodriguez-Lera, M.J. P918,
P1864
Rodríguez-Martínez, J.M. O52
Rodriguez-Nava, V. P1871
Rodriguez-Puig, D. P1240
Rodriguez-Villalobos, H. P448,
P449, P1451
Roggendorf, M. P1071
Rogues, A.M. P1470
Roh, K.H. P999
Rohacova, H. P750
Rohde, H. O95
Rohner, P. P1199
Roilides, E. E30, S40, O429,
P737, P800
Roine, R. O416
Roiz, M.P. P918, P1046,
P1864
Rojek-Zakrzewska, D. P970
Rojo, P. P1881
Rókusz, L. P910
Rolain, J.M. P565
Rolland, C. P942
Rollason, J. P532
Rolo, D. P898
Rolston, K. P681, P682,
P694, P695
Romaguera, J. O165
Romaní, V. O224
Romano, R. P1070
Romanova, J.M. P840
Romashov, O. P1466
Romeo, M.A. P1022
Romero, A. P738
Romero, L. O268
Romero, P.A. P1124, P1835
Roodbari, F. P576
Roohvand, F. P527
Roovers, A. O170
Ropero, F. P922, P1013
Rosa, C. P1129
Rosales, M.E. P1103
Rose, G. P1786
Rose, W. P1513
Rosenhagen, M. P683
Rosmus, L. P1747
Rossano, F. P1028, P1268
Rosselli, A. P484
Rossen, J.W.A. O63
Rossi, B. O276
Rossi, F. P1806, P1807
Rossi, G. P1203
Rossi, L. P736
Rossier, A. P1130
Rossolini, G.M.S47, O75, O171,
P506, P512, P911,
P913, P926, P930,
P934, P937, P1418
Rothgänger, J.
Rotily, M. P596
Rotter, M. O272
Rottiers, S. P517
Roubalova, K. P750
Rouli, V. P799
Roumbelaki, M. P1349,
Roumpelaki, M. P1625
Roure, C. P798
Rousseau, F. P1246
Roussel-Delvallez, M. O125,
P1612
Roussos, C. O363, P1177
Rovers, M.M. P818
Rovery, C. O420
Roveta, S. P1332
Rowland, I. P1165
Rowley, D.C. P1561
Roy, A. P1509
Rozalska, B. P821, P822,
P1179
Rozalski, A. P834, P1183
Rozentale, B. P592, P678,
P1078
Rozgonyi, F. P477, P796,
P1284
Rubin, C.J. P960
Rubino, C.M. O360, O361
Rubinovitch, B. O69
Rubio, C. P1122
Rubio, G. P1652
Rubio, M.C. P1596, P1597,
P1618
Rudakov, N. P546
Ruden, H. O432, P1361,
P1462
Rudnicka, W. P1179
page 166 Final Programme
Ruef, C. Workshop 3,
P1498
Ruf, B.R. P1516
Ruggiano, G. P484
Rugina, C.N. P1875
Rugina, S. P1080, P1082,
P1875
Ruhnke, M. S235, O424
Ruijs, G.J.H.M. P983, P1430
Ruiz, B. P446, P1734
Ruiz, Joaquim P1169, P1398,
P1603, P1615
Ruiz, Josefa P1837
Ruiz, M. O54, P938
Rumsby, K. P985
Ruppitsch, W. P1760
Ruskone Fourmestraux, A. P1174
Russell, J. P961
Russo, G. P1070
Russo, R. P1703
Russwurm, S. O213
Ruta, S. P1065
Ruthazer, R. P1813
Rutten, G.E.H.M. O122, O123,
O164
Ruzicka, F. P838, P859
Ruzickova, V. P1167
Ryabkova, E. P1632
Rybak, B. P812, P1306
Rybak, M. P713, P1393,
P1513
Saag, M. P1718
Saarela, U. P989
Sabah, M. O417, P1627,
P1699
Sabahi, F. P570, P576, P771
Saballs, M. P921
Sabaniauskaite, R. P1264
Sabat, A. P943, P1696
Sabbatani, S. P606, P612,
P733, P734, P1128,
P1608, P1609, P1830
Sabbe, L.J.M. O170
Sable, C. S7
Sabourian, R. P1031
Sacco, L. P735
Sachdeva, P. O128
Sachs, A.P.E. O66
Sachse, S. O213, O368
Sada, E. P1103
Sadeghifard, N. P1646
Sader, H.S. P713, P932, P933,
P1261, P1262, P1263,
P1265, P1325, P1326,
P1327, P1328, P1404,
P1405, P1440, P1553,
P1570, P1571, P1572,
P1573, P1574, P1610,
P1623, P1804, P1816
Sadowska, B. P821, P822,
P1179
Saeed, A. P1196
Sáez, A. P1734
Sáez-Llorens, X. P1667
Sáez-Nieto, J.A. P1596, P1597
Safdar, A. O165, P681,
P682
Sagiroglu, P. P1308
Sagnelli, E. P617, P767,
P774
Sahamas Vala, S. P894
Sahan, S. P1874
Sahly, H. P1197, P1264, P1602
Sahm, D. P1322, P1400,
P1629
Sahre, M. P1541
Sakac, D. P618
Sakalauskas, R. P1264
Sakata, H. P971
Saker, L. P1173
Sakka, V. P1343
Sakoulas, G. P1513
Sala, M. P1841
Salamon, S. P1758
Salari, M.H. P1646
Salari, N. P1192
Salas, C. P446
Saldana de Suman, O. P1667
Salehi, M. P1192
Salgado, M.J. P898, P931
Saliba, G. P601
Saliba, W. P979
Salihu, D. P659
Salizzoni, E. P1608
Salmanzadeh-Ahrabi, S. P527,
P537, P807,
P1684, P1687
Salmenlinna, S. P460
Salmon-Ceron, D. E31, S251
Salord, H. P798
Salotra, P. P584
Saloustros, E. P1349
Salta, A. P1126
Saltirov, I. P589
Saluja, D. O128
Saluja, S. P584
Salvo, S. P1597
Salza, M.F. P1268
Samarbaf-Zadeh, A.R. P949,
P1693
Sambatakou, H. S324, P737
Samet, A. P812, P1306
Sammeth, M. O171
Samonis, G. P722, P1049,
P1349
Sampaio, J.L. P1391
Samra, Z. P1286, P1367
San, T. P1232
San Millan, A. P1251
Sanabria, T. P765
Sancak, B. P1077
Sánchez, B. P674
Sanchez, Carlos P1436
Sánchez, Concepción P761
Sánchez, J. P467
Sánchez, Mónica P1764
Sanchez, Maria B. P1046, P1864
Sanchez, R. P690
Sanchez Sotelo, J. O70
Sánchez-Carrillo, C. P1422
Sanchez-Cespedes, J.O54, O129,
P833
Sanchez-Ortiz, S. P918
Sánchez-Zamora, C. P758
Sancho, S. O271, P915
Sand, C. P1204
Sandberg, A. P1157
Sanders, E.A. P818
Sandoval, P. P1256
Sandström, G. P1196
Sandvang, D. P1376, P1402,
P1562
Sanfeliu, I. P1723
Sanli Yürüdü, N. P837
Sansonetti, P. S140
Santacreu, R. P479
Santagati, M. O93, P501
Santamaria, S. P1058, P1853
Santantonio, M. P1694
Santerre Henriksen, A. O317,
P900
Santibanez, S. S410
Santos, L. P551
Santos-Sanches, I. O167, P898
Sanz, M. P480
Sanz-Rodriguez, C. P684, P1200
Saracoglu, F. P1665
Sarami Foroshani, R. P576
Sarasin, G. P597

List of Authors
Name Number Name Number Name Number Name Number
Saray, Y. P748
Saremi, M. P1031
Sarg, B. P1568
Sarid, N. O156
Sarkkinen, H. O416, P989
Sarkozy, D. P1785
Sarlangue, J. P967
Saroglou, G. P759, P779
Sarralde, A. P890
Sarris, I. P515
Saß, M. P1516
Sastry, R.A. P1787
Satishchandran, V. P1806, P1807
Sattar, S. O272
Sattar, T. P826
Saunte, D.M. P1149
Sauteron, M. P676
Savanis, S. P1528
Savelieva, N. P632, P994
Savelkoul, P.H.M. P524, P1620
Savelli, H. O65
Savicheva, A. P724
Savin, C. P942
Savón, C. P1655, P1658
Savov, E. P589
Savvala, M. P1504
Savvanis, S. P1210
Sawkeng, L. P1780
Sbarbati, A. K243
Sbokou, D. P1880
Scagnolari, C. O399
Scalzini, A. P895
Schaap, I. P1636
Schabereiter-Gurtner, C. P1760
Schaberg, T. P1055
Schachter, J. O390
Schaffer, K. P760
Schalen, C. P569, P1282, P1594
Schareck, W. P1516
Schaumann, R. P1548
Schelenz, S. P1732
Scheres, J. P529
Scherpe, S. O95, O305
Schilder, A.G. P818
Schilling, A.N. P1408
Schinella, M. P1737
Schipper, J. O218
Schipper, K. P1748
Schito, G.C. P836, P1280,
P1309, P1394
Schlaeffer, F. P1042
Schlamm, H.T. P739, P1205,
P1499
Schlesinger, Y. P1489
Schmetz, J. P969
Schmid, D. P1760
Schmid, F. P1119
Schmid, G. E191
Schmidt, K.H. O213, O368
Schmidt, Silke O55
Schmidt, StephanP1523, P1540,
P1541
Schmidt, T. P543
Schmidt-Ioanas, M. P1024, P1713
Schmit, J.L. P1139
Schmoor, C. O147
Schneeberger, P. O159,
P625, P1438
Schneider, F. P1818
Schneider, I. P502,
P1619
Schneider-Brachert, W. O153,
O154
Schoenberg, M.H. P1518
Schoevaerdts, D. O437
Scholing, M. O159
Scholz, H. P652
Schönemann, C. P1798
Schønheyder, H.C.O121, O266,
P1402, P1043
Schönitzer, D. P1669
Schønning, K. P1872
Schooley, S. P1532, P1533
Schrenzel, J. S135
Schröder, H. P1464, P1479
Schubert, S. O357, P463,
P1540
Schuetz, P. O217
Schülin-Casonato, T. P1720
Schultz, M.J. P1731
Schulz, S. O147
Schulz, T. P575
Schulze, H. P862
Schumann, R.R. P1189
Schuren, F.H. O166
Schutzbank, T.E. P959, P965
Schuurman, R. O63
Schuurman, T. O170
Schwab, F. O432, O439,
P1361, P1364,
P1462
Schwartz, E. P1069
Schwarz, P. P1211
Schwenk, A. E191
Schwesinger, G. P1231
Scicluna, E.A. P1460
Scott, G. P1475
Scott, J.C. P531
Scoulica, E. P911, P1349,
P1350, P1625
Scripcariu, D. P768
Scurtu, G. P1663
Sears, P. O150
Seaton, R.A. P1469
Seckova, S. P1091
Secmeer, G. P802, P936
Seedat, J. P1602
Sefers, S.E. O306
Segarra, P. P675,
P1075
Segatore, B. P934
Segura, D.R. P1562
Seguy, M. P1269
Sei, K. P441
Seifert, H. P988, P1250,
P1309, P1394
Seiler, C.M. O359
Seitanidis, V. P1708
Sekhon, J.S. O424
Selderina, S. P678
Semaille, C. P619
Sendid, B. P677
Sener, B. P1410, P1455
Sener, G. P860
Senn, L. P688
Senneville, E. E35
Senol, S. P1472
Senses, Z. P723
Sepp, E. P939
Sepp, K. P939
Seral, C. P1596, P1597,
P1618
Serefhanoglu, K. P1852
Sergounioti, A. P470, P885,
P1218, P1362
Sergouniotis, F. P885
Sergouniotis, P. P885
Sermaides, G. P1478, P1556
Seroogy, J. P1538, P1539
Serr, A. P1331, P1346
Serra, A. P1337
Serra, R. P560
Serrano, R. P1035, P1036
Serrera, A. O74
Sertznig, M. P1818
Sesma Sánchez, P. P1127
Seto, W.H. O99
Sevcikova, A. P729
Severin, J.A. P451
Severo, L.C. P811
Sevillano, D. P1551, P1552
Sevillano, E. P1820
Sezer, S. P982
Shadzi, S. P1224
Shafer, W.M. S210
Shah, H. P961
Shahcheraghi, F. P1712
Shahid, M. P1406, P1750
Shahsavan, S. P639
Shahzamani, K. P771
Shalaby, L P691
Shang, W. P925
Shangle, S. O150
Shannon, K. P1566
Sharbatkhory, M. P1034
Shariati, N. P703
Sharifi Moud, B. P1192
Sharma, A. P710
Sharma, S. P1159
Sharp, A. P1147
Sharvadze, L. P769
Shaw, J. P641
Shaw, M. P1069
Shchepetova, J. P939
Sheehy, N. P760
Shen, H. P1606
Sheng, R. P1606
Sheng, W. P1606
Shepstone, L. P1732
Shevchenko, N. P1483
Shevchenko, O. P1407
Shevelev, A. P724
Shi, G. P1223
Shields, M. P1877
Shigayeva, A. O227
Shilov, I. P468
Shin, B-M. P1647
Shin, J.H. O132
Shin, K.S. P909
Shin, S-S. P1015
Shin, S. P1761
Shin, S.Y. P999
Shin, W-S. P1009
Shiohira, C. P1115
Shipulina, O. O391
Shitova, O. P592
Shmuely, H. P1286
Shokoples, S. P456, P1747
Shortridge, D. P453
Shpynov, S. P546
Shue, Y.-K. O150
Shyr, J-M. P510
Si-Mohamed, A. P642
Siadat, S.D. P578, P579
Siafakas, N. P1343, P1727
Sibilia, J. O258
Sideri, A. P935, P1228,
P1600
Sideris, E. P1101
Sidorenko, S.V. P1048, P1809,
P1819
Siempos, I. P1018
Siemssen, N. O95
Sierra, A. P1213, P1740
Sierra, J.M. P1240
Sigh, J. P581
Signorini, L. P469, P1203
Siitonen, A. P1681
Sikalidou, P. P696, P808,
P1025
Siljander, T. P1866
Sillekens, P. P966
Sillerström, E. P1779
Silva, A. P931
Silva Lopes, M.F. P1774
Silva-Costa, C. O117
Silvestri, G. O397
Simcock, M. P1373
Simeone, E. P566
Simeoni, J. P1669
www.escmid.org/eccmid2006
Simin, N. P1303
Simitsopoulou, M. O429
Simões, J. P551
Simon, A. P442
Simonsen, G.S. P514, P1811
Simonsen, H. P1165
Simopoulos, C. P1765
Simor, A. P1428
Simsek, H. P723
Singh, A. P457 P458,
P1347, P1868
Sinto, S.I. P1391
Sioula, E. P1081
Sioulis, A. P697
Sipahi, H. P1472
Sipahi, O. P1215, P1472
Sirma, E. P906
Siroos Jafari, S. P1117
Sivaja, O. P1291
Sizer, E. P1020, P1780
Sjölin, J. P743
Skalioti, C. P1177
Skalkowska, M. P541
Skandami-Epitropaki, V. P1766
Skarmoutsou, N. P1642
Skinner, R. P1543
Skogen, V. P522
Skorupka, J. P1039, P1847
Skoura, I. P1052
Skouteli, H. P1287
Skoutelis, A. P1625
Skov, R.L. O115, O313,
O317, S402,
P459, P1157
Skov Simonsen, G. P1323
Skroubellou, A. P1125
Skulnick, M. O216
Sladeckova, V. P1091
Slakovic, M. P640
Slany, M. P544
Slater, C. P1411
Slaughter, J. P453
Slavcovici, A. P481, P1382
Sleator, R. P1691
Slizen, V. P1255
Slobodnikova, L. P845
Slusarczyk, J. P783
Small, G. O216
Smaoui, H. P794, P1454
Smedile, A. P653
Smeesters, P.R. P519, P815
Smet, J. P448, P449
Smidt, I. P583
Smirnova, M. P1519, P1520
Smirnova, T.A. P840
Smismans, A. P1066
Smit, V. O67
Smith, Darwin P879, P880
Smith, Derek O157
Smith, E.G. P1113
Smith, E.H. O214
Smith, H. P985
Smith, M. P641
Smith-Erichsen, N. O72
Smyth, B. P1030
Smyth, R. P1441, P1442
Snijders, S. P585
Snitsar, A. P1190
Snyder, T.A. P1806, P1807,
P1822
Snydman, D.R. P1813
Soares, A. P1249
Soares, D. P1428
Soavi, L. O275, P469,
P664, P1203
Sobreira, L. P898
Sobrino, B. P1058
Socha, A. P1561
Söderquist, B. P1697
Sofia, T. P542
page 167

List of Authors
Name Number Name Number Name Number Name Number
Sofianou, D. P696, P717,
P800, P808, P1002,
P1025, P1270,
P1384, P1631,
P1778
Søgaard, L.V. P1165
Sokeng, G. P1399
Soki, J. P554
Sola, C. P521
Solbiati, M. O77
Soleimanjahi, H. P570
Solemani, M. P1033
Solera, J. S113
Solon, E. P1537
Soltani, M. P1148
Soltysova, K. P750
Son, B.R. P909
Sondore, V. P592, P1078
Song, E.J. O132
Song, E.S. O132
Song, J. P1301
Song, J.Y. O163
Song, Y.G. P999
Sonnevend, Á. P568
Sonntag, A.K. O314
Soodbakhsh, A. P1117
Sordet, C. O258
Sørensen, H.T. O121, O266,
P1037, P1043,
P1059, P1060
Sorensen, S. P1495
Soresina, A. P1203
Soriano, Alex P1240
Soriano, Ana P921
Soriano, F. P1153, P1297
Soroush, M. P1031
Sosa, A. P1507
Sˇostar, Z. P1505
Sota, M. P766
Sotiriadis, S. P1029
Sotirova, P. P1619
Soto, S. O367, P833,
P1369
Sotode, A. P1860
Sotto, A. O364
Soubrier, S. P677
Soudbakhsh, A. P1033
Sougakoff, W. P975, P1762
Soula, G. P1069
Souli, M. P1343, P1413
Sourani, M.P. P594, P814,
P816
Sourdeau, L. P1474
Sousa, I. P871, P872
Sousa, J.C. P831, P924,
P1161, P1341,
P1626
Soussy, C.J.O50, O53, P1309,
P1394, P1769
Soy, D. P1158
Soyletir, G. P1232, P1308,
P1453, P1611
Spaan, W. O158
Spaargaren, J. O390
Spalla, M. P913, P1418
Spanakis, N. O127
Spanjaard, L. P580, P1834
Speck, R.F. O396
Speirs, K. P457
Speranskaya, L. P1299
Sperling, J. O70
Speth, J. O360, O361
Spicer, L. O214
Spiers, K. P458, P1868
Spigaglia, P. P1273, P1810
Spiliopoulou, A. P799
Spiliopoulou, I. P883, P1354,
P1592
Spina, D. O93
Spinillo, A. P762
Spitzmüller, B. P1364
Sprecher, H. O174, P1021
Spreer, A. P1175
Spyridis, N. P1125
Sredkova, M. P502, P1619
Stack, J.A. P1676
Stagno, S. S111
Stallforth-Siegel, U. P1197
Stålsby Lundborg, C. P1460
Stanek, R. O229
Stano, C. O399
Stapleton, K. P1555
Staprans, S. O397
Stass, H. O357, O358, O359
Stassi, G. P1185
Stathas, T. O419
Stathi, A. P534
Stauch, K. P1055
Stavrianou, A. P981
Stavrianou, E. P1855
Steehouder, M.F. P1491
Stefanaki, K. P1218
Stefanelli, P. P542
Stefani, S. O93, P501,
P1585
Stefaniuk, E. P445, P1735
Steib-Bauert, M. O439, P1467,
P1479
Stein, C. O396
Stein, G. P1532, P1533
Steinbach, W. S326
Steinbakk, M. P643, P644
Steiner, O. P1145
Stejskal, F. P552
Stellbrink, H.J. P562
Stellini, R. P1203
Stepanikova, O. P1733
Stepanova, M. P516, P1238
Stepanova, T.V. P840
Stepanovic, S. O94, P832
Stephens, P. O434
Stephenson, I. P1112
Stepinska, J. P1605
Stetsiouk, O.U. P1388, P1484
Stevart, O. P815
Stevens, N. P826
Stevens, T. P486, P487, P488,
P489, P490, P491, P492,
P493, P494, P495, P496,
P497, P498, P499, P500,
P1311, P1312, P1313,
P1314, P1315, P1316,
P1317, P1318, P1319
Stewart, E. P670
Stich, K. P1321
Stijnen, T. O211
Stillwell, M. P1325, P1570,
P1572
Stimac, D. P1505
Stoakes, L. P950, P1431
Stobberingh, E. O418
Stockelberg, D. O421, O422
Stockinger, H. P962
Stoczko, M. P926
Stoeger, A. P1760
Stöhr, K. S2274
Stogniew, M. P1536
Stoilov, R. P1739
Stoll, S. P1780
Stolte, M. O153, O154
Stolyarova, L.G. P1809
Stone, N. P447
Stoodley, P. O96
Stopa, J. O371
Storozenko, J. P678
Storr, J. P660
Stourac, P. P991
Stoycheva-Vartigova, M. P1295
Stoye, J. O171
Straach, P. P1467
page 168 Final Programme
Strabala, P. P1571, P1573,
P1574, P1804
Stradoni, R. P895
Straková, L. P1812
Strålin, K. O222
Stratchounski, L.S.O391, P724,
P1388, P1407,
P1484
Stratton, C.W. O306
Straube, E. O213, O368,
P1360
Strauss, R. P1569
Straut, M. P1745
Stray-Pedersen, B. E32
Strehl, E. P1462
Streit, J. P1261, P1816
Stricker, Rene P628, P629, P880
Stricker, Reto P628, P629, P880
Stroo, K. P939
Strouza, A. P1439
Strueber, M. P575
Struelens, M.S36, O316, P448,
P449, P517, P929,
P1309, P1387, P1394,
P1451, P1474, P1742
Strukova, E. P1520
Strus, M. P806
Strynadka, N.J. P1586
Stubberfield, E. P1677
Stubberfield, M.R. P531
Stürenburg, E. P727, P988
Sturm, P. P1720
Stylianakis, A. P935, P1228,
P1600
Su, L-H. P1166, P1290,
P1372
Suárez, A. P761
Suárez, D. P467
Subirats, M. P1087
Sucu, N. O102
Suda, K.J. O435
Suetens, C. Workshop 7,
O68, O316,
P1474, P1616
Sukhorukova, M. O391, P1633
Sullivan, Å. P586, P1689
Sultana, C. P1065
Sumerkan, B. P850, P1617
Sun, S. P1782
Sundsfjord, A. P514, P1811
Sundström, L. P940
Sung, H. P476
Sungkanuparph, S. P616
Supawita, T. P718
Suplotova, O. P1483
Supply, P. O134
Surdeanu, M. P1745
Suresh, R. O422
Surkova, L. P1255
Surman-Lee, S.B. P1680
Surrun, S.K. P1072
Suter-Riniker, F. P1116
Sutton, H. P961
Suvajdzic, L. P1303
Suvanakoot, U. P1554
Suwalak, S. P718
Svabic Vlahovic, M. P832
Svejgaard, E.L. P1149
Swine, C. O437
Symeonidis, S. O419
Syrjänen, J. P1866
Szabó, J. P796
Szabóová, M. P1749
Szczapa, J. P812
Szeimies, R.M. P1565
Szekeres, A. P528
Szkaradkiewicz, Andrzej P751,
P752
Szkaradkiewicz, Anna K. O371
Szostek, S. P763
Szpinda, I. P1131
Sztajzel, R. P1229
Szucs, G. P786, P1654
Szymczyk, I. P1039, P1847
Tabaraiee, B. P578, P579
Tacconelli, E. S294, O440
Tachtatzis, M. P935, P1228,
P1600
Tack, K.J. P707
Taddaion, R. P1207
Taffé, P. O396
Taghikhani, M. P1255
Tajbakhsh, S. P949, P1693
Takahashi, H. P976
Takala, A. P485
Takeda, N. P971
Takeshima, T. P971
Takesue, Y. O425
Takoudas, D. P696
Talapan, D. P1294
Talati, A. P1395
Talbott, J. O175, P456
Talebi, A. P1173
Talebi, M. P1624
Tam, V.H. O353, P1408
Tamisani, A.M. P1208
Tampellini, L. P613
Tamvakos, H. P1719
Tan, J. P533
Tanaka, H. O425
Tanase, D. P1875
Tang, B.S.F. O98
Tang, C. S139
Tang, Y.W. O306
Tanir, G. P571
Tanyeri, Y. P564
Tapalski, D. P708
Tarakci, H. P782
Tarazooei, B. P731
Taremi, M. P788, P1882
Targosz, A. P541, P1296
Tárraga, I. P1035, P1036
Tarrand, J. P681
Tarsevich, I. P546
Tarsitano, E. P475
Tasbakan, M. P1472
Tasseva, E. P854
Tassios, P.T. E190, P534,
P1802
Tato, M. P1405
Tattevin, P. P896
Tatu-Chitoiu, D. P1285, P1686
Tatulescu, D. P481, P1382
Tavío, M.M. O54, O129, P1243
Taylor, K.L. P1817
Taylor, M. P908
Taziarova, M. P1091
Tazir, M. P509
Tchilova, R. P1483
Tchorzewski, H. P588
Tejkalova, R. P838
Tekbiyik, S. P558
Tekeli, A. P1843
Tekin, N. P1016
Tekin Koruk, S. P1874
Telenti, A. K246, O396
Telles, J. P1660
Tellevik, M.G. P599
Temmam, S. O100
Temperli, P. P1229
Tempesta, M. P1670
Templeton, K.E. O67, P1636
ten Kate, M. O362
Tenea, C. P728
Teng, C.-W. P789
Tenk, M. P478
Tenke, P. P1525
Tenover, F.C. O115, O172,
S401, P447

List of Authors
Name Number Name Number Name Number Name Number
Téqui, B. P464
Ter Waarbeek, H.L.G. O392, P1066
Terlenghi, L. P649
Terrancle, I. P1035,
P1036
Terraza, S. O131, P1134
Tersmette, M. P1032
Terulla, C. P913
Terzioglu, S. P723
Tessarolo, F. P1791
Tessitore, N. O77
Tewick, D. P464
Tezer, Y. P1198, P1824
Theelen, J. P533
Theilacker, C. O366, P903
Thelin, S. P1683
Theodoridis, G. P1526
Theodoropoulos, M. P1439,
P1849
Theunissen, K. O60
Theuretzbacher, U. Workshop 6
Theyyathel, A. P866
Thiebaut, A. P701
Thiébaut, R. Workshop 1
Thiery, R. P825, P1701
Thies, F. O169
Thisyakorn, U. P1668
Thoelen, I. O60
Thomas, D. P1246
Thomas, S. P889
Thomsen, R.W. O121, P1037,
P1043, P1059,
P1060
Thoresen, S. P644
Thornsberry, C. P1322, P1400,
P1629
Thorsen, P. P1186
Thulliez, P. P881
Thurnherr, C. P1116
Tichota-Lee, J. P646
Tietz, A. S383
Tigaud, S. P798
Tikvesli, S. P1546
Tilley, R. P1496
Tillotson, G. P1576, P1578
Timen, A. P625, P1490
Timmerbeil, BS P727
Timurkaynak, F. P719, P720,
P721, P982
Tinica, G. P1005
Tiouiri ben Aissa, H. P1219
Tirczka, T. P526
Tishkov, V. P1819
Tissot Dupont, H. O101, O420
Titov, L. P1255
Tixier, V. P770
Tobeña, L. P797
Tobin, C.M. P1148
Tobudic, S. P1563, P1792
Tod, M. P737
Toelge, M. O218
Toga, I. O100
Togan, T. O267, P721
Tokatlidou, D. P1002, P1270
Toleman, M.A. P932
Tolsema, P.J.P. O418
Tomaselli, S. P1529
Tomasoni, D. P895
Tomic, S. P1505
Toniolo, A. O75, O394, P1164,
P1399, P1418
Tønjum, T. P1131
Tonziello, G. P774
Top, J. P1344
Torfoss, D. P698
Toropainen, M. P1866
Toropova, I. P1483
Torres, A. S196, P1061,
P1213
Torres, J.M. P1368
Torres, M.V. P1436
Torres-Lana, Á. P835
Torres-Narbona, M. P1201
Torresi, J. P1069
Tortoli, E. S412
Tortorelli, F. P974
Torun, A.N. P1852
Torzewska, A. P834, P1183
Tosiello, R. O152, P1710,
P1715, P1716,
P1717
Totaro, M. P1358
Tóth, Á. O118, O311,
P1409
Tóth, I. P523
Toth, M. P554
Toubol, P. O417
Touboul, P. O436, P1612,
P1627
Tourouki, G. P540
Toussaint, V. P1420
Toutouza, M. P1766
Tovar, V. P765
Trabasso, P. P1003
Tracevska, T. P887
Traczewski, M. P456
Trallero, G. P1652
Trampuz, A. Workshop 3,
O70, S145, O217
Tran, Q. P998
Trasancos Buitrago, V. P1127
Traub, F. P1507
Treimane, R. P887
Tremolieres, F. P1858
Treviño, M. P1835
Trevisan, M. O58, P597
Treyaprasert, W. P1523, P1554
Triantafyllou, S. P1352
Triassi, M. P1268
Trigueiro, G. P898
Trikka-Graphakos, E.P804, P805,
P1257
Trivelloni, C. P773
Troelstra, A. P1344
Trojanowska, D. P1296
Trope, A. P644
Truffot-Pernot, C. O57, O133,
P975, P1762
Trupl, J. P817
Truusalu, K. P939
Trzeciak, H. P1506, P1854
Tsaganos, T. O419, P1177,
P1178, P1193
Tsai, C.-H. O59
Tsai, M.H. P1057
Tsakona, E. P935, P1228,
P1600
Tsakris, A. O127, O269
Tsao, S-M. P510
Tsaroucha, A. P1765
Tschudin, S. P1373
Tselentis, Y. P722, P1349,
P1350, P1625,
P1870
Tsertsvadze, T. P769
Tsiakiri, E. P749
Tsiakou, M. P800
Tsiklauri, R. P1492
Tsilika, G.T. P1778
Tsimberakis, N. P1719
Tsimoraga, M. P1486
Tsiodra, P. P981
Tsiodras, S. P1343
Tsiplakou, S. P935, P1228,
P1600
Tsiringa, A. P1766
Tsivitanidou, M.T.P800, P1002,
P1778
Tsoi, H.W. O98, P1671
Tsolaki, V. P662
Tsona, A. P1526, P1549,
P1708
Tsui, M. P904
Tsuji, B. P1513
Tubau, F. P921, P1863
Tuchilus, C. P1310
Tudor, A.G. P1661
Tukiendorf, B. O371
Tulek, N. P851, P1293,
P1738, P1874
Tulkens, P.M. Workshop 6,
O356, P1515,
P1534, P1751
Tull, P. Workshop 7
Tumer, E. P782
Tumwasorn, S. P1111
Tunbridge, A. P1092
Tuncer, I. P1617, P1878
Tuncer, S. P1449
Túñez, V. P1124, P1835
Tunger, A. P1617
Tuo, P. P1208
Turan, D. P564, P1743
Turan, H. P1852
Turcinaviciene, J. P545
Türetgen, I. P837, P841,
P842
Türk, S. P1859
Turk Aribas, E. P1084, P1085,
P1133, P1662,
P1825
Turker, N. P1074
Turnbull, L. P1747
Turner, B. P533
Turner, M. P588
Turner, P.J. O301, P920,
P1237, P1381,
P1767
Turner, S. P985
Turriziani, O. O399
Turunc, T. P846, P1141,
P1217
Tuygun, N. P571
Tybring, H. P1729
Tyler, A. O216
Tyrrell, K. P1532
Tzagarakis, N. P1480
Tzanakari, A. P808
Tzolos, V. P1001
Tzouvelekis, L. P1802
Uçkay, I. P1199, P1229
Udomsantisuk, N. P1111
Ughetto, S. P770
Ugurlu, K. P853
Uh, Y. P1377
Ulanova, T. P631, P632, P633,
P638, P994
Uldum, S.A. P990
Ullberg, M. P960
Ullery, M. P453
Ullmann, A.J. O421, O422,
P737
Ulug, M. P790, P847, P848,
P1826, P1827,
P1867
Ulusoy, S. P1215, P1472
Ünal, S. S2273
Uncu, H. P846, P1141,
P1217
Unda, F. P444
Underwood, A. P972
Unemo, M. P522
Unger, S. P562
Ungureanu, V. P1285, P1775
Ungvári, E. O311
Unhasuta, C. P557
Unterdorfer, S. P587
Unzaga, J. P668, P669
Unzaga, M.J. P467, P1014
www.escmid.org/eccmid2006
Upton, M. P820
Ural, S. P1074
Urassa, W.K. P599
Urban, E. P554
Urbá_ková, P. P1812
Uribarri, G. P1853
Urrestarazu, M.I. P803
Ursi, D. O212
Ursic, T. P1675
Us, E. P1741
Us, T. P1589
Usein, C. P1686
Usluer, G. P483, P1016
Usmani, A. P568
Usta, Y. P1449
Utsalo, S. P1705
Uyanik, M.H. P1795
Uygun, S. P802, P936
Uysal, S. P986
Vaara, M. P1323
Vaccari, C. P756
Vacheva-Dobrevsky, R. P589
Vaessen, N. P1640
Vager, D. P457, P458,
P1347, P1457
Vagia, F. P1086
Vagiakou, E. P1802
Vagiakou, H. P1101
Vágvölgyi, C. P528
Vahaboglu, H. P563, P1288
Vähäkuopus, S. P1866
Vahdani, P. P1842
Vaidakis, E. P1081
Vainio, A. P459, P460,
P948
Valderrey, C. P1820
Valdes, O. P1658
Valdezate, S. P1416
Valencia, M.E. P614, P615
Valentini, C.G. O262, O423
Valentini, R. P905
Valerio, A. P1123
Valero, E. P1552
Valette, M. O160
Validakis, I. O363
Valiente, L. P1058
Valovic, S. P1507
Valter, J. P855
Valverde, A. P1417
van Aarle, P. P966
Van Bambeke, F. O356, P1534,
P1751
van Belkum, A. O311, O365,
P520, P585,
P620, P1696
van Bussel, M. O67
van Casteren, V. P1490
van de Beek, D. S348, P1731,
P1834
van de Sande, N. O309
Van de Vyvere, K. P1209
Van de Wiel, P. O65, P757,
P1660
Van Delden, C. P1199
van den Berg, R.J.P1636, P1639,
P1640, P1641
van den Boogaard, L. P620
Van den Enden, E. P1209
van den Hof, S. P1641
van den Hoogen, B. S289
van der Bijl, M.W. P524
van der Ende, A. P580, P1731
van der Ent, C.K. P818
van der Heyden, G. O71
van der Hoeven, M. O159
van der Kooi, T. P1641
van der Linden, M. P1595, P1821
van der Meer, J.W.M. P1152,
P1862
page 169

List of Authors
Name Number Name Number Name Number Name Number
van der Poll, T. S338
van der Vorm, E. P1639
van der Werff, S. S350
van der Wouden, J. O438
van der Zwaluw, W.K. O170
van Deursen, P. P636, P966
van Dijke, B. P474
van Duijn, I. P1425,
P1426
van Duynhoven, Y.T.H.P. O170
van Elden, L.J.R. O66
Van Eldere, J. O60, S106,
P452, P1375,
P1389, P1488,
P1614
van Essen, G. O161
van Gemert-Pijnen, J.E.W.C. P1491
van Gompel, A. E33
van Hannen, E.J. P535, P1044,
P1339
van Hees, B.C. P1032
Van Hoovels, L. P1698
Van Kerkhoven, D. P995
van Keulen, P.H.J. P1425,
P1426
van Kregten, E. P1641
Van Laethem, Y. P1751
van Leest, M. P1425, P1426
van Leeuwen, W. O311, P520,
P585, P620
Van Lint, M.T. O262, O423
van Loon, A.M. Workshop 4,
O63, O66, P877
Van Meensel, B. P984
Van Melderen, L. S248, P519
van Min, M. P620
van Pelt, W. P1032
Van Santen, R.J. P646
van Steenbergen, J. P1490
van Trijp, M.J.C.A. O274
Van Vaerenbergh, K. O60, P1698
van Wamel, W.J.B. O166
Van Wart, S. P1781
van Wijk, P.T.L . P625
Van Wijngaerden, E. P742
van Zwet, A.A. O170
Vancanneyt, M. O257
Vandenbroucke, J.P. O263
Vandenbroucke-Grauls, C.M.P1620,
P1748
Vandenesch, F. P634
Vanderschueren, S. P1838,
P1839
Vandierendonck, J. P950
Vandoorslaer, K. P1768
Vandyousefi, J. P1624
Vang, A. O126
Vankeerberghen, A. P1698
Vankerckhoven, V. O257
Vankova, O. P638
Vañó, D. P1129
Varesi, P. P504
Varetto, S. P653, P655
Varga, J. P528
Vargas, M. P1169
Varona, A. P1216
Varonen, H. O416
Varonou, E. P1125
Varzakakos, I. P791, P1880
Vasconcelos, C. P1334
Vasconcelos Lopes, H. P1579
Vasdeki, A. P941, P1759
Vasilaki, O. P450, P808,
P1526
Vasilakopoulou, A. O270
Vastert, D. P856, P857
Vata, A. P768, P1833
Vatiero, L.M. P774
Vatn, M. P1131
Vaughn, R. O172
Vauloup-Fellous, C. P635
Vaur, J-L. P1607
Vauterin, P. S9
Vautor, E. P825, P1699,
P1700, P1701
Vázquez, E. P761
Vearncombe, M. P1428
Veenendaal, D. P1641
Vela, M. P875
Velasco, C. O52
Velayati, A. P577
Veldman-Ariesen, M.J. P1032
Velegraki, A. P1218
Velinov, T. P1056
Veloni, V. P1343
Veltman, T. P1584
Venditti, M. P1585
Venezia, R. P1813
Venieri, D. P1844
Venkatesh, H. P899
Vennema, H. P1654
Verboom, P. O211
Verbrugh, H.A. O211, O365,
P451, P585,
P620
Verdaguer, R. O264
Verel, A. P1401
Vereschagina, S. P1299
Vergison, A. P519, P815
Verhaegen, J. P452, P742,
P984, P995,
P1132, P1375,
P1387, P1389,
P1614
Verheij, T.J.M. O66, O123,
O161, O164,
O438, P1471
Verhoef, J. P1309, P1394,
P1401
Verhoeven, A. P636
Verhoeven, F. O314, P1491
Vermeer, S. P757
Vernazza, P. P1116
Verra, C. P1855
Verschraegen, G. P1387
Verschraegen, I. P1768
Verstrepen, W. P1656
Verweij, P.E. S277
Vestweber, K.-H. O359
Vettor, R. P600
Veyssier, P. P1858
Vezali, E. P779
Veziris, N. O57, O133,
P1762
Vezzo, R. P1736
Vicaut, E. P1858
Vicente, J. P675
Vickstrom, R. P628
Vidal, L. P623
Viertel, A. P575
Vignon, D. P706
Vigorè, L. P1736
Viksna, L. P1078
Vila, J. O54, O129, S209,
O367, P833, P938,
P1169, P1240, P1369,
P1398, P1603, P1615
Vilar, J. P622
Vilas, A. P1723
Vilela, C.L. P823
Vilimova, M. P1091
Villa, A. P1123
Villa, L. P504
Villa Blanco, I. P1829
Villalobos, A. P1058, P1678,
P1837, P1853
Villari, P. P1268
Villarreal, A. P652
Villegas, J. P479
Villuendas, C. P1871
page 170 Final Programme
Vincart, B. P1650
Vince, A. P1176
Vincent, V. P1130
Vindel, A. P465, P466
Virolainen, A. P460, P948,
P1446
Visca, P. P1371
Viscoli, C. S5, S198
Visser, C.E. P1639, P1641
Vita, S. O399
Vitkauskiene, A. P1264
Vitoria, A. O131, P1122,
P1134
Vittecoq, D. P619
Vittoraki, A. P1444
Vives, L. P1580
Vizzini, G. P1340
Vlachou, E. P1086
Vlachou, M. P799
Vlieghe, E. P1209
Vogiatzi, A. P901
Voha, C. P1420
Volfova, P. P964
Volk, H.-D. P1798
Volpes, R. P1340
von Eiff, C. P461, P1730,
P1817
von Freyberg, J. O305
von Gottberg, A. O221, O228
von Linstow, M.-L. P603
Vora, S. O151
Voravuthikunchai, S.P. P718
Vornicu, A. P1310
Vorobieva, V. P522
Vorou, R. P1283
Vorwerk, C. P1548
Vos, F.J. P1862
Vos, M.A. O211
Voskuyl, R.A. P1521
Voss, A. O272, P474,
P625, P737
Vostrov, S. P1520
Votava, M. P838, P859
Vouillamoz, J. P1156
Vouis, J. P1779
Vourtsi, A. P1228
Voutsinas, D. P1503
Voyatzi, A. P791, P1880
Vranes, J. P1162
Vrioni, G. P1136
Vukusˇic, I. P1505
Vuopio-Varkila, J. P459, P460,
P948, P1446,
P1866
Wacke, R. P1522
Wagenlehner, F.M.E. O315, P1861
Waghorn, D.J. P889
Wagner, K. P1173
Wagner, S. P1024
Wahlund, E. P1779
Waitzl, B. P627
Wal, M. P751
Walder, G. P1669
Walencka, E. P821, P822
Walker, N. P1788
Wallace, P. Workshop 4,
P877
Wallace, R. E189, S413
Wallon, M. P874, P876
Walsh, B. O150
Walsh, F. P1237
Walsh, T.R. S176, O300,
S375, O429, P514, P932
Walter, C. P963
Walters, S. S290
Walton, C. P1432
Wan, J-H. P510
Wandall, J.H. O225
Wang, C.-J. O95
Wang, E.E.L. O152, P1710
Wang, F. P1606
Wang, J-W. P1290
Wang, J.Y. P1102
Wang, L-S. P510
Wang, L.-Y. P789
Wannet, W. P474
Ward, M.E. P1622
Wareham, D.W. P1770
Warn, P. P1147
Warner, G. P985
Warner, M. P1447, P1750
Warrell, M.J. S200
Wasilewska, A. P752
Waskin, H. P1577, P1579,
P1580
Wassermann, T. P1160
Watts, J. P1643
Watts, S. P670
Wauters, G. P992
Wcislo, M. P1296
Webber, M.A. P1143, P1390
Weber, D. S3, P1493,
P1494
Weersink, A.J. O63
Weiler, N. P1602
Weimer, M. P959
Weinberg, J. P1509
Weinberger, M. P1367
Weiner, M. P1685
Weinstein, M. P441
Weisfelt, M. P1731, P1834
Weisser, M. P556
Welte, T. O56, S195,
P1061
Wendon, J. P1020, P1780
Weng, W.-S. O59
Wenger, A. P454, P1366
Weniger, T. O171
Wenzler-Röttele, S. P1796
Werarak, P. P616
Werner, U. P1522
Wertheim, H. O365, P585
Westerhagen, U. P644
Westh, H. P471, P472,
P473, P529, P603,
P951, P1659
Westling, K. P882, P1271
Westphal, J.F. P1473
Wever, P. O159, P1438
Whaley, F. P1709
Whang, D.H. P912
Whatmore, A.M. P531, P1676
Whittier, S. P1421
Wiatrzyk, A.A. P783
Wible, W. P739
Widmer, A.F. S13, O147,
E192, S293,
S383, P1373
Wieckowska-Szakiel, M. P821,
P1179
Wieczorek, J. P1353
Wiedemann, B. S240, P463,
P1266, P1805
Wiegand, I. P988, P1266,
P1805
Wieland, W.F. P1861
Wiener-Well, Y. P1489
Wiese, N. P462
Wijkmans, C. P625
Wikander, E. P956
Wilcox, M. S177, P1637
Wilke, H. P856, P857
Wilkinson, B. P1690
Willems, R.J.L. O166, P1344
Willemse, P. P1425, P1426
Willey, B.M. O216
Williams, C. P844, P996
Williams, L. P1298
Williams, P. P447

List of Authors
Name Number Name Number Name Number Name Number
Wilson, C. O147
Wilson, H. P1260
Wilson, M. P880
Wilson, P. S87, P1475
Wilson, R. P686
Wilson, S. O96
Wimalaratne, O. P574
Windau, A. P1569
Winston, D.J. O421, O422
Winter, J.H. P1061
Wirsing von Koenig, C. P969
Wise, R. S297
Wiselka, M.J. P1112, P1832
Wiseman, S. P657, P1509
Wisplinghoff, H. P1250
Witte, W. Workshop 2,
O315, P529,
P1456
Wittebole, X. P1465
Woitrin, E. P878
Wold, A.E. P1171, P1182,
P1392
Wolfhagen, M.J.H.M. P983,
P1430
Wong, B.H.L. O98, P1671
Wong, G.K.M. O98, P1604
Wong, K.S. P1054
Wong, S.S.Y. P1671
Woo, P.C.Y. O98, P1604,
P1671
Wood, B.J. P952
Wood, C.A. P1822
Woodford, N. P507, P508,
P1236, P1239,
P1601, P1621,
P1622, P1750
Woodhead, M. S181
Woods, R. P1584
Woodward, M.J.P1143, P1245,
P1390, P1555
Wootton, C. P1496
Wootton, M. O300
Worthington, T. P532
Wretlind, B. O126, P586,
P1271
Wu, A.K.L. O98
Wu, C-T. P1372
Wu, D. P1258
Wu, H-H. P510
Wu, H-M. P510
Wu, J-J. P510
Wu, J. P1606
Wu, T.-S. P539
Wultanska, D. P520, P1638
Wunderink, R. P1465
Wybo, I. P1768
Xanthaki, A. P1766
Xavier, D.E. P1412
Xercavins, M. P482
Yadegarynia, D. P1842
Yaghobi, R. P1207
Yahav, D. O156
Yakovlev, S. P1048, P1466
Yamaguti, Y. P976
Yaman, S. P558
Yamane, N. P521, P1115
Yamazhan, T. P1472
Yan, J-J. P510
Yang, A. P533
Yang, L. P830
Yang, P.C. P1102
Yang, Y-C. P510
Yapar, G. P719, P720,
P982
Yaroshetskiy, A. P1466
Yayli, G. P781
Yazdanpanah, Y. P1139
Yazdanyar, A. P703
Yazgi, H. P1795
Yeh, R.F. O353
Yeon, J.E. O163
Yetkin, M.A. P851, P1293,
P1738, P1874
Yildirim, I. P801, P802,
P936
Yildirim, Umut P1546
Yildirim, Uzay P1665
Yildiz, F. P884
Yildiz, O. P555, P850
Yilmaz, Gürdal O102, P1094
Yilmaz, Gungor P1074
Yilmaz, Gul R. P851
Yilmaz, H. P1743
Yilmaz, M. P780
Yilmaz, N. P1665
Yilmaz, T. P1695
Yinnon, A.M. P1489
Yong, D. P912, P999, P1377
Yoo, J-H. P1009
Yoon, H.J. P999
Yoon, J.H. P1761
Young, C.L. P1542
Young, N. P908, P1138
Yount, A. P959
Yousefi mashouf, R. P894
Yu, J-K. P1274
Yu, V.L. P1813
Yu, W. P947
Yu, X. P1258
Yu, Y.Y. P1114
Yuce, N.U. P772
Yucesoy, M. P867, P868,
P869
Yuen, K.Y. O98, P573,
P1604, P1671
Yuksek, T. P1084
Yulugkural, Z. O124
Yung, R.W.H. O98
Yuritcina, N. P1299
Zaccariello, A. P617
Zacchello, G. P687
Zachariadou, L. P534, P594,
P814, P816
Zachos, N. P1503, P1504
Zad-Pecar, S. P1613
Zafiropoulou, A. P1008
Zagriadskaya, J. P632, P994
Zahar, J.R. P1481
Zahraeisalehi, T. P1673, P1755
Zaker, S. P1255
Zakharova, S. P1118
Zali, M.R. P527, P537,
P807, P1684,
P1687, P1882
Zalounina, A. O303
Zambardi, G. P453, P455
Zambon, M. S351
Zambou, A. P804
Zampitha, K. P1766
Zanc, V. P1382
Zanetti, G. O76, P1366
Zangane, M. P1860
Zangeneh, M. P703
Zanini, R.R. P811
Zara, F. P762
Zaragoza, R. O271, P915
Zarakolu, P. P927
Zarb, P. P1482
Zare Dehabadi, M. P1842
Zarghom, O. P1117
Zarrilli, R. P1268
Zawilinska, B. P755, P763,
P970
www.escmid.org/eccmid2006
Zeller, H. P1666
Zeltina, I. P592, P1078
Zenciroglu, A. P1665
Zentai, J. P786
Zentner, J. P1462
Zerrilli, E. P680
Zerva, L. P1329, P1343, P1727
Zervakis, D. P1177
Zervos, M. O73, P457,
P458, P1347, P1457,
P1468, P1868
Zeybek, Z. P837
Zhang, F. O64, P1657
Zhang, Y. P1606
Zheng, B.J. P573
Zheng, J. P1606
Zheng, L. P1606
Zhou, X. P1606
Zhou, Y. P573
Zick, G. P1602
Zidovec Lepej, S. P1176
Zielhuis, G.A. P818
Ziesing, S. P463
Ziglam, H. P1496
Zilevica, A. P678, P887
Zimenkovsky, B. P1557
Zimmer, B. P441
Zimmermann, K. P1231
Zingg, W. P1498
Zinner, S. O355, P1519,
P1520
Zintilini, C. P757
Ziogos, E. O155
Ziraman, I. P1665
Zitek, K. P855
Ziva, K. P1849
Ziyagil, F. P564
Zouglakis, G. P1502
Zoumberi, M. P1486
Zoutman, D. P659
Zouzov, S. P1012
Zozio, T. P521
Zurek, E. P1735
Zyczynski, T. P1499
page 171

Badges
General Information (in alphabetical order)
Access to all scientific events and to the
exhibits is only possible with your personal
badge, which you will receive upon registration.
All participants are requested to wear their
name badge throughout the congress.
€ 30 will be charged for replacement of a lost
badge. On-site changes of name badges due
to incorrect submission of names and/or
addresses will be charged at € 10.
Cameras and Recordings
Cassette recorders, cameras and video
cameras are not allowed in lecture halls
during all sessions.
CD-ROM
All accepted abstracts have been published as
an electronic supplement to Clinical Microbiology
and Infection (CMI), the official journal of
the European Society of Clinical Microbiology
and Infectious Diseases. For the first time in
2006, accepted abstracts are made available
to participants on CD-ROM only. No printed
abstract book will be distributed, however the
CD will in addition also include most of the
full posters (sponsored by Schering-Plough).
Cloakroom / Left Luggage
A cloakroom is available on level 1 below the
congress secretariat to keep your coats and
bags.
CME Credits
ESCMID has applied for accreditation of
ECCMID by the European Accreditation Council
for Continuing Medical Education (EACCME)
to provide CME credits for medical specialists
(excluding the satellite- and integrated symposia).
The EACCME is an institution of the
European Union of Medical Specialists
(UEMS, www.uems.be). EACCME credits are
recognised as Physician’s Recognition Award
by the American Medical Association. A form
for claiming CME credits will be inserted in
your congress bag.
page 172 Final Programme
Currency
The official currency in France is the Euro (€).
All major credit cards are accepted in most
hotels, restaurants and shops.
Electricity
The electrical power supply in France is
220 volts.
ESCMID Booth
During the congress, ESCMID staff will be
happy to answer your questions at the
ESCMID booth and help you with any matters
concerning the ESCMID. The ESCMID booth is
located next to the main entrance.
European Network Corner
Opposite to the ESCMID booth on the ground
floor you will find the European Network
Corner. All ESCMID Study Groups and many
other European agencies, networks and
project groups have been invited to present
their organisation and activities with a poster
and staff.
Exhibition
During the congress an industrial exhibition
will be arranged. Companies from all over the
world will be given ample opportunity to
display their latest products, services and
technical innovations (see p. 182 for a list of
exhibitors). The exhibition will be located on
Level 2 and 3 of the Acropolis Nice Congress
Centre. The opening hours are as follows:
Saturday, April 1 12.30–18.00
Sunday, April 2 09.30–18.00
Monday, April 3 09.30–18.00
Tuesday, April 4 09.30–13.00

Hotel Accommodation
General Information (in alphabetical order)
16 th ECCMID 2006
c/o AKM Travel
Messeplatz 10
P.O. Box
4016 Basel
Switzerland
Phone +41 61 690 94 11
Fax +41 61 690 94 14
E-mail eccmid@akmtravel.ch
AKM Travel will be present at a special desk in
the congress secretariat during the meeting.
Please refer to the Hotel-counter.
Insurance
The congress organisers cannot accept liability
for personal injuries sustained, or for loss or
damage of property belonging to congress
participants (or their accompanying persons),
either during or as a result of the congress.
Please check the validity of your own insurance.
Internet Corner
Internet terminals – available for all congress
participants – will be located in the exhibition
area on Level 2.
Language
The congress language is English. Simultaneous
translation will not be provided.
Message Centre
A message centre for the collection and
distribution of messages has been installed
at the congress secretariat on level 1.
Numerous display terminals throughout the
congress centre will announce the names of
persons for whom messages have been
received. If your name appears on the screen,
please proceed to the message centre to
collect it.
Mobile Phones
Please be aware that mobile telephones must
be switched off during all sessions.
Nice
The Promenade des Anglais, the Carnival,
the old city or the Nice Jazz Festival are
famous beyond its national boundaries, but
Nice offers thousands of other facets.
Let yourself be guided by your inspiration to
discover the numerous treasures: the variety
of the architectural heritage is evidence of the
richness of the successive influences of the
past. The number and quality of the museums
put Nice in first position after Paris, and the
many sculptures which decorate the streets
illustrate the particular affection artists have
always shown for our city. The diversity of the
countryside surrounding Nice, its hills and
mountains are a series of constantly changing
landscapes. Lovers of fine food, subtle and
sun-drenched flavours will take delight in
«Nissarde» dishes. Music festivals, the Opera,
lyrical or theatrical performances, numerous
possibilities for sports activities as well as top
level sporting events add to the city’s worldwide
renown. For further information on Nice
and its surrounding areas please see the tours
offered on pages 176–178.
Poster Exhibition
Please see pages 25,40,52,53 and 64 for further
details.
Press
Press representatives are kindly asked to
register at the on-site counters where at the
same time they will have to show their press
identification. The press centre is located on
Level 2. Various information such as press
releases and a press agenda can be found at
www.escmid.org («media»).
www.escmid.org/eccmid2006
page 173

Registration
General Information (in alphabetical order)
All pre-registered delegates are kindly
requested to use the separate entrance to the
right of the main building. A congress bag
including all documents (Final Programme,
name badge, vouchers, etc.) will be distributed
to the registered participants during the
following opening hours:
Saturday, April 1 12.30–18.30
Sunday, April 2 07.00–18.00
Monday, April 3 07.00–18.00
Tuesday, April 4 07.00–15.30
The same opening hours will be applied for
on-site registrations. Please note that on-site
registrants cannot be guaranteed to receive all
congress documents.
Registration Fees
as from as from
Dec. 15, 2005 March 2, 2006
to March 1, 2006 and on-site
ESCMID Member € 400 € 520
Non-member € 530 € 650
Non member
incl. 19-month
ESCMID
membership*
Physician /
scientist in
training
€ 620 € 740
(< 35 years) ** € 270 € 400
Student ***
Accompanying
€ 75 € 100
person € 50 € 50
* Regular ESCMID membership from June 2006 to
December 2007 incl. online and print subscription to
Clinical Microbiology and Infection (CMI)
** Colleagues in training, born after January 1, 1971
(copy of passport obligatory)
*** Students will need to provide proof
(written certification by head of department)
The registration fee for participants includes
a congress bag, Final Programme, Abstract
CD, admission to all parts of the congress,
Opening Ceremony and Welcome Reception.
The registration fee for accompanying
persons includes Opening Ceremony,
Welcome Reception and access to the
industrial exhibition.
page 174 Final Programme
Responsibility
The participant acknowledges that he/she has
no right to lodge damage claims against the
organisers should the holding of the congress
be hindered or prevented by unexpected
political or economic events or generally by
force majeure, or should the non-appearance
of speakers or other reasons necessitate
programme changes. With registration, the
participant accepts this proviso.
Smoking Policy
There is a strict no-smoking policy in the
entire Nice Acropolis Conference Venue.
Transportation within Nice
In addition to public busses and taxis, a limited
shuttle service to/from the official hotels is
running early morning as well as in the
evening. Please see schedule on page 208
for further details. The congress centre is
located in the heart of the city and can also
be reached by foot from many hotels.
On Tuesday, April 4 (12.00–16.00) a shuttle
service to the Airport will be provided.
Venue
The «Palais des Congrès et des Expositions
Nice Acropolis” is located in the very heart
of the city within walking distance of many
hotels. It features state-of-the-art lecture halls,
large foyers, purpose built exhibition halls and
has just the perfect size for the annual
ECCMID meeting. (www.nice-acropolis.com)

Opening Ceremony
Social Events
On the evening of Saturday, April 1, 2006
(18.00) all participants, accompanying persons
and exhibitors are invited to attend the
Opening Ceremony in the auditorium Apollon.
18.00 Welcome to Nice (short movie)
18.10 Prof. Pierre Dellamonica
President, 16 th ECCMID
18.15 Mr. Christian Estrosi
Ministre délégué à
l’aménagement du territoire
18.25 Prof. S. Ragnar Norrby
ESCMID President
18.35 Prof. Andreas Voss
ECCMID Programme Director
18.45 “Operaction”
Welcome Reception
Directly following the Opening Ceremony all
participants, accompanying persons and
exhibitors are invited to attend the Welcome
Cocktail, giving you an insight into the
culinary specialities of the Mediterranean
cuisine. The reception will be held on Level 3
of the Nice-Acropolis Congress Center.
Opening Ceremony and Welcome Reception
are included in the registration fee.
Concert
On Sunday evening, April 2, 20.30,
the Ensemble Vocal de Nice will perform
a unique programme of “Musique Baroque
Française” at the Baroque Sainte-Réparate
Cathedral within the old town:
Marc–Antoine Charpentier Concert (1643–1704)
Oratorio «In Nativitatem Domini
Canticum» (H 416)
Noels sur les instruments (H 534)
Messe de minuit (sur des airs
populaires français, H9)
Performed by:
Four vocal soloists (Soprano,
Counter Tenor, Tenor, Bass)
Thirty choristers of the
«Ensemble Vocal de Nice»
Musicians of the «Société de Musique
Ancienne» from Nice.
Amongst the internationally known
composers of this period, we have chosen
a programme comprising major compositions
of Marc-Antoine Charpentier (1643–1704),
musician at the court of Louis XIV and author
of the very famous Te Deum, also played
in the Eurovision credits.
Duration will be approximately 1h 20.
Admission € 35
Tickets may be purchased at the congress
secretariat on level 1.
www.escmid.org/eccmid2006
page 175

Daily Tours
An attractive choice of guided tours has been
prepared for all delegates and accompanying
persons. Below you will find the respective
schedules and short descriptions. Please note
that during all tours you will be accompanied
by knowledgeable, English speaking guides.
Tour prices include transfer by deluxe coach.
The organiser reserves the right to cancel the
tour in case of less than 15 registered persons.
On-site requests for tours are welcome but
can not be guaranteed. For further details
please refer to the Tours counter on level 1.
Grasse, the capital of perfumes and the
Florian sweet factory
TOUR 1: Sunday, April 2, 08.30–17.30
Meeting place: Acropolis, main entrance
Price: € 125
We commence with a guided tour of a perfume
factory in Grasse, where you will learn
the magical secrets of perfume creation. This
is followed with a sightseeing tour of Grasse
itself and a drive along the famous Napoleon
Road to reach the picturesque village of Saint-
Vallier de Thiey and a lunchstop.
Between the mountains behind Grasse and
the dramatic Loup river stands the Confiserie
Florian. A sweet factory decorated with local
The Principality of Monaco and the
village of Eze
TOUR 2: Monday, April 3, 08.30–17.30
Meeting place: Acropolis, main entrance
Price: € 140
This tour will take us along the middle
Corniche road to the village of Eze, perched
overlooking the Mediterranean sea. Here we
explore the village and visit the perfume
factory Fragonard. The tour continues to the
Principality of Monaco, the Mediterranean
jewel, where we view the historical old part
called the Rock and visit the Cathedral and
Palace square.
After lunch our tour continues through Monte
Carlo with the Casino Square and “Belle
Epoque” district with the famous opera house
built by Charles Garnier, the Hotel and Café de
Paris, gardens and luxurious shops.
Return to Nice is via the lower Corniche road
passing through the towns of Cap d’Ail,
page 176 Final Programme
Grasse
Monaco
furniture of the 17 th and 18 th century, their confectionery
marries tradition, refinement and
taste perfectly. A guided tour offers the visitor
an opportunity to watch the region's speciality,
flowers and fruit being made into sweets.
This tour includes:
Lunch including 1/4 of bottle of wine and
1 coffee per person
Guided tour of a perfume factory
Guided tour of Florian sweet factory
Eze- sur-Mer, Beaulieu-sur-Mer and Villefranche-sur-Mer.
This tour includes:
Lunch including 1 /4 of bottle of wine and
1 coffee per person

Daily Tours
San Remo and the medieval town of
Dolceacqua
TOUR 3: Wednesday, April 5, 08.30–18.00
Meeting place: Acropolis, main entrance
Price: € 125
This full day tour will take you along the
Mediterranean coast to Italy and the town of
San Remo. A town renowned for the cultivation
of flowers, with its luxuriant gardens full
of tropical vegetation.
The old town is known as “la Pigna” characterised
by houses built against one another in
mutual defense, steep streets, covered alleys,
and little squares – just a glimpse of the
Middle Ages. All this dominated from above
by the baroque sanctuary of the Madonna
della Costa.
Elegant boutiques are there to entice the
shopper before continuing our journey
through the Val Nervia, one of the most
beautiful valleys of the western Riviera.
Stretching from the sea to the majestic Alpes
Maritimes, we come upon the town of Dolce -
acqua. A guided tour of the picturesque old
town known as Téra including the achitecturally
significant castle concludes the tour.
This tour includes:
Lunch including 1 /4 of bottle of wine and
1 coffee per person
Nice city tour
TOUR 4: Sunday, April 2, 08.30–12.30
Meeting place: Acropolis, main entrance
Price: € 65
A panoramic tour with a drive along the
Promenade des Anglais and its Belle Epoque
buildings, Quai des Etats Unis, the harbour of
Nice and Mount Boron. We visit the residential
district of Cimiez with its former prestigious
hotels, the most glorious of which is the
Regina. We drive past the Russian orthodox
cathedral and continue with a two hour walk
through the narrow streets of old Nice and
a visit of baroque churches of Sainte Reparate
and Sainte Rita chapel. Finally a stroll on
Cours Saleya to see the famous flower market
with castle hill in the background.
Dolceacqua
The Maeght Fondation and
Saint Paul de Vence
TOUR 5: Monday, April 3, 14.00–18.00
Meeting place: Acropolis, main entrance
Price: € 80
In the 1950s, Cannes art dealer Aimé Maeght
founded the Aimé and Marguerite Maeght
Foundation, an extraordinary museum of
contemporary and modern art, designed to
harmonise with its natural surroundings.
High atop one of the foothills of the Alps,
the Maeght Foundation combines natural
scenic beauty with the whimsical art of such
artists as Giacometti, Léger, Braque, Calder,
and Joan Miró. Almost 9000 works of art make
this a veritable jewel of artistic expression.
A guided tour of Saint-Paul de Vence follows.
This village, built on a rocky outcrop and
surrounded by ramparts, offers a historical
counterpoint with its maze of narrow,
picturesque streets and magnificent stone
façades from the 16 th and 18 th centuries.
This tour includes:
The entrance fee to the Maeght Foundation
Maeght Foundation
www.escmid.org/eccmid2006
page 177

Daily Tours
In the footsteps of Picasso and Antibes
TOUR 6: Tuesday, April 4 and Wednesday,
April 5, 08.30–12.30
Meeting Place: Acropolis, main entrance
Price: € 70
The itinerary offers a visit to the Picasso
museum of Antibes, housed inside the old
castle where this most famous artist worked
in 1946, celebrating the joy of living and
working here in the Mediterranean light. The
tour continues with a drive to the beautiful
district of Cap d’Antibes and its stylish villas
owned by very famous people! We will also
take you to see the glittering Croisette in
Cannes and the stairs of the Palais des
Festivals where the International Film Festival
takes place each year.
This tour includes:
The entrance fee to the Picasso Museum
page 178 Final Programme
Glass factory in Biot and the pottery of Vallauris
TOUR 7: Tuesday, April 4, 14.00–18.00
Meeting Place: Acropolis, main entrance
Price: € 60
Departure from Nice to the glass factory of
Biot where you will be able to admire some
30 glassworkers who expertly blow, handle
and conjure the molten glass blob into an
work of art, be it a carafe or candle-holder.
From there we visit Vallauris, where Picasso
worked from 1948 to 1955. Since this time the
ceramics of Vallauris have become well known
and we shall have the opportunity of a guided
tour of a potter workshop.
This tour includes:
Guided tours of a glass factory and of a
potter workshop
Glass Factory Biot

Industrial Exhibition
www.escmid.org/eccmid2006
page 179

Exhibition Overview
page 180 Final Programme
Poster Desk

Exhibition Overview
www.escmid.org/eccmid2006
page 181

315 3M Health Care, Neuss / D
255 AB Biodisk, Solna / S
417 AdvanDx, Vedbaek / DK
263 AES Chemunex, Bruz / F
207 AID GmbH, Straßberg / D
457 American Society for Microbiology (ASM),
Washington DC / USA
303 AnagnosTec GmbH, Luckenwalde / D
339 Ani Labsystems Ltd Oy, Vantaa / SF
301 Applied Maths BVBA, Sint-Martens-Latem / B
223 Astellas Pharma Europe Ltd, Staines / UK
233 AstraZeneca, Macclesfield / UK
275 BAG Biologische Analysensystem GmbH,
Lich / D
225 Bayer HealthCare AG, Wuppertal / D
155 BD Diagnostics, Le Pont de Claix / F
281 BioMérieux, Marcy-l’Etoile / F
271 Bio-Rad, Marnes-la-Coquette / F
125 Biotage, Uppsala / S
113 Blackwell Publishing, Oxford / UK
151 Bristol-Myers Squibb, Rueil Malmaison / F
105 Cellestis Europe, Darmstadt / D
123 Cepheid, Maurens-Scopont / F
235 Chiron BioPharmaceuticals, Uxbridge / UK
143 Citrofresh International Ltd, North
Geelong / AUS
453 City eHealth Research Centre, London / UK
221 CLC bio A/S, Aarhus / DK
461 Clinical and Laboratory Standards Institute
(CLSI), Wayne PA / USA
351 Copan Italia, Brescia / I
431 Coris BioConcept, Gembloux / B
203 Cryo Bio System, Paris / F
141 Dade Behring Inc., West Sacramento CA / USA
245 Diagnostic Products Corporation,
Los Angeles CA / USA
419 Diagnostics for the Real World Ltd,
Sunnyvale CA / USA
243 DiaSorin S.p.a., Saluggia / I
283 Elsevier, London / UK
443 Eumedica Pharmaceuticals, Brussels / B
471 European Centre for Disease Prevention
and Control (ECDC), Stockholm / S
459 European Respiratory Society (ERS),
Lausanne / CH
401 Focus Bio-Inova Inc., Herndon VA / USA
313 G.R. Micro Ltd, London / UK
List of Exhibitors (in alphabetical order)
page 182 Final Programme
273 GeneOhm Sciences, Diegem / B
432 Genpoint AS, Oslo / N
253 Genzyme Virotech GmbH, Rüsselsheim / D
115 Gilead Sciences, Foster City CA / USA
341 Gloster Santé Europe, Labège / F
163 Hain Lifescience GmbH, Nehren / D
127 i2a (Intelligence artificielle applications),
Pérols / F
455 International Society for Infectious
Diseases (ISID), Brookline MA / USA
433 Inverness Medical, Bedford / UK
333 Iris Diagnostics France, Deuil la Barre / F
357 Izinta Trading Co. Ltd, Budapest / H
337 Kiestra Lab Automation, Drachten / NL
205 Mast Group Ltd, Bootle / UK
251 Merck Sharp & Dohme, Whitehouse
Station NJ / USA
111 Meridian Bioscience Europe, Villa Cortese / I
413 Nanogen Europe BV, Helmond / NL
473 National Collection of Type Cultures (NCTC),
London / UK
145 NeuTec Pharma plc, Manchester / UK
167 Nordic Pharma, Paris / F
323 Nunc A/S, Roskilde / DK
435 Oxford Immunotec Ltd, Abingdon / UK
321 Oxford University Press, Oxford / UK
257 Oxoid Limited, Basingstoke / UK
213 Pall Medical, Portsmouth / UK
227 Pfizer Inc., New York NY / USA
201 Prodesse Inc., Waukesha WI / USA
157 Qiagen Hamburg GmbH, Hamburg / D
331 R-Biopharm AG, Darmstadt / D
423 Roche Diagnostics France, Meylan / F
335 Sangtec Molecular Diagnostics AB,
Bromma / S
261 Sanofi-aventis, Paris / F
231 Schering-Plough Pharmaceuticals,
Kenilworth NJ / USA
353 Science / AAAS, Cambridge / UK
421 Sirs-Lab GmbH, Jena / D
165 Statens Serum Institut, Copenhagen / DK
311 Transgenomic Ltd, Elancourt / F
101 Trek Diagnostic Systems, East Grinstead / UK
355 Wisepress Ltd, London / UK
241 Wyeth Pharmaceuticals, Collegeville PA / USA
159 Zeneus Pharma Ltd, Oxford / UK

Exhibitors’ Guide
European Society for Clinical Microbiology
and Infectious Diseases (ESCMID)
Stand at main European Society for Clinical Microbiology
entrance and Infectious Diseases
Clarastrasse 57
P.O. Box 6
CH-4005 Basel / Switzerland
Phone +41 61 686 77 99
Fax +46 61 686 77 98
Internet www.escmid.org
E-mail info@escmid.org
Key contact Peter Schoch
ESCMID is the major organisation promoting
scientific and clinical excellence in microbiology
and infectious diseases in Europe. Founded
in 1983, ESCMID welcomes all those who
are interested in clinical microbiology and
infectious diseases. It currently has more than
3000 individual full members from 90 countries.
ESCMID is a non-profit organisation registered
in Germany with offices in Munich, Germany,
and Paris, France, and the administrative
headquarters in Basel, Switzerland.
ESCMID’s mission is to advance the diagnosis,
treatment and prevention of infectious diseases
in Europe and beyond by promoting and
supporting basic and applied research, education,
training and good medical practice in the
infection disciplines. The main activities are
comprised of postgraduate training, continuing
medical education, annual congresses,
scientific conferences, study groups, working
parties as well as professional and public
affairs. Regular publications include: Clinical
Microbiology and Infection (CMI), a monthly
peer-reviewed journal, and ESCMID News.
3M Health Care
Stand 315 3M Health Care
Hammfelddamm 11
D-41453 Neuss / Germany
Phone +49 2131 14 4264
Fax +49 2131 14 4397
Internet www.3mhealthcare.co.uk
E-mail mdelpilarsanchez@mmm.com
Key contact Maria Sanchez
3M is a diversified technology company
known worldwide for innovative and reliable
products. 3M Health Care is the company’s
largest major business segment. We’re committed
to providing healthcare professionals
and patients innovative solutions that help
make people’s lives better. The 3M Health
Care family of businesses serves the medical,
dental, pharmaceutical, animal health and
health information markets.
AB Biodisk
Stand 255 AB Biodisk
Dalvägen 10
S-169 56 Solna / Sweden
Phone +46 8 730 07 60
Fax +46 8 83 81 58
Internet www.abbiodisk.com
E-mail etest@abbiodisk.se
AB BIODISK manufactures innovative susceptibility
testing products to promote the rational
use of antibiotics.
Etest ® is a novel predefined gradient for MIC
determinations. It can be used for many
organisms and is invaluable for resistance
detection. The exact MIC is needed for PK/PD
therapy targeting especially for management
of critical infections.
AdvanDx
Stand 417 AdvanDx
Bygstubben 11
DK-2950 Vedbaek / Denmark
Phone +45 45 160 799
Fax +45 45 160 798
Internet www.advandx.com
E-mail ttj@advandx.com
Key contact Thais T. Johansen
AdvanDx is a provider of in vitro kits for the
diagnosis of infectious diseases based on its
PNA FISH and EVIGENE technologies.
EVIGENE product line provides rapid gene
detection form S.aureus isolates.
www.escmid.org/eccmid2006
page 183

AES Chemunex
Exhibitors’ Guide
Stand 263 AES Chemunex
Rue Maryse Bastié
Ker Lann CS17219
F-35172 Bruz Cedex / France
Phone +33 2 23 50 12 12
Fax +33 2 23 50 12 00
Internet www.aes-lab.com
E-mail stephanie.dagorn@
aeslaboratoire.com
Key contact Stéphanie Dagorn
For every laboratory AES CHEMUNEX
provides a comprehensive range of innovative
tools, from classical microbiology to rapid
technologies. At every step of the analysis,
AES CHEMUNEX offers its expertise in
microbiology for a wide range of products:
culture media, mediapreparator, Etest for
accurate MIC measure, bio-impactor Sampl’air,
incubator, temperature monitoring, anaerobic
workstation, etc.
AID GmbH
Stand 207 AID GmbH
Ebingerstrasse 4
D-72479 Straßberg / Germany
Phone +49 7434 9364 0
Fax +49 7434 9364 40
Internet www.aid-diagnostika.com
www.elispot.com
www.colony-counter.com
E-mail haeussler@aid-diagnostika.com
Key contact Juergen Haeussler
AID produces image devices and diagnostic
kits within the wide range of immunology and
infectious diseases, e.g. one of the most used
EliSpot readers (AID EliSpot reader System)
was developed and produced by AID. AID
BascSpot Robotic System is an automated
solution for fast and accurate enumeration of
bacterial colonies. A second software package
allows to perform agar dilution assays.
The system is designed for high throughput
analysis and is suitable for large clinical
laboratories, drug discovery programs,
environmental monitoring, food- and
cosmetics- industrial laboratories.
page 184 Final Programme
American Society for Microbiology (ASM)
Stand 457 American Society for Microbiology (ASM)
1752 N Street, N.W.
USA-Washington, DC 20036 / United States
Phone +1 202 942 9248
Fax +1 202 942 9340
Internet www.icaac.org
E-mail icaac@asmusa.org
The 46 th Interscience Conference on Anti -
microbial Agents and Chemotherapy (ICAAC),
will be held in San Francisco, California,
September 27–30, 2006. More than
12,000 physicians, researchers and other
healthcare professionals from around the
globe gather each year at ICAAC to foster
worldwide solutions to the problem of infectious
diseases. Stop by booth 457 for a copy
of the 46 th ICAAC Preliminary Program.
For information about exhibiting at ICAAC,
copies of the Exhibitor Prospectus will also
be available.
AnagnosTec GmbH
Stand 303 AnagnosTec GmbH
Im Biotechnologiepark, TGZ II
D-14943 Luckenwalde / Germany
Phone +49 3371 681 126
Fax +49 3371 681 127
Internet www.anagnostec.de
E-mail w.kallow@anagnostec.de
j.dyck@anagnostec.de
Key contact Wibke Kallow / Joachim Dyck
AnagnosTec offers SARAMIS for rapid
identification of any micro-organisms and
cells.
SARAMIS identifies bacteria, yeast and fungi
in just two minutes down to sub-species
level – based on characteristic MALDI-TOF
fingerprint mass spectra.
Our customers use it in clinical microbiology,
diagnostic of human and veterinary infectious
diseases, and drug discovery.
Lowest costs per sample are proven in various
user applications.

Ani Labsystems Ltd Oy
Exhibitors’ Guide
Stand 339 Ani Labsystems Ltd Oy
Tiilitie 3
FIN-01720 Vantaa / Finland
Phone +358 20 155 7523
Fax +358 20 155 7521
Internet www.anilabsystems.com
E-mail sales@anilabsystems.com
Key contact Ilari Tuominen
Marketing Manager
Ani Labsystems develops, manufactures,
markets and sells serologic diagnostic
products for various infectious diseases,
for neonatal screening and other disorders.
Products:
– Celiag IgA EIA
– 17-OH-progesterone EIA
– EIA kits for respiratory infections: C. pneumoniae,
M. pneumoniae, B. pertussis, also
MIF for C. pneumoniae
– EIA kits for HIV and hepatitis B
– Special tests: EIA kits for C. trachomatis
antibodies and Toxoplasma avidity.
– FEIA and EIA kits for neonatal screening
New EIA tests coming soon: IgD Quant,
DHEAS, Cortisol
Applied Maths BVBA
Stand 301 Applied Maths BVBA
Keistraat 120
B-9830 Sint-Martens-Latem / Belgium
Phone +32 9 2222 100
Fax +32 9 2222 102
Internet www.applied-maths.com
E-mail info@applied-maths.com
Applied Maths has been the leading
manufacturer of software for typing and
epidemiology since 1992.
BioNumerics: general bio-data basing and
analysis platform with powerful tools for
typing, clustering, identification, population
genetics, phylogeny of all biological data.
Kodon: Comprehensive sequence and
chromosome analysis package with unique
annotation and chromosome comparison tools.
Astellas Pharma Europe Ltd
Stand 223 Astellas Pharma Europe Ltd
Lovett House, Lovett Road
UK-Staines, Middx TW18 3AZ /
United Kingdom
Phone +44 1784 419 400
Fax +44 1784 419 527
Internet www.astellas.com
E-mail astellasmedia@eu.astellas.co.uk
On 1 st April 2005, Fujisawa and Yamanouchi
officially merged to form Astellas Pharma Inc.
Astellas develops and markets pharmaceuticals
which provide the promise of a healthier life
to people across the world.
The fusion of the two companies’ specialities
will increase the flow of drug discovery targets,
expand the chemical library and boost capacity
to produce life-enhancing compounds.
Astellas endeavours to maintain its track
record for developing high profile, marketleading
products that become new standards
of care.
Astellas is currently investigating micafungin,
a new member of the echinocandin class, for
the treatment of invasive fungal infections.
AstraZeneca
Stand 233 AstraZeneca
Alderley House, Alderley Park
UK-Macclesfield, Cheshire SK10 4TF /
United Kingdom
Phone +44 1625 582828
Website www.astrazeneca.com
AstraZeneca is a major international healthcare
business engaged in the research,
development, manufacture and marketing of
ethical (prescription) pharmaceuticals and the
supply of healthcare services.
‘Meronem’/’Merrem’ (meropenem): an ultrabroad
spectrum carbapenems antibiotic for
the empiric treatment of nosocomial infections.
In today’s evolving world of resistance,
when it is important to make your first choice
the right choice, ‘Meronem’ is an effective
weapon in the fight against infection.
www.escmid.org/eccmid2006
page 185

Exhibitors’ Guide
BAG BiologischeAnalysensystem GmbH
Stand 275 BAG BiologischeAnalysensystem GmbH
Amtsgerichtsstrasse 1–5
D-35423 Lich / Germany
Internet www.bag-germany.com
Bayer HealthCare AG
Stand 225 Bayer HealthCare AG
PH-PC-GSM AI
D-42096 Wuppertal / Germany
Phone +49 202 36 4992
Fax +49 202 36 4795
Internet www.bayerhealthcare.com
E-mail leonhard.forstmeier@
bayerhealthcare.com
Key contact Dr. Leonhard Forstmeier
Bayer HealthCare, a subsidiary of Bayer AG, is
one of the world’s leading, innovative companies
in the health care and medical products
industry based in Leverkusen/Germany.
In 2004, the Bayer HealthCare subgroup gener -
ated sales amounting to some 8.5 billion Euros.
Bayer HealthCare employed 35,300 people
worldwide in 2004.
The company combines the global activities of
the divisions Animal Health, Consumer Care,
Diabetes Care, Diagnostics and Pharmaceuticals.
Since January 1, 2006 the new Pharmaceutical
Division consists of the former
Biological Products and Pharmaceutical
Division and now comprises three business
units: Haematology/Cardiology, Oncology
and Primary Care. Bayer HealthCare’s aim
is to discover and manufacture innovative
products that will improve human and animal
health worldwide. The products enhance
well-being and quality of life by diagnosing,
preventing and treating diseases
Avelox ® (moxifloxacin HCL) is a fast-acting
broad-spectrum antibacterial agent. Avelox ®
oral is available for the treatment of respiratory
infections (CAP, AECB and acute sinusitis) in
85 countries. Avelox ® IV was approved for
the treatment of CAP, complicated SSSI and
IAI by the US FDA and is available in over
60 countries. Avelox ® IV as monotherapy has
been demonstrated to be clinically superior to
current standard therapy. Avelox ® has a wide
spectrum of activity, including Gram-positive
page 186 Final Programme
and Gram-negative pathogens, anaerobes and
atypicals, such as Chlamydia, Mycoplasma
and Legionella. Over 40 million patients have
been treated with Avelox ® since its launch in
1999, confirming the excellent safety profile of
this antibiotic.
BD Diagnostics
Stand 155 BD Diagnostics
Rue Aristide Bergès
F-38800 Le Pont de Claix / France
Phone +33 476 68 32 68
Fax +33 476 68 32 92
Internet www.bd.com/diagnostics
BD Diagnostics is a leading provider of pro -
ducts for the safe collection and transport of
diagnostic specimens and of instrumentation
for quick, accurate analysis for a broad range
of microbiology and infectious disease testing,
including the growing problem of healthcareassociated
infections (HCAIs). Diagnostic
Systems, one of the two operating units of the
segment, is a world leader in microbiology
products, specialising in lab automation in
areas such as blood culturing, identification
and susceptibility testing.
BD has just completed its acquisition of
GeneOhm Sciences, Inc. (GSI).
GSI has been an important pioneer in the
development of molecular diagnostic testing
for the rapid detection of bacterial organisms,
including those known to cause HCAI. The
acquisition of GeneOhm Sciences is a natural
complement to BD’s core strengths in micro -
biology and validates its commitment to
expansion in molecular diagnostics. It will also
enable BD to move quickly into the emerging
HAI field and positions the Company to
become a leader in the prevention of this
global healthcare problem
BD Diagnostics will have two stands at this
year’s exhibition.

BioMérieux
Exhibitors’ Guide
Stand 281 bioMérieux
Chemin de l’Orme
F-69280 Marcy l’Etoile / France
Phone +33 4 78 87 20 00
Fax +33 4 78 87 20 90
Internet www.biomerieux.com
bioMerieux® is a major global player for in
vitro infectious disease diagnostics, providing
solutions for medical analyses and industrial
controls.
VITEK ® 2 Compact 30: latest addition to the
VITEK ® 2 family of identification and susce p -
tibility testing systems for improved lab
productivity.
NucliSens ® easyMAG TM : new automated
sample preparation platform for nucleic acid
extraction providing simplicity and flexibility
for your molecular diagnostic assays.
Bio-Rad
Stand 271 Bio-Rad
3 Boulevard Raymond Poincaré
F-92430 Marnes-la-Coquette / France
Phone +33 1 47 95 60 75
Fax +33 1 47 95 61 39
Internet www.bio-rad.com
E-mail thomas.iff@bio-rad.com
Key contact Thomas Iff
Bio-Rad Laboratories, based in Hercules, California,
U.S.A., is one of the top 10 companies
in the diagnostic business. With approximately
5000 employees Bio-Rad serves customers
through its support organisations in more
than 100 countries.
Bio-Rad Laboratories offers innovative diagnostic
products in Clinical Microbiology:
Chromogenic Media and Pastorex ® range for
rapid testing, OSIRIS ® system for Suceptibility
testing and Platelia ® line for Serology.
Auto mation for Blood Virus and Infectious
disease testing is offered by the fully automated
EIA Microplate processor: EVOLIS ® .
The Multiplex technology based, fully automated
system: BioPlex ® 2200 completes the
product offer in Infectious disease testing.
In 2006, Bio-Rad introduces its new
Real Time TB assay (FRUO) which allows
direct detection and pre-differentiation of the
Mycobacterium tuberculosis complex by
real-time PCR.
Biotage
Stand 125 Biotage
Kungsgatan 76
S-753 18 Uppsala / Sweden
Phone +46 18 565 900
Fax +46 18 591 922
Internet www.biotagebio.com
(corporate site =
www.biotage.com)
E-mail info@biotage.com
Biotage presents PyroMark ID, a genetic
analysis system for microbial identification
and resistance detection. Recently used to
identify a massive growth in antiviral drug
resistance by influenza A(H3N2) and to
confirm the first avian influenza A(H5N1)
transmitted from human to human. PyroMark
Analyte Specific Reagents are available for
identification of MOTT and clinically
relevant fungal infections.
Blackwell Publishing
Stand 113 Blackwell Publishing
9600 Garsington Road
UK-Oxford OX4 2DQ / United Kingdom
Phone +44 1865 4763 72
Fax +44 1865 4713 72
Internet www.blackwellpublishing.com
E-mail helen.clements@
oxon.blackwellpublishing.com
Key contact Helen Clements
Publishers of the Official journal of ESCMID –
Clinical Microbiology and Infection
Sign up for a free online trial to all our microbiology
and infectious disease journals!
Speak to friendly and knowledgeable
representatives
www.escmid.org/eccmid2006
page 187

Bristol-Myers Squibb
Exhibitors’ Guide
Stand 151 Bristol-Myers Squibb
3 rue Joseph Monier
F-92506 Rueil Malmaison / France
Phone +33 1 58 83 66 36
Fax +33 1 57 61 50 86
Internet www.hope-for-helpB.com
Key contact Verena Kronenbitter
Alice Humbert
Bristol-Myers Squibb welcomes you to Nice.
Bristol-Myers Squibb is a global pharmaceu -
tical and related health care products company
whose mission is to extend and enhance
human life.
The company is focused on discovering and
developing innovative new medicines to
treat serious unmet medical needs, such as
hepatitis B.
Cellestis Europe
Stand 105 Cellestis Europe
Robert-Bosch-Strasse 7
D-64293 Darmstadt / Germany
Phone +49 6151 428 59-0
Fax +49 6151 428 59-110
Internet www.cellestis.com
E-mail europe@cellestis.com
Key contact Dr. Christian Stoeckigt
Cellestis was formed in late 2000 to research,
develop and market QuantiFERON technology
products for medical diagnosis and scientific
research. Cellestis is an Australian public
company with operations in the United States,
Europe and Australia.
QuantiFERON -TB Gold is an in vitro diagnostic
test to aid in the detection of Mycobacterium
tuberculosis infection. It combines the
simplicity of the whole blood QuantiFERON
methodology with the diagnostic power of
synthetic TB-specific proteins ESAT-6 and CFP-10.
Because QuantiFERON -TB Gold uses whole
blood, without any requirement for cell isolation
and fractionation, it is inexpensive and
fast. The assay measures Interferon-gamma
(IFN-y) secreted from stimulated T-cells previously
exposed to Mycobacterium tuberculosis
to assess TB infection status.
page 188 Final Programme
Cepheid
Stand 123 Cepheid
Vira Solelh
F-81470 Maurens-Scopont / France
Phone +33 563 825 304
Fax +33 563 825 301
Internet www.cepheid.com
E-mail lkandalaft@cepheideurope.fr
Key contact Laurianne Kandalaft
Cepheid manufactures fully-integrated
systems that perform genetic analysis.
Easy-to-use, they enable rapid, sophisticated
genetic testing by automating otherwise
complex manual laboratory procedures.
Our SmartCycler ® and GeneXpert ® systems
drive a panel of easy-to-use molecular-based
tests to perform a broad range of genetic
analysis. This includes identifying infectious
organisms, evaluating at-risk populations or
the stage of a disease, such as cancer.
Chiron
Stand 235 Chiron
Symphony House, 7 Cowley Business Park,
High Street, Cowley
UK-Uxbridge UB8 2AD / United Kingdom
Phone +44 208 580 4000
Fax +44 208 580 4097
Internet www.chiron.com
E-mail medicalinfo-europe@chiron.com
Chiron aims to develop and market products
that will transform human health worldwide.
Our mission is to prevent and treat diseases
thus improving the lives of people.
CUBICIN (daptomycin) received marketing
authorization from the European Commission
on 19 th January 2006, valid in all 25 member
states of the EU, for the treatment of
complicated skin and soft-tissue infections
in adults. CUBICIN is a novel cyclic against
Gram-positive bacteria.
Chiron will be launching CUBICIN in EU
countries during 2006, building on its usage
in the US where over 100.000 patients have
already been treated.
We look forward to seeing you on our
exhibition booth during ECCMID 2006!

Exhibitors’ Guide
Citrofresh International Ltd
Stand 143 Citrofresh International Ltd
8 Rodney Road
AUS-3215 North Geelong / Australia
Phone +61 3 5272 3013
Fax +61 3 5272 3144
Internet www.citrofresh.com
E-mail info@citrofresh.com
Key contact Ravi Narain
Citrofresh is a company focused on eliminating
toxic chemicals from our environment, and
determined to provide organic and non-toxic
alternatives.
Citrofresh is a phyto-pharmaceutical of citrus
fruit origin. The anti-pathogen power of
Citro fresh is due to a synergistic activity,
which is created between citrus fruit
bioflavonoid complex and certain natural
organic acids. Citrofresh is completely
certified organic by NASAA.
City eHealth Research Centre
Stand 453 City eHealth Research Centre
City University, Room G511
Gloucester Building, Northampton Square
UK-London EC1V 0HB / United Kingdom
Phone +44 207 040 41 36
Fax +44 207 040 87 95
Internet www.nric.org.uk
Developers of various online infection resour -
ces including the National electronic Library
of Infection and the National Resource for
Infection Control.
The National Resource for Infection Control
(NRIC – www.nric.org.uk) is an ongoing project
developed by and for infection professionals,
a single access point to the existing evidence
base and resources for infection prevention
and control.
CLC bio A/S
Stand 221 CLC bio A/S
Forskerparken
Gustav Wieds Vej 10
DK-8000 Aarhus C / Denmark
Phone +45 70 22 32 44
Internet www.clcbio.com
E-mail jrasmussen@clcbio.com
Key contact Jane Rasmussen
CLC bio sells bioinformatics software and
bioinformatics consulting services. We have a
strong scientific focus, and our employees
specialize in bioinformatics, mathematics, and
computer science.
Our product line covers solutions for lab
scientist working with molecular biology and
biochemistry.
All our programs work on Windows, Mac OS
X, and Linux and are fully integrated across
platforms and all CLC workbenches.
Clinical and Laboratory Standards
Institute (CLSI)
Stand 461 Clinical and Laboratory Standards Institute
(CLSI)
940 W. Valley Road, Suite 1400
USA-Wayne, PA 19087 / United States
Phone +1 610 688 0100 x134
Fax +1 610 688 0700
Internet www.clsi.org
E-mail csweeney@clsi.org
Key contact Colleen Bergan-Sweeney
Clinical and Laboratory Standards Institute
(CLSI, formally NCCLS) is a global, non-profit,
membership based organization dedicated to
developing standards and guidelines for
patient testing. Our Antimicrobial Susceptibility
Testing standards are updated with the latest
recommendation for detecting emerging
resistance.
www.escmid.org/eccmid2006
page 189

Copan Italia
Exhibitors’ Guide
Stand 351 Copan Italia
Via Perotti, 10
I-25125 Brescia / Italy
Phone +39 030 268 7211
Fax +39 030 268 7250
Internet www.copaninnovation.com
E-mail michela.ferrari@copanitalia.com
Key contact Michela Ferrari
Copan is a worldwide leading manufacturer of
specimen collection and preservation devices
for the pre-analytical phase of bacteriology,
virology and molecular biology.
Copan will be featuring a diverse line of
innovative devices designed to suit the new
challenges of molecular diagnostics assays.
An innovative TRANSYSTEM for superior
aerobic and anaerobic survival; UTM for
virology transport; FLOCKED SWABS a
new technology in sample collection and
release and URISWAB a new collection
system for urine.
Coris BioConcept
Stand 431 Coris BioConcept
Rue Jean Sonet 4A
B-5032 Gembloux / Belgium
Phone +32 81 719 917
Fax +32 81 719 919
Internet www.corisbio.com
E-mail info@corisbio.com
Coris BioConcept develops, produces and
sells rapid diagnostic kits to detect human
enteric and respiratory pathogens.
Tests are quick, simple to use, sensitive, specific,
need minimal sample manipulation, and do
not require any special equipment.
We are ISO 9001:2000 and ISO 13485:2003
certified.
All our products have received the CE marking
for In Vitro Diagnostics.
page 190 Final Programme
Cryo Bio System
Stand 203 Cryo Bio System
29, rue Tronchet
F-75008 Paris / France
Phone +33 1 49 24 05 05
Fax +33 1 49 24 05 01
Internet www.cryobiosystem.com
E-mail ag@cryobiosystem-imv.com
Key contact Alexis Génin
Cryo Bio System manufactures and markets a
concept for cryopreservation of biological
samples based on the CBS High Security
Straw TM . Product line includes High Security
Straws, specific equipment for filling, sealing
and labelling of straws, storage goblets and
racks for nitrogen freezers and mechanical
freezers.
Dade Behring Inc.
Stand 141 Dade Behring Inc.
MicroScan ® / Microbiology Systems
1584 Enterprise Boulevard
USA-West Sacramento, CA 95691 /
United States
Internet www.dadebehring.com
E-mail amos_czarny@dadebehring.com
eric_hubbard@dadebehring.com
Key contact Eric Hubbard
Dade Behring – MicroScan ® is a leader in
automated ID and susceptibility testing for the
microbiology lab. With primary focus on
accuracy and ensuring detection of emerging
resistance, MicroScan ® continues to be on the
forefront of the ever changing environment of
microbiology. With quality customer service
and passion to provide total lab solutions,
MicroScan ® is there “every minute of every
day”.

Exhibitors’ Guide
Diagnostics for the Real World Ltd
Stand 419 Diagnostics for the Real World Ltd
840 Del Rey Avenue
USA-Sunnyvale, CA 94085 / United States
Te. +1 408 773 1511
Fax +1 408 773 1553
E-mail caw@drw-ltd.com
Key contact Craig Wisniewski
Director of Manufacturing and
Engineering
Diagnostics for the Real World Ltd, is an ISO
13485 certified company based on technologies
developed by the Diagnostics Development
Unit, University of Cambridge, UK.
A range of innovative, simple and highperformance
rapid tests has been developed
for the detection of infectious diseases.
Using the proprietary Signal Amplification
System (SAS), the products achieve improved
sensitivity compared to other rapid tests.
The first product to enter the market (2006)
based on SAS is a Chlamydia rapid test, the
only rapid test with sufficient sensitivity to
allow testing of self-collected vaginal swabs
in women and first catch urine in men –
using a proprietary first catch urine device,
recipient of a recent Medical Futures
Innovation Award – Best Medical Device
Innovation.
Diagnostic Products Corporation
Stand 245 Diagnostic Products Corporation
5210 Pacific Concourse Drive
USA-Los Angeles, CA 90045 / United States
Phone +1 310 645 8200
Fax +1 310 645 9999
Internet www.dpcweb.com
E-mail info@dpconline.com
Key contact Hans Ijpelaar
Featured Diagnostic Products Corporation
(DPC) products including fully automated
serology assays for hepatitis B, ToRCH
(Toxoplasma IgG & IgM, Rubella IgG & IgM,
CMV IgG & IgM and Herpes I & II IgG), and
H. pylori IgG. Inflammation markers (IL-6 &
LBP), are available for early detection and
monitoring of sepsis. Assays for HAV (Total
and IgM) and Lyme antibody screening
Diagnostic Products Corporation
are coming soon. A syphilis antibody screen
and EBV markers are under development.
DPC has over 30 years of experience in the
immunoassay industry that extends to infectious
disease assay development. Our broad
menu provides accurate and efficient routine
and esoteric assays on our dependable
IMMULITE ® 2000 and IMMULITE ® 2500
continuous random access chemiluminescent
instruments. This, coupled with our award
winning RealTime Solutions TM , including
real time service and OnLine reports, puts
DCP in a unique position to help diagnostic
laboratories better assist clinicians in delivering
optimal patient care.
DiaSorin S.p.A
Stand 243 DiaSorin S.p.A
Strada Crescentino
I-13040 Saluggia VC / Italy
Phone +39 0161 487 093
Fax +39 0161 487 670
Internet www.diasorin.com
DiaSorin, the diagnostic specialist. A leading
manufacturer in infectious disease diagnostics
with own sales and support organizations in
most European countries.
The Liaison ® system, fully automated, offers
an ever expanding menu of tests. Among
others: full TORCH panel including avidity.
Newly developed Borrelia for both serum
and CSF, Treponema palladium and Varicella
Zoster Virus.
www.escmid.org/eccmid2006
page 191

Elsevier
Exhibitors’ Guide
Stand 283 Elsevier
32 Jamestown Road
UK-London NW1 7BY / United Kingdom
Phone +44 207 424 4200
Fax +44 207 424 4420
Internet intl.elsevierhealth.com
Key contact Arnaud d’Agostini
Elsevier is a leading publisher of health
science books and journals, incorporating a
family of outstanding imprints. With titles
available across a variety of media - print,
online and CD-ROM, we supply the
information you need in the most convenient
format. Please stop by the Elsevier stand 283
to sample the latest and greatest resources
in the field.
Eumedica Pharmaceuticals
Stand 443 Eumedica Pharmaceuticals
Avenue W. Churchill 67
B-1180 Brussels / Belgium
Phone +32 2 340 68 52
Fax +32 2 344 55 75
Internet www.eumedica.com
E-mail s.preudhomme@eumedica.com
Key contact Sonja Preud’homme
EUMEDICA Pharmaceuticals, a Belgian
pharmaceutical company, ensuring – in a
unique way – medical care continuity in the
hospital environment.
Temocillin (Negaban ® ) is indicated for the
treatment of gram-negative bacteria infections,
such as urinary tract infections, septicaemia
and lower respiratory tract infections.
Temocillin (Negaban ® ) offers an exclusive
activity on gram-negative strains and an
enhanced stability against beta-lactamases,
which is extremely important in the light of
the changing antibiotherapy environment and
the increasing level of antibiotics resistance.
page 192 Final Programme
European Centre for Disease Prevention
and Control (ECDC)
Stand 471 European Centre for Disease Prevention and
Control (ECDC)
Tomtebodavägen 11a
S-171 83 Stockholm / Sweden
Phone +46 8 30 00 56
Fax +46 8 30 00 57
Internet www.ecdc.eu.int
ECDC is a new EU agency tasked with reinforcing
Europe’s defences against infectious
diseases by pooling Europe’s health knowledge
and fostering cooperation between
national public health bodies. It is based in
Stockholm and became operational in May
2005. Key areas of activities are providing
scientific advice, strengthening Europe-wide
disease surveillance, supporting preparedness
and response to disease outbreaks.
European Respiratory Society (ERS)
Stand 459 European Respiratory Society (ERS)
4 Avenue St. Luce
CH-1003 Lausanne / Switzerland
Phone +41 21 213 01 01
Fax +41 21 213 01 00
Internet www.ersnet.org
The European Respiratory Society (ERS) is
a non-profit making, international medical
organisation with over 7000 members from
100 countries. It is the biggest society in
Europe in its field. ERS annual congress attracts
over 16.000 respiratory professionals, many
of whom manage patients with respiratory
infections on a regular basis in addition to
the other diseases of the lung.
We look forward to meeting you.

Focus Bio-Inova Inc.
Exhibitors’ Guide
Stand 401 Focus Bio-Inova Inc.
13665 Dulles Technology Drive
USA-Herndon, VA 20171 / United States
Phone +1 703 480 2568
Fax +1 703 480 2654
Internet www.focusbionova.com
Focus Bio-Inova provides global central laboratory
and custom microbiology services to
help biopharmaceutical researchers expedite
the discovery, development and commercialization
of new therapeutics. Focus Bio-Inova
also offers the power of The Surveillance
Network ® (TSN ® ), the world’s largest
electronic laboratory surveillance network
and antimicrobial susceptibility database.
For more information, visit
www.focusbioinova.com.
G.R. Micro Ltd
Stand 313 G.R. Micro Ltd
7-9 William Road
UK-London NW1 3ER / United Kingdom
Phone +44 207 388 7320
Fax +44 207 388 7324
Internet www.grmicro.co.uk
E-mail info@grmicro.co.uk
Key contact Dr Ian Morrissey
G.R. Micro Ltd, offer wide-ranging services to
the pharmaceutical industry utilising leadingedge
microbiological and molecular methods
supporting the global development of antiinfective
agents. These include pre-clinical
and clinical studies, molecular biology and
antimicrobial resistance surveillance. G.R.
Micro Ltd has a simple philosophy – to deliver
services of the highest professional standards.
– Microbiology and clinical trial consultancy
and research
– Data management, web design and hosting
GeneOhm Sciences
Stand 273 GeneOhm Sciences
Airport Boulevard Office Park
Bessenveldstaat 25
B-1831 Diegem / Belgium
Phone +32 2 716 4727
Internet www.geneohm.com
E-mail chowie@geneohm.com
Key contact Chris Howie
GeneOhm Sciences, is a molecular diagnostic
company at the forefront of developing rapid,
nucleic acid-based systems, to detect and
identify infectious agents.
The IDI-MRSA test from GeneOhm Sciences,
is the only rapid, molecular-based assay
cleared by the FDA, Health Canada and
bearing the CE Mark for the direct detection
of methicillin- resistant Staphylococcus
aureus from a nasal specimen.
Genpoint AS
Stand 432 Genpoint AS
Kjelsasveien 174
N-0884 Oslo / Norway
Phone +47 22 02 65 65
Fax +47 22 02 65 66
Internet www.genpoint.com
E-mail info@genpoint.com
Key contact Dagfinn Strømme
Biotechnology company specializing in the
sample preparation of nucleic acids from
bacteria, viruses and cells in difficult samples.
Genpoints technology is based on magnetic
particles. The unique BUGS’n BEADS principle
is different from the classical magnetic particle
system, and specifically suited to difficult
samples. Applications for Chlamydia, GC,
MRSA and Tuberculosis and others are
available.
www.escmid.org/eccmid2006
page 193

Exhibitors’ Guide
Genzyme Virotech GmbH
Stand 253 Genzyme Virotech GmbH
Löwenplatz 5
D-65428 Rüsselsheim / Germany
Phone +49 61 42 69 09 11
Fax +49 61 42 96 66 13
Internet www.virotech.de
E-mail info@virotech.de
Key contact Michael Becker
Genzyme Virotech GmbH successfully develops,
produces and distributes Medical Products in
the area of Infectious Diseases Diagnostics,
Microbiology and Tumour Diagnostics worldwide
since 1986.
Genzyme Virotech GmbH offers a wide range
of ELISAs and Western Blots/Line Immuno
Assays for the antibody detection of Infectious
Diseases (e.g. Lyme, Mycoplasma, VZV, Pertussis).
Our Microbiology Panel is based on a
microplate system for bacterial identification
and susceptibility testing. In addition we offer
a panel of enterodiagnostic antigen detection
ELISAs (e.g. Rota-, Adeno-, Astrovirus,
C.difficile Toxin A&B).
Gilead Science, Inc.
Stand 115 Gilead Science, Inc.
333 Lakeside Drive
USA-Foster City, CA 94404 / United States
Internet www.gilead.com
Gloster Santé Europe
Stand 341 Gloster Santé Europe
Proloque 1-La Pyrénéenne
BP 27201
F-31672 Labège / France
Phone +33 5 62 88 42 22
Fax +33 5 62 88 36 85
Internet www.sterinis.com
E-mail communication@
gloster-sante-europe.com
Key contact Frédéric Pradelle
The company markets a unique and patented
dry aerosol diffusion technology with ultrahigh
performance hydrogen peroxide (H2O2)based
disinfectant (STERINIS ® ). It guarantees
page 194 Final Programme
the destruction on a massive scale of patho
genic microorganisms by disinfecting all
surfaces, even those which are inaccessible
or hidden.
The innovative process meets all the requirements
of the biocide directive CE 98/8.
The results of the tests carried out under both
laboratory conditions and actual hospital
usage conditions in France and abroad,
cannot be disputed.
Hain Lifescience GmbH
Stand 163 Hain Lifescience GmbH
Hardwiesenstrasse 1
D-72147 Nehren / Germany
Phone +49 74 73 94 51 0
Fax +49 74 73 94 51 99
Internet www.hain-lifescience.de
E-mail info@hain-lifescience.de
Hain Lifesience is an innovative manufacturer
of molecular genetic test systems based on
DNA STRIP ® Technology. The GenoType ® test
systems are cost effective, safe, fast, easy to
combine and require minimum equipment
costs. By having these features Hain Lifesience
offers the solution for modern micro -
biology diagnostic in every lab working with
Mycobacteria, Staphylococci, EHEC, Blood -
culture, Enterococci and periodontal pathogens.
i2a (Intelligence artificielle applications)
Stand 127 i2a (Intelligence artificielle applications)
Parc de la Méditerranée –
District de Montpellier
BP 90002
F-34477 Pérols Cedex / France
Phone + 33 4 67 50 48 00
Fax + 33 4 67 17 09 06
Website www.i2a.info
E-mail intlenquiry@i2a.info
Key contact Christian Curel
i2a, a diagnostic company specialised in
microbiology, manufactures and sales
solutions (instruments and software) for
susceptibility testing using agar plates.

Exhibitors’ Guide
i2a presents its 3 rd generation susceptibility
test readers (SirScan Automatic & Micro),
which, using its rapid cultures MHR-SIR media,
combines rapidity, automation and tracking.
All integrated software (expert interpretation,
epidemiology, infections monitoring, …)
come from the internet / intranet technology.
International Society for Infectious Diseases
(ISID)
Stand 455 International Society for Infectious
Diseases (ISID)
1330 Beacon street, Suite 228
USA-Brookline, MA 02446 / United States
Phone +1 617 277 0551
Fax +1 617 278 9113
Internet www.isid.org
E-mail info@isid.org
Key contact Norman Stein
The ISID is an educational non-profit organization
with over 30,000 members worldwide.
Its objectives are to promote communication
among those engaged in all aspects of infectious
diseases. These goals are achieved
through international scientific meetings,
exchange fellowships, grants for infection
control programs, a newsletter, and the
International Journal of Infectious Diseases.
Inverness Medical
Stand 433 Inverness Medical
Stannard Way, Priory Business Park
UK-Bedford, MK44 3UP / United Kingdom
Phone +44 1234 835 000
Fax +44 1234 835 009
Website www.binax.com
www.biostar.com
E-mail anna.eyton-jones@unipath.com
Key contact Anna Eyton-Jones
Inverness Medical Innovations is a leading
provider of innovative diagnostic products for
women’s health and chronic disease management
as well as leading the way in advanced
technologies for both the consumer and
professional diagnostic markets. We remain
committed to advancing healthcare through
a continual flow of innovative new products
driven by our strategy of investing in R & D
and intellectual property. By maintaining
our own state-of-the-art manufacturing
facilities, we produce high-quality, cutting
edge products at the speed of life.
Through our internal R & D programmes,
some strategic acquisitions and further
planned acquisitions, our portfolio of rapid
tests are rapidly growing and evolving.
We currently have five key brands: Clearview,
TestPack, Binax, Determine and Biostar
ensuring that we are at the forefront of the
global clinical rapid diagnostics market.
Iris Diagnostics France
Stand 333 Iris Diagnostics France
38, avenue de la division Leclerc
F-95170 Deuil la Barre / France
Internet www.proiris.com
Izinta Trading Co. Ltd
Stand 357 Izinta Trading Co. Ltd
Konkoly-Thege Miklós út 29/33
P.O.P 64
H-1526 Budapest / Hungary
Phone +36 1 392 2654 58
Fax +36 1 392 2651 53
Internet www.izinta.hu
E-mail info@izinta.hu
Izinta Trading Co. Ltd.(Hungary) is a ISO
certified diagnostic company specialised in
microbial diagnostics.
We have recently acquired SeaFast technology
an rRNA based FISH method, developed to
detect of microorganisms of great medical
significance.
seaFAST ® IVD kits are highly sensitive and
specific and allow an approximately one hour
identification of bacteria and yeasts in approximately
one hour instead of days/weeks with
conventional methods.
www.escmid.org/eccmid2006
page 195

Kiestra Lab Automation
Exhibitors’ Guide
Stand 337 Kiestra Lab Automation
Dukdalf 11
NL-9206 BE Drachten / The Netherlands
Phone +31 512 510 710
Fax +31 512 524 585
Internet www.kiestra.nl
E-mail sales@kiestra.nl
Key contact L. de Boer
KIESTRA is specialized in the automation and
mechanisation of Bacteriology
Barcoding system petridishes, inoculation
systems, automatic incubators, screening/
reading systems.
Mast Group Ltd
Stand 205 Mast Group Ltd
Mast House, Derby Road.
UK- Bootle, Merseyside L20 1EA /
United Kingdom
Phone +44 151 933 7277
Fax +44 151 944 1332
Internet www.mastgrp.com
E-mail sales@mastgrp.com
Key contact Susan Thomson
Mast Group Ltd offers specialised services to
the pharmaceutical sector for investigation of
novel antimicrobial compounds including
stability studies and custom manufacture of
antibiotic susceptibility test discs and other
products.
As a manufacturer of diagnostic products
Mast is also presenting rapid and reliable
solutions for identification and detection of
high profile bacterial pathogens including
MRSA and ESßL producers.
page 196 Final Programme
Merck Sharp & Dohme
Stand 251 Merck Sharp & Dohme
One Merck Drive, P.O. Box 100
USA-Whitehouse Station, NJ 08889-0100 /
United States
Phone +1 908 423 1000
Fax +1 908 735 1122
Internet www.mercksharpdohme.com
Merck Sharp & Dhome continues its history of
breakthrough science and dedication to lifesaving
anti-infective solutions with therapies
including CANCIDAS (caspofungin), INVANZ
(ertapenem), TIENAM (imipenem/cilastatin
sodium), STOCRIN (efavirenz) and CRIXIVAN
(indinavir).
CANCIDAS is the first of a new class of antifungal
called echinocandins, which inhibit the
synthesis of beta (1,3)-D-glucan, an integral
component of the fungal cell wall.
CANCIDAS offers powerful antifungal efficacy
against some of the most prevalent fungi
species, including candida and aspergillus,
without compromising tolerability. Evidence
and experience support the role of CANCIDAS
for suspected and documented fungal
infections.
INVANZ is the first and only Group 1 carba -
penem. INVANZ offers the efficacy of carbape -
nems with rapid bactericidal activity in vitro
and excellent coverage of gram-positive and
gram-negative as well as aerobic and anaerobic
pathogens. INVANZ is indicated for the treatment
of moderate to severe infections caused
by susceptible strains of microorganisms,
as well as initial empiric therapy prior to the
identification of causative organisms.
Merck has been conducting HIV/AIDS research
for 20 years and our commitment to this area
remains as strong as ever.
The launch of CRIXIVAN in 1996 and STOCRIN
in 1998 solidified Merck’s foundation in
the commitment toward the fight against
HIV/AIDS. Merck was the first to elucidate
integrase-strand-transfer inhibition and to
define the mechanism of action of integrase
inhi bitors, and continues to develop novel
compounds, including the investigational
integrase inhibitor MK-0518.
Trademarks of Merck & Co., Inc., Whitehouse
Station, NJ, USA
TIENAM is marketed as PRIMAXIN ® in the UK.

Exhibitors’ Guide
Meridian Bioscience Europe
Stand 111 Meridian Bioscience Europe
Via dell’Industria 7
I-20020 Villa Cortese MI / Italy
Phone +39 0331 433636
Fax +39 0331 433616
Internet www.mdeur.com
www.meridianbioscience.com
E-mail info@mdeur.com
Key contact Christiano Burinato
Leader in gastrointestinal infectious diseases
tests, like Helicobacter pylori, C.difficile Rapid
Toxins A&B, Rotavirus and Parasites, Meridian
is introducing a new accurate assay for
detecting NOROVIRUS from faecal specimens,
allowing prompt infection control and reducing
the economical impact of outbreaks.
The respiratory panel of rapid tests includes a
highly sensitive product for Influenza.
Nanogen Europe BV
Stand 413 Nanogen Europe BV
Steenovenweg 3
NL-5708 HN Helmond / The Netherlands
Internet www.nanogen.com
National Collection of Type Cultures (NCTC)
Stand 473 National Collection of Type Cultures (NCTC)
Centre for Infections
Health Protection Agency
UK-London NW9 5HT / United Kingdom
Phone +44 208 327 67 74
+44 208 327 67 04
Fax +44 208 205 74 83
Internet www.hpa.org.uk/nctc
E-mail nctc@hpa.org.uk
The NATIONAL COLLECTION OF TYPE
CULTURES (NCTC) is one of the Health
Protection Agency’s specialised laboratories
located in the Centre for Infections,
Colindale, London.
NCTC collects, preserves and supplies globally
freeze dried authenticated cultures of bacteria
and mycoplasmas that are pathogenic to man
or other animals.
Founded in 1920, NCTC is the longestestablished
supply service collection in the
world.
The cultures are available to support scientific
and diagnostic examinations and research.
The collection also supports a range of
identification, characterisation and testing
services.
NCTC also provides a variety of bacteria and
fungi in a unique easy to use LENTICULE disc
format, developed by Health Protection
Agency staff.
NeuTec Pharma plc
Stand 145 NeuTec Pharma plc
Oxford Road
UK-Manchester M13 9WL / United Kingdom
Internet www.neutecpharma.com
Nordic Pharma
Stand 167 Nordic Pharma
216, Boulevard Saint-Germain
F-75007 Paris / France
Phone +33 1 53 63 88 77
Fax +33 1 45 48 76 50
Internet www.nordicpharmagroup.com
E-mail sebastien.meunier@
nordicpharma.com
Key contact Sébastien Meunier
Nordic Pharma focuses its activity on those
core therapeutic areas where unmet medical
needs remains: Critical care – Haematology –
Rheumatology – Oncology
Synercid ® (Quinupristin/Dalfopristin) is the
first injectable streptogramin approved for the
treatment of severe gram positive infections
such as nosocomial pneumonia, skin and soft
structure infections and infections caused by
Vancomycin-resistant Enterococcus faecium.
www.escmid.org/eccmid2006
page 197

Nunc A/S
Exhibitors’ Guide
Stand 323 Nunc A/S
Kampstrupvej 90
P.O Box 280
DK-4000 Roskilde / Denmark
Phone +45 4631 2000
Fax +45 4631 2175
Internet www.nuncbrand.com
E-mail infociety@nunc.dk
Key contact Helle Vittrup
Nunc is an ISO 9001, ISO 13485 and ISO 14001
– certified world leader in the production and
supply of laboratory plastic ware for use
within cell culture, immunology, genomics
and molecular biology. Our customers are
laboratories, hospitals, research centres as
well as diagnostic and pharmaceutical
companies throughout the world.
Oxford Immunotec Ltd
Stand 435 Oxford Immunotec Ltd
91 Milton Park
UK-Abingdon, Oxon OX14 4RY /
United Kingdom
Phone +44 1235 433 176
Fax +44 1235 442 781
Internet www.oxfordimmunotec.com
E-mail sstader@oxfordimmunotec.com
Key contact Sharon Stader
Oxford Immunotec will present the in-vitro
T-SPOT.TB test for active and latent tuberculosis.
It is extremely sensitive and specific
making it particularly suitable for immuno -
suppressed populations and extrapulmonary
TB. It is very specific with no cross-reactivity
to BCG vaccination or M. avium.
It can be used for contact tracing, regular
screening of healthcare workers, immigrants
and prisoners and the immunosuppressed.
page 198 Final Programme
Oxford University Press
Stand 321 Oxford University Press
Great Clarendon Street
UK-Oxford OX2 6DP / United Kingdom
Phone +44 1865 556767
Fax +44 1865 353835
Internet www.oxfordjournals.org
OUP publishes some of most respected
medical books and journals in the world.
Visit our stand to learn more.
As a foremost international journal in antimicrobial
research, the Journal of Antimicrobial
Chemotherapy features original articles on
the laboratory aspects and clinical use of
antimicrobials including antibacterial, antiviral,
antifungal, and antiprotozoal agents.
Pick up a free copy at our stand.
Oxoid Limited
Stand 257 Oxoid Limited
Wade Road
UK-Basingstoke RG24 8PW /
United Kingdom
Phone +44 1256 841144
Fax +44 1256 463388
Internet www.oxoid.com
E-mail martin.cunningham@oxoid.com
Key contact Martin Cunningham
Oxoid Limited is internationally renowned as
a leading supplier of high quality microbiology
products to clinical laboratories worldwide.
Oxoid now feature REMEL products to
complement our own extensive range of
Diagnostic Reagents. These will feature along -
side the Microbact TM range of manual identification
systems.
Oxoids extensive Ready Prepared Media in
a wide feature in a wide range of formats,
including the latest additions of innovative
chromogenic culture media for the isolation
and differentiation of pathogenic bacteria.
The Web Site with access to updated
information on Oxoid products QC and
Safety Data Sheets on line.

Pall Medical
Exhibitors’ Guide
Stand 213 Pall Medical
Walton Road, Farlington
UK-Porthmouth, Hampshire PO6 1TD /
United Kingdom
Phone +44 2392 303600
Fax +44 2392 303541
Internet www.pall.com
E-mail catherine_whapham@
europe.pall.com
Key contact Cathy Whapham
Pall is the largest and most diverse filtration
company in the world. Our specifically
engineered filters are used for critical
contamination control within blood processing
and transfusion medicine, cardiovascular
procedures, drug delivery, IV and respiratory
therapy, laboratory applications and healthcare
water.
Pathogenic bacteria, fungi and protozoa,
including Pseudomonas spp, Aspergillus spp,
Legionella spp and amoebae, can colonise
biofilm, which forms on internal plumbing
surfaces. Shearing force of water can disperse
biofilm and micro-organisms to point-of-use
where vulnerable patients may be adversely
affected.
Pall-Aquasafe range of water filters for taps,
showers, ice machine and medical device
reprocessing, intercept waterborne microbes
before they reach patients and staff.
Visit healthcare environment, and learn
more about our infection control products.
Pfizer Inc.
Stand 227 Pfizer Inc.
235 East 42 nd Street
USA-New York, NY 10017 / United States
Internet www.pfizer.com
Pfizer Inc. is an international healthcare
company dedicated to the research and
development of novel pharmaceutical
compounds.
This exhibit displays information about
“NEW” Zmax (azithromycin extended release
for oral suspension), a complete course of
therapy in a single dose for community respiratory
tract infections; VFEND (Voriconazole),
Pfizer’s anti-fungal agent, and ZYVOX
(linezo lid) shown to be clinically active against
medically-active gram-positive pathogens
including methicillin-resistant strains of
staphylococcus aureus (MRSA)
Prodesse Inc.
Stand 201 Prodesse Inc.
W229 N1870 Westwood Drive
USA-Waukesha, WI 53186 / United States
Phone +1 262 446 0700
Fax +1 262 446 0600
Internet www.prodesse.com
Prodesse, Inc. is a manufacturer of CE marked
molecular diagnostic products for the detection
of infectious disease. Specializing in
real time multiplex assays, Prodesse has an
extensive distributor network, is ISO 13485
certified and has customers at many prestigious
laboratories worldwide.
Qiagen Hamburg GmbH
Stand 157 Qiagen Hamburg GmbH
Koenigstrasse 4a
D-22767 Hamburg / Germany
Phone +49 40 41 36 47 00
Fax +49 40 41 36 48 20
Internet www.qiagen-diagnostics.com
E-mail qiagen-diagnostics@
qiagen-diagnostics.com
Key contact Dr. Angelika Storm
QIAGEN Hamburg is a biotechnology company
specialized in the development, production
and worldwide sale of PCR-licensed and CEmarked
diagnostic kits.
Molecular biological in vitro diagnostic assays
for clinical applications like infectiology and
pharmagogenetics. Assays are based on
real-time PCR technology and allow the
quantitative detection of nucleic acids from
viruses, bacteria and parasites as well as SNP
analyses.
www.escmid.org/eccmid2006
page 199

R-Biopharm AG
Exhibitors’ Guide
Stand 331 R-Biopharm AG
Landwehrstrasse 54
D-64293 Darmstadt / Germany
Phone +49 6151 8102 0
Fax +49 6151 8102 20/ -40
Internet www.r-biopharm.com
E-mail info@r-biopharm.de
R-Biopharm AG is a German company deve -
loping, manufacturing and distributing test
systems (mainly ELISA) both as for food&feed
and clinical diagnostics.
In clinical field R-Biopharm offers world wide
the brands RIDA ® and RIDASCREEN ® covering
a complete range of diagnostic test kits for
antigens in stool, serology of infectious
diseases and allergy.
Roche Diagnostics France
Stand 423 Roche Diagnostics France
2, Avenue du Vercors
F-38242 Meylan Cedex / France
Phone +33 4 76 76 16 21
Fax +33 4 76 76 46 51
Internet www.roche-diagnostics.com
E-mail remi.rabeuf@roche.com
Key contact Rémi Rabeuf
Roche Diagnostics is a leading supplier of
innovative systems and reagents for diagnosis
and for life science research e.g., with
SeptiiFast, the real-time PCR test for
detection and identification of pathogens
causing bloodstream infections directly
from blood. Another example is the Genome
Sequencer 20 Instrument; the ultra-fast
system can sequence more than 20 million
bases per 5.5 hour instrument run.
Sangtec Molecular Diagnostics AB
Stand 335 Sangtec Molecular Diagnostics AB
Bällstavägen 34-36
S-168 65 Bromma / Sweden
Phone +46 8 555 20 400
Fax +46 8 555 20 499
Internet www.sangtec.se
E-mail ekalstrom@sangtec.se
Key contact Eva Kalström
page 200 Final Programme
Sangtec Molecular Diagnostics (SMD) is a fully
licensed innovative company specialized in
developing, producing and marketing clinical
molecular diagnostic assays.
The affigene ® trender (and tracer) assays
allow correct monitoring of viral load with
high sensitivity and wide dynamic range
utilizing real-time PCR detection. Harmonised
test-profiles allow multitarget-runs with
different analytes tested simultaneously.
The assays are standardized, robust,
user-friendly and CE-labelled.
Sanofi-aventis
Stand 261 Sanofi-aventis
46, Quai de la Rapée
F-75012 Paris / France
Phone +33 1 55 71 30 00
Fax +33 1 55 71 30 50
Internet www.sanofi-aventis.com
E-mail aicha.zenini@sanofi-aventis.com
Key contact Aïcha Zenini
Sanofi-aventis is the world’s third largest
pharmaceutical company, ranking number
one in Europe.
Backed by a world-class R&D organization,
sanofi-aventis is developing leading positions
in seven major therapeutic areas:
cardiovas cular, thrombosis, oncology,
metabolic diseases, central nervous
system, internal medicine and vaccines.
The Group is inspired by a powerful vision:
– to find new compounds to prevent, combat
and eradicate diseases around the world,
– to provide therapeutic and preventive
solutions geared to populations in both
industrialized and developing countries,
– to support with equal dedication innovative
medicines and vaccines, mature products,
OTC medicines and generics.
Every day, everywhere sanofi-aventis is
working for what really matters: HEALTH.

Exhibitors’ Guide
Schering-Plough Pharmaceuticals
Stand 231 Schering-Plough Pharmaceuticals
2000 Galloping Hill Road
USA-Kenilworth, NJ 07033 / United States
Phone +1 908 298 4000
Fax +1 908 298 7136
Internet www.schering-plough.com
E-mail jill.york@spcorp.com
Key contact Jill York
International Director
Noxafil, a novel triazole antifungal agent was
discovered and developed by Schering-
Plough Research Institute. Invasive fungal
infections, which can be life threatening, most
often occur in people who are immunocompromised
or immunosuppresed, such as
organ transplant patients or cancer patients
undergoing either chemotherapy or stem cell
transplant. Noxafil is now approved in the
current European Union 25 member states as
well as in Iceland and Norway.
Science / AAAS
Stand 353 Science / AAAS
82-88 Hills Road
UK-Cambridge CB2 1LQ / United Kingdom
Phone +44 1223 326515
Fax +44 1223 326535
Internet www.sciencemag.org
www.aaas.org
E-mail subs@science-int.co.uk
Science magazine is published by the American
Association for the Advancement of Science
(AAAS), the world’s largest general scientific
society. Founded in 1880 by Thomas Edison,
Science ranks as the world’s leading scientific
journal, with over 130,000 subscribers.
Each week, Science provides the best in peerreviewed
original research, scientific research
articles and reports, commentaries on recent
news and events.
Sirs-Lab GmbH
Stand 421 Sirs-Lab GmbH
Winzerlaer Strasse 2
D-07745 Jena / Germany
Phone +49 3641 5084 30
Fax +49 3641 5084 32
Internet www.sirs-lab.com
E-mail dietzel@sirs-lab.com
Key contact Eva Dietzel
SIRS-Lab GmbH is specialized in the identification
of proprietary biomarkers and the development
of in vitro diagnostics to advance
the diagnosis of inflammatory/immunological
host responses and early identification of the
bacterial causes of infection in intensive care
medicine and sepsis. By the development of
the Pureprove TM technology, SIRS-Lab has
achieved a unique position in the field of
pathogen detection.
Statens Serum Institut
Stand 165 Statens Serum Institut
5, Artillerivej
DK-2300 Copenhagen S / Denmark
Phone +45 32 68 3268
Fax +45 32 68 3868
Internet www.ssi.dk
E-mail aam@ssi.dk
Key contact Aase Meyer
Statens Serum Institut is a manufacturer and
provider of in vitro diagnostic products and
related services. The product range includes
antigens, monoclonal and polyclonal
antibodies, culture media, diagnostic kits and
biological indicators. The products are
available worldwide through an extensive
distributor network and direct sales.
www.escmid.org/eccmid2006
page 201

Transgenomic Ltd
Exhibitors’ Guide
Stand 311 Transgenomic Ltd
Z.A. la Clef Saint Pierre
10B Rue Blaise Pascal
F-78990 Elancourt / France
Phone +33 1 30 68 90 00
Fax +33 1 30 68 90 01
Internet www.transgenomic.com
E-mail mdegraaff@transgenomic.com
Key contact Muriel De Graaff-Vincent
TRANSGENOMIC developed the WAVE ®
Microbial Analysis System, an ideal tool for:
Rapid and automated approach for identification
of bacteria and fungi.
Culture-independent identification of
«common», and fastidious or anaerobic
bacteria.
Reproducible and rapid with automated
fragment collection.
Profiling and sequencing-based
investigation of microbial communities.
Monitor qualitative and quantitative
changes of microbial communities over
time.
Trek Diagnostic Systems
Stand 101 Trek Diagnostic Systems
Imberhorne Lane
UK-East Grinstead, West Sussex RH 19 1QX /
United Kingdom
Phone +44 1342 318 777
Fax +44 1342 318 666
Internet www.trekds.com
E-mail info@trekds.com
TREK Diagnostic Systems is a dedicated
microbiology company offering blood culture,
identification, and susceptibility technologies
to provide cost effective improvements in
workflow efficiencies, ergonomics, and test
result performance, resulting in better
solutions for patient care.
Product lines include the VersaTREK ®
Automated Microbial Detection System
and the Sensititre ® ID/AST Microbiology
System.
page 202 Final Programme
Wisepress Ltd
Stand 355 Wisepress Ltd
25 High Path
UK-London SW19 2JL / United Kingdom
Phone +44 20 8715 1812
Fax +44 20 8715 1722
Internet www.wisepress.co.uk
E-mail bookshop@wisepress.co.uk
Wisepress Online Bookshop is pleased to
present a display of titles selected especially
for the 16th European Congress of Clinical
Microbiology & Infectious Disease from the
world’s leading publishing houses. All titles
can be bought or ordered at the congress or
via our website: www.wisepress.co.uk .
Whatever your book requirements, Wisepress
will be happy to help
Wyeth Pharmaceuticals
Stand 241 Wyeth Pharmaceuticals
500 Arcola Road
USA-Collegeville, PA 19426 / United States
Phone +1 484 865 3344
Fax +1 484 865 4310
Internet www.wyeth.com
E-mail hoppen@wyeth.com
Key contact Nancy Hoppe
Wyeth Pharmaceuticals, a division of Wyeth,
has leading products in the areas of women’s
health care, cardiovascular disease, central
nervous system, inflammation, transplantation,
haemophilia, oncology, vaccines and
nutritional products.

Zeneus Pharma Ltd
Exhibitors’ Guide
Stand 159 Zeneus Pharma Ltd
The Magdalen Centre
Oxford Science Park
UK-Oxford OX4 4GA / United Kingdom
Phone +44 1865 784800
Fax +44 1865 784801
Internet www.zeneuspharma.com
E-mail isabel.manterola@
zeneuspharma.com
Key contact Dr. Isabel Manterola
Is it CLEAR ® what the largest and most
comprehensive efficacy data set on proven
fungal infections is? Please visit our stand to
find out more about what over 3,500 ‘real
world’ patients with a diverse range of fungal
pathogens (including emerging ones), sites of
infection and underlying conditions can tell us.
Zeneus Pharma is a speciality pharmaceutical
company, focusing on hospital products for
life-threatening conditions.
www.escmid.org/eccmid2006
page 203

Notes
page 204 Final Programme

Notes
www.escmid.org/eccmid2006
page 205

Future ECCMIDs
17 th ECCMID & 25 th ICC 2007
…Joining Forces in Munich!
March 31–April 3, 2007
Munich, Germany
International Congress Center
Munich (ICM)
Prof. Bernhard Ruf,
Congress President
Abstract Deadline:
November 16, 2006
www.eccmid-icc.org
18 th ECCMID 2008
April 19–22, 2008
Barcelona, Spain
Centre Convencions
Internacional Barcelona (CCIB)
Prof. Fernando Baquero,
Congress President
Abstract Deadline:
December 5, 2007
www.escmid.org/eccmid2008
page 206 Final Programme

Ba
R ue du Ch.
Bo
p Garnier
Rou
R. J. AllegréAv. Maré
Bonfante
Rue de l'eau fra
Avenue
Av. Eden Park
Avenue Mirabeau
Rue Vernier
Rouget de Lisle
Bo l d
Rue Reine Jeann e R.
Nice City Map
Roquebilière Rue
Avenue des Diables Bleus
Bd.de l'Armée d. Alpes
Boulevard Pierre Sola
Av. de la République
des Arènes de
C i miez
Montée de Cimiez
Bd Villeboi
R. Gutem- berg
Féric
Av. duXVcorps Père Cartier Jugan
de l'ArbreInférieur
Ratti
ora
Av.
Rue de la Gendarmerie
Av. Jean R ichepin
Avenue
Av. de
Provence
de SteThé r è s e
Anc. Ch.
Av. Bro wn Sequart
Avenue Desambrois
Avenue Thiers
Pastorelli R. P. Devoluy
Dubouchage
Avenue Georges
Bd Risso
Deudon
Boulevard Gambetta Boulevard Gambetta
de
Rob. Moriez
Av. D r
R. P.
Saint
Strati
Av. de Gien
Ave nue de Picardie
Alsace
d'Anvers
Plaine de
R. de la
Av. de Bru x e lles
Boulevard Raimbaldi
de
Cimiez
de Savoie Av. de Savoie
Rue Clément Roassal
R. Al. Binet
R. Caste
R. Prince Maurice
Av. de Béarn
Dabray R. Dab
Pte Av.
Madeleine
Martin duGard
Rue de Dijon
D'Autun
R. Ch.
R. Miolis
Rue des combattants
d'Afrique
R.P. Pietri
RueTorrini
de Buenos aires
Paul Arène
d.
Co
Bovis
Groupe
scolaire
Jea
Rue J.
Av. G.
Cythère
R. Hum. Ricolfi
de l'Eglise St roch
N. Masse
Nadaud
Av. Paul Dufour mantel
Bergounier
R. d.
Gare
Av. Dr
du Sud
Parvi
Père Ch
Chesse
Sq. J.
Giono
Rue
R. Hoche
R. Thivin
Bellevue
Hanotaux
Bois
du
Ave n ue
Du Rocher
Avenue
St Joseph
Avenue
A venue
R. de
Villeneuve
Dauphiné
du
du
J. Aicard
Aven u e
Rou t e
Av.
Rue
Av.
El-Nouzah
d'
Av. de Normandie
Av. Emile
Rue Assalit
All. H . B osco
Mendiguren
Avenu e
Rue Pertinax
Pierr e
Rlle.St J.
Gal
Av d.
Dame
Rue de Paris
Rue de Belgique
R. d'Alsace Lorraine
Avenue Notre
Rue de Lépante
Bd Tzarewitch
R. E. et Ph.Tiranty
Rue Miron Rue Hancy
St Siagre
R. Cha brier
R. du Dr. Ardoin
Léotardi
Avenue
Bieckert Emile Bie ckert
Rue P. Blancon
Rue Auguste
Ch. de Sorgentino Beautruch
de RevelBattisti
XV corps
Rue Abbé Grégoire
Av. Gay
Bd du
Av. Anat. France
Avenue
Dauphin é
Imp. d'E stienne d'Orves
ue
R. Oscar II
R ue Col. Guide
Maraldi
R.L. Garne
Chemin du Bois Montée de
Apolinaire
Rue G.Garau
R. Th. Gasiglia
Av e nue
Rue d'Italie
d'Angleterre
Bd Fr. Grosso
Avenue M al Foch
Clémenceau
R. A. de Grasse
Rue de Châteauneuf
André
Boulevard Riquier
Rue Barbéris Rue Barbéris
Av. St Sébastien
Corniche
Avenue Félix Faure Av. St J. Baptiste
Boulevard
Gioffredo
des Postes
Rue Paul Déroulède
Rue de Russie
Rue Paganini
Avenue
Rue Ed. Béri
Rue Biscarra
Rue Delille
Rue Ed. Scoffier
Rue Arson
Rue de Orestis
Reboux Rue Dr P. Richelmi
Rue Auguste Gal
Rue Ribotti
Rue Georges Ville
Boulevard du Gal LouisDelfino Bld. du Gal Louis Delfino
Rue Beaumont
Rue de
Esplanade Kennedy
Av. Pauliani
Rue Scaliéro
Rue Smolett Rue Smolett
Rue Defly
Rue Pastorelli Rue
Rue Rossini Rue Rossini
Boulevard VictorHugo
Av. AuberAv. Auber
Rue Gounod Rue Gounod
Rue Verdi
Rue
Rue del'Hôtel
Rue Berlioz Rue Berlioz
Rue Herold Rue Herold
du Maréchal Joffre
Rue Gioffredo
Rue de la Liberté
deJoly
Boulevard François Grosso
Rue
Bd. Lech Walesa
Rue Cassini
R. BalestreRue Blacas Rue Chauvain
Cronstadt R. Guiglia Rue Guiglia
Rue Fr. Aune
Rue Fr. Passy
Rue Caïs Pierlas
av. Shakespeare
R. Père Aug.
Rue Gubernatis
R. Kosma
Rue Caffarelli Ch. St Philippe
Avenue des Orangers
Avenue des Fleurs
Rue
Rue Bottero
Masséna
Rue
St
Rue Dante
Av. de Verdun
de France
Place
Av. Baquis Rue du Congrès
Rue
Rue des Potiers Rue des Potiers
Col le
Rue Grimaldi
Rue Alphonse Karr
Baumettes
Rastelli
Rue Boyer
Rue Papon
R. Alfr. Mortier
Rue Foncet
Rue P. Soleau
R. d. Niel
Rue Alberti
R. G. Deloye
Rue du Lycée
Rue Maca- rani
Avenue Louis Cochois
Rue Dalpozzo R. Roya
Rue Meyerbeer
des
du
Avenue
M. Alba n
Rue S.
Guitry
Rue Fontaine d. L.Ville
Parc Impérial
de Av ets
Avenue Docteur Ménard
R
Sorgentino
Av.
Rue du Dr. Fighiera
Villermont R. Diderot
Malausséna
Pass.
R. Pauline
Imp.
Bonifassi
Cognet
Pass
R. Scoffier Cour
R.P.Grilli
Pass. du
Pet Parc
Primerose
Rue Sospel
Av.
Mtée de Cimiez Vieux chemin de Cimiez
Mtée du Grand
Pass.
Imp.
Grégoire
P a l a is
Grégoire
Rue
D'artois
Rég
Palladium
Nicolas II
Av.
Av. Beausoleil A v. Bea u Site Avenue
Giaume
Caissotti
Rue de
Massingy
de Suisse
Rue de Jussieu
Rue
Cluvier
R. Balzac
Rue
Avenue Beau S it e
Avenue Aurore
d'Estienne
Mtée Carabacel
Pass meynell
Candia R. la Bruyère
RlleSt Ca th.
d'Orves
R.de la Maloniére
R. Jacques
Dur- ante
Av. Comba
G. Marshall
Av. Depoilly
Saussure
R d.
prés
RueOffenbach
Schuman
Badat
R. Bouteilly
av.
Ru e
R.
d. V
Melch
ogûé
A bb é Salvet
Rlle R. fo
Raymond
Pellos
Allée Thiole
Comboul
Rue
Victor Hugo
Longchamp
Av. Emilia
Costa
R.E.
R. Louise Ackermann
Bauquier
Pas.
R. Voltaire
Raynardi
Av. L.
R. Eug.
Ro b ert
Rue Bavastro
Rue François Guisol
Passeroni
Emmanuel
Janion
Jos . Brès
R.
Pass. d.
T. Vaudois
R.Béal
Rue Bonaparte
Philibert
R. M. Seytour
Pass Em. Négrin
Rue
François
Rue
1er
Dr Barety
R. Spinetta
Passsage
Rue M.Rosanof
Meyerbeer
Passage
Chemin
Rue Arson
Rue A. Mossa
Av.
Rue Lascaris
Pass.d.
Avenue
A mata
Maeyer
l'Avenir
Rue de
Rue Fodéré
R. Paradis
Avenue
Rue Andrioli
I mp. de Terra
Ruisseau
Rue Em.
R. Barralis
Passage Merlanzone
Av. Château
La tour
Christine
Av. Marie-
Rue
R. G.
Av de Suède
Banco
Fauré
Rue Halévy
Raffali
Poullan
Des
Rue Massenet
R.A.
R. d. Cdt
Berretta
Fricero
Imp. d.
Violettes
ttes
Baume
R.Fodéré
Gustave V
le
Rue
Tr.
Philippe
Rue deFrance
Moy
R. Hon.
Sauvan
R. P. Valéry
B o ulevard
Q. d. deux Emmanuel
R. A. Renoir
R. H. Cordier
Lympia
Bosio
Louis de Coppet
Imp. S t Laurent
Urbain
Av. de la Palmeraie
Bo
Av Gustavin
L'ouest
Av. Lympia
Miramar
Imp.
Bd. de Stalingrad
Rue
Poincaré
Guimar d.
Marlin
R.
Gardon
des Isnards
Avenu e
Av. A. Leroux
Cdt Octobon
Carnot
Av. Winston Churchill
d'Alicante.
R.& Sq.
Boulevard
www.escmid.org/eccmid2006
Mo nt
Henry de Bournazel
La roseraie
Av.Fleurie
Ney
A v.de la Mer
Aignan
Rampe Quai du Commerce
Quai du commerce
Rue
Montée Av. St
Av. des
Franck
Av. du Parc Vigier
A v.d l.réserve
Petite Source
Ru e
Rue Maréchal Vauban
d'Utelle
Rue J.
Av. Pierre Loti
R. Veillon
Av. du
Bd
Printemps
Av. d. l' Olivetto
Av. Em. Bridault
Sen tierValentini
A. D a umas
Av.
Mon s eigneur R. St Roch.
Rue Marceau
Boissy
Rue
de L a Co line
R.
R. d. l.
Fayette
Anglas
Av. Malaussena
Rue Trachel
Bensa
del'Armée
R.
d'Orient
Collège Risso
Tunnel
Boulevard
d'Urfé
R.
Passage
Max Verola
Tennis
Voie Malraux
Mitron Lépante
R.
Av. SuzanneLenglen
R.thaon
Trav. J.
Monnet
R.
R
d'Angely
de Cimiez
Niço
R.
R.
Niepce
R.L. I
R.
R.
Sud
Ach
R.Dr Ciais
Acropolis
l'Hermitage Ch . St Charles
Montée
Desambrois
R.
Valperga
R.
Av.
Bd Carabacel
R.
d'Alger
R. A. de
Eco
Chambre de
commerce
et d'industrie
Rothschild
R. Pr.
Dr Alfr.
Urbaine
Boulevard du
R lle d. prés
Sq. Normandie
Niemen
R. Rancher R.Galléan
d. Leyni
Rue Lamartine Rue Lamartine
Avenue Jean Médecin
Imp.
Clinique
Av. de Gal
Weygand
R. de
Mozart
R.
Rue Penchienatti
R. Vict.
Juge
R.
Rue
Beethoven
Pass.
Gounod
Rue St
Saëns
Sq.
Charpentier
M
Pas. Sq Em.
R. du Dr
Ciaudo
Rue Tonduti de l'Escarène
Valentin
Pl. St
Philippe
Pass.
Musso
Rue
Av.
Caldera
R. des
Bastions
Autoroute
Av.
Tr. de la
Bourgada
du Fort
Rusca
R.
Pacho
R.
Boulevard JeanJaurès
Sq. H. Christiné
Rue
Jaubert
Rue dela Buffa
Bouleva d
Pl. G Maison
Breil/Roya
d'Arrêt
Police
Collège
Giono
Place de Nationale
Gendarmerie
Tende
Hospice
Centre Sportif
Municipal
Vauban
Place
Don bosco
Pôle
Palais des
Universitaire
Sports
St Jean
J. Bouin
d'Angely
Pl.de l'armée
du Rhin
Esplanade
M. de lattre
de Tassigny
Ecole
Centre
commercial
Nice TNL
SNCF - Gare
de Riquier
Pl.
A. Blanqui
Pl.
Pellegrini
St
Joseph
Centre Pl.
Administratif Arson Fourrière
Ecole
Stade
Ecole
Auto
Municipal
Bouliste
Ecole
Pas.
Rostan
Pierre Merle
Occelli
Place
Max
Barel
Groupe
scolaire
Lycée
Parc Castel des
Ecole
deux Rois
Pompiers
Musée de
paléontologie
Humaine de
Terra Amata
Collège
Port
Lympia
Bassin
Lympia
al Signoret Ecole Collège
de
Pisc. rue Nazareth
Gaulle Jardin
du Ingigliardi
Public Thiole
Piol
Gare des
Ecole
Rd Pt
Pl. d. la
chemins de ferGare
du Sud
S. M.
Biasani
Groupe
de Provence
Scolaire
Ecole
Ecole
Ecole
Centre
Roméo
Pl. Ph.
Administratif
Randon
Mus Muséee Musée
Conservatoire
M. M. Chagall national
Lycée
Pass. de région
Collège Acropolis
du Parc
St Lambert
Duruy
Impérial
CollègeExpositions
Expositions
R. de Roussillon
Collège
Don Bosco
St
Vernier
Egl.
Etienne
Collège
Ecole
Parvis de
Chirugie
Sq. Colonel
Rolland Garros
l'Europe
dentaire
Jean-Pierre
Collège
Carabacel
SNCF SNCF - - Gare Gare
Stanislas
R.
Rd pt
D'Ostende
Nice Ville ille
ANPE
35
20
Rue
12
Pompiers
Rue
Russe
Pl.
d'Auzac
Bergondi
31 Toselli Rue Raspail
Pl.
Bowling
Saëtone 19
Cinémathèque
Square
Poste
Basilique
Raimu
Lycée
Notre
Calmette Commissariat
Dame
Central
Acropolis
Théâtre
29
Place
Congrès Congr Congrèss
44
de la Cité
Sasserno
Théâtre de
Palais
Médiathèque
l'Alphabet P. J.
des Congrès
Ecole Ecole
Ecole
Hôpital
Moulin Esplanade
Rue
Théâtre
28
St Roch
F. Giordan
Spitalieri photographie
Bibliothèque
et l'image
Biblio-
47
thèque
Louis Nucéra
Théâtre
Sq. D.
Place
Pl. Yves
du Galop
Durandy
Trésorerie
Klein Mus Musée
Franklin
Auberge 42
26
de Jeunesse 38
Générale Centre
d'histoire
d'histoire
Infos
Sq. Dr
1
Naturelle
Naturelle
Pl.
Jeunesse
Zamenhof
Wilson
Musée Place d'Art
(Barla)
(Barla)
41
16
du Vœu Place
Jardin
Moderne
Garibaldi
Alsace- 24
Pl. Eug.
Lorraine
Mô
et contemporain
Jardin J.
Place
Imp.
Moréno
Lycée
Place
du Pin
Chimère
Temple
Vaudois Masséna
J. Toja
Place 30 37
Théâtre
Gare
St Martin
A. de
45
18
Routière
Malaussena Place 32
Pl.
Collège
Grimaldi
St Augustin
Pl.
Ségurane
Magenta
Place
Rue
La Buffa 39
5
46
Promenade
St François
Hospice de
Claudia
la Providence
Place Eglise
du Paillon
Place
de la croix Anglicane
du Carret
de Marbre
Place
Montée
Sacré
Masséna Espace
Place Rondelly
Sq.
Ste
St Claire
cœur
3
Masséna
Esc.
Leclerc
Croix
Couvent
Suche
St Pierre
Croix
Palais
de la Visitation
D'Arène
de Marbre
Jardin
Lascaris
Pl.Hall.
Mairie Palais
aux Herb. Pl.
Albert 1er
Annexe Rusca Place
Cath. Rossetti
Palais
Théâtre
du
Ste Réparate
Esc.
Grpe Sco.
Palais
Egl. St
Eynaudi
Hôtel Masséna
de Verdure
Pl. du Jacques
Mairie
Jésus
Negresco 8 13 14 9
St François
Espace
Eglise
de Paule
Mus Musée Musée
33 7
Casino Jacques COTTA
Opéra
Place
25 Notre Dame
P. Gautier
Groupe
d'Art d'Art et
et
4
Rlle Ste
Ruhl
Scolaire
Marché
Marie
du Château
du Port
Place
d'histoire
d'histoire
aux puces
Charles-
Départ petit train
34
Félix
Mass Masséna na
Parc de la Colline
touristique
Centre du
Patrimoine
du Château
R. de Bilbao
de Roquebilière Rue de
Rue
Behaine
Le Piol
Rue
Ch. de La
Rue
La Conque
Pte Av.
B. Aires
Gilette
R. d.
Imp. Taffe
All. Cavendish
R.
Av.
Saorges
R. d.
l'Authion
R. d.
R. P. Joseph
Bertaina
d'
Av.
A. Voisin
R.
Parking privée
Trav.
Flandre
Dunkerque
Rue
Fernandez
Ecole
R.
Sainson
R. R.
Rlle.du
Île de beauté
Ecole
Sq. Col
Bouvier
Collège
Magnan
Phocéens
Av. des
Av.
Av.
Cap. Scott
R.lle
d. Moulins
Av. J.
R.du Lazaret
R.A.
Allée
Av. de
Quai des Docks
Rue de Rivoli Rue
Av. R. Maurice Rue
Cathédrale
Sq.F.
Suarez
Av. Gallieni
Emi l e
Ecole
Beau Site
Lycée
Beau Site
axine
Beau Site
Inst. des
Sourds-Muets
PI. M.
Amoureux
Lycée
Estienne d'orves
Rue
Chemin du
Clos Boulogne
Résidence
Universitaire
Pass.
Ségurane
Rue Catherine Ségurane
Parc
Louisa
Av. de
Av.M al
Capitainerie
Quai
Quai
d'Entrecasteaux
Bassin des
Amiraux
Rlle S t André
Rue
Miralhti
R. Sincaire
St Martin
Rlle
R.
du Chœur
Ste Hospice
Droite R. St Fra nçois Rue Pairolière
R.d.
Rlle
St Augustin
la Tour
St Aug u stin
R.Fr. Zanin
Rue
Rue
Gioffredo
R.d.Four
ac de Droit
ciences Eco.
PI. E.
ugues
bliothèque
Rlle.St Fr.
Rue A.
R. d. l. Providence
R. J.Nicolas
Rue Guigonis
Collet
Gauthier
Montée Eberlé
Serruriers
R. des
Rue dela Croix
Rue Ste. Claire
R.
du Marché R.d.l. Bouch ie. Rue de R.Centrale
R. Maïsconat
de la Loge Rue
Montée du Château
Pertus
R. du
Rue Rossetti
Rue J. Gilly Rue Droite Rue
R. Centra le
Ste Réparate R.d. Pt. Vieux
Rue
Supérieur
Rue
St Joseph
la Condamine
Rue de
H. Ugo
Rue du Jésus
R.
Rue
du Château
R. Benoit Bunico
H. aux Herbes
Rlle
Rue Col. d'Istria
R. Fr. Gallo
Rue St Vin- ent
R.
Desc. Crotti
d.Pontin
R. Moulin
Rue de L'Abbaye
R.Robilante
Gassin
Rue de la Préfecture
Rue Raoul Bosio
R. d. l. Hôtel de Calada A. Escoffier
Quai de la
Douane Quai
Allée Professeur Benoît Allée François Aragon
d.l. Bouch ie
Rlle
Al. Font. aux Oiseaux
Relle du
Séminaire
Rue St Françoisde Paule
Rue Alexandre Mari
L'Opéra
Rue Vanloo Desboutins
Rue
R. d. l. Pl. Vieille
R. d. l.
R. du Malonat
Pass.
Mercédès
M. Robbins
Rue Sulzer
Rue Bréa
Ecole
Rlle
D. l'Anc
Rue Barillerie Sénat
C.U.M.
Rue
de Magnan
R. B.
Collège
Henriot Vieil
Rue de Foresta
R. St Gaëtan
Marché
aux Fleurs
R.l
PapacinoQuai Cassini
Bieckert
ippe
Rue Barla
17
Les Baumettes
Mus Musée e des des des
Beaux-Arts Beaux-Arts Beaux-Arts
Palais Palais de de
Justice Justice
Espace
J. Marro
Malonat
R.
Poissonnerie
Rue de la
Opéra
Rue
15
Rue du
COURS SALEYA
St Suaire
Cité du Parc
Lympia
Montée Montfort
Montée Lesage
La Tour
Bellanda
Monument
aux Morts
Rue des Ponchettes
Opéra plage
Beau rivage
Ruhl plage
Lido plage
Castel
plage
Galion plage
Sporting plage
Blue beach
Neptune plage
ESPACE
MAGNAN
36
Montée
Forum plage
Place du
8 Mai 1945
Voilier plage
11
21 22 23 40 43
6
Jardin
Public
Vigier
Gare Maritime
SNCM
Place
Guynemer Gare Maritime
CORSICA FERRIES
Bassin
du Commerce
Riboty
Florida plage
Iris
Club
Nautique
Quai
île de Beauté
Quai
Chem in des
Ch . Tordu du
St Aignan
du
Boulevard
Mt.Bo ron
Maison
du Séminaire
Infernet
C
Pilatte
Av. Mon
N.D
du Perpétuel
Secours
Tribunal
Administratif
Mercure
Californie
Malmaison
Acropole
Anis
Sportmen
Verdun
40
41
42
43
44
45
Av. Ste
Cécile
Rout
Montée
Gurnée
Carnot Bd M
Jardin
F.Rainaud
10
2-Star Hotels
Comfort Nice Vieux Port
Citea Nice Acropolis
www.escmid.org/eccmid2006
Imp.
Bd
n
Avenue
46
47
Ibis Centre Notre Dame
Mercure Grimaldi
Mercure Promenade
des Anglais
Mercure Marché aux
Fleurs
Sibill’s
Suisse
Univers
Vendôme
Windsor
5-Star Hotels
Sofitel
Novotel Arenas Aeroport
Boscolo Atlantic
West-End
Novotel Cap 3000
Boscolo Plaza
Westminster Concorde Park Inn Nice Airport
Beau Rivage
Splendid
Grand Hotel Aston
4-Star Hotels
La Pérouse
Four Points Sheraton 3-Star Hotels
Le Méridien
Holiday Inn Nice
Albert 1
Negresco
Hi
Palais de la Méditerranée Massena
Palais Maeterlinck
Mercure Notre Dame
Radisson SAS
Novotel Nice Centre
er
= Bus Stop (see schedule on page 208)
12
21
31
1
13
22
32
3
14
23
33
4
24
5
34
6
15
7
16
25
35
8
17
26 Apogia Nice
36
9
18 28 Best Western Nautica
37
10 19
29 Best Western New York
38
11 20 30 Busby
39
Ernes
page 207

Area/ Bus Stops Hotels included: Departure Return Departure Return Return Return
Bus Routes (please walk to your April 1 April 1 April 2–4 April 2 April 3 April 4
nearest bus stop)
1 JUAN-LES-PINS Ambassadeur Ambassadeur + Méridien 12:00 20:00/20:30 06:25/7:25 17:45/18:50 17:30/17:45/ 15:15
19:00 18:00
2 CAP-FERRAT Grand Hotel Cap-Ferrat Grand Hotel Cap-Ferrat 12:30 20:30 06:30/7:30 18:50 17:45 15:15
3 NICE AIRPORT Novotel Arenas Airport Novotel Arenas Airport 12:00 20:00/20:30 06:40/07:45 17:40/18:50 17:40/18:00 15:15
Shuttle Bus Schedule
A limited shuttle bus service is available in the mornings and in the evenings.
Delegates may use this service free of charge by wearing their congress badge.
Park-Inn Park-Inn 12:05 06:45/07:50
4 NICE WEST West-End West-End 12:00/12:15/12:30/ 06:30/06:45/07:30
12:45 07:45
Negresco Negresco + Sheraton 12:05/12:20/12:35/ from 19:30– 06:35/06:50/07:35
+ Westminster + Palais de 12:50 21:00 07:50 from 17:00– from 17:00– 15:10/15:20
la Méditerrannée 19:00 18.00
Mercure Californie Mercure Californie 12:15/12:30/12:45/ 06:45/07:00/07:45
+ Anis 13:00 08:00
5 RADISSON SAS Radisson SAS Radisson SAS 12:00/12:15 20:00/20:30/ 06:45/07:45 17:45/18:50/ 17:30/17:45/ 15:15
21:00 19:00 18:00
page 208 Final Programme
6 NICE PLAGE Aston Aston + Massena + Verdun 11:45/12:00/12:15/ 06:30/06:45/07:30/
12:30/12:45 07:45/08:00
Boscolo Plaza Boscolo Plaza + Univers 11:50/12:05/12:20/ 06:35/06:50/07:35
+ Meridien 12:35/12:50 from 19:30– 07:50/08:05 from 17:00– from 17:00– 15:00/15:10/
+ Mercure Promenade 21:00 19.00 18:00 15:20
Albert 1er Albert 1er + Beau Rivage 12:00/12:15/12:30/ 06:40/06:55/07:40/
12:45/13:00 07:55/08:10
7 NICE CENTRE Mercure Notre-Dame Mercure Notre-Dame 11:45/12:00/12:15 06:25/07:25/07:35
+ Alexandra + Beau Soleil 07:45
+ New York
Holiday Inn Holiday Inn + Splendid 11:55/12:10/12:25 from 19:30– 06:35/07:35/07:45 from 17:30– from 17:00– 15:10/15:20
+ Windsor + Busby 21:00 07:55 19:00 18.00
+ La Malmaison
Mercure Grimaldi Mercure Grimaldi 12:00/12:15/12:30 06:40/07:40/07:50
08:00
Vendôme Vendôme 12:05/12:20/12:35 06:45/07:45/07:55/
08:05
8 NICE EST Palais Maeterlinck Palais Maeterlinck 11:45 06:20/07:30
La Pérouse La Pérouse + Suisse 12:00 20:30 06:35/07:45 17:40/18:50 17:40/18:00 15:15
Mercure Marché aux fleurs Mercure Marché aux fleurs 12:05 06:40/07:50

16th ECCMID • Nice Acropolis Congress Centre, Nice, France • 1-4 April 2006
Fighting the threat of resistance:
an interactive symposium
08.30-10.30, Monday 3 April, 2006
Clio Room, Level 3, Nice Acropolis Congress Centre
Chair: P Montravers, Paris, France Co-chair: R Masterton, Kilmarnock, UK
Programme
For further information, contact:
AstraZeneca, Alderley House,
Alderley Park, Macclesfield, Cheshire, UK
8885/January 2006
08.30 Welcome and Introduction P Montravers, France
08.40 Porins, pumps, enzymes and other resistance threats D Livermore, UK
09.05 Novel dosage regimens to fight resistance G Drusano, USA
09.30 Panel discussion
While at
ECCMID
please visit the
AstraZeneca
stand 233
09.45 Interactive case history: A patient with a severe R Masterton, UK
abdominal gunshot wound P Montravers, France
10.25 Summary P Montravers, France
INFECTION

Now
Approved
in the EU
Copyright © 2006, SP Europe, Brussels, Belgium. All rights reserved. 2/06